<SEC-DOCUMENT>0001564590-21-057888.txt : 20211122
<SEC-HEADER>0001564590-21-057888.hdr.sgml : 20211122
<ACCEPTANCE-DATETIME>20211122163304
ACCESSION NUMBER:		0001564590-21-057888
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211122
DATE AS OF CHANGE:		20211122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		211432994

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>arwr-10k_20210930.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-11-22T20:54:41.6581715+00:00 -->
<!-- Version            : 5.0.1.702 -->
<!-- Package ID         : 591c69b5c8c44264a019b1bc2edccec6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:arwr="http://www.arrowheadresearch.com/20210930" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
arwr-10k_20210930.htm
</title>
</head>
<!-- NG Converter v5.0.2.67 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000879407_20201001_20210930">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0000879407_20201001_20210930">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0000879407_20201001_20210930">0000879407</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0000879407_20201001_20210930">--09-30</ix:nonNumeric>
			<ix:nonNumeric id="F_000373" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20210930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000375" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20210930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000378" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000380" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000381" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20210930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000382" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20210930">2020-10-01</ix:nonNumeric>
			<ix:nonNumeric id="F_000383" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20210930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000394" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20201001_20210930">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000395" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000396" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000765" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119">P10Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0000879407_20210930" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0000879407_20200930" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000104" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20201001_20210930">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000105" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20191001_20200930">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000106" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20181001_20190930">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000620" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0000879407_20201001_20210930">P5Y6M21D</ix:nonNumeric>
			<ix:nonNumeric id="F_000621" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0000879407_20201001_20210930">P4Y6M29D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000635" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000879407_20201001_20210930" decimals="INF">0.004</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000636" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000879407_20191001_20200930" decimals="INF">0.004</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000637" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000879407_20181001_20190930" decimals="INF">0.0150</ix:nonFraction>
			<ix:nonNumeric id="F_000646" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000879407_20201001_20210930">P6Y3M</ix:nonNumeric>
			<ix:nonNumeric id="F_000647" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000879407_20191001_20200930">P6Y3M</ix:nonNumeric>
			<ix:nonNumeric id="F_000648" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000879407_20181001_20190930">P6Y3M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000638" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000879407_20201001_20210930" decimals="INF">0.011</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000639" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000879407_20191001_20200930" decimals="INF">0.018</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000640" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000879407_20181001_20190930" decimals="INF">0.031</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000642" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0000879407_20201001_20210930" decimals="3">0.862</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000643" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0000879407_20191001_20200930" decimals="3">0.900</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000644" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0000879407_20201001_20210930" decimals="3">0.904</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000645" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0000879407_20191001_20200930" decimals="3">0.920</ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="arwr-20210930.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000879407_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_20211115">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-11-15</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20210101_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMaximumMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMinimumMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMaximumMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-09-27</xbrli:startDate>
					<xbrli:endDate>2016-09-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arwrAgreement">
				<xbrli:measure>arwr:Agreement</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160928">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-09-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseCollaborationAndStockPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-09-27</xbrli:startDate>
					<xbrli:endDate>2016-09-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20160928">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-09-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-10-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-10-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arwrTarget">
				<xbrli:measure>arwr:Target</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-10-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arwrObligation">
				<xbrli:measure>arwr:Obligation</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-10-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20211031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-07</xbrli:startDate>
					<xbrli:endDate>2020-10-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-07</xbrli:startDate>
					<xbrli:endDate>2020-10-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-07</xbrli:startDate>
					<xbrli:endDate>2020-10-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arwrBundle">
				<xbrli:measure>arwr:Bundle</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapBalanceSheetLocationAxis_arwrDeferredRevenueCurrentMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">arwr:DeferredRevenueCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapBalanceSheetLocationAxis_us-gaapAccruedLiabilitiesMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618_20210618">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-18</xbrli:startDate>
					<xbrli:endDate>2021-06-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-18</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20210618_20210618">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-18</xbrli:startDate>
					<xbrli:endDate>2021-06-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneYearMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapCashAndCashEquivalentsAxis_arwrCertificateOfDepositsDueWithinTwoYearsMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CertificateOfDepositsDueWithinTwoYearsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneYearMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:MarketableSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:MarketableSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_us-gaapTypeOfArrangementAxis_arwrAROENacAndAROHIF2CandidatesMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-01</xbrli:startDate>
					<xbrli:endDate>2019-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arwrOption">
				<xbrli:measure>arwr:Option</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-23</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023_20201023">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-23</xbrli:startDate>
					<xbrli:endDate>2020-10-23</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160101_20160131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-01-01</xbrli:startDate>
					<xbrli:endDate>2016-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2020-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HalozymeIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SubleaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HalozymeIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SubleaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210318">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-18</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionsUpToThreePercentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20201001_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionNextTwoPercentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-11-19</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119_20211119">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-11-19</xbrli:startDate>
					<xbrli:endDate>2021-11-19</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-11-19</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-11-22</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-11-22</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122_20211122">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-11-22</xbrli:startDate>
					<xbrli:endDate>2021-11-22</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="border-top:none 0pt;padding-top:0pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;border-top:Double 2.25pt;padding-top:1pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, DC 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000879407_20201001_20210930">10-K</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One) </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:DocumentAnnualReport" contextRef="C_0000879407_20201001_20210930" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000879407_20201001_20210930" format="ixt:datemonthdayyearen">September&#160;30, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0000879407_20201001_20210930">2021</ix:nonNumeric></ix:nonNumeric>. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:DocumentTransitionReport" contextRef="C_0000879407_20201001_20210930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number <ix:nonNumeric id="F_000022" name="dei:EntityFileNumber" contextRef="C_0000879407_20201001_20210930">001-38042</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0000879407_20201001_20210930">ARROWHEAD PHARMACEUTICALS, INC.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000879407_20201001_20210930" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:0.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:49.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000879407_20201001_20210930">46-0408024</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of incorporation or organization)</p></td>
<td valign="bottom" style="width:0.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityAddressAddressLine1" contextRef="C_0000879407_20201001_20210930">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric id="F_000026" name="dei:EntityAddressAddressLine2" contextRef="C_0000879407_20201001_20210930">Suite 700</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:EntityAddressCityOrTown" contextRef="C_0000879407_20201001_20210930">Pasadena</ix:nonNumeric>, <ix:nonNumeric id="F_000028" name="dei:EntityAddressStateOrProvince" contextRef="C_0000879407_20201001_20210930" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric id="F_000029" name="dei:EntityAddressPostalZipCode" contextRef="C_0000879407_20201001_20210930">91105</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000030" name="dei:CityAreaCode" contextRef="C_0000879407_20201001_20210930">626</ix:nonNumeric>) <ix:nonNumeric id="F_000031" name="dei:LocalPhoneNumber" contextRef="C_0000879407_20201001_20210930">304-3400</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address and telephone number of principal executive offices) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Exchange Act: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:36.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-weight:bold;font-size:7pt;">Title of each class</span></p></td>
<td valign="bottom" style="width:25.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:37.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom" style="width:36.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0000879407_20201001_20210930">Common Stock, $0.001 par value</ix:nonNumeric></p></td>
<td valign="bottom" style="width:25.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0000879407_20201001_20210930">ARWR</ix:nonNumeric></p></td>
<td valign="bottom" style="width:37.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000879407_20201001_20210930" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Exchange Act: None </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<ix:nonNumeric id="F_000009" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0000879407_20201001_20210930">Yes</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;No&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by a check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act.&#160;Yes&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;<ix:nonNumeric id="F_000011" name="dei:EntityVoluntaryFilers" contextRef="C_0000879407_20201001_20210930">No</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric id="F_000010" name="dei:EntityCurrentReportingStatus" contextRef="C_0000879407_20201001_20210930">Yes</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;No&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T <span style="color:#000000;">(&#167; 232.405 of this chapter) </span>during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric id="F_000019" name="dei:EntityInteractiveDataCurrent" contextRef="C_0000879407_20201001_20210930">Yes</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;No&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:24.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityFilerCategory" contextRef="C_0000879407_20201001_20210930" format="ixt-sec:entityfilercategoryen">Large&#160;accelerated&#160;filer</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:18.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:23.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated&#160;filer&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:30.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000013" name="dei:EntitySmallBusiness" contextRef="C_0000879407_20201001_20210930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
</tr>
<tr>
<td valign="top" style="width:24.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000014" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000879407_20201001_20210930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:18.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&#160;</p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:23.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&#160;</p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:30.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000016" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0000879407_20201001_20210930" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;Yes&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0000879407_20201001_20210930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;No&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of issuer&#8217;s voting and non-voting outstanding Common Stock held by non-affiliates was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000018" name="dei:EntityPublicFloat" contextRef="C_0000879407_20210331" decimals="-8" scale="9">5.9</ix:nonFraction> billion based upon the closing stock price of issuer&#8217;s Common Stock on March&#160;31, 2021. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding Common Stock have been excluded in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of November 15, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000017" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0000879407_20211115" decimals="INF" format="ixt:numdotdecimal">104,525,708</ix:nonFraction> shares of the issuer&#8217;s Common Stock were issued and outstanding. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-bottom:3pt;margin-top:3pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:5%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000034" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0000879407_20201001_20210930">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#8217;s 2022 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-top:4pt;border-top:none 0pt;padding-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="border-top:none 0pt;padding-top:0pt;text-align:center;margin-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;I</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:87.26%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM&#160;</span>1<span style="font-size:7.5pt;">.</span></p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">B</span><span style="font-size:7.5pt;text-decoration:underline;">USINESS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;1A.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Risk_Factors"><span style="text-decoration:underline;">R</span><span style="font-size:7.5pt;text-decoration:underline;">ISK</span><span style="text-decoration:underline;"> F</span><span style="font-size:7.5pt;text-decoration:underline;">ACTORS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;1B.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item1B_UnresolvedStaffComments"><span style="text-decoration:underline;">U</span><span style="font-size:7.5pt;text-decoration:underline;">NRESOLVED</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">TAFF</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">OMMENTS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;2.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item2_Properties"><span style="text-decoration:underline;">P</span><span style="font-size:7.5pt;text-decoration:underline;">ROPERTIES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;3.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item3_LegalProceedings"><span style="text-decoration:underline;">L</span><span style="font-size:7.5pt;text-decoration:underline;">EGAL</span><span style="text-decoration:underline;"> P</span><span style="font-size:7.5pt;text-decoration:underline;">ROCEEDINGS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;4.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item4_MineSafetyDisclosures"><span style="text-decoration:underline;">M</span><span style="font-size:7.5pt;text-decoration:underline;">INE</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">AFETY</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ISCLOSURES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:87.26%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;5.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item5_MarketForRegistrants"><span style="text-decoration:underline;">M</span><span style="font-size:7.5pt;text-decoration:underline;">ARKET</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">FOR</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">THE</span><span style="text-decoration:underline;"> R</span><span style="font-size:7.5pt;text-decoration:underline;">EGISTRANT</span><span style="text-decoration:underline;">&#8217;</span><span style="font-size:7.5pt;text-decoration:underline;">S</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">OMMON</span><span style="text-decoration:underline;"> E</span><span style="font-size:7.5pt;text-decoration:underline;">QUITY</span><span style="text-decoration:underline;">, R</span><span style="font-size:7.5pt;text-decoration:underline;">ELATED</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">TOCKHOLDER</span><span style="text-decoration:underline;"> M</span><span style="font-size:7.5pt;text-decoration:underline;">ATTERS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> I</span><span style="font-size:7.5pt;text-decoration:underline;">SSUER</span><span style="text-decoration:underline;"> P</span><span style="font-size:7.5pt;text-decoration:underline;">URCHASES</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">OF</span><span style="text-decoration:underline;"> E</span><span style="font-size:7.5pt;text-decoration:underline;">QUITY</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">ECURITIES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;6.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_RESERVED"><span style="text-decoration:underline;">Reserved</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;7.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item7_MDA"><span style="text-decoration:underline;">M</span><span style="font-size:7.5pt;text-decoration:underline;">ANAGEMENT</span><span style="text-decoration:underline;">&#8217;</span><span style="font-size:7.5pt;text-decoration:underline;">S</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ISCUSSION</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> A</span><span style="font-size:7.5pt;text-decoration:underline;">NALYSIS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">OF</span><span style="text-decoration:underline;"> F</span><span style="font-size:7.5pt;text-decoration:underline;">INANCIAL</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">ONDITION</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> R</span><span style="font-size:7.5pt;text-decoration:underline;">ESULTS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">OF</span><span style="text-decoration:underline;"> O</span><span style="font-size:7.5pt;text-decoration:underline;">PERATIONS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;7A.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item7A_QuantitativeAndQualitative"><span style="text-decoration:underline;">Q</span><span style="font-size:7.5pt;text-decoration:underline;">UANTITATIVE</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> Q</span><span style="font-size:7.5pt;text-decoration:underline;">UALITATIVE</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ISCLOSURES</span><span style="text-decoration:underline;"> A</span><span style="font-size:7.5pt;text-decoration:underline;">BOUT</span><span style="text-decoration:underline;"> M</span><span style="font-size:7.5pt;text-decoration:underline;">ARKET</span><span style="text-decoration:underline;"> R</span><span style="font-size:7.5pt;text-decoration:underline;">ISK</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;8.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item8_FinancialStatementsAndSuppData"><span style="text-decoration:underline;">F</span><span style="font-size:7.5pt;text-decoration:underline;">INANCIAL</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">TATEMENTS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">UPPLEMENTARY</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ATA</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;9.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item9_ChangesInAndDisagreements"><span style="text-decoration:underline;">C</span><span style="font-size:7.5pt;text-decoration:underline;">HANGES</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">IN</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ISAGREEMENTS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">WITH</span><span style="text-decoration:underline;"> A</span><span style="font-size:7.5pt;text-decoration:underline;">CCOUNTANTS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">ON</span><span style="text-decoration:underline;"> A</span><span style="font-size:7.5pt;text-decoration:underline;">CCOUNTING</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> F</span><span style="font-size:7.5pt;text-decoration:underline;">INANCIAL</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ISCLOSURE</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;9A.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item9A_ControlsAndProcedures"><span style="text-decoration:underline;">C</span><span style="font-size:7.5pt;text-decoration:underline;">ONTROLS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> P</span><span style="font-size:7.5pt;text-decoration:underline;">ROCEDURES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;9B.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item9B_OtherInformation"><span style="text-decoration:underline;">O</span><span style="font-size:7.5pt;text-decoration:underline;">THER</span><span style="text-decoration:underline;"> I</span><span style="font-size:7.5pt;text-decoration:underline;">NFORMATION</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;9C.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:9pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a href="#Item9c_Disclosures_Regarding_Foreign"><span style="text-decoration:underline;">Disclosure Regarding Foreign Jursidictions That Prevent Inspections</span></a><span style="font-size:9pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:87.26%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;10.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item10_DirectorsExecutives"><span style="text-decoration:underline;">D</span><span style="font-size:7.5pt;text-decoration:underline;">IRECTORS</span><span style="text-decoration:underline;">, E</span><span style="font-size:7.5pt;text-decoration:underline;">XECUTIVE</span><span style="text-decoration:underline;"> O</span><span style="font-size:7.5pt;text-decoration:underline;">FFICERS</span><span style="text-decoration:underline;">, </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">ORPORATE</span><span style="text-decoration:underline;"> G</span><span style="font-size:7.5pt;text-decoration:underline;">OVERNANCE</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;11.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item11_ExecutiveCompensation"><span style="text-decoration:underline;">E</span><span style="font-size:7.5pt;text-decoration:underline;">XECUTIVE</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">OMPENSATION</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;12.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item12_SecurityOwnership"><span style="text-decoration:underline;">S</span><span style="font-size:7.5pt;text-decoration:underline;">ECURITY</span><span style="text-decoration:underline;"> O</span><span style="font-size:7.5pt;text-decoration:underline;">WNERSHIP</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">OF</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">ERTAIN</span><span style="text-decoration:underline;"> B</span><span style="font-size:7.5pt;text-decoration:underline;">ENEFICIAL</span><span style="text-decoration:underline;"> O</span><span style="font-size:7.5pt;text-decoration:underline;">WNERS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> M</span><span style="font-size:7.5pt;text-decoration:underline;">ANAGEMENT</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> R</span><span style="font-size:7.5pt;text-decoration:underline;">ELATED</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">TOCKHOLDERS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;13.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item13_CertainRelationships"><span style="text-decoration:underline;">C</span><span style="font-size:7.5pt;text-decoration:underline;">ERTAIN</span><span style="text-decoration:underline;"> R</span><span style="font-size:7.5pt;text-decoration:underline;">ELATIONSHIPS</span><span style="text-decoration:underline;">, R</span><span style="font-size:7.5pt;text-decoration:underline;">ELATED</span><span style="text-decoration:underline;"> T</span><span style="font-size:7.5pt;text-decoration:underline;">RANSACTIONS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">IRECTORS</span><span style="text-decoration:underline;"> I</span><span style="font-size:7.5pt;text-decoration:underline;">NDEPENDENCE</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;14.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item14_PrincipalAccountantFees"><span style="text-decoration:underline;">P</span><span style="font-size:7.5pt;text-decoration:underline;">RINCIPAL</span><span style="text-decoration:underline;"> A</span><span style="font-size:7.5pt;text-decoration:underline;">CCOUNTANT</span><span style="text-decoration:underline;"> F</span><span style="font-size:7.5pt;text-decoration:underline;">EES</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">ERVICES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:87.26%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;15.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item15_Exhibits"><span style="text-decoration:underline;">E</span><span style="font-size:7.5pt;text-decoration:underline;">XHIBITS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> F</span><span style="font-size:7.5pt;text-decoration:underline;">INANCIAL</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">TATEMENT</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">CHEDULES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">Item 16. </p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:9pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a href="#Item_16"><span style="text-decoration:underline;">Form 10-K Summary</span></a><span style="font-size:9pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"> </span><span style="font-size:10pt;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="3" valign="middle" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:95.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Signature"><span style="text-decoration:underline;">SIGNATURE</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="3" valign="middle" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#IndexToFinancialStatementsAndSchedules"><span style="text-decoration:underline;">INDEX TO FINANCIAL STATEMENTS AND SCHEDULES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains certain forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933 and Section&#160;21E of the Securities Exchange Act of 1934, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Annual Report on Form 10-K except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221;&#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; or &#8220;continue&#8221; or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. <span style="Background-color:#FFFFFF;color:#000000;">In addition, many of these risks and uncertainties may be amplified by global business and economic conditions, including the COVID-19 pandemic.&#160;&#160;</span>As such, our actual results may differ significantly from those expressed in any forward-looking statements. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in Item&#160;1 (Business) and Item&#160;1A (Risk Factors) of Part I and Item&#160;7 (Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations) of Part II of this Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission. In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART I </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;" id="NotesToConsolidatedFinanStatements">Unless otherwise noted, (1)&#160;the term &#8220;Arrowhead&#8221; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation and its Subsidiaries, (2)&#160;the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3)&#160;the term &#8220;Subsidiaries&#8221; refers to Arrowhead Madison Inc. (&#8220;Arrowhead Madison&#8221;), and Arrowhead Australia Pty Ltd (&#8220;Arrowhead Australia&#8221;), (4)&#160;the term &#8220;Common Stock&#8221; refers to Arrowhead&#8217;s Common Stock, (5) the term &#8220;Preferred Stock&#8221; refers to Arrowhead&#8217;s Preferred Stock and (6) the term &#8220;Stockholder(s)&#8221; refers to the holders of Arrowhead Common Stock. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1_BUSINESS">BUSINESS </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220; RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfmvgbft1fv3000001.jpg" title="" alt="" style="width:720px;height:211px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pipeline Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of our RNAi technologies enables us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is focused on bringing the promise of RNAi to address diseases outside of the liver and our pipeline now includes disease targets in the liver, lung, muscle, and solid tumors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfmvgbft1fv3000002.jpg" title="" alt="" style="width:683px;height:323px;" /></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-APOC3<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and a key regulator of triglyceride metabolism. We believe that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. Arrowhead is currently investigating ARO-APOC3 in two Phase 2b and one Phase 3 clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hypertriglyceridemia</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Elevated triglyceride levels are an independent risk factor for cardiovascular disease. Severely elevated triglycerides (often over 2,000 mg/dL) in patients with familial chylomicronemia syndrome (FCS), a rare genetic disorder, can result in potentially fatal acute pancreatitis.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients with Familial Chylomicronemia Syndrome (FCS)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03783377</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04720534</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-APOC3 in Adults With Mixed Dyslipidemia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04998201</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome (FCS)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT05089084</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-ANG3</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-ANG3 is designed to reduce production of angiopoietin-like protein 3 (ANGPTL3), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum LDL, serum and liver triglyceride and has genetic validation as a novel target for cardiovascular disease. Arrowhead is currently investigating ARO-ANG3 in a Phase 2b clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dyslipidemia and Hypertriglyceridemia </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dyslipidemia and hypertriglyceridemia are risk factors for atherosclerotic coronary heart disease and cardiovascular events.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03747224</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-ANG3 in Adults With Mixed Dyslipidemia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04832971</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-ENaC<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-ENaC is designed to reduce production of the epithelial sodium channel alpha subunit (&#945;ENaC) in the airways of the lung. In cystic fibrosis patients, increased ENaC activity contributes to airway dehydration and reduced mucociliary transport. Arrowhead is currently investigating ARO-ENaC in a Phase 1/2a clinical trial, in which new enrollment was paused in July 2021 pending results from non-clinical chronic toxicology studies.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cystic Fibrosis</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cystic fibrosis (CF) is a rare disease caused by a genetic mutation that leads to mucus buildup in the lungs and pancreas. In CF lung disease, patients can have difficulty breathing and experience frequent and persistent lung infections.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients With Cystic Fibrosis</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04375514</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-HSD<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-HSD is designed to reduce production of HSD17B13, a hydroxysteroid dehydrogenase involved in the metabolism of hormones, fatty acids and bile acids. Published human genetic data indicate that a loss of function mutation in HSD17B13 provides strong protection against nonalcoholic steatohepatitis (NASH) cirrhosis and alcoholic hepatitis and cirrhosis. Arrowhead is currently investigating ARO-HSD in a Phase 1/2a clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nonalcoholic Steatohepatitis</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. This can cause scarring of the liver and in advanced cases can lead to cirrhosis.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1/2a Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-HSD in Normal Healthy Volunteers as Well as in Patients With NASH or Suspected NASH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04202354</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-C3</span><span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-C3 is designed to reduce production of complement component 3 (C3) as a potential therapy for patients with various complement mediated or complement associated renal and hematological diseases. Arrowhead has filed a CTA to begin investigation of ARO-C3 in a Phase 1/2a clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-C3 in Adult Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria and Complement-Mediated Renal Disease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria and Adult Patients With Complement-Mediated Renal Disease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT05083364</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-HIF2</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-HIF2 is being developed for the treatment of clear cell renal cell carcinoma (ccRCC). ARO-HIF2 is designed to inhibit the production of HIF-2&#945;, which has been linked to tumor progression and metastasis in ccRCC. Arrowhead believes it is an important target for intervention because over 90% of ccRCC tumors express a mutant form of the Von Hippel-Landau protein that is unable to degrade HIF-2&#945;, leading to its accumulation during tumor hypoxia and promoting tumor growth. Arrowhead is currently investigating ARO-HIF2 in a Phase 1b clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renal Cell Carcinoma</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Renal Cell Carcinoma (&#8220;RCC&#8221;) is a type of kidney cancer that originates in the cells that line the small tubes that filter waste material from the blood. RCC is the most common type of kidney cancer accounting for more than 90% of cases with approximately 50,000 diagnoses in the United States each year.&#160;&#160;Unfortunately, patients with advanced stages of RCC have a 5-year survival rate of only 12-25%. Surgical resection is the mainstay of current treatment while chemotherapy and radiation have not been successful at prolonging survival. The treatment options for patients with metastatic disease are extremely limited.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1b Adaptive Dose-Finding Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04169711</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-DUX4</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-DUX4 is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy. Arrowhead intends to file a CTA to begin a Phase 1 clinical trial in 2022.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Facioscapulohumeral Muscular Dystrophy</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disease associated with the failure to maintain complete epigenetic suppression of DUX4 expression in differentiated skeletal muscle, leading to overexpression of DUX4, which is myotoxic and can lead to muscle degeneration. As DUX4 expression is recognized as the cause of muscle pathology in FSHD patients, Arrowhead believes that the selective targeting and knockdown of DUX4 using RNAi may prevent or reverse downstream myotoxicity and lead to muscle repair and improvement in muscle function in patients. There are currently no effective treatments specifically for FSHD.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Partnered Programs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Takeda Pharmaceutical Company Limited</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead entered into a collaboration and license agreement in October 2020 with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) to develop and commercialize ARO-AAT. Under the terms of the agreement, Takeda and Arrowhead will co-develop ARO-AAT which, if approved, will be co-commercialized in the United States under a 50/50 profit-sharing structure. Outside the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S., Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with Arrowhead eligible to receive tiered royalties of 20-25% on net sales. Arrowhead receiv</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> an upfront payment of $300 million and is eligible to receive potential development, regulatory and commercial milestones up to $740 million.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-AAT<span style="font-size:12pt;font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-AAT is the Company&#8217;s subcutaneously administered RNAi therapeutic being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency (AATD), which is a rare genetic disorder that severely damages the liver and lungs of affected individuals. ARO-AAT is designed to reduce production of the mutant Z-AAT protein by silencing the AAT gene in order to prevent accumulation of Z-AAT in the liver, allow clearance of the accumulated Z-AAT protein, prevent repeated cycles of cellular damage, and possibly prevent or even reverse the progression of liver fibrosis.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Goal of ARO-AAT Treatment</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The goal of ARO-AAT treatment is prevention and potential reversal of Z-AAT accumulation-related liver injury and fibrosis. Reduction of inflammatory Z-AAT protein, which has been clearly defined as the cause of progressive liver disease in AATD patients, is important as it is expected to halt the progression of liver disease and allow fibrotic tissue repair.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Alpha-1 Antitrypsin Deficiency (AATD)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AATD is a genetic disorder associated with liver disease in children and adults, and pulmonary disease in adults. AAT is a circulating glycoprotein protease inhibitor that is primarily synthesized and secreted by liver hepatocytes. Its physiologic function is the inhibition of neutrophil proteases to protect healthy lung tissues during inflammation and prevent tissue damage. The most common disease variant, the Z mutant, has a single amino acid substitution that results in improper folding of the protein.&#160;&#160;The mutant protein cannot be effectively secreted and accumulates in globules in the hepatocytes. This triggers continuous hepatocyte injury, leading to fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current Treatments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individuals with the homozygous PiZZ genotype have severe deficiency of functional AAT leading to pulmonary disease and hepatocyte injury and liver disease. Lung disease in this patient population is frequently treated with AAT augmentation therapy. However, augmentation therapy does nothing to treat liver disease, and there is no specific therapy for hepatic manifestations. There is a significant unmet need as liver transplant, with its attendant morbidity and mortality, is currently the only available cure.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-AAT in Normal Adult Volunteers</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin Levels in Normal Adult Volunteers</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03362242</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Assessment of Changes in a Novel Histological Activity Scale in Response to ARO-AAT</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Pilot Open Label, Multi-dose, Phase 2 Study to Assess Changes in a Novel Histological Activity Scale in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03946449 </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Safety, Tolerability and Effect on Liver Histologic Parameters of ARO-AAT (SEQUOIA)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency (AATD)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03945292</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Janssen Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead entered into a license agreement in October 2018 with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;), part of the Janssen Pharmaceutical Companies of Johnson &#38; Johnson, to develop and commercialize JNJ-3989 (formerly referred to as ARO-HBV). In addition, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNAi therapeutics against new targets to be selected by Janssen.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the license agreement, Arrowhead received $175 million as an upfront payment. Separately, Johnson &#38; Johnson Innovation &#8211; JJDC, Inc. (JJDC) made a $75.0 million equity investment in Arrowhead Common Stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead is eligible to receive up to approximately $1.6 billion in milestone payments under the license agreement. Arrowhead is also eligible to receive approximately $1.9 billion in option and milestone payments for the collaboration and option agreement related to up to three additional targets. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead is further eligible to receive tiered royalties up to mid-teens under the license agreement and up to low teens under the collaboration and option agreement on product sales.</span><span style="font-size:12pt;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since signing the license agreement, Arrowhead has received $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0 million in developmental milestone payments from Janssen.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JNJ-3989 (also referred to as JNJ-73763989 and formerly referred to as ARO-HBV)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JNJ-3989 is being developed in collaboration with Janssen as a potential therapy for patients with chronic hepatitis B infection, when used in combination with other therapeutic modalities. JNJ-3989 is a subcutaneous, RNAi therapy candidate which is designed to silence all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside analogues act. The company believes this, especially the elimination of hepatitis B surface antigen (HBsAg), may allow the body&#8217;s natural immune defenses to clear the virus and potentially lead to a functional cure. JNJ-3989 is currently being investigated in multiple Phase 2 clinical trials being conducted by Janssen. The Phase 1/2a study and its preceding studies were conducted by Arrowhead. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03365947</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of JNJ-73763989 in Healthy Japanese Adult Participants</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 2b  Double-blind, Placebo-controlled, Randomized, Parallel, Single Dose Study to Investigate Pharmacokinetics, Safety, and Tolerability of JNJ-73763989 in Healthy Japanese Adult Participants</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04002752</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection (REEF-1)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03982186</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Randomized, Double Blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04129554</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of JNJ-73763989 in Healthy Chinese Adult Participants</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Randomized, Open-Label, Parallel, Single Dose Study to Investigate Pharmacokinetics, Safety, and Tolerability of JNJ-73763989 in Healthy Chinese Adult Participants</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04586439</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of JNJ-73763989</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04208386</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus (REEF-D)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled Study With Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04535544</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">tudy Name: </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A Study of JNJ-73763989 + JNJ-56136379 + </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nucleos</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(t)Ide Analog (NA) Regimen With or Without Pegylated Interferon Alpha-2a (</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PegIFN</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-&#945;2a) in Treatment-Naive Participants With Hepatitis B e Antigen (</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HBeAg</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">) Positive Chronic Hepatitis B Virus (HBV) Infection and Normal Alanine Aminotransferase (ALT)</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Response-guided Treatment With JNJ-73763989 + JNJ-56136379 + Nucleos(t)Ide Analog Regimen With or Without Pegylated Interferon Alpha-2a in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B Virus Infection and Normal ALT</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04439539</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (INSIGHT)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04585789</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of JNJ-73763989 in Adult Participants With Renal Impairment</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-73763989 in Adult Participants</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04963738</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection (PENGUIN-2)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 2, Open-label, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT05005507</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PENGUIN)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04667104</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JNJ-75220795 (formerly referred to as ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JNJ-75220795 (ARO-JNJ1) is an investigational therapeutic being developed by Janssen.&#160;&#160;It utilizes Arrowhead&#8217;s proprietary TRIM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform and is designed to reduce expression in the liver of patatin like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with non-alcoholic steatohepatitis (NASH).&#160;&#160;ARO-JNJ2 and ARO-JNJ3 are being developed against undisclosed liver-expressed targets as part of Arrowhead&#8217;s research collaboration and option agreement with Janssen.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amgen Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amgen Inc. (&#8220;Amgen&#8221;) acquired a worldwide, exclusive license in September 2016 to develop and commercialize Olpasiran (previously referred to as AMG 890 or ARO-LPA). Under the terms of the agreements taken together for Olpasiran and ARO-AMG1, the Company received $35.0 million in upfront payments and $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, and the Company was eligible to receive up to $617.0 million in option payments and development, regulatory and sales milestone payments. The Company remains eligible to receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments under the Olpasiran (ARO-LPA) agreement.&#160;&#160;Since signing the agreements, Arrowhead has received $30.0 million in developmental milestone payments from Amgen.&#160;&#160;The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran (AMG 890, ARO-LPA) agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Olpasiran (formerly AMG 890 and ARO-LPA)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Olpasiran is designed to reduce production of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. Amgen started a Phase 2 clinical study in July 2020 evaluating the efficacy, safety, and tolerability of Olpasiran in subjects with elevated levels of lipoprotein(a), triggering a $20 million milestone payment to Arrowhead. Amgen also reported Phase 1 clinical results at the American Heart Association Scientific Sessions conference in November 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Horizon Therapeutics Ireland DAC.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Horizon Therapeutics Ireland DAC. (&#8220;Horizon&#8221;) and Arrowhead announced a global collaboration and license agreement for ARO-XDH in June 2021.<span style="font-size:12pt;"> </span>Under the terms of the agreement, Arrowhead will conduct all activities through preclinical stages of development of the siRNA therapeutic. Horizon will receive a worldwide exclusive license to the therapeutic and will be wholly responsible for clinical development and commercialization. Arrowhead received a $40 million upfront payment from Horizon and is eligible to receive up to $660 million in potential development, regulatory and commercial milestones, and is further eligible to receive royalties in the low- to mid-teens range on net product sales.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-XDH</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-XDH is designed to reduce production of xanthine dehydrogenase (XDH) as a potential treatment for people with uncontrolled gout. Gout is a serious and painful form of arthritis that is caused by excess uric acid in the blood. In the United States, there are more than nine million gout patients and approximately a third of those patients are treated with oral urate-lowering therapies. However, a meaningful portion of treated patients do not respond sufficiently to treatment and therefore continue to experience painful and debilitating gout symptoms. XDH represents a clinically validated target that is the primary source of serum uric acid (sUA). High levels of sUA, if left untreated or undertreated, can potentially lead to serious long-term or even permanent damage to the bones, joints and organs.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RNA Interference &#38; the Benefits of RNAi Therapeutics</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Small molecule and antibody drugs have proven effective at inhibiting certain cell surface, intracellular, and extracellular targets. However, other drug targets have proven difficult to inhibit with traditional drug-based and biologic therapeutics. Developing effective drugs for these targets would have the potential to address large underserved markets for the treatment of many diseases. Using the ability to specifically silence any gene, RNAi therapeutics may be able to address previously &#8220;undruggable&#8221; targets, unlocking the market potential of such targets. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfmvgbft1fv3000003.jpg" title="" alt="" style="width:507px;height:339px;" /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This figure depicts the mechanism by which gene silencing occurs. Double stranded RNAi triggers are introduced into a cell and are loaded into the RNA-induced silencing complex, (&#8220;RISC&#8221;). The strands are then separated, leaving an active RISC/RNAi trigger complex. This complex can then pair with and degrade the complementary messenger RNAs (&#8220;mRNA&#8221;) and stop the production of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the target proteins. RNAi is a catalytic process, so each RNAi trigger can degrade mRNA hundreds of times, which results in a relatively long duration of effect for RNAi therapeutics.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Key Advantages of RNAi as a Therapeutic Modality</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Silences the expression of disease associated genes&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Potential to address any target in the transcriptome including previously "undruggable" targets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Rapid lead identification&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">High specificity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Opportunity to use multiple RNA sequences in one drug product for synergistic silencing of related targets&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">RNAi therapeutics are uniquely suited for personalized medicine through target and cell specific delivery and gene knockdown.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Targeted RNAi Molecule (TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup>) Platform</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead&#8217;s Targeted RNAi Molecule (TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup>) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. Targeting has been core to Arrowhead&#8217;s development philosophy and the TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform builds on more than a decade of work on actively targeted drug delivery vehicles. Arrowhead scientists have discovered ways to progressively &#8220;TRiM&#8221; away extraneous features and chemistries and retain optimal pharmacologic activity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform is comprised of a highly potent RNA trigger identified using Arrowhead&#8217;s proprietary trigger selection rules and algorithms with the following components optimized, as needed, for each drug candidate: a high affinity targeting ligand&#59; various linker and chemistries&#59; structures that enhance pharmacokinetics&#59; and highly potent RNAi triggers with sequence specific stabilization chemistries. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics developed with the TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform offer several advantages: simplified manufacturing and reduced costs&#59; multiple routes of administration&#59; and potential for improved safety because there are less metabolites from smaller molecules, thereby reducing the risk of intracellular buildup. At Arrowhead, we also believe that for RNAi to reach its true potential, it must target organs outside the liver. Arrowhead is leading this expansion with the TRiMTM platform, which has shown the potential to reach multiple tissues, including liver, lung, tumor, muscle and others.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfmvgbft1fv3000004.jpg" title="" alt="" style="width:683px;height:300px;" /></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RNA Chemistries</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The structure and chemistries of the oligonucleotide molecules used to trigger the RNAi mechanism can be tailored for optimal activity. Arrowhead&#8217;s broad portfolio of RNA trigger structures and chemistries, including some proprietary structures, enable the Company to optimize each drug candidate on a target-by-target basis and utilize the combination of structure and chemical modifications that yield the most potent RNAi trigger.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a component of the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TRiM</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> platform, Arrowhead&#8217;s design philosophy for RNA chemical modifications is to start with a structurally simple molecule and add only selective modification and stabilization chemistries as necessary to achieve the desired level of target knockdown and duration of effect. The conceptual framework for the stabilization strategy starts with a more sophisticated RNAi trigger screening and selection process that identifies potent sequences rapidly in locations that others may miss. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Facilities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead&#8217;s research and development operations are primarily located in Madison, Wisconsin, and San Diego, California. Substantially all of the Company&#8217;s assets are located either in these facilities or in our corporate headquarters in Pasadena, California. A summary of our research and development resources is provided below:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">273 R&#38;D personnel as of September 30, 2021&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">State-of-the-art laboratories consisting of 132,000 total sq. ft.&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Complete small animal facilities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Primate colony housed at the Wisconsin National Primate Research Center, an affiliate of the University of Wisconsin&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">In-house histopathology capabilities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Animal models for cardio metabolic, viral, lung, and oncologic diseases&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Animal efficacy and safety assessment&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">In-house drug manufacturing capabilities to produce GMP material&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Polymer, peptide, oligonucleotide and small molecule synthesis and analytics capabilities (HPLC, NMR, MS, etc.)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Polymer, peptide and oligonucleotide PK, biodistribution, clearance methodologies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Conventional and confocal microscopy, flow cytometry, Luminex platform, qRT-PCR and clinical chemistry analytics.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual Property and Key Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company controls approximately 406 issued patents (including 263 directed to RNAi trigger molecules&#59; 39 directed to targeting groups or targeting compounds&#59; and 5 for hydrodynamic gene delivery), including European validations, and approximately 640 currently pending patent applications worldwide from 57 different patent families. The Company&#8217;s patent applications have been filed throughout the world, including, in the United States, Argentina, ARIPO (Africa Regional Intellectual Property Organization), Australia, Brazil, Canada, Chile, China, Eurasian Patent Organization, Europe, GCC (Gulf Cooperation Council), Hong Kong, Israel, India, Indonesia, Iraq, Jordan, Japan, Republic of Korea, Lebanon, Mexico, New Zealand, OAPI (African Intellectual Property Organization), Peru, Philippines, Russian Federation, Saudi Arabia, Singapore, Thailand, Taiwan, Uruguay, Venezuela, Vietnam, and South Africa.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RNAi Triggers</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company owns issued patents or has filed patent applications directed to RNAi trigger molecules, which serve as the foundation of Arrowhead&#8217;s TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform, and are targeted to reduce expression of various gene targets, including the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.54%;width:80.46%;">
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Patent Group</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated Year(s) of Expiration*</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="background-color:#EEECE1;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:100%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RNAi Triggers Gene Target</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HBV </p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2032, 2036, 2037</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AAT</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2035, 2038</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LPA</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2036</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#945;-ENaC </p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028, 2038</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">APOC3</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2035, 2038, 2040</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANGPTL3</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2038</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIF2&#945;</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2034, 2036, 2040</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HSD17B13</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2039</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PNPLA3</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2041</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factor 12</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2036, 2038</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RRM2</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2031</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#946;-ENaC</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2031</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#946;-Catenin</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2033</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.54%;width:80.46%;">
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Patent Group</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated Year(s) of Expiration*</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cx43</span></p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2029</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HCV</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIF1A</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HRH1</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HSF1</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2030, 2032</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FRP-1</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KRAS</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2033</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PDtype4</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PI4Kinase</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SYK</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TNF-&#945;</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027, 2028</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Assuming issuance of any pending patent applications, and excluding any patent term adjustments or patent term extensions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delivery Technologies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The delivery technology-related patents and patent applications, which include components used in Arrowhead&#8217;s TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform, have been filed and/or issued in various jurisdictions worldwide including the United States, Argentina, Australia, Brazil, Canada, China, Eurasian Patent Organization, Europe (including validations in France, Germany, Italy, Spain, Switzerland, United Kingdom), GCC (Gulf Cooperation Council), Israel, India, Japan, Lebanon, Mexico, New Zealand, Philippines, Russia, South Korea, Singapore, Taiwan, Uruguay, and South Africa. The Company also controls a number of patents directed to hydrodynamic nucleic acid delivery, which issued in the United States, Australia and Europe (validated in Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, the United Kingdom, Hungary, Ireland, Italy, Netherlands and Sweden). The approximate year of expiration for each of these various groups of patents are set forth below:&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.54%;width:80.46%;">
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Patent Group</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-7.2pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated Year(s) of Expiration*</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="top" style="background-color:#EEECE1;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:100%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Targeting ligands and other RNAi delivery and platform technologies</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Targeting groups <span style="font-style:italic;">(</span>Galactose derivative trimer-PK<span style="font-style:italic;">)</span></p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2031</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Targeting groups (&#945;v&#946;3 integrin)</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2034, 2039, 2039</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Targeting groups (&#945;v&#946;6 integrin)</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2037, 2038</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Targeting groups (Galactose derivative ligands)</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2037, 2037</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNAi agent design (5&#8242;-phosphate mimic)</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2037</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Physiologically labile linkers</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2036</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biologically cleavable linkers</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2036</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trialkyne linkers</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2039</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transferrin targeting</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LDLR targeting</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peptide targeting (CPP-Arg) </p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peptide targeting (YM3-10H)</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2032</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:100%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="top" style="background-color:#EEECE1;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:100%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Hydrodynamic delivery</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:60.58%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third iteration</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:39.42%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Assuming issuance of any pending patent applications, and excluding any patent term adjustments or patent term extensions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RNAi and drug delivery patent landscapes are complex and rapidly evolving. As such, we may need to obtain additional patent licenses prior to commercialization of our candidates. You should review the factors identified in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-Exclusively Licensed Patent Rights from Roche</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 21, 2011, Arrowhead acquired the RNAi therapeutics business of Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche Ltd. (collectively, &#8220;Roche&#8221;).&#160;&#160;The acquisition provided us with two primary sources of value:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Broad freedom to operate with respect to key patents directed to the primary RNAi-trigger formats: canonical, UNA, meroduplex, and dicer substrate structures&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">A large team of scientists experienced in RNAi and oligonucleotide delivery. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to this acquisition, Roche assigned to Arrowhead its entire rights under certain licenses including: the License and Collaboration Agreement between Roche and Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;) dated July 8, 2007 (the &#8220;Alnylam License&#8221;)&#59; the Non-Exclusive Patent License Agreement between Roche and MDRNA, Inc. dated February 12, 2009 (&#8220;MDRNA License&#8221;)&#59; and the Non-Exclusive License Agreement between Roche and City of Hope dated September 19, 2011 (the &#8220;COH License&#8221;) (collectively the &#8220;RNAi Licenses&#8221;).&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RNAi Licenses include licenses to patents related to modifications of double-stranded oligonucleotides, including modifications to the base, sugar, or internucleoside linkage, nucleotide mimetics, and end modifications, which do not abolish the RNAi activity of the double-stranded oligonucleotides.&#160;&#160;Also included are patents relating to modified double-stranded oligonucleotides, such as meroduplexes described in U.S. Patent No. 9,074,205 assigned to Marina Biotech (f/k/a MDRNA, Inc.), as well as U.S. Patent Nos. 8,314,227, 9,051,570, and 9,303,260 related to unlocked nucleotide analogs (&#8220;UNA&#8221;). The UNA patents were assigned by Marina Biotech to Arcturus Therapeutics, Inc., but remain part of the MDRNA License.&#160;&#160;The RNAi Licenses further include patents related to dicer substrates and uses of the double-stranded oligonucleotides that function through the mechanism of RNA interference, such as described in City of Hope&#8217;s U.S. Patent Nos. 8,084,599, 8,658,356, 8,691,786, 8,796,444, 8,809,515, and 9,518,262.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2012 License to Alnylam</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for licenses obtained from Alnylam to certain RNAi intellectual property, in January 2012, we granted Alnylam a worldwide non-exclusive, sublicensable royalty-bearing license under our broad and target-specific DPC intellectual property rights to research, develop and commercialize RNAi-based products against a single undisclosed target in combination with DPC technology. Under the license to Alnylam, Alnylam may be obligated to pay us development and sales milestone payments of up to the low double-digit millions of dollars for each licensed product that progresses through clinical trials, receives marketing approval and is the subject of a first commercial sale.&#160;&#160;Additionally, Alnylam may be obligated to pay us low single-digit percentage royalties on sales of such products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of Assets from Novartis</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 3, 2015, the Company entered into an Asset Purchase and Exclusive License Agreement (the &#8220;RNAi Purchase Agreement&#8221;) with Novartis pursuant to which the Company acquired Novartis&#8217; RNAi assets and rights thereunder. Pursuant to the RNAi Purchase Agreement, the Company acquired or was granted a license to certain patents and patent applications owned or controlled by Novartis related to RNAi therapeutics, was assigned Novartis&#8217;s rights under a license from Alnylam (the &#8220;Alnylam-Novartis License&#8221;) and acquired a license to certain additional Novartis assets (the &#8220;Licensed Novartis Assets&#8221;).&#160;&#160;The patents acquired from Novartis include multiple patent families covering delivery technologies and RNAi-trigger design rules and modifications.&#160;&#160;The Licensed Novartis Assets include an exclusive, worldwide right and license, solely in the RNAi field, with the right to grant sublicenses through multiple tiers under or with respect to certain patent rights and know how relating to delivery technologies and RNAi-trigger design rules and modifications.&#160;&#160;Under the assigned Alnylam-Novartis License, the Company acquired a worldwide, royalty-bearing, exclusive license with limited sublicensing rights to existing and future Alnylam intellectual property (including intellectual property that came under Alnylam&#8217;s control on or before March 31, 2016), excluding intellectual property concerning delivery technology, to research, develop and commercialize 30 undisclosed gene targets. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cardiovascular Collaboration and License Agreements with Amgen</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 28, 2016, the Company entered into two Collaboration and License agreements and a Common Stock Purchase Agreement with Amgen. Under the First Collaboration and License Agreement, Amgen received an option to a worldwide, exclusive license to ARO-AMG1<sub style="font-size:85%; vertical-align:bottom">,</sub> an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to Arrowhead&#8217;s novel, RNAi AMG 890 (ARO-LPA) program, now referred to as Olpasiran. The Olpasiran RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. In both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35 million in upfront payments and $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock.&#160;&#160;The Company was eligible to receive up to $617.0 million in option payments and development, regulatory and sales milestone payments.&#160;&#160;In August 2018, the Company received a $10.0 million milestone payment from Amgen following the administration of the first dose of Olpasiran in a phase 1 clinical trial.&#160;&#160;In July 2020, the Company received a $20.0 million milestone payment from Amgen following the initiation of a Phase 2 clinical study of Olpasiran. The Company remains eligible to receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments under the Olpasiran agreement.&#160;&#160;The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran agreement.  </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, Arrowhead delivered to Amgen a candidate that met or exceeded the activity and safety requirements stipulated in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-AMG1 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaboration agreement. The option period expire</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 7, 2019 and Amgen </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advised </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">id</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not intend to exercise </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">option.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License and Research Collaboration Agreements with Janssen Pharmaceuticals, Inc.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 3, 2018, the Company entered into a License Agreement (&#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (&#8220;Janssen Collaboration Agreement&#8221;) with Janssen.&#160;&#160;<span style="color:#000000;">The Company also entered into a Stock Purchase Agreement (&#8220;JJDC Stock Purchase Agreement&#8221;) with JJDC.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Janssen License Agreement, Janssen received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), Janssen is wholly responsible for further clinical development and commercialization of JNJ-3989 (ARO-HBV).<span style="color:#000000;">&#160;&#160;</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Janssen Collaboration Agreement, Janssen will be able to select up to three new targets against which the Company will develop clinical candidates. These candidates are subject to certain restrictions and do not include candidates that were already in the Company&#8217;s pipeline. The Company will perform discovery, optimization and preclinical development on selected targets, entirely funded by Janssen, which on its own or in combination with Janssen development work, is sufficient to allow the filing of a U.S. Investigational New Drug application or equivalent, at which time Janssen will have the option to take an exclusive license to the Company&#8217;s intellectual property rights covering that compound. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned compound.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreements taken together, the Company has received (i) $175.0 million as an upfront payment, (ii) $75.0 million in the form of an equity investment by <span style="Background-color:#FFFFFF;">JJDC</span> in the Company&#8217;s common stock, (iii) milestone and option payments totaling $70.0 million, (iv) up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and (v) up to $1.9 billion in development and sales milestone payments for the three additional targets covered under the Janssen Collaboration Agreement. <span style="color:#000000;">The Company is further eligible to receive tiered royalties up to mid-teens under the Janssen License agreement and up to low teens under the Janssen Collaboration Agreement on product sales.&#160;&#160;</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License and Research Collaboration Agreements with Takeda Pharmaceuticals U.S.A., Inc.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 7, 2020, the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda Pharmaceuticals U.S.A., Inc.&#160;&#160;(&#8220;Takeda&#8221;).&#160;&#160;Under the Takeda License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with the Company eligible to receive tiered royalties of 20% to 25% on net sales.&#160;&#160;The Company will receive $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.&#160;&#160;</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research Collaboration And License Agreement with Horizon Therapeutics Ireland DAC.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 18, 2021, the Company entered into a Collaboration and License Agreement (the &#8220;Horizon License Agreement&#8221;) with Horizon Therapeutics Ireland DAC&#160;&#160;(&#8220;Horizon&#8221;).   Under the terms of the Horizon License Agreement, Arrowhead will develop an RNAi therapeutic against xanthine dehydrogenase (XDH), as a potential treatment for people with uncontrolled gout.&#160;&#160;The Company will conduct all activities through preclinical stages of development, and Horizon will receive a worldwide exclusive license to the RNAi therapeutic and be wholly responsible for clinical development and commercialization. The Company received $40 million as an upfront payment from Horizon and is eligible to receive up to $660 million in potential development, regulatory and commercial milestones, and is further eligible to receive royalties in the low- to mid-teens range on net product sales.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States, at the federal, state, and local levels, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs and biologic products.&#160;&#160;All of our foreseeable product candidates are expected to be regulated as drugs. The processes for obtaining regulatory approval in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities both pre- and post-commercialization, are a significant factor in the production and marketing of our products and our R&#38;D activities and require the expenditure of substantial time and financial resources.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Review and Approval of Drugs in the United States</span><span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA and other government entities regulate drugs under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), the Public Health Service Act, and the regulations promulgated under those statutes, as well as other federal and state statutes and regulations. Failure to comply with applicable legal and regulatory requirements in the United States at any time during the product development process, approval process, or after approval, may subject us to a variety of administrative or judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, withdrawal of approvals, delay or suspension of clinical trials, issuance of warning letters and other types of regulatory letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil monetary penalties, refusals of or debarment from government contracts, exclusion from the federal healthcare programs, restitution, disgorgement of profits, civil or criminal investigations by the FDA, U.S. Department of Justice, State Attorneys General, and/or other agencies, False Claims Act suits and/or other litigation, and/or criminal prosecutions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An applicant seeking approval to market and distribute a new drug in the United States must typically undertake the following:<span style="font-size:12pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)&#160;completion of pre-clinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) regulations&#59; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)&#160;submission to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;) for human clinical testing, which must become effective without FDA objection before human clinical trials may begin&#59; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)&#160;approval by an independent institutional review board (&#8220;IRB&#8221;), representing each clinical site before each clinical trial may be initiated&#59; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)&#160;performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s current good clinical practice (&#8220;cGCP&#8221;) regulations, to establish the safety and effectiveness of the proposed drug product for each indication for which approval is sought&#59; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)&#160;preparation and submission to the FDA of a New Drug Application (&#8220;NDA&#8221;)&#59;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)&#160;satisfactory review of the NDA by an FDA advisory committee, where appropriate or if applicable&#59;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)&#160;satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug product, and the active pharmaceutical ingredient or ingredients thereof, are produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;) regulations and to assure that the facilities, methods, and controls are adequate to ensure the product&#8217;s identity, strength, quality, and purity&#59; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8)&#160;payment of user fees, as applicable, and securing FDA approval of the NDA&#59; and</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9)&#160;compliance with any post-approval requirements, such as any Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) or post-approval studies required by the FDA. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Studies and an IND<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies can include <span style="font-style:italic;">in vitro </span>and animal studies to assess the potential for adverse events and, in some cases, to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Other studies include laboratory evaluation of the purity, stability and physical form of the manufactured drug substance or active pharmaceutical ingredient and the physical properties, stability and reproducibility of the formulated drug or drug product. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some preclinical testing, such as longer-term toxicity testing, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following commencement of a clinical trial under an IND, the FDA may place a clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Human Clinical Studies in Support of an NDA<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 3: The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites in late-stage clinical trials to assure compliance with cGCP and the integrity of the clinical data submitted. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Submission of an NDA to the FDA<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an application user fee, currently $3.117 million for fiscal year 2022, for applications requiring clinical data, and the sponsor of an approved NDA is also subject to an annual program fee, currently $369,413 for fiscal year 2022. These fees are adjusted annually.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under certain circumstances, the FDA will waive the application fee for the first human drug application that a small business, defined as a company with less than 500 employees, including employees of affiliates, submits for review. An affiliate is defined as a business entity that has a relationship with a second business entity if one business entity controls, or has the power to control, the other business entity, or a third-party controls, or has the power to control, both entities.&#160;&#160;In addition, an application to market a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require submission of a REMS plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s Decision on an NDA<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. After approval, the FDA may seek to prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. Some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety and effectiveness of drug products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a drug for this type of disease or condition will be recovered from sales in the U.S. for that drug. Orphan drug designation entitles the applicant to incentives such as grant funding towards clinical study costs, tax advantages, and waivers of FDA user fees.&#160;&#160;Orphan drug designation must be requested before submitting an NDA, and both the drug and the disease or condition must meet certain criteria specified in the Orphan Drug Act and FDA&#8217;s implementing regulations at 21 C.F.R. Part 316.&#160;&#160;The granting of an orphan drug designation does not alter the standard regulatory requirements and process for obtaining marketing approval.&#160;&#160;Safety and effectiveness of a drug must be established through adequate and well-controlled studies.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other application to market the same drug for the same indication, except in very limited circumstances, for seven years.&#160;&#160;Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expedited Review and Accelerated Approval Programs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA&#8217;s review and approval of NDAs.&#160;&#160;For example, Fast Track Designation may be granted to a drug intended for treatment of a serious or life-threatening disease or condition and data demonstrate its potential to address unmet medical needs for the disease or condition.&#160;&#160;The key benefits of Fast Track Designation are the eligibility for priority review, rolling review (submission of portions of an application before the complete marketing application is submitted), and accelerated approval, if relevant criteria are met.&#160;&#160;The FDA may grant the NDA a priority review designation, which sets the target date for FDA action on the application at six months after the FDA accepts the application for filing.&#160;&#160;Priority review is granted where there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may approve an NDA under the accelerated approval program if the drug treats a serious condition, provides a meaningful advantage over available therapies, and demonstrates an effect on either (1) a surrogate endpoint that is reasonably likely to predict clinical benefit, or (2) on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the drug&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Food and Drug Administration Safety and Innovation Act of 2012 (&#8220;FDASIA&#8221;) established the Breakthrough Therapy designation.&#160;&#160;A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as breakthrough therapy, FDA will provide more intensive guidance on the drug development program and expedite its review. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-Approval Requirements<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events or problems with manufacturing processes of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information&#59; imposition of post-market studies or clinical trials to assess new safety risks&#59; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fines, warning letters or holds on post-approval clinical trials&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product seizure or detention, or refusal to permit the import or export of products&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injunctions or the imposition of civil or criminal penalties. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Abbreviated New Drug Applications for Generic Drugs<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 1984, with passage of the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly referred to as the &#8220;Hatch-Waxman Amendments&#8221;) amending the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (&#8220;ANDA&#8221;) to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference listed drug (&#8220;RLD&#8221;). To reference that information, however, the ANDA applicant must demonstrate, and the FDA must conclude, that the generic drug does, in fact, perform in the same way as the RLD it purports to copy. Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the generic drug do not show a significant difference from the rate and extent of absorption of the RLD.&#8221;&#160;&#160;Upon approval of an ANDA, the FDA indicates that the generic product is &#8220;therapeutically equivalent&#8221; to the RLD and it assigns a therapeutic equivalence rating to the approved generic drug in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider the therapeutic equivalence rating to mean that a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of a therapeutic equivalence rating often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of nonpatent exclusivity for the RLD has expired. The FDCA provides a period of five years of data exclusivity for new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval. The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Hatch-Waxman Patent Certification and the 30 Month Stay<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, the applicant must certify with respect to each patent that: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the required patent information has not been filed&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the listed patent has expired&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the listed patent is invalid, unenforceable or will not be infringed by the new product. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that a Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric Studies and Exclusivity<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With the enactment of FDASIA, sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied&#59; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot accept or approve another application. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Patent Term Restoration and Extension<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments. Those Amendments permit a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of a NDA, plus the time between the submission date of a NDA and ultimate approval. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Legislative Developments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 21st Century Cures Act (the &#8220;Cures Act&#8221;), which was signed into law in December 2016, includes provisions to accelerate the development and delivery of new treatments.&#160;&#160;For example, the Cures Act requires the FDA to establish a program to evaluate the potential use of real world evidence to help to support the approval of a new indication for an approved drug and to help to support or satisfy post-approval study requirements, to issue guidance on adaptive and novel clinical trial designs for new drugs, and to establish a process for qualifying drug development tools used to support FDA approval for marketing or investigational use of a drug. The Cures Act also permits the FDA to rely on qualified data summaries to support the approval of a supplemental application for an already approved drug.&#160;&#160;The FDA has continued to issue guidance focused on implementing the Cures Act requirements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Review and Approval of Drug Products in the European Union<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any <span style="color:#000000;">pharmaceutical</span> product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions governing, among other things, research and development, testing, manufacturing, quality control, safety, efficacy, labeling, clinical trials, marketing authorization, packaging, storage, record keeping, reporting, export and import, advertising, marketing and other promotional practices involving <span style="color:#000000;">pharmaceutical</span> products, as well as commercial sales, distribution, authorization, approval and post-approval monitoring and reporting of our products. Whether or not it obtains FDA approval for a <span style="color:#000000;">pharmaceutical</span> product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the <span style="color:#000000;">pharmaceutical</span> product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the United Kingdom formally left the European Union on January 31, 2020 and the transition period, during which EU laws continued to apply to the United Kingdom, expired on December 31, 2020, EU laws now only apply to the United Kingdom in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland. The European Union and the United Kingdom have concluded a trade and cooperation agreement (&#8220;TCA&#8221;), which was ratified by the UK Parliament on December 30, 2020. The TCA was applied provisionally as of January 1, 2021 and entered into force on May 1, 2021.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TCA includes provisions affecting the life sciences sector (including on customs and tariffs), but areas for further discussion between the European Union and UK remain. In addition, there are some specific provisions concerning pharmaceuticals. These include the mutual recognition of Good Manufacturing Practice (&#8220;GMP&#8221;), inspections of manufacturing facilities for medicinal products and GMP documents issued. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since January&#160;1, 2021, the EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#8220;retained EU law&#8221;. As there is no general power to amend these regulations, the UK government has adopted the Medicines and Medical Devices Act 2021, which seeks to address this regulatory gap through introducing regulation-making, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The purpose of the act is to enable the existing regulatory frameworks to be updated, with the powers granted under it only exercisable in relation to four pieces of legislation: the Human Medicines Regulations 2012, the Medicines for Human Use (Clinical Trials) Regulations 2004, the Medicines (Products for Human Use) Regulations 2016 and limited parts of the Medicines Act 1968 (specifically those parts which make provision related to pharmacies). It is then further restricted to amending or updating only those provisions stated in the act, which include clinical trials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new Medicines and Medical Devices Act 2021 supplements the UK Medical Devices Regulations 2002 (&#8220;UK Regulations&#8221;), which are based on the EU Medical Devices Directive as amended to reflect the UK&#8217;s post-Brexit regulatory regime. Notably, the UK Regulations do not include any of the revisions that have been made by the EU Medical Devices Regulation (EU) 2017/745, which has gained full application in all EU Member States since May&#160;26, 2021. Additionally, the UK&#8217;s Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) launched a comprehensive consultation on September&#160;16, 2021 with proposals to amend the regulatory framework for medical devices in the UK. The stated objectives of the proposals include expansion of the scope of the UK Regulations (e.g. by expanding the in vitro diagnostic medical device definition to includes software and other products, including products without an intended medical purpose but with similar functioning and risk profiles) and potentially through use of internationally recognised definitions (e.g. by excluding products that contain viable biological substances and excluding food), remove trade barriers, further the availability of medical devices and improve the favourability of the UK market. The consultation period closes on November 25, 2021 with a view to new regulations coming into force on July&#160;1 2023 with appropriate transitional measures.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Drug and Biologic Development Process</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conduct of clinical trials in the European Union is currently governed by the EU Clinical Trial Directive 2001/20/EC (&#8220;Clinical Trials Directive&#8221;), pursuant to which a system for the approval of clinical trials in the European Union has been implemented through national legislation of the EU Member States. Under the current regime, before a clinical trial can be initiated, an applicant must obtain approval in each EU Member State where there is a site at which the clinical trial is to be conducted by two separate entities: The National Competent Authority (&#8220;NCA&#8221;), and one or more Ethics Committees. The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU Member State before the commencement of the trial. Any substantial changes to trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU Member State where they occur. Clinical trial applications (&#8220;CTAs&#8221;) must also be accompanied by an investigational <span style="color:#000000;">pharmaceutical</span> product dossier with supporting information prescribed by the corresponding national laws of the Member States and further detailed in applicable guidance documents. However, the EU Member States have transposed and applied the provisions of the Clinical Trials Directive in a manner that is not always uniform. This has led to variations in the rules governing the conduct of clinical trials in the individual EU Member States. The EU has, therefore, adopted the EU Clinical Trials Regulation (EU) No 536/2014 (&#8220;Clinical Trials Regulation&#8221;). The Clinical Trials Regulation, which will replace the Clinical Trials Directive, introduces a complete overhaul of the existing regulation of clinical trials for pharmaceutical products in the EU, including a new coordinated procedure for authorization of clinical trials that is reminiscent of the mutual recognition procedure for marketing authorization of pharmaceutical products, and increased obligations on sponsors to publish clinical trial results. The coming into effect of the Clinical Trials Regulation has been postponed several times due to technical difficulties with the underlying IT systems. On July&#160;31, 2021 the European Commission confirmed that the Clinical Trials Regulation will come into force on January&#160;31, 2022. The new Clinical Trials Information System (&#8220;CTIS&#8221;), which contains the centralized EU portal and database for clinical trials, will also go-live on this date.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new Clinical Trials Regulation seeks to simplify and streamline the approval of clinical trials in the European Union, in particular through a harmonized electronic submission and assessment process for clinical trials conducted in multiple EU Member States. For example, the sponsor will be able submit a single application for approval of a clinical trial through the CTIS. As part of the application process, the sponsor proposes a reporting EU Member State, which will take the lead in validating and evaluating the application. The reporting EU Member State consults and coordinates with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the CTIS. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU Member State may in limited circumstances declare an &#8220;opt-out&#8221; from an approval. In such a case, the clinical trial cannot be conducted in that EU Member State. The Clinical Trials Regulation also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the CTIS. Information stored in the CTIS will be made publicly available subject to transparency rules. While the authorization and oversight of clinical trials in the EU remains the responsibility of the EU Member States, the CTIS is set-up, maintained and supervised by the European Medicines Agency (&#8220;EMA&#8221;).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under both the current regime and the new Clinical Trials Regulation, national laws, regulations, and the applicable Good Clinical Practice and Good Laboratory Practice standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines on Good Clinical Practice (&#8220;GCP&#8221;), <span style="color:#231F20;">and the ethical principles that have their origin in the Declaration of Helsinki</span>.</p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the development of a pharmaceutical product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program.&#160;&#160;At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party (&#8220;SAWP&#8221;). A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marketing Authorization Procedures </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU and in Iceland, Norway and Liechtenstein (together the European Economic Area or &#8220;EEA&#8221;), after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a Marketing Authorization (&#8220;MA&#8221;). To obtain an MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all EU Member States and, after respective national implementing decisions, in the three additional member states of the European Economic Area (Iceland, Norway and Liechtenstein). The centralized procedure is compulsory for specific <span style="color:#000000;">pharmaceutical</span> products, including for medicines developed by means of certain biotechnological processes, products designated as orphan <span style="color:#000000;">pharmaceutical</span> products, advanced therapy <span style="color:#000000;">pharmaceutical</span> products and <span style="color:#000000;">pharmaceutical</span> products with a new active substance indicated for the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">containing</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a new active substance </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not yet authorized in the European Economic Area before May 20, 2004</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indicated for the treatment of other diseases</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">constitute significant therapeutic, scientific or technical innovations</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or for which </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the grant of a marketing authorization through the centralized procedure would be in the interest of public health at EU level</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an applicant may voluntarily submit an application for a marketing authorization</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> through the centralized procedure</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated assessment might be granted by the CHMP in exceptional cases when a <span style="color:#000000;">pharmaceutical</span> product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. On request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. However, the European Commission has final authority for granting the MA within 67 days after receipt of the CHMP opinion.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decentralized procedure permits companies to file identical MA applications for a pharmaceutical product to the competent authorities in various EU Member States simultaneously if such pharmaceutical product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The decentralized procedure provides for approval by one or more other, or concerned, EU Member States of an assessment of an application performed by one-member state designated by the applicant, known as the reference EU Member State. Under this procedure, an applicant submits an application based on identical dossiers and related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference EU Member State and concerned EU Member States. The reference EU Member State prepares a draft assessment report and drafts of the related materials within 120 days after receipt of a valid application. Within 90 days of receiving the reference EU Member State&#8217;s assessment report and related materials, each concerned EU Member State must decide whether to approve the assessment report and related materials. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an EU Member State cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the European Commission, whose decision is binding on all EU Member States. </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;), describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. RMPs and Periodic Safety Update Reports (&#8220;PSURs&#8221;) are routinely available to third parties requesting access, subject to limited redactions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketing Authorizations have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the European Commission or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Data and Market Exclusivity in the European Union<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the European Union that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received an MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. In the European Union, new chemical entities qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. The overall ten-year period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are deemed to bring a significant clinical benefit in comparison with existing therapies. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The data exclusivity period begins on the date of the product&#8217;s first MA in the European Union. After eight years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative one-year period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant pre-clinical or clinical studies were carried out in relation to the new indication. Another year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized on the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">same substance the competent authority will not refer to the results of those tests or trials for one year after the initial chan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e was authorized).</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include a new chemical entity. Even if a compound is considered to be a new chemical entity and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the drug if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain marketing approval of its pharmaceutical product.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Designation and Exclusivity</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The criteria for designating an orphan medicinal product in the European Union are similar in principle to those in the United States. The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (prevalence criterion). In addition, Orphan Drug Designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the European Union of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a marketing authorization, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application for marketing authorization of the medicinal product is submitted. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional marketing authorization.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for a marketing authorization&#59; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of marketing authorization review by the EMA and approval by the EC. Additionally, any marketing authorization granted for an orphan medicinal product must only cover the therapeutic indication(s) that are covered by the orphan drug designation. Upon the grant of a marketing authorization, orphan drug designation provides up to ten years of market exclusivity in the orphan indication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for marketing authorization, accept an application to extend an existing marketing authorization or grant marketing authorization for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition when the results of specific studies are reflected in the Summary of Product Characteristics (&#8220;SmPC&#8221;), addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a marketing authorization may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric Development</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, companies developing a new <span style="color:#000000;">pharmaceutical</span> product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee (&#8220;PDCO&#8221;). Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (<span style="font-style:italic;">e.g.</span> until enough information to demonstrate its effectiveness and safety in adults is available) or waiver&#160;&#160;(<span style="font-style:italic;">e.g.</span> because the relevant disease or condition occurs only in adults) has been granted by the EMA. The marketing authorization application for the <span style="color:#000000;">pharmaceutical</span> product must include the results of all pediatric clinical trials performed and details of all information collected in compliancewith the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. <span style="color:#000000;">Pharmaceutical</span> products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan <span style="color:#000000;">pharmaceutical</span> products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and is not automatically available when data in compliance with the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approved </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PIP are developed and submitted.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An approved PIP is also required when a marketing</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorization holder wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized and covered by intellectual property rights</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-Approval Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to the United States, both marketing authorization holders and manufacturers of <span style="color:#000000;">pharmaceutical</span> products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of <span style="color:#000000;">pharmaceutical</span> products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the EU Member State laws implementing Directive 2001/83/EC on <span style="color:#000000;">pharmaceutical</span> products for human use and other core legislation relating to pharmaceutical products, and other EU Member State laws that apply to the conduct of clinical trials, manufacturing approval, marketing authorization of <span style="color:#000000;">pharmaceutical</span> products and marketing of such products, both before and after grant of marketing authorization, manufacturing of <span style="color:#000000;">pharmaceutical</span> products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holder of an EU marketing authorization for a <span style="color:#000000;">pharmaceutical</span> product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of <span style="color:#000000;">pharmaceutical</span> products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These pharmacovigilance rules can impose on holders of marketing authorizations the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed <span style="color:#000000;">pharmaceutical</span> products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. Marketing authorization holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of PSURs in relation to <span style="color:#000000;">pharmaceutical</span> products for which they hold marketing authorizations The EMA reviews PSURs for <span style="color:#000000;">pharmaceutical</span> products authorized through the centralized procedure. If the EMA has concerns that the risk-benefit profile of a product has varied, it can adopt an opinion advising that the existing marketing authorization for the product be suspended, withdrawn or varied. The Agency can advise that the marketing authorization holder be obliged to conduct post-authorization Phase 4 safety studies. The EMA opinion is submitted to the European Commission for its consideration. If the Commission agrees with the opinion, it can adopt a decision varying the existing marketing authorization. Failure by the marketing authorization holder to fulfill the obligations for which the European Commission&#8217;s decision provides can undermine the on-going validity of the marketing authorization. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the marketing authorization for the <span style="color:#000000;">pharmaceutical</span> product or imposition of financial penalties or other enforcement measures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing process for pharmaceutical products in the European Union is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice, or GMP. These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the European Union with the intention to import the active pharmaceutical ingredients into the European Union.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, the distribution of pharmaceutical products into and within the European Union is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the European Union or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Advertising and Promotion</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The advertising and promotion of our products is also subject to EU laws concerning promotion of <span style="color:#000000;">pharmaceutical</span> products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legislation of individual EU Member States may apply to the advertising and promotion of </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products and may differ from one country to another. These laws require that promotional materials and advertising in relation to </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product. It forms an intrinsic and integral part of the marketing authorization granted for the </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product. Promotion of a </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product that does not comply with the SmPC is considered to constitute off-label promotion. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> off-label promotion of </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products is prohibited in the European Union. The applicable laws at the EU level and in the individual EU Member States also prohibit the direct-to-consumer advertising of prescription-only </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products. Violations of the rules governing the promotion of </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> products in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">European Union could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pricing and Reimbursement Environment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a <span style="color:#000000;">pharmaceutical</span> product obtains a marketing authorization in the European Union, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. The EU Member States are free to restrict the range of <span style="color:#000000;">pharmaceutical</span> products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of <span style="color:#000000;">pharmaceutical</span> products for human use. An EU Member State may approve a specific price or level of reimbursement for the <span style="color:#000000;">pharmaceutical</span> product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the <span style="color:#000000;">pharmaceutical</span> product on the market, including volume-based arrangements, caps and reference pricing mechanisms.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our product candidates, if any, to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, <span style="color:#000000;">pharmaceutical</span> products launched in the European Union do not follow price structures of the United States and generally published and actual prices tend to be significantly lower. Publication of discounts by third party payers or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The so-called health technology assessment (&#8220;HTA&#8221;) of <span style="color:#000000;">pharmaceutical</span> products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including France, Germany, Ireland, Italy and Sweden. The HTA process, which is governed by the national laws of these countries, is the procedure according to which the assessment of the public health impact, therapeutic impact, and the economic and societal impact of use of a given <span style="color:#000000;">pharmaceutical</span> product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual <span style="color:#000000;">pharmaceutical</span> products as well as their potential implications for the healthcare system. Those elements of <span style="color:#000000;">pharmaceutical</span> products are compared with other treatment options available on the market. The outcome of HTA regarding specific <span style="color:#000000;">pharmaceutical</span> products will often influence the pricing and reimbursement status granted to <span style="color:#000000;">pharmaceutical</span> products by the regulatory authorities of individual EU Member States. A negative HTA of one of our products by a leading and recognized HTA body could not only undermine our ability to obtain reimbursement for such product in the EU Member State in which such negative assessment was issued, but also in other EU Member States. For example, EU Member States that have not yet developed HTA mechanisms could rely to some extent on the HTA performed in other countries with a developed HTA framework, when adopting decisions concerning the pricing and reimbursement of a specific <span style="color:#000000;">pharmaceutical</span> product.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 31, 2018, the European Commission adopted a proposal for a regulation on health technology assessment. This legislative proposal is intended to boost EU level cooperation among EU Member States in assessing health technologies, including new <span style="color:#000000;">pharmaceutical</span> products, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The proposal provides that EU Member States will be able to use common HTA tools, methodologies and procedures across the European Union, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (<span style="font-style:italic;">e.g.</span>, economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement. While EU Member States could choose to delay participation in the joint work until three years after the rules enter into force, it would become mandatory after six years.The European Commission has stated that the role of the draft HTA regulation is not to influence pricing and reimbursement decisions in the individual EU Member States, but there can be no assurance that the draft HTA regulation will not have effects on pricing and reimbursement decisions if and when the draft HTA regulation comes into force. On June 22, 2021, following three years of discussions in the Council of the European Union, the Council of the European Union and the European Parliament reached a provisional agreement on the draft HTA regulation. The European Parliament and the Council of the European Union are now expected to formally adopt the content of the agreement in the coming months.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain reimbursement or pricing approval in some countries, including the EU Member States, we may be required to conduct studies that compare the cost-effectiveness of our product candidates to other therapies that are considered the local standard of care. There can be no assurance that any country will allow favorable pricing, reimbursement and market access conditions for any of our products, or that we will be feasible to conduct additional cost-effectiveness studies, if required.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain of the EU Member States, <span style="color:#000000;">pharmaceutical</span> products that are designated as orphan <span style="color:#000000;">pharmaceutical</span> products may be exempted or waived from having to provide certain clinical, cost-effectiveness and other economic data in connection with their filings for pricing/reimbursement approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">European Data Laws</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collection and use of personal health data and other personal information in the European Union is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May 2018 and related implementing laws in individual EU Member States. Under the GDPR, personal data can only be transferred to third countries in compliance with specific conditions for cross-border data transfers. A &#8220;third country&#8221; is a country other than the EU Member States and the three additional European Economic Area countries (Norway, Iceland and Liechtenstein) that have adopted a national law implementing the GDPR. Appropriate safeguards are required to enable transfers of personal data from the EU and EEA Member States. This status has a number of significant practical consequences, in particular for international data transfers, competent supervisory authorities and enforcement of the GDPR. The GDPR increased responsibility and liability in relation to personal data that we process. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GDPR imposes a number of strict obligations and restrictions on the ability to process (processing includes collection, analysis and transfer of) personal data of individuals within the European Union and in the EEA, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data or personal health data, notification of data processing obligations to the national data protection authorities and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national implementing legislation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GDPR also prohibits the transfer of personal data to countries outside of the European Union/EEA (including the United States) that are not considered by the European Commission to provide an adequate level of data protection, except if the data controller meets very specific requirements such as the use of standard contractual clauses (&#8220;SCCs&#8221;), issued by the European Commission. In this respect recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data from the EU/EEA. For example, following the Schrems II decision of the Court of Justice of the European Union on July 16, 2020, in which the Court invalidated the Privacy Shield under which personal data could be transferred from the EU/EEA to U.S. entities who had self-certified under the Privacy Shield scheme, there is uncertainty as to the general permissibility of international data transfers under the GDPR. The Court did not invalidate the then current SCCs, but ruled that data exporters relying on these SCCs are required to verify, on a case-by-case basis, if the law of the third country ensures an adequate level of data protection that is essentially equivalent to that guaranteed in the EU/EEA. In light of the implications of this decision we may face difficulties regarding the transfer of personal data from the European Union/EEA to third countries. However, on June&#160;4, 2021 the EU Commission has issued a new set of SCCs for data transfers from controllers of processors in the EU/EEA to controllers or processors established outside the EU/EEA. These SCCs replace the old sets of SCCs that were adopted under the previous European Data Protection Directive 95/46. Since September&#160;27, 2021, it is no longer possible to conclude contracts incorporating these previous versions of the SCCs. In addition, for contracts concluded before September&#160;27, 2021, it is still possible to rely on the previous SCCs until the end of an additional 15 months transitional period (until December&#160;27, 2022), provided that the processing operations which are the subject matter of the contract remain unchanged and reliance on previous SCCs ensures that the transfer is subject to appropriate safeguards. On November&#160;11, 2021, the European Data Protection Board has adopted recommendations on such appropriate safeguards that supplement transfer mechanisms. These recommendations aim to assist data exporters with their duty to identify and implement appropriate supplementary measures where they are needed to ensure an essentially equivalent level of protection to the personal data they transfer to third countries.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU&#160;Member States may result in significant monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and in certain cases their directors and officers as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the European Union. Guidance developed at both EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is, moreover, a growing trend towards required public disclosure of clinical trial data in the European Union which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation, EMA disclosure initiatives and voluntary commitments by industry. Failing to comply with </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the Clinical Trials Regulation and the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GDPR</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, further adds to the complexity that we face with regard to data protection regulation.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to the transfer of data from the European Union to the United Kingdom, the TCA provided for a transition period of up to six months as of January&#160;1, 2021 to enable the European Commission to complete its adequacy assessment of the UK&#8217;s data protection laws. On June&#160;28, 2021 the European Commission adopted two adequacy decisions for the United Kingdom &#8211; one under the GDPR and the other for the Law Enforcement Directive. Personal data may now freely flow from the European Union to the United Kingdom since the United Kingdom is deemed to have an adequate data protection level. Additionally, following the UK's withdrawal from the European Union and the EEA, companies have to comply also with the UK&#8217;s data protection laws (including the GDPR as incorporated into UK national law), the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four years after their entry into force.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Promotional Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of <span style="color:#000000;">pharmaceutical</span> products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the UK has left the EU, as mentioned above, it should be noted that the UK still has the strictest anti-bribery regime in Europe, the UK Bribery Act 2010. The Act is applicable English law and continues to apply to any company incorporated in or &#8220;carrying on business&#8221; in the United Kingdom, irrespective of where in the world the alleged bribery activity occurs. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:1.87%;text-indent:2.67%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Legislation Regarding Marketing, Authorization and Pricing of Pharmaceutical Products in the European Union</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:5.25%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other core legislation relating to the marketing, authorization and pricing of pharmaceutical products in the European Union includes the following:&#160;&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Directive 2001/83/EC, establishing the requirements and procedures governing the marketing authorization for medicinal products for human use, as well as the rules for the constant supervision of products following authorization.&#160;&#160;This Directive has been amended several times, most recently by Directive 2012/26/EU regarding pharmacovigilance, and the Falsified Medicines Directive 2011/62/EU.&#160;&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Regulation (EC) 726/2004, as amended, establishing procedures for the authorization, supervision and pharmacovigilance of medicinal products for human and veterinary use and establishing the EMA.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Regulation (EC) 469/2009, establishing the requirements necessary to obtain a Supplementary Protection Certificate, which extends the period of patent protection applicable to medicinal products at the EU-level.&#160;&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Directive 89/105/EEC, ensuring the transparency of measures taken by the European Union member states to set the prices and reimbursements of medicinal products. Specifically, while each member state has competence over the pricing and reimbursement of medicines for human use, they must also comply with this Directive, which establishes procedures to ensure that member state decisions and policies do not obstruct trade in medicinal products. The European Commission proposed to repeal and replace Directive 89/105/EEC, but this proposal was withdrawn in 2015.&#160;&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Directive 2003/94/EC, laying down the principles of good manufacturing practice in respect of medicinal products and investigational medicinal products for human use <span style="color:#000000;">(the "GMP Directive")</span>.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Directive 2005/28/EC of April 8, 2005, laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorization of the manufacturing or importation of such products (the "GCP Directive").</span><span style="font-size:11pt;">&#160;&#160;</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.94%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">New Legislation and Regulations</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.94%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, legislation is drafted, introduced and passed in the European Union, its member states and other states of Europe that could significantly change the statutory provisions governing the testing, approval, manufacturing, marketing, coverage </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and reimbursement of pharmaceutical products. In addition to new legislation, pharmaceutical regulations and policies are often revised or interpreted by the EMA and national agencies in ways that may significantly affect our business and our products.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.94%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the United Kingdom formally left the European Union on January&#160;31, 2020 and the transition period, during which EU laws continued to apply to the United Kingdom, expired on December&#160;31, 2020, EU laws now only apply to the United Kingdom in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland. However, the European Union and the United Kingdom have concluded the TCA, which entered into force on May 1, 2021. Since the TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards, future UK pharmaceutical regulations and product standards may differ from those in the European Union. To that end, the UK&#8217;s MHRA launched a comprehensive consultation on September&#160;16, 2021 with proposals to amend the regulatory framework for medical devices in the UK. The stated objectives of the proposals include expansion of the scope of the UK Regulations, remove trade barriers, further the availability of medical devices and improve the favourability of the UK market. The consultation period closes on November 25, 2021 with a view to new regulations coming into force on July&#160;1 2023 with appropriate transitional measures.&#160;&#160;&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical Coverage, Pricing and Reimbursement<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as, in the United States, Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor&#8217;s decision to provide coverage for a drug product does not necessarily imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on our investment in product development. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider a product to be cost effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, risk sharing, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals. As a result, the marketability of any product which receives regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, an increasing emphasis on managed care in the United States has increased and will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. In particular, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Even if favorable coverage and reimbursement status is attained for one or more products that receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements for any of our products.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Laws and Regulations<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with healthcare providers, physicians, third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal healthcare Anti-Kickback Statute prohibits, among other things, persons from soliciting, offering, receiving or providing any remuneration (in cash or in kind), directly or indirectly, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any item, facility or service for which payment may be made in whole or in part under a federal healthcare program such as Medicare and Medicaid&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">the federal&#160;Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits, among other things, U.S. corporations and persons acting on their behalf from offering, promising, authorizing or making payments to any foreign government official (including certain healthcare professionals in many countries), political party, or political candidate in an attempt to obtain or retain business or otherwise seek preferential treatment abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal False Claims Act, which may be enforced by the U.S. Department of Justice or private whistleblowers to bring civil actions (qui tam actions) on behalf of the federal government, imposes civil penalties, as well as liability for treble damages and for attorneys&#8217; fees and costs, on individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, making a false statement material to a false or fraudulent claim, or improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the Department of Health and Human Services&#8217; Civil Monetary Penalties authorities, which imposes administrative sanctions for, among other things, presenting or causing to be presented false claims for government payment and providing remuneration to government health program beneficiaries to influence them to order or receive healthcare items or services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal and civil liability for, among other conduct, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes criminal and civil liability and penalties on those who violate requirements, including mandatory contractual terms, intended to safeguard the privacy, security, transmission and use of individually identifiable health information&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal false statements statute relating to healthcare matters prohibits falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Physician Payment Sunshine Act requires manufacturers of drugs (among other products) to report to the Centers for Medicare and Medicaid Services within the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals, as well as physician ownership and investment interests in the reporting manufacturers&#59;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">similar state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by nongovernmental third-party payors, including private insurers&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">certain state laws require pharmaceutical companies to comply with voluntary compliance guidelines promulgated by a pharmaceutical industry association and relevant compliance guidance issues by HHS Office of Inspector General&#59; bar drug manufacturers from offering or providing certain types of payments or gifts to physicians and other health care providers&#59; and/or require disclosure of gifts or payments to physicians and other healthcare providers. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various state and foreign laws also govern the privacy and security of health information in some circumstances&#59; many of these laws differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain Financial Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial information required in this Item 1 is included in Part IV, Item&#160;15 of this Annual Report on Form 10-K.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Human Capital </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Management</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Arrowhead Employees</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021, Arrowhead employed 329 fulltime employees at three facilities in the US, including Pasadena, CA, Madison, WI and San Diego, CA.&#160;&#160;During fiscal year 2021, we grew our capabilities across the three sites by adding 97 new employees.&#160;&#160;The new employees were hired to support and extend our clinical and preclinical pipeline, with hires in clinical development and operations, research, manufacturing, and general and administrative functions. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc. Employees by Geography</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of Employees as of September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Site</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pasadena, CA</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Madison, WI</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">198</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, CA</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to add additional employees in fiscal year 2022 with a focus on expanding our in-house manufacturing capacity, as well as increasing expertise and bandwidth in clinical and preclinical research and development.&#160;&#160;The Company continually evaluates the business need and opportunity and balances in-house expertise and capacity with outsourced expertise and capacity.&#160;&#160;Currently, we outsource substantial clinical trial work to clinical research organizations and certain drug manufacturing to contract manufacturers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug development is a complex endeavor which requires deep expertise and experience across a broad array of disciplines.&#160;&#160;Pharmaceutical companies both large and small compete for a limited number qualified applicants to fill specialized positions.&#160;&#160;To attract qualified applicants to the Company, Arrowhead offers a total rewards package consisting of base salary and cash target bonus targeting the 50<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> to 75<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> percentile of market based on geography, a comprehensive benefit package and equity compensation for every employee.&#160;&#160;Bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility. Actual bonus payout is based on performance.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A large majority of Arrowhead&#8217;s employees have obtained advanced degrees in their professions.&#160;&#160;Arrowhead supports our employees&#8217; further development with individualized development plans, mentoring, coaching, group training, conference attendance and financial support including tuition reimbursement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Response to COVID-19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning in March 2020, Arrowhead has supported our employees and government efforts to curb the COVID-19 pandemic through a multifaceted communication, infrastructure, and behavior modification and enforcement effort:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Establishing clear and regular COVID-19 policies, safety protocols, and updates to all employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Decreasing density and increasing physical distancing in workspaces for employees working onsite by scheduling adjustments and adding work from home flexibility&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Adjusting attendance policies to encourage those who are sick to stay home&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increasing cleaning protocols across all locations&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Providing additional personal protective equipment and cleaning supplies&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Implementing protocols to address actual and suspected COVID-19 cases and potential exposure&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Prohibiting all domestic and international non-essential travel for all employees through mid-2021&#894; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Complying with local and national public health advisories.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020 through June 2021, we provided a childcare subsidy to support employees who incurred additional expenses related to the loss of in person schooling and childcare.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Diversity and Inclusion</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead is committed maintaining a welcome, healthy and equitable environment where all employees can excel and contribute to our mission of bringing safe and effective medicine to patients in need.&#160;&#160;In 2021, we initiated formal training and processes to promote awareness of inclusion and diversity issues for management and employees, including anti-bias training and employee outreach and engagement.&#160;&#160;In the coming year, we will continue and extend those efforts.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investor Information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our website address is <span style="text-decoration:underline;color:#000000;">http://www.arrowheadpharmaceuticals.com.</span>&#160;&#160;Our reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, including our annual reports on Form 10-K, our quarterly reports on Form 10-Q and our current reports on Form 8-K, and amendments to those reports, are accessible through our website, free of charge, as soon as reasonably practicable after these reports are filed electronically with, or otherwise furnished to, the SEC. These SEC reports can be accessed through the &#8220;Investors&#8221; section of our website. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding Arrowhead and other issuers that file electronically with the SEC. The SEC&#8217;s Internet website address is <span style="text-decoration:underline;color:#000000;">http://www.sec.gov</span>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:10.27%;text-indent:-10.27%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1A.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Risk_Factors">RISK FACTORS</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should carefully consider the risks discussed below and all of the other information contained in this report in evaluating us and an investment in our securities. If any of the following risks and uncertainties should occur, they could have a material adverse effect on our business, financial condition or results of operations. In that case, the trading price of our Common Stock could decline. Many of the following risks and uncertainties may be exacerbated by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. Additionally, we note that we have accrued net losses annually since inception given the stage of our drug development. We urge you to consider our likelihood of success and prospects in light of the risks, expenses and difficulties frequently encountered by entities at similar stages of development.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Risks Related to Our Discovery, Development, and Commercialization of Medicines</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our results of operations and financial condition may be adversely affected by the novel coronavirus (COVID-19) pandemic and other public health epidemics.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business and its operations, including but not limited to our research and development activities and our supply chain, could be adversely affected by health epidemics in regions where we have business operations, and such health epidemics could cause significant disruption in the operations of third parties upon whom we rely. In March 2020, the World Health Organization declared the COVID-19 outbreak a global pandemic. In response to public health directives and orders related to COVID-19, we implemented work-from-home policies for substantially all of our employees to the extent work can be performed effectively at home. The effects of executive and similar government orders, shelter-in-place orders and our work-from-home policies may negatively impact our productivity, disrupt our business, increase our expenses, including costs associated with preventive and precautionary measures that we, companies with which we conduct business, and governments are taking, and delay our clinical trials and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, results of operations and financial condition.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarantines, shelter-in-place, executive and similar government orders, or the perception that such orders, shutdowns or other restrictions, including vaccination requirements or mandates, on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, have impacted and may continue to impact personnel at our business partners in the United States and other countries, or our access to raw materials for our research and development facility discovery efforts, which would disrupt our supply chain.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our clinical trials and preclinical programs have been and continue to be affected by the COVID-19 pandemic. For example, we have experienced delays in our earlier stage programs due to a shortage in non-human primates which are critical for our preclinical programs.&#160;&#160;Additionally, we have experienced delays in enrollment in our clinical trials.&#160;&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company&#8217;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters in Pasadena, California have continued to operate with limited impact, other than for enhanced safety measures, including work from home policies. However, the Company cannot predict the impact that the progression of COVID-19 will have on future financial results due to a variety of factors including the ability of the Company&#8217;s clinical sites to continue to enroll subjects, the ability of the Company&#8217;s suppliers to continue to operate, the continued good health and safety of the Company&#8217;s employees, and ultimately the length of the COVID-19 pandemic, which in turn may be impacted by the efficacy, distribution and public acceptance of vaccines and treatments. If COVID-19 continues to spread in the United States and elsewhere, including as a result of mutations or variants, we may experience additional disruptions that could severely impact our business, preclinical studies and clinical trials, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays in receiving authorization from local regulatory authorities to initiate any planned clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays or difficulties in enrolling patients in our clinical trials&#59;&#160;&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>diversion of healthcare resources away from the conduct of clinical trials, including the&#160;diversion of hospitals serving as our clinical trial sites and hospital staff supporting the&#160;conduct of our clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>interruption of key clinical trial activities, such as clinical trial site monitoring and data entry and verification, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the completeness and integrity of clinical trial data and, as a result, the determine the outcomes of the trial&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risk that participants enrolled in our clinical trials will not be able to travel to our clinical trial sites as a result of quarantines or other restrictions resulting from COVID-</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>risk that participants enrolled in our clinical trials will not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>interruptions or delays in preclinical studies due to restricted or limited operations at our research and development laboratory facilities&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources, forced furlough of government employees or diversion of government resources to focus on the COVID-19 pandemic&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>refusal of the FDA to accept data from clinical trials in affected geographies&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>interruption or delays to our clinical activities.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the long-term economic impact brought by COVID-19, and the duration of such impact, may be difficult to assess or predict, the widespread pandemic has resulted in significant disruption of global financial markets, which could reduce our ability to access capital and negatively affect our future liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 and related government orders and restrictions could materially affect our business and the value of our common stock.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to evolve rapidly. The ultimate impact of the COVID-19 pandemic or a similar public health emergency is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems, or the global economy as a whole. However, any one or a combination of these events could have an adverse effect on our results of operations and financial condition.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">There are substantial risks inherent in attempting to commercialize our new drugs, and, as a result, we may not be able to successfully develop products for commercial use.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development efforts involve therapeutics based on RNA interference and our delivery systems, which are largely unproven technologies. Our scientists and engineers are working on developing technology in the early stages. However, such technology&#8217;s commercial feasibility and acceptance are unknown. Scientific research and development requires significant amounts of capital and takes a long time to reach commercial viability if it can be achieved at all. To date, our research and development projects have not produced commercially viable drugs and may never do so. During the research and development process, we may experience technological barriers that we may be unable to overcome. Because we use platform technology to develop drug candidates, toxicology signals that may emerge in the course of testing of one particular candidate may apply broadly across our drug candidate platform. Further, certain underlying premises in our development programs are not proven and many of the drug targets that we are pursuing have not yet been validated clinically.&#160;&#160;For instance, the reduction of the production of mutant alpha-1 antitrypsin in the liver may not lead to a reduction of globules in the liver, and even if it leads to a reduction in such globules, this may not lead to other beneficial hepatic changes.&#160;&#160;It is also unknown at this time what changes in the liver may be required to gain regulatory approval and/or favorable reimbursement for a drug that reduces the production of mutant alpha-1 antitrypsin in the liver.&#160;&#160;Similar uncertainties and risks exist that are specific to each of our development programs.&#160;&#160;Because of these and similar uncertainties, it is possible that no commercial products will be successfully developed. If we are unable to successfully develop commercial products, we will be unable to generate revenue or build a sustainable or profitable business.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">There can be no assurance that our product candidates will obtain regulatory approval.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sale of human therapeutic products in the United States and foreign jurisdictions is subject to extensive and time consuming regulatory approval which requires, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">controlled research and human clinical testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishment of the safety and efficacy of the product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">government review and approval of a submission containing manufacturing, pre-clinical and clinical data&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adherence to cGMP regulations during production and storage.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product candidates we currently have under development will require significant development, pre-clinical and clinical testing and investment of significant funds to gain regulatory approval before they can be commercialized. The results of our research and human clinical testing of our products may not meet regulatory requirements.&#160;&#160;Some of our product candidates, if approved, will require the completion of post-market studies. There can be no assurance that any of our products will be further developed and approved. The process of completing clinical testing and obtaining required approvals will take a number of years and require the use of substantial resources. Further, there can be no assurance that product candidates employing a new technology will be shown to be safe and effective in clinical trials or receive applicable regulatory approvals. If we fail to obtain regulatory approvals for any or all of our products, we will not be able to market such product and our operations may be adversely affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If testing of a particular product candidate does not yield successful results, then we will be unable to commercialize that product candidate.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must demonstrate our product candidates&#8217; safety and efficacy in humans through extensive clinical testing. Our research and development programs are at an early stage of development. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of any products, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the results of pre-clinical studies may be inconclusive, or they may not be indicative of results that will be obtained in human clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">safety and efficacy results attained in early human clinical trials may not be indicative of results that are obtained in later clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">after reviewing test results, we may abandon projects that we might previously have believed to be promising&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we or our regulators may suspend or terminate clinical trials because the participating subjects or patients are being exposed to unacceptable health risks&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our product candidates may not have the desired effects or may include undesirable side effects or other characteristics that preclude regulatory approval or limit their commercial use if approved.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Topline data may not accurately reflect the complete results of a particular study or trial.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may publicly disclose topline or interim data from time to time, which is based on a preliminary analysis of then-available efficacy and safety data such as the data reported from the AROAAT2002, AROANG31001, and AROAPOC31001 clinical studies which are based on preliminary analysis of key efficacy and safety data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimations, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or drug and our company in general. In addition, the information we may publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from a future analysis of results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">It may take us longer than we project to complete clinical trials, and we may not be able to complete them at all.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although for planning purposes, we project the commencement, continuation and completion of our clinical trials, a number of factors, including scheduling conflicts with participating clinicians and clinical institutions, and difficulties in identifying or enrolling patients who meet trial eligibility criteria, may cause significant delays. Enrollment of clinical trials may be particularly difficult in orphan diseases or limited-sized patient populations.&#160;&#160;The FDA or other regulatory bodies may require additional, longer or broader clinical trials to establish safety and effectiveness, notwithstanding guidance the Company may have received from those bodies during clinical trial planning and execution.&#160;&#160;Further, the cost for conducting clinical trials is significant and if our cash resources become limited we may not be able to commence, continue, and/or complete our clinical trials.&#160;&#160;We may not commence or complete clinical trials involving any of our product candidates as projected or may not conduct them successfully.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Breakthrough Therapy designation for&#160;ARO-AAT&#160;may not lead to a faster development or review process.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been granted a Breakthrough Therapy designation for&#160;ARO-AAT&#160;in the United States for the treatment of liver disease associated with AATD.&#160;&#160;Breakthrough Therapy designation is intended to facilitate the development and expedite the review of new therapies to treat serious conditions with unmet medical needs by providing sponsors with the opportunity for frequent interactions and additional drug development guidance with the FDA and its senior managers.Breakthrough Therapy designation applies to the combination of the drug candidate and the specific indication for which it is being studied. Product candidates that receive Breakthrough Therapy designation may receive more frequent interactions with the FDA regarding the product candidate&#8217;s development plan and clinical trials and may be eligible for the FDA&#8217;s Rolling Review.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:2.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite receiving</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Breakthrough Therapy</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> designation, ARO-AAT may not actually receive faster clinical development or regulatory review or approval any sooner than other product candidates that do not have such designation, or at all. Furthermore, such a designation does not increase the likelihood that ARO-AAT will receive marketing approval in the United States. The FDA may also</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> rescind</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breakthrough Therapy designation</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> if it determines that ARO-AAT no longer meets the relevant criteria.</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if our product candidates are approved for commercialization, failure to comply with regulatory requirements or unanticipated problems with our products may result in various adverse actions such as the suspension or withdrawal of one or more of our products, closure of a facility or enforcement of substantial penalties or fines.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval to sell any of our product candidates is received, regulatory agencies will subject any marketed product(s), as well as the manufacturing facilities, to continual review and periodic inspection. If previously unknown problems with a product or with regulatory requirements are discovered, such as adverse events of unanticipated severity or frequency, problems with a manufacturing process or laboratory facility, or failure to comply with applicable regulatory approval requirements, a regulatory agency may impose restrictions or penalties on that product or on us. Such restrictions or penalties may include, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on the marketing or manufacturing of the product, the withdrawal of the product from the market or product recalls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">warning letters or holds on clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product seizure or detention, or refusal to permit the import or export of our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">closure of the facility, enforcement of substantial fines, injunctions, or the imposition of civil or criminal penalties.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if our product candidates are approved for commercialization, future regulatory reviews or inspections may result in the suspension or withdrawal of one or more of our products, closure of a facility or enforcement of substantial fines.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval to sell any of our product candidates is received, regulatory agencies will subject any marketed product(s), as well as the manufacturing facilities, to continual review and periodic inspection. If previously unknown problems with a product or manufacturing and laboratory facility are discovered, or we fail to comply with applicable regulatory approval requirements, a regulatory agency may impose restrictions on that product or on us. The agency may require the withdrawal of the product from the market, closure of the facility or enforcement of substantial fines.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by clinical trial participants, consumers, health-care providers, pharmaceutical companies, or others selling our products. If we cannot successfully defend ourselves against these claims, we may incur substantial liabilities. Regardless of merit or eventual outcomes of such claims, product liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">decreased demand for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">impairment of our business reputation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawal of clinical trial participants&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs of litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">substantial monetary awards to patients or other claimants&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">loss of revenues.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our insurance coverage may not be sufficient to reimburse us for all expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of any approved drug candidate will depend in part on the availability of coverage and reimbursement from third-party payers such as government insurance programs, including Medicare and Medicaid, private health insurers, health maintenance organizations and other health care related organizations, who are increasingly challenging the price of medical products and services. Accordingly, coverage and reimbursement may be uncertain. Adoption of any drug by the medical community may be limited if third-party payers will not offer coverage. Additionally, significant uncertainty exists as to the reimbursement status of newly approved drugs. &#160;Cost control initiatives may decrease coverage and payment levels for any drug and, in turn, the price that we will be able to charge and/or the volume of our sales. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payers. Any denial of private or government payer coverage or inadequate reimbursement could harm our business and reduce our revenue. If we partner with third parties with respect to any of our product candidates, we may be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reliant on that partner to obtain reimbursement from government and private payors for the drug, if approved, and any failure of that partner to establish adequate reimbursement could have a negative impact on our revenues and profitability.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, both the federal and state governments in the United States and foreign governments continue to propose and pass new legislation, regulations, and policies affecting coverage and reimbursement rates, which are designed to contain or reduce the cost of health care.&#160;&#160;Further federal and state proposals and healthcare reforms are likely, which could limit the prices that can be charged for the product candidates that we develop and may further limit our commercial opportunity. There may be future changes that result in reductions in potential coverage and reimbursement levels for our product candidates, if approved and commercialized, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If future reimbursement for approved product candidates, if any, is substantially less than we project, or rebate obligations associated with them are substantially greater than we expect, our future net revenue and profitability could be materially diminished.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not enjoy the market exclusivity benefits of our orphan drug designations.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we may obtain orphan designations in the treatment of certain diseases our products are intended to treat, the designation may not be applicable to any particular product we might get approved and that product may not be the first product to receive approval for that indication.&#160;&#160;Under the Orphan Drug Act, the first product with an orphan designation receives market exclusivity, which prohibits the FDA from approving the &#8220;same&#8221; drug for the same indication.&#160;&#160;The FDA has stated that drugs can be the &#8220;same&#8221; even when they are not identical but has not provided guidance with respect to how it will determine &#8220;sameness&#8221; for RNAi drugs.&#160;&#160;It is possible that another RNAi drug could be approved for the treatment of a disease one of our orphan products is intended to treat before our product is approved, which means that we may not obtain orphan drug exclusivity and could also potentially be blocked from approval until the first product&#8217;s orphan drug exclusivity period expires or we demonstrate, if we can, that our product is superior. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Further, orphan drug exclusivity can be lost if the FDA later determines that the request for designation was materially defective or if the applicant is unable to assure the availability of sufficient quantities of the drug to meet the needs of patients with the disease or condition for which the drug was designated.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our success depends on the attraction and retention of senior management and scientists with relevant expertise.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future success depends to a significant extent on the continued services of our key employees, including our senior scientific, technical and managerial personnel. We do not maintain key person life insurance for any of our executives and we do not maintain employment agreements with many senior employees. Competition for qualified employees in the pharmaceutical industry is high, and our ability to execute our strategy will depend in part on our ability to continue to attract and retain qualified scientists, management and other employees. This will depend in part on our ability to create and maintain a desirable workplace culture, which may be impacted by the long-term effects of the COVID-19 pandemic on the nature of the office environment and employee preferences for remote working. If we are unable to find, hire and retain qualified individuals, we will have difficulty implementing our business plan in a timely manner, or at all.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Risks Related to Our Intellectual Property</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed rights to pending patents and have filed and expect to continue to file patent applications. Researchers sponsored by us may also file patent applications that we may need to license. Such patent applications may not be available for licensing or may not be economically feasible to license.&#160;&#160;Certain of our patents may not be granted or may not contain claims of the necessary breadth because, for example, prior patents exist.&#160;&#160;If a particular patent is not granted, the value of the invention described in the patent would be diminished. Further, even if these patents are granted, they may be difficult to enforce. Even if ultimately successful, efforts to enforce our patent rights could be expensive, distracting for management, cause our patents to be invalidated or held unenforceable, and thus frustrate commercialization of products. Even if patents are issued and are enforceable, others may develop similar, superior or parallel technologies to any technology developed by us and not infringe on our patents.&#160;&#160;Our technology may prove to infringe upon patents or rights owned by others. Patent prosecution and maintenance is expensive, and we may be forced to curtail prosecution or maintenance if our cash resources are limited. Thus, the patents held by or licensed to us may not afford us any meaningful competitive advantage. If we are unable to derive value from our licensed or owned intellectual property, the value of your investment may decline.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are party to technology license agreements with third parties that require us to satisfy obligations to keep them effective and, if these agreements are terminated, our technology and our business would be seriously and adversely affected.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to license agreements to incorporate third party proprietary technologies into our drug products under development. These license agreements require us to pay royalties and satisfy other conditions. If we fail to satisfy our obligations under these agreements, the terms of the licenses may be materially modified, such as by rendering currently exclusive licenses non-exclusive, or it may give our licensors the right to terminate their respective agreement with us, which could limit our ability to implement our current business plan and harm our business and financial condition.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to patent infringement claims, which could result in substantial costs and liability and prevent us from commercializing our potential products.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the intellectual property landscape in the fields in which we participate is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate without infringing on third party rights. However, if granted marketing approval, we are currently aware of certain patent rights held by third parties that, if found to be valid and enforceable, could be alleged to render one or more of our drug candidates infringing. If a claim should be brought and is successful, we may be required to pay substantial damages, be forced to abandon any affected drug candidates and/or seek a license from the patent holder. In addition, any patent infringement claims brought against us, whether or not successful, may cause us to incur significant expenses and divert the attention of our management and key personnel from other business concerns. These could negatively affect our results of operations and prospects. We cannot be certain that patents owned or licensed by us will not be challenged, potentially successfully, by others.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if our product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our customers, licensees, and other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as a result of these claims. The claims may require us to initiate or defend protracted and costly litigation on behalf of customers, licensees, and other parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, we may be unable to continue selling such products.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We license patent rights from third-party owners and we rely on such owners to obtain, maintain and enforce the patents underlying such licenses.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to a number of licenses that give us rights to third-party intellectual property that is necessary or useful for our business. We also expect to enter into additional licenses to third-party intellectual property in the future.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, in particular, those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents are issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our technology licensed from various third parties may be subject to retained rights.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. As our organization grows, so does the risk of unauthorized disclosure of confidential information. In addition, while the company undertakes efforts to protect its trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to effectively secure first-tier technologies when competing against other companies or investors.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future success may require that we acquire patent rights and know-how to new or complimentary technologies. However, we compete with a substantial number of other companies that may also compete for technologies we desire. In addition, many venture capital firms and other institutional investors, as well as other pharmaceutical and biotech companies, invest in companies seeking to commercialize various types of emerging technologies. Many of these companies have greater financial, scientific and commercial resources than us. Therefore, we may not be able to secure the technologies we desire. Furthermore, should any commercial undertaking by us prove to be successful, there can be no assurance competitors with greater financial resources will not offer competitive products and/or technologies.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Risks Related to Our Business Model</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business model assumes we will generate revenue by, among other activities, marketing or out-licensing the products we develop.&#160;&#160;Our drug candidates are in the early stages of development and because we have a short development history with both RNA interference and our delivery technologies, there is a limited amount of information about us upon which you can evaluate our business and prospects.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no approved drugs and thus have not begun to market or generate revenues from the commercialization of any products. We have only a limited history upon which one can evaluate our RNAi therapeutic business as our drug candidates are still at an early stage of development. Thus, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. For example, to execute our business plan, we will need to successfully:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Execute product development activities using unproven technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Build, maintain, and protect a strong intellectual property portfolio&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Demonstrate safety and efficacy of our drug candidates in multiple human clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Receive FDA approval and approval from similar foreign regulatory bodies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Gain market acceptance for the development and commercialization of any drugs we develop&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Ensure our products are reimbursed by commercial and/or government payors at a rate that permits commercial viability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Develop and maintain successful strategic relationships with suppliers, distributors, and commercial licensing partners&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Manage our spending and cash requirements as our expenses will increase in the near term if we add programs and additional preclinical and clinical trials&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Effectively market any products for which we obtain marketing approval.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unsuccessful in accomplishing these objectives, we may not be able to develop products, raise capital, expand our business or continue our operations.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may need to establish additional relationships with strategic and development partners to fully develop our drug candidates and market any approved products.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over the past several years we have entered into license and collaboration agreements with Takeda, Janssen, Amgen and Horizon. Our business strategy includes obtaining additional collaborations with other pharmaceutical and biotech companies to support the development of our RNAi therapeutics and other drug candidates. We do not possess all of the financial and development resources necessary to develop and commercialize products that may result from our technologies. Unless we expand our product development capacity and enhance our internal marketing capability, we may need to make appropriate arrangements with strategic partners to develop and commercialize any drug candidates that may be approved. We may not be able to attract such partners, and even if we are able to enter into such partnerships, the terms may be less favorable than anticipated. Further, entering into partnership agreements may limit our commercialization options and/or require us to share revenues and profits with our partners. If we do not find appropriate partners, or if our existing arrangements or future agreements are not successful, our ability to develop and commercialize products could be adversely affected. Even if we are able to find collaborative partners, the overall success of the development and commercialization of product candidates in those programs will depend largely on the efforts of other parties and will be beyond our control. In addition, in the event we pursue our commercialization strategy through collaboration or licenses to third parties, there are a variety of technical, business and legal risks, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may not be able to control the amount and timing of resources that our collaborators may be willing or able to devote to the development or commercialization of our drug candidates or to their marketing and distribution&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates or that result in costly litigation or arbitration that diverts our management&#8217;s resources.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any of the above events or other related events could impair our ability to generate revenues and harm our business and financial condition.</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to generate milestone and royalty payments under our current and potential future licensing and collaboration agreements is substantially controlled by our partners, and as such, we will likely need other sources of financing to continue to develop our internal drug candidates.&#160;&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For instance, under our licensing and collaboration agreements with Amgen, Janssen, Takeda and Horizon, our partners substantially control clinical development and commercialization for all of the candidates covered under those agreements. To the extent that (i) our partners&#8217; interests in advancing these candidates or targets changes, (ii) unforeseen scientific issues with the candidates arise, or (iii) the pace at which our partners move the candidates through clinical trials toward commercialization slows, our ability to collect milestones and royalties may be significantly diminished.&#160;&#160;This would further cause us to rely upon other sources of financing to continue to develop our other internal drug candidates.&#160;&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may lose a considerable amount of control over our intellectual property and may not receive anticipated revenues in strategic transactions, particularly where the consideration is contingent on the achievement of development or sales milestones.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business model has been to develop new technologies and to utilize the intellectual property created through the research and development process to develop commercially successful products. If the acquirers of our technologies fail to achieve performance milestones, we may not receive a significant portion of the total value of any sale, license or other strategic transaction.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to achieve commercial acceptance of our drug candidates to generate revenues and achieve profitability.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our research and development efforts yield technologically feasible applications, we may not successfully develop commercial products. &#160;Drug development takes years of study in human clinical trials prior to regulatory approval, and, even if we are successful, it may not be on a timely basis. During our drug development period, superior competitive technologies may be introduced which could diminish or extinguish the potential commercial uses for our drug candidates. Additionally, the degree to which the medical community and consumers will adopt any product we develop is uncertain. The rate and degree of market acceptance of our products will depend on a number of factors, including the establishment and demonstration in the medical community of the clinical efficacy and safety of our products, their potential advantage over alternative treatments, and the costs to patients and third-party payors, including insurance companies and Medicare. Recent efforts in the United States and abroad to reduce overall healthcare spending has put significant pressure on the price of prescription drugs and certain companies have been publicly criticized for the relatively high cost of their therapies.&#160;&#160;These pressures may force us to sell any approved drugs at a lower price than we or analysts may anticipate or may result in lower levels of reimbursement and coverage from third parties.&#160;&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict whether significant commercial market acceptance for our products, if approved, will ever develop, and we cannot reliably estimate the projected size of any such potential market. Our revenue growth and achievement of consistent profitability will depend substantially on our ability to introduce products that will be accepted by the medical community. If we are unable to cost-effectively achieve acceptance of our technology among the medical establishment and patients, or if the associated products do not achieve wide market acceptance, our business will be materially and adversely affected.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on outside sources for various components and processes for our products.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third parties for various components and processes for our product candidates. We may not be able to achieve multiple sourcing because there may be no acceptable second source, other companies may choose not to work with us, or the component or process sought may be so new that a second source does not exist or does not exist on acceptable terms. There may be a disruption or delay in the performance of our third-party contractors, suppliers or collaborators which is beyond our control. If such third parties are unable to satisfy their commitments to us, the development of our products would be adversely affected. Therefore, it is possible that our development plans will have to be slowed down or stopped completely at times due to our inability to obtain required raw materials, components, and outsourced processes at an acceptable cost, if at all, or to get a timely response from vendors, particularly as a result of recent labor market and global supply chain constraints.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have limited manufacturing capability and must rely on third-party manufacturers to manufacture our clinical supplies and commercial products, if and when approved, and if they fail to meet their obligations, the development and commercialization of our products could be adversely affected. &#160;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited manufacturing capabilities and experience. Our drug candidates are composed of multiple components and require specialized formulations for which scale-up and manufacturing could be difficult. We have limited experience in such scale-up and manufacturing requiring us to depend on a limited number of third parties, who may not be able to deliver in a timely manner, or at all. In order to develop products, apply for regulatory approvals, and commercialize our products, we will need to develop, contract </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for, or otherwise arrange for the necessary manufacturing capabilities. Our internal GMP manufacturing capabilities are limited to small-scale production of material.&#160;&#160;There are a limited number of manufacturers that supply synthetic oligonucleotides. There are risks inherent in pharmaceutical manufacturing that could affect the ability of our contract manufacturers to meet our delivery time requirements or provide adequate amounts of material to meet our needs. Included in these risks are synthesis and purification failures and contamination during the manufacturing process, which could result in unusable product and cause delays in our development process, as well as additional expense to us.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, our product candidates have not yet been manufactured for commercial use. If any of our product candidates become approved for commercial sale, we will need to establish either internal or third-party manufacturing capacity. Manufacturing partner requirements may require us to fund capital improvements, perhaps on behalf of third parties, to support the scale-up of manufacturing and related activities. We may not be able to establish scaled manufacturing capacity for an approved product in a timely or economic manner, if at all. If we or our third-party manufacturers are unable to provide commercial quantities of such an approved product, we will have to successfully transfer manufacturing technology to a different manufacturer. Engaging a new manufacturer for such an approved product could require us to conduct comparative studies or utilize other means to determine bioequivalence of the new and prior manufacturers&#8217; products, which could delay or prevent our ability to commercialize such an approved product. If we or any of these manufacturers is unable or unwilling to increase its manufacturing capacity or if we are unable to establish alternative arrangements on a timely basis or on acceptable terms, the development and commercialization of such an approved product may be delayed or there may be a shortage in supply. Any inability to manufacture our product candidates or future approved drugs in sufficient quantities when needed would seriously harm our business. For example, recent global supply chain constraints have led to intermittent lab supply shortages, which are critical for our preclinical programs. While we are exploring alternative suppliers for certain critical materials, there can be no assurance that our efforts will be successful.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers of our approved products, if any, must comply with cGMP requirements relating to methods, facilities and controls used in the manufacturing, processing and packaging of the product, which are intended to ensure that drug products are safe and that they consistently meet applicable requirements and specifications.&#160;&#160;These requirements include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our approved products, if any, may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. These requirements are enforced by the FDA and other health authorities through periodic announced and unannounced inspections of manufacturing facilities.&#160;&#160;A failure to comply with these requirements or to provide adequate and timely corrective actions in response to deficiencies identified in an inspection may result in enforcement action, including warning letters, fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, plant shutdown, or the delay, withholding, or withdrawal of product approval. If the safety of any quantities supplied is compromised due to a manufacturer&#8217;s failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, which would seriously harm our business.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to conduct our clinical trials, and if they fail to fulfill their obligations, the development of our products may be adversely affected.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our clinical trials. We contract with certain third-parties to provide certain services, including site selection, enrollment, monitoring and data management services. We rely on these parties to carry out our clinical trials in compliance with GCP and other relevant requirements.&#160;&#160;Although we depend heavily on these parties, we do not control them and therefore we cannot be assured that these third-parties will adequately perform all of their contractual obligations to us. These third parties may face disruptions due to the COVID-19 pandemic that may affect our ability to initiate and complete our clinical studies.&#160;&#160;If our third-party service providers cannot adequately and timely fulfill their obligations to us, or if the quality and accuracy of our clinical trial data is compromised due to failure by such third parties to adhere to our protocols, GCP, or other regulatory requirements or if such third-parties otherwise fail to meet deadlines, our development plans may be delayed or terminated. Further, if clinical study results are compromised, then we may need to repeat the affected studies, which could result in significant additional costs and delays to us.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face competition from various entities including large pharmaceutical companies, small biotech companies, private companies, and research institutions.<span style="font-weight:normal;font-style:normal;">&#160;&#160;</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many&#160;of our competitors have greater financial resources and may have more experience in research and development, manufacturing, managing clinical trials and/or regulatory compliance than we do.&#160;&#160;Our competitors may compete with us for lead clinical trial investigators, clinical trial site locations and patient enrollment.&#160;&#160;These competitors may also compete with us on recruiting scientific and management personnel.&#160;&#160;Because our products are in the early stages of development, along with many of the competing products, and given unpredictability inherent in drug development, it is difficult to predict which third parties may provide the most competition, and on what specific basis that competition may be based.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may have difficulty expanding our operations successfully as we evolve from a company primarily involved in discovery and pre-clinical testing into one that develops and commercializes drugs.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that as we increase the number of product candidates we are developing we will also need to expand our operations. This expected growth may place a strain on our administrative and operational infrastructure and information technology systems. As product candidates we develop enter and advance through clinical trials, we will need to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities for us. As our operations expand due to our development progress, we expect that we will need to manage additional relationships with various collaborators, suppliers, and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial, information technology and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business and operations could suffer in the event of information technology system failures.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, ransomware and other cyber-attacks, human error, natural disasters, terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations and loss of intellectual property. For example, the loss of pre-clinical trial data or data from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory filings and development efforts and significantly increase our costs. Further, cybersecurity breaches may allow hackers access to our preclinical compounds, strategies, discoveries, trade secrets, and/or other confidential information.&#160;&#160;To the extent that any disruption or security breach were to result in a loss of or damage to our data, or inappropriate disclosure of confidential, proprietary or private information, we could incur liability or regulatory penalties, including under laws and regulations governing the protection of health and other personally identifiable information, we could lose valuable trade secret rights, the development of our product candidates could be delayed, and we could suffer reputational damage and damage to key business relationships.&#160;&#160;The risk of a cyber-security breach or other informational technology disruption, particularly through cyber-attacks, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We have experienced cyber-security attacks in the past, which to date have not had a material impact on our operations or development programs&#59; however&#59; there is no assurance that such impacts will not be material in the future.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research, development and manufacturing activities involve the use of potentially harmful biological materials as well as materials, chemicals and various radioactive compounds that could be hazardous to human health and safety or the environment. We store most of these materials and various wastes resulting from their use at our facility in Madison, Wisconsin pending ultimate use and disposal. We cannot completely eliminate the risk of contamination, which could cause interruption to our research and development and manufacturing efforts, injury to our employees and others, environmental damage, and liabilities under federal, state and local law.&#160;&#160;In such an event, we may be held liable for any resulting damages, and any liability could exceed our resources. Although we carry insurance in amounts and types that we consider commercially reasonable, we do not have insurance coverage for losses relating to an interruption of our research, development or manufacturing efforts caused by contamination, and the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be affected.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If a natural or man-made disaster strikes our research and development facility or otherwise affects our business, it could delay our progress developing our product candidates.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct research and development in facilities in Madison, Wisconsin and San Diego, California.&#160;&#160;The facilities and the equipment we use are costly to replace and require substantial lead time to repair or replace. Our facilities may be harmed by natural or man-made disasters, including, without limitation, earthquakes, floods, fires and acts of terrorism&#59; and if our facilities are affected by a disaster, or in some cases even a loss of power, our development efforts would be delayed and significant costs could be incurred.&#160;&#160;Significant delays in our development efforts could materially impact our ability to obtain regulatory approval and to commercialize our products.&#160;&#160;Any insurance we maintain against damage to our property and the disruption of our business due to disaster may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.&#160; In addition, our development activities could be harmed or delayed by a shutdown of the U.S. government, including the FDA.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation claims may result in financial losses or harm our reputation and may divert management resources.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the market price of a stock is volatile, holders of that stock have often initiated securities class action litigation against the company that issued the stock. We cannot predict with certainty the eventual outcome of such litigation, arbitration or third-party inquiry. We may not be successful in defending ourselves or asserting our rights in current or future lawsuits, investigations, or claims </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that have been or may be brought against us and, as a result, our business could be materially harmed. These lawsuits, arbitrations, investigations or claims may result in large judgments or settlements against us, any of which could have a negative effect on our financial performance and business. Additionally, lawsuits, arbitrations and investigations can be expensive to defend, whether or not the lawsuit, arbitration or investigation has merit, and the defense of these actions may divert the attention of our management and other resources that would otherwise be engaged in running our business.</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operations, including our relationships with healthcare providers, physicians and third-party payers, are subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which, in the event of a violation, exposes us to liability for criminal sanctions, civil penalties, and contractual damages, and reputational harm and diminished profits and future earnings.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, including any arrangements that we enter into with healthcare providers, physicians, and third-party payers, are subject to broadly applicable fraud and abuse and other healthcare laws and regulations. Such laws and regulations, including applicable U.S. federal and state healthcare laws and regulations, as well as foreign laws, such as the federal Anti-Kickback Statute, the False Claims Act, the Health Insurance Portability and Accountability Act of 1996, or the Foreign Corrupt Practices Act, may constrain our operation and the business or financial arrangements through which we can market, sell and distribute any drug candidates for which we obtain marketing approval. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to confirm that our business arrangements with third parties comply with applicable healthcare laws and regulations involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we become subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Risks Related to Our Financial Condition</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses since our inception and we expect that our operating losses will continue for the foreseeable future as we continue our drug development and discovery efforts. To achieve profitability, we must, either directly or through licensing and/or partnering relationships, meet certain milestones, successfully develop and obtain regulatory approval for one or more drug candidates and effectively manufacture, market and sell any drugs we successfully develop. Even if we successfully commercialize drug candidates that receive regulatory approval, we may not be able to realize revenues at a level that would allow us to achieve or sustain profitability. Accordingly, we may never generate significant revenue and, even if we do generate significant revenue, we may never achieve consistent profitability.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will require substantial additional funds to complete our research and development activities.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business currently does not generate the cash that is necessary to finance our operations. Subject to the success of the research and development programs of our company and our partners, and potential licensing or partnering transactions, we may need to raise additional capital to:&#160;<span style="font-size:1pt;">&#160;</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Fund research and development infrastructure and activities relating to the development of our drug candidates, including pre-clinical and clinical trials and manufacturing to support these efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Fund a commercialization infrastructure and activities related to the sale, marketing, customer support, and distribution of our drug products if and when they become approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Fund our general and administrative infrastructure and activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Pursue business development opportunities for our technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Add to and protect our intellectual property&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Retain our management and technical staff.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital needs depend on many factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The scope, duration, and expenditures associated with our research and development, including the progression of our clinical trials, with late-stage trials generally requiring greater capital than early-stage trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Regulatory requirements for our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The extent to which our research and development and clinical efforts are successful&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The outcome of potential partnering or licensing transactions, if any, and the extent to which our business development efforts result in the acquisition of new programs or technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Competing technological developments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our intellectual property positions, if any, in our products&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The regulatory approval process and regulatory standards for our drug candidates.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to raise additional funds through public or private equity offerings, debt financings or additional strategic alliances and licensing arrangements in the future to continue our operations. We may not be able to obtain additional financing on terms favorable to us, if at all. General market conditions may make it very difficult for us to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities, further dilution to our stockholders will result, which may substantially dilute the value of your investment. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants that could limit our flexibility in conducting future business activities and, in the event of insolvency, would be paid before holders of equity securities received any distribution of corporate assets. In order to raise additional funds through alliance, joint venture or licensing arrangements, we may be required to relinquish rights to our technologies or drug candidates or grant licenses on terms that are not favorable to us. If adequate funds are not available, we may have to further delay, reduce or eliminate one or more of our planned activities. These actions would likely reduce the market price of our common stock.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements prove inaccurate, our actual results may vary from those reflected in our accruals.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions underlying them, will be correct.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The investment of our cash, cash equivalents and fixed income marketable securities is subject to risks which may cause losses and affect the liquidity of these investments.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September&#160;30, 2021, we had $428.9 million in fixed income, certificate of deposit, and equity marketable securities. Our investments may also include commercial paper, securities issued by the U.S. government obligations, and money market funds meeting the criteria of our investment policy, which is focused on the preservation of our capital. These investments are subject to general credit, liquidity, and market and interest rate risks, particularly in the current economic environment. We may realize losses in the fair value of these investments or a complete loss of these investments, which would have a negative effect on our consolidated financial statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to utilize net operating loss carryforwards and other tax benefits may be limited.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have historically incurred net losses. Under the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation is generally allowed a deduction for net operating losses (NOLs) carried forward from a prior taxable year. Under that provision, we can carryforward our NOLs to offset our future taxable income, if any, until such NOLs are used or expire. As of September 30, 2021, we had federal, and state NOL carryforwards of approximately $569.0 million and $626.5 million, respectively. As a result of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (&#8220;CARES Act&#8221;) and legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (&#8220;2017 Tax Act&#8221;), NOLs arising before January 1, 2018, and NOLs arising after January 1, 2018, are subject to different rules.&#160;&#160;Under the CARES Act and 2017 Tax Act, federal NOLs incurred in 2018, 2019 and 2020 can generally be carried back five years, carried forward indefinitely and can offset 100% of future taxable income for tax years before January 1, 2021 and up to 80% of future taxable income for tax years after December 31, 2020.&#160;&#160;Any NOLs arising on or after January 1, 2021, cannot be carried back, can generally be carried forward indefinitely and can offset up to 80% of future taxable income. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. These NOL carryforwards could expire unused before offsetting potential future income tax liabilities.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.83%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under Section 382 of the Code and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percent change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. It is possible that we have experienced an ownership change limitation. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an ownership change occurs and our ability to use our NOL carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our&#160;business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each year we are required to evaluate our internal controls systems in order to allow management to report on and our Independent Registered Public Accounting Firm to attest to, our internal controls as required by Section 404 of the Sarbanes-Oxley Act. As a result, we continue to incur additional expenses and divert our management's time to comply with these regulations. In addition, if we cannot continue to comply with the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory authorities, such as the SEC, the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) or The Nasdaq Global Select Market. Any such action could adversely affect our financial results and the market price of our Common Stock. </p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We could be subject to additional tax liabilities.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to U.S. federal, state, local and sales taxes in the United States and Australia. Significant judgment is required in evaluating our tax positions. During the ordinary course of business, there are many activities and transactions for which the ultimate tax determination is uncertain. In addition, our tax obligations and effective tax rates could be adversely affected by changes in the relevant tax, accounting and other laws, regulations, principles and interpretations, including those relating to income tax nexus, by recognizing tax losses or lower than anticipated earnings in jurisdictions where we have lower statutory rates and higher than anticipated earnings in jurisdictions where we have higher statutory rates, by changes in foreign currency exchange rates, or by changes in the valuation of our deferred tax assets and liabilities. We may be audited in various jurisdictions, and such jurisdictions may assess additional taxes, sales taxes and value-added taxes against us. Although we believe our tax estimates are reasonable, the final determination of any tax audits or litigation could be materially different from our historical tax provisions and accruals, which could have a material adverse effect on our operating results or cash flows in the period for which a determination is made.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Risks Related to Investment and Securities</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Board of Directors has the authority to issue shares of &#8220;blank check&#8221; preferred stock, which may make an acquisition of the Company by another company more difficult.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted and may in the future adopt certain measures that may have the effect of delaying, deferring or preventing a takeover or other change in control of the Company that a holder of our Common Stock might consider in its best interest.&#160;&#160;For example, our Board of Directors, without further action by our stockholders, currently has the authority to issue up to 5,000,000 shares of preferred stock and to fix the rights (including voting rights), preferences and privileges of these shares (&#8220;blank check&#8221; preferred). Such preferred stock may have rights, including economic rights, senior to our Common Stock. These factors could also reduce the price that certain investors might be willing to pay for shares of our Common Stock and result in the market price being lower than it would be without these provisions.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not intend to declare cash dividends on our Common Stock.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not distribute cash to our stockholders unless and until we can develop sufficient funds from operations to meet our ongoing needs and implement our business plan. The time frame for that is unpredictable and investors should not expect dividends in the near future, if at all.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research reports about our business or if they make adverse recommendations regarding an investment in our stock, our stock price and trading volume may decline.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our Common Stock can be influenced by the research and reports that industry or securities analysts publish about our business. Currently, coverage of our Company by industry and securities analysts is limited. Investors have many investment opportunities and may limit their investments to companies that receive greater coverage from analysts. If additional industry or securities analysts do not commence coverage of the Company, the trading price of our stock could be negatively impacted. If one or more of the analysts downgrade our stock or comment negatively on our prospects, our stock price may decline. If one or more of these analysts cease to cover our industry or us or fail to publish reports about the Company regularly, our Common Stock could lose visibility in the financial markets, which could also cause our stock price or trading volume to decline. Further, incorrect judgments, estimates or assumptions made by research analysts may adversely affect our stock price, particularly if subsequent performance falls below the levels that were projected by the research analyst(s), even if we did not set or endorse such expectations.&#160;&#160;Any of these events could cause further volatility in our stock price and could result in substantial declines in the value of our stock.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market for purchases and sales of our Common Stock may be limited, and the sale of a limited number of shares could cause the price to fall sharply.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although our Common Stock is listed for trading on the Nasdaq Global Select Market, at various times our securities are relatively thinly traded. Investor trading patterns could serve to exacerbate the volatility of the price of our stock. For example, mandatory sales of our Common Stock by institutional holders could be triggered if an investment in our Common Stock no longer satisfies their investment standards and guidelines. It may be difficult to sell shares of our Common Stock quickly without significantly depressing the value of the stock. Unless we are successful in developing continued investor interest in our stock, sales of our stock could result in major fluctuations in the price of the stock.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Common Stock price has fluctuated significantly over the last several years and may continue to do so in the future, without regard to our results of operations and prospects.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we are early in the stage of our drug development, there are few objective metrics by which our progress may be measured. Consequently, we expect that the market price of our Common Stock will continue to fluctuate significantly. We may not continue to generate substantial revenue from the license or sale of our technology for several years, if at all. In the absence of product revenue as a measure of our operating performance, we anticipate that investors and market analysts will assess our performance by considering factors such as:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Announcements of developments related to our business&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our ability to enter into or extend investigation phase, development phase, commercialization phase and other agreements with new and/or existing partners&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Announcements regarding the status of any or all of our collaborations or products, including clinical trial results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Market perception and/or investor sentiment regarding our technology&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Announcements of actions taken by regulatory authorities, such as the U.S. Food and Drug Administration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Announcements regarding developments in the RNA interference or biotechnology fields in general&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Announcements regarding clinical trial results with our products or competitors&#8217; products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Market perception and/or announcements regarding other companies developing products in the field of biotechnology generally or specifically RNA interference&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The issuance of competitive patents or disallowance or loss of our patent rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The addition or departure of key executives&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Variations in our operating results.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not have control over many of these factors but expect that they may influence our stock price. As a result, our stock price may be volatile and such volatility could result in the loss of all or part of your investment.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stockholder equity interest may be substantially diluted in any additional equity issuances.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Inherent in Our Industry</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Drug development is time consuming, expensive and risky.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focused on technology related to new and improved pharmaceutical candidates. Product candidates that appear promising in the early phases of development, such as in animal and early human clinical trials, often fail to reach the market for a number of reasons, such as:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Clinical trial results may be unacceptable, even though preclinical trial results were promising&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Inefficacy and/or harmful side effects in humans or animals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The necessary regulatory bodies, such as the U.S. Food and Drug Administration, may not approve our potential product for the intended use, or at all&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Manufacturing and distribution may be uneconomical.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, any positive pre-clinical results in animals for our pre-clinical programs may not be replicated in human clinical studies. These programs may be also found to be unsafe in humans, particularly at higher doses needed to achieve the desired levels of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efficacy. Also, the positive safety results from single dose human clinical studies may not be replicated in other human studies, including multiple dose studies. Clinical and pre-clinical study results are frequently susceptible to varying interpretations by scientists, medical personnel, regulatory personnel, statisticians and others, which often delays, limits, or prevents further clinical development or regulatory approvals of potential products. Clinical trials can take many years to complete, including the process of study design, clinical site selection and the recruitment of patients. As a result, we can experience significant delays in completing clinical studies, which can increase the cost of developing a drug candidate and shorten the time that an approved product may be protected by patents. If our drug candidates are not successful in human clinical trials, we may be forced to curtail or abandon certain development programs. If we experience significant delays in commencing or completing our clinical studies, we could suffer from significant cost overruns, which could negatively affect our capital resources and our ability to complete these studies.</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The healthcare system is under significant financial pressure to reduce costs, which could reduce payment and reimbursement rates for drugs.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Throughout the world and particularly in the United States the healthcare system is under significant financial pressure to reduce costs.&#160;&#160;The price of pharmaceuticals has been a topic of considerable public discussion that could lead to price controls or other price-limiting strategies by payors that have the effect of lowering payment and reimbursement rates for drugs or otherwise making the commercialization of pharmaceuticals less profitable. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. These effects could reduce or eliminate our ability to return value to our stockholders.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulatory standards are subject to change over time, making it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory standards are promulgated by various government entities and are subject to change based on factors such as scientific developments, public perceptions of risk, and political forces.&#160; Because clinical trials often take years to complete, it is sometimes possible for standards that exist during the conception and initiation of a clinical trial to change before the clinical trial is completed or reviewed by government regulators.&#160; For example, we may initiate clinical trials that are designed to show benefits on relatively short-term endpoints, but ultimately be required to show benefits in longer-term outcome studies. While some government entities have safeguards intended to ensure standards agreed upon by sponsors and regulators at the outset of a clinical trial are applied during regulatory review processes, those safeguards generally permit regulators to apply more rigorous standards where regulators believe doing so is necessary.&#160; As such, there can be no assurance that regulatory standards that are appropriate at the outset of a clinical trial program will not become more rigorous during the regulatory approval process and could potentially result in a delayed approval or denial of marketing authorization.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1B.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item1B_UnresolvedStaffComments">UNRESOLVED STAFF COMMENTS </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item2_Properties">PROPERTIES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not own any real property. The following table summarizes the Company&#8217;s leased facilities as of September 30, 2021.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Office</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Space</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Monthly</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Primary&#160;Use</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease&#160;Term</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pasadena, California</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,000&#160;sq.&#160;ft.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,490</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corp.&#160;Headqtrs.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April&#160;2027</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5&#160;years</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Madison, Wisconsin</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,000&#160;sq.&#160;ft.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,371</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research&#160;Facility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;2031</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15&#160;years</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,000&#160;sq.&#160;ft</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,821</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research&#160;Facility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January&#160;2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3&#160;years</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item3_LegalProceedings">LEGAL PROCEEDINGS </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal Proceedings are set forth in our financial statement schedules in Part&#160;IV,&#160;Item 15 of this Annual Report and are incorporated herein by reference. See Note 7 &#8212; <span style="font-style:italic;">Commitments and Contingencies </span>of Notes to Consolidated Financial Statements of Part&#160;IV,&#160;Item 15. <span style="font-style:italic;">Exhibits and Financial Statement Schedules</span>.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;4.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item4_MineSafetyDisclosures">MINE SAFETY DISCLOSURES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART II </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item5_MarketForRegistrants">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Common Stock is traded on The Nasdaq Global Select Market under the symbol &#8220;ARWR&#8221;. <span style="font-size:12pt;"> </span>At November 15, 2021, 104,525,708 shares of the Company&#8217;s Common Stock were issued and outstanding, and were owned by <span style="color:#000000;">100</span> stockholders of record, based on information provided by the Company&#8217;s transfer agent.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has never paid dividends on its Common Stock and does not anticipate that it will do so in the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance Under the Equity Compensation Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The disclosure required under this item related to equity compensation plans is incorporated by reference from Item&#160;12 of Part III of this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Repurchases of Equity Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not repurchase any shares of our Common Stock during the quarter ended September 30, 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Graph</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that we specifically incorporate it by reference into such filing.&#160;&#160;The graph compares the cumulative 5-year total return to stockholders on our Common Stock relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. We selected the Nasdaq Biotechnology Index because we believe the index reflects the market conditions within the industry in which we primarily operate. The comparison of total return on investment, defined as the change in year-end stock price plus reinvested dividends, for each of the periods assumes that $100 was invested on September 30, 2016, in each of our Common Stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index, with investment weighted on the basis of market capitalization.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The comparisons in the following graph are based on historical data and are not intended to forecast the possible future performance of our Common Stock.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfmvgbft1fv3000005.jpg" title="" alt="" style="width:720px;height:437px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90.84%;">
<tr style="height:20.25pt;">
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$100 investment in stock or index</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ticker</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2018</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:29.5pt;">
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARWR</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58.91</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260.82</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383.40</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">585.85</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">849.39</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:30.1pt;">
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NASDAQ Biotechnology Index</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#94;NBI</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115.39</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126.70</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103.32</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140.62</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167.98</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:30.1pt;">
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NASDAQ Composite Index</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#94;IXIC</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122.29</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151.47</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150.59</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210.23</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272.00</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.27%;text-indent:-10.27%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_RESERVED">ITEM 6. RESERVED</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.27%;text-indent:-10.27%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.27%;text-indent:-10.27%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TEM&#160; 7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item7_MDA">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unless otherwise noted, (1)&#160;the term &#8220;Arrowhead&#8221; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation, (2)&#160;the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3)&#160;the term &#8220;Subsidiaries&#8221; refers to Arrowhead Madison Inc. (&#8220;Arrowhead Madison&#8221;), and Arrowhead Australia Pty Ltd (&#8220;Arrowhead Australia&#8221;), (4)&#160;the term &#8220;Common Stock&#8221; refers to Arrowhead&#8217;s Common Stock, (5) the term &#8220;Preferred Stock&#8221; refers to Arrowhead&#8217;s Preferred Stock and (6) the term &#8220;Stockholder(s)&#8221; refers to the holders of Arrowhead Common Stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them.&#160;Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company&#8217;s pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-<span style="color:#000000;">LUNG2 for chronic obstructive pulmonary disorder, ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens</span> and ARO-C3 for complement mediated diseases<span style="color:#000000;">. ARO-XDH is being developed for uncontrolled gout under a collaboration agreement with Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;). ARO-JNJ2 and ARO-JNJ3 are being developed for undisclosed liver-expressed targets under a collaboration agreement with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;).&#160;&#160;JNJ-75220795 (ARO-JNJ1) is being developed by Janssen as a potential treatment for patients with non-alcoholic steatohepatitis (NASH).&#160;&#160;</span>ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) in October 2020. JNJ-3989 (formerly referred to as ARO-HBV) <span style="color:#000000;">for chronic hepatitis B virus was out-licensed to Janssen in October 2018.&#160;&#160;</span>Olpasiran (formerly referred to as AMG 890 or ARO-LPA) <span style="color:#000000;">for cardiovascular disease was out-licensed to Amgen Inc. (&#8220;Amgen&#8221;) in 2016.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.58%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During fiscal year 2021, the Company continued to develop its pipeline and partnered candidates.&#160;&#160;The Company announced positive interim clinical data on (i) AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the Company&#8217;s second-generation investigational RNAi therapeutic being co-developed with Takeda as a treatment for the rare genetic liver disease associated with AATD, (ii) AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH), and (iii) AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma.&#160;&#160;The Company also presented preclinical data on the development of ARO-DUX4, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with facioscapulohumeral muscular dystrophy (FSHD), at the 28th&#160;Annual&#160;FSHD Society International Research Congress. The Company hosted a key opinion leader webinar on its cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, and presented positive clinical data from the Phase 1/2 clinical studies of ARO-APOC3 and ARO-ANG3 at the American Heart Association Scientific Sessions 2020.&#160;&#160;The Company filed two Investigational New Drug Applications with the United States Food and Drug Administration (the &#8220;FDA&#8221;) to begin a Phase 2b clinical study of ARO-APOC3 in patients with severe hypertriglyceridemia and a Phase 2b clinical study of ARO-ANG3 in patients with mixed dyslipidemia, and initiated these two Phase 2b clinical studies in the third quarter of fiscal year 2021. The Company also filed for regulatory clearance to begin a Phase 1/2a study of ARO-C3 for treatment of complement mediated diseases. In July 2021, the Company voluntarily paused AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis, after receiving a preliminary update from an ongoing chronic toxicology study in rats that contained unexpected signals of local lung inflammation.&#160;&#160;New screening, enrollment and any further dosing of investigational ARO-ENaC have been paused pending additional data from ongoing nonclinical toxicology studies.&#160;&#160;The Company announced two collaborations during fiscal year 2021: a collaboration with Takeda to co-develop and co-commercialize ARO-AAT for alpha-1 antitrypsin-associated liver disease and a collaboration with Horizon to develop ARO-XDH, an investigational RNAi therapeutic for uncontrolled gout. In July 2021, the Company received Breakthrough Therapy designation from the FDA for ARO-AAT, which is a process designed to expedite the development and review of drugs that are intended to treat a serious life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s partnered candidates under its collaboration agreements also continued to progress.&#160;&#160;Janssen began dosing patients in a Phase 2b triple combination study called REEF-1,&#160;designed to enroll up to 450 patients with chronic hepatitis B infection.&#160;&#160;The Company is currently performing discovery, optimization and preclinical research and development for JNJ-75220795 (ARO-JNJ1), ARO-JNJ2 and ARO-JNJ3 for Janssen as part of the Company&#8217;s Research Collaboration and Option Agreement with Janssen (the &#8220;Janssen Collaboration Agreement&#8221;), and Janssen has began dosing patients in its Phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1).&#160;&#160;Amgen has initiated a Phase 2 clinical trial for Olpasiran (previously referred to as AMG 890 or ARO-LPA).&#160;&#160;The Company entered into two licensing deals during fiscal 2021: i) an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda for ARO-AAT, a<span style="color:#000000;">nd ii) a Collaboration and License Agreement (the &#8220;Horizon License Agreement&#8221;) with </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) for ARO-XDH.&#160;&#160;ARO-AAT is currently in Phase 2 clinical trials and ARO-XDH is in discovery-stage.&#160;&#160;During fiscal year 2021, the Company earned $340.0 million in upfront payments from its collaboration agreements, and $20.0 million in option and milestone payments.&#160;&#160;In total, the Company remains eligible for $5.3 billion in developmental, regulatory and sales milestones, in various royalties on net sales. </span><span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognition for these collaboration agreements is discussed further in Note 2 Notes to Consolidated Financial Statements of Part IV, Item 15. <span style="font-style:italic;">Exhibits and Financial Statement Schedules</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead operates lab facilities in Madison, Wisconsin and San Diego, California, where the Company&#8217;s research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead has focused its resources on therapeutics that exclusively utilize the Company&#8217;s Targeted RNAi Molecule (TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup>) platform technology. Therapeutics built on the TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform have demonstrated high levels of pharmacologic activity in multiple animal models spanning several therapeutic areas. TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> enabled therapeutics offer several potential advantages over prior generation and competing technologies, including: simplified manufacturing and reduced costs&#59; multiple routes of administration including subcutaneous injection and inhaled administration&#59; the ability to target multiple tissue types including liver, lung, muscle and tumors&#59; and the potential for improved safety and reduced risk of intracellular buildup, because there are less metabolites from smaller, simpler molecules.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to develop<span style="color:#000000;"> other clinical candidates for future clinical trials.&#160;</span>Clinical candidates are tested internally and through GLP toxicology studies at outside laboratories.&#160;&#160;Drug materials for such studies and clinical trials are either contracted to third-party manufacturers or manufactured internally.&#160;&#160;The Company engages third-party contract research organizations (&#8220;CROs&#8221;) to manage clinical trials and works cooperatively with such organizations on all aspects of clinical trial management, including plan design, patient recruiting, and follow up.&#160;&#160;These outside costs, relating to the preparation for and administration of clinical trials, are referred to as &#8220;candidate costs.&#8221;&#160;&#160;If the clinical candidates progress through human testing, candidate costs will increase.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is actively monitoring the ongoing COVID-19 pandemic. The financial results for the years ended September 30, 2021 and 2020 were not significantly impacted by COVID-19.&#160;&#160;Operationally, the Company experienced delays in its earlier stage programs due to a shortage in non-human primates, which are critical for the Company&#8217;s preclinical programs. Additionally, the Company experienced delays in enrollment in its clinical trials.&#160;&#160;The Company&#8217;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters in Pasadena, California have continued to operate with limited impact, other than for enhanced safety measures, including work from home policies, and intermittent lab supply shortages. However, the Company cannot predict the impact the progression of COVID-19 will have on future financial and operational results due to a variety of factors, including the ability of the Company&#8217;s clinical sites to continue to enroll subjects, the ability of the Company&#8217;s suppliers to continue to operate, the continued good health and safety of the Company&#8217;s employees and the length and severity of the COVID-19 pandemic.<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss was $140.8 million for the year ended September 30, 2021 as compared to net loss of $84.6 million for the year ended September 30, 2020 and net income of $68.0 million for the year ended September 30, 2019. Net loss per share &#8211; diluted was $1.36 for the year ended September 30, 2021 as compared to net loss per share-diluted of $0.84 for the year ended September 30, 2020 and net income per share-diluted of $0.69 for the year ended September 30, 2019. An increase in research and development and general and administrative expenses, partially offset by an increase in revenue due to the Takeda collaboration, were the drivers of the increase in net loss and net loss per share for the year ended September 30, 2021, as discussed further below.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has strengthened its liquidity and financial position through upfront and milestone payments received under its collaboration agreements, as well as equity financings. <span style="color:#000000;">Under the terms of the Company&#8217;s agreements with Janssen taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in Arrowhead Common Stock and four milestone payments totaling $70.0 million. Under the terms of the Company&#8217;s agreements with Amgen, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock and $30.0 million in milestone payments. </span><span style="Background-color:#FFFFFF;color:#000000;">T</span>he Company&#8217;s October 2020 licensing agreement with Takeda resulted in a $300.0 million upfront payment, and the Company&#8217;s June 2021 licensing agreement with Horizon resulted in a $40 million upfront payment, each of which was collected during fiscal year 2021. The Company had $184.4 million of cash and cash equivalents, $126.7 million of marketable securities, $56.6 million in short-term investments, $245.6 million of long-term investments and $710.1 million of total assets as of September 30, 2021, as compared to $143.6 million of cash and cash equivalents, $85.0 million of marketable securities, $86.9 million in short-term investments, $137.5 million of long-term investments and $522.5 million of total assets as of September 30, 2020, respectively. Based upon the Company&#8217;s current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund operations for at least the next twelve months. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management makes certain judgments and uses certain estimates and assumptions when applying accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) in the preparation of our Consolidated Financial Statements. We evaluate our estimates and judgments on an ongoing basis and base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances. Our experience and assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what we anticipate and different assumptions or estimates about the future could change our reported results. We believe the following accounting policies are the most critical to us, in that they require our most difficult, subjective or complex judgments in the preparation of our consolidated financial statements. For further information, see&#160;<span style="font-style:italic;">Note 1, Organization and Significant Accounting Policies</span>, to our Consolidated Financial Statements, which outlines our application of significant accounting policies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments&#8212;The Company may invest excess cash balances in short-term and long-term marketable debt and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 320, Investments &#8211; Debt and Equity Securities and ASC 321, Investments in Equity Securities.&#160;ASC 320-Investments-Debt and Equity Securities requires debt securities to be classified into three categories: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-Maturity&#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Securities&#8212;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale&#8212;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of stockholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2021, 2020 and 2019, all of the Company&#8217;s debt securities were classified as held-to-maturity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity investments are measured and recorded at amortized cost on the Company&#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests in shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#8217;s Consolidated Balance Sheet as &#8220;marketable securities&#8221; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets Subject to Amortization&#8212;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration&#8212;The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at September</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30, 202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and September 30, 20</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212; <span style="color:#000000;">On October 1, 2018, the Company adopted FASB Topic 606 &#8211; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#8217;s adoption of the revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#8217;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen, Takeda and Horizon, and the analysis of the impact of this guidance on those agreements is discussed further in </span>Note 2 of Notes to Consolidated Financial Statements of Part IV, Item 15. <span style="font-style:italic;">Exhibits and Financial Statement Schedules</span><span style="color:#000000;">.&#160;&#160;&#160;&#160; </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract&#59; (ii) identify the performance obligations&#59; (iii) determine the transaction price&#59; (iv) allocate the transaction price to the performance obligations in the contract&#59; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials&#59; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States&#59; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in our Consolidated Statements of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the new revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on the Company&#8217;s Consolidated Balance Sheets.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#8217;s current operating plan and, if the Company&#8217;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborative Arrangements&#8212;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB Topic 808&#8212;Collaborative Arrangements. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to Research and Development Expense or General and Administrative Expense, as appropriate.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development&#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation&#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes&#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:2.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases&#8212;The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following data summarizes our results of operations for the following periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,287</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,992</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,796</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Income (loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149,036</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,159</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,191</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (loss)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(140,848</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,553</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,975</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.36</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.84</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.69</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in revenue for the year ended September 30, 2021 compared to the year ended September 30, 2020 was driven by the timing of the recognition of the $300 million initial transaction price associated with our agreement with Takeda as we achieved progress toward completing our performance obligation. The increase in Net Losses during the year ended September 30, 2021 compared to year ended September 30, 2020 was driven by increases in research and development and general and administrative expenses as our pipeline of clinical candidates has continued to increase.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue for the years ended September 30, 2021, 2020, and 2019 was $138.3 million, $88.0 million and $168.8 million, respectively.&#160;&#160;Revenue in the current period is primarily related to the recognition of $90.8 million of revenue associated with the Takeda License Agreement, recognition of $20.2 million related to the $252.7 million initial transaction price associated with our agreements with Janssen and JJDC, recognition of $6.7 million of revenue associated with the Horizon License Agreement and $20.0 million in option and milestone payments from Janssen for JNJ-75220795 (ARO-JNJ1).</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amgen Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;28, 2016, the Company entered into two collaboration and license agreements and a common stock purchase agreement with Amgen.&#160;&#160;Under the Second Collaboration and License Agreement or Olpasiran Agreement, Amgen has received a worldwide, exclusive license to Arrowhead&#8217;s novel, RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the other collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, and $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement.&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers.&#160;&#160;The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement.&#160;&#160;Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study for Olpasiran, which resulted in a $20 million milestone payment to the Company. During the years ended September 30, 2021, 2020 and 2019, the Company recognized $0, $20.1 million and $0.3 million of Revenue associated with its agreements with Amgen, respectively.&#160;&#160;As of September 30, 2021, there were $0 in contract assets </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recorded as accounts receivable and $0 contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Janssen Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 3, 2018, the Company entered into the Janssen License Agreement and the Janssen Collaboration Agreement with Janssen, part of the Janssen Pharmaceutical Companies of Johnson &#38; Johnson.&#160;&#160;The Company also entered into a stock purchase agreement with JJDC (&#8220;JJDC Stock Purchase Agreement&#8221;).&#160;&#160;Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company is responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989.&#160;&#160;Under the Janssen Collaboration Agreement, Janssen will be able to select three new targets against which Arrowhead will develop clinical candidates.&#160;&#160;These candidates are subject to certain restrictions and do not include candidates that already were in the Company&#8217;s pipeline.&#160;&#160;The Company will perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, is sufficient to allow the filing of a U.S. Investigational New Drug Application or equivalent, at which time Janssen will have the option to take an exclusive license. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned candidate.&#160;&#160;Under the terms of the agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment <span style="color:#000000;">by JJDC in Arrowhead Common Stock under the JJDC </span>Stock Purchase Agreement, and milestone and option payments totaling $70.0 million, and may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $1.9 billion in development and sales milestone payments for the three additional targets covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers.&#160;&#160;At the inception of these agreements, the Company identified one distinct performance obligation.&#160;&#160;Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&#38;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&#38;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Janssen R&#38;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation.&#160;&#160;The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for this option is accounted for separately. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the transaction price totaled approximately $252.7 million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0 million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&#38;D Services to be performed.&#160;&#160;The Company has allocated the total $252.7 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&#38;D Services.&#160;&#160;The Company has recognized this transaction price in its entirety as of September 30, 2021 as the performance obligation had been substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. During the years ended September 30, 2021, 2020 and 2019, the Company recognized approximately $20.2 million, $65.0 million, and $167.5 million of revenue associated with this performance obligation, respectively. As of September 30, 2021, there were $0.1 million in contract assets recorded as accounts receivable, and $0 of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has begun to conduct its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2 and ARO-JNJ3 under the Janssen Collaboration Agreement.&#160;&#160;All costs and labor hours spent by the Company will be entirely funded by Janssen.&#160; During the years ended September 30, 2021, 2020 and 2019, the Company recognized $0.5 million, $2.9 million and $1.0 million of revenue associated with these efforts, respectively.  In May 2021, Janssen exercised its option right for for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0 million milestone payment to the Company, and in September 2021, Janssen dosed its fifth patient in its phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0 million milestone payment to the Company. Each of these milestone payments was recognized entirely during the year ended September 30, 2021.  As of September 30, 2021, there were $10.0 million of cont<span style="color:#000000;">ract assets recorded as accounts </span>receivable and $0 of contract liabilities recorded as curren<span style="color:#000000;">t deferred revenue on the Company&#8217;s Consolidated Balance</span> Sheets.&#160;The $10.0 million milestone payment for the dosing of the fifth patient in its Phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1) was received in October 2021. <span style="color:#000000;"> &#160;&#160;</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Takeda Pharmaceuticals U.S.A., Inc.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 7, 2020, the Company entered into the Takeda License Agreement with Takeda.&#160;&#160;Under the Takeda License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales.&#160;&#160;In January 2021, the Company received $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.&#160;&#160; </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the Takeda License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation.&#160;&#160;The Company determined that the key deliverables included the license and certain R&#38;D services, including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#8220;Takeda R&#38;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Takeda R&#38;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation.&#160;&#160;Beyond the Takeda R&#38;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States.&#160;&#160;Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States.&#160;&#160;The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts will be recorded as Research and Development Expenses or General and Administrative Expenses, as appropriate. <span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the initial transaction price totaled $300.0 million, including the upfront payment.&#160;&#160;The Company has excluded any future estimated milestones or royalties from this transaction price to date.&#160;&#160;The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&#38;D Services.&#160;&#160;Revenue will be recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). Revenue for the years ended September 30, 2021, 2020 and 2019 was $90.8 million, $0 and $0, respectively. As of September 30, 2021, there were $0 in contract assets recorded as accounts receivable, $84.4 million in contract liabilities recorded as deferred revenue, $124.8 million in contract liabilities recorded as deferred revenue, net of the current portion, and $3.1 million in contract liabilities recorded as accrued expenses.&#160;&#160;The $3.1 million in accrued expenses was primarily driven by co-development and co-commercialization activities.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Horizon Therapeutics Ireland DAC</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 18, 2021, the Company entered into the Horizon License Agreement with Horizon.&#160;&#160;Under the Horizon License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Horizon received a worldwide exclusive license for&#160;ARO-XDH,&#160;a previously undisclosed discovery-stage investigational RNAi therapeutic being developed by the Company as a potential treatment for people with uncontrolled gout. The Company will conduct all activities through the preclinical stages of development of&#160;ARO-XDH,&#160;and Horizon will be wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, the Company received $40&#160;million as an upfront payment and is eligible to receive up to $660&#160;million in potential development, regulatory and sales milestones.&#160;&#160;The Company is also eligible to receive royalties in the&#160;low-&#160;to&#160;mid-teens&#160;range on net product sales.&#160;&#160; </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the Horizon License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation.&#160;&#160;The Company determined that the key deliverables included the license and certain R&#38;D services including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#8220;Horizon R&#38;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Horizon R&#38;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation.&#160;&#160;Beyond the Horizon R&#38;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the initial transaction price totaled $40.0 million, including the upfront payment.&#160;&#160;The Company has excluded any future estimated milestones or royalties from this transaction price to date.&#160;&#160;The Company will allocate the total $40.0 million initial transaction price to its one distinct performance obligation for the ARO-XDH license and the associated Horizon R&#38;D Services.&#160;&#160;Revenue will be recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&#38;D Services.&#160;&#160;The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the years ended September 30, 2021, 2020 and 2019, was $6.7 million, $0 and $0, respectively. As of September 30, 2021, there were $0.1 million in contract assets recorded as accounts receivable, $26.7 million in contract liabilities recorded as deferred revenue and $6.7 million in contract liabilities recorded as deferred revenue, net of the current portion.&#160;&#160; &#160;&#160;<span style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The analysis below details the operating expenses and discusses the expenditures of the Company within the major expense categories. Certain reclassifications have been made to prior-period operating expense categories to conform to the current period presentation.&#160;&#160;For purposes of comparison, the amounts for the years ended September 30, 2021 and 2020 are shown in the tables below. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&#38;D expenses are related to the Company&#8217;s research and development discovery efforts and related candidate costs, which are comprised primarily of outsourced costs related to the manufacturing of clinical supplies, toxicity/efficacy studies and clinical trial expenses.&#160;&#160;Internal costs primarily relate to discovery operations at our research facilities in Madison, Wisconsin and San Diego, California, including facility costs and laboratory-related expenses. Salaries and stock compensation expense consist of salary, bonuses, payroll taxes and related benefits and stock compensation for our R&#38;D personnel.&#160;&#160;Depreciation and amortization expense relates to depreciation on lab equipment and leasehold improvements at our research facilities.&#160;&#160;We do not separately track R&#38;D expenses by individual research and development projects, or by individual drug candidates. The Company operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation expenses, depreciation and amortization expenses, and other expenses related to research and development activities.&#160;&#160;The following table provides details of research and development expenses for the periods indicated:<span style="font-style:italic;"> </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(table below in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Salaries</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,179</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,300</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,879</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities related</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,694</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,136</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,558</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Candidate costs</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,628</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,638</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,990</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&#38;D discovery costs</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,734</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,192</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,542</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expense, excluding non-cash expense</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,235</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,266</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,969</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,742</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,277</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,465</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation/amortization</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,365</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,332</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,033</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expense</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,342</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,875</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,467</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Salaries expense increased by $13,879,000 from $26,300,000 during the year ended September 30, 2020 to $40,179,000 during the current period. This increase is primarily due to an increase in R&#38;D headcount that has occurred as the Company has expanded its pipeline of candidates. We anticipate this expense to continue to increase as we continue to expand our pipeline of candidates and increase headcount to support our discovery efforts to identify new drug candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities-related expense increased by $3,558,000 from $4,136,000 during the year ended September 30, 2020 to $7,694,000 during the current period. This category includes rental costs for our research and development facilities in Madison, Wisconsin and San Diego, California. This increase is primarily due to the commencement of our sublease in San Diego, California in April 2020, the expansion of our Madison facility and increased repairs and maintenance expense on equipment. We anticipate this expense to increase in the future due to our plans to continue to increase our manufacturing capabilities and discovery efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Candidate costs increased by $31,990,000 from $60,638,000 during the year ended September 30, 2020 to $92,628,000 during the current period.&#160;&#160;This increase is primarily due to the progression of our pipeline of candidates into and through clinical trials, which results in higher outsourced clinical trial, toxicity study and manufacturing costs. We anticipate these expenses to continue to increase as our pipeline of candidates grows and progresses to later phase clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&#38;D discovery costs increased by $16,542,000 from $16,192,000 during the year ended September 30, 2020 to $32,734,000 in the current period.&#160;&#160;This increase is primarily due to the growth of our discovery efforts, including the addition of our research facility in San Diego. We anticipate this expense to continue to increase as we increase headcount to support our discovery efforts to identify new drug candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation expense, a non-cash expense, increased by $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">465</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,000</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,277,000 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during the year ended September 30, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">742</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,000</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> during the current period.&#160;&#160;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation expense is based upon the valuation of stock options and restricted stock units granted to employees, directors and certain consultants. Many variables affect the amount expensed, including the Company&#8217;s stock price on the date of the grant, as well as other assumptions. The increase in the expense in the current period is primarily due to the increased headcount discussed above and a mix of higher grant date fair values of awards amortizing during the current period due to the Company&#8217;s stock price at the time of the grants. We generally expect future stock compensation expense to increase as our headcount continues to increase to support our clinical pipeline.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense, a non-cash expense, increased by $2,033,000 from $5,332,000 during the year ended September 30, 2020 to $7,365,000 during the current period. The majority of depreciation and amortization expense relates to depreciation on lab equipment and leasehold improvements at our Madison and San Diego research facilities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General&#160;&#38; Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides details of our general and administrative expenses for the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(table below in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Salaries</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,681</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,781</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,900</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional/outside services</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,148</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,342</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,806</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities related</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,344</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,203</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other G&#38;A</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,976</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,233</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(257</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-8</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total general &#38; administrative expense, excluding non-cash expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,149</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,559</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,590</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,931</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,106</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,825</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation/amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">901</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">611</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">290</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total general &#38; administrative expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,981</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,276</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,705</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Salaries expense increased by $1,900,000 from $11,781,000 during the year ended September 30, 2020 to $13,681,000 during the current period. The increase is primarily driven by annual merit increases, performance bonuses and increased headcount needed to support our growing clinical pipeline.  We anticipate this expense to continue to increase as our pipeline expands. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional/outside services include legal, accounting, consulting, patent expenses, business insurance expenses and other outside services retained by the Company. Professional/outside services expense increased by $2,806,000 from $7,342,000 during the year ended September 30, 2020 to $10,148,000 during the current period. The increase is primarily related to an increase in consulting expenses in the current period.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities-related expense increased by $141,000 from $2,203,000 during the year ended September 30, 2020 to $2,344,000 during the current period. This category primarily includes rental costs for our corporate headquarters in Pasadena, California.&#160;&#160;The increase was due to the additional space leased for our corporate headquarters to accommodate the increase in headcount. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other G&#38;A expense decreased by $257,000 from $3,233,000 during the year ended September 30, 2020 to $2,976,000 during the current period. This category consists primarily of travel, communication and technology, office expenses, and franchise and property tax expenses.&#160;&#160;We anticipate this expense to increase in the future as our headcount increases in order to support our growing pipeline. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation expense, a non-cash expense, increased by $23,825,000 from $27,106,000 during the year ended September 30, 2020 to $50,931,000 during the current period.&#160;&#160;The increase is due to certain performance-based stock awards being deemed probable of being achieved in the current period.&#160;&#160;Stock compensation expense is based upon the valuation of stock options and restricted stock units granted to employees, directors and certain consultants. Many variables affect the amount expensed, including the Company&#8217;s stock price on the date of the grant, as well as other assumptions. We generally expect future stock compensation expense to increase as our headcount continues to increase to support our clinical pipeline.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense, a noncash expense, increased by $290,000 from $611,000 during the year ended September 30, 2020 to $901,000 during the current period. The increase is primarily related to amortization of leasehold improvements for our corporate headquarters. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income / Expense </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income/expense was income of $8.6 million during the year ended September 30, 2020 compared to income of $8.2 million during the current period. Other income/expense primarily consists of interest income. The change in interest income between the year ended September 30, 2021 and 2020 is primarily due to the amounts invested in and the interest rates earned on our bond portfolio. &#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead has historically financed its operations through the sale of its equity securities and revenue from its collaboration agreements. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have expanded significantly.&#160;&#160;Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials, as well as with the Company&#8217;s plans to increase its internal manufacturing capabilities and discovery efforts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2021, the Company had cash on hand of approximately $184.4 million as compared to $143.6 million at September 30, 2020.&#160;&#160;Cash invested in short-term fixed income securities and marketable securities was $183.4 million at September 30, 2021, compared to $171.9 million at September 30, 2020.&#160;&#160;Cash invested in long-term fixed income securities was $245.6 million at September 30, 2021, compared to $137.5 million at September 30, 2020.&#160;&#160;The Company also entered into an Open Market Sale Agreement (the &#8220;ATM&#8221; agreement), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s common stock through Jefferies LLC.&#160;&#160;As of the year ended September 30, 2021, no shares have been issued under the ATM agreement.&#160;&#160;The Company believes its current financial resources are sufficient to fund its operations through at least the next twelve months. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of cash flows for the years ended September 30, 2021, 2020, and 2019 as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash Flow from:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,224</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,391</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,035</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing Activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(141,678</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(240,778</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,746</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing Activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,305</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,948</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,382</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,851</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78,221</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,671</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of period</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,583</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,804</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,133</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,434</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,583</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,804</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended September 30, 2021, the Company generated $171.2 million in cash from operating activities, which was primarily related to the Takeda license agreement&#8217;s $300 million upfront payment, partially offset by the ongoing expenses of the Company&#8217;s research and development programs and general and administrative expenses.&#160;&#160;Cash used in investing activities was $141.7 million, which was primarily related to the purchase of investments of $240.7 million and purchase of property and equipment of $23.6 million, partially offset by maturities of fixed-income securities of $122.6 million.&#160;&#160;Cash provided by financing activities of $11.3 million was due to cash received from stock option exercises. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended September 30, 2020, the Company used $95.4 million in cash from operating activities, which was primarily related to the ongoing expenses of the Company&#8217;s research and development programs and general and administrative expenses.&#160;&#160;Cash used in investing activities was $240.8 million, which was primarily related to the purchase of investments of $279.0 million and purchase of property and equipment of $12.0 million, partially offset by maturities of fixed-income securities of $50.1 million.&#160;&#160;Cash provided by financing activities of $257.9 million was driven by the securities financing in December 2019, which generated $250.5 million in net cash proceeds, as well as $7.5 million in cash received from stock option exercises. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During <span style="color:#000000;">the year ended September 30, 2019, the Company generated $173.0 million in cash from operating activities, which was primarily related to the $175.0 million upfront payment and the two $25.0 million milestone payments received from Janssen, and the premium JJDC paid on the Company&#8217;s common stock during the period.&#160;&#160;These inflows were partially offset by approximately $66.5 million of cash used for the ongoing expenses of the Company&#8217;s research and development programs and general and administrative expenses.&#160;&#160;Cash used in investing activities was $47.7 million, which was primarily related to purchases of fixed-income investments of $90.3 million partially offset by maturities of fixed-income investments of $54.5 million.&#160;&#160;Cash provided by financing activities of $66.4 million was driven by the equity investment the Company received from JJDC during the period</span>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Contractual Obligations</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.59%;"><span style="Background-color:#FFFFFF;"></span><span style="Background-color:#FFFFFF;font-weight:normal;">For information related to our future commitments for our facility related obligaitons, see </span><span style="font-weight:normal;color:#000000;">Notes 8 and 14 of Notes to Consolidated Financial Statements of Part IV, Item 15. </span><span style="font-style:italic;font-weight:normal;color:#000000;">Exhibits and Financial Statement Schedules</span><span style="font-weight:normal;">.&#160;&#160;For information related to our future commitments relating to our collaboration and licensing agreements, see Notes 2 and 8 of </span><span style="font-weight:normal;color:#000000;">Notes to Consolidated Financial Statements of Part IV, Item 15. </span><span style="font-style:italic;font-weight:normal;color:#000000;">Exhibits and Financial Statement Schedules</span><span style="font-weight:normal;">.&#160;&#160;Commitments related to our clinical, manufacturing and business operation related agreements are $214.9 million as of the year ended September 30, 2021, however these agreements are cancelable.&#160;&#160; </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 7A.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item7A_QuantitativeAndQualitative">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risk related to changes in interest rates, which could adversely affect the value of our interest rate-sensitive assets and liabilities.&#160;&#160;We do not hold any instruments for trading purposes and investment criteria are governed by the Company&#8217;s Investment Policy. As of September 30, 2021 and 2020, we had cash and cash equivalents of $184.4 million and $143.6 million, respectively, and short-term and long-term investments and marketable securities of $428.9 million and $309.4 million, respectively. At times, we have invested our cash reserves in corporate bonds typically with maturities of less than 3 years, and we have historically classified these investments as held-to-maturity.&#160;We have also invested in <span style="color:#000000;">mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.</span> Due to the relatively short-term nature of the investments that we hold, we do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 8.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item8_FinancialStatementsAndSuppData">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is included in Item&#160;15 of this Annual Report on Form 10-K. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 9.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item9_ChangesInAndDisagreements">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 9A.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item9A_ControlsAndProcedures">CONTROLS AND PROCEDURES</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Chief Executive Officer and our Chief Financial Officer, after evaluating our &#8220;disclosure controls and procedures&#8221; (as defined in Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Annual Report on Form 10-K (the &#8220;Evaluation Date&#8221;) have concluded that as of the Evaluation Date, our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, where appropriate, to allow timely decisions regarding required disclosure.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.12%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). This process includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets&#59; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors&#59; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the internal control over financial reporting to future periods are subject to risk that the internal control may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.12%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Management&#8217;s Assessment of the Effectiveness of our Internal Control over Financial Reporting</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of the Company&#8217;s internal control over financial reporting based on the criteria set forth in Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on the Company&#8217;s assessment, management</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has concluded that its internal control over financial reporting was effective as of September&#160;30, 20</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;to provide reasonable assurance </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. The Company&#8217;s independent registered public accounting firm, Rose, Snyder and Jacobs LLP, has issued an audit report on the Company&#8217;s internal control over financial reporting, which appears in Item&#160;15 of this Form 10-K.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no change in our internal control over financial reporting that occurred during the fourth quarter of the year ended September&#160;30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 9B.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item9B_OtherInformation">OTHER INFORMATION </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive License Agreement with Glaxosmithkline Intellectual Property (No. 3) Limited</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 22, 2021, the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;) with Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;).&#160; Under the GSK License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">GSK has received an exclusive license for&#160;ARO-HSD,&#160;the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).&#160; The exclusive license is worldwide with the exception of greater China, for which the Company will retain rights to develop and commercialize.&#160; </span>Beyond the Company&#8217;s Phase 1/2 study of (ARO-HSD), which the Company is responsible for completing, GSK is wholly responsible for clinical development and commercialization of ARO-HSD in its terr<span style="Background-color:#FFFFFF;color:#000000;">itory.&#160;Under the terms of the agreement, Arrowhead will receive an upfront payment of $120 million and is eligible for additional payments of $30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to Arrowhead of up to $190 million at first commercial sale, and up to $590 million in sales-related milestone payments. Arrowhead is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent. The transactions contemplated under the GSK Agreement are subject to customary closing conditions, including clearance by the relevant competition authorities.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The description of the Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">San Diego Lease Agreement with ARE-SD Region No. 72 LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 19, 2021, the Company entered into a new lease for a San Diego, California research facility.&#160;&#160;The 15-year lease is for approximately 144,000 square feet of office and research and development laboratory space to be constructed in San Diego, California.&#160; This lease will replace the Company&#8217;s current research facility sublease for property located in San Diego, California.&#160;&#160;The increased capacity of this new facility compared to the Company&#8217;s current research facility in San Diego will accommodate increased personnel for the Company&#8217;s expanding pipeline of current and future drug candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated rent commencement date for the lease is in May 2023 after construction and leasehold improvements have been completed.&#160; The lease payments, which begin on the rent commencement date, will be approximately <span style="color:#000000;">$119.0</span> million over the initial 15-year term.&#160;&#160;The Company also estimates payments for operating expenses to be approximately $<span style="color:#000000;">3.0</span> million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $<span style="color:#000000;">31.0</span> million for leasehold improvements, net of tenant improvement allowances.&#160;&#160;Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The description of the Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 9C.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item9c_Disclosures_Regarding_Foreign">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART III </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 10.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item10_DirectorsExecutives">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information called for by this Item will be incorporated by reference from our Definitive Proxy Statement, under the headings Proposal One &#8212; Election of Directors, Equity Compensation Plan Information, and, if applicable, Delinquent Section 16(a) Reports, to be filed for our 2022 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 28, 2022.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Ethics, as part of our Code of Corporate Conduct, that applies to all of our directors, officers and employees, including our principal executive, principal financial and principal accounting officers, or persons performing similar functions. Our Code of Ethics is posted on our website located at https://arrowheadpharma.com/code-corporate-conduct/. We intend to disclose future amendments to certain provisions of the Code of Ethics, and waivers of the Code of Ethics granted to executive officers and directors, on the website within four business days following the date of the amendment or waiver.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 11.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item11_ExecutiveCompensation">EXECUTIVE COMPENSATION</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information called for by this Item will be incorporated by reference from our Definitive Proxy Statement, under the heading Executive Compensation, to be filed for our 2022 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 28, 2022.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 12.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item12_SecurityOwnership">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information called for by this Item will be incorporated by reference from our Definitive Proxy Statement, under the heading Voting Securities of Principal Stockholders and Management, to be filed for our 2022 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 28, 2022.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 13.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item13_CertainRelationships">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information called for by this Item will be incorporated by reference from our Definitive Proxy Statement, under the headings Review and Approval of Related-Party Transactions and Certain Relationships and Related Transactions, and Director Independence, to be filed for our 2022 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 28, 2022.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;14.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item14_PrincipalAccountantFees">PRINCIPAL ACCOUNTANT FEES AND SERVICES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information called for by this Item will be incorporated by reference from our Definitive Proxy Statement, under the heading Audit Fees, to be filed for our 2022 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 28, 2022.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART IV </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 15.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item15_Exhibits">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are filed as part of this Annual Report on Form 10-K: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Index to Financial Statements and Schedule on page F-1. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statement Schedules. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Index to Financial Statements and Schedule on page F-1. All other schedules are omitted as the required information is not present or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements or notes thereto. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibits. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form 10-K: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.05pt;">
<td valign="bottom" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:35%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference&#160;Herein</p></td>
</tr>
<tr style="height:3pt;">
<td valign="bottom" style="width:9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:2.8pt;">
<td valign="top" style="width:9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:23.3pt;">
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459020036812/arwr-ex11_467.htm"><span style="text-decoration:underline;">Open Market Sale Agreement, dated as of August 5, 2020, by and between Arrowhead Pharmaceuticals, Inc. and Jefferies LLC</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 1.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 5, 2020</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2.1&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex21.htm"><span style="text-decoration:underline;">Stock and Asset Purchase Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K as Exhibit 2.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">December&#160;20, 2011</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459015003902/arwr-ex21_20150331298.htm"><span style="text-decoration:underline;">Asset Purchase and Exclusive License Agreement between Arrowhead Research Corporation and Novartis Institutes for BioMedical Research, Inc., dated March 3, 2015&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 2.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">May 11, 2015</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm"><span style="text-decoration:underline;">Amended and Restated Certificate of Incorporation</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K as Exhibit 3.3</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 6, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex34.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K as Exhibit 3.4</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 6, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex41.htm"><span style="text-decoration:underline;">Form of Common Stock Certificate of Arrowhead Pharmaceuticals, Inc.</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K, as Exhibit 4.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 6, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000119312519304271/d807419ds3asr.htm"><span style="text-decoration:underline;">Form of Indenture</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registration Statement on Form S-3, as Exhibit 4.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 2, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312517092797/d319463dex41.htm"><span style="text-decoration:underline;">Rights Agreement dated as of March 21, 2017, between the Company and Computershare Trust Company, N.A., as rights agent, which includes as Exhibit B the Form of Rights Certificate</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K, as Exhibit 4.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 23, 2017</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-ex44_92.htm"><span style="text-decoration:underline;">Description of Registrant&#8217;s Securities</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex104_153.htm"><span style="text-decoration:underline;">Registration Rights Agreement by and between Arrowhead Pharmaceuticals, Inc. and Johnson &#38; Johnson Innovation-JJDC, Inc., dated October 3, 2018</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 4.4</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.4</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 25, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 7, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312512009893/d275001ddef14a.htm"><span style="text-decoration:underline;">Arrowhead Research Corporation 2004 Equity Incentive Plan, as amended</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 14C, as Annex B</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 12, 2012</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312513481209/d647635ddef14a.htm"><span style="text-decoration:underline;">Arrowhead Research Corporation 2013 Incentive Plan</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 14C, as Annex A</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 20, 2013</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312514048097/d675317dex101.htm"><span style="text-decoration:underline;">Form of Stock Option Agreement for use with the 2013 Incentive Plan</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 12, 2014</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4**</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5**</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6**</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7**</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312514048097/d675317dex102.htm"><span style="text-decoration:underline;">Form of Restricted Stock Unit Agreement for use with the 2013 Incentive Plan</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000119312521019640/d76219ddef14a.htm"><span style="text-decoration:underline;">Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan</span></a></p>

<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex101_33.htm"><span style="text-decoration:underline;">Form of Performance RSU Agreement for use with the 2021 Incentive Plan</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex102_32.htm"><span style="text-decoration:underline;">Form of Stock Option Agreement for use with the 2021 Incentive Plan</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex103_31.htm"><span style="text-decoration:underline;">Form of RSU Agreement for use with the 2021 Incentive Plan</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K, as Exhibit 10.2</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 14A, Exhibit A</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.2</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.3</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 12, 2014</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 28, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 5, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 5, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 5, 2021</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.05pt;">
<td valign="bottom" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:35%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference&#160;Herein</p></td>
</tr>
<tr style="height:3pt;">
<td valign="bottom" style="width:9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312506253375/dex1011.htm"><span style="text-decoration:underline;">Executive Incentive Plan, adopted December 12, 2006</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.11</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 14, 2006</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312508133616/dex101.htm"><span style="text-decoration:underline;">Employment Agreement between Arrowhead and Dr. Christopher Anzalone, dated June 11, 2008</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 13, 2008</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312509258134/dex108.htm"><span style="text-decoration:underline;">Amendment to Employment Agreement between Arrowhead and Dr. Christopher Anzalone, effective May 12, 2009</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.8</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 22, 2009</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex1033.htm"><span style="text-decoration:underline;">Non-Exclusive License Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.33</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 20, 2011</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex1036.htm"><span style="text-decoration:underline;">Collaboration Agreement by and among Alnylam Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc., dated October&#160;29, 2009 &#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.36</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 20, 2011</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459014003557/arwr-ex10_20140630353.htm"><span style="text-decoration:underline;">License Agreement by and between Alnylam Pharmaceuticals, Inc., Arrowhead Research Corporation and Arrowhead Madison, Inc.&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 12, 2014</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459016030217/arwr-ex1018_310.htm"><span style="text-decoration:underline;">First Collaboration and Licensing Agreement between Arrowhead Pharmaceuticals, Inc. and Amgen Inc., dated September 28, 2016&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.18</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">December 14, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459016030217/arwr-ex1019_309.htm"><span style="text-decoration:underline;">Second Collaboration and Licensing Agreement between Arrowhead Pharmaceuticals, Inc. and Amgen Inc., dated September 28, 2016&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.19</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">December 14, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312516776646/d272157dex101.htm"><span style="text-decoration:underline;">Common Stock Purchase Agreement between the Company and Amgen Inc., dated September 28, 2016</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amendment No. 1 to the Registration Statement on Form S-3, as Exhibit 10.1)</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 25, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex101_156.htm"><span style="text-decoration:underline;">License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated October 3, 2018&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 7, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex102_155.htm"><span style="text-decoration:underline;">Research Collaboration and Option Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated October 3, 2018&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 7, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex103_154.htm"><span style="text-decoration:underline;">Stock Purchase Agreement by and between Johnson &#38; Johnson Innovation-JJDC, Inc. and Arrowhead Pharmaceuticals, Inc., dated October 3, 2018</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.3</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 7, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22&#8224;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459019044376/arwr-ex1019_310.htm"><span style="text-decoration:underline;">Amendment No. 1 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated December 18, 2018&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-Q, as Exhibit 10.19</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 25, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-ex1020_311.htm"><span style="text-decoration:underline;">Amendment No. 2 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated February 4, 2019&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.20</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 25, 2019</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:2.45pt;">
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-ex1021_309.htm"><span style="text-decoration:underline;">Amendment No. 1 to Research Collaboration and Option Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated November 14, 2019&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.21</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 25, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459019028760/arwr-ex101_67.htm"><span style="text-decoration:underline;">Office Lease by and between 177 Colorado Owner LLC and Arrowhead Pharmaceuticals, Inc., dated April 17, 2019</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">August 5, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:14.15pt;">
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex102_50.htm"><span style="Background-color:#FFFFFF;"></span><span style="Background-color:#FFFFFF;text-decoration:underline;">Amendment No. 1 to Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and 177 Colorado Owner LLC., dated October 23, 2020</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459016012515/arwr-ex101_83.htm"><span style="text-decoration:underline;">Lease Agreement between University Research Park, Incorporated and Arrowhead Madison, Inc., dated January 8, 2016</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.2</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 4, 2021</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 9. 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.05pt;">
<td valign="bottom" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:35%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference&#160;Herein</p></td>
</tr>
<tr style="height:3pt;">
<td valign="bottom" style="width:9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1023_125.htm"><span style="text-decoration:underline;">Amendment No. 1 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated October 22, 2018</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.23</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 23, 2020</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.29</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1024_124.htm"><span style="text-decoration:underline;">Amendment No. 2 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 10, 2019</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.24</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 23, 2020</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1025_123.htm"><span style="text-decoration:underline;">Amendment No. 3 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 11, 2019</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.25</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 23, 2020</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1026_121.htm"><span style="text-decoration:underline;">Amendment No. 4 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated September 19, 2019 </span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual report on Form 10-K, as Exhibit 10.26</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 23, 2020</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1027_122.htm"><span style="text-decoration:underline;">Amendment No. 5 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated May 14, 2020</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual report on Form 10-K, as Exhibit 10.27</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 23, 2020</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.33</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex103_51.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Amendment No. 6 to Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and University Research Park, dated November 23, 2020</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.3</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 4, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.34</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex104_52.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Amendment No. 7 to Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and University Research Park, dated December 9, 2020</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.4</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 4, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.35&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459020022860/arwr-ex101_202.htm"><span style="text-decoration:underline;">Sublease Agreement by and between Halozyme, Inc. and Arrowhead Pharmaceuticals, Inc. dated March 3, 2020&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">May 7, 2020</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.36&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex104_195.htm"><span style="text-decoration:underline;">Collaboration and License &#160;Agreement by and between Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics Ireland DAC, dated June 18, 2021</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.4</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">August 5, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.37&#8224;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex101_863.htm"><span style="text-decoration:underline;">Exclusive License and Co-Funding Agreement by and between Arrowhead Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc., dated October 7, 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 4, 2021&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex21_11.htm"><span style="text-decoration:underline;">List of Subsidiaries</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex23_12.htm"><span style="text-decoration:underline;">Consent of Independent Public Registered Accounting Firm</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex311_6.htm"><span style="text-decoration:underline;">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex312_15.htm"><span style="text-decoration:underline;">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1***</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex321_10.htm"><span style="text-decoration:underline;">Certification by Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2***</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex322_14.htm"><span style="text-decoration:underline;">Certification by Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Schema Document</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Calculation Linkbase Document</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Label Linkbase Document</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Presentation Linkbase Document</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.05pt;">
<td valign="bottom" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:35%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference&#160;Herein</p></td>
</tr>
<tr style="height:3pt;">
<td valign="bottom" style="width:9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Definition Linkbase Document</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2021, formatted in Inline XBRL (included as Exhibit 101)</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates compensation plan, contract or arrangement.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Furnished herewith</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM 16.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item_16">FORM 10-K SUMMARY </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0.83%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="Signature"><span style="text-decoration:underline;">SIGNATURE </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form&#160;10-K to be signed on its behalf by the undersigned, thereunto duly authorized, on this 22nd day of November 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: November 22, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:54.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:45.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD PHARMACEUTICALS, INC.</p></td>
</tr>
<tr>
<td valign="top" style="width:54.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:2.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:42.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:54.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:2.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:0.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:42.42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top" style="width:54.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:2.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:42.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top" style="width:54.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:2.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:42.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report on Form&#160;10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 1pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Christopher Anzalone</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer, President and</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 22, 2021</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Christopher Anzalone</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director (Principal Executive Officer)</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <span style="color:#000000;">Kenneth A. Myszkowski</span></p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer (Principal</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 22, 2021</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kenneth A. Myszkowski</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial and Accounting Officer)</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/<span style="font-weight:bold;color:#000000;"> </span><span style="color:#000000;">Douglass Given</span></p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director, Chairman of the Board of Directors</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 22, 2021</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Douglass Given</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <span style="color:#000000;">Mauro Ferrari</span></p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 22, 2021</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Mauro Ferrari</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <span style="color:#000000;">Michael S. Perry</span></p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 22, 2021</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Michael S. Perry</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <span style="color:#000000;">William Waddill</span></p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 22, 2021</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">William Waddill</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Marianne De Backer</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 22, 2021</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marianne De Backer</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Adeoye Olukotun</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 22, 2021</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Adeoye Olukotun</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3.8pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="IndexToFinancialStatementsAndSchedules">INDEX TO FINANCIAL STATEMENTS AND SCHEDULE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Reports of Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Balance_Sheets"><span style="text-decoration:underline;">Consolidated Balance Sheets of Arrowhead Pharmaceuticals, Inc., September&#160;30, 2021 and 2020</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Statements_of_Operations"><span style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Income (Loss) of Arrowhead Pharmaceuticals, Inc. for the years ended September&#160;30, 2021, 2020 and 2019</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENT_STOCKHOLDERS_EQUI"><span style="text-decoration:underline;">Consolidated Statements of Stockholders&#8217; Equity of Arrowhead Pharmaceuticals, Inc. for the years ended September 30, 2021, 2020, and 2019</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Statements_of_Cash_Flows"><span style="text-decoration:underline;">Consolidated Statements of Cash Flows of Arrowhead Pharmaceuticals, Inc. for the years ended September&#160;30, 2021, 2020 and 2019</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Notes_to_Consolidated"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements of Arrowhead Pharmaceuticals, Inc.</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Board of Directors and<br />Stockholders of Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Arrowhead Pharmaceuticals, Inc. and Subsidiaries (the Company) as of September 30, 2021 and 2020, and the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended September 30, 2021, and the related notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended September 30, 2021, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of September 30, 2021, based on criteria established in <span style="font-style:italic;">Internal Control&#8212;Integrated Framework (2013)</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated November 22, 2021, expressed an unqualified opinion.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Audit Matters</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition &#8211; Revenue Recognized Over Time</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description of the Matter</span></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 1 and Note 2 to the Consolidated Financial Statements, the Company earns its revenue through license and collaboration agreements. For performance obligations related to services that are required to be recognized over time, the Company measures its progress to completion using various measures, including an input measure of total labor costs incurred divided by total labor costs expected to be incurred, time elapsed, and an output measure of total patient visits divided by total patient visits expected. The selection of measurement criteria is based on the nature and phase of trials being conducted.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auditing revenue recognition is complex and highly judgmental due to the variability and uncertainty associated with the Company&#8217;s assessment of measure of progress. Changes in these estimates would have a significant effect on the amount of revenue recognized. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">How We Addressed the Matter in Our Audit</span></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls that address the risk of material misstatement of license and collaboration agreement revenue including those associated with cost to complete estimates. We tested controls over management&#8217;s process to collect, review, and approve the data used in assessing revenue recognized over time. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="keyword">To test the measures of progress used for performance obligations related to services that are required to be recognized over time, our&#160;audit&#160;procedures included, among others, evaluating the appropriateness of the Company&#8217;s accounting policy for each type of arrangement, testing the identified measure of performance by reading contracts with customers, including all amendments, and reviewing the contract analyses prepared by management. We evaluated whether the selected measures of progress towards satisfaction of performance obligations were applied consistently. We also tested the completeness and accuracy of the underlying data used for the measure of progress by testing and or analyzing the underlying data and conducting interviews of project personnel. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50.09%;">
<tr>
<td style="width:40.83%;"></td>
<td style="width:8.43%;"></td>
<td style="width:0.83%;"></td>
</tr>
<tr>
<td colspan="2" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;text-align:left;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rose, Snyder &#38; Jacobs LLP</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="margin-bottom:6pt;text-align:left;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2004.</p></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="margin-bottom:6pt;text-align:left;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Encino, California</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="top">
<p style="margin-bottom:6pt;text-align:left;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 22, 2021</p></td>
<td colspan="2" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:-4.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Board of Directors and<br />Stockholders of Arrowhead Pharmaceuticals, Inc. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on Internal Control over Financial Reporting</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited Arrowhead Pharmaceuticals, Inc. and Subsidiaries (the Company&#8217;s) internal control over financial reporting as of September 30, 2021, based on criteria established in <span style="font-style:italic;">Internal Control&#8212;Integrated Framework (2013)</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of September 30, 2021, based on criteria established in <span style="font-style:italic;">Internal Control&#8212;Integrated Framework (2013)</span> issued by COSO.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets as of September 30, 2021 and 2020 and the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the three years in the period ended September 30, 2021 and related notes, and our report dated November 22, 2021 expressed an unqualified opinion thereon.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Definition and Limitations of Internal Control over Financial Reporting</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company&#59; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company&#59; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rose, Snyder &#38; Jacobs LLP</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Encino, CA</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 22, 2021</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I_FINANCIAL_INFORMATION">PART I. FINANCIAL INFORMATION </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1_FINANCIAL_STATEMENTS">FINANCIAL STATEMENTS </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="Balance_Sheets">Consolidated Balance Sheets </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CURRENT ASSETS</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">184,434</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">143,583</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">10,255</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0000879407_20200930" decimals="-3" scale="3">846</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,362</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,251</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:OtherAssetsCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,191</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:OtherAssetsCurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,782</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">126,728</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">85,020</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short term investments</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">56,627</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">86,890</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL CURRENT ASSETS</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:AssetsCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">384,597</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:AssetsCurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">322,372</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">48,675</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">30,881</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">13,663</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">15,363</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term investments</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">245,595</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">137,487</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">17,346</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">16,137</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0000879407_20210930" decimals="-3" scale="3">272</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0000879407_20200930" decimals="-3" scale="3">264</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TOTAL ASSETS</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:Assets" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">710,148</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:Assets" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">522,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CURRENT LIABILITIES</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:AccountsPayableCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">9,457</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:AccountsPayableCurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,829</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">14,001</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">5,389</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and benefits</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">9,773</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,061</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,250</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,095</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">111,055</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">19,291</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0000879407_20200930" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL CURRENT LIABILITIES</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:LiabilitiesCurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">146,536</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:LiabilitiesCurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">40,682</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LONG-TERM LIABILITIES</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities, net of current portion</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">23,295</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">20,043</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">131,495</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL LONG-TERM LIABILITIES</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">154,790</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">20,043</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 7)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000079">&#160;</span></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000080">&#160;</span></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000093" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0000879407_20210930" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000094" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0000879407_20200930" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000095" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0000879407_20210930" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0000879407_20200930" decimals="INF" format="ixt:numdotdecimal" scale="3">145,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:CommonStockSharesIssued" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">104,327</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:CommonStockSharesIssued" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">102,376</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2021 and September 30, 2020, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:CommonStockValue" contextRef="C_0000879407_20210930" decimals="-3" scale="3">197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:CommonStockValue" contextRef="C_0000879407_20200930" decimals="-3" scale="3">195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,053,386</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">965,410</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income (loss)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000879407_20210930" decimals="-3" sign="-" scale="3">69</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000879407_20200930" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0000879407_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">644,692</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0000879407_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">503,844</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">408,822</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">461,779</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">710,148</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">522,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="Statements_of_Operations">Consolidated Statements of Operations and Comprehensive Income (Loss)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">REVENUE</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">138,287</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">87,992</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">168,796</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OPERATING EXPENSES</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">206,342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">128,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">81,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">80,981</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">52,276</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">26,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL OPERATING EXPENSES</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:OperatingExpenses" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">287,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:OperatingExpenses" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">181,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:OperatingExpenses" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">107,605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPERATING INCOME (LOSS)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20201001_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">149,036</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">93,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">61,191</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OTHER INCOME (EXPENSE)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income (expense), net</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">9,191</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,070</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" scale="3">583</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL OTHER INCOME (EXPENSE)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,190</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,608</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INCOME (LOSS) BEFORE INCOME TAXES</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000879407_20201001_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">140,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">68,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000879407_20201001_20210930" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000879407_20191001_20200930" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000879407_20181001_20190930" decimals="-3" scale="3">174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET INCOME (LOSS)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:NetIncomeLoss" contextRef="C_0000879407_20201001_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">140,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:NetIncomeLoss" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:NetIncomeLoss" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">67,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET INCOME (LOSS) PER SHARE - BASIC</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000136" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20201001_20210930" decimals="2" sign="-">1.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000137" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20191001_20200930" decimals="2" sign="-">0.84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000138" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20181001_20190930" decimals="2">0.72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET INCOME (LOSS) PER SHARE - DILUTED</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000139" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20201001_20210930" decimals="2" sign="-">1.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000140" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20191001_20200930" decimals="2" sign="-">0.84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000141" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20181001_20190930" decimals="2">0.69</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding - basic</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000142" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">103,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000143" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">100,722</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000144" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">93,859</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding - diluted</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000145" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">103,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000146" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">100,722</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000147" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">98,608</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20201001_20210930" decimals="-3" sign="-" scale="3">87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20191001_20200930" decimals="-3" scale="3">410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20181001_20190930" decimals="-3" sign="-" scale="3">370</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPREHENSIVE INCOME (LOSS)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000879407_20201001_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">140,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84,143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">67,605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENT_STOCKHOLDERS_EQUI">Consolidated Statements of Stockholders&#8217; Equity </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:7pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000154" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930" decimals="-3" format="ixt:numdotdecimal" scale="3">88,505</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930" decimals="-3" scale="3">181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180930" decimals="-3" format="ixt:numdotdecimal" scale="3">582,903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180930" decimals="-3" sign="-" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">487,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180930" decimals="-3" sign="-" scale="3">555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20180930" decimals="-3" format="ixt:numdotdecimal" scale="3">95,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">12,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">12,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000163" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,276</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock - restricted stock units vesting</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000167" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930" decimals="-3" sign="-" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock - issued for cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000170" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">60,518</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">60,521</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181001_20190930" decimals="-3" sign="-" scale="3">370</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20181001_20190930" decimals="-3" sign="-" scale="3">370</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) for the twelve months ended September 30, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:ProfitLoss" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">67,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">67,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000178" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">95,506</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930" decimals="-3" scale="3">188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">664,086</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930" decimals="-3" sign="-" scale="3">392</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">419,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930" decimals="-3" sign="-" scale="3">555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">244,036</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000185" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">95,506</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930" decimals="-3" scale="3">188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">664,086</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930" decimals="-3" sign="-" scale="3">392</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">419,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930" decimals="-3" sign="-" scale="3">555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">244,036</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">43,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">43,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000194" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,111</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">7,468</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">7,469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock - restricted stock units vesting</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000198" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930" decimals="-3" sign="-" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock - issued for cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000201" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">250,474</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">250,479</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191001_20200930" decimals="-3" scale="3">410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20191001_20200930" decimals="-3" scale="3">410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deconsolidation of Ablaris Therapeutics, Inc.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191001_20200930" decimals="-3" scale="3">555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" contextRef="C_0000879407_20191001_20200930" decimals="-3" scale="3">555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) for the twelve months ended September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:ProfitLoss" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000211" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">102,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930" decimals="-3" scale="3">195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">965,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200930" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">503,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">461,779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000217" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">102,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930" decimals="-3" scale="3">195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">965,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200930" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">503,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">461,779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">76,673</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">76,673</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000225" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,052</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20210930" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">11,304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">11,305</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock - restricted stock units vesting</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000229" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20210930" decimals="-3" scale="3">899</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20210930" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201001_20210930" decimals="-3" sign="-" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201001_20210930" decimals="-3" sign="-" scale="3">87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20201001_20210930" decimals="-3" sign="-" scale="3">87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) for the twelve months ended September 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:ProfitLoss" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201001_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">140,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20201001_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">140,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000236" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">104,327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930" decimals="-3" scale="3">197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,053,386</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210930" decimals="-3" sign="-" scale="3">69</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">644,692</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">408,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:7pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="Statements_of_Cash_Flows">Consolidated Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended September 30,</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20201001_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">140,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">67,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:ShareBasedCompensation" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">76,673</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:ShareBasedCompensation" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">43,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:ShareBasedCompensation" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">12,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:DepreciationAndAmortization" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:DepreciationAndAmortization" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">5,942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:DepreciationAndAmortization" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,439</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization/(accretion) of note premiums</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0000879407_20201001_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0000879407_20181001_20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">9,409</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0000879407_20191001_20200930" decimals="-3" scale="3">184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0000879407_20181001_20190930" decimals="-3" scale="3">334</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0000879407_20201001_20210930" decimals="-3" scale="3">360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0000879407_20191001_20200930" decimals="-3" scale="3">387</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" scale="3">821</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">9,522</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,989</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">223,258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">63,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">82,804</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,229</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,106</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">171,224</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">95,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">173,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">23,567</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">11,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">12,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">240,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">278,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">90,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">122,592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">50,138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">54,521</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0000879407_20201001_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">141,678</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">240,778</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0000879407_20181001_20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">47,746</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal payments on notes payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:RepaymentsOfNotesPayable" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the exercises of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">11,305</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">7,469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,275</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">250,479</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">60,522</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">11,305</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">257,948</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">66,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET INCREASE (DECREASE) IN CASH</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">40,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0000879407_20191001_20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">78,221</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">191,671</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">143,583</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">221,804</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20180930" decimals="-3" format="ixt:numdotdecimal" scale="3">30,133</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH AND CASH EQUIVALENTS AT END OF PERIOD</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">184,434</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">143,583</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20190930" decimals="-3" format="ixt:numdotdecimal" scale="3">221,804</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplementary disclosures:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest paid</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:InterestPaidNet" contextRef="C_0000879407_20181001_20190930" decimals="-3" scale="3">27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes (Paid)/Refunded</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0000879407_20201001_20210930" decimals="-3" sign="-" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0000879407_20191001_20200930" decimals="-3" scale="3">103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0000879407_20181001_20190930" decimals="-3" sign="-" scale="3">302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="Notes_to_Consolidated">Notes to Consolidated Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unless otherwise noted, (1)&#160;the term &#8220;Arrowhead&#8221; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation and its Subsidiaries, (2)&#160;the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3)&#160;the term &#8220;Subsidiaries&#8221; refers to Arrowhead Madison Inc. (&#8220;Arrowhead Madison&#8221;) and Arrowhead Australia Pty Ltd (&#8220;Arrowhead Australia&#8221;), (4)&#160;the term &#8220;Common Stock&#8221; refers to Arrowhead&#8217;s Common Stock, (5) the term &#8220;Preferred Stock&#8221; refers to Arrowhead&#8217;s Preferred Stock&#160;and (6) the term &#8220;Stockholder(s)&#8221; refers to the holders of Arrowhead Common Stock.  </p><ix:nonNumeric id="F_000309" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true" continuedAt="F_000309_dcnt_0d5cf1f0-a075-42c5-b9a1-b077daa893b4">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1. <span style="font-style:italic;">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Nature of Business and Recent Developments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them.&#160;Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company&#8217;s pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-<span style="color:#000000;">LUNG2 for chronic obstructive pulmonary disorder, ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens</span> and ARO-C3 for complement mediated diseases<span style="color:#000000;">. ARO-XDH is being developed for uncontrolled gout under a collaboration agreement with Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;). ARO-JNJ2 and ARO-JNJ3 are being developed for undisclosed liver-expressed targets under a collaboration agreement with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;).&#160;&#160;JNJ-75220795 (ARO-JNJ1) is being developed by Janssen as a potential treatment for patients with non-alcoholic steatohepatitis (NASH).&#160;&#160;</span>ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) in October 2020. JNJ3989 (formerly referred to as ARO-HBV) <span style="color:#000000;">for chronic hepatitis B virus was out-licensed to Janssen in October 2018.&#160;&#160;</span>Olpasiran (formerly referred to as AMG 890 or ARO-LPA) <span style="color:#000000;">for cardiovascular disease was out-licensed to Amgen Inc. (&#8220;Amgen&#8221;) in 2016.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.58%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During fiscal year 2021, the Company continued to develop its pipeline and partnered candidates.&#160;&#160;The Company announced positive interim clinical data on (i) AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the Company&#8217;s second-generation investigational RNAi therapeutic being co-developed with Takeda as a treatment for the rare genetic liver disease associated with AATD, (ii) AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH), and (iii) AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma.&#160;&#160;The Company also presented preclinical data on the development of ARO-DUX4, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with facioscapulohumeral muscular dystrophy (FSHD), at the 28th&#160;Annual&#160;FSHD Society International Research Congress. The Company hosted a key opinion leader webinar on its cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, and presented positive clinical data from the Phase 1/2 clinical studies of ARO-APOC3 and ARO-ANG3 at the American Heart Association Scientific Sessions 2020.&#160;&#160;The Company filed two Investigational New Drug Applications with the United States Food and Drug Administration (the &#8220;FDA&#8221;) to begin a Phase 2b clinical study of ARO-APOC3 in patients with severe hypertriglyceridemia and a Phase 2b clinical study of ARO-ANG3 in patients with mixed dyslipidemia, and initiated these two Phase 2b clinical studies in the third quarter of fiscal year 2021. The Company also filed for regulatory clearance to begin a Phase 1/2a study of ARO-C3 for treatment of complement mediated diseases. In July 2021, the Company voluntarily paused AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis, after receiving a preliminary update from an ongoing chronic toxicology study in rats that contained unexpected signals of local lung inflammation.&#160;&#160;New screening, enrollment and any further dosing of investigational ARO-ENaC have been paused pending additional data from ongoing nonclinical toxicology studies.&#160;&#160;The Company announced two collaborations during fiscal year 2021: a collaboration with Takeda to co-develop and co-commercialize ARO-AAT for alpha-1 antitrypsin-associated liver disease and a collaboration with Horizon to develop ARO-XDH, an investigational RNAi therapeutic for uncontrolled gout. In July 2021, the Company received Breakthrough Therapy designation from the FDA for ARO-AAT, which is a process designed to expedite the development and review of drugs that are intended to treat a serious life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s partnered candidates under its collaboration agreements also continued to progress.&#160;&#160;Janssen began dosing patients in a Phase 2b triple combination study called REEF-1,&#160;designed to enroll up to 450 patients with chronic hepatitis B infection.&#160;&#160;The Company is currently performing discovery, optimization and preclinical research and development for ARO-JNJ2 and ARO-JNJ3 for Janssen as part of the Company&#8217;s Research Collaboration and Option Agreement with Janssen (&#8220;Janssen Collaboration Agreement&#8221;), and Janssen has began dosing patients in its Phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1).&#160;&#160;Amgen has initiated a Phase 2 clinical trial for Olpasiran (previously referred to as AMG 890 or ARO-LPA).&#160;&#160;The Company entered into two licensing deals during fiscal 2021: i) an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda for ARO-AAT, a<span style="color:#000000;">nd ii) a Collaboration and License Agreement (the &#8220;Horizon License Agreement&#8221;) with Horizon Therapeutics Ireland DAC </span></p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000309_dcnt_0d5cf1f0-a075-42c5-b9a1-b077daa893b4" continuedAt="F_000309_dcnt_31883f06-fab7-46b2-89d9-101d9092bc97">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">(&#8220;Horizon&#8221;) for ARO-XDH.&#160;&#160;ARO-AAT is currently in phase 2 clinical trials and ARO-XDH is in discovery-stage.&#160;&#160;During fiscal year 2021, the Company earned</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="arwr:CashReceivedAsDueUnderAgreement" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20201001_20210930" decimals="-5" scale="6">340.0</ix:nonFraction><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="color:#000000;"> in upfront payments from its collaboration agreements</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;">and </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="arwr:MilestonePaymentEarned" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_20210930" decimals="-5" scale="6">20.0</ix:nonFraction><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million </span><span style="color:#000000;">in option and milestone payments. In total, the Company remains eligible fo</span><span style="color:#000000;">r</span><span style="color:#000000;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_20210930" decimals="INF" scale="9">5.3</ix:nonFraction><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;">billion in developmental, regulatory and sales milestones and various royalties on net sales.&#160;&#160;The revenue recognition for these collaboration agreements is discussed further in Note 2 below</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead operates lab facilities in Madison, Wisconsin and San Diego, California, where the Company&#8217;s research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is actively monitoring the ongoing COVID-19 pandemic. The financial results for the years ended September 30, 2021 and 2020 were not significantly impacted by COVID-19. Operationally, the Company experienced delays in its earlier stage programs due to a shortage in non-human primates, which are critical to the Company&#8217;s preclinical programs.&#160;&#160;Additionally, the Company experienced delays in enrollment in its clinical trials.&#160;&#160;The Company&#8217;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters in Pasadena, California have continued with limited impact, other than for enhanced safety measures, including work from home policies, and intermittent lab supply shortages. However, the Company cannot predict the impact the progression of COVID-19 will have on future financial and operational results due to a variety of factors, including the ability of the Company&#8217;s clinical sites to continue to enroll subjects, the ability of the Company&#8217;s suppliers to continue to operate, the continued good health and safety of the Company&#8217;s employees and the length and severity of the COVID-19 pandemic.<span style="color:#000000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Consolidated Financial Statements have been prepared in conformity with the accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), which contemplate the continuation of the Company as a going concern.&#160; Historically, the Company&#8217;s primary sources of financing have been through the sale of its securities and revenue from its licensing and collaboration agreements.&#160;&#160;Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded significantly.&#160;&#160;Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials, as well as with the Company&#8217;s plans to increase its internal manufacturing capabilities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2021, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20210930" decimals="-5" scale="6">184.4</ix:nonFraction> million in cash and cash equivalents (including $<ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20210930" decimals="-5" scale="6">2.4</ix:nonFraction> million in restricted cash), $<ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="C_0000879407_20210930" decimals="-5" scale="6">56.6</ix:nonFraction> million in short-term investments and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:MarketableSecurities" contextRef="C_0000879407_20210930" decimals="-5" scale="6">126.7</ix:nonFraction> million in marketable securities, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" contextRef="C_0000879407_20210930" decimals="-5" scale="6">245.6</ix:nonFraction> million in long-term investments to fund operations.&#160;&#160;During the year ended September 30, 2021, the Company&#8217;s cash and investments balance increased by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="arwr:IncreaseDecreaseInCashAndInvestments" contextRef="C_0000879407_20201001_20210930" decimals="-5" scale="6">160.4</ix:nonFraction> million, was primarily the result of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="arwr:CashReceivedAsDueUnderAgreement" contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20210101_20210131" decimals="-5" scale="6">300.0</ix:nonFraction> million upfront payment from the Takeda License Agreement and the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="arwr:CashReceivedAsDueUnderAgreement" contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20201001_20210930" decimals="-6" scale="6">40</ix:nonFraction> million upfront payment from the Horizon License Agreement, partially offset by cash used to fund the Company&#8217;s research and development operations and general and administrative expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Summary of Significant Accounting Policies </p><ix:nonNumeric id="F_000322" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation&#8212;The Consolidated Financial Statements include the accounts of Arrowhead and its Subsidiaries.&#160;&#160;Arrowhead&#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#8217;s research and development facility is located.&#160;&#160;All significant intercompany accounts and transactions are eliminated in consolidation. </p></ix:nonNumeric><ix:nonNumeric id="F_000323" name="arwr:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation and Use of Estimates&#8212;The <span style="color:#000000;">preparation of financial statements in conformity GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation</span>.&#160;&#160; </p></ix:nonNumeric><ix:nonNumeric id="F_000324" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents&#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&#160;&#160;Included within Cash and cash equivalents on the Consolidated Balance Sheets is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20210930" decimals="-5" scale="6">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20200930" decimals="-5" scale="6">1.8</ix:nonFraction> restricted cash at September 30, 2021 and September 30, 2020, respectively.&#160;&#160;Amounts included in restricted cash are primarily held as collateral associated with a letter of credit for the Company&#8217;s <span style="color:#000000;">lease for its corporate headquarters in Pasadena, California.</span>&#160;&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000325" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk&#8212;The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:CashFDICInsuredAmount" contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_20210930" decimals="INF" format="ixt:numdotdecimal">250,000</ix:nonFraction> per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p></ix:nonNumeric>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000309_dcnt_31883f06-fab7-46b2-89d9-101d9092bc97" continuedAt="F_000309_dcnt_2b3a6504-9c5b-4f2c-9306-7a2d34d5f19c"><ix:nonNumeric id="F_000326" name="us-gaap:InvestmentPolicyTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments&#8212;The Company may invest excess cash balances in short-term and long-term marketable debt and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investments in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 320, Investments &#8211; Debt and Equity Securities and ASC 321, Investments in Equity Securities.&#160;ASC 320-Investments-Debt and Equity Securities requires debt securities to be classified into three categories: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-Maturity&#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Securities&#8212;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale&#8212;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of stockholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2021, 2020 and 2019, all of the Company&#8217;s debt securities were classified as held-to-maturity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity investments are measured and recorded at amortized cost on the Company&#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests in shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#8217;s Consolidated Balance Sheet as &#8220;marketable securities&#8221; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss). </p></ix:nonNumeric><ix:nonNumeric id="F_000327" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment&#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from <ix:nonNumeric id="F_000364" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000879407_srtRangeAxis_srtMinimumMember_20201001_20210930" format="ixt-sec:durwordsen" continuedAt="C_b7bb943e-e3e9-431d-9685-3b8473deff64">three</ix:nonNumeric> to <ix:nonNumeric id="F_000365" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_20201001_20210930" format="ixt-sec:durwordsen">seven<ix:continuation id="C_b7bb943e-e3e9-431d-9685-3b8473deff64"> years</ix:continuation></ix:nonNumeric>. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p></ix:nonNumeric><ix:nonNumeric id="F_000328" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets Subject to Amortization&#8212;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000329" name="arwr:ContingentConsiderationPolicyTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration&#8212;The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $<ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="C_0000879407_20200930" decimals="-6" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="C_0000879407_20210930" decimals="-6" scale="6">0</ix:nonFraction></ix:nonFraction> at September 30, 2021 and September 30, 2020. </p></ix:nonNumeric><ix:nonNumeric id="F_000330" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true" continuedAt="F_000330_dcnt_cee906a8-c899-4eed-b7ef-9d2be4d4934c">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212; <span style="color:#000000;">On October 1, 2018, the Company adopted FASB Topic 606 &#8211; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and </span></p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000309_dcnt_2b3a6504-9c5b-4f2c-9306-7a2d34d5f19c" continuedAt="F_000309_dcnt_6baff6c9-f926-493a-b3e0-0a47e809a469"><ix:continuation id="F_000330_dcnt_cee906a8-c899-4eed-b7ef-9d2be4d4934c" continuedAt="F_000330_dcnt_9b169b7b-9869-4f44-9779-6ef3c9b29ee0">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">across all industries. The Company&#8217;s adoption of the revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#8217;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen, Takeda and Horizon, and the analysis of the impact of this guidance on those agreements is discussed further in </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note 2 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract&#59; (ii) identify the performance obligations&#59; (iii) determine the transaction price&#59; (iv) allocate the transaction price to the performance obligations in the contract&#59; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials&#59; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States&#59; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in our Consolidated Statements of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</p>
</ix:continuation></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000309_dcnt_6baff6c9-f926-493a-b3e0-0a47e809a469" continuedAt="F_000309_dcnt_ef7125dd-c214-4945-bd75-0d29676f6ec0"><ix:continuation id="F_000330_dcnt_9b169b7b-9869-4f44-9779-6ef3c9b29ee0">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the Company determines that </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">goods or services promised in a contract</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> should be accounted for as a </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combined performance obligation over time</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> either</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the proportional performance method</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or on a straight-line basis if efforts will be expended evenly over time</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company determines that</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the performance </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligation is satisfied over time, any upfront</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> payment </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received is initially recorded </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deferred</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> revenue </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the Company&#8217;s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Consolidated Balance Sheets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#8217;s current operating plan and, if the Company&#8217;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.</p></ix:continuation><ix:nonNumeric id="F_000331" name="us-gaap:CollaborativeArrangementAccountingPolicy" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborative Arrangements&#8212;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB Topic 808 - Collaborative Arrangements. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to Research and Development Expense or General and Administrative Expense, as appropriate.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000332" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="C_0000879407_20201001_20210930" escape="true">Allowance for Doubtful Accounts&#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed.</ix:nonNumeric> </p><ix:nonNumeric id="F_000333" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development&#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000334" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">Net Income (Loss) per Share&#8212;Basic net income (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees.&#160;&#160;During the years ended September 30, 2021, 2020 and 2019, the calculation of the effect of dilutive stock options and restricted stock units was <ix:nonFraction unitRef="U_xbrlishares" id="F_000370" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="C_0000879407_20201001_20210930" decimals="INF">0</ix:nonFraction> shares, <ix:nonFraction unitRef="U_xbrlishares" id="F_000368" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="C_0000879407_20191001_20200930" decimals="INF">0</ix:nonFraction> shares, and <ix:nonFraction unitRef="U_xbrlishares" id="F_000369" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="C_0000879407_20181001_20190930" decimals="INF" format="ixt:numdotdecimal">4,748,958</ix:nonFraction> shares, respectively.&#160;&#160;During the year ended September 30, 2021 and 2020,<span style="color:#000000;"> the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect. During the year ended September 30, 2019, the calculation of the effect of dilutive stock options and restricted stock units excluded <ix:nonFraction unitRef="U_xbrlishares" id="F_000371" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">1,007,500</ix:nonFraction> stock options and <ix:nonFraction unitRef="U_xbrlishares" id="F_000372" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">11,500</ix:nonFraction> restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;&#160;&#160;&#160;&#160; </span></ix:nonNumeric> </p><ix:nonNumeric id="F_000335" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation&#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. </p></ix:nonNumeric>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000309_dcnt_ef7125dd-c214-4945-bd75-0d29676f6ec0" continuedAt="F_000309_dcnt_f9d14637-f498-421b-bab6-d7b44acc9465">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000336" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">Income Taxes&#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.</ix:nonNumeric><span style="font-size:12pt;">&#160;</span></p><ix:nonNumeric id="F_000337" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases<span style="color:#000000;">&#8212;</span>The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its&#160;&#160;leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term.&#160;Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </p></ix:nonNumeric><ix:nonNumeric id="F_000338" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and became effective for the Company in the first quarter of fiscal 2019. In April 2016, the FASB issued an amendment to ASU No. 2014-09 with update ASU 2016-10 which provided more specific guidance around the identification of performance obligations and licensing arrangements.&#160;&#160;On <ix:nonNumeric id="F_000374" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20210930" format="ixt:datemonthdayyearen">October 1, 2018</ix:nonNumeric>, the Company adopted this standard using the modified retrospective method. The Company&#8217;s implementation approach included reviewing the status of each of its ongoing license agreements and collaboration agreements and designing appropriate internal controls to enable the preparation of financial information.&#160;&#160;The Company completed its assessment of the impact of the new revenue recognition guidance and determined that there will be no material impact.&#160;&#160;The Company&#8217;s existing performance obligations under its ongoing license and collaboration agreements as of October 1, 2018 and prior were substantially completed prior to September 30, 2018.&#160;&#160;For these agreements that were ongoing as of October 1, 2018, any future option, milestone or royalty payments received will be accounted for under the sales-based royalty exception provided for under this new revenue recognition guidance.&#160;&#160;Additionally, there will be no impact to cash from or used in operating, financing or investing activities on the Company&#8217;s Consolidated Statement of Cash Flows as a result of the adoption of the new standard.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842).&#160;&#160;Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases).&#160;&#160;The Company adopted this standard effective <ix:nonNumeric id="F_000379" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210930" format="ixt:datemonthdayyearen">October 1, 2019</ix:nonNumeric> and <span style="color:#000000;">elected the package of three practical expedients that permits an entity to i) not reassess whether expired or existing contracts contain leases, ii) not reassess lease classification for existing or expired leases, and iii) not consider whether previously capitalized initial direct costs would be appropriate under the new standard.&#160;&#160;At September 30, 2021, the Company has recorded right-of-use assets of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000879407_20210930" decimals="-5" scale="6">17.3</ix:nonFraction> million and lease liabilities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:OperatingLeaseLiability" contextRef="C_0000879407_20210930" decimals="-5" scale="6">25.5</ix:nonFraction> million on its Consolidated Balance Sheets for its research and development facility leases in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below.&#160;&#160;The adoption of this standard did not have a material impact on the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss) and the Company&#8217;s Consolidated Statements of Cash Flows.&#160;&#160; </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808).&#160;&#160;This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 became effective for the Company in the first quarter of fiscal 2021 with early adoption permitted.&#160;&#160;The adoption of this update did not have a material effect on the Company&#8217;s Consolidated Financial Statements. </p></ix:nonNumeric>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000309_dcnt_f9d14637-f498-421b-bab6-d7b44acc9465">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000310" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true" continuedAt="F_000310_dcnt_3544d803-7887-412b-a7f1-fd5b6aeb0471">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2. <span style="font-style:italic;">COLLABORATION AND LICENSE AGREEMENTS</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amgen Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <ix:nonNumeric id="F_000384" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928" format="ixt:datemonthdayyearen">September&#160;28, 2016</ix:nonNumeric>, the Company entered into <ix:nonFraction unitRef="U_arwrAgreement" id="F_000385" name="arwr:NumberOfAgreements" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160928" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> collaboration and license agreements and a common stock purchase agreement with Amgen.&#160;&#160;Under the Second Collaboration and License Agreement or Olpasiran Agreement, Amgen has received a worldwide, exclusive license to Arrowhead&#8217;s novel, RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the other collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928" decimals="-5" scale="6">35.0</ix:nonFraction> million in upfront payments, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928" decimals="-5" scale="6">21.5</ix:nonFraction> million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="arwr:MilestonePaymentReceived" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20160928" decimals="INF" scale="6">30.0</ix:nonFraction> million in milestone payments, and may receive up to an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20210930" decimals="INF" scale="6">400.0</ix:nonFraction> million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement.&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement.&#160;&#160;Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study for Olpasiran, which resulted in a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="arwr:MilestonePaymentReceived" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200731" decimals="-6" scale="6">20</ix:nonFraction> million milestone payment to the Company. During the years ended September 30, 2021, 2020 and 2019, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20201001_20210930" decimals="-6" scale="6">0</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930" decimals="-5" scale="6">20.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930" decimals="-5" scale="6">0.3</ix:nonFraction> million of Revenue associated with its agreements with Amgen, respectively.  As of September 30, 2021, there were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20210930" decimals="-6" scale="6">0</ix:nonFraction> in contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20210930" decimals="-6" scale="6">0</ix:nonFraction> contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Janssen Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <ix:nonNumeric id="F_000399" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003_20181003" format="ixt:datemonthdayyearen"><ix:nonNumeric id="F_000400" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003" format="ixt:datemonthdayyearen"><ix:nonNumeric id="F_000401" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003" format="ixt:datemonthdayyearen">October 3, 2018</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>, the Company entered into the Janssen License Agreement and the Janssen Collaboration Agreement with Janssen, part of the Janssen Pharmaceutical Companies of Johnson &#38; Johnson.&#160;&#160;The Company also entered into a stock purchase agreement with JJDC (&#8220;JJDC Stock Purchase Agreement&#8221;).&#160;&#160;Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company is responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989.&#160;&#160;Under the Janssen Collaboration Agreement, Janssen will be able to select three new targets against which Arrowhead will develop clinical candidates.&#160;&#160;These candidates are subject to certain restrictions and do not include candidates that already were in the Company&#8217;s pipeline.&#160;&#160;The Company will perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, is sufficient to allow the filing of a U.S. Investigational New Drug Application or equivalent, at which time Janssen will have the option to take an exclusive license. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned candidate.&#160;&#160;Under the terms of the agreements taken together, the Company has received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003" decimals="-5" scale="6">175.0</ix:nonFraction> million as an upfront payment, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003" decimals="-5" scale="6">75.0</ix:nonFraction> million in the form of an equity investment <span style="color:#000000;">by JJDC in Arrowhead Common Stock under the JJDC </span>Stock Purchase Agreement, and milestone and option payments totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="arwr:MilestonePaymentEarned" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_20181003" decimals="-5" scale="6">70.0</ix:nonFraction> million, and may receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003" decimals="INF" scale="9">1.6</ix:nonFraction> billion in development and sales milestones payments for the Janssen License Agreement, and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003" decimals="INF" scale="9">1.9</ix:nonFraction> billion in development and sales milestone payments for the <ix:nonFraction unitRef="U_arwrTarget" id="F_000406" name="arwr:NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> additional targets covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers.&#160;&#160;At the inception of these agreements, the Company identified <ix:nonFraction unitRef="U_arwrObligation" id="F_000408" name="arwr:NumberOfDistinctPerformanceObligations" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003_20181003" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> distinct performance obligation.&#160;&#160;Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&#38;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&#38;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Janssen R&#38;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation.&#160;&#160;The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for this option is accounted for separately. </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000310_dcnt_3544d803-7887-412b-a7f1-fd5b6aeb0471" continuedAt="F_000310_dcnt_1be5fb54-68ee-4dc5-aba1-f3f4522cfc51">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the transaction price totaled approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="arwr:InitialTransactionPrice" contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003" decimals="-5" scale="6">252.7</ix:nonFraction> million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $<ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="arwr:MilestonePaymentEarned" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003" decimals="-5" scale="6">25.0</ix:nonFraction> million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&#38;D Services to be performed.&#160;&#160;The Company has allocated the total $<ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="arwr:InitialTransactionPrice" contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003" decimals="-5" scale="6">252.7</ix:nonFraction> million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&#38;D Services.&#160;&#160;The Company has recognized this transaction price in its entirety as of September 30, 2021 as efforts on its performance obligation have been substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. During the years ended September 30, 2021, 2020 and 2019, the Company recognized approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20201001_20210930" decimals="-5" scale="6">20.2</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20191001_20200930" decimals="-5" scale="6">65.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181001_20190930" decimals="-5" scale="6">167.5</ix:nonFraction> million of revenue associated with this performance obligation, respectively. As of September 30, 2021, there were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20210930" decimals="-5" scale="6">0.1</ix:nonFraction> million in contract assets recorded as accounts receivable, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20210930" decimals="-6" scale="6">0</ix:nonFraction> of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has begun to conduct its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2 and ARO-JNJ3 under the Janssen Collaboration Agreement.&#160;&#160;All costs and labor hours spent by the Company will be entirely funded by Janssen.&#160; During the years ended September 30, 2021, 2020 and 2019, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20201001_20210930" decimals="-5" scale="6">0.5</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20191001_20200930" decimals="-5" scale="6">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20181001_20190930" decimals="-5" scale="6">1.0</ix:nonFraction> million of revenue associated with these efforts, respectively.&#160;&#160;In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0 million milestone payment to the Company, and in September 2021, Janssen dosed its fifth patient in its phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1), which resulted in $<ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="arwr:MilestonePaymentReceived" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20210930" decimals="-5" scale="6">10.0</ix:nonFraction> million milestone payment to the Company. Each of these milestone payments was recognized entirely during the year ended September 30, 2021.&#160;&#160;As of September 30, 2021, there were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20210930" decimals="-5" scale="6">10.0</ix:nonFraction> million of cont<span style="color:#000000;">ract assets recorded as accounts </span>receivable and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20210930" decimals="-6" scale="6">0</ix:nonFraction> of contract liabilities recorded as curren<span style="color:#000000;">t deferred revenue on the Company&#8217;s Consolidated Balance</span> Sheets.&#160;The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="arwr:MilestonePaymentReceived" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20211031" decimals="-5" scale="6">10.0</ix:nonFraction> million milestone payment for the dosing of the fifth patient in its Phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1) was received in October 2021. <span style="color:#000000;"> &#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Takeda Pharmaceuticals U.S.A., Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <ix:nonNumeric id="F_000424" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" format="ixt:datemonthdayyearen">October 7, 2020</ix:nonNumeric>, the Company entered into the Takeda License Agreement with Takeda.&#160;&#160;Under the Takeda License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a <ix:nonNumeric id="F_000425" name="arwr:RatioOfProfitSharingStructureForCommercialization" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">50/50 profit sharing</ix:nonNumeric> structure.&#160;Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while the Company will be eligible to receive tiered royalties of <ix:nonFraction unitRef="U_xbrlipure" id="F_000426" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="2" scale="-2">20</ix:nonFraction>% to <ix:nonFraction unitRef="U_xbrlipure" id="F_000427" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="2" scale="-2">25</ix:nonFraction>% on net sales.&#160;&#160;In January 2021, the Company received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210131" decimals="-5" scale="6">300.0</ix:nonFraction> million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210131" decimals="-5" scale="6">740.0</ix:nonFraction> million.&#160;&#160;&#160;&#160;</span>&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the Takeda License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Takeda License Agreement, the Company identified <ix:nonFraction unitRef="U_arwrObligation" id="F_000431" name="arwr:NumberOfDistinctPerformanceObligations" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> distinct performance obligation.&#160;&#160;The Company determined that the key deliverables included the license and certain R&#38;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#8220;Takeda R&#38;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Takeda R&#38;D Services and their direct relationship with the license, the Company determined that these deliverables represent <ix:nonFraction unitRef="U_arwrBundle" id="F_000430" name="arwr:NumberOfDistinctBundle" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> distinct bundle and, thus, one performance obligation.&#160;&#160;Beyond the Takeda R&#38;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States.&#160;&#160;Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the <ix:nonNumeric id="F_000432" name="arwr:RatioOfProfitSharingStructureForCommercialization" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">50/50 profit sharing</ix:nonNumeric> structure within the United States.&#160;&#160;The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts will be recorded as Research and Development Expenses or General and Administrative Expenses, as appropriate. <span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="arwr:InitialTransactionPrice" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="-5" scale="6">300.0</ix:nonFraction> million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date.&#160;&#160;The Company has allocated the total $<ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="arwr:InitialTransactionPrice" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="-5" scale="6">300.0</ix:nonFraction> million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&#38;D Services.&#160;&#160;Revenue will be recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). Revenue for the years ended September 30, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201001_20210930" decimals="-5" scale="6">90.8</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20191001_20200930" decimals="-6" scale="6">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20181001_20190930" decimals="-6" scale="6">0</ix:nonFraction>, respectively. As of September 30, 2021, there were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930" decimals="-6" scale="6">0</ix:nonFraction> in contract assets recorded as accounts receivable, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapBalanceSheetLocationAxis_arwrDeferredRevenueCurrentMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930" decimals="-5" scale="6">84.4</ix:nonFraction> million in contract liabilities recorded as deferred revenue, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930" decimals="-5" scale="6">124.8</ix:nonFraction> million in contract liabilities recorded as deferred revenue, net of the current portion, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapBalanceSheetLocationAxis_us-gaapAccruedLiabilitiesMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930" decimals="-5" scale="6">3.1</ix:nonFraction> million in contract liabilities recorded as accrued expenses.&#160;&#160;The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapBalanceSheetLocationAxis_us-gaapAccruedLiabilitiesMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930" decimals="-5" scale="6">3.1</ix:nonFraction> million in accrued expenses was primarily driven by co-development and co-commercialization activities. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Horizon Therapeutics Ireland DAC</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <ix:nonNumeric id="F_000443" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618_20210618" format="ixt:datemonthdayyearen">June 18, 2021</ix:nonNumeric>, the Company entered into the Horizon License Agreement with Horizon.&#160;&#160;Under the Horizon License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Horizon received a worldwide exclusive license for&#160;ARO-XDH,&#160;a previously undisclosed discovery-stage investigational </span></p>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000310_dcnt_1be5fb54-68ee-4dc5-aba1-f3f4522cfc51">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;">RNAi therapeutic being developed by the Company as a potential treatment for people with uncontrolled gout. The Company will conduct all activities through the preclinical stages of development of&#160;ARO-XDH,&#160;and Horizon will be wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, the Company received $</span><span style="Background-color:#FFFFFF;color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210731" decimals="-6" scale="6">40</ix:nonFraction></span><span style="Background-color:#FFFFFF;color:#000000;">&#160;million as an upfront payment and is eligible to receive up to $</span><span style="Background-color:#FFFFFF;color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618" decimals="-6" scale="6">660</ix:nonFraction></span><span style="Background-color:#FFFFFF;color:#000000;">&#160;million in potential development, regulatory and sales milestones.&#160;&#160;The Company is also eligible to receive royalties in the&#160;low-&#160;to&#160;mid-teens&#160;range on net product sales.&#160;&#160; </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the Horizon License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation.&#160;&#160;The Company determined that the key deliverables included the license and certain R&#38;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#8220;Horizon R&#38;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Horizon R&#38;D Services and their direct relationship with the license, the Company determined that these deliverables represented <ix:nonFraction unitRef="U_arwrBundle" id="F_000446" name="arwr:NumberOfDistinctBundle" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20210618_20210618" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="U_arwrObligation" id="F_000447" name="arwr:NumberOfDistinctPerformanceObligations" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20210618_20210618" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> performance obligation.&#160;&#160;Beyond the Horizon R&#38;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="arwr:InitialTransactionPrice" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618_20210618" decimals="-5" scale="6">40.0</ix:nonFraction> million, including the upfront payment.&#160;&#160;The Company has excluded any future estimated milestones or royalties, from this transaction price to date.&#160;&#160;The Company will allocate the total $<ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="arwr:InitialTransactionPrice" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618_20210618" decimals="-5" scale="6">40.0</ix:nonFraction> million initial transaction price to its <ix:nonFraction unitRef="U_arwrObligation" id="F_000450" name="arwr:NumberOfDistinctPerformanceObligations" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618_20210618" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> distinct performance obligation for the ARO-XDH license and the associated Horizon R&#38;D Services.&#160;&#160;Revenue will be recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&#38;D Services.&#160;&#160;The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the years ended September 30, 2021, 2020 and 2019, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20201001_20210930" decimals="-5" scale="6">6.7</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20191001_20200930" decimals="-6" scale="6">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20181001_20190930" decimals="-6" scale="6">0</ix:nonFraction>, respectively. As of September 30, 2021, there were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210930" decimals="-5" scale="6">0.1</ix:nonFraction> million in contract assets recorded as accounts receivable, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210930" decimals="-5" scale="6">26.7</ix:nonFraction> million in contract liabilities recorded as deferred revenue and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210930" decimals="-5" scale="6">6.7</ix:nonFraction> million in contract liabilities recorded as deferred revenue, net of the current portion.&#160;&#160;&#160;&#160; <span style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000311" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 3. <span style="font-style:italic;">PROPERTY AND EQUIPMENT</span></p><ix:nonNumeric id="F_000339" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s major classes of property and equipment:<span style="font-size:11pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers, office equipment and furniture</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:FurnitureAndFixturesGross" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,661</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:FurnitureAndFixturesGross" contextRef="C_0000879407_20200930" decimals="-3" scale="3">662</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="arwr:ResearchEquipmentGross" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">27,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="arwr:ResearchEquipmentGross" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">20,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="C_0000879407_20210930" decimals="-3" scale="3">509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="C_0000879407_20200930" decimals="-3" scale="3">631</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:LeaseholdImprovementsGross" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">41,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:LeaseholdImprovementsGross" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">25,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross fixed assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">71,539</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">47,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">22,864</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">16,304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">48,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">30,881</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense for property and equipment for the years ended September 30, 2021, 2020, and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0000879407_20201001_20210930" decimals="-5" scale="6">6.6</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">4.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0000879407_20181001_20190930" decimals="-5" scale="6">2.7</ix:nonFraction> million respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000312" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true" continuedAt="F_000312_dcnt_b8845744-d996-49b5-8ee3-3747a04b0d65">
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 4. <span style="font-style:italic;">INVESTMENTS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments at September 30, 2021 primarily consisted of corporate bonds that have maturities of less than 36 months, a certificate of deposit and marketable equity securities. The Company&#8217;s investments in corporate bonds consist of both short-term and long-term bonds and are classified as &#8220;held-to-maturity&#8221; on the Company&#8217;s Consolidated Balance Sheets. The Company&#8217;s certificate of deposit matures in less than 24 months and is classified as &#8220;held-to-maturity&#8221; on the Company&#8217;s Consolidated Balance Sheet.&#160;&#160;The Company&#8217;s marketable equity securities consist of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, corporate bonds and other asset-backed debt securities. Dividends from these funds are automatically reinvested.&#160;&#160;The Company may also invest excess cash balances in money market accounts, government-sponsored enterprise securities, and/or commercial paper.&#160;&#160;The Company accounts for its held to maturity investments in accordance with FASB ASC 320, Investments &#8211; Debt and Equity Securities and its marketable equity securities in accordance with ASC 321, Investments &#8211; Equity Securities.&#160;&#160;</p><ix:nonNumeric id="F_000340" name="arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true" continuedAt="F_000340_dcnt_d3fdd0bc-fa38-402e-b3f5-e33acdec152f">
</ix:nonNumeric></ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000312_dcnt_b8845744-d996-49b5-8ee3-3747a04b0d65"><ix:continuation id="F_000340_dcnt_d3fdd0bc-fa38-402e-b3f5-e33acdec152f">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s short-term, long-term investments and marketable securities as of September 30, 2021 and September 30, 2020 by measurement category. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Held to Maturity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">56,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20210930" decimals="-3" scale="3">803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">57,430</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">195,595</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20210930" decimals="-3" scale="3">103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">196,643</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of deposit (due within two years)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_us-gaapCashAndCashEquivalentsAxis_arwrCertificateOfDepositsDueWithinTwoYearsMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">50,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapCashAndCashEquivalentsAxis_arwrCertificateOfDepositsDueWithinTwoYearsMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">50,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">302,222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,954</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0000879407_20210930" decimals="-3" scale="3">103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">304,073</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">86,890</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,590</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">88,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">137,487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,574</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930" decimals="-3" scale="3">79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">141,982</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">224,377</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,164</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0000879407_20200930" decimals="-3" scale="3">79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">230,462</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized Gains/(Losses)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:EquitySecuritiesFvNiCost" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">125,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,481</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930" decimals="-3" scale="3">135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930" decimals="-3" scale="3">888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:EquitySecuritiesFvNi" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">126,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:EquitySecuritiesFvNiCost" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">125,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,481</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000879407_20210930" decimals="-3" scale="3">135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000879407_20210930" decimals="-3" scale="3">888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:EquitySecuritiesFvNi" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">126,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized Gains/(Losses)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:EquitySecuritiesFvNiCost" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">85,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930" decimals="-3" scale="3">95</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930" decimals="-3" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="us-gaap:EquitySecuritiesFvNi" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">85,020</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:EquitySecuritiesFvNiCost" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">85,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" contextRef="C_0000879407_20200930" decimals="-3" scale="3">95</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000879407_20200930" decimals="-3" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:EquitySecuritiesFvNi" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">85,020</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p></ix:continuation></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><ix:nonNumeric id="F_000313" name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true" continuedAt="F_000313_dcnt_eea54320-fb97-4a87-883d-82115db7337d">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5. <span style="font-style:italic;">INTANGIBLE ASSETS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The license agreement associated with the Novartis RNAi asset acquisition is being amortized over the estimated life remaining at the time of acquisition, which was <ix:nonNumeric id="F_000516" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20201001_20210930" format="ixt-sec:duryear">21</ix:nonNumeric> years, and the accumulated amortization of the asset is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20210930" decimals="-5" scale="6">1.0</ix:nonFraction> million.&#160;&#160;The patents associated with the Novartis RNAi asset acquisition are being amortized over the estimated life remaining at the time of acquisition, which was <ix:nonNumeric id="F_000518" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201001_20210930" format="ixt-sec:duryear">14</ix:nonNumeric> years, and the accumulated amortization of the assets is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20210930" decimals="-5" scale="6">10.2</ix:nonFraction> million.&#160;&#160;Amortization expense for the years ended September 30, 2021, 2020, and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0000879407_20201001_20210930" decimals="-5" scale="6">1.7</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0000879407_20181001_20190930" decimals="-5" scale="6">1.7</ix:nonFraction> million, respectively. Amortization expense is expected to be $<ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="C_0000879407_20210930" decimals="-5" scale="6">1.7</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="C_0000879407_20210930" decimals="-5" scale="6">1.7</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="C_0000879407_20210930" decimals="-5" scale="6">1.7</ix:nonFraction> million in 2024, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="C_0000879407_20210930" decimals="-5" scale="6">1.7</ix:nonFraction> million in 2025, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="C_0000879407_20210930" decimals="-5" scale="6">1.7</ix:nonFraction> million in 2026 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="C_0000879407_20210930" decimals="-5" scale="6">5.2</ix:nonFraction> million thereafter.</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000313_dcnt_eea54320-fb97-4a87-883d-82115db7337d"><ix:nonNumeric id="F_000341" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides details on the Company&#8217;s intangible asset balances: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">15,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">13,663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000314" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6. <span style="font-style:italic;">STOCKHOLDERS&#8217; EQUITY</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2021, the Company had a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000532" name="us-gaap:CapitalUnitsAuthorized" contextRef="C_0000879407_20210930" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction> shares of capital stock authorized for issuance, consisting of <ix:nonFraction unitRef="U_xbrlishares" id="F_000533" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0000879407_20210930" decimals="INF" format="ixt:numdotdecimal">145,000,000</ix:nonFraction> shares of Common Stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000534" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0000879407_20210930" decimals="INF">0.001</ix:nonFraction> per share, and <ix:nonFraction unitRef="U_xbrlishares" id="F_000535" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0000879407_20210930" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares of Preferred Stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000536" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0000879407_20210930" decimals="INF">0.001</ix:nonFraction> per share. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2021, <span style="color:#000000;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000537" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000879407_20210930" decimals="INF" format="ixt:numdotdecimal">104,326,672</ix:nonFraction></span> shares of Common Stock were outstanding.&#160;&#160;At September 30, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000538" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_20210930" decimals="INF" format="ixt:numdotdecimal">15,228,479</ix:nonFraction> shares of Common Stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under Arrowhead&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into an Open Market Sale Agreement (the &#8220;ATM Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="arwr:CommonStockCapitalSharesValueReservedForFutureIssuance" contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200831" decimals="INF" format="ixt:numdotdecimal">250,000,000</ix:nonFraction> in shares of the Company&#8217;s Common Stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000540" name="arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200801_20200831" decimals="3" scale="-2">3.0</ix:nonFraction>% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At September 30, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000541" name="us-gaap:SharesIssued" contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20210930" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares have been issued under the ATM Agreement.</p></ix:nonNumeric><ix:nonNumeric id="F_000315" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7. <span style="font-style:italic;">COMMITMENTS AND CONTINGENCIES</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Litigation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business.&#160;&#160;If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss.&#160;&#160;There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="C_0000879407_20210930" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> contingent liabilities recorded as of the year ended September 30, 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Technology License Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has licensed from third parties the rights to use certain technologies for its research and development&#160;activities,&#160;as well as in any products the Company may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. &#160;Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and upon certain sales level milestones. &#160;These milestone payments could amount to the mid to upper double-digit millions of dollars. During the year ended September 30, 2021, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="arwr:MilestonePayments" contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20201001_20210930" decimals="INF" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction>t incur any milestone payments. During the year ended September 30, 2020, the Company triggered $<ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="arwr:MilestonePayments" contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_us-gaapTypeOfArrangementAxis_arwrAROENacAndAROHIF2CandidatesMember_20191001_20200930" decimals="-5" scale="6">2.4</ix:nonFraction> million of milestone payments related to the progression of the ARO-ENaC and ARO-HIF2 candidates. During the year ended September 30, 2019, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="arwr:MilestonePayments" contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20181001_20190930" decimals="INF" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction>t incur any milestone payments.&#160;&#160;In certain agreements, the Company may be required to make mid to high single-digit percentage royalty payments based on a percentage of the sales of the relevant products.<span style="font-size:12pt;">&#160;</span>&#160;&#160;&#160;&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000316" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true" continuedAt="F_000316_dcnt_b1bb8343-4370-42a4-9c6e-ae9f14b7d94f">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8. <span style="font-style:italic;">LEASES</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the Company entered into a lease for its corporate headquarters in Pasadena, California.&#160;&#160;The <ix:nonNumeric id="F_000546" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430" format="ixt-sec:durmonth">91</ix:nonNumeric> month office building lease between the Company and 177 Colorado Owner, LLC is for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000547" name="us-gaap:LandSubjectToGroundLeases" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430" decimals="0" format="ixt:numdotdecimal">24,000</ix:nonFraction> square feet of office space located at 177 E. Colorado Blvd, Pasadena, California. &#160;The increased capacity of this new office space compared to the Company&#8217;s prior corporate headquarters will accommodate increased personnel as the Company&#8217;s pipeline of drug candidates expands and moves </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000316_dcnt_b1bb8343-4370-42a4-9c6e-ae9f14b7d94f">
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">closer to market.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease payments began on </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000548" name="arwr:LeasePaymentsCommencementDate" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430" format="ixt:datemonthdayyearen">September 30, 2019</ix:nonNumeric></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and are estimated to total</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> approximately</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430" decimals="-5" scale="6">8.7</ix:nonFraction><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million over the term</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:12pt;color:#000000;">&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease expires on </span><ix:nonNumeric id="F_000550" name="us-gaap:LeaseExpirationDate1" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430" format="ixt:datemonthdayyearen"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 30</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2027</span></ix:nonNumeric><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has paid</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> approximately $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430" decimals="-5" scale="6">3.5</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million for leasehold improvements, net of tenant improvement allowances.&#160;&#160;The lease contains an option to renew for </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_arwrOption" id="F_000553" name="arwr:NumberOfOptionsToRenew" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> term of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000552" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The exercise of this option was not determined to be reasonably certain and thus was not included in </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ease liabilities on the Company&#8217;s Consolidated Balance Sheet at</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> September</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 202</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 23, 2020, the Company entered into a lease expansion to add an additional approximately&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_utrsqft" id="F_000554" name="us-gaap:LandSubjectToGroundLeases" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023" decimals="0" format="ixt:numdotdecimal">24,000</ix:nonFraction>&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">square feet of office space at the same location for its corporate headquarters. Lease payments for the expansion began in&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000555" name="arwr:LeaseExpansionCommencementMonthAndYear" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023_20201023" format="ixt:datemonthyearen">July 2021</ix:nonNumeric></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;and the lease for the expansion expires in&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000556" name="arwr:LeaseExpansionExpirationMonthAndYear" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023_20201023" format="ixt:datemonthyearen">April 2027</ix:nonNumeric></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The lease payments for the expansion are expected to total $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023" decimals="-5" scale="6">6.9</ix:nonFraction>&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million.&#160;&#160;The Company has paid approximately $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023_20201023" decimals="-5" scale="6">4.0</ix:nonFraction>&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million of leasehold improvements, net of tenant improvement allowances, for the lease expansion.&#160;&#160;The increased capacity of this additional office space&#160;</span><span style="Background-color:#FFFFFF;">compared to the Company&#8217;s current corporate headquarters is intended to accommodate increased personnel as the Company&#8217;s pipeline of drug candidates continues to expand and move closer to ma</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rket.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the Company entered into a lease for its research facility in Madison, Wisconsin.&#160;&#160;The lease was for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000559" name="us-gaap:LandSubjectToGroundLeases" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160131" decimals="0" format="ixt:numdotdecimal">60,000</ix:nonFraction> square feet of office and laboratory space and had an expiration date of <ix:nonNumeric id="F_000560" name="us-gaap:LeaseExpirationDate1" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160101_20160131" format="ixt:datemonthdayyearen">September 30, 2026</ix:nonNumeric>. The lease was amended in January 2019 and May 2020 to expand the rentable square feet by an additional <ix:nonFraction unitRef="U_utrsqft" id="F_000561" name="arwr:AdditionalLandSubjectToLease" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20200531" decimals="INF" format="ixt:numdotdecimal">40,000</ix:nonFraction> square feet and to extend the lease expiration date to <ix:nonNumeric id="F_000562" name="us-gaap:LeaseExpirationDate1" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20200531" format="ixt:datemonthdayyearen">September 30, 2031</ix:nonNumeric>. Lease payments are estimated to total approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200531" decimals="-5" scale="6">26.2</ix:nonFraction> million for the term. <span style="Background-color:#FFFFFF;color:#000000;">The Company incurred approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="arwr:ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20200531" decimals="-5" scale="6">11.0</ix:nonFraction>&#160;million of leasehold improvements for the additional 40,000 square feet, net of tenant improvement allowances.</span>&#160;<span style="color:#000000;">The lease contains <ix:nonFraction unitRef="U_arwrOption" id="F_000566" name="arwr:NumberOfOptionsToRenew" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> options to renew for two terms of <ix:nonNumeric id="F_000565" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201231" format="ixt-sec:durwordsen">five years</ix:nonNumeric>. The exercise of these options were not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#8217;s Consolidated Balance Sheet at September 30, 2021. In November 2020 and December 2020, the Company entered into amendments to expand the rentable square space by an additional&#160;<ix:nonFraction unitRef="U_utrsqft" id="F_000567" name="arwr:AdditionalLandSubjectToLease" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201101_20201231" decimals="INF" format="ixt:numdotdecimal">10,743</ix:nonFraction>&#160;square feet and these amendments added a total of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201231" decimals="-5" scale="6">1.2</ix:nonFraction>&#160;million of lease payments for the remainder of the term.&#160;</span> &#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with Halozyme, Inc. for additional research and development facility space in San Diego, California.&#160; The Sublease provides additional space needed to accommodate the recent growth of the Company&#8217;s personnel and discovery efforts. The sublease is for approximately <span style="Background-color:#FFFFFF;color:#000000;"><ix:nonFraction unitRef="U_utrsqft" id="F_000569" name="us-gaap:LandSubjectToGroundLeases" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331" decimals="0" format="ixt:numdotdecimal">21,000</ix:nonFraction></span> rentable square feet.&#160; The term of the Sublease commenced on <ix:nonNumeric id="F_000570" name="arwr:SubleaseCommencementDate" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331" format="ixt:datemonthdayyearen">April 1, 2020</ix:nonNumeric> and will end on <ix:nonNumeric id="F_000571" name="us-gaap:LeaseExpirationDate1" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331" format="ixt:datemonthdayyearen">January 14, 2023</ix:nonNumeric>.&#160;&#160;Sublease payments are estimated to total approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331" decimals="-5" scale="6">2.0</ix:nonFraction> million over the term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost during the years ended September 30, <span style="color:#000000;">2021, 2020 and 2019 </span>was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="us-gaap:OperatingLeaseCost" contextRef="C_0000879407_20201001_20210930" decimals="-5" scale="6">5.1</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="us-gaap:OperatingLeaseCost" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="us-gaap:OperatingLeaseCost" contextRef="C_0000879407_20181001_20190930" decimals="-5" scale="6">1.3</ix:nonFraction> million respectively.&#160;&#160;Variable lease costs during the year ended September 30, 2021, 2020, and 2019 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="us-gaap:VariableLeaseCost" contextRef="C_0000879407_20201001_20210930" decimals="-5" scale="6">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:VariableLeaseCost" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:VariableLeaseCost" contextRef="C_0000879407_20181001_20190930" decimals="-5" scale="6">0.5</ix:nonFraction> million respectively.&#160;&#160;There was <ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:ShortTermLeaseCost" contextRef="C_0000879407_20201001_20210930" decimals="-3" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="us-gaap:ShortTermLeaseCost" contextRef="C_0000879407_20191001_20200930" decimals="-3" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="us-gaap:ShortTermLeaseCost" contextRef="C_0000879407_20181001_20190930" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> short-term lease cost during the years ended September 30, <span style="color:#000000;">2021, 2020 and 2019</span>. </p><ix:nonNumeric id="F_000342" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September 30, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,708</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,786</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,621</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,749</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">5,050</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027 and thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">13,200</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">37,114</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">11,569</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities (includes current portion)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="us-gaap:OperatingLeaseLiability" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">25,545</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for the amounts included in the measurement of the operating lease liabilities on the Company&#8217;s Consolidated Balance Sheet and included in Other changes in operating assets and liabilities within cash flows from operating activities on the Company&#8217;s Consolidated Statements of Cash Flow for the years ended September 30, 2021, 2020 and 2019 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000591" name="us-gaap:OperatingLeasePayments" contextRef="C_0000879407_20201001_20210930" decimals="-5" scale="6">3.1</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000592" name="us-gaap:OperatingLeasePayments" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000593" name="us-gaap:OperatingLeasePayments" contextRef="C_0000879407_20181001_20190930" decimals="-5" scale="6">1.3</ix:nonFraction> million, respectively.&#160;The weighted-average remaining lease term and weighted-average discount rate for all leases as of September 30, 2021 was <span style="color:#000000;"><ix:nonNumeric id="F_000594" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0000879407_20210930" format="ixt-sec:duryear">8</ix:nonNumeric> years</span> and <ix:nonFraction unitRef="U_xbrlipure" id="F_000595" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0000879407_20210930" decimals="3" scale="-2">8.5</ix:nonFraction>%, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000317" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true" continuedAt="F_000317_dcnt_1cd3e26a-1cea-49ba-bfa2-24887d5fdb0b">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 9. <span style="font-style:italic;">STOCK-BASED COMPENSATION</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan and 2013 Incentive Plan, as of September 30, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000596" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20210930" decimals="INF" format="ixt:numdotdecimal">429,141</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000597" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930" decimals="INF" format="ixt:numdotdecimal">5,225,983</ix:nonFraction> shares, respectively, of Arrowhead&#8217;s Common Stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others. No further grants may be made under the 2004 Equity Incentive Plan.&#160;&#160;As of September 30, 2021, there were options granted and outstanding to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000598" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20210930" decimals="INF" format="ixt:numdotdecimal">429,141</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000599" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930" decimals="INF" format="ixt:numdotdecimal">2,066,533</ix:nonFraction> shares of Common Stock under the 2004 Equity Incentive Plan </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000317_dcnt_1cd3e26a-1cea-49ba-bfa2-24887d5fdb0b" continuedAt="F_000317_dcnt_fc6aca89-5bec-4eb4-ae7d-ae3904b95e06">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the 2013 Incentive Plan, respectively, and there were </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930" decimals="INF" format="ixt:numdotdecimal">3,159,450</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> restricted stock units granted and outstanding under the 2013 Incentive Plan. Also, as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, there were </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000603" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20210930" decimals="INF" format="ixt:numdotdecimal">957,565</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares reserved for options and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000604" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20210930" decimals="INF" format="ixt:numdotdecimal">602,000</ix:nonFraction> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares reserved for restricted stock units issued as inducement grants to new employees </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">granted outside of the Company&#8217;s equity-based compensation plans </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under Rule 5635(c)(4) of the N</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">asdaq</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Listing Rules</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 18, 2021, the Company&#8217;s stockholders approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (&#8220;2021 Incentive Plan&#8221;), which authorizes </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000605" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210318" decimals="INF" format="ixt:numdotdecimal">8,000,000</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of Arrowhead&#8217;s Common Stock. The maximum number of shares authorized under the 2021 Incentive Plan will be (</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) reduced by any shares subject to awards made under the 2013 Incentive Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Incentive Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021, there were options granted and outstanding to purchase </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000600" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930" decimals="INF" format="ixt:numdotdecimal">3,000</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of Common Stock and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000602" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930" decimals="INF" format="ixt:numdotdecimal">70,400</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> restricted stock units granted and outstanding under the 2021 Incentive Plan.&#160;&#160;As of September 30, 2021, the total number of authorized shares under the 2021 Incentive Plan was </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000606" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930" decimals="INF" format="ixt:numdotdecimal">8,013,790</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares, which includes </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000607" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20201001_20210930" decimals="INF" format="ixt:numdotdecimal">87,190</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares that were forfeited under the 2013 Incentive Plan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p><ix:nonNumeric id="F_000343" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 2020</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000608" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000879407_20200930" decimals="INF" format="ixt:numdotdecimal">4,539,403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000614" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0000879407_20200930" decimals="2">16.67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000609" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0000879407_20201001_20210930" decimals="INF" format="ixt:numdotdecimal">186,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000615" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0000879407_20201001_20210930" decimals="2">65.57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000610" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_0000879407_20201001_20210930" decimals="INF" format="ixt:numdotdecimal">217,820</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000616" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0000879407_20201001_20210930" decimals="2">40.12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000611" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0000879407_20201001_20210930" decimals="INF" format="ixt:numdotdecimal">1,051,344</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000617" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0000879407_20201001_20210930" decimals="2">10.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September 30, 2021</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000612" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000879407_20210930" decimals="INF" format="ixt:numdotdecimal">3,456,239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000618" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0000879407_20210930" decimals="2">19.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000620">5.56</span></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000622" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0000879407_20210930" decimals="0" format="ixt:numdotdecimal">149,501,055</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable At September 30, 2021</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000613" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0000879407_20210930" decimals="INF" format="ixt:numdotdecimal">2,510,091</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000619" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0000879407_20210930" decimals="2">12.23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000621">4.58</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0000879407_20210930" decimals="0" format="ixt:numdotdecimal">126,302,948</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense related to stock options for the years ended September 30, 2021, 2020, and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930" decimals="-5" scale="6">12.4</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930" decimals="-5" scale="6">9.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930" decimals="-5" scale="6">4.0</ix:nonFraction> million, respectively.  For non-qualified stock options, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant date fair value of the options granted by the Company for the years ended September 30, 2021, 2020, and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930" decimals="-5" scale="6">9.0</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930" decimals="-5" scale="6">34.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930" decimals="-5" scale="6">12.1</ix:nonFraction> million, respectively.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intrinsic value of the options exercised during the years ended September 30, 2021, 2020, and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930" decimals="-5" scale="6">66.9</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930" decimals="-5" scale="6">44.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000632" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930" decimals="-5" scale="6">24.6</ix:nonFraction> million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000633" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210930" decimals="-5" scale="6">26.3</ix:nonFraction> million will be recognized in the Company&#8217;s results of operations over a weighted average period of <span><span style="color:#000000;"><ix:nonNumeric id="F_000634" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930" format="ixt-sec:duryear">2.4</ix:nonNumeric> </span>years</span>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </p><ix:nonNumeric id="F_000344" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true" continuedAt="F_000344_dcnt_e6b92107-2b19-479b-a3b1-ef82decab42a">
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000317_dcnt_fc6aca89-5bec-4eb4-ae7d-ae3904b95e06"><ix:continuation id="F_000344_dcnt_e6b92107-2b19-479b-a3b1-ef82decab42a">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value stock options are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years&#160;ended&#160;September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000635">0.4 &#8211; 1.1%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000636">0.4 &#8211; 1.8%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000637">1.50 &#8211; 3.1%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.2 &#8211; 90.4%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90.0 &#8211; 92.0%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000641" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0000879407_20181001_20190930" decimals="2" scale="-2">115</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000646">6.25</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000647">6.25</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000648">6.25</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant date fair value per share of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; options granted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000879407_20201001_20210930" decimals="2">48.64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000650" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000879407_20191001_20200930" decimals="2">36.35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000651" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000879407_20181001_20190930" decimals="2">13.80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The dividend yield is <ix:nonFraction unitRef="U_xbrlipure" id="F_000652" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction> as the Company currently does not pay a dividend. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk-free interest rate is based on that of the U.S. Treasury bond. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility is estimated based on volatility average of the Company&#8217;s Common Stock price. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units (&#8220;RSUs&#8221;), including time-based and performance-based awards, have been granted under the Company&#8217;s 2013 Incentive Plan, 2021 Incentive Plan, and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans.  <ix:nonNumeric id="F_000653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_0000879407_20201001_20210930">At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s Common Stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</ix:nonNumeric>&#160;&#160;</p><ix:nonNumeric id="F_000345" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity of the Company&#8217;s RSUs:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September&#160;30, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000654" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930" decimals="INF" format="ixt:numdotdecimal">3,524,025</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000659" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930" decimals="2">44.11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000655" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930" decimals="INF" format="ixt:numdotdecimal">1,672,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000660" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930" decimals="2">76.34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000656" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930" decimals="INF" format="ixt:numdotdecimal">899,025</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000661" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930" decimals="2">30.65</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000657" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930" decimals="INF" format="ixt:numdotdecimal">465,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000662" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930" decimals="2">44.91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September 30, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000658" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210930" decimals="INF" format="ixt:numdotdecimal">3,831,850</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000663" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210930" decimals="2">61.24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended September 30, 2021, 2020 and 2019, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930" decimals="-5" scale="6">64.2</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930" decimals="-5" scale="6">33.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930" decimals="-5" scale="6">8.4</ix:nonFraction> million of expense related to RSUs, respectively. Such expense is included in stock-based compensation expense in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss). For RSUs, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For RSUs, the grant date fair value of the award is based on the Company&#8217;s closing stock price at the grant date, with consideration given to the probability of achieving performance conditions for performance-based awards. The grant date fair value of the RSUs granted by the Company for the years ended September 30, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930" decimals="-5" scale="6">127.7</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930" decimals="-5" scale="6">149.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930" decimals="-5" scale="6">17.8</ix:nonFraction> million, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021, the pre-tax compensation expense for all unvested RSUs in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210930" decimals="-5" scale="6">118.0</ix:nonFraction> million will be recognized in the Company&#8217;s results of operations over a weighted average period of <ix:nonNumeric id="F_000671" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930" format="ixt-sec:duryear">2.7</ix:nonNumeric> years.  Unvested RSUs that we have deemed not probable of vesting as of September 30, 2021, have the potential of generating an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="arwr:EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930" decimals="-5" scale="6">35.7</ix:nonFraction> million of pre-tax compensation expense if we deem them probable of vesting in a future reporting period.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;</p></ix:continuation><ix:nonNumeric id="F_000318" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true" continuedAt="F_000318_dcnt_12c2ee86-2a7b-439c-aca8-bbe3b36f8e1e">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000318_dcnt_12c2ee86-2a7b-439c-aca8-bbe3b36f8e1e">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 10. <span style="font-style:italic;">FAIR VALUE MEASUREMENTS</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level&#160;1 provides the most reliable measure of fair value while Level&#160;3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&#8217;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. </p><ix:nonNumeric id="F_000346" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes fair value measurements at September 30, 2021 and September&#160;30, 2020 for assets and liabilities measured at fair value on a recurring basis.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">184,434</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">184,434</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">126,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">126,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (held to maturity)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">57,430</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">57,430</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (held to maturity)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">246,643</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">246,643</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, <span style="color:#000000;">2020</span>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">143,583</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">143,583</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">85,020</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">85,020</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (held to maturity)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">88,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">88,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (held to maturity)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">141,982</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">141,982</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a liability for contingent consideration related to its acquisition of the Roche RNAi business completed in 2011. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s assumptions and experience. Estimating timing to complete the development and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining FDA and other regulatory approvals. In determining the probability of regulatory approval and commercial success, the Company utilizes data regarding similar milestone events from several sources, including industry studies and its own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. In November 2016, the Company announced the discontinuation of its clinical trial efforts for ARC-520, ARC-AAT and ARC-521.&#160;&#160;Given this development, the Company assessed the fair value of its contingent consideration obligation to be $<ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="C_0000879407_20210930" decimals="0"><ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="C_0000879407_20200930" decimals="0">0</ix:nonFraction></ix:nonFraction> at September 30, 2021 and September 30, 2020.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000319" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true" continuedAt="F_000319_dcnt_9269d399-ede3-4a5c-a413-f0cf53a2c373">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 11. <span style="font-style:italic;">INCOME TAXES</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes the guidance issued by the FASB for accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000319_dcnt_9269d399-ede3-4a5c-a413-f0cf53a2c373" continuedAt="F_000319_dcnt_733d6285-dee5-4420-8dbd-950f41937057">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.</span></p><ix:nonNumeric id="F_000347" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of the net deferred tax asset (liability) at September 30, 2021 and 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued Compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,086</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">22,454</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">10,937</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized Research &#38; Development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost" contextRef="C_0000879407_20210930" decimals="-3" scale="3">324</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost" contextRef="C_0000879407_20200930" decimals="-3" scale="3">625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">California Alternative Minimum Tax</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" contextRef="C_0000879407_20210930" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" contextRef="C_0000879407_20200930" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Operating Losses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">185,431</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000700" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">151,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,562</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,818</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,702</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of Use Assets/Lease Liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,938</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,016</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital Loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="C_0000879407_20200930" decimals="-3" scale="3">710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">216,259</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">171,080</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">194,255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000710" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">156,604</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000711" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,547</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="arwr:DeferredTaxLiabilitiesStateTaxes" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">15,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000714" name="arwr:DeferredTaxLiabilitiesStateTaxes" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">11,929</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0000879407_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">22,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0000879407_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">14,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company may not realize the benefit of all of its deferred tax assets. Accordingly, management has provided a <ix:nonFraction unitRef="U_xbrlipure" id="F_000717" name="arwr:PercentageOfValuationAllowance" contextRef="C_0000879407_20210930" decimals="INF" scale="-2">100</ix:nonFraction>% valuation allowance against its deferred tax assets until such time as management believes that its projections of future profits as well as expected future tax rates make the realization of these deferred tax assets more-likely-than-not. Significant judgment is required in the evaluation of deferred tax benefits and differences in future results from our estimates could result in material differences in the realization of these assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax asset in accordance with FASB ASC 740-10, &#8220;Accounting for Income Taxes.&#8221; This assessment included the evaluation of scheduled reversals of deferred tax liabilities, the availability of carry forwards and estimates of projected future taxable income.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2021, the Company had available gross federal net operating loss (&#8220;NOL&#8221;) carry forwards of approximately $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000718" name="arwr:FederalNetOperatingLossCarryForward" contextRef="C_0000879407_20210930" decimals="-5" scale="6">569.0</ix:nonFraction></span> million and gross state NOL carry forwards of $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000719" name="arwr:StateNetOperatingLossCarryForwards" contextRef="C_0000879407_20210930" decimals="-5" scale="6">626.5</ix:nonFraction>&#160;</span>million. The NOLs expire at various dates through 2041.</p><ix:nonNumeric id="F_000348" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions for income taxes for the years ended September 30, 2021 and 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Federal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000720" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0000879407_20201001_20210930" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000721" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0000879407_20191001_20200930" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total State</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000722" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="C_0000879407_20201001_20210930" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000723" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="C_0000879407_20191001_20200930" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision from income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000724" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000879407_20201001_20210930" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000879407_20191001_20200930" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000319_dcnt_733d6285-dee5-4420-8dbd-950f41937057">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000349" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended September 30, 2021 and 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At U.S. federal statutory rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000726" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0000879407_20201001_20210930" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000727" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0000879407_20191001_20200930" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal effect</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000728" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0000879407_20201001_20210930" decimals="3" scale="-2">7.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000729" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">7.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000730" name="arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" contextRef="C_0000879407_20201001_20210930" decimals="3" sign="-" format="ixt:numdotdecimal" scale="-2">1.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000731" name="arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" contextRef="C_0000879407_20191001_20200930" decimals="3" sign="-" format="ixt:numdotdecimal" scale="-2">13.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark-to-market adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000732" name="arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" contextRef="C_0000879407_20201001_20210930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000733" name="arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000734" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0000879407_20201001_20210930" decimals="3" sign="-" scale="-2">29.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000735" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0000879407_20191001_20200930" decimals="3" sign="-" scale="-2">43.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000736" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0000879407_20201001_20210930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000737" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">2.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">True-up on deferred taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000738" name="arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" contextRef="C_0000879407_20201001_20210930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000739" name="arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax rate change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000740" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="C_0000879407_20201001_20210930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000741" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000742" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0000879407_20201001_20210930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000743" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense.&#160;&#160;The Company has <ix:nonFraction unitRef="U_iso4217USD" id="F_000744" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0000879407_20210930" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0000879407_20200930" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t recognized any unrecognized tax benefits and does <ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" contextRef="C_0000879407_20201001_20210930" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" contextRef="C_0000879407_20191001_20200930" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" contextRef="C_0000879407_20201001_20210930" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t have any interest or penalties related to uncertain tax positions as of September 30, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns with the Internal Revenue Service (&#8220;IRS&#8221;), the state of California and certain other taxing jurisdictions. The Company is subject to income tax examinations by the IRS and by state tax authorities until the net operating losses are settled.&#160;&#160;</p></ix:continuation><ix:nonNumeric id="F_000320" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 12. <span style="font-style:italic;">EMPLOYEE BENEFIT PLANS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2005, the Company adopted a defined contribution 401(k) retirement savings plan covering substantially all of its employees. The Plan is administered under the &#8220;safe harbor&#8221; provision of ERISA. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000750" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20201001_20210930" decimals="INF" scale="-2">100</ix:nonFraction>% of each participant&#8217;s first <ix:nonFraction unitRef="U_xbrlipure" id="F_000751" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20201001_20210930" decimals="2" scale="-2">3</ix:nonFraction>% of compensation contributed plus <ix:nonFraction unitRef="U_xbrlipure" id="F_000752" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20201001_20210930" decimals="INF" scale="-2">50</ix:nonFraction>% of each participant&#8217;s next <ix:nonFraction unitRef="U_xbrlipure" id="F_000753" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20201001_20210930" decimals="2" scale="-2">2</ix:nonFraction>% of compensation contributed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended September&#160;30, 2021, 2020, and 2019, the Company recorded expenses under this plan of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0000879407_20201001_20210930" decimals="-5" scale="6">1.3</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0000879407_20181001_20190930" decimals="-5" scale="6">0.5</ix:nonFraction> million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the employee benefit plans described above, the Company provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000321" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0000879407_20201001_20210930" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 13. <span style="font-style:italic;">SUBSEQUENT EVENTS</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">San Diego Lease Agreement with ARE-SD Region No. 72 LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 19, 2021, the Company entered into a new lease for a San Diego, California research facility.&#160;&#160;The <ix:nonNumeric id="F_000757" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119" format="ixt-sec:duryear">15</ix:nonNumeric>-year lease is for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000758" name="us-gaap:LandSubjectToGroundLeases" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119" decimals="0" format="ixt:numdotdecimal">144,000</ix:nonFraction> square feet of office and research and development laboratory space to be constructed in San Diego, California.&#160; This lease will replace the Company&#8217;s current research facility sublease for property located in San Diego, California.&#160;&#160;The increased capacity of this new facility compared to the Company&#8217;s current research facility in San Diego will accommodate increased personnel for the Company&#8217;s expanding pipeline of current and future drug candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated rent commencement date for the lease is in <ix:nonNumeric id="F_000759" name="arwr:LeaseCommencementMonthAndYear" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119_20211119" format="ixt:datemonthyearen">May 2023</ix:nonNumeric> after construction and leasehold improvements have been completed.&#160; The lease payments, which begin on the rent commencement date, will be approximately <span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119" decimals="-5" scale="6">119.0</ix:nonFraction></span> million over the initial 15-year term.&#160;&#160;The Company also estimates payments for operating expenses to be approximately $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="arwr:EstimatedPaymentsForOperatingExpensesYearOne" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119" decimals="-5" scale="6">3.0</ix:nonFraction></span> million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000762" name="arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119_20211119" decimals="-5" scale="6">31.0</ix:nonFraction></span> million for leasehold improvements, net of tenant improvement allowances.&#160;&#160;<ix:nonNumeric id="F_000763" name="us-gaap:LesseeOperatingLeaseDescription" contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119_20211119">Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to <ix:nonFraction unitRef="U_arwrOption" id="F_000764" name="arwr:NumberOfOptionsToRenew" contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> additional <span style="-sec-ix-hidden:F_000765">ten-year</span> term, with certain annual increases in base rent</ix:nonNumeric>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive License Agreement with Glaxosmithkline Intellectual Property (No. 3) Limited</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 22, 2021, the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;) with Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;).&#160; Under the GSK License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">GSK has received an exclusive license for&#160;ARO-HSD,&#160;the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).&#160; The exclusive license is worldwide with the exception of greater China, for which the Company will retain rights to develop and commercialize.&#160; </span>Beyond the Company&#8217;s Phase 1/2 study of (ARO-HSD), which the Company is responsible for completing, GSK is wholly responsible for clinical development and commercialization of ARO-HSD in its terr<span style="Background-color:#FFFFFF;color:#000000;">itory.&#160;Under the terms of the agreement, Arrowhead will receive an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="arwr:MilestonePaymentEarned" contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122" decimals="-6" scale="6">120</ix:nonFraction> million and is eligible for additional payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000767" name="arwr:MilestonePaymentReceivableAtStartOfPhaseTwo" contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122" decimals="-6" scale="6">30</ix:nonFraction> million at the start of Phase 2 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000768" name="arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122" decimals="-6" scale="6">100</ix:nonFraction> million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to Arrowhead of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000769" name="arwr:CommercialMilestonePaymentsAtFirstCommercialSale" contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122" decimals="-6" scale="6">190</ix:nonFraction> million at first commercial sale, and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000770" name="arwr:SalesRelatedMilestonePayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122" decimals="-6" scale="6">590</ix:nonFraction> million in sales-related milestone payments. <ix:nonNumeric id="F_000771" name="arwr:TieredRoyaltiesOnNetProductSalesReceiveDescription" contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122_20211122">Arrowhead is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</ix:nonNumeric> The transactions contemplated under the GSK Agreement are subject to customary closing conditions, including clearance by the relevant competition authorities.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>arwr-ex211_11.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex211_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.67 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary </p></td>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Madison Inc. </p></td>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Australia Pty Ltd</p></td>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australia</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>arwr-ex231_12.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex231_12.htm
</title>
</head>
<!-- NG Converter v5.0.2.67 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hereby consent to the incorporation by reference in the Registration Statements on Forms S-1 (Nos. 333-164039 and 333-161344), Forms S-3 (Nos. 333-235324, 333-228598, 333-214315, 333-214311, 333-213484, 333-202737, 333-191922, 333-188718, 333-178532, 333-178073, 333-178072, 333-144109, 333-137329, 333-132310, 333-124065, and 333-113065), and Forms S-8 (Nos. 333-256255, 333-238616, 333-230621, 333-223836, 333-210117, 333-202741, 333-198920, 333-194596, 333-190970, 333-180692, 333-170252, 333-136225, 333-124066, and 333-120072) of Arrowhead Pharmaceuticals, Inc. of our report dated November 22, 2021, with respect to the consolidated balance sheets of Arrowhead Pharmaceuticals, Inc. and Subsidiaries as of September 30, 2021 and September 30, 2020, and the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the years in the three-year period ended September 30, 2021, and the effectiveness of internal control over financial reporting as of September 30, 2021, which reports appear in the September 30, 2021 annual report on Form 10-K of Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rose, Snyder &amp; Jacobs LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Encino, California</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 22, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>arwr-ex311_6.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex311_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.67 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SECURITIES EXCHANGE ACT OF 1934 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc., certify that: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Annual Report on Form 10-K of Arrowhead Pharmaceuticals, Inc.; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 22, 2021</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>arwr-ex312_15.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex312_15.htm
</title>
</head>
<!-- NG Converter v5.0.2.67 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF FINANCIAL OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SECURITIES EXCHANGE ACT OF 1934 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc., certify that: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Annual Report on Form 10-K of Arrowhead Pharmaceuticals, Inc.; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 22, 2021</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kenneth A. Myszkowski</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Kenneth A. Myszkowski,</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>arwr-ex321_10.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex321_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.67 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SECURITIES EXCHANGE ACT OF 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND 18 U.S.C. SECTION 1350 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section&#160;1350, that (i)&#160;the Annual Report on Form 10-K of the Company for the year ended September 30, 2021, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii)&#160;the information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 22, 2021</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of these written statements required by 18 U.S.C. Section&#160;1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>arwr-ex322_14.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex322_14.htm
</title>
</head>
<!-- NG Converter v5.0.2.67 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF FINANCIAL OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SECURITIES EXCHANGE ACT OF 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND 18 U.S.C. SECTION 1350 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section&#160;1350, that (i)&#160;the Annual Report on Form 10-K of the Company for the year ended September 30, 2021, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii)&#160;the information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 22, 2021</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kenneth A. Myszkowski</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Kenneth A. Myszkowski</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of these written statements required by 18 U.S.C. Section&#160;1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gfmvgbft1fv3000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfmvgbft1fv3000002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /T"%8# 2(  A$! Q$!_\0
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M0:/^'_WQS_Z)=IG_ (%6_P#\@U^%1NE$!N Q:(#.47>?IM4%L^V*S_[<M/\
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MI?/\OZZ?CZ ?NC_P_P#OCG_T2[3/_ JW_P#D&C_A_P#?'/\ Z)=IG_@5;_\
MR#7X8;F]?Y?X54EU"&&589&DWMTVPNZ#TS(JE!SZD4_F_P"OE_5_0#]VO^'_
M -\<_P#HEVF?^!5O_P#(-'_#_P"^.?\ T2[3/_ JW_\ D&OPPWMZ_P JS9-8
MMHI&C?[3N4D$K:3NO!P<,L9!^N<>]'S?]?+^K^@'[P_\/_OCG_T2[3/_  *M
M_P#Y!H_X?_?'/_HEVF?^!5O_ /(-?A3;WD=TI:%R<#)5E*.![HP#=0>U5)-8
MMXW9'%R&4X.+2=ES[,L94_@:7S_+^O\ A_0#]X?^'_WQS_Z)=IG_ (%6_P#\
M@T?\/_OCG_T2[3/_  *M_P#Y!K\)[:]2[#-%YHVD@B6%XCQZ"1%)HN;V.T7=
M*SX](XFE;M_"BDCK3^;_ *^7]7] /W8_X?\ WQS_ .B7:9_X%6__ ,@T?\/_
M +XY_P#1+M,_\"K?_P"0:_"V.<3(LB,2K<@E=I_%6 (/L:?N;U_E_A1\W_7R
M_J_H!^Y%S_P<!_'2"&25?A;IFY1D?Z5;_P#R :_035_^"K'Q(T_]@>P_:D3P
M+9OXMNM3^Q-I)N83;",-MW?\>6TL>N=F<^]?R3W[-]DFY_A]O\*_9WQ,3_PY
MVT8]_P"WF_\ 1M'EY;_=^('<6_\ P<!?'26"&1OA=IFZ2-'/^EP'E@#_ ,^'
MO4W_  _^^.?_ $2[3/\ P*M__D&OPGLV;[);<_\ +"+T_N#VJSN;U_E_A1_7
M]?UU] /W/_X?_?'/_HEVF?\ @5;_ /R#1_P_^^.?_1+M,_\  JW_ /D&OPPW
M-Z_R_P *-S>O\O\ "CYO^OE_5_0#]S_^'_WQS_Z)=IG_ (%6_P#\@T?\/_OC
MG_T2[3/_  *M_P#Y!K\,-S>O\O\ "C<WK_+_  H^;_KY?U?T _<__A_]\<_^
MB7:9_P"!5O\ _(-'_#_[XY_]$NTS_P "K?\ ^0:_##<WK_+_  HW-Z_R_P *
M/F_Z^7]7] /W/_X?_?'/_HEVF?\ @5;_ /R#1_P_^^.?_1+M,_\  JW_ /D&
MOPPW-Z_R_P *-S>O\O\ "CYO^OE_5_0#]S_^'_WQS_Z)=IG_ (%6_P#\@T?\
M/_OCG_T2[3/_  *M_P#Y!K\,-S>O\O\ "C<WK_+_  H^;_KY?U?T _<__A_]
M\<_^B7:9_P"!5O\ _(-'_#_[XY_]$NTS_P "K?\ ^0:_##<WK_+_  HW-Z_R
M_P */F_Z^7]7] /W/_X?_?'/_HEVF?\ @5;_ /R#1_P_^^.?_1+M,_\  JW_
M /D&OPPW-Z_R_P *-S>O\O\ "CYO^OE_5_0#]S_^'_WQS_Z)=IG_ (%6_P#\
M@T?\/_OCG_T2[3/_  *M_P#Y!K\,-S>O\O\ "C<WK_+_  H^;_KY?U?T _<_
M_A_]\<_^B7:9_P"!5O\ _(-'_#_[XY_]$NTS_P "K?\ ^0:_##<WK_+_  HW
M-Z_R_P */F_Z^7]7] /W/_X?_?'/_HEVF?\ @5;_ /R#1_P_^^.?_1+M,_\
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M:9_X%6__ ,@T?\/_ +XY_P#1+M,_\"K?_P"0:_##<WK_ "_PI"Y )+  <DG
M ^IH^;_KY?U?T _=#_A_]\<_^B7:9_X%6_\ \@T?\/\ [XY_]$NTS_P*M_\
MY!K\'I-8M8F*;Y9".IAMY9E'./O1HR\=3S5FWOH;H9ADR>Z.OEN.>/D<!O3M
M2^;T_P"!Y?U?[@_=C_A_]\<_^B7:9_X%6_\ \@T?\/\ [XY_]$NTS_P*M_\
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MT?\ #_[XY_\ 1+M,_P# JW_^0:_##<WK_+_"C<WK_+_"CYO^OE_5_0#]S_\
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MRH^;_KY?U?T _='_ (?_ 'QS_P"B7:9_X%6__P @T?\ #_[XY_\ 1+M,_P#
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M!5O_ /(-?AAN;U_E_A1N;U_E_A1\W_7R_J_H!^Y__#_[XY_]$NTS_P "K?\
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M^B7:9_X%6_\ \@T?\/\ [XY_]$NTS_P*M_\ Y!K\))]1AMI$CD,NY\8\N%Y
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M)=IG_@5;_P#R#7X8;F]?Y?X4;F]?Y?X4?-_U\OZOZ ?N?_P_^^.?_1+M,_\
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M_P"0:_"JWNENHO.B+[.?OQM&PQU^5U#?I3(KZ.69H$\WS$Z[X71?^ NRA6_
MG-/YO^OE_5_0#]V/^'_WQS_Z)=IG_@5;_P#R#1_P_P#OCG_T2[3/_ JW_P#D
M&OPM>;RU+NQ"KR<#)_  9)]A4%M?1W88PF3Y3@B2)XC]0'5<CW%'S?\ 7R_J
M_H!^[/\ P_\ OCG_ -$NTS_P*M__ )!H_P"'_P!\<_\ HEVF?^!5O_\ (-?A
M9).L*&21PJJ,D\?D!C)/L*IPZK;32>6K2JQZ&6"2)3]'=%4_@>U+Y_EY?U\_
M0#]W_P#A_P#?'/\ Z)=IG_@5;_\ R#1_P_\ OCG_ -$NTS_P*M__ )!K\)KJ
M_CL]OG>:=W3RH7E_/RU;'XU636;:1Q&OVG<W3-K,J_BS1@#\33^;_KY?U?T
M_>+_ (?_ 'QS_P"B7:9_X%6__P @T?\ #_[XY_\ 1+M,_P# JW_^0:_##<WK
M_+_"J=QJ4%L0)&D9C_##"\Q'7J(U8C\:7S_+^NGXOR _=O\ X?\ WQS_ .B7
M:9_X%6__ ,@T?\/_ +XY_P#1+M,_\"K?_P"0:_"FWO([E-\3DC."K*4<'W1@
M&'XBI]S>O\O\*/G^7E_7S] /W/\ ^'_WQS_Z)=IG_@5;_P#R#1_P_P#OCG_T
M2[3/_ JW_P#D&OPPW-Z_R_PHW-Z_R_PI_-_U\OZOZ ?N?_P_^^.?_1+M,_\
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M09P<''/3%?RX;F]?Y?X5^EO_  29)/[27B_)_P"9#O\ _P!)IZ/Q_KR_K7T
M^Q_'7_!>;XW>&?B!XU\*VOPRTV:S\.>(=1TFUF:ZM]TL5I-Y:.W^@?>91D\^
ME<U_P_\ OCG_ -$NTS_P*M__ )!K\:OBVS?\+C^*G/\ S.VN>G_/V:X7<WK_
M "_PH _<_P#X?_?'/_HEVF?^!5O_ /(-'_#_ .^.?_1+M,_\"K?_ .0:_"*Y
MU2"U<1R^>6(R/+MY91CIUC1A^'7TIUOJ,%T2L3N&'\,L3PMVZ"15)_*CYO\
MKY?U?T _=O\ X?\ WQS_ .B7:9_X%6__ ,@T?\/_ +XY_P#1+M,_\"K?_P"0
M:_##<WK_ "_PHW-Z_P O\*/F_P"OE_5_0#]S_P#A_P#?'/\ Z)=IG_@5;_\
MR#1_P_\ OCG_ -$NTS_P*M__ )!K\,-S>O\ +_"C<WK_ "_PH^;_ *^7]7]
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MO_\ (-'_  _^^.?_ $2[3/\ P*M__D&OPPW-Z_R_PHW-Z_R_PH^;_KY?U?T
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M\^S+$UROE)+$9 Q7G<&SDYYH _DU_; ^#^I?L^_M ?$SX<2VTMII^GZK<3:
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MVUM8V,,VH)%"'9E7.XR2;]W\.?QK^7CX"9_X:#^#>.O_  F.G8_\"(J_K?\
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MU#2K""61KO2K2]<2)<QJ?N/$F"6[$\5_0#K&A_LS?\%E/@EK?BOPMI4'@?\
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MS\Q?GJ.H].,U^1TMC:3MOGLX)GZ;I80[8],D4D5A:0-O@LX(7'\<<*JWY@4
M7K?5?%<=K' OC/Q)!!L :RBOYEMAQ\T8C$@&P^F "*^B_P!D_P#:G^(G[(/Q
M6L?B5X(F>\LY62'Q+HLK,T6K618>>)(\,KR,"Y)*]^^:^<,'T/Y48;T/Y&@#
M^D#Q+^UC_P $GOVGO[.\?_&;P!_PBGCUXXY=:@@M8X7N[Q<-*TH14#+)(.XR
M1C))Y/RU^V]^W[^S7XM^"-_^S/\ LO\ PATO3_#5Q;QP-XIN+")9U,*.BO;S
M!-P9RP+?/G('/%?BS)I]E*Q>6QMY'/5GA5F/U)%3Q01P+MAA6)?[L:;1^0H
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MXV?$#QIX%^*GB3POX-U:\N%\.:197\L%O;V8D<0[(P1M^0J>G'K7Q'+;0W
MG@28+]T2IO ^F1Q4@3: JKA1P %P /8=J /VP\ _MX?#CXL?L#^/OV=OVH?$
M5[J_Q,6*Y?P?J]XYFEGE&TVSO*_.[((X/.?:O5_V+/VS/V-_"O[%<?[+W[15
M[+<6?]J7WVVR7D3V<C*;:4#U4!QG/(?G.!C^?.2U@E=9);:.21/N2/&&=?\
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M_P""3/\ R=Z__8H:]_Z1FOC'XZ_\E[^+G_8TWW_I7-7V?_P295O^&O7^4_\
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M+@^A_*C!]#^5 "44N#Z'\J,'T/Y4 )12X/H?RHP?0_E0 E%+@^A_*C!]#^5
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MAAU"1O/@*XQDPLZ#C@D$8XKMOC=XH_X)%ZKX#\<7_P .-.N$^(FKI?7NDR[
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MP(./X<J?Q7CM((G:2*VCCD;[TB1A7;/7<P&3G.33Y8(YUV30I,G]V1-R_D:
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M^[&<U;P?0_E0 E%+@^A_*C!]#^5 "44N#Z'\J,'T/Y4 )12X/H?RHP?0_E0
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M.$?!/_16->_\ M*_^0*/^'"/@G_HK&O?^ 6E?_(%?T0446\OP_KLON _G?\
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M7O\ P"TK_P"0*_H@HHMY?A_79?<!_.__ ,.$?!/_ $5C7O\ P"TK_P"0*/\
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M]$%%%O+\/Z[+[@/YW_\ APCX)_Z*QKW_ (!:5_\ (%'_  X1\$_]%8U[_P
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M/@G_ **QKW_@%I7_ ,@5_1!11;R_#^NR^X#^=_\ X<(^"?\ HK&O?^ 6E?\
MR!4%S_P0*\#W,#P-\6?$"JY0Y6STH$;&#?\ 0//7Z5_1/11\@/R+^*'_  2S
MT/XF_LT?#']G*_\ 'E_9Z5\.+^ZO;;6;>RTT7MYYY.Q)2;-D^4'G"#_'Y3'_
M  00\$A44?%C7L(BH,V>E9(0  G_ $#J0.:_H@HH _G?_P"'"/@G_HK&O?\
M@%I7_P @4?\ #A'P3_T5C7O_  "TK_Y K^B"BBWE^']=E]P'\[__  X1\$_]
M%8U[_P  M*_^0*/^'"/@G_HK&O?^ 6E?_(%?T0446\OP_KLON _G?_X<(^"?
M^BL:]_X!:5_\@4?\.$?!/_16->_\ M*_^0*_H@HHMY?A_79?<!_._P#\.$?!
M/_16->_\ M*_^0*/^'"/@G_HK&O?^ 6E?_(%?T0446\OP_KLON _G?\ ^'"/
M@G_HK&O?^ 6E?_(%'_#A'P3_ -%8U[_P"TK_ .0*_H@HHMY?A_79?<!_._\
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ME?\ R!1_PX1\$_\ 16->_P# +2O_ ) K^B"BBWE^']=E]P'\[_\ PX1\$_\
M16->_P# +2O_ ) H_P"'"/@G_HK&O?\ @%I7_P @5_1!11;R_#^NR^X#^=__
M (<(^"?^BL:]_P" 6E?_ "!1_P .$?!/_16->_\  +2O_D"OZ(**+>7X?UV7
MW ?SO_\ #A'P3_T5C7O_  "TK_Y H_X<(^"?^BL:]_X!:5_\@5_1!11;R_#^
MNR^X#^=__APCX)_Z*QKW_@%I7_R!1_PX1\$_]%8U[_P"TK_Y K^B"BBWE^']
M=E]P'XN_LO?\$B/#G[,_Q7'Q1T?XB:GK5V=+O]+>QO[+36@\N]A,)=0EE&=R
M_>'S?RKR'QE_P0Q\'^,?&OBGQI=?%+6[>\\4:G/J-Q;PV>EB"!IIGE$<2FQ8
M@+O*\LQXZU_0!10!_.__ ,.$?!/_ $5C7O\ P"TK_P"0*/\ APCX)_Z*QKW_
M (!:5_\ (%?T0446\OP_KLON _G?_P"'"/@G_HK&O?\ @%I7_P @4?\ #A'P
M3_T5C7O_  "TK_Y K^B"BBWE^']=E]P'\[__  X1\$_]%8U[_P  M*_^0*/^
M'"/@G_HK&O?^ 6E?_(%?T0446\OP_KLON _G?_X<(^"?^BL:]_X!:5_\@4?\
M.$?!/_16->_\ M*_^0*_H@HHMY?A_79?<!_._P#\.$?!/_16->_\ M*_^0*/
M^'"/@G_HK&O?^ 6E?_(%?T0446\OP_KLON _G?\ ^'"/@G_HK&O?^ 6E?_(%
M'_#A'P3_ -%8U[_P"TK_ .0*_H@HHMY?A_79?<!_._\ \.$?!/\ T5C7O_ +
M2O\ Y H_X<(^"?\ HK&O?^ 6E?\ R!7]$%%%O+\/Z[+[@/YW_P#APCX)_P"B
ML:]_X!:5_P#(%'_#A'P3_P!%8U[_ , M*_\ D"OZ(**+>7X?UV7W ?SO_P##
MA'P3_P!%8U[_ , M*_\ D"C_ (<(^"?^BL:]_P" 6E?_ "!7]$%%%O+\/Z[+
M[@/YW_\ APCX)_Z*QKW_ (!:5_\ (%'_  X1\$_]%8U[_P  M*_^0*_H@HHM
MY?A_79?<!_.__P .$?!/_16->_\  +2O_D"C_APCX)_Z*QKW_@%I7_R!7]$%
M%%O+\/Z[+[@/YW_^'"/@G_HK&O?^ 6E?_(%'_#A'P3_T5C7O_ +2O_D"OZ(*
M*+>7X?UV7W ?SO\ _#A'P3_T5C7O_ +2O_D"C_APCX)_Z*QKW_@%I7_R!7]$
M%%%O+\/Z[+[@/YW_ /APCX)_Z*QKW_@%I7_R!1_PX1\$_P#16->_\ M*_P#D
M"OZ(**+>7X?UV7W ?SO_ /#A'P3_ -%8U[_P"TK_ .0*/^'"/@G_ **QKW_@
M%I7_ ,@5_1!11;R_#^NR^X#^=_\ X<(^"?\ HK&O?^ 6E?\ R!1_PX1\$_\
M16->_P# +2O_ ) K^B"BBWE^']=E]P'\[_\ PX1\$_\ 16->_P# +2O_ ) H
M_P"'"/@G_HK&O?\ @%I7_P @5_1!11;R_#^NR^X#^=__ (<(^"?^BL:]_P"
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M_P!%8U[_ , M*_\ D"OZ(**+>7X?UV7W ?SO_P##A'P3_P!%8U[_ , M*_\
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MK_Y H_X<(^"?^BL:]_X!:5_\@5_0Q/<0VJ>9<W,-O'TWSO'$G_?;LJ_K5/\
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MT/*?_A-B_+_IQYH/^)@?"3_HKL-_X28_R_ZAO-'[IT5^%G_#XF+_ *)Q<_\
M@58__)-'_#XF+_HG%S_X%6/_ ,DT?\12X&_Z'E/_ ,)L7Y?]./-!_P 3 ^$G
M_178;_PDQ_E_U#>:/W3HK\+/^'Q,7_1.+G_P*L?_ ))H_P"'Q,7_ $3BY_\
M JQ_^2:/^(I<#?\ 0\I_^$V+\O\ IQYH/^)@?"3_ **[#?\ A)C_ "_ZAO-'
M[IT5^%G_  ^)B_Z)Q<_^!5C_ /)-'_#XF+_HG%S_ .!5C_\ )-'_ !%+@;_H
M>4__  FQ?E_TX\T'_$P/A)_T5V&_\),?Y?\ 4-YH_=.BOPL_X?$Q?]$XN?\
MP*L?_DFC_A\3%_T3BY_\"K'_ .2:/^(I<#?]#RG_ .$V+\O^G'F@_P")@?"3
M_HKL-_X28_R_ZAO-'[IT5^%G_#XF+_HG%S_X%6/_ ,DT?\/B8O\ HG%S_P"!
M5C_\DT?\12X&_P"AY3_\)L7Y?]./-!_Q,#X2?]%=AO\ PDQ_E_U#>:/W3HK\
M+/\ A\3%_P!$XN?_  *L?_DFC_A\3%_T3BY_\"K'_P"2:/\ B*7 W_0\I_\
MA-B_+_IQYH/^)@?"3_HKL-_X28_R_P"H;S1^Z=%?A9_P^)B_Z)Q<_P#@58__
M "31_P /B8O^B<7/_@58_P#R31_Q%+@;_H>4_P#PFQ?E_P!./-!_Q,#X2?\
M178;_P ),?Y?]0WFC]TZ*_"S_A\3%_T3BY_\"K'_ .2:/^'Q,7_1.+G_ ,"K
M'_Y)H_XBEP-_T/*?_A-B_+_IQYH/^)@?"3_HKL-_X28_R_ZAO-'[IT5^%G_#
MXF+_ *)Q<_\ @58__)-'_#XF+_HG%S_X%6/_ ,DT?\12X&_Z'E/_ ,)L7Y?]
M./-!_P 3 ^$G_178;_PDQ_E_U#>:/W3HK\+/^'Q,7_1.+G_P*L?_ ))H_P"'
MQ,7_ $3BY_\  JQ_^2:/^(I<#?\ 0\I_^$V+\O\ IQYH/^)@?"3_ **[#?\
MA)C_ "_ZAO-'[IT5^%G_  ^)B_Z)Q<_^!5C_ /)-'_#XF+_HG%S_ .!5C_\
M)-'_ !%+@;_H>4__  FQ?E_TX\T'_$P/A)_T5V&_\),?Y?\ 4-YH_=.BOPL_
MX?$Q?]$XN?\ P*L?_DFC_A\3%_T3BY_\"K'_ .2:/^(I<#?]#RG_ .$V+\O^
MG'F@_P")@?"3_HKL-_X28_R_ZAO-'[IT5^%G_#XF+_HG%S_X%6/_ ,DT?\/B
M8O\ HG%S_P"!5C_\DT?\12X&_P"AY3_\)L7Y?]./-!_Q,#X2?]%=AO\ PDQ_
ME_U#>:/W3HK\+/\ A\3%_P!$XN?_  *L?_DFC_A\3%_T3BY_\"K'_P"2:/\
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MG%S_ .!5C_\ )-'_ !%+@;_H>4__  FQ?E_TX\T'_$P/A)_T5V&_\),?Y?\
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M\D?+/[6W[77PY_9*^'EQXN\8WD4^KW$3Q^'_  ]'(OVW5+PJ1&%CSO$>_ +
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MU_PR^X3'U_,_XT8^OYG_ !I:*+OS_K_AE]P7?G_7_#+[A,?7\S_C1CZ_F?\
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MOVN?#?[/'CG7/A=\2+A;7P'\01]FM]2N#FWL;F8J'\W.%"2%F1LGE&8=>O\
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MBNK_ .$*\0_] ^]_\%VH?_&*/^$*\0_] ^]_\%VH?_&*/95/^?=7_P %5/\
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MCV53_GW5_P#!53_Y#^K>ESZOB/\ H&Q/_A-7\O\ IWY_UI?E**ZO_A"O$/\
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M^K>ESZOB/^@;$_\ A-7\O^G?G_6E^4HKJ_\ A"O$/_0/O?\ P7:A_P#&*/\
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M/_D/ZMZ7/J^(_P"@;$_^$U?R_P"G?G_6E^4HKJ_^$*\0_P#0/O?_  7:A_\
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M3_X35_+_ *=^?]:7Y2BNK_X0KQ#_ - ^]_\ !=J'_P 8H_X0KQ#_ - ^]_\
M!=J'_P 8H]E4_P"?=7_P54_^0_JWI<^KXC_H&Q/_ (35_+_IWY_UI?E**ZO_
M (0KQ#_T#[W_ ,%VH?\ QBC_ (0KQ#_T#[W_ ,%VH?\ QBCV53_GW5_\%5/_
M )#^K>ESZOB/^@;$_P#A-7\O^G?G_6E^4HKJ_P#A"O$/_0/O?_!=J'_QBC_A
M"O$/_0/O?_!=J'_QBCV53_GW5_\ !53_ .0_JWI<^KXC_H&Q/_A-7\O^G?G_
M %I?E*^U_P!@_P#Y+YX%_P"PJ_\ Z,@KY3_X0KQ#_P! ^]_\%VH?_&*_07_@
MGQ\%?'FM_&KPMK-II%\FE:/<R7VHZA-9W$%K''OB"Q!YD0M(Q60D $*%&[J#
M7N\+X3%5^),BA1P]>I-9K@JCC&E4NH4Z\)U)R;BDHPBFY2;LDO2_V?AUEV88
MOCOA&EAL#C*U1<0996E&&&KMPHT,33JUJLVX*,*=*G&4ISDTDEYJ_P#5+'_J
MX_\ <7_T$4^D4;5"_P!T ?D,4M?W.?ZWA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4C8P<C(QR#W]OQZ4M-8D#(]: /
MYG?^"NW[#OB'2/%/_#2WPIT66_TFZMHH?&^CV$+220RI$L;ZCY<29(94,A.,
M L0.17X.1S6>J191BKQMS$2$N[68'D;?OQ.I'H"/K7^AKJFEZ?K>G7.DZM8V
M^HZ;J$#VU[9W42S03P2KM=)(V!4@@]^1U!!%?B!^U1_P1D\"?$75]1\9_!+5
MCX&UV_EDN;C0U80Z5+,Y+L4(*JH8\;>.N .N?Z[\(?'O 9;E>$X5XVJU:-'
MP6'RO/%&5:-/"_8PF/IQYJG+2UC2KQ3M#W9JRN_YM\2O"'&8W'8C/N%*5.I/
M%R=7,,J<E1<Z[LY8C"2=H.53>=)N/OZQ=WI_/5X6^/7Q\\#:=_8_A3XH^(M.
MTK88TM9+^[E$4>-NU27^50,8QCI7GWB'7?%'C'43K'C3Q'JGB:_+&0S:G>37
M,*'DDJDS,JX]NE?HKKG_  2+_;!T>]DL[2WTG48 Y6.YCE9@Z9P&)#'.1WKU
MKX7?\$4OCWXIU"T;XE^)['PUH1D1KQ;&X_TIHMP+JB;MS'' P/K[?ND_$CPC
MRJ-3-J6?<-TZU:[G6R["TWCJUU=I*C15;FEM9VYG:[O<_)8\#^(N.E# 5<HS
MRI3C448TL57J+"TTK>]>K5]DHQ[V:MJKZGY<_";X3^,_C[X\TKX<> +*:XDO
MKE/[=UQ$8Z9HFF(RO=3W%TF8H@+<2<,>M?7?[:?Q(\'^"OA_H7[&WP6NX[KP
MIX'M&F^(/B&S8&/7M<\IOM4+RQG;*(;@$#/I[U^T?BC_ ()M>+OAU\.1\+?V
M7M;L?!@URS$'B[QY=-'#K]ZKJ4GBBF)61 X9O]7)G\>!\+_\.*OBGB=I?B;;
M7-Q>2/-?74]]YD]W-+S+)([N6)<G)RYR>:^#POB[P%Q%GF$SO/N(*669-D6(
M=?AW(*F'KU<7B\Q7[MY[F[IP=*$J--RCEV#NW2YY5IRY[)?65_#GB_)<HQ.5
MY1DM;'9GFU*G2SC-H5*=.CA\"G&I_9.7\TE.:J3M+&8FR4U%4H7C>_ZI_P#!
M)R]BN/V2?!MO%)&WV*&V@,:,I:/%G"/G4?<)V\ ^E?IK7YE_L#?L:?$G]DK^
MV='\0^.?^$D\,W]O%]DTY;EI([.X2WBC.R,L1MWID$ 5^FE?R)XDXC*\;QOQ
M%C\FQ]+,LMS',*F/PV*HPJ4XN.*M5E3E"HE-3I3E*$[K=7V9_2O ]''87A3)
M<)F6#J8'&X/!T\+6P]5Q<HNA>FI7@W&TXI25F]'OT"BBBOASZL**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *0L!U('U('\Z6OF+]HGX1_%#XHP:/%\.?B3-\/I+%V:\EA
M@$QNU.<(0>!C@Y]J /IO>O\ >7\Q_C1O7^\OYC_&OS(_X9%_:?P/^,EK_.!G
M_05ZXY[>M'_#(O[3W_1R]_\ ^ *_X4 ?IOO7^\OYC_&C>O\ >7\Q_C7YD?\
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M\,B_M/?]'+W_ /X K_A0!^F^]?[R_F/\:-Z_WE_,?XU^9'_#(O[3W_1R]_\
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M^T]_T<O?_P#@"O\ A0!^F^]?[R_F/\:-Z_WE_,?XU^9'_#(O[3W_ $<O?_\
M@"O^%'_#(O[3W_1R]_\ ^ *_X4 ?IOO7^\OYC_&C>O\ >7\Q_C7YD?\ #(O[
M3W_1R]__ . *_P"%'_#(O[3W_1R]_P#^ *_X4 ?H_K6@Z!XBMOL>NZ9I^K6H
M.1!?017$8/J%<''X5Q__  J'X5]O OA<?33;8?TKX0_X9%_:>_Z.7O\ _P
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MPR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\
MR!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]
M_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]
M1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\
M\%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/
M1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4
M?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_
M /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7
M_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K
M_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PG
MI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR
M+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R
M7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(W
MA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_
M /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;
M;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T
M<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"
MH?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__
M ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X
M7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7P
MA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_
M )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_
M $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'
MU;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_
M /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^
MT]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W
M_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'
M+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_
M $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM
M_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\
M!4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A
M^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"
MO^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"
M-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_
MPR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\
MR!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]
M_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]
M1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\
M\%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/
M1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4
M?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_
M /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7
M_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K
M_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PG
MI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR
M+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R
M7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(W
MA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_
M /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;
M;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T
M<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"
MH?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__
M ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X
M7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7P
MA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_
M )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_
M $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'
MU;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_
M /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^
MT]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W
M_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'
M+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_
M $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM
M_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\
M!4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A
M^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"
MO^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"
M-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_
MPR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\
MR!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]
M_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]
M1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\
M\%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/
M1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4
M?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_
M /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7
M_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K
M_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PG
MI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR
M+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R
M7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(W
MA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_
M /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;
M;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T
M<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"
MH?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__
M ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X
M7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7P
MA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_
M )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_
M $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'
MU;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_
M /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^
MT]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W
M_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'
M+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_
M $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM
M_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\
M!4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A
M^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"
MO^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"
M-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]_P!'+W__ ( K_A1_
MPR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]1P7_ $!X7_PGI?\
MR!]W_P#"H?A7_P!"-X7_ /!;;?X4?\*A^%?_ $(WA?\ \%MM_A7PA_PR+^T]
M_P!'+W__ ( K_A1_PR+^T]_T<O?_ /@"O^%'U;#_ /0/1_\ !4/_ )'R7W!]
M1P7_ $!X7_PGI?\ R!]W_P#"H?A7_P!"-X7_ /!;;?X5U&A>%O"_AE'C\/Z+
MI>CI)_K%L+:&W#_[VP FOSH_X9%_:>_Z.7O_ /P!7_"C_AD7]I[_ *.7O_\
MP!7_  IQH48/FA1I0EMS1IPB_O23+AA<-2DIT\-0IR6TH4:<)+TE&*?XGZ;[
MU_O+^8_QHWK_ 'E_,?XU^9'_  R+^T]_T<O?_P#@"O\ A1_PR+^T]_T<O?\
M_@"O^%:FY^F^]?[R_F/\:-Z_WE_,?XU^9'_#(O[3W_1R]_\ ^ *_X4?\,B_M
M/?\ 1R]__P" *_X4 ?IOO7^\OYC_ !HWK_>7\Q_C7YD?\,B_M/?]'+W_ /X
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MR_F/\:-Z_P!Y?S'^-?F1_P ,B_M/?]'+W_\ X K_ (4?\,B_M/?]'+W_ /X
MK_A0!^F^]?[R_F/\:-Z_WE_,?XU^9'_#(O[3W_1R]_\ ^ *_X4?\,B_M/?\
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MF/\ &C>O]Y?S'^-?F1_PR+^T]_T<O?\ _@"O^%'_  R+^T]_T<O?_P#@"O\
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MC7YD?\,B_M/?]'+W_P#X K_A1_PR+^T]_P!'+W__ ( K_A0!^F^]?[R_F/\
M&C>O]Y?S'^-?F1_PR+^T]_T<O?\ _@"O^%'_  R+^T]_T<O?_P#@"O\ A0!^
MF^]?[R_F/\:-Z_WE_,?XU^9'_#(O[3W_ $<O?_\ @"O^%'_#(O[3W_1R]_\
M^ *_X4 ?IOO7^\OYC_&C>O\ >7\Q_C7YD?\ #(O[3W_1R]__ . *_P"%'_#(
MO[3W_1R]_P#^ *_X4 ?IOO7^\OYC_&C>O]Y?S'^-?F1_PR+^T]_T<O?_ /@"
MO^%'_#(O[3W_ $<O?_\ @"O^% 'Z;[U_O+^8_P :-Z_WE_,?XU^9'_#(O[3W
M_1R]_P#^ *_X4?\ #(O[3W_1R]__ . *_P"% 'Z;[U_O+^8_QH+*01N7GW'^
M-?F1_P ,B_M/?]'+W_\ X K_ (4?\,B_M/?]'+W_ /X K_A0!^FP./XA^/\
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M1?VGO^CE[_\ \ 5_PH _3?>O]Y?S'^-&]?[R_F/\:_,C_AD7]I[_ *.7O_\
MP!7_  H_X9%_:>_Z.7O_ /P!7_"@#]-]Z_WE_,?XT;U_O+^8_P :_,C_ (9%
M_:>_Z.7O_P#P!7_"C_AD7]I[_HY>_P#_  !7_"@#]-]Z_P!Y?S'^-&]?[R_F
M/\:_,C_AD7]I[_HY>_\ _ %?\*/^&1?VGO\ HY>__P# %?\ "@#]-]Z_WE_,
M?XT;U_O+^8_QK\R/^&1?VGO^CE[_ /\  %?\*/\ AD7]I[_HY>__ / %?\*
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MG>'/_ ^W_P#CE'_#8W[.7_13O#G_ ('V_P#\<H_MG*/^AI@/_"NA_P#+//\
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M%.\.?^!]O_\ '*/[9RC_ *&F _\ "NA_\L\_ZLP_UDX>_P"A[E'_ (<L'_\
M+O/^K,^G:*^8O^&QOV<O^BG>'/\ P/M__CE'_#8W[.7_ $4[PY_X'V__ ,<H
M_MG*/^AI@/\ PKH?_+//^K,/]9.'O^A[E'_ARP?_ ,N\_P"K,^G:*^8O^&QO
MV<O^BG>'/_ ^W_\ CE'_  V-^SE_T4[PY_X'V_\ \<H_MG*/^AI@/_"NA_\
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M_+O/^K,^G:*^8O\ AL;]G+_HIWAS_P #[?\ ^.4?\-C?LY?]%.\.?^!]O_\
M'*/[9RC_ *&F _\ "NA_\L\_ZLP_UDX>_P"A[E'_ (<L'_\ +O/^K,^G:*^8
MO^&QOV<O^BG>'/\ P/M__CE'_#8W[.7_ $4[PY_X'V__ ,<H_MG*/^AI@/\
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M_+//^K,/]9.'O^A[E'_ARP?_ ,N\_P"K,^G:*^8O^&QOV<O^BG>'/_ ^W_\
MCE'_  V-^SE_T4[PY_X'V_\ \<H_MG*/^AI@/_"NA_\ +//^K,/]9.'O^A[E
M'_ARP?\ \N\_ZLSZ=HKYB_X;&_9R_P"BG>'/_ ^W_P#CE'_#8W[.7_13O#G_
M ('V_P#\<H_MG*/^AI@/_"NA_P#+//\ JS#_ %DX>_Z'N4?^'+!__+O/^K,^
MG:*^8O\ AL;]G+_HIWAS_P #[?\ ^.4?\-C?LY?]%.\.?^!]O_\ '*/[9RC_
M *&F _\ "NA_\L\_ZLP_UDX>_P"A[E'_ (<L'_\ +O/^K,^G:*^8O^&QOV<O
M^BG>'/\ P/M__CE'_#8W[.7_ $4[PY_X'V__ ,<H_MG*/^AI@/\ PKH?_+//
M^K,/]9.'O^A[E'_ARP?_ ,N\_P"K,^G:*^8O^&QOV<O^BG>'/_ ^W_\ CE'_
M  V-^SE_T4[PY_X'V_\ \<H_MG*/^AI@/_"NA_\ +//^K,/]9.'O^A[E'_AR
MP?\ \N\_ZLSZ=HKYB_X;&_9R_P"BG>'/_ ^W_P#CE'_#8W[.7_13O#G_ ('V
M_P#\<H_MG*/^AI@/_"NA_P#+//\ JS#_ %DX>_Z'N4?^'+!__+O/^K,^G:*^
M8O\ AL;]G+_HIWAS_P #[?\ ^.4?\-C?LY?]%.\.?^!]O_\ '*/[9RC_ *&F
M _\ "NA_\L\_ZLP_UDX>_P"A[E'_ (<L'_\ +O/^K,^G:*^8O^&QOV<O^BG>
M'/\ P/M__CE'_#8W[.7_ $4[PY_X'V__ ,<H_MG*/^AI@/\ PKH?_+//^K,/
M]9.'O^A[E'_ARP?_ ,N\_P"K,^G:*^8O^&QOV<O^BG>'/_ ^W_\ CE'_  V-
M^SE_T4[PY_X'V_\ \<H_MG*/^AI@/_"NA_\ +//^K,/]9.'O^A[E'_ARP?\
M\N\_ZLSZ=HKYB_X;&_9R_P"BG>'/_ ^W_P#CE'_#8W[.7_13O#G_ ('V_P#\
M<H_MG*/^AI@/_"NA_P#+//\ JS#_ %DX>_Z'N4?^'+!__+O/^K,^G:*^8O\
MAL;]G+_HIWAS_P #[?\ ^.4?\-C?LY?]%.\.?^!]O_\ '*/[9RC_ *&F _\
M"NA_\L\_ZLP_UDX>_P"A[E'_ (<L'_\ +O/^K,^G:*^8O^&QOV<O^BG>'/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%VOQ#UOXB^%M/\'WJ(]KK5QJUFEK,LG*;&:89W=O8BNK\ ?$OP+\4="A\2^
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MI2KR2:AHMOJ*VM[/(X\P3R6LDP:1B)/G.0#]H**:@VHJ@Y"JH!]0  #^-.H
M**** "BBB@ HHHH *X#XIZ_K/A?X>>+M=\.Z;)K&O:=HE[-I&F19\R]U#RBM
MO F <%G8$''&,UW],D\L(QEV>6 2YDQL"CJ6W?+@>] '\Y'[,'_!)WQ9\2]
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M2_D^$5]X_N)_CO\ "1;V6W\/W O-+FBM_%UA916\T/\ ;5AJD6G>8LGV?S[
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M_P#GW#_P%?U_P_I;0_M;4?\ GLO_ 'S_ /6H_M;4?^>R_P#?/_UJSZ*.6/\
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MI;0_M;4?^>R_]\__ %J/[6U'_GLO_?/_ -:L^BCEC_)#_P !7E_E^+#V=/\
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M_P !7E_E^+#V=/\ Y]P_\!7]?\/Z6T/[6U'_ )[+_P!\_P#UJ/[6U'_GLO\
MWS_]:L^BCEC_ "0_\!7E_E^+#V=/_GW#_P !7]?\/Z6T/[6U'_GLO_?/_P!:
MC^UM1_Y[+_WS_P#6K/HHY8_R0_\  5Y?Y?BP]G3_ .?</_ 5_7_#^EM#^UM1
M_P">R_\ ?/\ ]:C^UM1_Y[+_ -\__6K/HHY8_P D/_ 5Y?Y?BP]G3_Y]P_\
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M$,QLYDR2W4G/?-?&/AGPQXH\=^)-+\%>"=%N==\2:Q-';6.GV<;N(R[!=S[
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M:M\:=3\/Z]J&K_\ "X_'>L>.]3BOKF:X6TU+67C>Y2V$C,(8?W2[88]J)SM
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MEEDGDFD::1S(Q-?,OBG_ ((]?#GQ+^R5^S=^RA+XM\0Q>%?V</&'@+Q=X9U
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M1T5)Y4O_ #RD_P"^&_PH\J7_ )Y2?]\-_A1?^OZ]5]X7_K^O5?>1T5)Y4O\
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M/^B<RS_P1Z>?E_6EC_B#WAC_ -$3D'_A!2Z6\O[J/S-_X=0?!W_H/:K^3?\
MQVC_ (=0?!W_ *#VJ_DW_P =K],O^$W\'_\ 0RZ-_P"!\'_Q='_";^#_ /H9
M=&_\#X/_ (NC_4#@S_HG,L_\$>GGY?UI8_X@]X8_]$3D'_A!2Z6\O[J/S-_X
M=0?!W_H/:K^3?_':/^'4'P=_Z#VJ_DW_ ,=K],O^$W\'_P#0RZ-_X'P?_%T?
M\)OX/_Z&71O_  /@_P#BZ/\ 4#@S_HG,L_\ !'IY^7]:6/\ B#WAC_T1.0?^
M$%+I;R_NH_,W_AU!\'?^@]JOY-_\=H_X=0?!W_H/:K^3?_':_3+_ (3?P?\
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M/_!'IY^7]:6/^(/>&/\ T1.0?^$%+I;R_NH_,W_AU!\'?^@]JOY-_P#':/\
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M'?\ H/:K^3?_ !VOTR_X3?P?_P!#+HW_ ('P?_%T?\)OX/\ ^AET;_P/@_\
MBZ/]0.#/^B<RS_P1Z>?E_6EC_B#WAC_T1.0?^$%+I;R_NH_,W_AU!\'?^@]J
MOY-_\=H_X=0?!W_H/:K^3?\ QVOTR_X3?P?_ -#+HW_@?!_\71_PF_@__H9=
M&_\  ^#_ .+H_P!0.#/^B<RS_P $>GGY?UI8_P"(/>&/_1$Y!_X04NEO+^ZC
M\S?^'4'P=_Z#VJ_DW_QVC_AU!\'?^@]JOY-_\=K],O\ A-_!_P#T,NC?^!\'
M_P 71_PF_@__ *&71O\ P/@_^+H_U X,_P"B<RS_ ,$>GGY?UI8_X@]X8_\
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M_AU!\'?^@]JOY-_\=H_X=0?!W_H/:K^3?_':_3+_ (3?P?\ ]#+HW_@?!_\
M%T?\)OX/_P"AET;_ ,#X/_BZ/]0.#/\ HG,L_P#!'IY^7]:6/^(/>&/_ $1.
M0?\ A!2Z6\O[J/S-_P"'4'P=_P"@]JOY-_\ ':/^'4'P=_Z#VJ_DW_QVOTR_
MX3?P?_T,NC?^!\'_ ,71_P )OX/_ .AET;_P/@_^+H_U X,_Z)S+/_!'IY^7
M]:6/^(/>&/\ T1.0?^$%+I;R_NH_,W_AU!\'?^@]JOY-_P#':/\ AU!\'?\
MH/:K^3?_ !VOTR_X3?P?_P!#+HW_ ('P?_%T?\)OX/\ ^AET;_P/@_\ BZ/]
M0.#/^B<RS_P1Z>?E_6EC_B#WAC_T1.0?^$%+I;R_NH_,W_AU!\'?^@]JOY-_
M\=H_X=0?!W_H/:K^3?\ QVOTR_X3?P?_ -#+HW_@?!_\71_PF_@__H9=&_\
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M_@__ *&71O\ P/@_^+H_X3?P?_T,NC?^!\'_ ,70!U-%<M_PF_@__H9=&_\
M ^#_ .+H_P"$W\'_ /0RZ-_X'P?_ != '4T5RW_";^#_ /H9=&_\#X/_ (NC
M_A-_!_\ T,NC?^!\'_Q= '4T5RW_  F_@_\ Z&71O_ ^#_XNC_A-_!__ $,N
MC?\ @?!_\70!U-%<M_PF_@__ *&71O\ P/@_^+H_X3?P?_T,NC?^!\'_ ,70
M!U-%<M_PF_@__H9=&_\  ^#_ .+H_P"$W\'_ /0RZ-_X'P?_ != '4T5RW_"
M;^#_ /H9=&_\#X/_ (NC_A-_!_\ T,NC?^!\'_Q= '4T5RW_  F_@_\ Z&71
MO_ ^#_XNC_A-_!__ $,NC?\ @?!_\70!U-%<M_PF_@__ *&71O\ P/@_^+H_
MX3?P?_T,NC?^!\'_ ,70!U-%<M_PF_@__H9=&_\  ^#_ .+H_P"$W\'_ /0R
MZ-_X'P?_ != '4T5RW_";^#_ /H9=&_\#X/_ (NC_A-_!_\ T,NC?^!\'_Q=
M '4T5RW_  F_@_\ Z&71O_ ^#_XNC_A-_!__ $,NC?\ @?!_\70!U-%<M_PF
M_@__ *&71O\ P/@_^+H_X3?P?_T,NC?^!\'_ ,70!U-%<M_PF_@__H9=&_\
M ^#_ .+H_P"$W\'_ /0RZ-_X'P?_ != '4T5RW_";^#_ /H9=&_\#X/_ (NC
M_A-_!_\ T,NC?^!\'_Q= '4T5RW_  F_@_\ Z&71O_ ^#_XNC_A-_!__ $,N
MC?\ @?!_\70!U-%<M_PF_@__ *&71O\ P/@_^+H_X3?P?_T,NC?^!\'_ ,70
M!U-%<M_PF_@__H9=&_\  ^#_ .+H_P"$W\'_ /0RZ-_X'P?_ != '4T5RW_"
M;^#_ /H9=&_\#X/_ (NC_A-_!_\ T,NC?^!\'_Q= '4T5RW_  F_@_\ Z&71
MO_ ^#_XNC_A-_!__ $,NC?\ @?!_\70!U-%<M_PF_@__ *&71O\ P/@_^+H_
MX3?P?_T,NC?^!\'_ ,70!U-%<M_PF_@__H9=&_\  ^#_ .+H_P"$W\'_ /0R
MZ-_X'P?_ != '4T5RW_";^#_ /H9=&_\#X/_ (NC_A-_!_\ T,NC?^!\'_Q=
M '4T5RW_  F_@_\ Z&71O_ ^#_XNC_A-_!__ $,NC?\ @?!_\70!U-%<M_PF
M_@__ *&71O\ P/@_^+H_X3?P?_T,NC?^!\'_ ,70!U-%<M_PF_@__H9=&_\
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M ,#X/_BZ/^$W\'_]#+HW_@?!_P#%T =317+?\)OX/_Z&71O_  /@_P#BZ/\
MA-_!_P#T,NC?^!\'_P 70!U-%4K#4M/U.'[1IUY;WL!.!+;2K*A/^\A(HH N
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7SO\ '?\ 9N\)?'^'2(?%&L^(])71
MY'D@.@:A+8-(7!!$K12(6'/0DCVS@CZ(HH _/'_AV]\(>,^+OB,> /\ D9+W
ML,?\_%'_  [>^$/_ $-WQ&_\*2]_^2*_0ZB@#\\?^';WPA_Z&[XC?^%)>_\
MR11_P[>^$/\ T-WQ&_\ "DO?_DBOHSXK?M3_  %^"=Y9Z=\2?B1X=\.7UZZQ
MPVES?V[7 9C@"6)9=\7/4N!COCFO0+#XI>!]9\"WGQ&T#7]/UWPK9:5<:Q)J
M6EW,-W%]DMH&N)"3"[A6$2EMIYQ0!\9_\.WOA#_T-WQ&_P#"DO?_ )(H_P"'
M;WPA_P"AN^(W_A27O_R17U!\!/C]\/OVC?!/_"?_  UU)=6\._VC=Z8MXARC
M75E*\%P@.!_JY8W0^X(KVZ@#\\?^';WPA_Z&[XC?^%)>_P#R11_P[>^$/_0W
M?$;_ ,*2]_\ DBOT.HH _/'_ (=O?"'_ *&[XC?^%)>__)%'_#M[X0_]#=\1
MO_"DO?\ Y(K] [^\33[*[OI5=X[2WEN'6-2SLL*%V"J.2Q"\ 5Y;\(OC#H?Q
M@TO4]5T+3]7L(-+U*YTR9=6L+BPD>:UE:)VCCN(XV>-F4E'&5=<,I(.: /D[
M_AV]\(?^AN^(W_A27O\ \D4?\.WOA#_T-WQ&_P#"DO?_ )(K]#J* /SQ_P"'
M;WPA_P"AN^(W_A27O_R11_P[>^$/_0W?$;_PI+W_ .2*_0ZB@#\\?^';WPA_
MZ&[XC?\ A27O_P D4?\ #M[X0_\ 0W?$;_PI+W_Y(K]#J* /SQ_X=O?"'_H;
MOB-_X4E[_P#)%'_#M[X0_P#0W?$;_P *2]_^2*_0ZB@#\\?^';WPA_Z&[XC?
M^%)>_P#R11_P[>^$/_0W?$;_ ,*2]_\ DBOT.HH _/'_ (=O?"'_ *&[XC?^
M%)>__)%'_#M[X0_]#=\1O_"DO?\ Y(K]#J* /SQ_X=O?"'_H;OB-_P"%)>__
M "11_P .WOA#_P!#=\1O_"DO?_DBOT.HH _/'_AV]\(?^AN^(W_A27O_ ,D4
M?\.WOA#_ -#=\1O_  I+W_Y(K]#J* /SQ_X=O?"'_H;OB-_X4E[_ /)%/C_X
M)P_"*-TD'BWXBDH=P!\1WI&1ZC[1@_C7Z%T4 ?" _8 ^%@  \4>/.!C_ )#U
MUV_[;4O_  P#\+?^AH\>?^#ZZ_\ CU?=Q..3P!R2>U1>?#_SVB_[^)_C1<+G
MPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)
M_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?
M\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5
M]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/G
MP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH
M\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_
M[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G
M_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WG
MPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)
M_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?
M\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5
M]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/G
MP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH
M\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_
M[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G
M_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WG
MPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)
M_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?
M\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5
M]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/G
MP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH
M\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_
M[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G
M_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WG
MPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)
M_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?
M\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5
M]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/G
MP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH
M\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_
M[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G
M_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WG
MPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)
M_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?
M\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5
M]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/G
MP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH
M\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_
M[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G
M_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WG
MPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)
M_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?
M\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5
M]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/G
MP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH
M\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_
M[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G
M_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WG
MPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)
M_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?
M\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5
M]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/G
MP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH
M\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_
M[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G
M_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WG
MPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)
M_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?
M\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5
M]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/G
MP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH
M\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_
M[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G
M_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WG
MPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)
M_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?
M\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5
M]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/G
MP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH
M\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_
M[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G
M_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WG
MPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)
M_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?
M\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5
M]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/G
MP_\ /:+_ +^)_C1Y\/\ SVB_[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH
M\>?^#ZZ_^/4?\, _"W_H:/'G_@^NO_CU?=/GP_\ /:+_ +^)_C1Y\/\ SVB_
M[^)_C1?^OZ]5]X7_ *_KU7WGPM_PP#\+?^AH\>?^#ZZ_^/4?\, _"W_H:/'G
M_@^NO_CU?=/GP?\ /:+_ +^)_C4@(89!!!Z$'(/XBBX7/A+_ (8!^%O_ $-'
MCS_P?77_ ,>H_P"& ?A;_P!#1X\_\'UU_P#'J^[J* /A'_A@'X6_]#1X\_\
M!]=?_'J/^& ?A;_T-'CS_P 'UU_\>K[NHH ^$?\ A@'X6_\ 0T>//_!]=?\
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M>H_X8!^%O_0T>//_  ?77_QZONZB@#X1_P"& ?A;_P!#1X\_\'UU_P#'J/\
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M1_PP#\+?^AH\>?\ @^NO_CU?=U% 'PC_ ,, _"W_ *&CQY_X/KK_ ./4?\,
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MPC\,P^%]#O\ 4]1LX79UGU:X>ZNCNYPTKLQ/YT5Z?10 4444 %%%% !1110
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MO+_J)\OQ?<^P_P#AN/\ :#_Z*%XA_P"_EA_\AT?\-Q_M!_\ 10O$/_?RP_\
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M]8>(/^A[G'_ARQGE_P!/O+\6'^O7&W_17\3?^'S,O+_J)\OQ?<^P_P#AN/\
M:#_Z*%XA_P"_EA_\AT?\-Q_M!_\ 10O$/_?RP_\ D.OCRBC_ %AX@_Z'N<?^
M'+&>7_3[R_%A_KUQM_T5_$W_ (?,R\O^HGR_%]S[#_X;C_:#_P"BA>(?^_EA
M_P#(='_#<?[0?_10O$/_ '\L/_D.OCRBC_6'B#_H>YQ_X<L9Y?\ 3[R_%A_K
MUQM_T5_$W_A\S+R_ZB?+\7W/L/\ X;C_ &@_^BA>(?\ OY8?_(='_#<?[0?_
M $4+Q#_W\L/_ )#KX\HH_P!8>(/^A[G'_ARQGE_T^\OQ8?Z]<;?]%?Q-_P"'
MS,O+_J)\OQ?<^P_^&X_V@_\ HH7B'_OY8?\ R'1_PW'^T'_T4+Q#_P!_+#_Y
M#KX\HH_UAX@_Z'N<?^'+&>7_ $^\OQ8?Z]<;?]%?Q-_X?,R\O^HGR_%]S[#_
M .&X_P!H/_HH7B'_ +^6'_R'1_PW'^T'_P!%"\0_]_+#_P"0Z^/**/\ 6'B#
M_H>YQ_X<L9Y?]/O+\6'^O7&W_17\3?\ A\S+R_ZB?+\7W/L/_AN/]H/_ **%
MXA_[^6'_ ,AT?\-Q_M!_]%"\0_\ ?RP_^0Z^/**/]8>(/^A[G'_ARQGE_P!/
MO+\6'^O7&W_17\3?^'S,O+_J)\OQ?<^P_P#AN/\ :#_Z*%XA_P"_EA_\AT?\
M-Q_M!_\ 10O$/_?RP_\ D.OCRBC_ %AX@_Z'N<?^'+&>7_3[R_%A_KUQM_T5
M_$W_ (?,R\O^HGR_%]S[#_X;C_:#_P"BA>(?^_EA_P#(='_#<?[0?_10O$/_
M '\L/_D.OCRBC_6'B#_H>YQ_X<L9Y?\ 3[R_%A_KUQM_T5_$W_A\S+R_ZB?+
M\7W/L/\ X;C_ &@_^BA>(?\ OY8?_(='_#<?[0?_ $4+Q#_W\L/_ )#KX\HH
M_P!8>(/^A[G'_ARQGE_T^\OQ8?Z]<;?]%?Q-_P"'S,O+_J)\OQ?<^P_^&X_V
M@_\ HH7B'_OY8?\ R'1_PW'^T'_T4+Q#_P!_+#_Y#KX\HH_UAX@_Z'N<?^'+
M&>7_ $^\OQ8?Z]<;?]%?Q-_X?,R\O^HGR_%]S[#_ .&X_P!H/_HH7B'_ +^6
M'_R'1_PW'^T'_P!%"\0_]_+#_P"0Z^/**/\ 6'B#_H>YQ_X<L9Y?]/O+\6'^
MO7&W_17\3?\ A\S+R_ZB?+\7W/L/_AN/]H/_ **%XA_[^6'_ ,AT?\-Q_M!_
M]%"\0_\ ?RP_^0Z^/**/]8>(/^A[G'_ARQGE_P!/O+\6'^O7&W_17\3?^'S,
MO+_J)\OQ?<^P_P#AN/\ :#_Z*%XA_P"_EA_\AT?\-Q_M!_\ 10O$/_?RP_\
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M]8>(/^A[G'_ARQGE_P!/O+\6'^O7&W_17\3?^'S,O+_J)\OQ?<^P_P#AN/\
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MO+_J)\OQ?<^P_P#AN/\ :#_Z*%XA_P"_EA_\AT?\-Q_M!_\ 10O$/_?RP_\
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M]8>(/^A[G'_ARQGE_P!/O+\6'^O7&W_17\3?^'S,O+_J)\OQ?<^P_P#AN/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK2M-+$QV[7EP[[<\;BED54@?W6;![]"?>O@;_P ' _B:WU*ST_XQ^"8I[!Y
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MP,\0?''6O \MCH?AR>X6^MX29IA%:SO!.46 L9'0QN0J!F;@ '(K\Q?V2O\
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M_/:]*OBJ.9U,+!TL/'#QA2AAL+4Y7"+E>7/4FVV^MK62+E%%%?AY^L!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !117F_Q>\0:AX6^&OC#7M*#'4-.T>XFM2HR5D.U-^/]D,30!C>-?CM\-O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ()__LT_"OQ-IVD>%/!FN_$#6K"XT_1-,T:.TN[B.YDB<+*[QY\L(<[F8*$
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MT6U9%VH'CM%@65L <NRAF;J?7O7HOF1_WT_[Z'^-'F1_WT_[Z'^- 'PG\./
MG[4GPS\)R> ],/@>]L(+K4&TW6)6F6YB@O)6=&D4$J9(U(Y)ZC(Q7N7P3^#]
M]\/8]7U[Q5K#^(_&_B2Y:[U;5)3N2#>2?LEF3DI;IG"J.,#OGCWKS(_[Z?\
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M'O\ Z D'_?R;_P")K^I[S(_[Z?\ ?0_QH\R/^^G_ 'T/\:/^(+\(_P ^9_\
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MA_C1_P 07X1_GS/_ ,+)>7]WR_K6Y_Q*SX9]\^_\.M7_ "/Y8?\ AV'\>_\
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M"_"/\^9_^%DO+^[Y?UK<_P")6?#/OGW_ (=:O^1_+#_P[#^/?_0$@_[^3?\
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M/X]_] 2#_OY-_P#$U_4]YD?]]/\ OH?XT>9'_?3_ +Z'^-'_ !!?A'^?,_\
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M0_QH_P"(+\(_SYG_ .%DO+^[Y?UK<_XE9\,^^??^'6K_ )'\L/\ P[#^/?\
MT!(/^_DW_P 31_P[#^/?_0$@_P"_DW_Q-?U/>9'_ 'T_[Z'^-'F1_P!]/^^A
M_C1_Q!?A'^?,_P#PLEY?W?+^M;G_ !*SX9]\^_\ #K5_R/Y8?^'8?Q[_ .@)
M!_W\F_\ B:/^'8?Q[_Z D'_?R;_XFOZGO,C_ +Z?]]#_ !H\R/\ OI_WT/\
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M^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^A_C1YD?]]/\
MOH?XT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[
MZ'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'^-'F1_WT_P"^
MA_C0 ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH
M?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^- #Z*9YD?]]/\ OH?XT>9'_?3_ +Z'
M^- #Z*9YD?\ ?3_OH?XT>9'_ 'T_[Z'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_
MC0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^A_C1YD?]]/\ OH?X
MT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^-
M #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'^-'F1_WT_P"^A_C0
M ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT
M/K\ZO^"FUK\6/$'[-7B?P5\'] O]=\3^*XCIZQV. \,,GR22%C@ JA<J"0"V
M,D"OT2\R/^^G_?0_QIK&!_O&)L=-Q1L?G7HY1F#RG-,!F:P]'%RP&+H8N.'Q
M*DZ%:="I&I&%:,7&4J;E%<T5)-K2Z.3'X18_!8O!.M5PZQ>'JX>5:@U&M2C5
M@X2G2DTU&I%-N,FFD[.S/X__ /@F3_P3F^.OA#]J/0/'/Q;\!7>AZ#X>AN;^
M.YOF6X$NH22VQMRI95VM''%/OSG<91Z<_P!@@      &  ,  =  .@%1J8%^
MZ8ESUV[!G\J=YD?]]/\ OH?XU])QWQUFO'^;T\XS6CA</5I82GA*5#!QG##T
MZ=-RDW&-2<Y*4YRE*=Y.\GI9:'A<(\)9;P;E3RG*YXBI1EB*N*G5Q4XU*]2K
M5Y4^>4(P348QC&/NJT4MWJ?S:_\ !:G]ECXY?M">._ \OPR\%WOB:QTZU<3R
MVNV*."0VQB!D?:Q.-QW<$\YY.:\!^!?[&W[2'A;]AKXK_#+4O EY:^+-7U"X
M?2=,E =Y893N7YPJY8?=SC@8!R<FOZQF,#<MY3$="VPX_.D_T?&/W.#V^3'Y
M5]#@O%K.L%PME'"<,NRN> R;'8;'X>O.G6^M5*V&Q4\7%59*JH.$YU)1FHPB
M^2WO7U/*K^'V55^(LRXFEBL?''9G@*N7UZ<:E/ZM&A5HTJ+=.'L^95(QI1E&
M3F[2<G;4_CY_X)C_ +#?[2?P8_:D\)^+?''PZU'1- M]_P!JOYW$D2!G0KG"
MK@@(23SU YYQ^CO_  6Q_9<^*/[0OASX>GX7>$I_$NHZ7JK/?K;861+9[*YM
M1^\*G:%DFC9NY4, .>/WI'V=3N7R0?4; ?S'-*S0M]XQ-CIN*G'YT9AXMYYF
M/&V5\<U,#EM+,LKHTZ%+#4H5E@ZL81J1_>P=5U'=56GRU(WM'S,\!X<9+E_"
M6.X.I8C'SRS'RK2J5:E6F\73=:492]G45)15I1O"\':_5'\X?_!$[]DKXP?
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ME4^4[CACR?ZU\6WI!^4=+_H^,?N<>GR8_*OIL[\?N*,]PV#PN+RS)XT\%FF
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MZ.?U/_P66O\ A1_PR9^U9_T<_J?_ (++7_"OT[HH _,3_ADS]JS_ *.?U/\
M\%EK_A1_PR9^U9_T<_J?_@LM?\*_3NB@#\Q/^&3/VK/^CG]3_P#!9:_X4?\
M#)G[5G_1S^I_^"RU_P *_3NB@#\Q/^&3/VK/^CG]3_\ !9:_X4?\,F?M6?\
M1S^I_P#@LM?\*_3NB@#\Q/\ ADS]JS_HY_4__!9:_P"%'_#)G[5G_1S^I_\
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M_P"CG]3_ /!9:_X4?\,F?M6?]'/ZG_X++7_"OT[HH _,3_ADS]JS_HY_4_\
MP66O^%'_  R9^U9_T<_J?_@LM?\ "OT[HH _,3_ADS]JS_HY_4__  66O^%'
M_#)G[5G_ $<_J?\ X++7_"OT[HH _,3_ (9,_:L_Z.?U/_P66O\ A1_PR9^U
M9_T<_J?_ (++7_"OT[HH _,3_ADS]JS_ *.?U/\ \%EK_A1_PR9^U9_T<_J?
M_@LM?\*_3NB@#\Q/^&3/VK/^CG]3_P#!9:_X4?\ #)G[5G_1S^I_^"RU_P *
M_3NB@#\Q/^&3/VK/^CG]3_\ !9:_X4?\,F?M6?\ 1S^I_P#@LM?\*_3NB@#\
MQ/\ ADS]JS_HY_4__!9:_P"%'_#)G[5G_1S^I_\ @LM?\*_3NB@#\Q/^&3/V
MK/\ HY_4_P#P66O^%'_#)G[5G_1S^I_^"RU_PK].Z* /S$_X9,_:L_Z.?U/_
M ,%EK_A1_P ,F?M6?]'/ZG_X++7_  K].Z* /S$_X9,_:L_Z.?U/_P %EK_A
M1_PR9^U9_P!'/ZG_ ."RU_PK].Z* /S$_P"&3/VK/^CG]3_\%EK_ (4?\,F?
MM6?]'/ZG_P""RU_PK].Z* /S$_X9,_:L_P"CG]3_ /!9:_X4?\,F?M6?]'/Z
MG_X++7_"OT[HH _,3_ADS]JS_HY_4_\ P66O^%'_  R9^U9_T<_J?_@LM?\
M"OT[HH _,3_ADS]JS_HY_4__  66O^%'_#)G[5G_ $<_J?\ X++7_"OT[HH
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MCG]3_P#!9:_X4?\ #)G[5G_1S^I_^"RU_P *_3NB@#\Q/^&3/VK/^CG]3_\
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M  66O^%'_#)G[5G_ $<_J?\ X++7_"OT[HH _,3_ (9,_:L_Z.?U/_P66O\
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M 3PK_P!]W'_R/1_P^D_:#_Z GA7_ +[N/_D>OQ=HH_X@5X/_ /1OLBZ=<?\
MW?\ J+\OP7F'_$V'TCO^CL9YT_YEW#G3E_ZDW]W\3]HO^'TG[0?_ $!/"O\
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M2._Z.QGG3_F7<.=.7_J3?W?Q/VB_X?2?M!_] 3PK_P!]W'_R/1_P^D_:#_Z
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M 3PK_P!]W'_R/1_P^D_:#_Z GA7_ +[N/_D>OQ=HH_X@5X/_ /1OLBZ=<?\
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MF2W5R%\V4H"(T4,#R ,=?6O[X\*_![A[A+(L+Q)Q1AL'C<\KX.&9XF>8QA/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M^V'_  1<_P"2XZ]_V ;+_P!&WE?B?7[8?\$7/^2XZ]_V ;+_ -&WE?E'CI_R
M:#CW_L30_P#4["']#?1._P"4B_"S_L<9C_ZH<T/ZH****_QV/^A(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\C^/-]/IWP@^(%W;.8Y
MH_#6I[67@C-M)T/OC'TKURO/OBMH$GBCX<^,M"A!,VH>']2AA4?Q2&UDVCZG
MD#WQ77E\H0Q^"E4M[..+PTJE]N15H.=_+E3.?%*3PN(4-9.A544MV^25DO-[
M(_@H\5W#W.NZM?R$M/=SM<3.22SO@<ECU/O_ (5^Z_\ P11^&_AJR\'_ !2^
M.VJ6%OJ?B'3+6]&GO+&LTMHEA%),?)W M&[K$4W(0022#D5^'GQ'T:Z\,?$'
MQ=X6U&&2&\T/4FM)H70HP!0'D'!QC'( ^O%?IG_P2:_:P\*? KQGXA^#WQ*N
MXK#P;\05,&GZE<OMM+:ZN2$DCE8_*J2AVC;)^Z6'IC_1OQHP6;9QX6YU1X>]
MI5JRP^78KV6&NZE;+8*G5FJ<8:U(*#A4G"-^>G!JSMK_ !#X:8K 9=QW@*V:
M5*5"*J8_#1KU[>RH8^HI0HRJ.6D6JMXJ;M:33NKW/'_VA?VQOV@/C!\6/%VJ
M6OCO5O#.C:)J]Y8:%I.G3RQ16ZV=P\*%PDJ < '!&/T%?KE_P3L^.'B+]L#X
M(_$CX&_&;'B.YL;"YT:/5KQ!/YUHR-&AD:3>!*C8D5L[P<@'!.?-OCG_ ,$A
M5^)7CO4/B#\#_B#I5EX9\87!U&ZM7N5DAA%XWG/+;2(Q1OOY 7YN.5#<#Z3\
M'Z/\"?\ @E=\!=>N=8\3Z=K/Q O[62YD@$Z27^JZLT3F*"*')D6#SL%]ZJ2,
M84ALU_D!X?<*>)4?$"$TL?6J5<;5Y?9UIUEC*TJT?J:PU!-NE*E/DDGRP5&,
M7>RNS](X3X>XZR3C#-LYXJQLZ?#;IYC+-,9C,PC5P&98:JI>Q]AAW.27N-<J
M4(N,?=29^-7_  4>TO1/@L_@O]E[PM<QW&G>&;PZ[<B!PRPB9B!"P7H5W<@^
ME?!/PG\(W/C_ .+_ ,//"5I$TRR:U9WMRJC.VULKB.20MCHH0$G(Q@]J7XJ?
M$SQ%\;/B7XK^*?BF21K_ ,0:A=W%G!*Q)L]/=V>*$ XV[% P !@_2OK_ /85
M\+67A[3?B]^TUXFC$'ASX<>&]2M-&N9U"Q76HWEFZPB!FP'9)@/NY.:_V1HT
M<1P'X<2I8RL\1GWU*5.M43YJF/XFSR:I1C&2^*J\5745R_$J4G>R9^55)T>+
M.-N?#4OJ^5+$)T$W[N$R7*X*HI2B[\D(T:7,U+K.U[L_K\^%U[HL_@WP_8Z%
M)&]IH^AZ-IS"(@JDD.FVJLO!/.0<^^:]$K\^O^":?BN_\=?LS>&_&.IR227F
MO7$]TYD))$7'D#)Y_P!4R]>V,5^@M?YQ\2Y;4R?/\VRNK.52M@,=6PU:<OBE
M7IRM6;_[B\_R/[<R#'QS/)<LS"$>6GB\)2K4XVM:G*/[O36WN<NG0****\,]
M<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%8.K4PV'H5\'B*&)A:3A4H2G2K4IRC*G.,9*,HMR_FQP?0_E1@^A_*OZ3?\
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MDO\ XDV7^7EZ_P!)G\V6#Z'\J,'T/Y5_2;_PY"T'_HI&M?\ @/H'_P JJ/\
MAR%H/_12-:_\!] _^55'_$S?@Q_T4^*_\,^/_P#D/ZMZ!_Q([](W_HELE_\
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M?_\ (?U;T#_B1WZ1O_1+9+_XDV7^7EZ_TF?S98/H?RHP?0_E7])O_#D+0?\
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M_2-_Z);)?_$FR_R\O7^DS^;+!]#^5&#Z'\J_I-_X<A:#_P!%(UK_ ,!] _\
ME51_PY"T'_HI&M?^ ^@?_*JC_B9OP8_Z*?%?^&?'_P#R']6] _XD=^D;_P!$
MMDO_ (DV7^7EZ_TF?S98/H?RHP?0_E7])O\ PY"T'_HI&M?^ ^@?_*JC_AR%
MH/\ T4C6O_ ?0/\ Y54?\3-^#'_13XK_ ,,^/_\ D/ZMZ!_Q([](W_HELE_\
M2;+_ "\O7^DS^;+!]#^5&#Z'\J_I-_X<A:#_ -%(UK_P'T#_ .55'_#D+0?^
MBD:U_P" ^@?_ "JH_P")F_!C_HI\5_X9\?\ _(?U;T#_ (D=^D;_ -$MDO\
MXDV7^7EZ_P!)G\V6#Z'\J,'T/Y5_2;_PY"T'_HI&M?\ @/H'_P JJ/\ AR%H
M/_12-:_\!] _^55'_$S?@Q_T4^*_\,^/_P#D/ZMZ!_Q([](W_HELE_\ $FR_
MR\O7^DS^;+!]#^5&#Z'\J_I-_P"'(6@_]%(UK_P'T#_Y54?\.0M!_P"BD:U_
MX#Z!_P#*JC_B9OP8_P"BGQ7_ (9\?_\ (?U;T#_B1WZ1O_1+9+_XDV7^7EZ_
MTF?S98/H?RHP?0_E7])O_#D+0?\ HI&M?^ ^@?\ RJH_X<A:#_T4C6O_  'T
M#_Y54?\ $S?@Q_T4^*_\,^/_ /D/ZMZ!_P 2._2-_P"B6R7_ ,2;+_+R]?Z3
M/YLL'T/Y48/H?RK^DW_AR%H/_12-:_\  ?0/_E51_P .0M!_Z*1K7_@/H'_R
MJH_XF;\&/^BGQ7_AGQ__ ,A_5O0/^)'?I&_]$MDO_B39?Y>7K_29_-E@^A_*
MC!]#^5?TF_\ #D+0?^BD:U_X#Z!_\JJ/^'(6@_\ 12-:_P# ?0/_ )54?\3-
M^#'_ $4^*_\ #/C_ /Y#^K>@?\2._2-_Z);)?_$FR_R\O7^DS^;+!]#^5&#Z
M'\J_I-_X<A:#_P!%(UK_ ,!] _\ E51_PY"T'_HI&M?^ ^@?_*JC_B9OP8_Z
M*?%?^&?'_P#R']6] _XD=^D;_P!$MDO_ (DV7^7EZ_TF?S8G(Z@_E7[;_P#!
M%VTO!\;=>G^RR_9_[!L\S[&\L%9+QG4G& 0K(PYY#].#7TRO_!$/0 1GXD:S
MC(SFWT'CGJ/^)5_0_P"/Z@?LI?L=_#[]EK0);/PXGV[6[X*=1UB=%-S,_EK$
M<R8!/R(J8 "A0 H"@ ?EWC)](GPVSWP\X@X>X;S#%YOFF>X:G@:5-X#$82CA
MH?6*-:IB*U6ORI\L:?+"$%)RD[NR6O[K]&WZ'_C!P9XO<+<:\:8/*,DR7A>I
MC,?+V&;4,QQ685\1E^)P-+"T:.'IM4XQEBG6JU:M2'*J<8PC-RER_8%%%%?Y
MUG^M@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C8P=PR
M",$$9!!XP1WSTYI:0YQQ^OI0!_+Y_P %=OV)_$/A#QLW[27PRT6:_P##.KPQ
M1^,],L87EDL[M8TCDO3'$A.QE4R;N  <=B1^'T<EKJD,<]O(P:-@\;(VRZM9
M0<@_WXI%(&> <C![U_H6:[H6D>)M(O-"U[3K75=(U*W>UOK&\B6:">&1"K*R
M.".A^]P1U!K\&OVI_P#@BUH/BG6-2\9_L_:V/"NH7\LMS/X9F81Z>97.\^4Y
M*@*S< #!Y/ XS_87A!X]9;@LKP?"W&U:IAE@(+#Y9GKC*K2>$2M#"9A&*<XJ
MDKQI5TI+V?NU++5_S/XE>$..Q./Q&?<*4(5EBZCKX_*XR5*HL0_>EB,(Y-0E
M[1ZRI:-3UBW=H_#GP?\ M2?M*_#_ $S^Q/"WQ4UN#2@GE16]U>74YACQM"HQ
M)VX7 &",8KROQ?XP\<_$;4_[7^('BO5_%%]O\Q?M][-/:QMDG*Q2DA<9['BO
MMO7?^"6W[96A7SV2^&;*_6-]BW,,C.K@<;@P;&6 S^->M_"__@C;^TSXXOK,
M^.-2L/!N@R2*;R2*<?:O*R-X2-WRS;>@ S[9K]P?''A%E'M<YI9SPIAJU6[E
MBLOP]!XRM=)M1C0I>VYI+1I*+D]+ZGY0N$_$;,.7+JV5\0UZ<9J,</B9U_J\
M>6R3DZM14E"-TUJU97ML?FQ\-/AIXP^-_CK2/AE\/K">^U35KF./4-1AC=[#
M1=/#J;JXNKE T4*K 7/SD 8/X_:'[9GCKPE\*_A;H7[%WP>OX[W3/#-H;OXG
M^(K%@4U?67B)GM6FB)63[/< K@],'Z5^O>M_\$XOB#\%_AVWPZ_95O=/T;7/
M$=E]F\7?$K4&C367252D\=L\A22+<&;!C<,%(/%?!;_\$0OV@YVNI[SQ[8WM
M]J$DEQJ-[<7JRSW<\Q+2O)(\I<[F)."W>OAL-XK\"<2YWA,YSOB/"97D.0XK
MZSD.1UH5I8[,<SA^[6>9K&%.=.A##P<EEV"<I2C*7MZGOV2^KK>'W%^195B<
MMRO(L5C\WS>A&AFV9TG3CAL'E[<9O*\!.4U.I.M)+ZYB4N5QBJ4+IL_7[_@D
MY=1S?LC>"X(F0K9PVT&Q2,IBS@&& S@G;GWK]-*_+S_@GM^R1\9OV4H=9\-^
M-O%T>O>%+JWB;3K&&X$L=G<+;Q)@('<8#J?F  Z5^H=?Q_XE5LMQ7''$>-RC
M,*&:9=F&8U<?A<7AE-4Y0Q=JS@U449*=.4G"::6J['],<#4L;A^%,DPN88.K
M@,9A,%3PM;#5K<\94+TU+W6URS24HV;T84445\,?6!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%5
M;ZZ2QLKN]D!,=G;3W4@'4I!$TK >^%- %JBOP,\=_P#!PO\ L=?#_P"+GB_X
M0ZKH_P 0;_6/ .NKH'C/5M!\*^(->T+PO=M#;76?$&K:1I%YI^C*+.]M;QO[
M1NK8K:SQW!Q"PDK]EO@A\<?AO^T-\/-"^)_PL\16/B;PEX@M(KNRU&PGCGB*
MRQK(%+QLPR W7B@#UVBC/&>WKVKY)_;._;'^%?[#OP<O_CA\8KI[#P1I=[:6
M>I:@'6.*R^USQ6\<\\K@I'"LDR;W8A4&2S 9( /K:BN.^'WC33OB)X)\+^.=
M(22/3/%>C6>M6"2_ZP6U[$)8@_3YMI&>*['/;N* "BC/.._7'?'KBB@ HH!S
MTY^E&: "BC/Z=?:C- !129&,Y&#T/;GI2YH **0,K9VD''!P0<?7'2@D 9)
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M!_S\^#__  $HQ_P4 _Y^?!__ ("4 ?H]17YPX_X* ?\ /SX/_P# 2C'_  4
M_P"?GP?_ . E 'Z/45^<./\ @H!_S\^#_P#P$HQ_P4 _Y^?!_P#X"4 ?H]17
MYPX_X* ?\_/@_P#\!*,?\% /^?GP?_X"4 ?H]17YPX_X* ?\_/@__P !*,?\
M% /^?GP?_P" E 'Z/45^<./^"@'_ #\^#_\ P$HQ_P % /\ GY\'_P#@)0!^
MCU%?G#C_ (* ?\_/@_\ \!*,?\% /^?GP?\ ^ E 'Z/45^<./^"@'_/SX/\
M_ 2C'_!0#_GY\'_^ E 'Z/45^<./^"@'_/SX/_\  2C'_!0#_GY\'_\ @)0!
M^CU%?G#C_@H!_P _/@__ ,!*,?\ !0#_ )^?!_\ X"4 ?H]17YPX_P""@'_/
MSX/_ / 2C'_!0#_GY\'_ /@)0!^CU%?G#C_@H!_S\^#_ /P$HQ_P4 _Y^?!_
M_@)0!^CU%?G#C_@H!_S\^#__  $HQ_P4 _Y^?!__ ("4 ?H]17YPX_X* ?\
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M_!0#_GY\'_\ @)0!^CU%?G#C_@H!_P _/@__ ,!*,?\ !0#_ )^?!_\ X"4
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M #\^#_\ P$HQ_P % /\ GY\'_P#@)0!^CU%?G#C_ (* ?\_/@_\ \!*,?\%
M/^?GP?\ ^ E 'Z/45^<./^"@'_/SX/\ _ 2C'_!0#_GY\'_^ E 'Z/45^<./
M^"@'_/SX/_\  2C'_!0#_GY\'_\ @)0!^CU%?G#C_@H!_P _/@__ ,!*,?\
M!0#_ )^?!_\ X"4 ?H]17YPX_P""@'_/SX/_ / 2C'_!0#_GY\'_ /@)0!^C
MU%?G#C_@H!_S\^#_ /P$HQ_P4 _Y^?!__@)0!^CU%?G#C_@H!_S\^#__  $H
MQ_P4 _Y^?!__ ("4 ?H]17YPX_X* ?\ /SX/_P# 2C'_  4 _P"?GP?_ . E
M 'Z/45^<./\ @H!_S\^#_P#P$HQ_P4 _Y^?!_P#X"4 ?H]17YPX_X* ?\_/@
M_P#\!*,?\% /^?GP?_X"4 ?H]17YPX_X* ?\_/@__P !*,?\% /^?GP?_P"
ME 'Z/45^<./^"@'_ #\^#_\ P$HQ_P % /\ GY\'_P#@)0!^CU%?G#C_ (*
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MX/\ _ 2C'_!0#_GY\'_^ E 'Z/45^<./^"@'_/SX/_\  2C'_!0#_GY\'_\
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M_P % /\ GY\'_P#@)0!^CU%?G#C_ (* ?\_/@_\ \!*,?\% /^?GP?\ ^ E
M'Z/45^<./^"@'_/SX/\ _ 2C'_!0#_GY\'_^ E 'Z/45^<./^"@'_/SX/_\
M 2C'_!0#_GY\'_\ @)0!^CU%?G#C_@H!_P _/@__ ,!*,?\ !0#_ )^?!_\
MX"4 ?H]17YPX_P""@'_/SX/_ / 2C'_!0#_GY\'_ /@)0!^CU%?G#C_@H!_S
M\^#_ /P$HQ_P4 _Y^?!__@)0!^CU%?G#C_@H!_S\^#__  $HQ_P4 _Y^?!__
M ("4 ?H]17YPX_X* ?\ /SX/_P# 2C'_  4 _P"?GP?_ . E 'Z/45^<./\
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M#_GY\'_^ E 'Z/4'D$>M?G#C_@H!_P _/@__ ,!*4+^W^2 ;GP>!Z_9#_@:
M/T: ;^\!] /_ *U+AO[WZ"OSG\K]OW_G_P#!O_@&?_B:/*_;^_Y__!O_ (!G
M_P"(H _1C#?WOT%&&_O?H*_.?ROV_O\ G_\ !O\ X!G_ .(H\K]O[_G_ /!O
M_@&?_B* /T8PW][]!1AO[WZ"OSG\K]O[_G_\&_\ @&?_ (BCROV_O^?_ ,&_
M^ 9_^(H _1@ YR3D]/PIU?G(T?[?RCB]\'/["S(Q^@IF/^"@'_/SX/\ _ 2@
M#]'J*_.''_!0#_GY\'_^ E&/^"@'_/SX/_\  2@#]'J*_.''_!0#_GY\'_\
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M^X+R_P"GOG^#/VEHK\6O^'S?P7_Z VK_ /@!>?\ QFC_ (?-_!?_ * VK_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4\-_"WX1?#_]GOQSX?\ "W_"%Z-IFF:_/K]C)?F^CMHX%GBBV21E6RL@5R2
M6S@BOLSP[X"\$^$I)YO#'A30-!FN6+SRZ7I=I9RRLQR2TD,2N<GJ,X/>NMH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT!KS_OU)_P#$4?\ "'^)O^@->?\ ?J3_ .(H^:^]>7GYH/8UO^?-;_P54_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY%P:\C_:)_X*2? /X ?#"]^"O[)&E6L^KW=G-IJ:GI\2I9V(E0PM>><G^MN
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M]I33YENGN%%%%?!GUX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*G=1YZD)2LGLKV1]D_\ #-/P3_Z$+1?_  &B_P#B*/\ AFGX)_\ 0A:+_P"
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M?@G_ -"%HO\ X#1?_$5\;?\ #;/Q\_Z-D\1_G)_\=H_X;9^/G_1LGB/\Y/\
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M_P!#S-O_  X8K_Y:'^K^1?\ 0FRO_P (,+Y?].O)'V3_ ,,T_!/_ *$+1?\
MP&B_^(H_X9I^"?\ T(6B_P#@-%_\17QM_P -L_'S_HV3Q'^<G_QVC_AMGX^?
M]&R>(_SD_P#CM'^LG$/_ $/,V_\ #ABO_EH?ZOY%_P!";*__  @POE_TZ\D?
M9/\ PS3\$_\ H0M%_P# :+_XBC_AFGX)_P#0A:+_ . T7_Q%?&W_  VS\?/^
MC9/$?YR?_':/^&V?CY_T;)XC_.3_ ..T?ZR<0_\ 0\S;_P .&*_^6A_J_D7_
M $)LK_\ "#"^7_3KR1]D_P##-/P3_P"A"T7_ ,!HO_B*/^&:?@G_ -"%HO\
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MT?\ #;/Q\_Z-D\1_G)_\=H _3^BOS _X;9^/G_1LGB/\Y/\ X[1_PVS\?/\
MHV3Q'^<G_P =H _3^BOS _X;9^/G_1LGB/\ .3_X[1_PVS\?/^C9/$?YR?\
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MT?\ #;/Q\_Z-D\1_G)_\=H _3^BOS _X;9^/G_1LGB/\Y/\ X[1_PVS\?/\
MHV3Q'^<G_P =H _3^BOS _X;9^/G_1LGB/\ .3_X[1_PVS\?/^C9/$?YR?\
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MT?\ #;/Q\_Z-D\1_G)_\=H _3^BOS _X;9^/G_1LGB/\Y/\ X[1_PVS\?/\
MHV3Q'^<G_P =H _3^BOS _X;9^/G_1LGB/\ .3_X[1_PVS\?/^C9/$?YR?\
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MT?\ #;/Q\_Z-D\1_G)_\=H _3^BOS _X;9^/G_1LGB/\Y/\ X[1_PVS\?/\
MHV3Q'^<G_P =H _3^BOS _X;9^/G_1LGB/\ .3_X[1_PVS\?/^C9/$?YR?\
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MT?\ #;/Q\_Z-D\1_G)_\=H _3^BOS _X;9^/G_1LGB/\Y/\ X[1_PVS\?/\
MHV3Q'^<G_P =H _3^BOS _X;9^/G_1LGB/\ .3_X[1_PVS\?/^C9/$?YR?\
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MT?\ #;/Q\_Z-D\1_G)_\=H _3^BOS _X;9^/G_1LGB/\Y/\ X[1_PVS\?/\
MHV3Q'^<G_P =H _3^BOS _X;9^/G_1LGB/\ .3_X[1_PVS\?/^C9/$?YR?\
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MJ_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\
M?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_P
MIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU%
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M_C1O7^\OYC_&@ V+_=7_ +Y'^%&Q?[J_]\C_  HWK_>7\Q_C1O7^\OYC_&@
MV+_=7_OD?X4;%_NK_P!\C_"C>O\ >7\Q_C1O7^\OYC_&@ V+_=7_ +Y'^%&Q
M?[J_]\C_  HWK_>7\Q_C1O7^\OYC_&@ V+_=7_OD?X4;%_NK_P!\C_"C>O\
M>7\Q_C1O7^\OYC_&@ V+_=7_ +Y'^%&Q?[J_]\C_  HWK_>7\Q_C1O7^\OYC
M_&@ V+_=7_OD?X4;%_NK_P!\C_"C>O\ >7\Q_C1O7^\OYC_&@ V+_=7_ +Y'
M^%&Q?[J_]\C_  HWK_>7\Q_C1O7^\OYC_&@ V+_=7_OD?X4;%_NK_P!\C_"C
M>O\ >7\Q_C1O7^\OYC_&@ V+_=7_ +Y'^%&Q?[J_]\C_  HWK_>7\Q_C1O7^
M\OYC_&@ V+_=7_OD?X4;%_NK_P!\C_"C>O\ >7\Q_C1O7^\OYC_&@ V+_=7_
M +Y'^%&Q?[J_]\C_  HWK_>7\Q_C1O7^\OYC_&@ V+_=7_OD?X4;%_NK_P!\
MC_"C>O\ >7\Q_C1O7^\OYC_&@ V+_=7_ +Y'^%&Q?[J_]\C_  HWK_>7\Q_C
M1O7^\OYC_&@ V+_=7_OD?X4;%_NK_P!\C_"C>O\ >7\Q_C1O7^\OYC_&@ V+
M_=7_ +Y'^%&Q?[J_]\C_  HWK_>7\Q_C1O7^\OYC_&@ V+_=7_OD?X4;%_NK
M_P!\C_"C>O\ >7\Q_C1O7^\OYC_&@ V+_=7_ +Y'^%&Q?[J_]\C_  HWK_>7
M\Q_C1O7^\OYC_&@ V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK
M_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\
MC_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G
M44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -
MV+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=
M7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD
M?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;
M%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK
M_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\
MC_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G
M44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -
MV+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=
M7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD
M?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;
M%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK
M_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\
MC_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G
M44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -
MV+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=
M7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD
M?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;
M%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK_P!\C_"G44 -V+_=7_OD?X4;%_NK
M_P!\C_"G44 -Z<*OY8'^>E&6_N_J*0=6P?TZ'G^5?G%^V-_P4D^#O[*D,V@"
MYC\8?$.2)Q;^'--F24VTK JC7;HS!2KXS&< 8YW<BO6R3(LWXCS"CE>28#$9
MCCZ[M3P^'@YRM=)SF](TZ<;WE4FXQBMV>=FN;Y=DF#J8_-<71P6$I*\ZU:2B
MKO:,5\4YRZ1@FWV/T>RW]W]11EO[OZBOX\?B5_P5N_:Q\?7]Q)X>N;3P?I$L
MC&ULXXMLD<9)V;F1?O;3ACU)'<=>#\-?\%.OVR_#%V+S_A,(-556!:"XCD<,
MN02N&7'3CC^M?NE'Z,O']3!K$5,3D6'Q#A&4<'4QTI5+O>$JD*,J4)Q>C7,U
MYV/R6MX[\'4\0Z5.AFM>BI6^M0PT53:O;GC&515&NMFD[=#^TK+?W?U%&6_N
M_J*_ S]C?_@L/+\4/&NC?"GXQ>%FTOQ%K:O%IFN68"6UQ<Q1;]KQJ ,.<#)P
M02"#UKQ+X\?\%@/CK\,OC7XU^'6D>%=.N])\/W;QV5VUO&S30^:4C9B4ZD#/
M)_QKXZCX)>(=7/<5PX\HI4<RPN"CF-JV,H0P^(P4JOL57PN(YG3KQ]I>-H^\
MFG>*L[?25?%;@NEE-#.O[0JU<%7Q?U']UAJLZU+%*FJKI5J5DX-0=T]8OHWN
M?TP;B.2O'U%&U?[J_P#?(K\._P#@G-_P4>^+/[6GQF\2_#WQKX;L],TG2O#L
MVJ0W-O D;^?#.$ 9E4'!4X(SR<'''/[C5\7Q7PGG/!>;2R3/J-*AF$*%'$2I
MT:T*\%2KINF^>'NW:3O'==3ZGASB3+.*<MCFN45*M3"2K5:"E5I2I2]I2:4U
MRRULKK4;L7^ZO_?(_P *-B_W5_[Y'^%.HKYH]X;L7^ZO_?(_PHV+_=7_ +Y'
M^%.HH ;L7^ZO_?(_PHV+_=7_ +Y'^%.HH ;L7^ZO_?(_PHV+_=7_ +Y'^%.H
MH ;L7^ZO_?(_PHV+_=7_ +Y'^%.HH ;L7^ZO_?(_PHV+_=7_ +Y'^%.HH ;L
M7^ZO_?(_PHV+_=7_ +Y'^%.HH ;L7^ZO_?(_PHV+_=7_ +Y'^%.HH ;L7^ZO
M_?(_PHV+_=7_ +Y'^%.HH ;L7^ZO_?(_PHV+_=7_ +Y'^%.HH  ,=!CZ"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\3^(M,\)>'M9\3:S<1VF
MEZ)I]SJ-[<2L%CB@MHR[,S,0 . ,D]ZW:YSQ=X6TGQMX<U;PKKT'VG1];M)+
M'4;8_=GMI1B2)O\ 98<$=Q0!_)UX(U;]IS]J;X@_M>?&;PQ^S_X>^*WPV^(-
MQ>^$/A/XDU^_^SW$5OX9MY;-KVTCEMYPMI+J1EEM9;9]TL:K)CYE-??_ /P3
MA^/7B?QK^Q-\8_@/\:(+?1_C?\ M \0>%_'_ (9$[R_8P^GS7=J]J\P6>>QE
MM)8)+2=T1I(FRR(P<#]K?AM\-?!WPE\):=X(\":-::%X<TL/]DT^SB2*&,R$
M%V"HH&6(R2<G/>N*M/V=OA1I_C#QOXYL/#%C9>(OB+9FP\87EO$D3:U;F)H0
MMX$"B7;$Q12P)5>,T ?R&?LY> _C+H7COX.']JSXO6/B7]A#QGX_M[OX;>%9
M-">V&A^.[K6YKG1+'7=>?4)K.[L89!!'ID1TRTD2Z5?,GG8Q"OU^^/NMZ+^S
M;_P49^#_ ,;?B1ILMQ\#?$_@:W\#^%?&JVGVW1/ VIEK>:![NZ8&'3[;4(\1
MI=YCC+PQJSJ73/ZN:O\ LK?!'7/ASI_PKU+P7IEQX,TG4XM8TS2WMXS%8ZC!
M.+F&ZM_ES'+%.!(C*05;D8-=YXM^#WP\\>^!4^'/C3PUIWB7PK'81Z<FG:K
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M1./O^BSXG_\ #SCO_EW]?-GW+_P\"_:._P"BAZG_ . UK_\ $4?\/ OVCO\
MHH>I_P#@-:__ !%?#5%'^M/$O_0_SC_PX8GR_P"GGE^+[A_Q$3C[_HL^)_\
MP\X[_P"7?U\V?<O_  \"_:._Z*'J?_@-:_\ Q%'_  \"_:._Z*'J?_@-:_\
MQ%?#5%'^M/$O_0_SC_PX8GR_Z>>7XON'_$1./O\ HL^)_P#P\X[_ .7?U\V?
M<O\ P\"_:._Z*'J?_@-:_P#Q%'_#P+]H[_HH>I_^ UK_ /$5\-44?ZT\2_\
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MVCO^BAZG_P" UK_\11_P\"_:._Z*'J?_ (#6O_Q%?#5%'^M/$O\ T/\ ./\
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M9]R_\/ OVCO^BAZG_P" UK_\11_P\"_:._Z*'J?_ (#6O_Q%?#5%'^M/$O\
MT/\ ./\ PX8GR_Z>>7XON'_$1./O^BSXG_\ #SCO_EW]?-GW+_P\"_:._P"B
MAZG_ . UK_\ $4?\/ OVCO\ HH>I_P#@-:__ !%?#5%'^M/$O_0_SC_PX8GR
M_P"GGE^+[A_Q$3C[_HL^)_\ P\X[_P"7?U\V?<O_  \"_:._Z*'J?_@-:_\
MQ%'_  \"_:._Z*'J?_@-:_\ Q%?#5%'^M/$O_0_SC_PX8GR_Z>>7XON'_$1.
M/O\ HL^)_P#P\X[_ .7?U\V?<O\ P\"_:._Z*'J?_@-:_P#Q%'_#P+]H[_HH
M>I_^ UK_ /$5\-44?ZT\2_\ 0_SC_P .&)\O^GGE^+[A_P 1$X^_Z+/B?_P\
MX[_Y=_7S9]R_\/ OVCO^BAZG_P" UK_\11_P\"_:._Z*'J?_ (#6O_Q%?#5%
M'^M/$O\ T/\ ./\ PX8GR_Z>>7XON'_$1./O^BSXG_\ #SCO_EW]?-GW+_P\
M"_:._P"BAZG_ . UK_\ $4?\/ OVCO\ HH>I_P#@-:__ !%?#5%'^M/$O_0_
MSC_PX8GR_P"GGE^+[A_Q$3C[_HL^)_\ P\X[_P"7?U\V?<O_  \"_:._Z*'J
M?_@-:_\ Q%'_  \"_:._Z*'J?_@-:_\ Q%?#5%'^M/$O_0_SC_PX8GR_Z>>7
MXON'_$1./O\ HL^)_P#P\X[_ .7?U\V?<O\ P\"_:._Z*'J?_@-:_P#Q%'_#
MP+]H[_HH>I_^ UK_ /$5\-44?ZT\2_\ 0_SC_P .&)\O^GGE^+[A_P 1$X^_
MZ+/B?_P\X[_Y=_7S9]R_\/ OVCO^BAZG_P" UK_\11_P\"_:._Z*'J?_ (#6
MO_Q%?#5%'^M/$O\ T/\ ./\ PX8GR_Z>>7XON'_$1./O^BSXG_\ #SCO_EW]
M?-GW+_P\"_:._P"BAZG_ . UK_\ $4?\/ OVCO\ HH>I_P#@-:__ !%?#5%'
M^M/$O_0_SC_PX8GR_P"GGE^+[A_Q$3C[_HL^)_\ P\X[_P"7?U\V?<O_  \"
M_:._Z*'J?_@-:_\ Q%'_  \"_:._Z*'J?_@-:_\ Q%?#5%'^M/$O_0_SC_PX
M8GR_Z>>7XON'_$1./O\ HL^)_P#P\X[_ .7?U\V?<O\ P\"_:._Z*'J?_@-:
M_P#Q%'_#P+]H[_HH>I_^ UK_ /$5\-44?ZT\2_\ 0_SC_P .&)\O^GGE^+[A
M_P 1$X^_Z+/B?_P\X[_Y=_7S9]R_\/ OVCO^BAZG_P" UK_\11_P\"_:._Z*
M'J?_ (#6O_Q%?#5%'^M/$O\ T/\ ./\ PX8GR_Z>>7XON'_$1./O^BSXG_\
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M5%'^M/$O_0_SC_PX8GR_Z>>7XON'_$1./O\ HL^)_P#P\X[_ .7?U\V?<O\
MP\"_:._Z*'J?_@-:_P#Q%'_#P+]H[_HH>I_^ UK_ /$5\-44?ZT\2_\ 0_SC
M_P .&)\O^GGE^+[A_P 1$X^_Z+/B?_P\X[_Y=_7S9]R_\/ OVCO^BAZG_P"
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MMUI^K1*8_-*LZ2QO$S,RNK!689=0)5PY.<?L-7\M?_!+( _M"Z'D?\PJZ_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,FO<@DD;OPP^#GQ:^-VI-IGPK\&:GXC,;JDVH+;2G3XF)Q_Q\(-@Y([U[/\
M$']A7]J_X6Z-)X@\2_#F]N=,BB\^Y?38I[F6"( %F*+D@*.Y_$XK]_?C=\9O
MAO\ \$P/@7X*\!_#+PG87?CK6])M2FZW0S7-V85^T75])@LP\[>41B5VA202
M1CYE_9K_ ."M7C/QA\1M+^'?QW\+Z5+X<\9W2Z;!=P0(R0O>L46&<%-ICVL
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS?\ ?Z7_ .,4?\.W_P!H#_H4YO\ O]+_ /&*_K(HH_X@IPM_T$YK_P"%$/\
MY4'_ !*IX<_]!?$7_AQ7_P I/Y-_^';_ .T!_P!"G-_W^E_^,4?\.W_V@/\
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MS?\ ?Z7_ .,4?\.W_P!H#_H4YO\ O]+_ /&*_K(HH_X@IPM_T$YK_P"%$/\
MY4'_ !*IX<_]!?$7_AQ7_P I/Y-_^';_ .T!_P!"G-_W^E_^,4?\.W_V@/\
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MS?\ ?Z7_ .,4?\.W_P!H#_H4YO\ O]+_ /&*_K(HH_X@IPM_T$YK_P"%$/\
MY4'_ !*IX<_]!?$7_AQ7_P I/Y-_^';_ .T!_P!"G-_W^E_^,4?\.W_V@/\
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MS?\ ?Z7_ .,4?\.W_P!H#_H4YO\ O]+_ /&*_K(HH_X@IPM_T$YK_P"%$/\
MY4'_ !*IX<_]!?$7_AQ7_P I/Y-_^';_ .T!_P!"G-_W^E_^,4?\.W_V@/\
MH4YO^_TO_P 8K^LBBC_B"G"W_03FO_A1#_Y4'_$JGAS_ -!?$7_AQ7_RD_DW
M_P"';_[0'_0IS?\ ?Z7_ .,4?\.W_P!H#_H4YO\ O]+_ /&*_K(HH_X@IPM_
MT$YK_P"%$/\ Y4'_ !*IX<_]!?$7_AQ7_P I/Y-_^';_ .T!_P!"G-_W^E_^
M,4?\.W_C_P!_"<V._P"^EZ8)/_+#\*_K(HH_X@KPM_T$YK_X40_^5!_Q*IX<
M_P#09Q%_X<8__*3\=/\ @G]^PWXL^#GB:7XB>/4CL;RWM_LFDZ<CNT@1LM(]
MP6"[G9\'A0%54&2<D_L7117Z-P]P_E_#.64LJRV$XX>G*=1RJS=2K5JU'S5*
ME26EY2?9))625D?N'!G!V2\"9#AN'LAI5*>!P\ZM5RKU)5J]>O7ESUJ]:K+6
M52I+5[))*,4DD@HHHKVSZH**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH BDBCF26*5$EBE1DECD ='1PRNCJ005920RD$$'
M!K\(OV\O^"2]E\3M6U+XM?L_-;>'_%\WG7FL>&QB'3]5E^_(\,:[099"/N@;
MNOID_N_T)X)!]!GUSG\Z7..BM^5?3\)\89_P5FM/-^'\;/"8F*Y*U/X\/BJ+
M=Y4,51?N5:<O-<T7[T'%ZG@<1\,Y1Q5E\\MSC#*O1;YZ52+Y*^'J_9JT*JUA
M-==XR6DDT?P,^./@%\?/ACJ=SI/C/X8>)(IK21HWN;33I7MGPS+O1L$%3C(/
M.<C'%<18^#?B3JUPMIIGPY\5W=R[!5C339CEB< <(._!]*_T -7\,^'-?&-;
MT'3=5XQF^L8+@XQ@#,B,3@<#GBL6R^&WP^TZ87%CX+\.VLP.X2PZ19HX/J"(
M\BOZ0P_TJL?'#)8GA+ U,:J=G4I8VM3PTZG\[HN$I15_LQF]['XA6^CWA'B)
M2P_$F+AAF_=A5PE*I6C%M/\ B*48R:6EW%7W>I_(=\ ?^"9WQQ^*41\:?%/1
MM0\%_#;2%&H:C8K"\6N:K!#B7[-;PDY<S;?+(P>&YQ71_M)Z1^TE\2=(TOX*
M_!GX(^(_!?P$\',(+>RM],EM;GQ1/ =AOM2V"-I/-^^"^X$\^]?U_M!;O#]G
M:W1K?:%\@Q+Y6T=%\O&P*.PQBF+:6:*$6S@51P%%O$%'T 7 KXF?T@\_Q>>T
M<]S7),JS)Y>W+)<LJSQ%/+,JK2CRSQL,/"7^U8]Q;C#$XAMTD_W<8MW7T\/!
MC*<-E57*L!FV.P:QB4<TQL*=&6-Q].+36&=5K]Q@[J\Z%*WM=%4E)*Q_'#^Q
MU\'_ -JKX%_'70/B):_"36Q:VQT_3=0$NGRF&&PDU" 2S''7:K$MC. #GO7]
MB6@7]QJFBZ7J-W!]FN;VQM[B>WPP\F66,,\>&^8;&)'//%7Q#"H(C@C3< #M
MB1 0#G!P!D9YP>]6 ,# & .@ P*^(\2/$C%>)&,R_,,?E& RW&8'#SPDJV"G
M6D\30<^>E&K&JVDZ+<E%QW4M=3ZW@;@BCP/A,9@L+F6)QV'Q5>.(C#$PA#V%
M104)\C@]5.T6[JZM:]@HHHK\U/N@HHHH **** "BBB@ HHHH **** "BBB@
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M ,^'C+_PF=6_^1:^X_\ A77@3_H4M _\%MM_\11_PKKP)_T*6@?^"VV_^(H
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MO_B* /AS_AY=\"_^?#QE_P"$SJW_ ,BT?\/+O@7_ ,^'C+_PF=6_^1:^X_\
MA77@3_H4M _\%MM_\11_PKKP)_T*6@?^"VV_^(H ^'/^'EWP+_Y\/&7_ (3.
MK?\ R+1_P\N^!?\ SX>,O_"9U;_Y%K[C_P"%=>!/^A2T#_P6VW_Q%'_"NO G
M_0I:!_X+;;_XB@#X<_X>7? O_GP\9?\ A,ZM_P#(M'_#R[X%_P#/AXR_\)G5
MO_D6ON/_ (5UX$_Z%+0/_!;;?_$4?\*Z\"?]"EH'_@MMO_B* /AS_AY=\"_^
M?#QE_P"$SJW_ ,BT?\/+O@7_ ,^'C+_PF=6_^1:^X_\ A77@3_H4M _\%MM_
M\11_PKKP)_T*6@?^"VV_^(H ^'/^'EWP+_Y\/&7_ (3.K?\ R+1_P\N^!?\
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M_P"%=>!/^A2T#_P6VW_Q%'_"NO G_0I:!_X+;;_XB@#X<_X>7? O_GP\9?\
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M3_H4M _\%MM_\11_PKKP)_T*6@?^"VV_^(H ^'/^'EWP+_Y\/&7_ (3.K?\
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M ,^'C+_PF=6_^1:^X_\ A77@3_H4M _\%MM_\11_PKKP)_T*6@?^"VV_^(H
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MO_B* /AS_AY=\"_^?#QE_P"$SJW_ ,BT?\/+O@7_ ,^'C+_PF=6_^1:^X_\
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M\11_PKKP)_T*6@?^"VV_^(H ^'/^'EWP+_Y\/&7_ (3.K?\ R+1_P\N^!?\
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M_P"%=>!/^A2T#_P6VW_Q%'_"NO G_0I:!_X+;;_XB@#X<_X>7? O_GP\9?\
MA,ZM_P#(M'_#R[X%_P#/AXR_\)G5O_D6ON/_ (5UX$_Z%+0/_!;;?_$4?\*Z
M\"?]"EH'_@MMO_B* /AS_AY=\"_^?#QE_P"$SJW_ ,BT?\/+O@7_ ,^'C+_P
MF=6_^1:^X_\ A77@3_H4M _\%MM_\11_PKKP)_T*6@?^"VV_^(H ^'/^'EWP
M+_Y\/&7_ (3.K?\ R+1_P\N^!?\ SX>,O_"9U;_Y%K[C_P"%=>!/^A2T#_P6
MVW_Q%'_"NO G_0I:!_X+;;_XB@#X<_X>7? O_GP\9?\ A,ZM_P#(M'_#R[X%
M_P#/AXR_\)G5O_D6ON/_ (5UX$_Z%+0/_!;;?_$4?\*Z\"?]"EH'_@MMO_B*
M /AS_AY=\"_^?#QE_P"$SJW_ ,BT?\/+O@7_ ,^'C+_PF=6_^1:^X_\ A77@
M3_H4M _\%MM_\11_PKKP)_T*6@?^"VV_^(H ^'/^'EWP+_Y\/&7_ (3.K?\
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M ,^'C+_PF=6_^1:^X_\ A77@3_H4M _\%MM_\11_PKKP)_T*6@?^"VV_^(H
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MP\9?^$SJW_R+7W(?A[X&D.]O"7A_)]-+M%''H%B4#/7H*3_A77@3_H4M _\
M!;;?_$4 ?#G_  \N^!?_ #X>,O\ PF=6_P#D6C_AY=\"_P#GP\9?^$SJW_R+
M7W'_ ,*Z\"?]"EH'_@MMO_B*/^%=>!/^A2T#_P %MM_\10!\.?\ #R[X%_\
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MX5UX$_Z%+0/_  6VW_Q% 'PY_P /+O@7_P ^'C+_ ,)G5O\ Y%H_X>7? O\
MY\/&7_A,ZM_\BU]Q_P#"NO G_0I:!_X+;;_XBC_A77@3_H4M _\ !;;?_$4
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M+0/_  6VW_Q% 'PY_P /+O@7_P ^'C+_ ,)G5O\ Y%I#_P %+_@4.MAXR_\
M"8U?_P"1:^Y/^%=>!/\ H4M _P#!;;?_ !%!^'7@0\'PCH'_ (+;;_XB@#G/
MA!\7?#GQG\*P^+?#$.H0Z;.Q5$U&TFL[C(Z[H9D1U_$45Z-INE:;H]N+72[&
MUT^V!R(+2%(8@?9$ 'Z44 :%%%% !1110 4444 %%%% !1110 4444 %%%%
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MX]\8?$WP5X,TS1/&OCR19?%.MVT,276J.@(0SNL:NVT$A=SM@$XZT ?S"_\
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MI^"'P-T2Q^$7B/XO^)KGPYHEAXC.E3I'-ILABA$MQ=-.\61$)&+\[L)A5)H
M^^/%?B33O!_AO6_$^KS)!INAZ==:E=RNP55BMHFD(R2!\Q 4?6ORG_X)S?\
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M;-$_\#8Z/^%D^ O^ALT3_P #8Z_BC_X6GXV_Z&37_P#P>ZQ_\GT?\+3\;?\
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M/^%D^ O^ALT3_P #8Z/^%D^ O^ALT3_P-CK^*/\ X6GXV_Z&37__  >ZQ_\
M)]'_  M/QM_T,FO_ /@]UC_Y/H_XCM_U3DO_  OCY?\ 3GU_K<_XF\A_T1%;
M_P .U+R_Z<>O];_VN?\ "R? 7_0V:)_X&QT?\+)\!?\ 0V:)_P"!L=?Q1_\
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MC_A9/@+_ *&S1/\ P-CK^*/_ (6GXV_Z&37_ /P>ZQ_\GT?\+3\;?]#)K_\
MX/=8_P#D^C_B.W_5.2_\+X^7_3GU_K<_XF\A_P!$16_\.U+R_P"G'K_6_P#:
MY_PLGP%_T-FB?^!L='_"R? 7_0V:)_X&QU_%'_PM/QM_T,FO_P#@]UC_ .3Z
M/^%I^-O^ADU__P 'NL?_ "?1_P 1V_ZIR7_A?'R_Z<^O];G_ !-Y#_HB*W_A
MVI>7_3CU_K?^US_A9/@+_H;-$_\  V.C_A9/@+_H;-$_\#8Z_BC_ .%I^-O^
MADU__P 'NL?_ "?1_P +3\;?]#)K_P#X/=8_^3Z/^([?]4Y+_P +X^7_ $Y]
M?ZW/^)O(?]$16_\ #M2\O^G'K_6_]KG_  LGP%_T-FB?^!L='_"R? 7_ $-F
MB?\ @;'7\4?_  M/QM_T,FO_ /@]UC_Y/H_X6GXV_P"ADU__ ,'NL?\ R?1_
MQ';_ *IR7_A?'R_Z<^O];G_$WD/^B(K?^':EY?\ 3CU_K?\ M<_X63X"_P"A
MLT3_ ,#8Z/\ A9/@+_H;-$_\#8Z_BC_X6GXV_P"ADU__ ,'NL?\ R?1_PM/Q
MM_T,FO\ _@]UC_Y/H_XCM_U3DO\ POCY?].?7^MS_B;R'_1$5O\ P[4O+_IQ
MZ_UO_:Y_PLGP%_T-FB?^!L='_"R? 7_0V:)_X&QU_%'_ ,+3\;?]#)K_ /X/
M=8_^3Z/^%I^-O^ADU_\ \'NL?_)]'_$=O^J<E_X7Q\O^G/K_ %N?\3>0_P"B
M(K?^':EY?]./7^M_[7/^%D^ O^ALT3_P-CH_X63X"_Z&S1/_  -CK^*/_A:?
MC;_H9-?_ /![K'_R?1_PM/QM_P!#)K__ (/=8_\ D^C_ (CM_P!4Y+_POCY?
M].?7^MS_ (F\A_T1%;_P[4O+_IQZ_P!;_P!KG_"R? 7_ $-FB?\ @;'1_P +
M)\!?]#9HG_@;'7\4?_"T_&W_ $,FO_\ @]UC_P"3Z/\ A:?C;_H9-?\ _![K
M'_R?1_Q';_JG)?\ A?'R_P"G/K_6Y_Q-Y#_HB*W_ (=J7E_TX]?ZW_M<_P"%
MD^ O^ALT3_P-CH_X63X"_P"ALT3_ ,#8Z_BC_P"%I^-O^ADU_P#\'NL?_)]'
M_"T_&W_0R:__ .#W6/\ Y/H_XCM_U3DO_"^/E_TY]?ZW/^)O(?\ 1$5O_#M2
M\O\ IQZ_UO\ VN?\+)\!?]#9HG_@;'1_PLGP%_T-FB?^!L=?Q1_\+3\;?]#)
MK_\ X/=8_P#D^C_A:?C;_H9-?_\ ![K'_P GT?\ $=O^J<E_X7Q\O^G/K_6Y
M_P 3>0_Z(BM_X=J7E_TX]?ZW_M<_X63X"_Z&S1/_  -CH_X63X"_Z&S1/_ V
M.OXH_P#A:?C;_H9-?_\ ![K'_P GT?\ "T_&W_0R:_\ ^#W6/_D^C_B.W_5.
M2_\ "^/E_P!.?7^MS_B;R'_1$5O_  [4O+_IQZ_UO_:Y_P +)\!?]#9HG_@;
M'1_PLGP%_P!#9HG_ (&QU_%'_P +3\;?]#)K_P#X/=8_^3Z/^%I^-O\ H9-?
M_P#![K'_ ,GT?\1V_P"J<E_X7Q\O^G/K_6Y_Q-Y#_HB*W_AVI>7_ $X]?ZW_
M +7/^%D^ O\ H;-$_P# V.C_ (63X"_Z&S1/_ V.OXH_^%I^-O\ H9-?_P#!
M[K'_ ,GT?\+3\;?]#)K_ /X/=8_^3Z/^([?]4Y+_ ,+X^7_3GU_K<_XF\A_T
M1%;_ ,.U+R_Z<>O];_VN?\+)\!?]#9HG_@;'1_PLGP%_T-FB?^!L=?Q1_P#"
MT_&W_0R:_P#^#W6/_D^C_A:?C;_H9-?_ /![K'_R?1_Q';_JG)?^%\?+_ISZ
M_P!;G_$WD/\ HB*W_AVI>7_3CU_K?^US_A9/@+_H;-$_\#8Z/^%D^ O^ALT3
M_P #8Z_BC_X6GXV_Z&37_P#P>ZQ_\GT?\+3\;?\ 0R:__P"#W6/_ )/H_P"(
M[?\ 5.2_\+X^7_3GU_K<_P")O(?]$16_\.U+R_Z<>O\ 6_\ :Y_PLGP%_P!#
M9HG_ (&QT?\ "R? 7_0V:)_X&QU_%'_PM/QM_P!#)K__ (/=8_\ D^C_ (6G
MXV_Z&37_ /P>ZQ_\GT?\1V_ZIR7_ (7Q\O\ ISZ_UN?\3>0_Z(BM_P"':EY?
M]./7^M_[7/\ A9/@+_H;-$_\#8Z/^%D^ O\ H;-$_P# V.OXH_\ A:?C;_H9
M-?\ _![K'_R?1_PM/QM_T,FO_P#@]UC_ .3Z/^([?]4Y+_POCY?].?7^MS_B
M;R'_ $1%;_P[4O+_ *<>O];_ -KG_"R? 7_0V:)_X&QT?\+)\!?]#9HG_@;'
M7\4?_"T_&W_0R:__ .#W6/\ Y/H_X6GXV_Z&37__  >ZQ_\ )]'_ !';_JG)
M?^%\?+_ISZ_UN?\ $WD/^B(K?^':EY?]./7^M_[7/^%D^ O^ALT3_P #8Z/^
M%D^ O^ALT3_P-CK^*/\ X6GXV_Z&37__  >ZQ_\ )]'_  M/QM_T,FO_ /@]
MUC_Y/H_XCM_U3DO_  OCY?\ 3GU_K<_XF\A_T1%;_P .U+R_Z<>O];_VN?\
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M.C_A9/@+_H;-$_\  V.OXH_^%I^-O^ADU_\ \'NL?_)]'_"T_&W_ $,FO_\
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M!L='_"R? 7_0V:)_X&QU_%'_ ,+3\;?]#)K_ /X/=8_^3Z/^%I^-O^ADU_\
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M_P"ALT3_ ,#8Z_BC_P"%I^-O^ADU_P#\'NL?_)]'_"T_&W_0R:__ .#W6/\
MY/H_XCM_U3DO_"^/E_TY]?ZW/^)O(?\ 1$5O_#M2\O\ IQZ_UO\ VN?\+)\!
M?]#9HG_@;'1_PLGP%_T-FB?^!L=?Q1_\+3\;?]#)K_\ X/=8_P#D^C_A:?C;
M_H9-?_\ ![K'_P GT?\ $=O^J<E_X7Q\O^G/K_6Y_P 3>0_Z(BM_X=J7E_TX
M]?ZW_M<_X63X"_Z&S1/_  -CH_X63X"_Z&S1/_ V.OXH_P#A:?C;_H9-?_\
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M"]G-57.FW)-KE;4F]ES:'[X?MZ?\%)OC3\*O%7PXNO@^+.'PQXU\-6VM&WU
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OM
M?]@__DOG@7_L*O\ ^C(*^**^U_V#_P#DOG@7_L*O_P"C(*]GAS_DH<B_[&^7
M_P#J33/K. O^2XX0_P"RDR?_ -3J)_7]'_JX_P#<7_T$4^F1_P"KC_W%_P#0
M13Z_N\_U\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_)G_@KEXJU#1O@-!HMK,\5OKMVL5T$8C>H<C!P1D8!R.ASCUK]9J_)/_@KM
MX9U#5O@3:ZS:P/+;:)>"6Z9%)"*7SEL XX/7@>M?HGA*J+\2.#EB.7V?]MX3
MX_AYU)^S6O7GY;>=CX[Q!]I_J5Q+[._/_96*M;>W)K\K7OY'\D]VKP0+:VXV
MRW5TUI!VQ)--@-R1ZY K^I+X!Z/\//\ @GO^PY9?&270;/4O'GBS24U7[7-
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M,?M5?!;]H"\U"R^%7BA/$\FEKNO9+:-?)@XZ-(LCC)["OHROYQ?@O\2_V@?
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M!O#_ (U^,WA+P3?ZGX\\J+P_X1TIDEU.UO;LA8(9;=&9U:-SMD4ICC!K[O\
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MV_Z-><>W^>];W[(&J6"?"M_-U2RQ'JU]N$EU"IA GFR'#."F.F#TQ7T#X?\
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M_7R9^#-%?O-_PYYOO^ATA_\  *R_^-4?\.>;[_H=(?\ P"LO_C5'_$+N./\
MH2O_ ,*\)Y?]/O7[O,/^)>_%K_HF5_X<\N_^:/Z^3/P9HK]YO^'/-]_T.D/_
M (!67_QJC_ASS??]#I#_ . 5E_\ &J/^(7<<?]"5_P#A7A/+_I]Z_=YA_P 2
M]^+7_1,K_P .>7?_ #1_7R9^#-%?O-_PYYOO^ATA_P# *R_^-4?\.>;[_H=(
M?_ *R_\ C5'_ !"[CC_H2O\ \*\)Y?\ 3[U^[S#_ (E[\6O^B97_ (<\N_\
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M , K+_XU1_PYYOO^ATA_\ K+_P"-4?\ $+N./^A*_P#PKPGE_P!/O7[O,/\
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M^ODS\&:*_>;_ (<\WW_0Z0_^ 5E_\:H_X<\WW_0Z0_\ @%9?_&J/^(7<<?\
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M<<?]"5_^%>$\O^GWK]WF'_$O?BU_T3*_\.>7?_-']?)GX,T5^\W_  YYOO\
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MBU_T3*_\.>7?_-']?)GX,T5^\W_#GF^_Z'2'_P  K+_XU1_PYYOO^ATA_P#
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MC_H2O_PKPGE_T^]?N\P_XE[\6O\ HF5_X<\N_P#FC^ODS\&:*_>;_ASS??\
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M%0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)OC?\
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MCXVU_P""MU=3-=3:/I%Q)-I!N&8NWD6LN^"%"V-J"-57I_M5TFG?LQ?MLZ5
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M;3P5IYRMQ=:+%-:75Z'&V22XG@C(>1U9PS,<G<V<9-?:?_#.G[<'_1TFH_\
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M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>?>.?BK\/OALMJ_CGQ3I7A
MM+YBMJVIW*6ZS,,DA"Y ) !/TKT&O'_BI\"OAK\9X["'X@^'[?78]-8O9I<
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M^SW_ -%5\)?^#2#_ .*KSW_A@_\ 9G_Z)YIG_?I/_B:/^&#_ -F?_HGFF?\
M?I/_ (F@#T+_ (:J_9[_ .BJ^$O_  :0?_%4?\-5?L]_]%5\)?\ @T@_^*KS
MW_A@_P#9G_Z)YIG_ 'Z3_P")H_X8/_9G_P"B>:9_WZ3_ .)H ]"_X:J_9[_Z
M*KX2_P#!I!_\51_PU5^SW_T57PE_X-(/_BJ\]_X8/_9G_P"B>:9_WZ3_ .)H
M_P"&#_V9_P#HGFF?]^D_^)H ]"_X:J_9[_Z*KX2_\&D'_P 51_PU5^SW_P!%
M5\)?^#2#_P"*KSW_ (8/_9G_ .B>:9_WZ3_XFC_A@_\ 9G_Z)YIG_?I/_B:
M/0O^&JOV>_\ HJOA+_P:0?\ Q5'_  U5^SW_ -%5\)?^#2#_ .*KSW_A@_\
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M7PE_X-(/_BJ\]_X8/_9G_P"B>:9_WZ3_ .)H_P"&#_V9_P#HGFF?]^D_^)H
M]"_X:J_9[_Z*KX2_\&D'_P 51_PU5^SW_P!%5\)?^#2#_P"*KSW_ (8/_9G_
M .B>:9_WZ3_XFC_A@_\ 9G_Z)YIG_?I/_B: /0O^&JOV>_\ HJOA+_P:0?\
MQ5'_  U5^SW_ -%5\)?^#2#_ .*KSW_A@_\ 9G_Z)YIG_?I/_B:/^&#_ -F?
M_HGFF?\ ?I/_ (F@#T+_ (:J_9[_ .BJ^$O_  :0?_%4?\-5?L]_]%5\)?\
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M_P 51_PU5^SW_P!%5\)?^#2#_P"*KSW_ (8/_9G_ .B>:9_WZ3_XFC_A@_\
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MKSW_ (8/_9G_ .B>:9_WZ3_XFC_A@_\ 9G_Z)YIG_?I/_B: /0O^&JOV>_\
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M^SW_ -%5\)?^#2#_ .*KSW_A@_\ 9G_Z)YIG_?I/_B:/^&#_ -F?_HGFF?\
M?I/_ (F@#T+_ (:J_9[_ .BJ^$O_  :0?_%4?\-5?L]_]%5\)?\ @T@_^*KS
MW_A@_P#9G_Z)YIG_ 'Z3_P")H_X8/_9G_P"B>:9_WZ3_ .)H ]"_X:J_9[_Z
M*KX2_P#!I!_\51_PU5^SW_T57PE_X-(/_BJ\]_X8/_9G_P"B>:9_WZ3_ .)H
M_P"&#_V9_P#HGFF?]^D_^)H ]"_X:J_9[_Z*KX2_\&D'_P 51_PU5^SW_P!%
M5\)?^#2#_P"*KSW_ (8/_9G_ .B>:9_WZ3_XFC_A@_\ 9G_Z)YIG_?I/_B:
M/0O^&JOV>_\ HJOA+_P:0?\ Q5'_  U5^SW_ -%5\)?^#2#_ .*KSW_A@_\
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M7PE_X-(/_BJ\]_X8/_9G_P"B>:9_WZ3_ .)H_P"&#_V9_P#HGFF?]^D_^)H
M]"_X:J_9[_Z*KX2_\&D'_P 51_PU5^SW_P!%5\)?^#2#_P"*KSW_ (8/_9G_
M .B>:9_WZ3_XFC_A@_\ 9G_Z)YIG_?I/_B: /0O^&JOV>_\ HJOA+_P:0?\
MQ5'_  U5^SW_ -%5\)?^#2#_ .*KSW_A@_\ 9G_Z)YIG_?I/_B:/^&#_ -F?
M_HGFF?\ ?I/_ (F@#T+_ (:J_9[_ .BJ^$O_  :0?_%4?\-5?L]_]%5\)?\
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MXI^%VQR#'?)(..WR;CGGN,<UPW_#!_[,_P#T3S3/^_2?_$U+'^PM^S;"28O
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MJOA+_P &D'_Q5'_#57[/?_15?"7_ (-(/_BJ\]_X8/\ V9_^B>:9_P!^D_\
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MA'6K+7=+D.$O;&42P.?]EUX-%9?P[^&GA#X6:#'X:\%Z9'I.D0G,=I%]Q/\
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M9>,O^$ST2QO[A(/"/B+5K^6]?3=.G5T>*PB:Z @,1C3RF1D5,A0 ?II\&?\
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MJC[7<_\ />3_ +ZH_P"(U\4_] >4?^"<1Y?]1/K]_P!Q_P 37>('_0HX9_\
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MB!_T*.&?_"?'^5_^8WU^_P"[^LW_ (>7_LN?]#7/_P" EQ_\9H_X>7_LN?\
M0US_ /@)<?\ QFOY,OM=S_SWD_[ZH^UW/_/>3_OJC_B-?%/_ $!Y1_X)Q'E_
MU$^OW_<?\37>('_0HX9_\)\?Y7_YC?7[_N_K-_X>7_LN?]#7/_X"7'_QFC_A
MY?\ LN?]#7/_ . EQ_\ &:_DR^UW/_/>3_OJC[7<_P#/>3_OJC_B-?%/_0'E
M'_@G$>7_ %$^OW_<?\37>('_ $*.&?\ PGQ_E?\ YC?7[_N_K-_X>7_LN?\
M0US_ /@)<?\ QFC_ (>7_LN?]#7/_P" EQ_\9K^3+[7<_P#/>3_OJC[7<_\
M/>3_ +ZH_P"(U\4_] >4?^"<1Y?]1/K]_P!Q_P 37>('_0HX9_\ "?'^5_\
MF-]?O^[^LW_AY?\ LN?]#7/_ . EQ_\ &:/^'E_[+G_0US_^ EQ_\9K^3+[7
M<_\ />3_ +ZH^UW/_/>3_OJC_B-?%/\ T!Y1_P""<1Y?]1/K]_W'_$UWB!_T
M*.&?_"?'^5_^8WU^_P"[^LW_ (>7_LN?]#7/_P" EQ_\9H_X>7_LN?\ 0US_
M /@)<?\ QFOY,OM=S_SWD_[ZH^UW/_/>3_OJC_B-?%/_ $!Y1_X)Q'E_U$^O
MW_<?\37>('_0HX9_\)\?Y7_YC?7[_N_K-_X>7_LN?]#7/_X"7'_QFC_AY?\
MLN?]#7/_ . EQ_\ &:_DR^UW/_/>3_OJC[7<_P#/>3_OJC_B-?%/_0'E'_@G
M$>7_ %$^OW_<?\37>('_ $*.&?\ PGQ_E?\ YC?7[_N_K-_X>7_LN?\ 0US_
M /@)<?\ QFC_ (>7_LN?]#7/_P" EQ_\9K^3+[7<_P#/>3_OJC[7<_\ />3_
M +ZH_P"(U\4_] >4?^"<1Y?]1/K]_P!Q_P 37>('_0HX9_\ "?'^5_\ F-]?
MO^[^LW_AY?\ LN?]#7/_ . EQ_\ &:/^'E_[+G_0US_^ EQ_\9K^3+[7<_\
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M^5_^8WU^_P"[^LW_ (>7_LN?]#7/_P" EQ_\9H_X>7_LN?\ 0US_ /@)<?\
MQFOY,OM=S_SWD_[ZH^UW/_/>3_OJC_B-?%/_ $!Y1_X)Q'E_U$^OW_<?\37>
M('_0HX9_\)\?Y7_YC?7[_N_K-_X>7_LN?]#7/_X"7'_QFC_AY?\ LN?]#7/_
M . EQ_\ &:_DR^UW/_/>3_OJC[7<_P#/>3_OJC_B-?%/_0'E'_@G$>7_ %$^
MOW_<?\37>('_ $*.&?\ PGQ_E?\ YC?7[_N_K-_X>7_LN?\ 0US_ /@)<?\
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M] >4?^"<1Y?]1/K]_P!Q_P 37>('_0HX9_\ "?'^5_\ F-]?O^[^LW_AY?\
MLN?]#7/_ . EQ_\ &:/^'E_[+G_0US_^ EQ_\9K^3+[7<_\ />3_ +ZH^UW/
M_/>3_OJC_B-?%/\ T!Y1_P""<1Y?]1/K]_W'_$UWB!_T*.&?_"?'^5_^8WU^
M_P"[^LW_ (>7_LN?]#7/_P" EQ_\9H_X>7_LN?\ 0US_ /@)<?\ QFOY,OM=
MS_SWD_[ZH^UW/_/>3_OJC_B-?%/_ $!Y1_X)Q'E_U$^OW_<?\37>('_0HX9_
M\)\?Y7_YC?7[_N_K-_X>7_LN?]#7/_X"7'_QFC_AY?\ LN?]#7/_ . EQ_\
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M3_OJC[7<_P#/>3_OJC_B-?%/_0'E'_@G$>7_ %$^OW_<?\37>('_ $*.&?\
MPGQ_E?\ YC?7[_N_K-_X>7_LN?\ 0US_ /@)<?\ QFC_ (>7_LN?]#7/_P"
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M:W\/^\*=7E'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"2KXC_ .QOB_\ TM'^27BA_P G&XV_[*'&_P#M@4445\X?"!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7VO^P?_P E\\"_]A5__1D%?%%?:_[!_P#R7SP+_P!A5_\ T9!7L\.?
M\E#D7_8WR_\ ]2:9]9P%_P EQPA_V4F3_P#J=1/Z_H_]7'_N+_Z"*?3(_P#5
MQ_[B_P#H(I]?W>?Z^!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,9_&OUV_:H_;<UC]@3_@EI\,_C9X:^%]Y\5]1@^'?A;2[3PY96<M]%$UQIL
M6\NK>)7#VT#.&<,-N%8XXX_6*O .'K\+^'F8Y5#$8K.>+LTS' UL-4Q%*CAY
MO"UXTZ4*-2?+&BY1;YISDTG?39'R5+/,0\?GM"O.%/#Y=>-&4:3G*,G]75-R
M2?-4<I5GS+1+W=4KL]EN?^"I/A9_MMSH_P $OB9JFEV,DB27ZVWDK*L1^=XE
MDM!E< E?O9KU_P#9?_X*/?LS?M4^)-4\ >"/%UOI7Q0T0M_:WPZUJ:.+Q'9[
M.&/D!4,FTA@V$7&.I)Q7Y7_L+^/_ (I?MP_!SPU\>OB-\?\ X6?#>#Q1"EU'
M\,(='TO2+W0X)D#_ &._B=XY/-C4^6Y<9)'S8-?B7\%?"NC_  W_ .#D_3-%
M\!>)IO$NG7VEW3ZUKGAJW:+P_>SL'+B=K7-L^&'.\GJ>M?0X;P\X>S"EQC@)
MJMEN<<,9)C<UB\-B,7BZ$L1@)0A6P5>IB\-0HU%-R=JF':]Y?N^:*;?C0XCS
M:C6R^<G];PN/K.G%U*&&H2Y='SJ%"O4JTHJ',[U5NE=7>O\ 85^V+_P48_9H
M_8?D\-V'QN\6)I6N^+Y$A\,Z#"5-_J\\C^7'%;*0Q9G<A1A6Y/3O7SU=?\%;
MO MAH:^++WX*?$Z'PH81>'5Q9LR+IY&\7I LSF+RP9.!]T=:_GY_X.<K;3;C
M]MC]@07NG2Z@1XRT+,7V0W5LR?VI%Q,N"NWID'ZU_7QX?\(^#+WX":2EUX0\
M-SV;_#"!Y+*71;)X'4>&]SHT;PLWSG.1G().TCC'@YCPYPQP_P )<#YYB\%C
MLTQ?%%+&UL9#Z_\ 5*>&CA<4J,88>-.$FW.-Y<U1O6VEKH]2EF&;YCF6;87#
M8RC@Z67SJ0@GA%6]IR3Y8N4Y23T2]])+5V7<X;]E+]N7]G']LO0K[5_@;X^T
MSQ+=Z._DZ_H22@:OHERO$D%[;\,C1M\K$A<-D%17B/[0_P#P51_9=^ 'Q'3X
M+R>('\>_&1LF3X=>%)8Y]=M@.,W$921EP<[E\OMPWI_,C_P;C0PZ7_P4T_X*
M Z7I$%]I.AQ^+]:^RZ.D,EKI,(^VW.?L]O@0KMR-NW_9]*_2W]I;_@F-^S!X
MN_;3U[]L'X%_M+>&OA1^TW8S3MK]CXQNK34],:X7<TD<5A=N!$6(*_=&!A>0
M :]/,.!N#LCXVS#)LSQN;SRB&28/,\ME2HRK/Z[C\+1Q%#"9GB,'2J5*.%IN
MI*G4Q-"C*;<4K197]K9M6RNG6H?55B_:SIU)/D@YJ-.G-.C1KU80<WSZIS:2
M2:C9Z?K;^S_^WUX8^.GCJ/X>-\,_'7@C7I8EFC;Q%:/%:.C<J!(;6)<XQ_'S
MVJO^U#_P4P_9?_96\7:;\,_&?B^#6/BQK)4:5\-M%F1_$=YN^Z5@97*Y. ,(
MW7-?AC^SC_P6(^.OA;_@H;H?[#WQ2^&OAWXW-K$MM96WQM\ ^'8K6RTI&&T3
M3WME&T0C14_>%F 7*YQN!KZ;_;[_ ."8O[*/[0W[7>C?M+:%^T!HWPB_:I\&
MBVN+<>)KVWNM&/V<-Y!?3+EU4,"Q'W3M!(#?,0>2KP3DV5<2X3#<4X7&95D^
M/R1YGE\LJQ-3-Z>*G.RPU6O5C1^NX/!59/EK.>%5>DTDH>\FLZ><8^KELYX3
M%4L3BXU^64J]"EA9P@X2Y81IRK*A5J.<'&ZJ?#>7*[*_Z*_!_P#X*/\ A+XI
M^.](\ WGPH^(?@W4==,9T^\UNS=;)XY3\C/)]D11N!!_U@&*^M/CW^T;\'/V
M9_!-UX^^,WC?1_!GA^W#+!)J5RL=QJ%P,;+2QM\F2XGD8JJJJXR>I/!_EO7_
M (*[_M!?LK_MN_"G]DWXD^#_  ?^U+I?C.XT_1K3XA_#WPS;H_AJ%Y?LB74U
MW81R>685"N_F$ =3QQ7FG_!S!X3^/!^.7['_ ,98]'\2>(/V9_#^M:#>^,](
MTR"[O],L;XSVDDMQK6FP(\<\$:G>XG7&T'-=E#PPHXSB[AO*,8J6195G^78G
M,<'B*.8_7GF-/"TY5(T<,\52H5L-B<5**H4Z>)HI\[<E&5B(<0XFGE6.Q,:C
MQ^+P\XQ5.IAHX9TE)3C:7LYSIU?WM*<%)3C=M7LK-_NW!_P5N^'6JZ5)XI\-
M?!_XF:_X+1#<1^)+6QD6UN;)5WM>PJUEDP^7\XX.5[]!7UM^R[^W!^SQ^UUI
MM]-\(/'6EZKKNC,8O$/A*6YC3Q!H<Z$B2*\LCME_=D89@@P<\8&:_-CX1_$6
M[^*'PH\'W?PW_:-^!OA[P)>^%["#_A';KPUHUC/86TMDL4ME<VLFUEFBA 1P
MZ@[@2<G-<'_P3[_X)?\ P$^"7[97CS]JSX7?M%6WC7QGXH2[/C/P/X8N8X/#
M7VF[#^;,NG6CFW4@NS XXZ]Z\;,>'^$J679VZ\,PR;,\!!RRR%-8_,*>)JPJ
M*$L+F7M\%AZ6$E):JM3J<JJ:.+CJ/+LVSBMB<)SNGB</B80=15(83#2A*3IW
M5!4\54J3Y(2FVIQO>"TO+3[F_:9_X*Q_LG?LO_%2Q^!WB_Q--J_Q<U-5_L_P
M-HX#ZK<LYVHJ1[)&)+<<(:\Z\2_\%??A=X T^/Q!\1OA1\1O"'A3*->>(KZT
M;[%IT#G_ (^+L_9!MC4?,QW+@ \BOYB?VU[?1Y_^#EKX)/?:.=25K[3%=+O3
MS=6)D#D ON0H0H9OF/W2V.YS_8?^WWX*\"W?['?Q\74_!GAW4+=/AQX@9(7T
M2QD,;BQD,<D"K &62,\IMZ>E>MG'"?"?#J\/\/B,#F.95>+<IR_,,=B/[16&
M>&J8W$JA.GAJ4*3@E234U[7F;>DM&<U'-\ZQBSO$4\50P]/*HRJ4Z#P:J>VC
M!UY-<[GS6E&@H*25U*3MHK'MG[/?[2OP7_:D\!V7Q(^"/C?2?&_A>\50UWID
MZRM:3$9:WND!)BE4Y!4^G;I7N]?Q_?\ !I!,Z_ ;]HNPCFU,6-G\3-12TL+X
M3)!9QC49PD=I%)A4C"_+A  ,8]J_L!KX3C_AO#\(\79UP]A,14Q6&R[$QIT*
M]9156=.I1IUH^TY/<<HJIRN4=)6YDE>Q]5DN/JYEE]+%5H*G4E.K"44FE^ZJ
MRIWY7K%RY;N-WRMVNPKY-_;._9C\"?M3_ SQI\/O&=BLDKZ)J-UHFI1Y6[TW
M4;:UFF@D@D#*5#2* PR.Q]C]95Y=\:O'FB?#/X5>//&WB&\@L=,T+PSJ]U+/
M<2+'&9/L,ZPQ[F(&Z20JJC.37AY'B\QP.<Y9BLHJUJ.9T<=AIX&IAW)5EB56
MA[)0Y=6Y2M%Q^TFTTTS'B7"97CL@SC"YU2H5<JJY=BOKT,0HNDJ$:,YSG)RT
MBZ?+SPG=.,XQDFFD?Y8GQL\(:]\,OB#XX^'5YX@UG[3X0US4-,\Q+ZY42Q17
M$@BZ2=?+"Y!_E47[%_[(_B#]O']I70/V=XOB+K?A9=>P9=5?4+K$<;]<8EX(
M ./4XXS6Q^TCXWA^(7Q?^*'Q"R$L=?\ $NJ7L#DX7R1=3*C G@[E"D<]_;G]
MT/\ @V?_ &-/%/C'XV>+/VL_$NE75CX-\.6_]E^%;FYMWB34-220@RVYD11)
M&1DAT+# ST-?ZS>)/%5;A#PRQ_$.*K4<#G4,GH1PTW2HN7]M8FC3C&-*G*+C
M4FJ[E/DL[13;V/\ /GP@P.)SGB?#X+"RKUL']=HW;>D:,:U.I5;E;3_9X3YV
M](.2VNCZI^%__!HU^S=I-W%>_$[XZ?%#Q*R%6>WT[6+R*)F!R1B2>,8)]>WZ
M_L!^R'_P1)_8L_8T\:Z?\1/AOH6O:IXPTM EGK/B+49+V:+!SN4,[@'=SU_K
MG]@**_S#SSQ1X_XCA6I9OQ/F.(H5X.G5P\9PH4)TY:2@Z="%-.+6C3NC_0_#
MY1E^&C&-/#Q]UIQ<VYM-6L_>?2R:TT^X:W\/^\*=36_A_P!X4ZO@#T@HHHH
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M!,O_ /#@O+_IQZ_=YA_Q+-XK?] .2?\ AX_^\_7^GI_-;L?^ZW_?)_PHV/\
MW6_[Y/\ A7]*7_#I'X:_]!_4O_ F7_&C_ATC\-?^@_J7_@3+_C1_Q"'C?_H$
MR_\ \."\O^G'K]WF'_$LWBM_T Y)_P"'C_[S]?Z>G\UNQ_[K?]\G_"C8_P#=
M;_OD_P"%?TI?\.D?AK_T']2_\"9?\:/^'2/PU_Z#^I?^!,O^-'_$(>-_^@3+
M_P#PX+R_Z<>OW>8?\2S>*W_0#DG_ (>/_O/U_IZ?S6['_NM_WR?\*-C_ -UO
M^^3_ (5_2E_PZ1^&O_0?U+_P)E_QH_X=(_#7_H/ZE_X$R_XT?\0AXW_Z!,O_
M /#@O+_IQZ_=YA_Q+-XK?] .2?\ AX_^\_7^GI_-;L?^ZW_?)_PHV/\ W6_[
MY/\ A7]*7_#I'X:_]!_4O_ F7_&C_ATC\-?^@_J7_@3+_C1_Q"'C?_H$R_\
M\."\O^G'K]WF'_$LWBM_T Y)_P"'C_[S]?Z>G\UNQ_[K?]\G_"C8_P#=;_OD
M_P"%?TI?\.D?AK_T']2_\"9?\:/^'2/PU_Z#^I?^!,O^-'_$(>-_^@3+_P#P
MX+R_Z<>OW>8?\2S>*W_0#DG_ (>/_O/U_IZ?S6['_NM_WR?\*-C_ -UO^^3_
M (5_2E_PZ1^&O_0?U+_P)E_QH_X=(_#7_H/ZE_X$R_XT?\0AXW_Z!,O_ /#@
MO+_IQZ_=YA_Q+-XK?] .2?\ AX_^\_7^GI_-;L?^ZW_?)_PHV/\ W6_[Y/\
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MH_X=(_#7_H/ZE_X$R_XT?\0AXW_Z!,O_ /#@O+_IQZ_=YA_Q+-XK?] .2?\
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MOQ1\7N)_%+,85LVG'!Y5A9S>79+A92^J8;FT]K4;L\1B7&RE6FE9>[",5O\
MK?AMX79'X<99'#X*4L=F56G&.,S2M%1J57O*%&FFU0I.6K5Y5)NSJ3D]$444
M5^4GZ:-;^'_>%.IK?P_[PIU !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !56YO[&SV_;+RUM=_P!W[3<0P;L==OFNN?PS5JOFK]H+
M]G2U^/5OI$%SXQ\1>$_[)D:19- NI;5YRP(VRM&Z%E&> <T ?0']NZ)_T&=*
M_P#!A:?_ !ZC^W=$_P"@SI7_ (,+3_X]7YQC_@G'I8 '_"Y_B1P,?\ABZ_\
MCU+_ ,.X],_Z+/\ $C_P<77_ ,>H _1O^W=$_P"@SI7_ (,+3_X]1_;NB?\
M09TK_P &%I_\>K\Y/^'<>F?]%G^)'_@XNO\ X]1_P[CTS_HL_P 2/_!Q=?\
MQZ@#]&_[=T3_ *#.E?\ @PM/_CU']NZ)_P!!G2O_  86G_QZOSD_X=QZ9_T6
M?XD?^#BZ_P#CU'_#N/3/^BS_ !(_\'%U_P#'J /T;_MW1/\ H,Z5_P"#"T_^
M/4?V[HG_ $&=*_\ !A:?_'J_.3_AW'IG_19_B1_X.+K_ ./4?\.X],_Z+/\
M$C_P<77_ ,>H _1O^W=$_P"@SI7_ (,+3_X]1_;NB?\ 09TK_P &%I_\>K\Y
M/^'<>F?]%G^)'_@XNO\ X]1_P[CTS_HL_P 2/_!Q=?\ QZ@#]&_[=T3_ *#.
ME?\ @PM/_CU']NZ)_P!!G2O_  86G_QZOSD_X=QZ9_T6?XD?^#BZ_P#CU'_#
MN/3/^BS_ !(_\'%U_P#'J /T;_MW1/\ H,Z5_P"#"T_^/4?V[HG_ $&=*_\
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MOSD_X=QZ9_T6?XD?^#BZ_P#CU'_#N/3/^BS_ !(_\'%U_P#'J /T;_MW1/\
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M>F?]%G^)'_@XNO\ X]1_P[CTS_HL_P 2/_!Q=?\ QZ@#]&_[=T3_ *#.E?\
M@PM/_CU']NZ)_P!!G2O_  86G_QZOSD_X=QZ9_T6?XD?^#BZ_P#CU'_#N/3/
M^BS_ !(_\'%U_P#'J /T;_MW1/\ H,Z5_P"#"T_^/4?V[HG_ $&=*_\ !A:?
M_'J_.3_AW'IG_19_B1_X.+K_ ./4?\.X],_Z+/\ $C_P<77_ ,>H _1O^W=$
M_P"@SI7_ (,+3_X]1_;NB?\ 09TK_P &%I_\>K\Y/^'<>F?]%G^)'_@XNO\
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M ./4?\.X],_Z+/\ $C_P<77_ ,>H _1O^W=$_P"@SI7_ (,+3_X]1_;NB?\
M09TK_P &%I_\>K\Y/^'<>F?]%G^)'_@XNO\ X]1_P[CTS_HL_P 2/_!Q=?\
MQZ@#]&_[=T3_ *#.E?\ @PM/_CU']NZ)_P!!G2O_  86G_QZOSD_X=QZ9_T6
M?XD?^#BZ_P#CU'_#N/3/^BS_ !(_\'%U_P#'J /T;_MW1/\ H,Z5_P"#"T_^
M/4?V[HG_ $&=*_\ !A:?_'J_.3_AW'IG_19_B1_X.+K_ ./4?\.X],_Z+/\
M$C_P<77_ ,>H _1O^W=$_P"@SI7_ (,+3_X]1_;NB?\ 09TK_P &%I_\>K\Y
M/^'<>F?]%G^)'_@XNO\ X]1_P[CTS_HL_P 2/_!Q=?\ QZ@#]&_[=T3_ *#.
ME?\ @PM/_CU']NZ)_P!!G2O_  86G_QZOSD_X=QZ9_T6?XD?^#BZ_P#CU'_#
MN/3/^BS_ !(_\'%U_P#'J /T;_MW1/\ H,Z5_P"#"T_^/4?V[HG_ $&=*_\
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MOSD_X=QZ9_T6?XD?^#BZ_P#CU'_#N/3/^BS_ !(_\'%U_P#'J /T;_MW1/\
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M>F?]%G^)'_@XNO\ X]1_P[CTS_HL_P 2/_!Q=?\ QZ@#]&_[=T3_ *#.E?\
M@PM/_CU']NZ)_P!!G2O_  86G_QZOSD_X=QZ9_T6?XD?^#BZ_P#CU'_#N/3/
M^BS_ !(_\'%U_P#'J /T;_MW1/\ H,Z5_P"#"T_^/4?V[HG_ $&=*_\ !A:?
M_'J_.3_AW'IG_19_B1_X.+K_ ./4?\.X],_Z+/\ $C_P<77_ ,>H _1O^W=$
M_P"@SI7_ (,+3_X]1_;NB?\ 09TK_P &%I_\>K\Y/^'<>F?]%G^)'_@XNO\
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M ./4?\.X],_Z+/\ $C_P<77_ ,>H _1O^W=$_P"@SI7_ (,+3_X]1_;NB?\
M09TK_P &%I_\>K\Y/^'<>F?]%G^)'_@XNO\ X]1_P[CTS_HL_P 2/_!Q=?\
MQZ@#]&_[=T3_ *#.E?\ @PM/_CU']NZ)_P!!G2O_  86G_QZOSD_X=QZ9_T6
M?XD?^#BZ_P#CU'_#N/3/^BS_ !(_\'%U_P#'J /T;_MW1/\ H,Z5_P"#"T_^
M/4?V[HG_ $&=*_\ !A:?_'J_.3_AW'IG_19_B1_X.+K_ ./4?\.X],_Z+/\
M$C_P<77_ ,>H _1O^W=$_P"@SI7_ (,+3_X]1_;NB?\ 09TK_P &%I_\>K\Y
M/^'<>F?]%G^)'_@XNO\ X]1_P[CTS_HL_P 2/_!Q=?\ QZ@#]&_[=T3_ *#.
ME?\ @PM/_CU']NZ)_P!!G2O_  86G_QZOSD_X=QZ9_T6?XD?^#BZ_P#CU'_#
MN/3/^BS_ !(_\'%U_P#'J /T;_MW1/\ H,Z5_P"#"T_^/4?V[HG_ $&=*_\
M!A:?_'J_.3_AW'IG_19_B1_X.+K_ ./4?\.X],_Z+/\ $C_P<77_ ,>H _1O
M^W=$_P"@SI7_ (,+3_X]1_;NB?\ 09TK_P &%I_\>K\Y/^'<>F?]%G^)'_@X
MNO\ X]1_P[CTS_HL_P 2/_!Q=?\ QZ@#]&_[=T3_ *#.E?\ @PM/_CU)_;>A
MD_\ (8THG_L(6G])J_.7_AW'IG_19_B1_P"#BZ_^/4H_X)R:8,X^,WQ')[;M
M8N\ _A./Q_3!H _1G^V=#_Z"VE_^#"U_^/4?VSH?_06TO_P86O\ \>K\Y?\
MAWC'CY?C'XYQVS>WQ_47@S^G^!_P[Q3_ *+)XX_\#+[_ .3: /T:_MG0_P#H
M+:7_ .#"U_\ CU']LZ'_ -!;2_\ P86O_P >K\Y?^'>*?]%D\<?^!E]_\FT?
M\.\4_P"BR>./_ R^_P#DV@#]&O[9T/\ Z"VE_P#@PM?_ (]1_;.A_P#06TO_
M ,&%K_\ 'J_.7_AWBG_19/''_@9??_)M'_#O%/\ HLGCC_P,OO\ Y-H _1K^
MV=#_ .@MI?\ X,+7_P"/4?VSH?\ T%M+_P#!A:__ !ZOSE_X=XI_T63QQ_X&
M7W_R;1_P[Q3_ *+)XX_\#+[_ .3: /T:_MG0_P#H+:7_ .#"U_\ CU']LZ'_
M -!;2_\ P86O_P >K\Y?^'>*?]%D\<?^!E]_\FT?\.\4_P"BR>./_ R^_P#D
MV@#]&O[9T/\ Z"VE_P#@PM?_ (]1_;.A_P#06TO_ ,&%K_\ 'J_.7_AWBG_1
M9/''_@9??_)M'_#O%/\ HLGCC_P,OO\ Y-H _1K^V=#_ .@MI?\ X,+7_P"/
M4?VSH?\ T%M+_P#!A:__ !ZOSE_X=XI_T63QQ_X&7W_R;1_P[Q3_ *+)XX_\
M#+[_ .3: /T:_MG0_P#H+:7_ .#"U_\ CU']LZ'_ -!;2_\ P86O_P >K\Y?
M^'>*?]%D\<?^!E]_\FT?\.\4_P"BR>./_ R^_P#DV@#]&O[9T/\ Z"VE_P#@
MPM?_ (]1_;.A_P#06TO_ ,&%K_\ 'J_.7_AWBG_19/''_@9??_)M'_#O%/\
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M_$C_ ,'%U_\ 'J /T;_MW1/^@SI7_@PM/_CU']NZ)_T&=*_\&%I_\>K\Y/\
MAW'IG_19_B1_X.+K_P"/4?\ #N/3/^BS_$C_ ,'%U_\ 'J /T;_MW1/^@SI7
M_@PM/_CU']NZ)_T&=*_\&%I_\>K\Y/\ AW'IG_19_B1_X.+K_P"/4U_^"<.E
MNI7_ (71\21GN-8N^/\ R/0!^E=O=6UTGF6MQ!<Q_P!^WECF3_OJ-F7]:*\E
M^"OPE@^#GA*#PI!X@U7Q&D#%A?ZQ,\]VV>SR.SLV/4FB@#V&BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBD9@H+,0%4$L3P  ,DGV YH X;Q9\3OA]X$
MO-)T_P 8^+]"\.7VO7*VFCVFJWT5K/J-RYPL%K&YS+(QZ*O)[5UUSJ%E9V,N
MI75S%#806YNI;MV ACME3S#,S]!&$^;=TQS7\@G_  4FT[PG^W[^T[XS>#]H
M+4OA4?V%->\)_$/PU8:'K:Z=+K?BO0V_MBXT_55#%+W2+ZQB;3M0L&4B>UOI
MOFBD\J1/W=_9Z_:$TG]J+_@GO)\2?#VL0ZC/?_#+5K"YOK>429N[/3Y;?SPR
MDG]YY1=2<<<T ?6WAO\ ::^ /B_Q&_A#PU\6?!6L^)4D,3:-9:U:RWWF@E3'
MY*MG>"""O!KUO7O$6A>%]+N-:\1:M8Z-I-HAEN=0U"XCMK6&-1N+/*Y P ,\
M9XK^'']G;X@_ ?XXWOA/]E_]F;P!XX\&_MI^"OBQ9^(/''Q)NO#VM:'9SZ)%
MXAEN=5O8/$FHV4.F^);+5+:*XM6BTNYO_)>=5G^SN%K]ROV@-/\ $_[27[;/
MP;_9(\;>+M6T/X:>!_ %EXK\>Z-IU\]A+\0M4*QVL6GW$@VM<V$<@>:ZBC8&
M5FA23,996 /U^\ _'_X+_%&]N=-^'WQ*\)^+-0LY&CN+/1]6M[JXC9/O QJV
MXX/'&3GMR*]?K\'_ -O7]CSX8_LL?":']IK]G,R_";Q_\*-4T:]*:'="PT_Q
M=I@N0MWHVLVL86._-Y"K1H61YUF9)(V# @_J?X"_:!\(_P#"H/AAXY^)/B#3
M/"5_XU\-Z7?B'59A:&6[N(4W(BR $NQ*G&,DMZF@#UWQ)\1/!'@_4='TGQ1X
METK0K_7[@6NC6^I7*6S:C<GI!:[R!)*>R#FCQ-\1?!'@VYT:R\3^)M)T:\\0
MSK;:':7MU'%<:K.YPL=E&3NF8_[/'?L:^2?VXO@9X#_:(^ >I:W=:ZF@:MX+
MMAXX\#>.K6Y%L^BZMI)2^LKR.Y)4&%WA5'4DI+&SQL&5R*_$K_@D5\0_&G_!
M3?XQ>,?C]^T3JD'G_LE_$+Q;\)/AOX(MY[L66JKX:NUTI/B%<6EW#:F=M>AC
M6_L7C2XM[>SN=L5S,[R-0!_1QX]_:(^"/POO[?2_B#\3/"?A+4;J,2P66M:K
M!9W$L; ,'2.4AF4@@Y&1CD\5Z!X6\:^$_&^C1>(?"/B#2O$6B3*7CU+2KN.[
MM64#<3YD9..,GD#H?2OP@\>_ GX7?'S_ (*W7VB_%GPU#XOTK0?A+>/HFFW\
M8N;'3YKB\DBDG6WDW1I*4AB0R[2RHI /:NQ^"OAQ_P!CW_@H?K?[-O@'6]3O
MO@[\6/AU=^-+#P?=WKW=KX+U>!E2X3383DV5E="="(25C5T=HE <B@#]IO#O
MC[P9XLDU6+PWXCTK69-#E>#5TL+E)VT^6/.^.Z"_ZIUQRK<CTI_AKQUX0\8R
MZC#X7\0Z9KDND7!M=333KE;AK&Y4X:"X"_ZN0'@J>17\U'[+'[8^F?LT?&G]
MMGP!=?"WXE?$!S\0M>U1=8\.:?=:AIL4,MNK"S$JI(B-&#AHDVN#R&7)KZT_
MX(L>+X_B)I7[1WQ AT_6-&B\4_%76KU-#UU98]1TP)=F'R)X93OA/[O(3 &"
M#T(H _<^BBB@ HHHH **** "BBB@ HHHH **** "BBB@".6:*!#)-)'#&OWG
MD=40=^68@#\ZR_\ A(="_P"@OI_'7_2H>/\ QZOP;_X*4_M<^/\ PYX\NOAC
MX2U6^T#3-.LK>:XN]/D,-U<SW+SHL2RC[J?Z,[2/@L-RA,$@C\D/^&A_BX>3
MXZ\49/\ U'=2!_'%R.?\^U?D'$'B_E>29KB\JI99B\=/!5'0KUX5:5*E[:-N
M>%-3O*2A?EE)I+F32OJU_,_&OTF>'>$N(LQX=HY#FF<5LJK?5<9BJ%;"X?#K
M$J,95*5+VT^>I[-249SY5'G347*S/[4_^$@T/_H+:?\ ^!4/_P 51_PD&A_]
M!;3_ /P*A_\ BJ_BL_X:&^+?_0]>*?\ P?:G_P#)5'_#0WQ;_P"AZ\4_^#[4
M_P#Y*KQ?^(Z8#_H08W_PJP_^7K_3T^4_XF[R?_HC,X_\+L!Y7^WZ_=]_]J?_
M  D&A_\ 06T__P "H?\ XJC_ (2#0_\ H+:?_P"!4/\ \57\5G_#0WQ;_P"A
MZ\4_^#[4_P#Y*H_X:&^+?_0]>*?_  ?:G_\ )5'_ !'3 ?\ 0@QO_A5A_P#+
MU_IZ'_$W>3_]$9G'_A=@/*_V_7[OO_M3_P"$@T/_ *"VG_\ @5#_ /%4?\)!
MH?\ T%M/_P# J'_XJOXK/^&AOBW_ -#UXI_\'VI__)5'_#0WQ;_Z'KQ3_P"#
M[4__ )*H_P"(Z8#_ *$&-_\ "K#_ .7K_3T/^)N\G_Z(S./_  NP'E?[?K]W
MW_VI_P#"0:'_ -!;3_\ P*A_^*H_X2#0_P#H+:?_ .!4/_Q5?Q6?\-#?%O\
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M?\3=Y/\ ]$9G'_A=@/*_V_7[OO\ [4_^$@T/_H+:?_X%0_\ Q5'_  D&A_\
M06T__P "H?\ XJOXK/\ AH;XM_\ 0]>*?_!]J?\ \E4?\-#?%O\ Z'KQ3_X/
MM3_^2J/^(Z8#_H08W_PJP_\ EZ_T]#_B;O)_^B,SC_PNP'E?[?K]WW_VI_\
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M/M3_ /DJC_B.F _Z$&-_\*L/_EZ_T]#_ (F[R?\ Z(S./_"[ >5_M^OW??\
MVI_\)#H7_07T_P#\"H?_ (JM&WN;>ZC$MM/%<1GH\,BR+GTRI(!]CS7\3?\
MPT-\7!T\=>*/QUW4S_.Y//I7Z+?L ?M@?$^W^*'A[P1K^MZEXBT'Q%=O:7,>
MJ7#W,]G)M+QF"1R6>(A6#>82Z,!AF#?+Z>3>,N5YIF>#RZME6,P2QM:GAZ>(
M=6C6A"M5DH4U4C"TU&4FH\R4K-JZ2/H>%?I1<.\19]EF1XKA[-LJ_M7%4<#A
M\94K87$T88K$2C3H1K0HS=2,*E22I^T2DHN2<K1O(_I5HIJ.'1''1U5A]& (
M_G3J_9C^H@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*** "BBB@ HHHH **** "BBB@#^4W_@IR,?M":]C_GVTP_\ C^I5^;-?I/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\ZIJ.E(B6D$N/(0QX*MUZAAD<5[K:6EO8VL%G:1+!;6T20P1(,+'%& J(H]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIO\ W[/_ ,DT?\0YXV_Z)[%_^#,+Y?\ 3_S_ "[A_P 0+\5_^B.QW_A3E_\
M\U^O]/3\5Z^T?V%6V_'_ ,!$YQ_:Y'3OY,AP/7@9XK[6/_!(OXA8XU73<_\
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M<9\ %%%% !1110 4444 %%%% !1110 4444 %-7^+_>-.IJ_Q?[QH =1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !117R7^T[\.OVA_'EMH2? CXAZ7X#N+25VU:74K=[A;N,@[41$9,$''.>@
MH ^M**_)+_AG;_@HO_T<5X4_\%L__P ?H_X9V_X*+_\ 1Q7A3_P6S_\ Q^@#
M];:*_)+_ (9V_P""B_\ T<5X4_\ !;/_ /'Z/^&=O^"B_P#T<5X4_P#!;/\
M_'Z /UMHK\DO^&=O^"B__1Q7A3_P6S__ !^C_AG;_@HO_P!'%>%/_!;/_P#'
MZ /UMHK\DO\ AG;_ (*+_P#1Q7A3_P %L_\ \?H_X9V_X*+_ /1Q7A3_ ,%L
M_P#\?H _6VBOR2_X9V_X*+_]'%>%/_!;/_\ 'Z/^&=O^"B__ $<5X4_\%L__
M ,?H _6VBOR2_P"&=O\ @HO_ -'%>%/_  6S_P#Q^C_AG;_@HO\ ]'%>%/\
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MX4_\%L__ ,?H _6VBOR2_P"&=O\ @HO_ -'%>%/_  6S_P#Q^C_AG;_@HO\
M]'%>%/\ P6S_ /Q^@#];:*_)+_AG;_@HO_T<5X4_\%L__P ?H_X9V_X*+_\
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M_AG;_@HO_P!'%>%/_!;/_P#'Z /UMHK\DO\ AG;_ (*+_P#1Q7A3_P %L_\
M\?H_X9V_X*+_ /1Q7A3_ ,%L_P#\?H _6VBOR2_X9V_X*+_]'%>%/_!;/_\
M'Z/^&=O^"B__ $<5X4_\%L__ ,?H _6VBOR2_P"&=O\ @HO_ -'%>%/_  6S
M_P#Q^C_AG;_@HO\ ]'%>%/\ P6S_ /Q^@#];:*_)+_AG;_@HO_T<5X4_\%L_
M_P ?H_X9V_X*+_\ 1Q7A3_P6S_\ Q^@#];:*_)+_ (9V_P""B_\ T<5X4_\
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M5X4_\%L__P ?H_X9V_X*+_\ 1Q7A3_P6S_\ Q^@#];:*_)+_ (9V_P""B_\
MT<5X4_\ !;/_ /'Z/^&=O^"B_P#T<5X4_P#!;/\ _'Z /UMHK\DO^&=O^"B_
M_1Q7A3_P6S__ !^C_AG;_@HO_P!'%>%/_!;/_P#'Z /UMHK\DO\ AG;_ (*+
M_P#1Q7A3_P %L_\ \?H_X9V_X*+_ /1Q7A3_ ,%L_P#\?H _6VBOR2_X9V_X
M*+_]'%>%/_!;/_\ 'Z/^&=O^"B__ $<5X4_\%L__ ,?H _6VBOR2_P"&=O\
M@HO_ -'%>%/_  6S_P#Q^C_AG;_@HO\ ]'%>%/\ P6S_ /Q^@#];:*_)+_AG
M;_@HO_T<5X4_\%L__P ?H_X9V_X*+_\ 1Q7A3_P6S_\ Q^@#];:*_)+_ (9V
M_P""B_\ T<5X4_\ !;/_ /'Z/^&=O^"B_P#T<5X4_P#!;/\ _'Z /UMHK\DO
M^&=O^"B__1Q7A3_P6S__ !^C_AG;_@HO_P!'%>%/_!;/_P#'Z /UMHK\DO\
MAG;_ (*+_P#1Q7A3_P %L_\ \?H_X9V_X*+_ /1Q7A3_ ,%L_P#\?H _6VBO
MR2_X9V_X*+_]'%>%/_!;/_\ 'Z/^&=O^"B__ $<5X4_\%L__ ,?H _6VBOR2
M_P"&=O\ @HO_ -'%>%/_  6S_P#Q^C_AG;_@HO\ ]'%>%/\ P6S_ /Q^@#];
M:*_)+_AG;_@HO_T<5X4_\%L__P ?H_X9V_X*+_\ 1Q7A3_P6S_\ Q^@#];:*
M_)+_ (9V_P""B_\ T<5X4_\ !;/_ /'Z/^&=O^"B_P#T<5X4_P#!;/\ _'Z
M/UMHK\DO^&=O^"B__1Q7A3_P6S__ !^C_AG;_@HO_P!'%>%/_!;/_P#'Z /U
MMHK\DO\ AG;_ (*+_P#1Q7A3_P %L_\ \?H_X9V_X*+_ /1Q7A3_ ,%L_P#\
M?H _6VBOR2_X9V_X*+_]'%>%/_!;/_\ 'Z/^&=O^"B__ $<5X4_\%L__ ,?H
M _6VBOR2_P"&=O\ @HO_ -'%>%/_  6S_P#Q^C_AG;_@HO\ ]'%>%/\ P6S_
M /Q^@#];:*_)+_AG;_@HO_T<5X4_\%L__P ?H_X9V_X*+_\ 1Q7A3_P6S_\
MQ^@#];:*_)+_ (9V_P""B_\ T<5X4_\ !;/_ /'Z/^&=O^"B_P#T<5X4_P#!
M;/\ _'Z /UMHK\DO^&=O^"B__1Q7A3_P6S__ !^C_AG;_@HO_P!'%>%/_!;/
M_P#'Z /UMHK\DO\ AG;_ (*+_P#1Q7A3_P %L_\ \?H_X9V_X*+_ /1Q7A3_
M ,%L_P#\?H _6VBOR2_X9V_X*+_]'%>%/_!;/_\ 'Z/^&=O^"B__ $<5X4_\
M%L__ ,?H _6VBOR2_P"&=O\ @HO_ -'%>%/_  6S_P#Q^C_AG;_@HO\ ]'%>
M%/\ P6S_ /Q^@#];:*_)+_AG;_@HO_T<5X4_\%L__P ?H_X9V_X*+_\ 1Q7A
M3_P6S_\ Q^@#];:*_)+_ (9V_P""B_\ T<5X4_\ !;/_ /'Z/^&=O^"B_P#T
M<5X4_P#!;/\ _'Z /UMHK\DO^&=O^"B__1Q7A3_P6S__ !^C_AG;_@HO_P!'
M%>%/_!;/_P#'Z /UMHK\DO\ AG;_ (*+_P#1Q7A3_P %L_\ \?H_X9V_X*+_
M /1Q7A3_ ,%L_P#\?H _6VBOR2_X9V_X*+_]'%>%/_!;/_\ 'Z/^&=O^"B__
M $<5X4_\%L__ ,?H _6VBOR2_P"&=O\ @HO_ -'%>%/_  6S_P#Q^C_AG;_@
MHO\ ]'%>%/\ P6S_ /Q^@#];:*_)+_AG;_@HO_T<5X4_\%L__P ?H_X9V_X*
M+_\ 1Q7A3_P6S_\ Q^@#];:*_)+_ (9V_P""B_\ T<5X4_\ !;/_ /'Z/^&=
MO^"B_P#T<5X4_P#!;/\ _'Z /UMHK\DO^&=O^"B__1Q7A3_P6S__ !^C_AG;
M_@HO_P!'%>%/_!;/_P#'Z /UMHK\DO\ AG;_ (*+_P#1Q7A3_P %L_\ \?H_
MX9V_X*+_ /1Q7A3_ ,%L_P#\?H _6VBOR2_X9V_X*+_]'%>%/_!;/_\ 'Z/^
M&=O^"B__ $<5X4_\%L__ ,?H _6VBOR2_P"&=O\ @HO_ -'%>%/_  6S_P#Q
M^C_AG;_@HO\ ]'%>%/\ P6S_ /Q^@#];:*_)+_AG;_@HO_T<5X4_\%L__P ?
MH_X9V_X*+_\ 1Q7A3_P6S_\ Q^@#];:*_)+_ (9V_P""B_\ T<5X4_\ !;/_
M /'Z/^&=O^"B_P#T<5X4_P#!;/\ _'Z /UMHK\DO^&=O^"B__1Q7A3_P6S__
M !^C_AG;_@HO_P!'%>%/_!;/_P#'Z /UMHK\DO\ AG;_ (*+_P#1Q7A3_P %
ML_\ \?H_X9V_X*+_ /1Q7A3_ ,%L_P#\?H _6VBOR2_X9V_X*+_]'%>%/_!;
M/_\ 'Z/^&=O^"B__ $<5X4_\%L__ ,?H _6VBOR2_P"&=O\ @HO_ -'%>%/_
M  6S_P#Q^C_AG;_@HO\ ]'%>%/\ P6S_ /Q^@#];:*_)+_AG;_@HO_T<5X4_
M\%L__P ?H_X9V_X*+_\ 1Q7A3_P6S_\ Q^@#];:*_)+_ (9V_P""B_\ T<5X
M4_\ !;/_ /'Z/^&=O^"B_P#T<5X4_P#!;/\ _'Z /UMHK\DO^&=O^"B__1Q7
MA3_P6S__ !^C_AG;_@HO_P!'%>%/_!;/_P#'Z /UMHK\DO\ AG;_ (*+_P#1
MQ7A3_P %L_\ \?H_X9V_X*+_ /1Q7A3_ ,%L_P#\?H _6VBOR2_X9V_X*+_]
M'%>%/_!;/_\ 'Z/^&=O^"B__ $<5X4_\%L__ ,?H _6VBOR2_P"&=O\ @HO_
M -'%>%/_  6S_P#Q^C_AG;_@HO\ ]'%>%/\ P6S_ /Q^@#];:*_)+_AG;_@H
MO_T<5X4_\%L__P ?H_X9V_X*+_\ 1Q7A3_P6S_\ Q^@#];:*_)+_ (9V_P""
MB_\ T<5X4_\ !;/_ /'Z/^&=O^"B_P#T<5X4_P#!;/\ _'Z /UMHK\DO^&=O
M^"B__1Q7A3_P6S__ !^C_AG;_@HO_P!'%>%/_!;/_P#'Z /UMHK\DO\ AG;_
M (*+_P#1Q7A3_P %L_\ \?H_X9V_X*+_ /1Q7A3_ ,%L_P#\?H _6VBOR2_X
M9V_X*+_]'%>%/_!;/_\ 'Z/^&=O^"B__ $<5X4_\%L__ ,?H _6VBOR2_P"&
M=O\ @HO_ -'%>%/_  6S_P#Q^C_AG;_@HO\ ]'%>%/\ P6S_ /Q^@#];:*_)
M+_AG;_@HO_T<5X4_\%L__P ?H_X9V_X*+_\ 1Q7A3_P6S_\ Q^@#];:*_)+_
M (9V_P""B_\ T<5X4_\ !;/_ /'Z/^&=O^"B_P#T<5X4_P#!;/\ _'Z /UMH
MK\DO^&=O^"B__1Q7A3_P6S__ !^C_AG;_@HO_P!'%>%/_!;/_P#'Z /UMHK\
MDO\ AG;_ (*+_P#1Q7A3_P %L_\ \?H_X9V_X*+_ /1Q7A3_ ,%L_P#\?H _
M6VBOR2_X9V_X*+_]'%>%/_!;/_\ 'Z/^&=O^"B__ $<5X4_\%L__ ,?H _6V
MBOR2_P"&=O\ @HO_ -'%>%/_  6S_P#Q^C_AG;_@HO\ ]'%>%/\ P6S_ /Q^
M@#];:*_)+_AG;_@HO_T<5X4_\%L__P ?H_X9V_X*+_\ 1Q7A3_P6S_\ Q^@#
M];:*_)+_ (9V_P""B_\ T<5X4_\ !;/_ /'Z/^&=O^"B_P#T<5X4_P#!;/\
M_'Z /UMHK\DO^&=O^"B__1Q7A3_P6S__ !^C_AG;_@HO_P!'%>%/_!;/_P#'
MZ /UMHK\DO\ AG;_ (*+_P#1Q7A3_P %L_\ \?H_X9V_X*+_ /1Q7A3_ ,%L
M_P#\?H _6VBOR2_X9V_X*+_]'%>%/_!;/_\ 'Z/^&=O^"B__ $<5X4_\%L__
M ,?H _6VBOR2_P"&=O\ @HO_ -'%>%/_  6S_P#Q^C_AG;_@HO\ ]'%>%/\
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M_6HV_P"TWY__ %J_)^+]G3_@H.4_TG]HWPTK]@FF2XQSW-Q_(5)_PSE^W_\
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M_!1?_HXKPI_X+9__ (_1_P ,[?\ !1?_ *.*\*?^"V?_ ./T ?K7M_VF_/\
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M"_V?_"?Q7\'>!K;2?C!XKL_&'BN-B;C5[&-HH)1VVQLS%?ID_6B@#W2BBB@
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M2BWF_M:QU41ZD$>9)9+:6X@C:2W:.0%D968 _=RBBB@ HHHH **** "BBB@
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MU9A_Q-9X>?\ 0OXE_P#"##>7_49Y_P!:V_K5HK^2K_AY!^TW_P!#S%_X+/\
M[LH_X>0?M-_]#S%_X+/_ +LH_P"(V<+_ /0'F_\ X(H?_-'G_5F'_$UGAY_T
M+^)?_"##>7_49Y_UK;^M6BOY*O\ AY!^TW_T/,7_ (+/_NRC_AY!^TW_ -#S
M%_X+/_NRC_B-G"__ $!YO_X(H?\ S1Y_U9A_Q-9X>?\ 0OXE_P#"##>7_49Y
M_P!:V_K5HK^2K_AY!^TW_P!#S%_X+/\ [LH_X>0?M-_]#S%_X+/_ +LH_P"(
MV<+_ /0'F_\ X(H?_-'G_5F'_$UGAY_T+^)?_"##>7_49Y_UK;^M6BOY*O\
MAY!^TW_T/,7_ (+/_NRC_AY!^TW_ -#S%_X+/_NRC_B-G"__ $!YO_X(H?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MES'BSAFEG.9TL/2Q%7%XJBHX:,HT_9T9*,7:4I.[N[N^O8****_,S[T****
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MJSI.L:7K=HM[I%W!>V9)19K=@T>5X*@CCCIQ0!IT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '\IO_!3E0/VA->]?LVF9/<_O-2-?FS7Z3_\%.?^
M3A->_P"O;3/_ $/4J_-BOX:XP_Y*OB/_ +&^+_\ 2T?Y)>*'_)QN-O\ LH<=
M^/(%%%%?.'P@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_B"GBM_T0^;_ /@[+?+_ *C?-_>C\AMP]1^=&X>H_.OUY_X='_'#_H*>&?\
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M*^"5"CA\'7IXBJW['$U:DIRC!QIQC!\TI1NTKL_9*W_X]X/^N,7_ * M34@
M   P   /0#@"EK^O5HDNQ_I8M$EV"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /P:_X+4? C4]8\ 6/QJT"SDN
M6\-M:66MB!"[Q63W2%YY !P@"C<Q.W/N.?YHK>9[B.QU/3KEK>[@DAO;"[B8
MAH9XG$B893D-N1>AX_6O]!+QWX(\/_$CPCX@\$>*K&+4-!\1Z?+IVH6LB*ZM
M#-G#@."!)&X#HW!# 8(K^/?]MK_@GK\3OV5O&&K:]X2T:_\ %OPCU6[FO+"Z
MTZ&2XGT6.5RP@G W>6D*Y&,#&*_M7Z//B;EE3)Z? F=8JC@\=@ZE5Y'6Q,HP
MP^.PF(GSU<OE.;4%7A.4W3C-I5:<G%.ZL?RUXS\"8ZEF53B_*Z=;$87%1I1S
M.E1BYU,)B*48PIXN,8IR5*4(I2:3Y)Q4G9,^Y_V6/^"IGPRU_P"'5A\%/VM]
M#BU""RM8M,BURZMUO8KRTC58HVE$A.QXU PZLC'E2:^B;K]N'_@G9^S38W_B
M7X.^'M/U/Q5=PNUO%9Z>BS-,^66(3F21X0S'#&,H5S@'O7\O9N],NQY=PRQR
M*<-#,C1S1L,;E;*J0PZ'KS^98O\ 8EO\ZR0@@]7=GQCOA@<']!7UV;_1H\.<
MYS_^WJF%Q^&G.K*O4P6%5#ZOSSGSR6&JSHSKX:E-W]RG)J/,^1I6/B,'XN<1
MX7"X>E4P^39AC<%1]AA<XQV#C5S&A"*48MU;KF<-DWJW\3;/I[]J/]IWQ_\
MM:_$B?QWXS>6TT:T=X?#?AP2-]FL;96_<ML!*[@JKDXS]!S6;^S!\&M0^/WQ
MQ\,^$H(6_P"$9\/747B+QAJ+*?L=C8Z7(MU)'<RX,:>9&A #XW$X[UYC\._A
M_P"/?C'X@M/"GPVT&\U.[O)5BN-9-O)_9&E6[$":YNKC 6-8HR[9S_#[5]Y?
M$CXG_#G]B[X/7_[//P=URT\3?&KQO;A/BCX^L,S+I*.N)M-LKQ5++CYHF"R
M]1V-??9M7I9'EV"X"X)PM*.>8G"/ 9;@<(N:CP_E\_=Q6>9I.%_8QP].4ZE+
MVS5;%XEQ45JV>%EM&MFN.Q/%?%&(J2RS#U_K>/Q-?2IF^+C:5'*\#&2O.=:H
MHPE[).%##J7,UH?7_P"RS\9;#XJ?\%.+K2O"TB_\(%\./"">%O#HB;_1G%K=
M16UQ)$ 2O^MB8DC%?TP5_$C_ ,$TOB?X5^%7[56AZ[XAO9(].U2SAT^6\*R%
MY=1OM2C8EV9>2TCDY)/7K7]L=A?6VI65KJ%G();6]@BN;>0='BF0.C?B"*_D
M+Z1'#L.'.(>&\'A*-2.7TN%\#A:&(E%_[37PU2LL75E/:=:K6G*K5ZJ52SON
M?TEX*9Q+.LESO%UYP>+KY]B<35I0:M1IUJ=+V%.,=XPITX*G"^ZA=%NBBBOY
M[/V<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO
MS5^*GQF_;ET+QOJ>F_#SX%:5XE\)0&,6&K7&M164UQNCS)F%H7V[9,@'=R.P
MZ5Y]_P +^_X*,?\ 1M>B?^%-!_\ (U 'ZUT5^2G_  O[_@HQ_P!&UZ)_X4T'
M_P C4?\ "_O^"C'_ $;7HG_A30?_ "-1?U^Y_P!?UY,#]:Z*_)3_ (7]_P %
M&/\ HVO1/_"F@_\ D:C_ (7]_P %&/\ HVO1/_"F@_\ D:B_K]S_ *_KR8'Z
MUT5^2G_"_O\ @HQ_T;7HG_A30?\ R-1_PO[_ (*,?]&UZ)_X4T'_ ,C47]?N
M?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_"F@_P#D:C_A?W_!1C_HVO1/_"F@_P#D
M:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_X4T'_R-1_PO[_@HQ_T;7HG_A30
M?_(U%_7[G_7]>3 _6NBOR4_X7]_P48_Z-KT3_P *:#_Y&H_X7]_P48_Z-KT3
M_P *:#_Y&HOZ_<_Z_KR8'ZUT5^2G_"_O^"C'_1M>B?\ A30?_(U'_"_O^"C'
M_1M>B?\ A30?_(U%_7[G_7]>3 _6NBOR4_X7]_P48_Z-KT3_ ,*:#_Y&H_X7
M]_P48_Z-KT3_ ,*:#_Y&HOZ_<_Z_KR8'ZUT5^2G_  O[_@HQ_P!&UZ)_X4T'
M_P C4?\ "_O^"C'_ $;7HG_A30?_ "-1?U^Y_P!?UY,#]:Z*_)3_ (7]_P %
M&/\ HVO1/_"F@_\ D:C_ (7]_P %&/\ HVO1/_"F@_\ D:B_K]S_ *_KR8'Z
MUT5^2G_"_O\ @HQ_T;7HG_A30?\ R-1_PO[_ (*,?]&UZ)_X4T'_ ,C47]?N
M?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_"F@_P#D:C_A?W_!1C_HVO1/_"F@_P#D
M:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_X4T'_R-1_PO[_@HQ_T;7HG_A30
M?_(U%_7[G_7]>3 _6NBOR4_X7]_P48_Z-KT3_P *:#_Y&H_X7]_P48_Z-KT3
M_P *:#_Y&HOZ_<_Z_KR8'ZUT5^2G_"_O^"C'_1M>B?\ A30?_(U'_"_O^"C'
M_1M>B?\ A30?_(U%_7[G_7]>3 _6NBOR4_X7]_P48_Z-KT3_ ,*:#_Y&H_X7
M]_P48_Z-KT3_ ,*:#_Y&HOZ_<_Z_KR8'ZUT5^2G_  O[_@HQ_P!&UZ)_X4T'
M_P C4?\ "_O^"C'_ $;7HG_A30?_ "-1?U^Y_P!?UY,#]:Z*_)3_ (7]_P %
M&/\ HVO1/_"F@_\ D:C_ (7]_P %&/\ HVO1/_"F@_\ D:B_K]S_ *_KR8'Z
MUT5^2G_"_O\ @HQ_T;7HG_A30?\ R-1_PO[_ (*,?]&UZ)_X4T'_ ,C47]?N
M?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_"F@_P#D:C_A?W_!1C_HVO1/_"F@_P#D
M:B_K]S_K^O)@?K2RAU9&&592K ]U88(_$&L_3='TS2%F73;&WLQ<2F:?R(PA
MFE/620CEF.>IK\IO^%_?\%&/^C:]$_\ "F@_^1J/^%_?\%&/^C:]$_\ "F@_
M^1J+^OW/^OZ\F!^M1 88(!!Z@C(/X&@      <  8 ^@K\E?^%_?\%&/^C:]
M$_\ "F@_^1J/^%_?\%&/^C:]$_\ "F@_^1J+^OW/^OZ\F!^M=%?DI_PO[_@H
MQ_T;7HG_ (4T'_R-1_PO[_@HQ_T;7HG_ (4T'_R-1?U^Y_U_7DP/UKI H485
M0H]  !^0K\E?^%_?\%&/^C:]$_\ "F@_^1J/^%_?\%&/^C:]$_\ "F@_^1J+
M^OW/^OZ\F!^M=(  ,  #T P/TK\E?^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MKHK\E/\ A?W_  48_P"C:]$_\*:#_P"1J/\ A?W_  48_P"C:]$_\*:#_P"1
MJ+^OW/\ K^O)@?K717Y*?\+^_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7H
MG_A30?\ R-1?U^Y_U_7DP/UKHK\E/^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MKHK\E/\ A?W_  48_P"C:]$_\*:#_P"1J/\ A?W_  48_P"C:]$_\*:#_P"1
MJ+^OW/\ K^O)@?K717Y*?\+^_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7H
MG_A30?\ R-1?U^Y_U_7DP/UKHK\E/^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MKHK\E/\ A?W_  48_P"C:]$_\*:#_P"1J/\ A?W_  48_P"C:]$_\*:#_P"1
MJ+^OW/\ K^O)@?K717Y*?\+^_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7H
MG_A30?\ R-1?U^Y_U_7DP/UKHK\E/^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MKHK\E/\ A?W_  48_P"C:]$_\*:#_P"1J/\ A?W_  48_P"C:]$_\*:#_P"1
MJ+^OW/\ K^O)@?K717Y*?\+^_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7H
MG_A30?\ R-1?U^Y_U_7DP/UKHK\E/^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MKHK\E/\ A?W_  48_P"C:]$_\*:#_P"1J/\ A?W_  48_P"C:]$_\*:#_P"1
MJ+^OW/\ K^O)@?K717Y*?\+^_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7H
MG_A30?\ R-1?U^Y_U_7DP/UKHK\E/^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MKHK\E/\ A?W_  48_P"C:]$_\*:#_P"1J/\ A?W_  48_P"C:]$_\*:#_P"1
MJ+^OW/\ K^O)@?K717Y*?\+^_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7H
MG_A30?\ R-1?U^Y_U_7DP/UKHK\E/^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MKHK\E/\ A?W_  48_P"C:]$_\*:#_P"1J/\ A?W_  48_P"C:]$_\*:#_P"1
MJ+^OW/\ K^O)@?K717Y*?\+^_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7H
MG_A30?\ R-1?U^Y_U_7DP/UKHK\E/^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MKHK\E/\ A?W_  48_P"C:]$_\*:#_P"1J/\ A?W_  48_P"C:]$_\*:#_P"1
MJ+^OW/\ K^O)@?K717Y*?\+^_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7H
MG_A30?\ R-1?U^Y_U_7DP/UKHK\E/^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MKHK\E/\ A?W_  48_P"C:]$_\*:#_P"1J/\ A?W_  48_P"C:]$_\*:#_P"1
MJ+^OW/\ K^O)@?K717Y*?\+^_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7H
MG_A30?\ R-1?U^Y_U_7DP/UKHK\E/^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MKHK\E/\ A?W_  48_P"C:]$_\*:#_P"1J/\ A?W_  48_P"C:]$_\*:#_P"1
MJ+^OW/\ K^O)@?K717Y*?\+^_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7H
MG_A30?\ R-1?U^Y_U_7DP/UKHK\E/^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MKHK\E/\ A?W_  48_P"C:]$_\*:#_P"1J/\ A?W_  48_P"C:]$_\*:#_P"1
MJ+^OW/\ K^O)@?K717Y*?\+^_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7H
MG_A30?\ R-1?U^Y_U_7DP/UKHK\E/^%_?\%&/^C:]$_\*:#_ .1J/^%_?\%&
M/^C:]$_\*:#_ .1J+^OW/^OZ\F!^M=%?DI_PO[_@HQ_T;7HG_A30?_(U'_"_
MO^"C'_1M>B?^%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_  IH/_D:
MC_A?W_!1C_HVO1/_  IH/_D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_P"%
M-!_\C4?\+^_X*,?]&UZ)_P"%-!_\C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO
M1/\ PIH/_D:C_A?W_!1C_HVO1/\ PIH/_D:B_K]S_K^O)@?K717Y*?\ "_O^
M"C'_ $;7HG_A30?_ "-1_P +^_X*,?\ 1M>B?^%-!_\ (U%_7[G_ %_7DP/U
MHZ%LGJ.,_CQ67J^BZ/X@TZ?2==TZQU;3;E2EQ97T,=Q;RHP((>.0$'@D9&#C
MO7Y=6OQP_P""A5Q&9+C]G;2H7'&U?$]KM^IW6;D?0'\ZL?\ "Z?^"@G_ $;[
MI/\ X5%K_P#*^G&4HR4HMQE%IQE%M2BT[IIK5--)IKJ*48R3C**E%IIQDKII
M[IIZ-/LSL/BG_P $LOV4OB?J%UJLOA4^'+ZZ=Y)&T1HX(-[MN)$0"X&2>,FO
M+/#_ /P1G_95TB^2[O(]9U)$?=]GFG7RWPVX*V688SU^4^F.]='_ ,+I_P""
M@G_1OND_^%1:_P#ROH_X73_P4$_Z-]TG_P *BU_^5]?9T/$7CK#87ZE0XKSR
M&&Y%35/Z_6?+!62C&<I.<596LI(^7K<$<(XBN\36X>RJ=9OF<WA*:YG>]Y12
M46[ZZH^SO _[+OP5^&_A"]\'>"?!^F:!9:A:O:7=_8PQ1ZI+&XVD_:]NX$KE
M<CJ&.<\8\;7_ ()S_LI&>YN[CX>65Y?7DKSW=]<E);FYED.YVED9"6)/.>M>
M*_\ "Z?^"@G_ $;[I/\ X5%K_P#*^C_A=/\ P4$_Z-]TG_PJ+7_Y7UXM'B3B
M##U<1B*&=9G1KXN2EBJ]/&XB%;$-;>VJQJ*I4MT4I-+HCTZF0Y)6IT*-7*<O
MJ4<-%QP]*>%HRIT4[7]G!PY8-VU:2;ZL^@M*_8"_9<T2ZCOM/^'.F17<$L$\
M$P6,/%-!.D\<B,$!5E= <_6OL;3[&WTRQM-.M$\NULH([:!.NV*)0J+^ &*_
M+?\ X73_ ,%!<$K^SYI1*J2 /%%ISC_MP'X8_,5D'X^_\%%U9E'[-FBE0<*Q
M\309(_\  ?U[]_T'/C\XS7-52699CC<>J'-[!8O$U<1[+VC3G[/VDI<G,TG*
MUKV39O@LKR[+?:?V?@<+@O;.+J_5J%.BJCBK1<U3C'F<5HF]D?K717Y*?\+^
M_P""C'_1M>B?^%-!_P#(U'_"_O\ @HQ_T;7HG_A30?\ R-7FW]?N?]?UY,[S
M]:Z*_)3_ (7]_P %&/\ HVO1/_"F@_\ D:C_ (7]_P %&/\ HVO1/_"F@_\
MD:B_K]S_ *_KR8'ZUT5^2G_"_O\ @HQ_T;7HG_A30?\ R-1_PO[_ (*,?]&U
MZ)_X4T'_ ,C47]?N?]?UY,#]:Z*_)3_A?W_!1C_HVO1/_"F@_P#D:C_A?W_!
M1C_HVO1/_"F@_P#D:B_K]S_K^O)@?K717Y*?\+^_X*,?]&UZ)_X4T'_R-1_P
MO[_@HQ_T;7HG_A30?_(U%_7[G_7]>3 _6NBOR4_X7]_P48_Z-KT3_P *:#_Y
M&H_X7]_P48_Z-KT3_P *:#_Y&HOZ_<_Z_KR8'ZUT5^2G_"_O^"C'_1M>B?\
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MOB?_ -$MT/\ \"K;_&C_ (B*OB?_ -$MT/\ \"K;_&OHO^)8?&/_ *)W#?\
MAXRS_P":/-?>>=_Q$W@O_H;_ /EKBO\ Y3Y_U9G]=U%?R(_\1%7Q/_Z);H?_
M (%6W^-'_$15\3_^B6Z'_P"!5M_C1_Q+#XQ_]$[AO_#QEG_S1YK[P_XB;P7_
M -#?_P M<5_\I\_ZLS^NZBOY$?\ B(J^)_\ T2W0_P#P*MO\:/\ B(J^)_\
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M /+7%?\ RGS_ *LS^NZBOY$?^(BKXG_]$MT/_P "K;_&C_B(J^)__1+=#_\
M JV_QH_XEA\8_P#HG<-_X>,L_P#FCS7WA_Q$W@O_ *&__EKBO_E/G_5F?UW4
M5_(C_P 1%7Q/_P"B6Z'_ .!5M_C1_P 1%7Q/_P"B6Z'_ .!5M_C1_P 2P^,?
M_1.X;_P\99_\T>:^\/\ B)O!?_0W_P#+7%?_ "GS_JS/Z[J*_D1_XB*OB?\
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M@O\ Z&__ ):XK_Y3Y_U9G]=U%?R(_P#$15\3_P#HENA_^!5M_C1_Q$5?$_\
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M(BKXG_\ 1+=#_P# JV_QH_XEA\8_^B=PW_AXRS_YH\U]X?\ $3>"_P#H;_\
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M1_Q+#XQ_]$[AO_#QEG_S1YK[P_XB;P7_ -#?_P M<5_\I\_ZLS^NZBOY$?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWXEC\51'PEH\FN:<=172-%\-&W?P]:6&D*$M]+6XM+J[$40:\N[V>>:6:/\
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MG<_%'S?.\07L&G*W]F2:Q9Z>^FZ;-?K$;A%$EHSKY;I7]>*J$554!54!54#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M->U2YUG6&T^VB@DU'4KR0S7-W<NBJ99II69W=R69CDFO8J** "BBB@ HHHH
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M2R*,&2//.&ZGZUXK>?M7?"R#1C?6M[>7NK^4NSP_#97'V]KIES]EQY>-P?\
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M?]#7*O\ PYX#R_ZB//\ !]@_LW,?^A?C_P#PCQ/_ ,J\U]YXA17M_P#PS?\
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MT?VKE7_0URK_ ,.> \O^HCS_  ?8/[-S'_H7X_\ \(\3_P#*O-?>>(45[?\
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M!\(Y51Q5&IAZW)6J.E5@X5(QJ5IS@Y0DE*+E%J5I)-)ZI,****_##[8****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]$ ^,G_A*WW_ ,31_P /.M-_Z(!\9/\ PE;[_P")H _5"BORO_X>=:;_ -$
M^,G_ (2M]_\ $T?\/.M-_P"B ?&3_P )6^_^)H _5"BORO\ ^'G6F_\ 1 /C
M)_X2M]_\31_P\ZTW_H@'QD_\)6^_^)H _5"BORO_ .'G6F_]$ ^,G_A*WW_Q
M-'_#SK3?^B ?&3_PE;[_ .)H _5"BORO_P"'G6F_]$ ^,G_A*WW_ ,31_P /
M.M-_Z(!\9/\ PE;[_P")H _5"BORO_X>=:;_ -$ ^,G_ (2M]_\ $T?\/.M-
M_P"B ?&3_P )6^_^)H _5"BORO\ ^'G6F_\ 1 /C)_X2M]_\31_P\ZTW_H@'
MQD_\)6^_^)H _5"BORO_ .'G6F_]$ ^,G_A*WW_Q-'_#SK3?^B ?&3_PE;[_
M .)H _5"BORO_P"'G6F_]$ ^,G_A*WW_ ,31_P /.M-_Z(!\9/\ PE;[_P")
MH _5"BORO_X>=:;_ -$ ^,G_ (2M]_\ $T?\/.M-_P"B ?&3_P )6^_^)H _
M5"BORO\ ^'G6F_\ 1 /C)_X2M]_\31_P\ZTW_H@'QD_\)6^_^)H _5"BORO_
M .'G6F_]$ ^,G_A*WW_Q-'_#SK3?^B ?&3_PE;[_ .)H _5"BORO_P"'G6F_
M]$ ^,G_A*WW_ ,31_P /.M-_Z(!\9/\ PE;[_P")H _5"F21I*C1RHLD;C:Z
M.H96'HRG((]C7Y9?\/.M-_Z(!\9/_"5OO_B:/^'G6F_]$ ^,G_A*WW_Q- 'Z
MA/IFG26IL9+&U>S8Y-JT$;0$YSGRBNS.1G.,U+]BM#;?8S;0M:;/+^SM&C0[
M/[OEL"NWG &*_+C_ (>=:;_T0#XR?^$K??\ Q-'_  \ZTW_H@'QD_P#"5OO_
M (F@#](K+P%X-T^\:_L_#FDPW;-N\Y;*WW!LYW+^[X/7FNK:.-XS$\:/$R[6
MC9%:,K_=*$%2OL1BORR_X>=:;_T0#XR?^$K??_$T?\/.M-_Z(!\9/_"5OO\
MXF@#]((O '@R&_.IQ>&](6]+;_.^PVY._.=^"A&[/.:ZY55%"(JHJC"JJA54
M>@48 'L!7Y8_\/.M-_Z(!\9/_"5OO_B:/^'G6F_]$ ^,G_A*WW_Q- 'ZH45^
M5_\ P\ZTW_H@'QD_\)6^_P#B:/\ AYUIO_1 /C)_X2M]_P#$T ?JA17Y7_\
M#SK3?^B ?&3_ ,)6^_\ B:/^'G6F_P#1 /C)_P"$K??_ !- 'ZH45^5__#SK
M3?\ H@'QD_\ "5OO_B:/^'G6F_\ 1 /C)_X2M]_\30!^J%%?E?\ \/.M-_Z(
M!\9/_"5OO_B:/^'G6F_]$ ^,G_A*WW_Q- 'ZH45^5_\ P\ZTW_H@'QD_\)6^
M_P#B:/\ AYUIO_1 /C)_X2M]_P#$T ?JA17Y7_\ #SK3?^B ?&3_ ,)6^_\
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M7_0J:!_X*[3_ .-5^;G_  \ZTW_H@'QD_P#"5OO_ (FC_AYUIO\ T0#XR?\
MA*WW_P 31]8K_P#/ZM_X,G_GY+[@Y(_RQ_\  5_D?I'_ ,(%X*_Z%30/_!7:
M?_&J/^$"\%?]"IH'_@KM/_C5?FY_P\ZTW_H@'QD_\)6^_P#B:/\ AYUIO_1
M/C)_X2M]_P#$T?6*_P#S^K?^#)_Y^2^X.2/\L?\ P%?Y'Z1_\(%X*_Z%30/_
M  5VG_QJC_A O!7_ $*F@?\ @KM/_C5?FY_P\ZTW_H@'QD_\)6^_^)H_X>=:
M;_T0#XR?^$K??_$T?6*__/ZM_P"#)_Y^2^X.2/\ +'_P%?Y'Z1_\(%X*_P"A
M4T#_ ,%=I_\ &J/^$"\%?]"IH'_@KM/_ (U7YN?\/.M-_P"B ?&3_P )6^_^
M)H_X>=:;_P!$ ^,G_A*WW_Q-'UBO_P _JW_@R?\ GY+[@Y(_RQ_\!7^1^D?_
M  @7@K_H5- _\%=I_P#&J/\ A O!7_0J:!_X*[3_ .-5^;G_  \ZTW_H@'QD
M_P#"5OO_ (FC_AYUIO\ T0#XR?\ A*WW_P 31]8K_P#/ZM_X,G_GY+[@Y(_R
MQ_\  5_D?I'_ ,(%X*_Z%30/_!7:?_&J/^$"\%?]"IH'_@KM/_C5?FY_P\ZT
MW_H@'QD_\)6^_P#B:/\ AYUIO_1 /C)_X2M]_P#$T?6*_P#S^K?^#)_Y^2^X
M.2/\L?\ P%?Y'Z1_\(%X*_Z%30/_  5VG_QJC_A O!7_ $*F@?\ @KM/_C5?
MFY_P\ZTW_H@'QD_\)6^_^)H_X>=:;_T0#XR?^$K??_$T?6*__/ZM_P"#)_Y^
M2^X.2/\ +'_P%?Y'Z1_\(%X*_P"A4T#_ ,%=I_\ &J/^$"\%?]"IH'_@KM/_
M (U7YN?\/.M-_P"B ?&3_P )6^_^)H_X>=:;_P!$ ^,G_A*WW_Q-'UBO_P _
MJW_@R?\ GY+[@Y(_RQ_\!7^1^D?_  @7@K_H5- _\%=I_P#&J/\ A O!7_0J
M:!_X*[3_ .-5^;G_  \ZTW_H@'QD_P#"5OO_ (FC_AYUIO\ T0#XR?\ A*WW
M_P 31]8K_P#/ZM_X,G_GY+[@Y(_RQ_\  5_D?I'_ ,(%X*_Z%30/_!7:?_&J
M/^$"\%?]"IH'_@KM/_C5?FY_P\ZTW_H@'QD_\)6^_P#B:/\ AYUIO_1 /C)_
MX2M]_P#$T?6*_P#S^K?^#)_Y^2^X.2/\L?\ P%?Y'Z1_\(%X*_Z%30/_  5V
MG_QJC_A O!7_ $*F@?\ @KM/_C5?FY_P\ZTW_H@'QD_\)6^_^)H_X>=:;_T0
M#XR?^$K??_$T?6*__/ZM_P"#)_Y^2^X.2/\ +'_P%?Y'Z1_\(%X*_P"A4T#_
M ,%=I_\ &J/^$"\%?]"IH'_@KM/_ (U7YN?\/.M-_P"B ?&3_P )6^_^)H_X
M>=:;_P!$ ^,G_A*WW_Q-'UBO_P _JW_@R?\ GY+[@Y(_RQ_\!7^1^D?_  @7
M@K_H5- _\%=I_P#&J/\ A O!7_0J:!_X*[3_ .-5^;G_  \ZTW_H@'QD_P#"
M5OO_ (FC_AYUIO\ T0#XR?\ A*WW_P 31]8K_P#/ZM_X,G_GY+[@Y(_RQ_\
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M\)6^_P#B:/\ AYUIO_1 /C)_X2M]_P#$T?6*_P#S^K?^#)_Y^2^X.2/\L?\
MP%?Y'Z1_\(%X*_Z%30/_  5VG_QJC_A O!7_ $*F@?\ @KM/_C5?FY_P\ZTW
M_H@'QD_\)6^_^)H_X>=:;_T0#XR?^$K??_$T?6*__/ZM_P"#)_Y^2^X.2/\
M+'_P%?Y'Z1_\(%X*_P"A4T#_ ,%=I_\ &J/^$"\%?]"IH'_@KM/_ (U7YN?\
M/.M-_P"B ?&3_P )6^_^)H_X>=:;_P!$ ^,G_A*WW_Q-'UBO_P _JW_@R?\
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MHK\K_P#AYUIO_1 /C)_X2M]_\31_P\ZTW_H@'QD_\)6^_P#B: /U0HK\K_\
MAYUIO_1 /C)_X2M]_P#$T?\ #SK3?^B ?&3_ ,)6^_\ B: /U0HK\K_^'G6F
M_P#1 /C)_P"$K??_ !-'_#SK3?\ H@'QD_\ "5OO_B: /U0HK\K_ /AYUIO_
M $0#XR?^$K??_$T?\/.M-_Z(!\9/_"5OO_B: /U0HK\K_P#AYUIO_1 /C)_X
M2M]_\31_P\ZTW_H@'QD_\)6^_P#B: /U0HK\K_\ AYUIO_1 /C)_X2M]_P#$
MT?\ #SK3?^B ?&3_ ,)6^_\ B: /U0HK\K_^'G6F_P#1 /C)_P"$K??_ !-'
M_#SK3?\ H@'QD_\ "5OO_B: /U0HK\K_ /AYUIO_ $0#XR?^$K??_$T?\/.M
M-_Z(!\9/_"5OO_B: /U0HK\K_P#AYUIO_1 /C)_X2M]_\31_P\ZTW_H@'QD_
M\)6^_P#B: /U0HK\K_\ AYUIO_1 /C)_X2M]_P#$T?\ #SK3?^B ?&3_ ,)6
M^_\ B: /U0HK\K_^'G6F_P#1 /C)_P"$K??_ !-'_#SK3?\ H@'QD_\ "5OO
M_B: /U0HK\K_ /AYUIO_ $0#XR?^$K??_$T?\/.M-_Z(!\9/_"5OO_B: /U0
MHK\K_P#AYUIO_1 /C)_X2M]_\31_P\ZTW_H@'QD_\)6^_P#B: /U0HK\K_\
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MHK\K_P#AYUIO_1 /C)_X2M]_\31_P\ZTW_H@'QD_\)6^_P#B: /U0HK\K_\
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MHK\K_P#AYUIO_1 /C)_X2M]_\31_P\ZTW_H@'QD_\)6^_P#B: /U0HK\K_\
MAYUIO_1 /C)_X2M]_P#$T?\ #SK3?^B ?&3_ ,)6^_\ B: /U0HK\K_^'G6F
M_P#1 /C)_P"$K??_ !-'_#SK3?\ H@'QD_\ "5OO_B: /U0HK\K_ /AYUIO_
M $0#XR?^$K??_$T?\/.M-_Z(!\9/_"5OO_B: /U0HK\K_P#AYUIO_1 /C)_X
M2M]_\31_P\ZTW_H@'QD_\)6^_P#B: /U0HK\K_\ AYUIO_1 /C)_X2M]_P#$
MT?\ #SK3?^B ?&3_ ,)6^_\ B: /U0HK\K_^'G6F_P#1 /C)_P"$K??_ !-'
M_#SK3?\ H@'QD_\ "5OO_B: /U0HK\K_ /AYUIO_ $0#XR?^$K??_$T?\/.M
M-_Z(!\9/_"5OO_B: /U0HK\K_P#AYUIO_1 /C)_X2M]_\31_P\ZTW_H@'QD_
M\)6^_P#B: /U0HK\K_\ AYUIO_1 /C)_X2M]_P#$T?\ #SK3?^B ?&3_ ,)6
M^_\ B: /U0HK\K_^'G6F_P#1 /C)_P"$K??_ !-'_#SK3?\ H@'QD_\ "5OO
M_B: /U.&<GGL/PZUY9\6/@I\-OC;X;G\+?$CPQIWB+39D=5-S;Q&ZMRRE=T%
MP4:2-AG(P<9 XZY^$K?_ (*26=W'YJ? CXOHHXPWA.])ZG'1E]^V?4#O/_P\
M:M?^B%?%W_PDK[_XY6V'Q%?"5Z6)PM:KA\11FJE&O0G*E5I3B[J4*D&I1DGU
M33,J]"CBJ52AB:5.O0JQ<*E*K!5*<XO>,X23C)>J/DCXJ?\ !#?X?:Q?W.H_
M#+QQ?>&8IY7==*FCW10AF)"QR$E=J@A><8QP*\K\/_\ !"6_>^3_ (2/XKRB
MPWCS!!&LCLF>1A,D$CCCU]J_0O\ X>-6O_1"OB[_ .$E??\ QRC_ (>-6O\
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M-I/!JWP8\2R>%O$S2ME1J26\5UL08'!MYX9,],2"@#Z[_P"$>T+_ * ^F_\
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MWQ5\<?%CQ9!X6T?1H[^TTV*UFFBDF:^O;N\=$CL[=(B9C&LLQW 1PR-Q7,_
MS]O[XEV?QA\+_ +]KGX2M\'?''CZW>X\!:O;Z@FJ>'/$4L,:O/I\.I(D,<=_
M$&W&VEC1WC!DBWJK[0#]3?\ A'M"_P"@/IO_ (!P?_$4?\(]H7_0'TW_ , X
M/_B*^(?!'[7.M>*?VM_B]^SG-X4DM=.^&_A.#Q+:^(RZ&#5!=+=&*"-0Q8,G
MV8-)E0 )$QGFN&^!?[9OQ!_: ^%/[07BGP=X#9/&'PA\9^*/"NC>'YYHU/B)
M_#DTJ+)%(K.$2]6,&(MALN-R@] #]%_^$>T+_H#Z;_X!P?\ Q%'_  CVA?\
M0'TW_P  X/\ XBOR-U?_ (*O>&;3]FJQ\=Z=X0OK_P#:%O\ 58_"<7P%C:'_
M (2M?%?VW^S[BUDMVE 2W@G^=[MB+86^;CS/+P3^B&B?%6\\)? RT^*?QOCL
MO!E]9^&_^$@\2V4US&(M-8VOVHV2RN55Y5'[O Y+=!VH ]B_X1[0O^@/IO\
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M_P 11_Q%S@7_ *&E7_PBQ?E_TY\W]P?\0:X^_P"A52_\+<+Y?]//-_<?<?\
MPCVA?] ?3?\ P#@_^(H_X1[0O^@/IO\ X!P?_$5\.?\ #6VJ?\^&F?\ @8/_
M (BC_AK;5/\ GPTS_P #!_\ $4?\1<X%_P"AI5_\(L7Y?].?-_<'_$&N/O\
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M<?\ PCVA?] ?3?\ P#@_^(H_X1[0O^@/IO\ X!P?_$5\.?\ #6VJ?\^&F?\
M@8/_ (BC_AK;5/\ GPTS_P #!_\ $4?\1<X%_P"AI5_\(L7Y?].?-_<'_$&N
M/O\ H54O_"W"^7_3SS?W'W'_ ,(]H7_0'TW_ , X/_B*/^$>T+_H#Z;_ . <
M'_Q%?#G_  UMJG_/AIG_ (&#_P"(H_X:VU3_ )\-,_\  P?_ !%'_$7.!?\
MH:5?_"+%^7_3GS?W!_Q!KC[_ *%5+_PMPOE_T\\W]Q]Q_P#"/:%_T!]-_P#
M.#_XBC_A'M"_Z ^F_P#@'!_\17PY_P -;:I_SX:9_P"!@_\ B*/^&MM4_P"?
M#3/_  ,'_P 11_Q%S@7_ *&E7_PBQ?E_TY\W]P?\0:X^_P"A52_\+<+Y?]//
M-_<?<?\ PCVA?] ?3?\ P#@_^(H_X1[0O^@/IO\ X!P?_$5\.?\ #6VJ<_\
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M@_\ B*V** ,?_A'M"_Z ^F_^ <'_ ,11_P (]H7_ $!]-_\  .#_ .(K8HH
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M_P 11_PCVA?] ?3?_ .#_P"(K8HH Q_^$>T+_H#Z;_X!P?\ Q%'_  CVA?\
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MCVA?] ?3?_ .#_XBMBB@#'_X1[0O^@/IO_@'!_\ $4?\(]H7_0'TW_P#@_\
MB*V** ,?_A'M"_Z ^F_^ <'_ ,11_P (]H7_ $!]-_\  .#_ .(K8HH Q_\
MA'M"_P"@/IO_ (!P?_$4?\(]H7_0'TW_ , X/_B*V** ,?\ X1[0O^@/IO\
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M_H#Z;_X!P?\ Q%'_  CVA?\ 0'TW_P  X/\ XBMBB@#'_P"$>T+_ * ^F_\
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MVA?] ?3?_ .#_P"(K8HH Q_^$>T+_H#Z;_X!P?\ Q%'_  CVA?\ 0'TW_P
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M1;^;XC^%+*Q\)W?AN&:'3-%T^VL)0NAG[0SS7-REY--,]X! LBR)$+=/)WR
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MQ2.64@?D=_P2@^!7[=7@7]J/_@H=X\\3?'6RU#PSX8\8>(YKG2[31X+.>[U
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M/H$LESHWP_T>SL7^R^&;"_FM;&XU98KN:[FEU2YLK26\GN-RVMM"L<$?J?\
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MV:/@)K5QXB^''PRT#2-;G8E-2^Q0R7-LI.[9;R,I,:CHJKPHZ 5];T ?@O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\OOV=/"VE>-_VAOA3X6US8VDZAK]JUU%-CRI1%/#(JL"<$9['Z=:_P!&/!C
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M_L5XW_TQ,_8*'_51?]<T_P#014E1P_ZJ+_KFG_H(J2O[X6R]%^1_G@]WZO\
M,****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^'A'[*/_13+3_P%F_QH_P"'A'[*/_13+3_P%F_QHO\ U_7JOO ^U:*^*O\
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MS6EW$T,\3#*R1MU4^QKXV_X>$?LH_P#13+3_ ,!9O\:/^'A'[*/_ $4RT_\
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M3+3_ ,!9O\:+_P!?UZK[P/M6BOBK_AX1^RC_ -%,M/\ P%F_QH_X>$?LH_\
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MP\(_91_Z*9:?^ LW^-'_ ! [A7_H.SC_ ,*J7E_TY\_Q7S/^(^<5?]"_*/\
MP7B/+_I_Y?BSYK_X9R\;?]"Q>_\ @0W_ ,31_P ,Y>-O^A8O?_ AO_B:^E/^
M'A'[*/\ T4RT_P# 6;_&C_AX1^RC_P!%,M/_  %F_P :/^('<*_]!V<?^%5+
MR_Z<^?XKYG_$?.*O^A?E'_@O$>7_ $_\OQ9\U_\ #.7C;_H6+W_P(;_XFC_A
MG+QM_P!"Q>_^!#?_ !-?2G_#PC]E'_HIEI_X"S?XT?\ #PC]E'_HIEI_X"S?
MXT?\0.X5_P"@[./_  JI>7_3GS_%?,_XCYQ5_P!"_*/_  7B/+_I_P"7XL^:
M_P#AG+QM_P!"Q>_^!#?_ !-'_#.7C;_H6+W_ ,"&_P#B:^E/^'A'[*/_ $4R
MT_\  6;_ !H_X>$?LH_]%,M/_ 6;_&C_ (@=PK_T'9Q_X54O+_ISY_BOF?\
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M_P!?UZK[P/M6BOBK_AX1^RC_ -%,M/\ P%F_QH_X>$?LH_\ 13+3_P !9O\
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M !HO_7]>J ^U:*^*O^'A'[*/_13+3_P%F_QH_P"'A'[*/_13+3_P%F_QHO\
MU_7JOO ^U:*^*O\ AX1^RC_T4RT_\!9O\:/^'A'[*/\ T4RT_P# 6;_&B_\
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MO^'A'[*/_13+3_P%F_QH_P"'A'[*/_13+3_P%F_QHO\ U_7JOO ^U:*^*O\
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MZT7"K1KPC4I3B]U*$DXOR=KKHT?DY\3O^"%D#ZI=7?PH^(DUA82R.\-AJLC
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M\!9O\:+_ -?UZK[P/M6BOBK_ (>$?LH_]%,M/_ 6;_&C_AX1^RC_ -%,M/\
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M#7_@!#_\11_PRC^S]_T3'PU_X 0__$5]#T4 ?/'_  RC^S]_T3'PU_X 0_\
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MWAU3QAX=\7SZ=:^&=/\ "=L^JZOK5UJAC2SMK&SMEDDGFEDE10J XY8D*"0
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M^#,__$4?\1UP/_1/8[_PKPOEY^;^X/\ B;O)O^B,SC_PX9?Y?W_-_<?UD?\
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MW@/_ +ZT[_XNC_AG?]ES_H3O ?\ WUIW_P 77\F__#0GQ1_Z&SQ!_P"#,_\
MQ%'_  T)\4?^AL\0?^#,_P#Q%'_$=<#_ -$]CO\ PKPOEY^;^X/^)N\F_P"B
M,SC_ ,.&7^7]_P W]Q_61_PSO^RY_P!"=X#_ .^M._\ BZ/^&=_V7/\ H3O
M?_?6G?\ Q=?R;_\ #0GQ1_Z&SQ!_X,S_ /$4?\-"?%'_ *&SQ!_X,S_\11_Q
M'7 _]$]CO_"O"^7GYO[@_P")N\F_Z(S./_#AE_E_?\W]Q_61_P ,[_LN?]"=
MX#_[ZT[_ .+H_P"&=_V7/^A.\!_]]:=_\77\F_\ PT)\4?\ H;/$'_@S/_Q%
M'_#0GQ1_Z&SQ!_X,S_\ $4?\1UP/_1/8[_PKPOEY^;^X/^)N\F_Z(S./_#AE
M_E_?\W]Q_61_PSO^RY_T)W@/_OK3O_BZ/^&=_P!ES_H3O ?_ 'UIW_Q=?R;_
M /#0GQ1_Z&SQ!_X,S_\ $4?\-"?%'_H;/$'_ (,S_P#$4?\ $=<#_P!$]CO_
M  KPOEY^;^X/^)N\F_Z(S./_  X9?Y?W_-_<?UD?\,[_ ++G_0G> _\ OK3O
M_BZ/^&=_V7/^A.\!_P#?6G?_ !=?R;_\-"?%'_H;/$'_ (,S_P#$4?\ #0GQ
M1_Z&SQ!_X,S_ /$4?\1UP/\ T3V._P#"O"^7GYO[@_XF[R;_ *(S./\ PX9?
MY?W_ #?W']9'_#._[+G_ $)W@/\ [ZT[_P"+H_X9W_9<_P"A.\!_]]:=_P#%
MU_)O_P -"?%'_H;/$'_@S/\ \11_PT)\4?\ H;/$'_@S/_Q%'_$=<#_T3V._
M\*\+Y>?F_N#_ (F[R;_HC,X_\.&7^7]_S?W']9'_  SO^RY_T)W@/_OK3O\
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M,[_LN?\ 0G> _P#OK3O_ (NOY-_^&A/BC_T-GB#_ ,&9_P#B*/\ AH3XH_\
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M615^&\VRQYMBZ6!HXR>(P>)I4L17:C156%&I[14YS:@YQC+E;3DE&[7[J?\
M#*/[/W_1,?#7_@!#_P#$4?\ #*/[/W_1,?#7_@!#_P#$5]#T5^SG]1GSQ_PR
MC^S]_P!$Q\-?^ $/_P 11_PRC^S]_P!$Q\-?^ $/_P 17T/10!\\?\,H_L_?
M]$Q\-?\ @!#_ /$4?\,H_L_?]$Q\-?\ @!#_ /$5]#T4 ?/'_#*/[/W_ $3'
MPU_X 0__ !%'_#*/[/W_ $3'PU_X 0__ !%?0]% 'SQ_PRC^S]_T3'PU_P"
M$/\ \11_PRC^S]_T3'PU_P" $/\ \17T/10!\\?\,H_L_?\ 1,?#7_@!#_\
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M#7_@!#_\11_PRC^S]_T3'PU_X 0__$5]#T4 ?/'_  RC^S]_T3'PU_X 0_\
MQ%'_  RC^S]_T3'PU_X 0_\ Q%?0]% 'SQ_PRC^S]_T3'PU_X 0__$4?\,H_
ML_?]$Q\-?^ $/_Q%?0]% 'SQ_P ,H_L_?]$Q\-?^ $/_ ,11_P ,H_L_?]$Q
M\-?^ $/_ ,17T/10!\\?\,H_L_?]$Q\-?^ $/_Q%'_#*/[/W_1,?#7_@!#_\
M17T/10!\\?\ #*/[/W_1,?#7_@!#_P#$4?\ #*/[/W_1,?#7_@!#_P#$5]#T
M4 ?/'_#*/[/W_1,?#7_@!#_\11_PRC^S]_T3'PU_X 0__$5]#T4 ?/'_  RC
M^S]_T3'PU_X 0_\ Q%'_  RC^S]_T3'PU_X 0_\ Q%?0]% 'SQ_PRC^S]_T3
M'PU_X 0__$4?\,H_L_?]$Q\-?^ $/_Q%?0]% 'SQ_P ,H_L_?]$Q\-?^ $/_
M ,11_P ,H_L_?]$Q\-?^ $/_ ,17T/10!\\C]E/]G]>1\,O#0R,?\>$/0_\
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MS]_T3'PU_P" $/\ \17T/10!\\?\,H_L_?\ 1,?#7_@!#_\ $4?\,H_L_?\
M1,?#7_@!#_\ $5]#T4 ?/'_#*/[/W_1,?#7_ ( 0_P#Q%'_#*/[/W_1,?#7_
M ( 0_P#Q%?0]% 'SQ_PRC^S]_P!$Q\-?^ $/_P 11_PRC^S]_P!$Q\-?^ $/
M_P 17T/10!\\?\,H_L_?]$Q\-?\ @!#_ /$4?\,H_L_?]$Q\-?\ @!#_ /$5
M]#T4 ?/'_#*/[/W_ $3'PU_X 0__ !%'_#*/[/W_ $3'PU_X 0__ !%?0]%
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MB@ I#T/T/\J6D/0_0_RH _DP_P""DW_)QFN_]>-K_P"ENJ5^>]?H1_P4F/\
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MX(_9@\*_M6#6;C6OAWXRU&WT;0S8X^TW&L7$@A73SE&_>I,0C?)U/2N)O_\
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M^ -W_P#(]'_#R;]F'_H:KC_P!N__ )'H ^_**^ _^'DW[,/_ $-5Q_X W?\
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M5_\ !=<__$4?\*3^(W_0O:K_ ."ZY_\ B*_I6_X;G_8K]=,_\$4G_P B4?\
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M77/_ ,11_P *3^(W_0O:K_X+KG_XBOZ5O^&Y_P!BOUTS_P $4G_R)1_PW/\
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M5_\ !=<__$4?\*3^(W_0O:K_ ."ZY_\ B*_I6_X;G_8K]=,_\$4G_P B4?\
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M77/_ ,11_P *3^(W_0O:K_X+KG_XBOZ5O^&Y_P!BOUTS_P $4G_R)1_PW/\
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M$;_H7M5_\%US_P#$5_2M_P -S_L5^NF?^"*3_P"1*/\ AN?]BOUTS_P12?\
MR)1_Q J'_11U?_""C_\ )^O]/0_XE$PW_1:XK_PU8;R_O^OW^1_-3_PI/XC?
M]"]JO_@NN?\ XBC_ (4G\1O^A>U7_P %US_\17]*W_#<_P"Q7ZZ9_P""*3_Y
M$H_X;G_8K]=,_P#!%)_\B4?\0*A_T4=7_P (*/\ \GZ_T]#_ (E$PW_1:XK_
M ,-6&\O[_K]_D?S4_P#"D_B-_P!"]JO_ (+KG_XBC_A2?Q&_Z%[5?_!=<_\
MQ%?TK?\ #<_[%?KIG_@BD_\ D2C_ (;G_8K]=,_\$4G_ ,B4?\0*A_T4=7_P
M@H__ "?K_3T/^)1,-_T6N*_\-6&\O[_K]_D?S4_\*3^(W_0O:K_X+KG_ .(H
M_P"%)_$;_H7M5_\ !=<__$5_2M_PW/\ L5^NF?\ @BD_^1*/^&Y_V*_73/\
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MJ_\ @NN?_B*/^%)_$;_H7M5_\%US_P#$5_2M_P -S_L5^NF?^"*3_P"1*/\
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M_P  ;O\ ^1Z/^'DW[,/_ $-5Q_X W?\ \CT ??E%? ?_  \F_9A_Z&JX_P#
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MY-^S#_T-5Q_X W?_ ,CT?\/)OV8?^AJN/_ &[_\ D>@#[\HKX#_X>3?LP_\
M0U7'_@#=_P#R/1_P\F_9A_Z&JX_\ ;O_ .1Z /ORBO@/_AY-^S#_ -#5<?\
M@#=__(]'_#R;]F'_ *&JX_\  &[_ /D>@#[\HKX#_P"'DW[,/_0U7'_@#=__
M "/1_P /)OV8?^AJN/\ P!N__D>@#[\HKX#_ .'DW[,/_0U7'_@#=_\ R/1_
MP\F_9A_Z&JX_\ ;O_P"1Z /ORBO@/_AY-^S#_P!#5<?^ -W_ /(]'_#R;]F'
M_H:KC_P!N_\ Y'H ^_**^ _^'DW[,/\ T-5Q_P" -W_\CT?\/)OV8?\ H:KC
M_P  ;O\ ^1Z /ORBO@/_ (>3?LP_]#5<?^ -W_\ (]'_  \F_9A_Z&JX_P#
M&[_^1Z /ORBO@/\ X>3?LP_]#5<?^ -W_P#(]'_#R;]F'_H:KC_P!N__ )'H
M ^_**^ _^'DW[,/_ $-5Q_X W?\ \CT?\/)OV8?^AJN/_ &[_P#D>@#[\HKX
M#_X>3?LP_P#0U7'_ ( W?_R/1_P\F_9A_P"AJN/_  !N_P#Y'H ^_**^ _\
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M5<?^ -W_ /(]'_#R;]F'_H:KC_P!N_\ Y'H ^_**^ _^'DW[,/\ T-5Q_P"
M-W_\CT?\/)OV8?\ H:KC_P  ;O\ ^1Z /ORBO@/_ (>3?LP_]#5<?^ -W_\
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M:ZG<OK^A_P *^!?^'DW[,/\ T-5Q_P" -W_\CT?\/)OV8?\ H:KC_P  ;O\
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M]%@<8/<>OJ*=7P'_ ,/)OV8?^AJN/_ &[_\ D>C_ (>3?LP_]#5<?^ -W_\
M(]9&I]^45\!_\/)OV8?^AJN/_ &[_P#D>C_AY-^S#_T-5Q_X W?_ ,CT ??E
M%? ?_#R;]F'_ *&JX_\  &[_ /D>C_AY-^S#_P!#5<?^ -W_ /(] 'WY17P'
M_P /)OV8?^AJN/\ P!N__D>C_AY-^S#_ -#5<?\ @#=__(] 'WY17P'_ ,/)
MOV8?^AJN/_ &[_\ D>C_ (>3?LP_]#5<?^ -W_\ (] 'WY17P'_P\F_9A_Z&
MJX_\ ;O_ .1Z/^'DW[,/_0U7'_@#=_\ R/0!]^45\!_\/)OV8?\ H:KC_P
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M6\<CQQ7:PO.QF*$!$6&-V+-Q\N,Y.* /7_\ A0_P>_Z)UX4_\$]E_P#&:/\
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M3V7_ ,9H_P"%#_![_HG7A3_P3V7_ ,9KUNB@#R3_ (4/\'O^B=>%/_!/9?\
MQFC_ (4/\'O^B=>%/_!/9?\ QFO6Z* /)/\ A0_P>_Z)UX4_\$]E_P#&:/\
MA0_P>_Z)UX4_\$]E_P#&:];HH \D_P"%#_![_HG7A3_P3V7_ ,9H_P"%#_![
M_HG7A3_P3V7_ ,9KUNB@#R3_ (4/\'O^B=>%/_!/9?\ QFC_ (4/\'O^B=>%
M/_!/9?\ QFO6Z* /)/\ A0_P>_Z)UX4_\$]E_P#&:/\ A0_P>_Z)UX4_\$]E
M_P#&:];HH \D_P"%#_![_HG7A3_P3V7_ ,9JI?\ [/?P4U"V^S7OPS\(7$ 8
MMY<FBV14DXY8>5@XQD9Z'\,>S4C=#0!XI+\$O@5HME$+GP'X(TVTA4*C7&FZ
M=;QJO]T-*BY SP,G%9'_  K[]FX]-!^''_?G2/\ "OPZ_P""E?[3'Q#_ .%H
MW?P[TW5[[2_#FF:<&6WT^YDM)9[B>YNHD9IHF$B)&D#'"%79F4^8 I5ORF_X
M6'XM[^(?$>?^Q@U7_P"3:_%L_P#&/"9/F^,RO#Y/6QJP57V%7$2Q4,/&=5*+
MFJ<'3J-QCS6YI-7:=E;4_ECC/Z3V6<+\29GP_@^&<7FJRJLL-B,;/'4L%">(
M4*<ZD:--TJTY0I\_*YRY.:49<J<;2?\ 8]_PKW]F[_H ?#C_ +\Z1_A1_P *
M]_9N_P"@!\./^_.D?X5_'#_PL/Q;_P!##XC_ /"@U7_Y-H_X6'XM_P"AA\1_
M^%!JO_R;7C?\1UC_ -$Y/_PXP\O^H?S_ *UM\O\ \3>4?^B'K_\ AZH^7_4'
MYO[C^Q[_ (5[^S=_T /AQ_WYTC_"C_A7O[-W_0 ^''_?G2/\*_CA_P"%A^+?
M^AA\1_\ A0:K_P#)M'_"P_%O_0P^(_\ PH-5_P#DVC_B.L?^B<G_ .'&'E_U
M#^?]:V/^)O*/_1#U_P#P]4?+_J#\W]Q_8]_PKW]F[_H ?#C_ +\Z1_A1_P *
M]_9N_P"@!\./^_.D?X5_'#_PL/Q;_P!##XC_ /"@U7_Y-H_X6'XM_P"AA\1_
M^%!JO_R;1_Q'6/\ T3D__#C#R_ZA_/\ K6Q_Q-Y1_P"B'K_^'JCY?]0?F_N/
M['O^%>_LW?\ 0 ^''_?G2/\ "C_A7O[-W_0 ^''_ 'YTC_"OXX?^%A^+?^AA
M\1_^%!JO_P FT?\ "P_%O_0P^(__  H-5_\ DVC_ (CK'_HG)_\ AQAY?]0_
MG_6MC_B;RC_T0]?_ ,/5'R_Z@_-_<?V/?\*]_9N_Z 'PX_[\Z1_A1_PKW]F[
M_H ?#C_OSI'^%?QP_P#"P_%O_0P^(_\ PH-5_P#DVC_A8?BW_H8?$?\ X4&J
M_P#R;1_Q'6/_ $3D_P#PXP\O^H?S_K6Q_P 3>4?^B'K_ /AZH^7_ %!^;^X_
ML>_X5[^S=_T /AQ_WYTC_"C_ (5[^S=_T /AQ_WYTC_"OXX?^%A^+?\ H8?$
M?_A0:K_\FT?\+#\6_P#0P^(__"@U7_Y-H_XCK'_HG)_^'&'E_P!0_G_6MC_B
M;RC_ -$/7_\ #U1\O^H/S?W']CW_  KW]F[_ * 'PX_[\Z1_A1_PKW]F[_H
M?#C_ +\Z1_A7\</_  L/Q;_T,/B/_P *#5?_ )-H_P"%A^+?^AA\1_\ A0:K
M_P#)M'_$=8_]$Y/_ ,.,/+_J'\_ZUL?\3>4?^B'K_P#AZH^7_4'YO[C^Q[_A
M7O[-W_0 ^''_ 'YTC_"C_A7O[-W_ $ /AQ_WYTC_  K^.'_A8?BW_H8?$?\
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M6/\ T3D__#C#R_ZA_/\ K6Q_Q-Y1_P"B'K_^'JCY?]0?F_N/['O^%>_LW?\
M0 ^''_?G2/\ "C_A7O[-W_0 ^''_ 'YTC_"OXX?^%A^+?^AA\1_^%!JO_P F
MT?\ "P_%O_0P^(__  H-5_\ DVC_ (CK'_HG)_\ AQAY?]0_G_6MC_B;RC_T
M0]?_ ,/5'R_Z@_-_<?V/?\*]_9N_Z 'PX_[\Z1_A1_PKW]F[_H ?#C_OSI'^
M%?QP_P#"P_%O_0P^(_\ PH-5_P#DVC_A8?BW_H8?$?\ X4&J_P#R;1_Q'6/_
M $3D_P#PXP\O^H?S_K6Q_P 3>4?^B'K_ /AZH^7_ %!^;^X_L>_X5[^S=_T
M/AQ_WYTC_"C_ (5[^S=_T /AQ_WYTC_"OXX?^%A^+?\ H8?$?_A0:K_\FT?\
M+#\6_P#0P^(__"@U7_Y-H_XCK'_HG)_^'&'E_P!0_G_6MC_B;RC_ -$/7_\
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M^#W_ $3KPI_X)[+_ .,T?\*'^#W_ $3KPI_X)[+_ .,UZW10!Y)_PH?X/?\
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M^%#_  >_Z)UX4_\ !/9?_&:];HH \D_X4/\ ![_HG7A3_P $]E_\9H_X4/\
M![_HG7A3_P $]E_\9KUNB@#R3_A0_P 'O^B=>%/_  3V7_QFC_A0_P 'O^B=
M>%/_  3V7_QFO6Z* /)/^%#_  >_Z)UX4_\ !/9?_&:/^%#_  >_Z)UX4_\
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MR?PQ&*]:IC=5^O\ 44 >4_\ "C?@[_T33PE_X);7_P")H_X4;\'?^B:>$O\
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MU"3BFVHNUCS"#X*_!6Y02VWP[\&7$9.!)!I-E*A(ZC<@9<CN,U-_PHWX._\
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M]$Z\*?\ @GLO_C->MT4 >2?\*'^#W_1.O"G_ ()[+_XS1_PH?X/?]$Z\*?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH :_W3^'\Q3J:_W3^'\Q3J "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ J*/J_U'\JEJ*/J_U'\J ):*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBE%*,4HQ2LDE9)=DD%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH ****
M&+U;Z_U-%"]6^O\ 4T4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO!OC-^
MT)X,^!_]E_\ "5VVK7!U9G6V&F6DETP*#)WB-'*C&3DX'O0![S17P=_P\)^"
M_P#T#_%?_@HN?_C%'_#PCX,?] _Q7_X*+G_XQ0!]XT5\'?\ #PCX,?\ 0/\
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MUO\ M_\ P)UFP@>\T3Q+<P3*)%AN=$GE"Y'!&ZW(SMQR/7!Z5G_\-N?LY?\
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M$G_@HO?_ (Q7]+7_  VY^SE_T*6L?^$])_\ (]'_  VY^SE_T*6L?^$])_\
M(]'_ ! K!_\ 10XS_P ),/Y>?K^'F'_$H>4_]%GFW_A!@O\ +^OFS^:7_AG[
MXI_]"7XD_P#!1>__ !BC_AG[XI_]"7XD_P#!1>__ !BOZ6O^&W/V<O\ H4M8
M_P#">D_^1Z/^&W/V<O\ H4M8_P#">D_^1Z/^(%8/_HH<9_X28?R\_7\/,/\
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MS2_\,_?%/_H2_$G_ (*+W_XQ1_PS]\4_^A+\2?\ @HO?_C%?TM?\-N?LY?\
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M#_%?_@HN?_C%'_#PCX,?] _Q7_X*+G_XQ0!]XT5\'?\ #PCX,?\ 0/\ %?\
MX*+G_P",4?\ #PCX,?\ 0/\ %?\ X*+G_P",4 ?>-%?!W_#PCX,?] _Q7_X*
M+G_XQ1_P\(^#'_0/\5_^"BY_^,4 ?>-%?!W_  \(^#'_ $#_ !7_ ."BY_\
MC%'_  \(^#'_ $#_ !7_ ."BY_\ C% 'WC17P=_P\(^#'_0/\5_^"BY_^,4?
M\/"/@Q_T#_%?_@HN?_C% 'WC17P=_P /"/@Q_P! _P 5_P#@HN?_ (Q1_P /
M"/@Q_P! _P 5_P#@HN?_ (Q0!]XT5\'?\/"/@Q_T#_%?_@HN?_C%'_#PCX,?
M] _Q7_X*+G_XQ0!]XT5\'?\ #PCX,?\ 0/\ %?\ X*+G_P",4?\ #PCX,?\
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M\(^#'_0/\5_^"BY_^,4?\/"/@Q_T#_%?_@HN?_C% 'WC17P=_P /"/@Q_P!
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M[QJ.3M^/]*^$O^'A'P8_Z!_BO_P47/\ \8K,U;_@HS\$]+MDN9=+\6NKOY8
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M[OW?[+?E1N_V6_*OA#_AX1\&/^@?XK_\%%S_ /&*/^'A'P8_Z!_BO_P47/\
M\8H ^[]W^RWY4;O]EORKX0_X>$?!C_H'^*__  47/_QBC_AX1\&/^@?XK_\
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M8+'58A/;QW,92<(>?G4@8/S>@/'('<H [JBBB@ HHHH **** "BBB@ HHHH
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M%?\ "M_ /_0G>'/_  4V?_QJC_A6_@'_ *$[PY_X*;/_ .-5VM% '%?\*W\
M_P#0G>'/_!39_P#QJC_A6_@'_H3O#G_@IL__ (U7:T4 <5_PK?P#_P!"=X<_
M\%-G_P#&J/\ A6_@'_H3O#G_ (*;/_XU7:T4 <5_PK?P#_T)WAS_ ,%-G_\
M&J/^%;^ ?^A.\.?^"FS_ /C5=K10!Q7_  K?P#_T)WAS_P %-G_\:H_X5OX!
M_P"A.\.?^"FS_P#C5=K10!Q7_"M_ /\ T)WAS_P4V?\ \:H_X5OX!_Z$[PY_
MX*;/_P"-5VM% '%?\*W\ _\ 0G>'/_!39_\ QJC_ (5OX!_Z$[PY_P""FS_^
M-5VM% '%?\*W\ _]"=X<_P#!39__ !JH;GX9?#NYA\FX\$^&9H@<B.31[)ER
M3UP8>3]:[NFM]T_A_.@#AQ\.?AW;01I_PA_AB"",813I5C&B@\X&8@/H.W0
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M_B.>5?\ 0AS/_P '83R_Z>>?]75S_B;?AK_HD\^Z?\O\O_N_]/\ S?X=]?[
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M'^&7_0M^$?\ P!TW_P")K^/_ /X:R^,G_0Z>)/\ P.:C_AK+XR?]#IXD_P#
MYJ/^(YY5_P!"',__  =A/+_IYY_U=7/^)M^&O^B3S[I_R_R_^[_T_P#-_AWU
M_L _X0?X9?\ 0M^$?_ '3?\ XFC_ (0?X9?]"WX1_P# '3?_ (FOX_\ _AK+
MXR?]#IXD_P# YJ/^&LOC)_T.GB3_ ,#FH_XCGE7_ $(<S_\ !V$\O^GGG_5U
M<_XFWX:_Z)//NG_+_+_[O_3_ ,W^'?7^P#_A!_AE_P!"WX1_\ =-_P#B:/\
MA!_AE_T+?A'_ , =-_\ B:_C_P#^&LOC)_T.GB3_ ,#FH_X:R^,G_0Z>)/\
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M_AWU_L _X0?X9?\ 0M^$?_ '3?\ XFC_ (0?X9?]"WX1_P# '3?_ (FOX_\
M_AK+XR?]#IXD_P# YJ/^&LOC)_T.GB3_ ,#FH_XCGE7_ $(<S_\ !V$\O^GG
MG_5U<_XFWX:_Z)//NG_+_+_[O_3_ ,W^'?7^P#_A!_AE_P!"WX1_\ =-_P#B
M:/\ A!_AE_T+?A'_ , =-_\ B:_C_P#^&LOC)_T.GB3_ ,#FH_X:R^,G_0Z>
M)/\ P.:C_B.>5?\ 0AS/_P '83R_Z>>?]75S_B;?AK_HD\^Z?\O\O_N_]/\
MS?X=]?[ /^$'^&7_ $+?A'_P!TW_ .)H_P"$'^&7_0M^$?\ P!TW_P")K^/_
M /X:R^,G_0Z>)/\ P.:C_AK+XR?]#IXD_P# YJ/^(YY5_P!"',__  =A/+_I
MYY_U=7/^)M^&O^B3S[I_R_R_^[_T_P#-_AWU_L _X0?X9?\ 0M^$?_ '3?\
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M.\.9)R?^)39]_P#ME78C[Y^G^%/H XK_ (5OX!_Z$[PY_P""FS_^-4?\*W\
M_P#0G>'/_!39_P#QJNUHH XK_A6_@'_H3O#G_@IL_P#XU1_PK?P#_P!"=X<_
M\%-G_P#&J[6B@#BO^%;^ ?\ H3O#G_@IL_\ XU1_PK?P#_T)WAS_ ,%-G_\
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M  K?P#_T)WAS_P %-G_\:KM:* .*_P"%;^ ?^A.\.?\ @IL__C5'_"M_ /\
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M.?\ @IL__C5=K10!Q7_"M_ /_0G>'/\ P4V?_P :H_X5OX!_Z$[PY_X*;/\
M^-5VM% '%?\ "M_ /_0G>'/_  4V?_QJC_A6_@'_ *$[PY_X*;/_ .-5VM%
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MS_P4V?\ \:H_X5OX!_Z$[PY_X*;/_P"-5VM% '%?\*W\ _\ 0G>'/_!39_\
MQJC_ (5OX!_Z$[PY_P""FS_^-5VM% '%?\*W\ _]"=X<_P#!39__ !JC_A6_
M@'_H3O#G_@IL_P#XU7:T4 <5_P *W\ _]"=X<_\ !39__&J/^%;^ ?\ H3O#
MG_@IL_\ XU7:T4 <5_PK?P#_ -"=X<_\%-G_ /&J/^%;^ ?^A.\.?^"FS_\
MC5=K10!Q7_"M_ /_ $)WAS_P4V?_ ,:H_P"%;^ ?^A.\.?\ @IL__C5=K10!
MQ7_"M_ /_0G>'/\ P4V?_P :H_X5OX!_Z$[PY_X*;/\ ^-5VM% '%?\ "M_
M/_0G>'/_  4V?_QJC_A6_@'_ *$[PY_X*;/_ .-5VM% '%?\*W\ _P#0G>'/
M_!39_P#QJC_A6_@'_H3O#G_@IL__ (U7:T4 <5_PK?P#_P!"=X<_\%-G_P#&
MJ/\ A6_@'_H3O#G_ (*;/_XU7:T4 <5_PK?P#_T)WAS_ ,%-G_\ &J/^%;^
M?^A.\.?^"FS_ /C5=K10!Q7_  K?P#_T)WAS_P %-G_\:H_X5OX!_P"A.\.?
M^"FS_P#C5=K10!Q7_"M_ /\ T)WAS_P4V?\ \:H_X5OX!_Z$[PY_X*;/_P"-
M5VM% '%?\*W\ _\ 0G>'/_!39_\ QJC_ (5OX!_Z$[PY_P""FS_^-5VM% '%
M?\*W\ _]"=X<_P#!39__ !JJUW\,/AU=1K%<^"?#,Z*25231[)E!.,G!BQGW
MP?2N^J.3M^/]* .-7X;> $1(T\&^'%1!A%&DV>%'H/W7_P"KI2_\*W\ _P#0
MG>'/_!39_P#QJNUHH XK_A6_@'_H3O#G_@IL_P#XU1_PK?P#_P!"=X<_\%-G
M_P#&J[6B@#BO^%;^ ?\ H3O#G_@IL_\ XU1_PK?P#_T)WAS_ ,%-G_\ &J[6
MB@#BO^%;^ ?^A.\.?^"FS_\ C5'_  K?P#_T)WAS_P %-G_\:KM:* .*_P"%
M;^ ?^A.\.?\ @IL__C5'_"M_ /\ T)WAS_P4V?\ \:KL@,C.YN?0TNW_ &F_
M/_ZU '&?\*W\ _\ 0G>'/_!39_\ QJC_ (5OX!_Z$[PY_P""FS_^-5V>W_:;
M\_\ ZU&W_:;\_P#ZU '&?\*W\ _]"=X<_P#!39__ !JC_A6_@'_H3O#G_@IL
M_P#XU79[?]IOS_\ K4;?]IOS_P#K4 <9_P *W\ _]"=X<_\ !39__&J/^%;^
M ?\ H3O#G_@IL_\ XU79[?\ :;\__K4;?]IOS_\ K4 <9_PK?P#_ -"=X<_\
M%-G_ /&J/^%;^ ?^A.\.?^"FS_\ C5=GM_VF_/\ ^M1M_P!IOS_^M0!QG_"M
M_ /_ $)WAS_P4V?_ ,:H_P"%;^ ?^A.\.?\ @IL__C5>&_';XP_$[X17,.K:
M%\,[SQUX3*?Z?<:?=8O;-AR6CMT!=P!V(.>M?,X_X*J? +1V%MXZT7Q[X0O4
M.RY2[T&>2&&0'#@2,8@0ISSG! SFOM,N\/N+<YP%/,LERJ><X6HKR_LROA\7
MB*#O9PQ&$I57B:$[]*E)7T:NF?F68^+_  #DF<U\@XASF7#F94:SI4X9[@L9
ME^&QB23C6P..JT?J6+HSB[QG2KMK6,U&6A^A7_"M_ /_ $)WAS_P4V?_ ,:H
M_P"%;^ ?^A.\.?\ @IL__C5? <W_  5K_8JM8?/N_'VM6Z8R?,T&0$<9/_+S
MVKZJ^ /[4'P9_::T>^USX/\ BA_$>GZ:ZQWKM;FV>!V("JZ%Y"I)/0D&O,S+
MA/B?)J$L3FN09MEV'A-4Y5\9@<10I1FVDHRJ5(**;;22;U>B/K\KXIX<SMQ6
M49WEF9.:YH1P>,HUY25N:ZC"3;]W7;;79'J7_"M_ /\ T)WAS_P4V?\ \:H_
MX5OX!_Z$[PY_X*;/_P"-5V>W_:;\_P#ZU"YY[X)%?/'O'&?\*W\ _P#0G>'/
M_!39_P#QJC_A6_@'_H3O#G_@IL__ (U7:T4 <5_PK?P#_P!"=X<_\%-G_P#&
MJ/\ A6_@'_H3O#G_ (*;/_XU7:T4 <5_PK?P#_T)WAS_ ,%-G_\ &J/^%;^
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MA^6*W@B2.*,>BHH"CH.W:BKB]6^O]310 ^BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "J6HZC8Z397&HZE=0V5C:QF6YNKAQ'##&O5Y'/"J.Y[5=K$\2>'
M]-\5:'J?A[6(C/INK6DMG>1 [2\,RE7 ;L<'@T ?B=\3O%WA3Q;_ ,%7/@#/
MX2U_2O$RP> _$PO'T:=+W^SSLTWFZDBW+$&;*+EEW$'&:^)C^R#X8_:+_;2_
M:^^-W@@6VE?M*? 7Q)HLW@OQ-8KY&J36.FV#:K%X;N[J+RYKC2[^:[F$]A)(
M]NS2";9YBJP_<C]G[_@G[^SO^S=X\\4?$GX?Z!>MXN\5S2S7NJZS?3:G/:B8
M!7AT][EY&M(-H $,!2('YMF2:]?^&O[-GPQ^%/Q ^(7Q,\(Z9):>*?B=?1ZA
MXMO&DW"_N88A#$[+ZI$%09_A4"@#^<S_ ()A_MI77[8/_!1SXN1^/_"][X ^
M-'P"\#:7X&^*WA?5;=H9[.[N[K4+C3]1CG">3=Z?JEE8?VC87$4K[K6>,S+#
M*6C7[A_X*'>+?"/C']IG]C+3_"GB?1M>U>Q^)EVUWINF7,=Y>VRV=A/]H,L<
M6XQ"/*[RVW!(&<D"OTJ\-?L<? GPA\</&/[0?AOPE:Z3\2/'VE1:/XKU6SCC
MA_M>SM_/^SK="-%:5H/M,WDERVSS&"_>-><^!O\ @G7^S=X!^.FI_M"Z3X?U
M"[^(&HW$UTLVJ:A-?6&GW%QL,\FG64S/#9M,8T,I@2,R;1O+4 >3?M!>,/@;
M^U!H?Q4_9GT[XU3_  7^*GAKP[:2:YJMC+8:=XA@M+NT<0O!)?(_FVDGDRH9
M KCAQM)4X\B_X(R^.Y+GX5_$WX-)IXO[+X(?$#4O MM\1(55K?XB#3MN[Q']
MHCCCCGGN7D9+QX\I]M2X"_*!GZV_:*_X)V?LV_M+>*+'QMXV\/7^D^+;2/R)
M_$/A/4)]!U74K,YW66HW=B\,UU:."0\$KM&>NW-?2WP=^"WP[^!'@VP\"_#7
MP]9Z!H5@BJ([:)%EN9 /FN+J10#-.Y^9Y&RS,2Q.30!ZM1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2'H?H?Y4M(>A^A_E0!_)?\ \%)@
M!^T9KN!C_0;7_P!+=3%?GQ7Z$?\ !2;_ ).,UW_KQM?_ $NU2OSWK^&>+O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 U_NG\/YBG4U_NG\/YBG4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !44?5_J/Y5+44?5_J/Y
M4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1R=OQ_I4E1R=OQ_
MI0!)1110 4444 %%%% !1110!P?Q"^)?@?X3^%[CQA\0O$.G^&/#=I+'#<:K
MJ4RP6T<LQ81(SL0 7VG'/:N8\2_'7X>>&?!V@^/;C5UO/"_B:!+G1-3L0)H+
M^"10R2PMD!D96!!SCFORM_X+YZMH]G^P!XITR_U)[._UGQ5H%OI-I;,WV_4;
MA7N-T%K%&?.<YD0-L5@"ZYKYG\=>(OVIM#_9Y_8%\#> _AO_ &[\#=0\#>&5
M^*.O7=E)-K.AH4B,VUS&TT4@B=S\V.@!ZBOT3)N"Z&99)D^;3QBI5,QSG-,!
M4HXBK2PM!87+<!3Q;J4*]3^)B*DINE"E;WYVA%\S/F,=GE?#8_,<'"AS1PF
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M44\/?M0>-] U+XA_!CQ7X*ATV31HQ)=67@K7KFU02QBV4$1_9Y7=5( P$ [
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M3J3UNY59N<F[);O9:;)(=1117E&P4444 %%%% !1110 4444 %%%% !1110
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MDRS#X/-L4L8L/CL-BI8BA5G3IPJTW.C)PG3YH.4)64E&7*TW&\OX]_[-OO\
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M_P#$T?\ $#L__P"AQE?_ (+Q7^7K_2U/^)2.+?\ HJLA_P#"3'>7GZ_TE?\
MCW_LV^_Y]9O^_;__ !-']FWW_/K-_P!^W_\ B:_L(_X85_9>_P"B6^'_ /P"
M@_\ B:/^&%?V7O\ HEOA_P#\ H/_ (FC_B!V?_\ 0XRO_P %XK_+U_I:G_$I
M'%O_ $560_\ A)CO+S]?Z2O_ ![_ -FWW_/K-_W[?_XFC^S;[_GUF_[]O_\
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M_P"&%?V7O^B6^'__  "@_P#B:/\ B!V?_P#0XRO_ ,%XK_+U_I:G_$I'%O\
MT560_P#A)CO+S]?Z2O\ Q[_V;??\^LW_ '[?_P")H_LV^_Y]9O\ OV__ ,37
M]A'_  PK^R]_T2WP_P#^ 4'_ ,31_P ,*_LO?]$M\/\ _@%!_P#$T?\ $#L_
M_P"AQE?_ (+Q7^7K_2U/^)2.+?\ HJLA_P#"3'>7GZ_TE?\ CW_LV^_Y]9O^
M_;__ !-']FWW_/K-_P!^W_\ B:_L(_X85_9>_P"B6^'_ /P"@_\ B:/^&%?V
M7O\ HEOA_P#\ H/_ (FC_B!V?_\ 0XRO_P %XK_+U_I:G_$I'%O_ $560_\
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M&@!]%,WCW_S^-&\>_P#G\: 'T4S>/?\ S^-&\>_^?QH ?13-X]_\_C1O'O\
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M3-X]_P#/XT;Q[_Y_&@!]%,WCW_S^-&\>_P#G\: 'T4S>/?\ S^-&\>_^?QH
M?13-X]_\_C1O'O\ Y_&@!]%,WCW_ ,_C1O'O_G\: 'T4S>/?_/XT;Q[_ .?Q
MH ?13-X]_P#/XT;Q[_Y_&@!]%,WCW_S^-&\>_P#G\: 'T4S>/?\ S^-&\>_^
M?QH ?13-X]_\_C1O'O\ Y_&@!]%,WCW_ ,_C1O'O_G\: 'T4S>/?_/XT;Q[_
M .?QH ?13-X]_P#/XT;Q[_Y_&@!]%,WCW_S^-&\>_P#G\: 'T4S>/?\ S^-&
M\>_^?QH ?13-X]_\_C1O'O\ Y_&@!]%,WCW_ ,_C1O'O_G\: 'T4S>/?_/XT
M;Q[_ .?QH ?13-X]_P#/XT;Q[_Y_&@!]11]7^H_E3MX]_P#/XTQ&P6R.ISQ^
M&._3K[T 344S>/>C>/?_ #^- #Z*9O'O_G\:-X]_\_C0 ^BF;Q[_ .?QHWCW
M_P _C0 ^BF;Q[_Y_&C>/?_/XT /HIF\>_P#G\:-X]_\ /XT /HIF\>_^?QHW
MCW_S^- #Z*9O'O\ Y_&C>/?_ #^- #Z*9O'O_G\:-X]_\_C0 ^BF;Q[_ .?Q
MHWCW_P _C0 ^BF;Q[_Y_&C>/?_/XT /HIF\>_P#G\:-X]_\ /XT /HIF\>_^
M?QHWCW_S^- #Z*9O'O\ Y_&C>/?_ #^- #Z*9O'O_G\:-X]_\_C0 ^BF;Q[_
M .?QHWCW_P _C0 ^BF;Q[_Y_&C>/?_/XT /HIF\>_P#G\:-X]_\ /XT /HIF
M\>_^?QHWCW_S^- #Z*9O'O\ Y_&C>/?_ #^- #ZCD[?C_2EWCW_S^--8@X]1
M_44 2T4S>/>C>/?_ #^- #Z*9O'O_G\:-X]_\_C0 ^BF;Q[_ .?QHWCW_P _
MC0 ^BF;Q[_Y_&C>/?_/XT ?.GQL_98^#_P"T/J_@S5OBOH,GB6+P/=G4-&TF
MXN"-*:]$GFQ7%W9E6CN&C;IN7D #(Q7OEOHVDVFF6VC6^FV,6DVD$5K;::MM
M";*&WA4)%#';E#$$10 HV_J35W*>A_S^-&4]#_G\:Z:F,Q=6CA\-4Q%:>'PG
M/]6HRJ2=*A[27/4=*%^6#G+64DDY-*[T1E&A1A4JU84H1J5FG5FHKFJ<J48\
MSW=DDDGH5[33M/L 5L;"RLE;AA:6L%L&^HAC0'\:LK%$F[9%&F[[VU%7=_O8
M S^-)E/0_P"?QHRGH?\ /XUSMMW;;;>]VW?U-+);)+Y$<MG9SQ/!-:6TT,G+
MPRP121/_ +\;H4;\0:99Z=I^GQ-#86%G8PN<O%9VL%M$YP1EHX416."1D@\$
MU/E/0_Y_&C*>A_S^-'-*UKNS=VKNS?>W<++>RNM%H4[;1])LYVNK/2].M;E\
MA[BVL;:"=PWW@TT42R-N[Y8Y[U9NK2UOH3;WMK;W<#$%H+J".XA8CH3'*KH2
M,G!*\4_*>A_S^-&4]#_G\:?-)M-RDVK6=W=6VL_+H%E:UE;M;3[MBK9Z5I>G
M[OL&FV%CO&'^QV=O;;QZ-Y,:;A['-6UBB0%4BC13G*JBJ#GKD  '/?-)E/0_
MY_&C*>A_S^-)RD]6VV][MN]@22V27HK#DCCC&V.-(UZX154?DH K\YOVN/'O
M[6OB:UU3X6?LS>!)K+4M4CDL+SXBZ@7@MM(@N%,,LT!D79N5&8AE.<CJ>E?H
MO\GH?\_C3%2!"2D:J3U*J%)^I'7\:]SA[.*&19C3S*ME& SFIA[3PV&S15:F
M"AB(M.%:OAZ<Z?UF,&KJC4E[*3^-2C=/Y?BWA['<39='*L+Q#F7#N'K5&LQQ
M&41H0S#$X-QY9X3#XNM"H\#[2[4L11@ZRC=0E!OF/P<_8W_X(D?#OX7>.A\=
M_P!I'6C\9/C#>WK:T[ZH/M&GZ=J<TBSLQ$P=9O+E&Y ,A<!05QQ^\MO;P6L$
M-M;0QV]O;QI#!!"BQQ111J%2..- %1$4 *J@  8%+E/0_P"?QHRGH?\ /XUV
M<6<9\1\;YE_:G$>95<?B(05'#T[1I83!8>/P8;!86FHT<-0@K)0IP5TES.3U
M'PGP;P_P3ED,JX?P*PM!6E6JSG*MB\542LZN*Q-1RJUJCWU?+&[Y8Q1+35_B
M_P!XTS*>A_S^-.#*!QG_ #^-?+'U ^BF;Q[_ .?QHWCW_P _C0 ^BF;Q[_Y_
M&C>/?_/XT /HIF\>_P#G\:-X]_\ /XT /HIF\>_^?QHWCW_S^- #Z*9O'O\
MY_&C>/?_ #^- #Z*9O'O_G\:-X]_\_C0 ^BF;Q[_ .?QHWCW_P _C0 ^BF;Q
M[_Y_&C>/?_/XT "]6^O]310O5CZG_']?\:* 'T444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gfmvgbft1fv3000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfmvgbft1fv3000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'E M4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=HQDX)Z<CKZU63QM:"^:RNK"^MK@$@*T8()'7D''<?G6D8NDW-:&%J*5N_\
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M0 4444 %%%% !129 (!(R>@]:6@ HHHH **** "BBB@ HHHH **** "BBB@
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MWX9R*W],UBTU5&\ARLJ??A<8=?J/ZBNRUCG::+]%%% @HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *9+$LJX8?0]Q3ZR[OQ#I5DY22[1I!U2
M(%R/RZ47L%KEJ[O8=-LFN+N0!$&"0.6/8 >IKGAJ^MZJ_P#H,*6D/8LN]S]>
MP_6L[6=8AU?4K1(UE6WB4L!(NW<_K^ _F:Z"PO(5MUC0A>*Y:M;WN5.QT4Z:
MY.;<I&'Q- "XU 2?[+Q)C] *L:?XD<W2V>J0K!,YVI*I^1SZ<]#6@9QC)>N;
M\0>3/$_3IUK/V[B[WNBU24]+6.UHKB+76=>6WAD,\,OR E9(NO'J#6WIGB2&
M[E6VNX_LMTW"JQRCG_9;^AKOLSE<6C<JLE['+J$MI&K,T2!I''W5)Z+]<<_3
M'J*AU*]DMUCM[8![VX)6%3T'J[?[*]?R'>IK&RCL+584)<Y+/(WWI&/)8^Y-
M(19HHHH **** "BBB@ HHIDDT<7WW ]J 'U!>WD-A:275PVV.,9/J?8>YJ96
M#J&4Y!&17*^,IF,EA;9.QB\I'J5P!_Z%2D[*X7TN95YJ5_K<I5V:* GY;=&Q
MQ_M'N?;I5BVT(+'SA0/[HP!51]0MM$LEN)0))Y/]5#G&[W/H!3;-M4U?[29A
M(D\,4<R(T>U75R<!,\#@'WZ4X8>4J?M:CLOS]$<CKJ57V4=9;^27F^A:GT"?
M=YMLVY@.JG-0":]LGQ,AX[BH-?\ !YF%Y=:?=7T5RTT*VHM[ACM4[0Y9?0?,
M:SI;WQ1X=%PEPT6NZ=;W MC(R[9"YQA1W)Y [\TIX.E/X9Z^>GXG1#$5J26F
MC;5M_P -]3H9-4W1!MU58H9;RX1Y%(13D ]2:KZ7KFA7USLE9[&YS_J;H;<'
MV-=:8[>WC$CS0QQGHY<8-9T\%*G*]3?H=*QE.I"\'ZC$MU9 NP$XK,U'39+:
M1+JW9H9DY20=1[>X]JLW&L6XVP6S;C(PC!!P78]!G^$'U/X47"?9;5H7??*[
M;I""< ^@]A76X-+WON,85E.5HZHV]&U(:IIRSE0DRDI*@_A8=?P[_C6A7*^$
MF(O=20?<Q&WXG</Z"NI9E7[Q ^M8C>C%HHZ]**!!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 445G76LVUO%.ZGS#;S)%,HX*;L<G/L0:3:6X+5V-&F22)#$\LC!
M8T!9F/0 5D7/B."T.I--$QCLFB7,9!,ADQC ^IJ/Q),+K3;BRMI TP>,3(O5
M5)SS]<4Y)QW!.ZYNFJ^[<P;_ %>\UV8Q1%XK,G"1*<,X]6/]*!9Z=IN([F0&
M8#)ACP-H_P!H]J6TBN([:86IBCNR,(TO1??Z^E1Z5X;:TN+>]NK[?=1W!DD1
M1O25<$8.>^2#GMBBC"E*+J57Z(Y*LZKFH06^[>R_S96U&\MH8X'BT:^NDF#-
M&;8;B0O4@=>,U1TWQ5HU_)Y4-Z]M,#CRKI=AS]>E=Q;Q0PM (X5#1F0P[CEE
MW<MMK%OO".FSV-O!):BYBM+618XG.V260\@EQCW_ !--K#S24H?<S=.M33]G
M*[NK)[6ZW)'GG2#<>1V8'(/XUGF*>^<!U98R><]36;:^%M8T)573M8(:&T%Q
M<QW(S"&YRH/.>A_*MNTUG6O(B6XT2V>YEM?M2-'/M4H,9)'4'D<5$,#3OSQE
M=>>GYFTL<X/V<XV?EJGZ>IM6MNJ6^9-JHHRS-P *HW4-I?,\*P-A4WL^?N^G
MT)[50@AU?7WL9[J]2"RN8#<0K;QY5>!C=GOSWSTK44&RTN&W?R_.VYF:,DAW
M[G)Y.:Z6H15KW?X(QC.M.=G'E7GN_P#+\Q?"<\DEQ=I?/YM^@ 60]X?X0/H>
MOJ374UQ6B$_\)1#M[PR!OIQ_7%=K6+5F:R5F%%%%(0444C.J+N8@#WH 6H9K
MJ* ?.W/H.M9]UJA.5AX']ZJ<4$UT_ )]S6BI]692J](EF?5)'XC^5:JK%/<-
MP&8UJ6^F1QX,GS-Z5>50HPH 'H*?.E\)*IREK(AM$DC@"2=1TK%\6V,D]E#>
M0J6:U8EE Y*'KCZ8!_"NAHK*7O;FR5E8\\@O8S&HDAAF7'RET#<5HC5I)1AF
MX]*O:EX3BFD:;3Y1;2,<M&1F-C]/X?P_*L&?2-6M#^\L9' _C@.\?EU_2L&I
MK3=$<K6QJ)>#.=Q!J9KBWF:![B-9#;R^='G^%\$;O<X)KF6N6B_U@DC_ .ND
M;+_,4@U&,G F4GT!S4\S0)R6QJ7MEIUZD"3Q0S8N_M$\DR#>Z\G:#Z9P/H*@
MAT/2WC$L0AC*WPFC'S,/)!&8\9XSS4=O::AJ#8MK25\_QNI1!^)_I5W_ (1W
M6;)=B117*Y+;HY-IR>O#8KII5:EN6[201I0E4]I-*_F73+9V\=Q%%$K133";
MRV4;488QC\0#6;>WH(:1VP.]3)HNM3''V1(L_P 4LPP/RS6SIGAB*UF6YO91
M<SKR@VX1#Z@=S[FKNEL=%TB3PSI\EEI[33J5GN6\QE/51C"C\OYUM%0RD, 0
M>H-+14&;U,ZYM)(QYENQ&.2H-4UU&YC.&8GV-;M4;VP$P+QC#CMZUI&2>DC*
M<&M8E1=6E'55/X5<M+U[I\;  .IK$92K;2,$5+#/+:OE<CV]:T<%;0RC4:>I
MT=%5+:^CN.#\K^GK5NL&FMSI335T%%%%(84444 %%%% !1110 4444 %%%%
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M+1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2YGH<[KTY2Y8.[\CJJ*9#*L\$<R?=D4,/H:?6)84444 %%%% !1110 4444
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M%6JKEY="XRTT,2W\*:9"X>59;IAT\]\C\A@?I6T %4*H  & !VI:* N%%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[0@'.Q<"L.!/.NE7KD]_2IANV74V43>MUV6\:]]O-2445B;K0**** "BBB@
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M-!@-OH5FK??:,2/_ +S?,?U-.O;V2WDV*H^M.G25MM2ZV(DKQ3T\B\ %
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MH+J_><[4RJ^@[TZST]IB'DX3^=:J*CK(PE-RTB16EF]R^3PO<FMV.-8D"(,
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MBBB@!&564JP!!Z@BJ$VA:5<-NDT^V+>HC /Z5H44 9/_  C&C9S]A3_OIO\
M&K=KIEC9<VMI#$?5$ /YU;HH **** "BBB@ HHHH ***1F"J68@ =2: %K/O
M;\1 QQ'+=SZ5#>:CG,</3N:K6MF]R^3PO<FM8PMK(QE-O2(VWMY+J7V[FMZ*
M)88PB#@?K1%$D*!$&!3ZF4[EPARA1114%A1110 4444 %%%% !1110 4444
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M[N$O:1[KC<A<QR8&-ORD#: >>IQ7H]SI]G>6RVUQ;120(R.L;+\H*D%2![$
MCZ5%-H^G7 OA-90O]O01W6Y<^<H! #>HP2* /*?$S3SW'C=_[-M);&5;/[7=
M2'=+:HT*YD1,?,5!W#YAR*OS1SZ3XVUWQ%8&2?\ LTVD=X@.3/:-"-Y]V7 <
M?1AWKT@Z1IQ2\4V4)6]0)<@H,2J%V@-ZC;Q]*=;:996;S/;VL4;3*BR%5^^%
M7:H/K@<4 >3P7,=[X"\,:%':S:A;ZC>7%Q<0VH5C);1S.YX) P6,8Z]Z[?X<
MW\UUX2BL[I9$O-,E>QF24 ./+/R[L9Y*%#^-;ECH6E:8T+6.GV]N88C!%Y:
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MIII?#S<+V%:RJJ*%48 [4M%3*39T1BH[!1114E!1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gfmvgbft1fv3000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfmvgbft1fv3000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )0 \\# 2(  A$! Q$!_\0
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MRI:* $VK_='Y4;5_NC\J6B@!-J_W1^5&U?[H_*EHH 3:O]T?E1M7^Z/RI:*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2)T*@LRX0[2,>O.:Y3P(-1\,?!^VM=4\':CJ4<UW,EW8"W_>K$<D-Y3C+#(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 45FS:_I-OK<.C2WT2:C.F^. GDC^0)P< \G!QG!K2
MIN+6X!1167>:_:6.N:?I,JRF>^W;'5040A2P#G/&X*V..2I'IE :E%9<WB70
M;=YDGUO38F@.)5>Z13&>?O9/'W6Z_P!T^E2RZYI$%]#8RZI8QWD\?FPV[W""
M21.?F5<Y(X/(]#Z4 7Z*J#4]/*[A?6Q7REGSYRX\MLA7Z_=.#@]#BJFG>)-*
MU.^GL(+R$7T,DB-:O*OFX1RA?8#G;D<&@#6HK('BKPZVFMJ(U_2S8K+Y)N1>
M1^4),9V[LXW8YQG--UCQ5HNAZ;]MN[^WVO T\$2S)ON55=Q\H$C?QCIZB@#9
MHK-UG5QH]O!)]BN;R2>=8(H;;8'9B">KLJ@8!ZFLZS\;Z)<SPP3W L)I5PJ7
MLB1DR>:\1B'S<N'C<$#(XX)H Z.BLZ/7]&EN;NVCU:P>XLU9KF);E"T '4N,
MY4#OFHQXGT M$HUS3"9I!%&!=Q_.Y)4*.>3E2,>H/I0!JT5E'Q-H TP:F=<T
MT:>S^6+HW<?E%O[N_.,^V:EGUW1[5K-;C5;&%KW'V027"*;C.,;,GYOO#IGJ
M/6@#0HK/AUW1[B2ZCAU6QD>TD$5RJ7"$PN6*A7 /RDL" #W&*BU/Q/H6C*K:
MEJ]E:J9Q;YEF4 2;0VT^AP0>>@(/>@#5HK*F\1Z39VC76HW]II\(N'MP]U<Q
M(K.I(P#N(S\I."<CN <BFS>)]%CCU'RM2M;J?3X7FN;:WG1Y45!DY7.0>W..
M: ->BJ,.LZ;-?)8+?6WVYHA-]D,R^<$/\6S.<>]%YJUK87EO;7+%/.CED\UB
M B+& 6+$GC@T 7J*H0ZYI%Q:75W!JEC+;6A87,R7",D)498.0<+@=<]*FL=0
MLM4M$N]/N[>[MGSLFMY!(C8.#A@<'D$4 6:*** "BBB@ HHHH **** "BBB@
M HKEK7XA^&[PVODW-Z4NWCC@E?3+E(W,C!4^=HPH!+  DXYKJ: "BBN<L_&F
MF7HN_+BNE:UU+^S71T )<RF(..>4+!N>ORGC(Q0!T=%9"^([ ZY>Z2?-6:TA
M\Z20K\A "E@,')*AXR>/XUZ]J0\81_V#_:S:-JB1N]NMO$PAWW G=4C*$2;!
MDL,AF4CN!D9 .DHKGO\ A+K5-+O[NXL;ZWN+%UCFL9$0S[W($87:Q1MY8 $,
M1DX)!!Q+<^)[9(M/-C:7>I3:A#]H@@M FXQ84F0F1E4+\RCELDL, \X -RBL
M7_A)K+_A%;KQ!Y=P+>T@FEG@* 31F(-YD9&<;P5(ZXR.#CFFVGB:.X6<3Z==
MV5Q!<Q6TD%T\(8&3;M;<LA0@[N@8MQ@*20" ;E%8][XK\/Z>+[[5K5A&]A'Y
MMU'YZF2%>.60'<.2 !CDD <D5*GB+1)#9!-8T]FOAFT N4S<=OD&?F_"@#3H
MK&OO%.C6,&IM]OM[B?38&GN;6WF1YD51DY3.1^..M2?\)-H'V%K[^W--^R+(
M8FG^UQ^6' R5+9QD#G% &K16?=Z]H]A:6]W>:M8VUM<X\B::Y1$ER,C:Q.&R
M.>*B;Q'I<*:A)>745E!87(MIIKN18TWE$<88G&,2 <XYS0!JT5ES^)-"M9+6
M.XUK3HI+M%>V62Z13,K?=* GY@>Q'6KD-_9W'D^3=P2>>C20[) ?,48!9<=0
M-PR1ZCUH L4444 %%%% !1110 4444 %%%% !169_P )#H_]J?V;_:5M]MW^
M7Y/F#.[&=O\ O8YQUK3HN%PHHKG+;QKIER;U4BNE>SU%-.D1D4$L\OE*XYYC
M+[AGK\K<<4 ='162OB*Q;Q!<Z-B43V\!G>0J-A VEE!SG<HDC)&.DB]:HIXQ
MB?0&U@Z1J:P-Y!MT98MURLS!8V0^9M&2PX8J1W XH Z2BN?7Q9;#3[^>>POK
M>ZL61);"1$,Q9\",+M8HV\D $-C/!((.'S>*;7[-ILEC:7>HS:E!]IMK>U"!
MVBPI+DNRJJC>@Y;JP S0!NT5E6OB&PN-!EUB1GM;:!9#<K<+M>W,9(=7 SRI
M!Z9!Z@D$&F67B!)K>XN+_3[S2(8(Q*9-1\M$*'/S;E=@N,<AB".XH V**RG\
M3^'X[*"]?7-,6TGW>3.;N,))M8*VULX.&(!QT)Q4J:[I$EO<7":K8M#;2^3/
M(MPA6*3(&QCG"MD@8//(H T**SO^$@T4:2-6_M>P_LTG O/M*>3G.W&_.WKQ
MUZTHUW2&N+2W35+)KB\B\ZUA6X3?<)C(9!GYA@$Y'% &A16+8^+=#OKN"R34
MK5+^:U2[%J9T9Q&R[@<JQ5N.?E)&.<X()OZ=JFGZO;?:=,O[6]M]Q7S;:99%
MR.HRI(SS0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#C?&'PTT;QMJ$%[J5SJ$4L$7E*+:554C)/1E///45SG_"@?"O_ $$-9_[_
M $7_ ,;KU6BO1HYMC:,%3IU&DNA#IQ;NT>6CX/1V]N^B6NHG_A'[EO-N#+&A
MNPX[(P7;@\<D97&!G/RL_P"% ^%?^@AK/_?Z+_XW7JM%$,WQM-MPJ-7W\Q>R
MAV/.-'^"OAO1=9L]3MKW5FGM)5E19)DVD@Y&<(#CVS6IK'A'5=2O]2U.+5F@
MNC+ UE;IY?E,L&'C$K&(N/WAD)V'&U\8/.>SHKGQ.,KXJ2E7DY-=RXQ4=CEH
M_#$Z_9MWV8^7K<NI/U^96\S;V^\-Z_EUX%0W_AO4[G6;P(+%M.O=0M;^2X>1
MA/ 81%\B)M(8$PC#;ACS&X..>OHKF&<!:>!=1@N;,/=6QM8+GRRJ,P(LHWCD
M@C'')#1 $$XVNWKBI]1\#W5]I\MJEQ;V[3WM_/),F=P2XBFC4]!EAYB9&1]W
MKP*[BB@#@$\)ZTFG$0P1VUR\\;7*)XCO7^U1(C@)Y[)YD(#.K84'.W!.#5>3
MP/KL?AYM-A;2YI+K1(M,N))Y9,0O&9&#)\A+!C+W*D;0?FZ5Z/10!C>(M$.N
MPV,'F/''#>)/*8YWA?:%8?*Z$,#DCH1WK&U+P2'M]3M]-CM88Y]'^P6WF,Q9
M'WR,69L$G)926R22"3D\UV5% 'G]QX.UV[UC4KF>YADCGM;^"*62^F?(F(\I
M?)*[(@B@*2N2V,GGBM#5O!\NH)>HJ6>V;28M/C#@X4J[,P^[]T@K^73BNPHH
M X[4_#6K/)J+Z?-&L=UJ4=TUNE[+:&6(6RQ%#+&I9#O56^4'(4 ]3AF@>'=<
M\/2Z:T::==@:;;V%WON9$,1B=R7C^1M^X2'AMOW%Y].THH \YT[P'J-EHTEF
MT<#7=O!'%;7DNKW4PF\N1' :%U*PAC&N=A;&3C(K4&@:Z;6[NGCT[^T)=7CU
M%+<7+^5M6*--AD\O(/R'G8<\<#/'944 <</#^M:?J,&I6*:?=31SWQ,%Q</$
MNRXE5U8.(VPZ[ ,;<89N?6A/X.UZ[U?4;FXN8'2>UOH(I'OYGSYY'E*(2NR(
M(H"DKDMC)YXKT"B@#CFLM;T;6WO[*RA:UF\M)XHKMW:[DVQQJ[(8L1;%!RRL
M<JH# \;=#Q-H5UK.W[-)"N+*[M_WA(^:5 JG@'C(Y_K70T4 <=?>$[R1+[[&
MUFF^WTX01,2J%[:5I"KX'",-JY /&>. #TEC+JD@7^T+.SMR4RPM[IIL-D\#
M,:9&,'/J2,<9-VB@ HHHH **** "BBB@ HHHH \UUSX(^&M?UN\U:ZOM72>Z
MD,KK'.FT$^FY"0/;/%9__#//A+_H(ZW_ -_XO_C=>M45U+&XA*RFR>5'F&F^
M"_%-OIFB:9<0Z,L%A+9&2>._E9F6"2-R0AA R0G3=WZUZ%K&EP:WH]WIER\J
M0W41B=H7VN ?0^M7:*YDVG=%' >%/A#H'@_78]7T^\U22XC1D"SS(4(88.0J
M#/YU,_@F^$MA<P7%LD\>K37%UDMB6V:\>X11Q]]=PQV^9QGG-=S15U*LZKYI
MN[$DEL<7:>$=7MM1M=6&LEKT74T\]LZQFW5900P4B-9&V_N\!FYV#IQBLOA3
M6EL+XP6VEV327-C<0:9;W<AM5>"=99'#&(>69  "%3&5W')8UWM%9C.*F\+:
MWJNI"^O;Z'3I)9TED6P82F(1*PB56EB*OEG9R2BXPH .,TMAX<UW0?L<EA+9
MZ@]JL]J$O)C#YEN[AXR72,A67&W:$P0>HQ@]I10!QL&AZQ>>!?$.CWT$%OJ>
MH+>+YBS;[=FF#;2I W!1N"G<H.5/!X)KV7@Z]B2X,=EI.DPR7MC.NGV$C- O
MD2AY),^6G[QQA<!1_JUR?3NJ* .!F\&:M>6,NF3-I\5M$E_]GNHW<R2M<B0?
M.A4!0/,))#-N*@\5)<^%-3O=;BU&\M+:9)8K=)X(]:NH%A,3,<@(@68<@@.J
MX(/KQW5% '&'P[K+^%-:\./%IOD7,5TMM=+.^Z1I7=AYD?EX7[_)#-DC..>+
M,OA:9_%EOJ:BU%I%=I<>7SN&VVDB&!C&<LN.>@]@*ZJB@#B!X7UBQM;(6<>F
M7,D=C<6$D=S*Z(BR.K!E(1L@!0"F!GCD8Y;:^$=4T@P36+V5Y+:7PGBCN96C
M$B?8TM\E@C;'RI/"MP2.,\=S10!Y+!I&J:)XLL[5K.[N;=I+>26.U61(&?S'
M?(86[#;&7. TT60H!7GGKO#6D3VOB+69YD86D$S0:?O0J0DA$TI&?X=[A1CC
M$8QTKK** "BBB@ HHHH **** "BBB@#B-5^%FAZOJESJ%Q=ZDLMPY=E25-H)
M],J3C\:OZUX$TO7--T^QNKF^6*Q39&8YAEA@#YL@@GCKBNHHK+V%/73<Q^KT
MM?=WW/.E\$ZDNA#PJ(+3^RQ/N^W^;^\\K?OSLV_ZWMG.._M6AHWPQT70]6@U
M&UNM1::$Y59)5VGZX4']:[6BCV%.]["^KTKIM;'.6G@O3;+Q5-XBCGO#>2EB
MR-*#&-PYXQG'L3Q^%9%QX(OGEL[BWN+:.X35WN;C);$MJ;LW 7I]\$+CL,N,
M\YKNJ*N,8QV-8PC#2*.+M_".KP:E;ZO_ &PS7HO9;B:U98_LX60%2 1&)&PN
MS 9L$H.G&*P\*:U]BU'R;?2[)II;26+3[>[D-MYD,XE>3)C'EEP "%0\KDEB
M>.]HJBCBI_"VMZMJ?V^]O8=.>:6%Y%L7$K1+"',2JTL6UR7D9R2@QA0,XW4M
MCX;UW0GM9K&:TU![3[1;HE[,8?,@E=9%)9(R%967;M";2IZC&*[2B@#DM.T/
M4;WPQK6E:Q&EI>7TL[//;N)8CYG*F/.&(4%5(8*25/8@U)>V'B76-(,5]!I$
M-Q!-;SQ1Q3R21SO%(LA#DH"@.T 8#X//.,5U-% '"CP;J%S>W5_="P2>[MK]
M7AC=G2&6=;=$VL4!(VP,6; .7. :CUOPS?6VGS&SM[>8.=&@BMT5BH,%T"Y8
M!>$"L.1T53D#%=]10!Q@\/:VGDZDL>G-J*ZI)J#637#^0-T)APLOEY#8^?=Y
M?4L,<YINC^&-7TG5+"6#[)!'\S7\L5TY\T,TLGE"$Q[<*\N%D#*V!R,?+7:T
M4 <$G@O55T"'2?.M LGAV+2+B82N#')&C#<H"C>I+8.2A '?/&]X7T>?2X;I
MKJT6WN)W4L5U:XO]^!@$M,H*^F!FM^B@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"::[AUU3=W,\,3RF.!516@
MD4@?*<?,'SW;C@@=36[6<NC6RZDUX=[ L)%B+L463YLN%SC)R.W&,]Z ,5=9
MU"UF4W+3&9H[AY8);?;&A0$KL;:-PXQ]YLYI)=1U*WO=/LS?M)]OCC9I#&FZ
M(Y^;;@8P1_>!QBN@BTNTAFDE"/)(Z%&,TKR?*>2!N)P#Z"H%T#35CV>0YX4*
MS3.60*<J%8G*X/H10 NCW$\R7D5Q+YK6]RT*R$ %EP",X &?FQP!TIVIZG_9
MWE?N?,\S/\6,8Q[>]6;6T@LH?*@0JI8L26+%B>I)/)/N:K:W_P @B?\ X#_Z
M$* )X[Z":,21F1D/0B)L']*?]IC_ +LO'_3)O\*JZ)_R"(/^!?\ H1K0H A^
MTQ_W9>/^F3?X4?:8_P"[+Q_TR;_"IJ* (?M,?]V7C_IDW^%'VF/^[+Q_TR;_
M  J:B@"'[3'_ '9>/^F3?X4?:8_[LO'_ $R;_"IJ* (?M,?]V7C_ *9-_A1]
MIC_NR\?],F_PJ:B@"'[3'_=EX_Z9-_A1]IC_ +LO'_3)O\*FHH A^TQ_W9>/
M^F3?X4?:8_[LO'_3)O\ "IJ* (?M,?\ =EX_Z9-_A1]IC_NR\?\ 3)O\*FHH
M A^TQ_W9>/\ IDW^%'VF/^[+Q_TR;_"IJ* (?M,?]V7C_IDW^%'VF/\ NR\?
M],F_PJ:B@"'[3'_=EX_Z9-_A1]IC_NR\?],F_P *FHH A^TQ_P!V7C_IDW^%
M'VF/^[+Q_P!,F_PJ:B@"'[3'_=EX_P"F3?X4?:8_[LO'_3)O\*FHH A^TQ_W
M9>/^F3?X4?:8_P"[+Q_TR;_"IJ* (?M,?]V7C_IDW^%'VF/^[+Q_TR;_  J:
MB@"'[3'_ '9>/^F3?X4?:8_[LO'_ $R;_"IJ* (?M,?]V7C_ *9-_A1]IC_N
MR\?],F_PJ:B@"'[3'_=EX_Z9-_A1]IC_ +LO'_3)O\*FHH A^TQ_W9>/^F3?
MX4?:8_[LO'_3)O\ "IJ* (?M,?\ =EX_Z9-_A1]IC_NR\?\ 3)O\*FHH A^T
MQ_W9>/\ IDW^%'VF/^[+Q_TR;_"IJ* (?M,?]V7C_IDW^%'VF/\ NR\?],F_
MPJ:B@"'[3'_=EX_Z9-_A1]IC_NR\?],F_P *FHH A^TQ_P!V7C_IDW^%'VF/
M^[+Q_P!,F_PJ:B@"'[3'_=EX_P"F3?X4?:8_[LO'_3)O\*FHH A^TQ_W9>/^
MF3?X4?:8_P"[+Q_TR;_"IJ* (?M,?]V7C_IDW^%'VF/^[+Q_TR;_  J:B@"'
M[3'_ '9>/^F3?X4?:8_[LO'_ $R;_"IJ* (?M,?]V7C_ *9-_A1]IC_NR\?]
M,F_PJ:B@"'[3'_=EX_Z9-_A1]IC_ +LO'_3)O\*FHH A^TQ_W9>/^F3?X4?:
M8_[LO'_3)O\ "IJ* (?M,?\ =EX_Z9-_A1]IC_NR\?\ 3)O\*FHH A^TQ_W9
M>/\ IDW^%'VF/^[+Q_TR;_"IJ* (?M,?]V7C_IDW^%'VF/\ NR\?],F_PJ:B
M@"'[3'_=EX_Z9-_A1]IC_NR\?],F_P *FHH A^TQ_P!V7C_IDW^%'VF/^[+Q
M_P!,F_PJ:B@"'[3'_=EX_P"F3?X4?:8_[LO'_3)O\*FHH A^TQ_W9>/^F3?X
M4?:8_P"[+Q_TR;_"IJ* (?M,?]V7C_IDW^%'VF/^[+Q_TR;_  J:B@"'[3'_
M '9>/^F3?X4?:8_[LO'_ $R;_"IJ* (?M,?]V7C_ *9-_A1]IC_NR\?],F_P
MJ:B@"'[3'_=EX_Z9-_A1]IC_ +LO'_3)O\*FHH A^TQ_W9>/^F3?X4?:8_[L
MO'_3)O\ "IJ* (?M,?\ =EX_Z9-_A1]IC_NR\?\ 3)O\*FHH A^TQ_W9>/\
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M]IC_ +LO'_3)O\* )J*A^TQ_W9>/^F3?X4?:8_[LO'_3)O\ "@":BH?M,?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BHYIXK:!YYY4BBC&YY)&"JH]23TKRK6/B%K/B[49-
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MTG_/M+^:_P#Q5'G2?\^TOYK_ /%5-10!#YTG_/M+^:__ !5'G2?\^TOYK_\
M%5-10!#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%5-10!#YTG_/M+^:__ !5'G2?\
M^TOYK_\ %5-10!#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%5-10!#YTG_/M+^:__
M !5'G2?\^TOYK_\ %5-10!#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%5-10!#YTG
M_/M+^:__ !5'G2?\^TOYK_\ %5-10!#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%5
M-10!#YTG_/M+^:__ !5'G2?\^TOYK_\ %5-10!#YTG_/M+^:_P#Q5'G2?\^T
MOYK_ /%5-10!#YTG_/M+^:__ !5'G2?\^TOYK_\ %5-10!#YTG_/M+^:_P#Q
M5'G2?\^TOYK_ /%5-10!#YTG_/M+^:__ !5'G2?\^TOYK_\ %5-10!#YTG_/
MM+^:_P#Q5'G2?\^TOYK_ /%5-10!#YTG_/M+^:__ !5'G2?\^TOYK_\ %5-1
M0!#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%5-10!#YTG_/M+^:__ !5'G2?\^TOY
MK_\ %5-10!#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%5-10!#YTG_/M+^:__ !5'
MG2?\^TOYK_\ %5-10!#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%5-10!#YTG_/M+
M^:__ !5'G2?\^TOYK_\ %5-10!#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%5-10!
M#YTG_/M+^:__ !5'G2?\^TOYK_\ %5-10!#YTG_/M+^:_P#Q5'G2?\^TOYK_
M /%5-10!#YTG_/M+^:__ !5'G2?\^TOYK_\ %5-10!#YTG_/M+^:_P#Q5'G2
M?\^TOYK_ /%5-10!#YTG_/M+^:__ !5'G2?\^TOYK_\ %5-10!#YTG_/M+^:
M_P#Q5'G2?\^TOYK_ /%5-10!#YTG_/M+^:__ !5'G2?\^TOYK_\ %5-10!#Y
MTG_/M+^:_P#Q5'G2?\^TOYK_ /%5-10!#YTG_/M+^:__ !5'G2?\^TOYK_\
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M(P&[D%<'YCZFKWG2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOYK_\
M%4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\
M^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__
M !5'G2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG
M_/M+^:__ !5'G2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4
M 345#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^T
MOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q
M5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 345#YTG_/
MM+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 3
M45#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOY
MK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'
MG2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+
M^:__ !5'G2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345
M#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_
M /%4 345#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2
M?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 345#YTG_/M+^:
M_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 345#Y
MTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOYK_\
M%4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\
M^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__
M !5'G2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG
M_/M+^:__ !5'G2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4
M 345#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^T
MOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q
M5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 345#YTG_/
MM+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOYK_\ %4 3
M45#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'G2?\^TOY
MK_\ %4 345#YTG_/M+^:_P#Q5'G2?\^TOYK_ /%4 345#YTG_/M+^:__ !5'
MG2?\^TOYK_\ %4 345#YTG_/M+^:_P#Q5<7XQ^)NG^&'_L^WMI+_ %F3Y8K.
M(AL,>F_:21].I_6M\/AJN)J*G2C=B;25V=5K.MZ=X?TV34-4NH[:VCZLQY)]
M .I/L*\KFU7Q3\6IWM-%631O"P?;+>.,23@=0,'G_=!QZGM4^D^ =:\5:FFO
M?$#S9V7!M],B95CC'HPSQ]!R>Y/2O5(<6\*PP6+1Q1@*B($50/0 'BO3]IA\
MOTI6J5>_V8^G\S\WIV(LY[Z(R?"W@[1_!^GBUTNW =@/-N'P9)3_ +1_H.*W
MZA\Z3_GVE_-?_BJ/.D_Y]I?S7_XJO)JU9U9NI4=V^K+225D345#YTG_/M+^:
M_P#Q5'G2?\^TOYK_ /%5F,FHJ'SI/^?:7\U_^*H\Z3_GVE_-?_BJ )J*1264
M$J5/H:6@ HHHH **** "LY=&MEU)KP[V!82+$78HLGS9<+G&3D=N,9[UHT4
M01V<$1N"BE6N&W2,&.YCC'7.1P!C'3M54Z'I[*V^*21FV_O))W9UVG(VN6W+
M@^A%:-% $%K:064/E0(54L6)+%BQ/4DGDGW-5M;_ .01/_P'_P!"%:%9^M_\
M@B?_ (#_ .A"@ T3_D$0?\"_]"-:%9^B?\@B#_@7_H1K0H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD_Y]I?S7_P"*H\Z3_GVE_-?_ (J@":BH?.D_Y]I?S7_XJCSI/^?:7\U_^*H
MFHJ'SI/^?:7\U_\ BJ/.D_Y]I?S7_P"*H FHJ'SI/^?:7\U_^*H\Z3_GVE_-
M?_BJ )J*A\Z3_GVE_-?_ (JCSI/^?:7\U_\ BJ )J*A\Z3_GVE_-?_BJ/.D_
MY]I?S7_XJ@":BH?.D_Y]I?S7_P"*H\Z3_GVE_-?_ (J@":BH?.D_Y]I?S7_X
MJCSI/^?:7\U_^*H FHJ'SI/^?:7\U_\ BJ/.D_Y]I?S7_P"*H FHJ'SI/^?:
M7\U_^*H\Z3_GVE_-?_BJ )J*A\Z3_GVE_-?_ (JCSI/^?:7\U_\ BJ )J*A\
MZ3_GVE_-?_BJ/.D_Y]I?S7_XJ@":BH?.D_Y]I?S7_P"*H\Z3_GVE_-?_ (J@
M":BH?.D_Y]I?S7_XJCSI/^?:7\U_^*H FHJ'SI/^?:7\U_\ BJ/.D_Y]I?S7
M_P"*H FHJ'SI/^?:7\U_^*H\Z3_GVE_-?_BJ )J*A\Z3_GVE_-?_ (JCSI/^
M?:7\U_\ BJ )J*A\Z3_GVE_-?_BJ/.D_Y]I?S7_XJ@":BH?.D_Y]I?S7_P"*
MH\Z3_GVE_-?_ (J@":BH?.D_Y]I?S7_XJCSI/^?:7\U_^*H FHJ'SI/^?:7\
MU_\ BJ/.D_Y]I?S7_P"*H FHJ'SI/^?:7\U_^*H\Z3_GVE_-?_BJ )J*A\Z3
M_GVE_-?_ (JCSI/^?:7\U_\ BJ )J*A\Z3_GVE_-?_BJ/.D_Y]I?S7_XJ@":
MBH?.D_Y]I?S7_P"*H\Z3_GVE_-?_ (J@":BH?.D_Y]I?S7_XJCSI/^?:7\U_
M^*H FHJ'SI/^?:7\U_\ BJ/.D_Y]I?S7_P"*H FHJ'SI/^?:7\U_^*H\Z3_G
MVE_-?_BJ )J*A\Z3_GVE_-?_ (JCSI/^?:7\U_\ BJ )J*A\Z3_GVE_-?_BJ
M/.D_Y]I?S7_XJ@":BH?.D_Y]I?S7_P"*H\Z3_GVE_-?_ (J@":BH?.D_Y]I?
MS7_XJCSI/^?:7\U_^*H FHJ'SI/^?:7\U_\ BJ/.D_Y]I?S7_P"*H FHJ'SI
M/^?:7\U_^*H\Z3_GVE_-?_BJ )J*A\Z3_GVE_-?_ (JCSI/^?:7\U_\ BJ )
MJ*A\Z3_GVE_-?_BJ/.D_Y]I?S7_XJ@":BH?.D_Y]I?S7_P"*H\Z3_GVE_-?_
M (J@":BH?.D_Y]I?S7_XJCSI/^?:7\U_^*H FHJ'SI/^?:7\U_\ BJ/.D_Y]
MI?S7_P"*H FHJ'SI/^?:7\U_^*H\Z3_GVE_-?_BJ )J*A\Z3_GVE_-?_ (JC
MSI/^?:7\U_\ BJ )J*A\Z3_GVE_-?_BJ/.D_Y]I?S7_XJ@":BH?.D_Y]I?S7
M_P"*H\Z3_GVE_-?_ (J@":BH?.D_Y]I?S7_XJCSI/^?:7\U_^*H FHJ'SI/^
M?:7\U_\ BJ/.D_Y]I?S7_P"*H FHJE>:G#IUG-=WBF"WA7<\LCHJJ/KNKRS4
MO&_B+X@74ND>!;:6WL%(6YU63Y"!W"_W?_0C[5VX3 U<3=K2*WD]$OZ[;DRD
MHG2^,OB98>')_P"R]-B.JZ[(VQ+.#+;&/3?CO_LCGZ=:Q-"^&^I>(M13Q!\0
M;DW=P1F'30?W<(SG#8X_X"/Q)KH_!O@/2_!T)DAM)KK4G'[V^FV;VSU"_-\H
M]OS)KK?.D_Y]I?S7_P"*KKGCJ6%BZ6!WZS?Q/T_E7X]R5%RUD21QI%&L<:*D
M: *JJ,  = !3JA\Z3_GVE_-?_BJ/.D_Y]I?S7_XJO'-":BH?.D_Y]I?S7_XJ
MCSI/^?:7\U_^*H FHJ'SI/\ GVE_-?\ XJCSI/\ GVE_-?\ XJ@":BH?.D_Y
M]I?S7_XJCSI/^?:7\U_^*H FHJ'SI/\ GVE_-?\ XJCSI/\ GVE_-?\ XJ@"
M:BH?.D_Y]I?S7_XJCSI/^?:7\U_^*H FHJ'SI/\ GVE_-?\ XJCSI/\ GVE_
M-?\ XJ@":BD4EE!*E3Z&EH **** "BBB@ JFFEV2:D^H+;QBY=0I?8,C&>0<
M9R<X/L!5RB@"NMA9I++*MI LDP(D<1@%P>H)[TQ-+T^."2!+"U6&3&^-85"M
MCID8YJW10!'#!%;0K#!$D4:_=1%"@?0"J>M_\@B?_@/_ *$*T*S];_Y!$_\
MP'_T(4 &B?\ ((@_X%_Z$:T*S]$_Y!$'_ O_ $(UH4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !112,RHI9F"JHR23@ 4 +7,>,/'F
MC>#+3??2^;=N/W-I$09'^O\ ='N?PS7*^(OB;=ZGJ3>'? =M_:.I,=KWH ,,
M([D'H<?WC\OUK1\'_#&UT:[_ +:UZ<ZMK\C;WGE)9(V_V0>I_P!H_@!7KT\#
M3P\55QVE]H+XGZ_RKS>O9&;DWI$YZS\*>)OB9=Q:KXQDDT[15.^VTN$E6<=B
MWI]3SZ "O5]/TZRTFQCLM/MHK:VB&$CC7 '_ -?WJU17+B\?4Q-H_#!;16R_
MS?F]2HQ2"BBBN(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N=<&WUU+JXEDF62Y,,$T-QD1Y !B>,\ 9&<C)R 3BNBJFFEV2:D
M^H+;QBY=0I?8,C&>0<9R<X/L!0!S=OJ=VD;7DZNTURERT++=.54Q@_+Y6 H
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MTOYK_P#%4>=)_P ^TOYK_P#%5-10!#YTG_/M+^:__%4>=)_S[2_FO_Q5344
M0^=)_P ^TOYK_P#%4>=)_P ^TOYK_P#%5-10!#YTG_/M+^:__%4>=)_S[2_F
MO_Q5344 0^=)_P ^TOYK_P#%4>=)_P ^TOYK_P#%5-10!#YTG_/M+^:__%4>
M=)_S[2_FO_Q5344 0^=)_P ^TOYK_P#%4>=)_P ^TOYK_P#%5-10!#YTG_/M
M+^:__%4>=)_S[2_FO_Q5344 0^=)_P ^TOYK_P#%4>=)_P ^TOYK_P#%5-10
M!#YTG_/M+^:__%4>=)_S[2_FO_Q5344 0^=)_P ^TOYK_P#%4>=)_P ^TOYK
M_P#%5-10!#YTG_/M+^:__%4>=)_S[2_FO_Q5344 0^=)_P ^TOYK_P#%4>=)
M_P ^TOYK_P#%5-10!#YTG_/M+^:__%4>=)_S[2_FO_Q5344 0^=)_P ^TOYK
M_P#%4>=)_P ^TOYK_P#%5-10!#YTG_/M+^:__%4>=)_S[2_FO_Q5344 0^=)
M_P ^TOYK_P#%4>=)_P ^TOYK_P#%5-10!#YTG_/M+^:__%4>=)_S[2_FO_Q5
M344 0^=)_P ^TOYK_P#%4C7#(K,UO(%49)+(!C_OJI)9HH(7EFD2.-!EG=@
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MHKR:E2=23G-W;ZLW2ML0^=)_S[2_FO\ \51YTG_/M+^:_P#Q5345 $/G2?\
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MG_GE%_W]/_Q-&ZY_YY1?]_3_ /$T 345#NN?^>47_?T__$T;KG_GE%_W]/\
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M^[KZN[*C!+4+:TMK.(Q6MO%!&79RL2!068Y)P.Y)R34U0[KG_GE%_P!_3_\
M$T;KG_GE%_W]/_Q-<-[E$U%0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\ $T 3
M45#NN?\ GE%_W]/_ ,31NN?^>47_ ']/_P 30!-14.ZY_P">47_?T_\ Q-&Z
MY_YY1?\ ?T__ !- $U%0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\ $T 345#N
MN?\ GE%_W]/_ ,31NN?^>47_ ']/_P 30!-14.ZY_P">47_?T_\ Q-&ZY_YY
M1?\ ?T__ !- $U%0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\ $T 345#NN?\
MGE%_W]/_ ,31NN?^>47_ ']/_P 30!-14.ZY_P">47_?T_\ Q-&ZY_YY1?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT;KG_GE%_P!_3_\ $U-10!#NN?\ GE%_W]/_ ,31NN?^>47_ ']/_P 34U%
M$.ZY_P">47_?T_\ Q-&ZY_YY1?\ ?T__ !-344 0[KG_ )Y1?]_3_P#$T;KG
M_GE%_P!_3_\ $U-10!#NN?\ GE%_W]/_ ,31NN?^>47_ ']/_P 34U% $.ZY
M_P">47_?T_\ Q-&ZY_YY1?\ ?T__ !-344 0[KG_ )Y1?]_3_P#$T;KG_GE%
M_P!_3_\ $U-10!#NN?\ GE%_W]/_ ,31NN?^>47_ ']/_P 34U% $.ZY_P">
M47_?T_\ Q-&ZY_YY1?\ ?T__ !-344 0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_
M3_\ $U-10!#NN?\ GE%_W]/_ ,31NN?^>47_ ']/_P 34U% $.ZY_P">47_?
MT_\ Q-&ZY_YY1?\ ?T__ !-344 0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\
M$U-10!#NN?\ GE%_W]/_ ,31NN?^>47_ ']/_P 34U% $.ZY_P">47_?T_\
MQ-&ZY_YY1?\ ?T__ !-344 0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\ $U-1
M0!#NN?\ GE%_W]/_ ,31NN?^>47_ ']/_P 34U% $.ZY_P">47_?T_\ Q-&Z
MY_YY1?\ ?T__ !-344 0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\ $U-10!#N
MN?\ GE%_W]/_ ,31NN?^>47_ ']/_P 34U% $.ZY_P">47_?T_\ Q-&ZY_YY
M1?\ ?T__ !-344 0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\ $U-10!#NN?\
MGE%_W]/_ ,31NN?^>47_ ']/_P 34U% $.ZY_P">47_?T_\ Q-&ZY_YY1?\
M?T__ !-344 0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\ $U-10!#NN?\ GE%_
MW]/_ ,31NN?^>47_ ']/_P 34U% $.ZY_P">47_?T_\ Q-&ZY_YY1?\ ?T__
M !-344 0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\ $U-10!#NN?\ GE%_W]/_
M ,31NN?^>47_ ']/_P 34U% $.ZY_P">47_?T_\ Q-&ZY_YY1?\ ?T__ !-3
M44 0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\ $U-10!#NN?\ GE%_W]/_ ,31
MNN?^>47_ ']/_P 34U(2%4LQ  &23VH BW7/_/*+_OZ?_B:BNKPV5M)<W1MH
M((QN>26?:JCU)*\5POB3XM:;877]E^';=]=U=SL6.V!,:GW8?>^B_F*R;7X>
M^)O&MS'J'CW5'BM@=T>EVK8"_7' _4^XKU:66.,%5Q<O9Q\_B?I'?YNR(<^D
M=2;4_BQ>:K?/H_@?26U2]/'VK!\E/?D#CW) ^M-TSX57^J:@-7\<ZA_:]YU6
MU$S+%'[<+T]EP/K7I&DZ-INA62V>EV4-K;K_  1KC)]2>I/N:OTY9E&BG# Q
MY%_-O-_/IZ(7)?66I4MK<V5LEM:6=K!!&-L<4;;54>@ 7BI=US_SRB_[^G_X
MFIJ*\IMMW9H0[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\ $U-12 AW7/\ SRB_
M[^G_ .)HW7/_ #RB_P"_I_\ B:FHH AW7/\ SRB_[^G_ .)HW7/_ #RB_P"_
MI_\ B:FHH AW7/\ SRB_[^G_ .)HW7/_ #RB_P"_I_\ B:FHH AW7/\ SRB_
M[^G_ .)HW7/_ #RB_P"_I_\ B:FHH AW7/\ SRB_[^G_ .)HW7/_ #RB_P"_
MI_\ B:FHH AW7/\ SRB_[^G_ .)HW7/_ #RB_P"_I_\ B:FHH AW7/\ SRB_
M[^G_ .)HW7/_ #RB_P"_I_\ B:FHH AW7/\ SRB_[^G_ .)HW7/_ #RB_P"_
MI_\ B:FHH AW7/\ SRB_[^G_ .)HW7/_ #RB_P"_I_\ B:FHH AW7/\ SRB_
M[^G_ .)HW7/_ #RB_P"_I_\ B:FHH AW7/\ SRB_[^G_ .)HW7/_ #RB_P"_
MI_\ B:FHH AW7/\ SRB_[^G_ .)HW7/_ #RB_P"_I_\ B:FHH AW7/\ SRB_
M[^G_ .)HW7/_ #RB_P"_I_\ B:FHH 1=VT;@ W< YI:** "BBB@ HHHH ***
MYUP;?74NKB6299+DPP30W&1'D &)XSP!D9R,G(!.* .BHKE[+4+F[\1D2->1
M>=;2[()(9$6/##:3D8SC)+>IQGI58R7-C+9Z3=/,MQ,T(FG2^DD#KD@_>P4)
M8?P^O6@#L:S];_Y!$_\ P'_T(5%H;N4OH6E>6."[>.)I&+,%P#@D\G!)'-,\
M02S)9K&D>Z)_]8VT_+@C'/:@"QHG_((@_P"!?^A&M"LO1VG&E0[(XROS8)D(
M/WC[5>W7/_/*+_OZ?_B: )J*AW7/_/*+_OZ?_B:-US_SRB_[^G_XF@":BH=U
MS_SRB_[^G_XFC=<_\\HO^_I_^)H FHJ'=<_\\HO^_I_^)HW7/_/*+_OZ?_B:
M )J*AW7/_/*+_OZ?_B:-US_SRB_[^G_XF@":BH=US_SRB_[^G_XFC=<_\\HO
M^_I_^)H FHJ'=<_\\HO^_I_^)HW7/_/*+_OZ?_B: )J*AW7/_/*+_OZ?_B:-
MUS_SRB_[^G_XF@":BH=US_SRB_[^G_XFC=<_\\HO^_I_^)H FHJ'=<_\\HO^
M_I_^)HW7/_/*+_OZ?_B: )J*AW7/_/*+_OZ?_B:-US_SRB_[^G_XF@":BH=U
MS_SRB_[^G_XFC=<_\\HO^_I_^)H FHJ'=<_\\HO^_I_^)HW7/_/*+_OZ?_B:
M )J*AW7/_/*+_OZ?_B:-US_SRB_[^G_XF@":BH=US_SRB_[^G_XFC=<_\\HO
M^_I_^)H FHJ'=<_\\HO^_I_^)HW7/_/*+_OZ?_B: )J*AW7/_/*+_OZ?_B:-
MUS_SRB_[^G_XF@":BH=US_SRB_[^G_XFC=<_\\HO^_I_^)H FHJ'=<_\\HO^
M_I_^)HW7/_/*+_OZ?_B: )J*AW7/_/*+_OZ?_B:-US_SRB_[^G_XF@":BH=U
MS_SRB_[^G_XFC=<_\\HO^_I_^)H FHJ'=<_\\HO^_I_^)HW7/_/*+_OZ?_B:
M )J*AW7/_/*+_OZ?_B:-US_SRB_[^G_XF@":BH=US_SRB_[^G_XFC=<_\\HO
M^_I_^)H FHJ'=<_\\HO^_I_^)HW7/_/*+_OZ?_B: )J*AW7/_/*+_OZ?_B:-
MUS_SRB_[^G_XF@":BH=US_SRB_[^G_XFC=<_\\HO^_I_^)H FHJ'=<_\\HO^
M_I_^)HW7/_/*+_OZ?_B: )J*AW7/_/*+_OZ?_B:-US_SRB_[^G_XF@":BH=U
MS_SRB_[^G_XFC=<_\\HO^_I_^)H FHJ'=<_\\HO^_I_^)HW7/_/*+_OZ?_B:
M )J*AW7/_/*+_OZ?_B:-US_SRB_[^G_XF@":BH=US_SRB_[^G_XFC=<_\\HO
M^_I_^)H FHJ'=<_\\HO^_I_^)HW7/_/*+_OZ?_B: )J*AW7/_/*+_OZ?_B:-
MUS_SRB_[^G_XF@":BH=US_SRB_[^G_XFC=<_\\HO^_I_^)H FHKF/$_CG2O"
M,!?5)X!,1F.VCE+2O]%QQ]3@>]<(;_X@?$Q2-.B_X1S07_Y;NQ$LJ^QX)_#
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MG_GE%_W]/_Q-&ZY_YY1?]_3_ /$T 345#NN?^>47_?T__$T;KG_GE%_W]/\
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M9L]0"2/_ $(_G0!R(;4/[;N)9+.YCO9K"?;\Z,$PPV!=K=!P.F2S$XYXHO\
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MG_GE%_W]/_Q-&ZY_YY1?]_3_ /$U-10!#NN?^>47_?T__$T;KG_GE%_W]/\
M\34U% $.ZY_YY1?]_3_\31NN?^>47_?T_P#Q-344 0[KG_GE%_W]/_Q-&ZY_
MYY1?]_3_ /$U-10!#NN?^>47_?T__$T;KG_GE%_W]/\ \34U% $.ZY_YY1?]
M_3_\31NN?^>47_?T_P#Q-344 0[KG_GE%_W]/_Q-&ZY_YY1?]_3_ /$U-10!
M#NN?^>47_?T__$T;KG_GE%_W]/\ \34U% $.ZY_YY1?]_3_\31NN?^>47_?T
M_P#Q-344 0[KG_GE%_W]/_Q-&ZY_YY1?]_3_ /$U-10!#NN?^>47_?T__$T;
MKG_GE%_W]/\ \34U% $.ZY_YY1?]_3_\31NN?^>47_?T_P#Q-344 0[KG_GE
M%_W]/_Q-&ZY_YY1?]_3_ /$U-10!#NN?^>47_?T__$T;KG_GE%_W]/\ \34U
M% $.ZY_YY1?]_3_\31NN?^>47_?T_P#Q-344 0[KG_GE%_W]/_Q-&ZY_YY1?
M]_3_ /$U-10!#NN?^>47_?T__$T;KG_GE%_W]/\ \34U% $.ZY_YY1?]_3_\
M31NN?^>47_?T_P#Q-4-8\2Z)H$>_5=4M;3C(620;S]%ZG\!7F>O?%C3]?N8]
M(T9[^+3G)_M#44A*E(\= >J*><N0,#IZCLH8#$5X\\(/E76VA$IQCN>IQ:BD
M]O)<0RV<D$997E2YRJE3A@2!@8(.?3%>?ZW\78OMQTGPKI_]N:FW"M 6:)3Z
MY &X?3CWKGM2\(6FNZQI^BZ3)<0V\CQR:A:V<FR$0 8$C=5#X&%X);&.@R/6
M= \,Z/X9LOLND6,5NA^^P&7<^K,>377&G@L*N>K><ND=E\WN_16(A.5176AY
MS:_#3Q!XHO$U/Q[J1N,?,FFPS%$C]B5&!_P'G_:KTS3M/BTBR2ST[3[2UMD^
M['$VT?7[O7WK0HKDQ6/KXFRF[16T5HEZ+^F:1BH[$.ZY_P">47_?T_\ Q-&Z
MY_YY1?\ ?T__ !-345QE$.ZY_P">47_?T_\ Q-&ZY_YY1?\ ?T__ !-344 0
M[KG_ )Y1?]_3_P#$T;KG_GE%_P!_3_\ $U-10!#NN?\ GE%_W]/_ ,31NN?^
M>47_ ']/_P 34U% $.ZY_P">47_?T_\ Q-&ZY_YY1?\ ?T__ !-344 0[KG_
M )Y1?]_3_P#$T;KG_GE%_P!_3_\ $U-10!#NN?\ GE%_W]/_ ,31NN?^>47_
M ']/_P 34U% $.ZY_P">47_?T_\ Q-&ZY_YY1?\ ?T__ !-344 0[KG_ )Y1
M?]_3_P#$T;KG_GE%_P!_3_\ $U-10!#NN?\ GE%_W]/_ ,31NN?^>47_ ']/
M_P 34U% $.ZY_P">47_?T_\ Q-&ZY_YY1?\ ?T__ !-344 0[KG_ )Y1?]_3
M_P#$T;KG_GE%_P!_3_\ $U-10!#NN?\ GE%_W]/_ ,31NN?^>47_ ']/_P 3
M4U% $.ZY_P">47_?T_\ Q-&ZY_YY1?\ ?T__ !-344 0[KG_ )Y1?]_3_P#$
MT;KG_GE%_P!_3_\ $U-10!#NN?\ GE%_W]/_ ,31NN?^>47_ ']/_P 34U%
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MRB_[^G_XFN/$8W$8EWK3<OR^[8I12V*FCZ%I>@6TEOI5E':Q2.9&5,\D^Y[
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MEE#L"P7/) QDX_$?F* '4444 %9^M_\ ((G_ . _^A"M"L_6_P#D$3_\!_\
M0A0 :)_R"(/^!?\ H1K0K/T3_D$0?\"_]"-:% !1110 4444 %%%% !1110
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MUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\
MXJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<
M_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_S
MUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\
MXJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<
M_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_S
MUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\
MXJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<
M_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_S
MUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\
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M7_H1K0K+T=9SI4.R2,+\V 8R3]X^]7MMS_SUB_[]'_XJ@":BH=MS_P ]8O\
MOT?_ (JC;<_\]8O^_1_^*H FHJ';<_\ /6+_ +]'_P"*HVW/_/6+_OT?_BJ
M)J*AVW/_ #UB_P"_1_\ BJ-MS_SUB_[]'_XJ@":BH=MS_P ]8O\ OT?_ (JC
M;<_\]8O^_1_^*H FHJ';<_\ /6+_ +]'_P"*HVW/_/6+_OT?_BJ )J*AVW/_
M #UB_P"_1_\ BJ-MS_SUB_[]'_XJ@":BH=MS_P ]8O\ OT?_ (JC;<_\]8O^
M_1_^*H FHJ';<_\ /6+_ +]'_P"*HVW/_/6+_OT?_BJ )J*AVW/_ #UB_P"_
M1_\ BJ-MS_SUB_[]'_XJ@":BH=MS_P ]8O\ OT?_ (JC;<_\]8O^_1_^*H F
MHJ';<_\ /6+_ +]'_P"*HVW/_/6+_OT?_BJ )J*AVW/_ #UB_P"_1_\ BJ-M
MS_SUB_[]'_XJ@":BH=MS_P ]8O\ OT?_ (JC;<_\]8O^_1_^*H FHJ';<_\
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MH_\ Q5&VY_YZQ?\ ?H__ !5 $U%0[;G_ )ZQ?]^C_P#%4;;G_GK%_P!^C_\
M%4 345#MN?\ GK%_WZ/_ ,51MN?^>L7_ 'Z/_P 50!-14.VY_P">L7_?H_\
MQ5&VY_YZQ?\ ?H__ !5 $U%0[;G_ )ZQ?]^C_P#%4;;G_GK%_P!^C_\ %4 3
M45#MN?\ GK%_WZ/_ ,51MN?^>L7_ 'Z/_P 50!-14.VY_P">L7_?H_\ Q5&V
MY_YZQ?\ ?H__ !5 $U%0[;G_ )ZQ?]^C_P#%4;;G_GK%_P!^C_\ %4 345#M
MN?\ GK%_WZ/_ ,51MN?^>L7_ 'Z/_P 50!-14.VY_P">L7_?H_\ Q5&VY_YZ
MQ?\ ?H__ !5 $U%0[;G_ )ZQ?]^C_P#%4;;G_GK%_P!^C_\ %4 345G7&IVU
MI)Y=SJNGP.3@+*P4Y_%ZR]=\8Z7X=N!;:AJ,:7!4.(DMW<X]\'%3*<8J[9$J
MD(J\G8Z6BN2D\9>=X8.N:5:SW\9E\I88[=@^?4\GCW]Z9X<\0^)M;NYEO/#_
M /9EL(RT<LX;);(PI!P>>>1Z5/M87274GV\+J*=[G845P4%G\2KJ]CDN-2TV
MRMU<%XT0/E<\_P )/_CPJWXA\#W?B'4FN)?$5Y!;E0OV6)2$&.I'S=_I4^TD
MU>,7\]"?;2<;Q@_GH=7=WMI80>?>7,-O$#C?-($7\S6?:>*-$OQ<_8]2@G^S
M1F641G<54=3[_A6<O@?3F\.VNB71^UVML^^,S;MP;G/*L/4\=*OZ3X;L-#W_
M -F6MI;,XPS+"2Q'H26SBJO4;6UAWJN2T27XG/VGQ1TC4-3@LK&QU&<RR"/S
M%A&%R<9ZYQWZ5/KVO>+H-8EL=$\.+/"@&VZF?Y7R!GN ,'CKVKJDAEC7;&T"
M#T6$C_V:G;;G_GK%_P!^C_\ %5/)-JSE]PO9U'&TI_<K?YG.:C;>+]3T"Q%K
M>6>EZD3F[ &Y<=@IPW^>]8T'AOQ'HEW!K-YJ4^NR1[XY+8=8XWP6:/)Y(*+Q
MQD9QZ'O-MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJFZ,6[ML'0BW=M_><H[W/B&
M\LK:VL+R"TAN8[FXN;J!H-OEL'5%5P&8EE ) P!GGD ]C2+NVC<06[D#%+5P
M@HJR-(04%9!1115%A1110 4P0QK.\X7]XZJC-GJ 21_Z$?SI]-+H)!&64.P+
M!<\D#&3C\1^8H =1110 5GZW_P @B?\ X#_Z$*T*S];_ .01/_P'_P!"% !H
MG_((@_X%_P"A&M"L_1/^01!_P+_T(UH4 %%%% !1110 4444 %%%% !1110
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MK>W@M+=+>VACAAC&$CC4*JCT ' J6BBO*;;=V:!1112 **** "BBB@ HHHH
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M*J:B@"';<_\ /6+_ +]'_P"*HVW/_/6+_OT?_BJFHH AVW/_ #UB_P"_1_\
MBJ-MS_SUB_[]'_XJIJ* (=MS_P ]8O\ OT?_ (JC;<_\]8O^_1_^*J:B@"';
M<_\ /6+_ +]'_P"*HVW/_/6+_OT?_BJFHH AVW/_ #UB_P"_1_\ BJ-MS_SU
MB_[]'_XJIJ* (=MS_P ]8O\ OT?_ (JC;<_\]8O^_1_^*J:B@"';<_\ /6+_
M +]'_P"*HVW/_/6+_OT?_BJFHH AVW/_ #UB_P"_1_\ BJ-MS_SUB_[]'_XJ
MIJ* (=MS_P ]8O\ OT?_ (JC;<_\]8O^_1_^*J:B@"';<_\ /6+_ +]'_P"*
MHVW/_/6+_OT?_BJFHH AVW/_ #UB_P"_1_\ BJ-MS_SUB_[]'_XJIJ* (=MS
M_P ]8O\ OT?_ (JC;<_\]8O^_1_^*J:B@"';<_\ /6+_ +]'_P"*HVW/_/6+
M_OT?_BJFHH AVW/_ #UB_P"_1_\ BJ-MS_SUB_[]'_XJIJ* (=MS_P ]8O\
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MS_SUB_[]'_XJIJ* (=MS_P ]8O\ OT?_ (JC;<_\]8O^_1_^*J:B@"';<_\
M/6+_ +]'_P"*HVW/_/6+_OT?_BJFHH AVW/_ #UB_P"_1_\ BJ-MS_SUB_[]
M'_XJIJ* (=MS_P ]8O\ OT?_ (JC;<_\]8O^_1_^*J:B@"';<_\ /6+_ +]'
M_P"*HVW/_/6+_OT?_BJFHH AVW/_ #UB_P"_1_\ BJ-MS_SUB_[]'_XJIJ*
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M .*HVW/_ #UB_P"_1_\ BJFHH AVW/\ SUB_[]'_ .*HVW/_ #UB_P"_1_\
MBJFHH AVW/\ SUB_[]'_ .*HVW/_ #UB_P"_1_\ BJFHH AVW/\ SUB_[]'_
M .*HVW/_ #UB_P"_1_\ BJFHH AVW/\ SUB_[]'_ .*HVW/_ #UB_P"_1_\
MBJFHH AVW/\ SUB_[]'_ .*HVW/_ #UB_P"_1_\ BJFHH AVW/\ SUB_[]'_
M .*HVW/_ #UB_P"_1_\ BJFHH AVW/\ SUB_[]'_ .*HVW/_ #UB_P"_1_\
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M\:7%V\L:NI4[< 9(/(R03SZU'X@BF>S61)-L2?ZQ<GYLD8X[T 6-$_Y!$'_
MO_0C6A67HZSG2H=DD87YL QDG[Q]ZO;;G_GK%_WZ/_Q5 $U%0[;G_GK%_P!^
MC_\ %4;;G_GK%_WZ/_Q5 $U%0[;G_GK%_P!^C_\ %4;;G_GK%_WZ/_Q5 $U%
M0[;G_GK%_P!^C_\ %4;;G_GK%_WZ/_Q5 $U%0[;G_GK%_P!^C_\ %4;;G_GK
M%_WZ/_Q5 $U%0[;G_GK%_P!^C_\ %4;;G_GK%_WZ/_Q5 $U%0[;G_GK%_P!^
MC_\ %4;;G_GK%_WZ/_Q5 $U%0[;G_GK%_P!^C_\ %4;;G_GK%_WZ/_Q5 $U%
M0[;G_GK%_P!^C_\ %4;;G_GK%_WZ/_Q5 $U%0[;G_GK%_P!^C_\ %4;;G_GK
M%_WZ/_Q5 $U%0[;G_GK%_P!^C_\ %4;;G_GK%_WZ/_Q5 $U%0[;G_GK%_P!^
MC_\ %4;;G_GK%_WZ/_Q5 $U%0[;G_GK%_P!^C_\ %4;;G_GK%_WZ/_Q5 $U%
M0[;G_GK%_P!^C_\ %4;;G_GK%_WZ/_Q5 $U%0[;G_GK%_P!^C_\ %4;;G_GK
M%_WZ/_Q5 $U%96L:S:Z!9->:KJ=I:0#HTB')/H!NRQ]A7FLOC_Q9XVN9+#P/
MIWE6@.U]4N8]@7Z9) _4^PKMPN7UL2G.*M%;R>B7S_1:DRFD>A^)/%^B>%+7
MSM7ODA9AF.%?FDD_W5'/X]/>O.SXA\=?$@F+P[:MH.AOP;^<XDD'^R>O_?/X
MM6OX?^$=E8WAU37;S^V]5<[VDNT+HK>P+?-]6_(5WLDXM5VR7EI"H' 9=H _
M[ZKK]O@\'_ 7M)_S27NKTCU]7]Q-I/XM$<MX4^%^@>%W6[,9U#4\[FO+H;B&
M]5'1?KR?>NUK-O=4MM-B26]U2QMDD_U;3$*&^F6Y_"J\?B'3I[&ZO8=8L9;:
MU&9I(P6$8]\-^5>9B,74Q%3GK3N_,:<(Z7-JBN4L?'FAZGJ45A9ZM%)<3';&
M/LDH!/IDX%9^J_$_2=)U&XL93<RS02&-_*M1C<.#UD&:Y76II7YD0\122YN9
M6.[HKD=<\87.E6.GW5MI=U>_;H_,1$MV!08!PW)P>>GUHTSQ+KNJ:'?WRZ!-
M;W%O_J;:92IG^A..GTI^UA?EZC]O#FY;Z_,ZZBN(T77O&NH:K#%>^'8+.R8G
MS)7)RG'7!;GGMBF:E)\1I-1N$L(=,CM Y$,A(RR]B<D\_A4^V5KI/[B?K"Y>
M9)OY'=5F:MKEKI#012)-/=7!/DVT";I),=2.@ &1DD@<CUK'UK3O&5Y9V*Z;
MK%C:3"/%WB(X9\#[I(;C.>PK&M;;5O#&K&_\37YOX;F 0B\6,[+4JQ;:QQP&
MW=>F5 XXHE4DM%%A.M).RB_4ZW3/$-MJ-X]D]O<V5\J>9]FNE 8IG&Y2I*L,
MG!P3C\16O7%17*>(O$.ERZ/,)+>P=YYKU%W1'*,@B5NC$[@QQT"CVJ+4?!/B
M*[U&XN8/&M]!'+(76%58+&">%&'Q@?2A5)\MU&XE5GRW4;G=45RFM>&M=U*U
ML8K7Q3<6;6\>V1XXB#.<#YF(8<\'CIS1I_AK7;70[ZQG\43SW%Q_J[EHB6A^
MF6SS5<\KVY?R+]I/FMR_D=717%Z-X4\2Z=JD-S=>+I[N"/.Z"2-B'XQSEJAU
M'PAXINM2N+BW\8SPPR.66(1D!!Z !L<5/M)VORO\"?:SY;\C_#_,[JBN4UKP
M]XBU"VL8[/Q,]H\$>R5TB(,S8'S'!Z\'CWI=/\/^([;0KVSN/$K37<W,-PT.
M3#]#GG/Z57/*]N7\BO:2YK<K_#_,ZJBN*T;PSXKL-4AN+SQ6UU;IDO"T18/Q
MTY-1:CX7\87.I7$]MXM,4+R%HXA&0$4]!CVJ?:2M?E?X$^UGRWY'^'^9W5%<
MIK6A^)[ZUL8[#Q&MM)#'MG80;?-; ^;@GWXX'-+I^B>*+?0[VUNO$:37DO\
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MS_SUB_[]'_XJC;<_\]8O^_1_^*JBB:BH=MS_ ,]8O^_1_P#BJ-MS_P ]8O\
MOT?_ (J@":BH=MS_ ,]8O^_1_P#BJ-MS_P ]8O\ OT?_ (J@":BH=MS_ ,]8
MO^_1_P#BJ-MS_P ]8O\ OT?_ (J@":BH=MS_ ,]8O^_1_P#BJ0BX4$F:$#U,
M9X_\>H GHJC'>I-<-;Q:A9/.!DQKRP'KC=FN8\6WNLQ>(-)L+/6);&&>UNII
M#;01%F9&@"Y\Q7X_>-T H:: [6BO)[GQQ-X-UVT/B#Q%>7.GW5K/A9K2)L2J
MT6W'E1H?NL_4XZ47'Q\\+Q;O+-]-CILLP,_]]2"MJ>&JU%>$6T)M(]8HKF_"
M/BF/QEHIU2PCFMX?-,06ZMMK$@ Y&'((YZYK(\9>,?$OAW4H;/2?"=UK2RQ>
M8;B&-PB')&T[0W/&><=:2HS<_9VU"ZM<[NBO(AXZ^*5UQ:^ 8XR>GGEA_-EJ
M2/6?C3=2+CPWHMJF>LD@/'O^])_(5M]3FMY17S0N8]9HJ!5N]@W2PAL#.(R1
MGO\ Q5YC=^$?BI>7<K-XXM(8&<E!##M(7MP$';W/UK&E34[WDEZC;/5:*\E_
MX5;XTN/^/KXFZFH/41+)C_T8*V_"?PXOO#&LMJ4OBW4=2<QF,Q7()0YQR07.
M>E:2I4HQ;52[]&%WV.]=TC0O(RHHZLQP!6;/XET&U.+C6]-A(_YZ72+_ #-5
MO$WAF#Q9HLNE:E)_HTC*W[H%6!!XYW?SKCX/@7X/B^_;R3?]=)9/_96%33C1
M:O4;OY+_ ((._0ZB?XA^#K;_ %GB;2S_ -<[E7_]!S6MI&M:;K]B+W2KR*[M
MBQ3S(SD!AU'L:Y.'X0^#8!A-$M#_ -=#*_\ .2NHTO1;?1+(6>EP6EI;!BPC
MB@*C)ZD_-R:*GL+?N[W\[ K]3!\5?$[PWX.U%=/U26Y-T8Q+Y<,);Y3G'/ [
M'O7,/^T!X99MEKIFLW#]@L*#/_C^?TKTJ?3TN9!)/%9RR*,*TEMN('U)J9(9
M8EVQM @[!82/_9JJ$Z"C[T&WZ_\  "S/,8/C1/>W$<=CX(URX5V RJ<\_0$?
MJ*]5R<9QSCI46VY_YZQ?]^C_ /%4;;G_ )ZQ?]^C_P#%5G5G"5N2-OG<%<\N
MF\4_%R:>1+/P181*&(4S3AOU\Q0:9]H^-EU_RYZ)9Y]U./\ QYJ]4VW/_/6+
M_OT?_BJ-MS_SUB_[]'_XJM?K26U./W/_ #%R^9QW@VQ^(=OJDTOBW5M-N;$Q
M$1PV\8W!\C!R$7C&>YJ3QA8ZI)K^D7]AI5QJ$4%K=0RB"2)61G: K_K'7(_=
MMTS76[;G_GK%_P!^C_\ %4;;G_GK%_WZ/_Q585)\\N:R7IH-*QQ7AVQUA_&4
M%_>:)=V%K#I]Q"7N)8&W.\D!4 1R,>D;=<5W=(N[:-Q!;N0,4M0,**** "BB
MB@ IH10Y<*-Y !;') S@?J?SIU5CJ%F+];$W,7VIE+"'<-V!@]/H<_3/H: +
M-%1K/$\LD22HTD>-Z!@2N>F1VS4":II\D4LJ7ULT<./,83*0F>F3GB@"W6?K
M?_((G_X#_P"A"KD,\-S"LT$J2Q-]UXV#*?H17,>+/%NBZ4YT>[N)AJ$\:21P
MQ6LLN5+''**0"=C\$Y^4T!>QMZ)_R"(/^!?^A&M"N<\*:_IVIP2:?;23"\M%
M#3PS6TD+*&9MIPZC/0],X[UT="=P33V"BBB@ HIOF)O";UW'HN>:JW6KZ;8R
M>7=ZA:6[XSMFF5#C\32;2W$VEN7**S[O7=*L+.*[NM1MHK>;_5R&0;7_ -T]
M_P *HQ^-?#,B2,NN6($?7?*%)^@/7\,TN:-[7U)]I"]KF]17)+\3?"+3+'_:
MP4,<;WA=5'U)7@>]5+OXL^%[:9HXII[Q1_RTM4#(WT)(S4^UAR\U]"'B*25^
M96.XHKE=4\=V6F^';/6EL;V>WNP2H6/!0#NV3Q7-Q_''PT(IS=I-;R*N84^_
MYI],K]WMR>*J$E.7)'5^0>WI\W+?4].HKQU/CY8BYC\_38TM]P\QH[K>X7N0
M-HR?:K=A\4M9\57]U'X1T:*[@@ )-QE7 /\ >^8#KG@&F^90]IRNWHR?K--J
MZN_DSU>BO//&OC'Q%X:\-:5=_P!GQI>W+,MRL<;3+$<< 8/?\>E<?8_%_P 3
MBWNDFT"^O)I$Q;O#9LHB;GDC'S#IQ[5=.G5J/W8.W?H5[=<W+9_<>YT5\_VG
MCSXE?;89SHFO7<:."\)TW8LBYY4D)QGUKNUT+Q;XGB35GUV]T(7*AO[.(.ZW
M/0KD%<],YP#SS4SC5A#F<']Z_P R57DXW4'^'^9Z+17C/C"#XD331:+I^FW5
MY:6:C;J$5V(VNB5&2P+=CD8_G63I>E_%W3[._M8-#B,5ZFR0W5ZC,HP1E2)1
M@\^E:1H59-;)/O)?D/VD^:W+H>]>8F\)O7<>BYYK!U77KA-671M)CAEOA$)I
MY)L^7;H20N0.69B#A01TR<<9\D\*?#SQU8>)],O;[3M.CMH+E))6-QDA0<G&
MUCSZ=L]>*ZS79KSPM\1+R_L-&O[NROK*%[A;6SFF,DN^4$JR*R@J GRG'#9K
M&K"K!:VOY.XN>JXW<;/U.D'BB?1;I(/$KVD<$JDPWT"LD;,.J,A+%3C)!R0<
M'ICG2M/%FA7UI>75KJ,4L-FF^=E!^1>><8YZ'I7FFM6WBGXE,MOI6G/HEI8,
MLQ;6K62-IG8.ORJR%3M .>OWQ45C\-/B-812QVWBK2K59AB58+8 .!TSB,9Z
MG\ZNC1G-7E.*7G>_X"BZU]=OQ.\L?B1X<U'4[>PM9YWFG<1H?(8*2>E5]8^)
M-CI.K7&FC2]1N)X&VL4C 4_3G./PIG@/P?K?AN2Z?6]6M=0\P*(5BME3R\9R
M=V ><]/:M+QGX=UCQ%8VT.C^([C1)(I"[O"I/FC&,$A@1BI]C/FY'47K9V'R
MUG'623]/^",U;Q7?V6CZ=?V'AR_OFO%W-"H(:'@8W *W7/Z4:-X@U_5=+U&:
M;PW)974*9M8IY,"=L'CD#'('/OVKC'^%7BP1M)<?%35T1068_O  /4GSJ\ZU
MJ&Z745TKP_XW\0^(]08X*VQD$8_X%O;=]0,>]>CALJGB9VI5+VWTT7FVUI\V
M)J:E=RT[:'LEIX@\:P7<=SKVF:7IVD(<W$\DP4HOKGS#S^%<A<?$;Q1XA\47
M6G^$7-W;*^(W@M1M5>Q9I!Q]3QZ59T+X3ZWK<%G-X\UNZN(K=0(M/6<MM'^V
M_3/TR?\ :K4U/X(:)?:A+/:ZIJ6GV[XVVELZB-, #C([XSSWS5O!Y?0BZ=2K
M*<^Z^%?-:OY67F3[&;C;F?WZF7<_!_6];E&I:YX@2ZU%VRR2H72)>RKT'X8
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MZQ?]^C_\54U% $.VY_YZQ?\ ?H__ !5&VY_YZQ?]^C_\54U% $.VY_YZQ?\
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M_OT?_BJFHH AVW/_ #UB_P"_1_\ BJ-MS_SUB_[]'_XJIJ* (=MS_P ]8O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"M?JDFG7*21R21M$RLD0RS CD#WKF@TUS92&".2\LX9+=A,UL4EF17
M)9,8&_:,= .XY-==38XTB0)&BH@Z*HP!0!EZ0C->:E=B*2*&XF4QK)&48X0
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M (JMBB@#'_LB\_Z"T_Z__%4?V1>?]!:?]?\ XJMBB@#'_LB\_P"@M/\ K_\
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M^*K8HH Q_P"R+S_H+3_K_P#%4?V1>?\ 06G_ %_^*K8HH Q_[(O/^@M/^O\
M\51_9%Y_T%I_U_\ BJV** ,?^R+S_H+3_K_\51_9%Y_T%I_U_P#BJV** ,?^
MR+S_ *"T_P"O_P 51_9%Y_T%I_U_^*K8HH Q_P"R+S_H+3_K_P#%4?V1>?\
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gfmvgbft1fv3000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfmvgbft1fv3000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" );" <# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *R=9\2:9H46Z]N )",K"GS.WX
M?U.!69XR\6)X>M!!;E7U"8?(IY"#^\?Z"O'+FYGO+F2XN96EFD.6=CDDUWX7
M!.JN>>B.:MB%#W8[G=W_ ,4KMR5T^QBB7^],2Y/X# 'ZUCR_$+Q)(<K>)'[)
M G]0:Y>BO5CA:,=HHXG6J/J=)_PGWB;_ *"?_D"/_P")H_X3[Q-_T$__ "!'
M_P#$US=%5]7I?RK[D+VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!/_ ,@1_P#Q-'_"?>)O^@G_ .0(
M_P#XFN;HH^KTOY5]R#VL^[.D_P"$^\3?]!+_ ,@1_P#Q-7(/B3KT3#S#;3 =
M0\6,_D17'T4GAJ+^RON!5:BZGK.D?$O3[R18M0A:R<\"3.]/QXR/\\UVL4L<
M\2RQ.LD;#*LIR"/8U\XUTOA3Q=<^'[E8I&:73W;]Y%UV?[2^A]N]<.(R]6YJ
M7W'32Q3O:9[914=O<175O'/!(LD4BAD=>A!J2O(V.X**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "HKJXCL[2:YF.(X4+N?8#)J6N7^(%TUMX0N0AP9F6
M+/L3D_H#5TH<\U'N3.7+%L\CU;4IM7U2XOIS\\SYQ_='8?@,"J5%%?4))*R/
M';;=V%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >D_#;7'-K=:2YR8D:>#/
MI_$OYD'\37:K>W;*&"P\C/>O'?!URUKXMTYE.-\HB8>H;Y?ZU[!MV?+Z<5XF
M.IJ-6ZZGI8:;<+=A_P!LN_[L'ZT?;+O^[!^M,HKCLC<?]LN_[L'ZT?;+O^[!
M^M,HHL@'_;+O^[!^M'VR[_NP?K3**+(!_P!LN_[L'ZT?;+O^[!^M,HHL@'_;
M+O\ NP?K1]LN_P"[!^M,HHL@'_;+O^[!^M'VR[_NP?K3**+(!_VR[_NP?K1]
MLN_[L'ZTRBBR ?\ ;+O^[!^M'VR[_NP?K3**+(!_VR[_ +L'ZT?;+O\ NP?K
M3**+(!_VR[_NP?K1]LN_[L'ZTRBBR ?]LN_[L'ZT?;+O^[!^M,HHL@'_ &R[
M_NP?K1]LN_[L'ZTRBBR ?]LN_P"[!^M'VR[_ +L'ZTRBBR ?]LN_[L'ZT?;+
MO^[!^M,HHL@'_;+O^[!^M'VR[_NP?K3**+(!_P!LN_[L'ZT?;+O^[!^M,HHL
M@'_;+O\ NP?K1]LN_P"[!^M,HHL@'_;+O^[!^M'VR[_NP?K3**+(!_VR[_NP
M?K1]LN_[L'ZTRBBR ?\ ;+O^[!^M'VR[_NP?K3**+(!_VR[_ +L'ZT?;+O\
MNP?K3**+(!_VR[_NP?K1]LN_[L'ZTRBBR ?]LN_[L'ZT?;+O^[!^M,HHL@'_
M &R[_NP?K1]LN_[L'ZTRBBR ?]LN_P"[!^M'VR[_ +L'ZTRBBR ?]LN_[L'Z
MT?;+O^[!^M,HHL@'_;+O^[!^M'VR[_NP?K3**+(!_P!LN_[L'ZT?;+O^[!^M
M,HHL@'_;+O\ NP?K1]LN_P"[!^M,HHL@'_;+O^[!^M'VR[_NP?K3**+(!_VR
M[_NP?K1]LN_[L'ZTRBBR ?\ ;+O^[!^M'VR[_NP?K3**+(!_VR[_ +L'ZT?;
M+O\ NP?K3**+(!_VR[_NP?K1]LN_[L'ZTRBBR ?]LN_[L'ZT?;+O^[!^M,HH
ML@'_ &R[_NP?K1]LN_[L'ZTRBBR ?]LN_P"[!^M'VR[_ +L'ZTRBBR ?]LN_
M[L'ZT?;+O^[!^M,HHL@'_;+O^[!^M'VR[_NP?K3**+(!_P!LN_[L'ZT?;+O^
M[!^M,HHL@'_;+O\ NP?K1]LN_P"[!^M,HHL@'_;+O^[!^M'VR[_NP?K3**+(
M!_VR[_NP?K1]LN_[L'ZTRBBR ?\ ;+O^[!^M'VR[_NP?K3**+(!_VR[_ +L'
MZT?;+O\ NP?K3**+(!_VR[_NP?K1]LN_[L'ZTRBBR ?]LN_[L'ZT?;+O^[!^
MM,HHL@'_ &R[_NP?K1]LN_[L'ZTRBBR ?]LN_P"[!^M'VR[_ +L'ZTRBBR ?
M]LN_[L'ZT?;+O^[!^M,HHL@'_;+O^[!^M'VR[_NP?K3**+(!_P!LN_[L'ZT?
M;+O^[!^M,HHL@'_;+O\ NP?K1]LN_P"[!^M,HHL@'_;+O^[!^M'VR[_NP?K3
M**+(!_VR[_NP?K1]LN_[L'ZTRBBR ?\ ;+O^[!^M'VR[_NP?K3**+(!_VR[_
M +L'ZT?;+O\ NP?K3**+(!_VR[_NP?K1]LN_[L'ZTRBBR ?]LN_[L'ZT?;+O
M^[!^M,HHL@'_ &R[_NP?K1]LN_[L'ZTRBBR ?]LN_P"[!^M'VR[_ +L'ZTRB
MBR ?]LN_[L'ZT?;+O^[!^M,HHL@'_;+O^[!^M'VR[_NP?K3**+(!_P!LN_[L
M'ZT?;+O^[!^M,HHL@'_;+O\ NP?K1]LN_P"[!^M,HHL@'_;+O^[!^M'VR[_N
MP?K3**+(!_VR[_NP?K1]LN_[L'ZTRBBR ?\ ;+O^[!^M'VR[_NP?K3**+(!_
MVR[_ +L'ZT?;+O\ NP?K3**+(!_VR[_NP?K1]LN_[L'ZTRBBR ?]LN_[L'ZT
M?;+O^[!^M,HHL@'_ &R[_NP?K1]LN_[L'ZTRBBR ?]LN_P"[!^M'VR[_ +L'
MZTRBBR ?]LN_[L'ZT?;+O^[!^M,HHL@'_;+O^[!^M'VR[_NP?K3**+(!_P!L
MN_[L'ZT?;+O^[!^M,HHL@'_;+O\ NP?K1]LN_P"[!^M,HHL@'_;+O^[!^M'V
MR[_NP?K3**+(!_VR[_NP?K1]LN_[L'ZTRBBR ?\ ;+O^[!^M'VR[_NP?K3**
M+("07MR/O1QGZ$BI8]0C)"RJT1/<\C\ZK4$ C!&12L@-0$$9!R#2UE0S-:-U
M)A)Y']VM0$$ @Y!Z&H:L-"T444AA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<3\4"1X9M\=[Q0?\
MOAZ[:N)^*/\ R+-M_P!?B_\ H#UT83^-$RK_ ,-GDE%%%?2'DA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 :7A[_D9M*_Z_(?\ T,5[;+_K7_WC7B7A[_D9
MM*_Z_(?_ $,5[;+_ *U_]XUY&8_''T._"?"QE%%%>>=04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,%?SE R3GI@GTK:KSOX7?Z[7/^NR?^S5Z)36P!6;KNMVWA_33?7:2O$'"8B
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M&,X!.#R,\5ZG13L!Y#J^NRZ_XTT&X^Q36MJMQ&(/.7#2#S!EO3'TSTZUN>)
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MM"+?6O"T()(CF= 3WQ$173446 YW3O\ D>M:_P"O>W_]FK)\10W^GZ\\.F8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-;SQ')-4TKW6AG&ES1YFSS<:/J;1^8-.NS'_ 'A V/SQ5,@J2"""."#77?\
M"R=?\[?FUVY_U?E?+_//ZUNQMI?Q$T^53 EGK<*[@P_B'UZE?U&?S3K5*>M2
M.G==!JG"6D'J>9T4^:*2WGDAE4I)&Q5U/4$<$5Z'86.G>!]"AU;4[<7&JW S
M#"W\'? ], C)]\?76K64$K:M[(B$')]DCADT?4Y(_,33KMD/\2P,1^>*ILK(
MQ5U*L#@@C!%=?+\2M>>;>GV6-,\((LC\R<UM6E_IOQ"MI+&^MX[35T0M%,G1
ML>G?'JISQR/;)UJL/>J1T\GL6J<):1>IYK7>^./^14\,_P#7N/\ T!*XBZMI
M;.[FMIUVRQ.4<>A%=OXX_P"14\,_]>X_] 2G5=ZM-^OY"A\$OZZG-:3XAUC2
M+2>WTZ=DAD^9@$#;3CJ..#@5DA7D;Y0S,>>!DUW?@+_D7O$O_7N/_0)*I?#7
M_D;!_P!>[_TI.JH.HU';\=!J#ERIO<Y$([.$56+DX"@<YJS-I>H6T7FSV-S%
M'_?DA91^9%=YK&J6/@N\N(=.@CN-8N':6:XE'$08Y"@?0_U/I698?$G5H[M3
M?K#<VK'$B",*0O?&/ZT*M5FN:$=/7<'3A%VD]3BZ*Z[Q[HMKINH6U[8*JV=\
MA=57[H;C./0$$''UJAX2\.MXCU;R79DM8AOF<=<=@/<_XUJJ\'3]KT(=.2GR
M=3%@M;BZ<I;P2S,!DB-"Q'Y5)<Z?>V8S=6=Q ,X_>Q,O\Q7<:IX[BTACIOAN
MSMX[:$E3,5R&/J!_4YS56P^)-^)/*U6V@O+5^)%";6Q_(_0BLE5KM<RAIZZE
M\E-:.1Q%* 68*H)8G  [UUOC#P_9VT%MK>CG.FW?\(Z1L>?P!YX[$8K!T345
MTG6K2_>+S5A?<4]?I[]ZVA54X<\?Z\C.4.67*RI<6MQ:2>7<P2PR8SMD0J<?
M0U%74^-?%%KXDN+4VEO)'' K#=* &8G''!/ QZ]S7+4Z4I2@G)68II*5D[A1
M116A(4444 %%%% &EX>_Y&;2O^OR'_T,5[;+_K7_ -XUXEX>_P"1FTK_ *_(
M?_0Q7MLO^M?_ 'C7D9C\<?0[\)\+&45DZ_XCT_PY:I/?,Y\P[8XXURS^N!QT
MI^AZ]8^(;'[58NQ56VNCC#(?0BO/.HTZ*Q?%]P+;PCJDA.,P,@/NWR_UIOA6
M\GGTG[)>X%]8M]GGYSD@#:WT*D'\Z -RBN3\>WEP-&?3++!N+F*220D_=A0;
MG/X\#\:?K[:??>!HKO4FNC:^7#,QM2 Y)QCKQU-%P.IHK-DU6VL+^QTV5)D^
MT)MAF8 HS#^ MG.['/(Y]:=)J\":U%I21RRW#QF5R@&V)>Q8D\9/3&: -"BB
ML&_\6V%G>O9P07NH7,?^MBL8#*8_][H* -ZBLK2/$-AK+210&6*ZB&9+:X39
M*GU!_I7):K<6NI>/UAOM)U6XCMH56%8XV 1_,_UO##Y.G/MTHN!Z%116'KWB
MW2?#I5+V5VG8;EAB7<Y'KV _$T ;E%<WHGCG1==N1;022PW#?<BG4*6^A!(_
M#-7==\2:;X=@62_E(9_N11C<[_0?U.*+@:]%<6OQ0\/FV:79>!U('DF(;B/4
M?-C]<UJ:AXQTW3+#3;VXCN!#J"AHRJJ2@(!^;GW[9HN@.@HKS/QEXCL_$?@^
M:2QCG$4%XB>9*H4.<-TYS^>.M=#I_BBRTY=#T>YAN$EN;6'RI=H\LY4 #.<]
M>.G>E<#JZ*S-=UVS\/:=]MO/,*;PBI& 68GT!(]S5NPNUO[""[2.2-)D#JDH
M 8 ],@$TP+%%%8&L^,-,T+5(;"^$Z-+'YGFJH**,D<\Y[=@: -^BN1L_B1X?
MO+[[-YDT /"S3H%C/XYX_$"FI\2_#SWXMMUR$+;1<-$!']>N['X470'845P?
MBA;%_'>A-->WT<QV>6D**4/S<?-N!7/?@Y%;VO\ B_2?#KK'>22/.PR(85W-
MCU.2 /Q-%P-ZBO(?'7BG3/$FEV!L7D$D<S%XI5PRC'![C\C7KB?<7Z47 =11
M6?J^M6&AV7VJ_F$<><* ,LQ] .] &A17%Q?%#P_)'(S+>1L@RJ/$,O[##$9^
MI%:X\5V+>%CXA$5S]D'\&U?,^_LZ9QU]Z+H#=HKBY/B?X?01$+>.9!E@L0_=
M^S9/\LUU$.JV,^E+J:7*?8RGF>:3@ >_I1<"Y17&K\3?#S7GD9NA'G'GF+Y/
MKUW?I65\,'634=?=""K2(01W&7I7 ]'HKGO'/_(EZE_US'_H0JGX2U"UTOX>
MV-W>S+#!&K;F;_?;@#N?:G?4#K:*XR'XG^'Y9F1A=Q  X=XAAOI@D\^^*EN/
M&NFWOA"^U2."Z$"L;8JR+NW,HP?O8Q\P[T70'745YQ\+=9MA9SZ05D%PK/<E
MR!LV_*.N<Y_"M:\^)?A^TNC"AN;D X,D$8*?F2,_A2N!V-%9=EXAT[4=(FU*
MSF,T$*LT@489<#)!![UD:?\ $'1]3O+.TM8KQI[EBH0QK^[]V^;IU/&:=P.K
MHHK'UWQ+I_A]8OM9E>68XBAA3<[_ $% &Q17.6GC72KS3;V\C%PK62EY[=XP
MLBCZ9Q^M<;\.-<M8M<O;)HYO,U"7?$0!A0H9CNY]/3-*X'JM%<GJGQ$T+2[U
MK4M/<.AVN;= 54^F21G\,U-I_CO1]4UBWTVS%Q))."5D\L!!@$D')SGCTIW0
M'345@Z_XOTGPZZQWDDCSL,B&%=S8]3D@#\362_Q/T!;>.55O'9C@Q+&NY/KE
ML?D31= =I15#5-9L-%L?M=_.(HB<+QDL?0 =37.V?Q,\/W5R(7-U; G DFC&
MW]"<?C1<#L:*16#*&4@J1D$=Z1W2.-I)&5$499F. !ZF@!U%<RWCBP9F:TT_
M5;VW4X-S;6A:(>O)(Z?2MS3]1M-5LDN[*99H'Z,/Y$=C1<"U17-S>-+$7$D5
ME9:EJ*Q-MDELK8R(I],Y'Z5:TSQ3IFKZ@ME9O(\IA,S97&S#!2K \ALGTHN!
MM45S<WC;3(YYK:.&\N+N*=X3;00[Y&V]6 !^[]<5HZ1KMKK'FI''<6]Q#CS;
M>YC\N1 >A(]#1<#3HK'U7Q+8:5<K:,MQ=7C#<+:TB,DF/7';\:YKQ5XELM3\
M)ZC:&*ZL[S:C"WO(3$[+O7D=C^!HN!WM%<YJ<&G'Q5H4MP;O[8RR+;B-@(_E
M7)W]_P OQJ_J^OV&B^6ER[O/*<16\*%Y)/HHH U**Y#4O%=E>:-J%K/:WVGS
MRVLHB2^@,7F'8?NGD9]JU=$NX+'P9IUS=2K%#'91,[L> -HHN!M45S"^.; K
MYS:=JR677[8UF?)V_P![/7'X5>M_$EI>:=>WMG#<W4=K*8BL"!VE(QR@!Y'S
M>U%P-FBN(\'ZWYNIZG;_ -EZDGVF_DD\U[?"1?*/E<Y^5N.GN*W=4\3V&EW0
ML]ES=WI&[[-:1&20#U([?B:+@;5%8NE>)K'5+HV?EW-G>!=WV:\B,<A'J!T/
MYTFJ>*+/2[X69M[RZN GF2):0^9Y2?WF]!1<#;HJ"SO+>_M(KJUE66"5=R.O
M0BN7^(&I_9] NK'[#>R>=$#]HCBS$GS#AFSP>/UH Z^BLW2]62_T][J2TN[%
M(B0PO8_*.  =W7[OO[&LK_A.+%RSVVGZK=6H)!NX+0M%QU.<YX^E%P.GHK&L
M/%&FZG]M:S=YH[2)97D4##!@3@<YR,'((%0Z9XLL]8N8(K&TOI4D7+3B']U$
M=N=K-G&?89YHN!OT5@7WBZPM;V2SM[:^U&XB.)DL8/-\K_>.0*+/QAI=]?6M
MC%YZW4[LAADCV/$57<=X)R..XS1<#?HK*U?Q#8:,8X[@R27,O^JMH$+R/] /
MZU6L/%MC>7J6<]M>Z?<R_P"JCOH#$9/]T\BBX&]17(?$#4_L^@75C]AO9/.B
M!^T1Q9B3YAPS9X/'ZTNM7UAK'@^XN=3LM7L[6"1-R-&(I6((P0"<$9;]#1<#
MKJ*Q]2U_3O#_ -CAO9'CCF1MDAY " 'GG))R,8!R:JVWC*QGN(HY;+4K2*9@
MD5Q=6Q2)R>@#9[^]%P.BHJGJ6J66D6;7=_.L,*G&3U)] !R3]*QH_&UCO7[7
M8:I80.0JW%W:E(B3T^;)Q^-%P.EHJCI.J0:SIL=];!Q#(6"[P,_*Q7L3Z54U
M[Q-8^'/LIOEF*W#E5:-00N,9)R1QSVS0!LT5AZ3XKTW6+2\O(?-BM;1L//.H
M53WR.<]/7'45DCXG>'C=^3F[$><>>8?D^O7=^E%T!V5%<]I/C'3=9@U":UBN
M0EBF^0NJC</F^[@_[)ZXJKI_Q!T?4[RSM+6*\:>Y8J$,:_N_=OFZ=3QFBZ Z
MNBN<USQQHV@W)MKB26:X7[T4"ABOU)('X9S4V@^+M)\1,T=G*ZSJ-QAE7:V/
M7N#^!HN!NT45S6M^.M%T*[-K.\T]POWX[=0Q3ZDD#\,T =+17)0?$;0[F[L[
M: 74DETZQ@",#RV)  ;)]^V:NZUXPTS0=4AL;X3JTL?F>:J HHR1SSGMV!HN
M@.@HKE=*^(.B:MJ2V,1N(I';;&TR *Y] 03^N*T]=\2:;X=@62_E(9_N11C<
M[_0?U.*+@:]%>6^+O&>D^(O"\EO:&:.X$R-Y4R8) [C!(_6N^\-?\BMI/_7I
M%_Z"*+@:E%>>?$UUCO?#[N0JK,Y)/892M6'XD>'YM16T62X56;:MPT>(R?SR
M/Q%%P.NHK@_%*63>/-#,UY?1SDIY:0HI0_.>Y8%<]^#D5O:_XOTGPZZQWDDC
MSL,B&%=S8]3D@#\31<#>HKBW^)^@+;QRJMX[,<&)8UW)]<MC\B:S_B9(J7GA
M^1B%03,Q)[#*4K@>B45R,/Q(\/S:BMHLEPJLVU;AH\1D_GD?B*ZZF 45E:_K
M]KX<L%O+R.9XVD$8$*@G)!/<CTK!F^)_A^*1$47<H8 EDB&%]CDCI[9HN!V=
M%9,OB33D\/R:W%(UQ9HN28A\W7&,'&#ST-4=(\;:7KFI16-E'=-(\7FLQ0!8
MQZ,<]>G3(YHN!TE%<IJWQ"T+2;MK5FGN94.UQ;H"%/IDD#\LUJ:-XETW7[:2
M73Y6D:,9>$KM=?P/\^E%P->BL;P_XFL?$:7!M$GB>W8+)'.H5AGH>"?0_E26
MGB:ROO$-SHMO'.\]N"9)0H\L8QD9SG.3CIUHN!M45R>J?$30M+O6M2T]PZ':
MYMT!53Z9)&?PS4VG^.]'U36+?3;,7$DDX)63RP$& 20<G.>/2BZ Z:BO.O"G
M_)3O$'TD_P#0UK:U;XA:%I-VUJS3W,J':XMT!"GTR2!^6:5P.KHK)T/Q'IGB
M&%I+"<LR??C<;73ZC^HK(N?B+HEG=WEK.MTDMJY0CRP?,8'!"X/\\4[@=;16
M'X?\6:9XD\Q;)I4EC&6BF4*V/7@D$?C4.N>-=&T";[/<RR2W ^]# H9E^N2
M/IG-%P.BHKGM"\::/X@F\BUEDBN,$B&==K$#TP2#],YJ77O%ND^'2J7LKM.P
MW+#$NYR/7L!^)HN!N45S>B>.=%UVY%M!)+#<-]R*=0I;Z$$C\,UTE !16?J^
MM6&AV7VJ_F$<><* ,LQ] .]<3K?C[1=;\.:E9P_:(9WBQ&LZ ;SD< @G]<47
M ]&HKRIUM6^$6G?:[BYAC^T-S @<D[WX*EER/QZXKKW\2:9X>T'2Q/+=3M-
M@@C"[II!@<D9QGD=Z5P.FHK&T+Q-I_B#SEM/-CFA/[R"9-KK]>WZUFZM\0M"
MTF[:U9I[F5#M<6Z A3Z9) _+-.X'5T5DZ'XCTSQ#"TEA.69/OQN-KI]1_450
MUOQUHNA79M9WFGN%^_';J&*?4D@?AFBX'2T5R4'Q&T.YN[.V@%U))=.L8 C
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M6*_B)9,^7*APZ9]#_0\46 YGXHG3_P"P8A+Y?V[S1Y']_;_%^'Z9Q74>&O\
MD5M)_P"O2+_T$5SZ_"_P^+9HM]X78@^<91N ]!\N/TS766-I'I]A;V<19HX(
MUC4N>2 ,#/O1U X'XHQB:YT*(C(>5U/XE*=\4[:"'0-.\J%$\J?RTVKC:NT\
M#VX'Y5U>N>&K/7YK.6ZEG1K1R\?E, "3CKD'T%.\0^'+/Q+9Q6UY)/&D<GF
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MD,6<9]2?S''?-8MIXSUJPU>TL?$NE16JWA BDA/3/'(W-GDC/((HN!W=%%%
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M[33;JYC"EXH7=0W0D GFL;P9K]UXBT5[V\CA219FC A4@8 ![D^M '14444
M%%%% !1110 4444 %%%<IXC\3WND>)=(TVWBMVAO'59&D5BPRX7C! Z>U '5
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4^S_
M .0@W_7+^M,I]G_R$&_ZY?UH>P&E1116104444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$_%'_D6;;_
M *_%_P#0'KMJXGXH_P#(LVW_ %^+_P"@/71A/XT3*O\ PV>24445](>2%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%\0-L-#LYI<8%XMV%BSZE#\WX9J2'0+BT\-:I"\OVK4[^.1YI!P'D92 HST
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M2_KC#-SVY(QZ4,#T0$,H(.01D&O./BKO\S1?*.V3?)M.>A^3%>C@!5  P ,
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M4^+%Q9P74MJ)$42RPG#!!&I(!]\8_&KNE>&_$R^/;76-52.9,,9)HY%VIE&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "GV?_(0;_KE_6F4^S_Y"#?\ 7+^M#V TJ***R*"BBB@
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MKSSJ"BBB@ HHHH **** "BBB@ HHHH **** *][96VHV<EI>0K-!*,.C=_\
M ^]8)\$VC'8VJZRUK_SZF]/E8_NXQG'XUTU% $-K:P65K';6T2Q0QKM1%' %
M0:AID.I?9?.:1?LUPMPFP@99<X!R.G-7:* "BBB@"EJ&F0ZE]E\YI%^S7"W"
M;"!EES@'(Z<U=HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,73/#%EI6M7NJP2W#3WA8R*[*5&6W<8 /7WK:HHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !3[/_C_;_KE_6F5-8+NFFD[#"#^M
M#V OT445D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5QOQ-B,GA9&'_+.Y1C^3#^M=E6/XITXZIX:
MOK51F0Q[T _O+\P_/&/QK:A)1JQD^Y%5<T&CP:BBBOICQPHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** -3PVC/XGTH+U^UQ'\F!KVISF1CZDUY7\/[#[5XC%
MTRDQ64;3-Z9QA1^N?PKTQ;B/8NYOFQSP:\?'RO4271'H856A<FHJ+[1%_>_0
MT?:(O[WZ&N&S.DEHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS
MEHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:
M(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[
M1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ
M&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_
M0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS E
MHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(
MO[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1
M%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&
MBS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0
MT?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EH
MJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O
M[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%
M_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&B
MS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T
M?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ
M+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[
MWZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_
M>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS
M EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?
M:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+
M[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[W
MZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>
M_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS
MEHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:
M(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[
M1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ
M&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_
M0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS E
MHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ+[1%_>_0T?:(
MO[WZ&BS EHJ+[1%_>_0T?:(O[WZ&BS EHJ,3QGH2?H#4B13S'"1E!_>?C]*
M&L6+".,9D;@#^M:4$(@A6,=NI]33;>U2W!(^9SU8]ZGK.3OHAH****D84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M51_P@/AG_H&?^1Y/_BJS?^%HZ)_SZZA_W[3_ .+H_P"%HZ)_SZZA_P!^T_\
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MZZA_W[3_ .+H_P"%HZ)_SZZA_P!^T_\ BZ.3&>?WAS4/(TO^$!\,_P#0-_\
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M[%%F!+147VF#_GO'_P!]BC[3!_SWC_[[%%F!+147VF#_ )[Q_P#?8H^TP?\
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M[%%F!+147VF#_GO'_P!]BC[3!_SWC_[[%%F!+147VF#_ )[Q_P#?8H^TP?\
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MY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4
M,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\
M\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YY
MK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]%
M #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?
M_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^
M>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?
M10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5
M'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/
M_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*
MGT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'
ME1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*
MC_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?
MRI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E
M1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 S
MRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS
M7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFO
MY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4
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M%J.I))=7%UN<L9679R1V/)[\YIW TM$U[4KOXA:KI<]SOLH$<QQ[%&TAE Y
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MN(O(T\:^*-7NHCYEI96++ >Q;:=O_CQ8_A73?#J<W?@E8 ?FADDBY[9^8?\
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M!C&!D=^@_"N^HI6 Y;0_#5YIGBW5M6FE@:"\W>6J,2PRP/((Q^M<[X]^P_\
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MZWH&H"QOW&)%<?(_OT/IR""#UKL**+ <EI&A>)QJL=[K7B#S%C&/L]L,(_\
MO#:!^F?<5SGCNS.H?$#2+03-"TL2*)%ZH=[<BO4*SKK0=-O=4M]3N+;?>6X
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M],?E4MWX0U"?5_#UVLUL(]-AB28%FRQ4Y.WY>?QQ7:T4K(#C];\'7<FM'6]
MU 6-^XQ(KCY']^A].000>M/TC0O$XU6.]UKQ!YBQC'V>V&$?_>&T#],^XKK:
M*=@.6U;PU>7_ (UTS68I8!;6J!75F.\X+'@8QW'>F^*_#-[KNK:3=VLMND=F
M^Z02LP)^93Q@'TKJZ*+ <OXF\(?VS=PZE87;6.IP#"RJ.& Z9QR#[^G&#68G
MA?Q;J%W;MK/B)5A@<.OV,88G_OE1G'<Y^E=W118#E-=\,7NI^+-)U6"6!8+,
MKYBR,0QPV>,#'ZTZ+PU>1_$";7S+!]E>+8$#'?G8!TQCMZUU-%%@.4U#PS>W
M?CNQUR.6W%K;H%9&9MYQNZ#&.X[URWB,VR>.7DTZ_ET?51]^2[4+!)P,$,"<
M CU&#CL:]4K.U30=+UI5&HV4<^WA6.0P^C#!I- >0>(H[W4M1L(+C7(=7OY6
MV!;3#1Q D 8( !)[X Z<U[>HPH'H*RM+\,:+HTIEL-/CBEQC>278?0L216M0
MD 4444P"BBB@ HHHH **** "BBB@ HHHH *?9_\ (0;_ *Y?UIE/L_\ D(-_
MUR_K0]@-*BBBLB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "N)^*/_ "+-M_U^+_Z ]=M7$_%'_D6;
M;_K\7_T!ZZ,)_&B95_X;/)****^D/)"BBB@ HHHH **** "BBB@ HHHH ***
M* /2/"UU/9?#/5+FVD,<T<SLC@=#M2N6/C;Q&1C^U)/^^%_PKH] _P"24ZQ_
MUU?^25Y[7%1IPE.;DKZG14E)1C9]"W?:I?ZFX:]O)K@CH)') ^@[5/X>_P"1
MFTK_ *_(?_0Q6;6EX>_Y&;2O^OR'_P!#%=,TE!I&46W)7.@^)DC/XI12>$MD
M _-C_6LOP7$DWC#35D *B0L,^H4D?J!6A\2#_P 5:_M"G]:YK3KV33=1M[V+
MEX) X'K@]/QK"C%O#**ZHTF[5FWW-KQU/)-XQOO,)_=E44>@"C_]?XUSE>B>
M+-"_X22"'Q'H:FX$J 3Q)]_(XSCN1T(]A7 BTN3-Y(MY3)G&S8<_E58:<732
M[:,FK%J;?<W_  #-)#XQLA&3B0.CCU&TG^8!_"JGB^)(?%NIK'C:9BW'J>3^
MI-=5X5T7_A%[6;Q'KB^04C*P0M]_)]O4] /<YK@[^\DU#4+B\E_UD\C2,!VR
M<XJ:;4Z[G'9*WS*DN6FHO?<[GXDSR_8]%M\D0F(N1V+84?H#^M>?5[#XHT2/
M7]%LK2*6-=2CB\VW1CC>N &'\OTKR>\T^\T^<PW=K+#(#C:Z$9^GK4X*I%T^
M7JAXB+4[D".T;JZ,593D$=0:[WXF 21Z)<NN)I87W_\ CI_FQK+\*^#[O5+R
M.ZO86@TZ,AW>4;?, YP,]O4U#XWUV/7-=S;-NM;9?*B8=&]6_$_H!52:G7CR
M_9O?YB2<:3OU-_QC(P^'OAZ,'Y62$G\(O_KUYW7H'C(_\4+X:'_3&/\ ]%"O
M/Z>#_A_-_F*O\?W'>^./^14\,_\ 7N/_ $!*VY3HUK\/-)AU4SK9S(A/D=W(
M+8/XY/X5B>./^14\,_\ 7N/_ $!*F\.R0>*O!TOAV:58[VV^>W+'J!R#^&2#
M[$5R<O[F,GLF[_>]3>_[QKJT4O\ BWW_ %$/UI?^+??]1#]:Y74=(O\ 2KAH
M+VUDB93C)7Y3]#T-:GA_PAJ6MW4>8)(+//[R=UP,?[.>IKIE"$8\SJ.WJ9*4
MF[**^XT/'&OZ7KL6G_8))7DMPRN9$P2#C'/?I^M9W@C_ )'+3?\ ?;_T$U'X
MLATBVUM[?1@WDQ +(=^Y2_?&?\YJ3P1_R.6F_P"^W_H)IJ,8X9J.UGN)MNJK
M]P\;_P#(Y:E_OK_Z"*Z'P6S6O@CQ!=P<7 5@&'483@_ADFN>\;_\CEJ7^^O_
M *"*T/ .M6]C?7&FWQ46=^NPEN@;D#/L02/RJ*D6\,K=D.+2K._F<?170^(_
M".H:%=R;89)K(G,<Z+D8[!L=#65I^DW^JSK#8VLLS$XRJ\#ZGH/QKJC5A*/.
MGH8N$D^5K4[+PK/(_P /?$,+$F.-6*Y[93G^55_A=_R,US_UYM_Z&E=-'I-O
MH?@#5M/29);I(':Z*'.'*]/P&/Y]ZYGX7?\ (S7/_7FW_H:5Y[DITJLEL=23
MC."9R^LR-+KFH2,?F:YD)_[Z-1:?>RZ;J-O>P'$D+AQ[X[?0]*74CG5+LGO,
M_P#Z$:JUZ,4G"S.5O6YW/Q!L8KC[#XALQFWO8U#G_:QD9]\<?\!JQHG_ !2_
M@&[UAOEO+\^7;^H'(7_V9OP%.\&-#XB\-7OAJ\<@Q_O86[JI.>/HW_H59_Q#
MU*.34X-(M<+:Z?&$VCIN('\A@?G7!&\FL,^C_#H=+LE[5=?S.,HHHKTCD"BB
MB@ HHHH **** "BBB@ HHHH **** -+P]_R,VE?]?D/_ *&*]ME_UK_[QKQ+
MP]_R,VE?]?D/_H8KVV7_ %K_ .\:\C,?CCZ'?A/A8RBN+^(/B>_\/V]I%I^(
MY;@L3,RAMH7' !XSSWJ;P#XCO?$.EW!OPK36[A?-5=N\$9Y XS]/:O/OK8ZC
M=UK6(-#L!=W$,\JF18PD"AF)/3 )%9/_  FUM$-]YH^M6< ^]/<61"+]2":3
MQY)Y.AV\NQWV7L+;4&6;#= /6FW'B>YO[66VL_#.KM-*A11=VXBCY'\1)Z4@
M.HCD2:))8G#QNH964Y!!Z&G5S?GR^%/"VG62Q_:[\A+:&,' >0^_91SSZ"H_
M[.\8%?M/]O6@F^]]D^QCRL_W=_WL>].X'452T_4X=2>\6%9%-K<-;OO &6 !
M)&#TYK.T_4KO7=)NH4?^S-4MY/)F^02"-Q@Y /!!'2L;P?8ZLFIZG+)K7F01
M7\BSP_94'GOM'S;NJ]1P/3WHN!V]%<L]_K6OZA=6^C7$5A8VLAA>\>(2O)(.
MH53Q@=,FGQ76MZ%>6\6KW4.H6-Q((5NDB\J2-S]W<HXVD\9]Z+@=-17):UJN
MN)XMBTG2?*(FLQ(3*!MA.\@N>,G@8QG&2*?YNNZ!=V;ZEJL6I6EU.MNP^S+"
M\3-]TKMZC/7-%P-W4=3ATQ+=IUD87%PENNP X9C@$Y/2H=7UVUT9[-+F.=S=
M2^4GE)NP?>N=\:V6J/<6,T6L>7;O?0)%!]F4^4^>'W=3@\X/%7]5N=4T;3]'
MC?4?M%Q+J,4$\_D*GF(Q.1MY XP,CGBE<#IJ*Y_6-4U"35(]%T58A=M'YL]Q
M,,I!'G X[L>P_P C/U%?%FA:;<7HU6#54CC9G1[98708^\I&0<=<'L*=P.CU
M+4X=+AAEG61EEF2!=@!.YC@9R1Q5VN.U6YEO/".@7,[[YIKBS=VP!EB02<"N
MMF61X)$BD\J1E(63;NVG'!QWQ0!6M]3AN=4O-/19!-:*C2$@;3O!(QS[5=K@
M]'TW6U\9:FK>(-S0_9VN&^QH/M"X)"XS\N!D9'K6Q?ZCJNHZO-I6B-%;BV"_
M:KV5-VQF&0J+T)QSSQ2N!TE%<E<7'B+PTGVV_O8M7TY2/M!%N(98EZ;E"\,!
MWKJT=9(U="&5@"I'<4P*EMJ<-UJ5[8HL@EL]GF%@-IW#(QS5VN)5]6?QGKUK
MI0BB:3R#)=3#<L0$?0+W8Y^G!JS<R^)/#<7VZ\OXM7L$(-POV<0R1KW9=O!Q
MUYI7 ZVBL+6M<GMTL;;28H[F^U#_ (]]YPBH!DNWL 150Z?XOMA]HCURUO7'
M)M);01H?8.O/TS^-.X'451UC58-%TN;4+E)'AAQN6, L<D#C)'K2Z3J4>K:9
M#>QHT?F AHVZHP.&4_0@BL?Q_P#\B3J/T3_T-:.@&SI6I0ZQID%_;K(L4R[E
M$@ 8<XYP3Z5<KS'P\OC6\\,VG]DS6EE:0JRQ^8 7FY//*L.O':M[PIXNGU!+
MZTUF)8+ZP4M*0,!E'4X]1[<<TDP.PHKR_P#X3'7-?NIGT[5=*T>TC;""\E0.
MX]]P;] !]:VO"OB^ZO-7DT35'M9KD*6BN;1PR2@#)Z<9QSV^@HN!VU9NNZW;
M>']--]=I*\0<)B( MD_4BN 7Q?KNK:K>QV>I6E@T#D6]E/&H,^"?EW,.&X]1
MR:M_$5-:?PU9S7,EO%"-HNH(^<RGH5)&<#GO^=%P/0+2Y2\LX+J,,$FC610W
M4 C(S67K_BC3O#?V87WG$W#$*(DS@#&2>1QR/>H?!D6IQ>'+?^T[B*8LJM!Y
M8QLBVKM4\#D<^OUK%^(^HW%@FE>1Y/SS,3YL"28(Q@C<#@\]11?0#N58,H93
MD$9%+7 >,/$FMZ7XJT^QTN166>)3Y#1J0[EF')QD=NA%0-K_ (I\.^)+&UUR
M>VNK:]8 ")  N3C@X!R,CKFBX'HU%%<?XG\4W]MJ\.@Z';I+J,RY9WY$8/MZ
MXYR> /6F!V%8NI>)K+2]:LM*GBN&GN\>6R*"HR<<Y(/Z5SRO\0-)N8'N/LNK
M0R.%:*(!2GX[5Q]3D54\7$GXB^'"1@DQY![?O#2N!Z-17":SXEUS4?$KZ!X;
M6.-X/]=<R $ \9Z@@ 9QT)S6/XBUWQMX<BMX;VZMCYA)6Z@B5M_JIRN!CZ#\
M:+@>IT5Q'C;Q3?:/=:?8VDR6OVD;I+N2/>$&<<#!Z=3QZ5?\/ZAK0L+ZXU&>
MTU"UA4O;W-L1F; R1@<#T['/K3N!U%%>7:5XJ\2ZW*T]GJ=@)Q, NF2(%W(>
MX8\GZ YX_"O3TW;%W@!\?,%.1GVH3N!B^(?%>G>&EA^VB9WFSLCA4$X'4\D#
MO6EIM_#JFG07UN'$4Z[E#C!Q[UYE\08-3;QCIX%Q%ME919#'^J.5!W<?WN>]
M=)K?B34_#^GZ=II6*^UZZ&W*_<SG&<8'4\#IT-*X'9T5YY=WWCKPY;?VGJ,U
MG?6BD>;"@ ,8)]0H^F>:D\5>,;R#2-%U/1YBD=VS%T9%;=C'RG(]<CBBX'?U
MBZ_XFLO#@MC>17#_ &ABJ>2H.",=<D>M'AV'7DMYI->NH9996#1Q0J (EQTS
M@9/XGIUKE?BI]S1_^NS_ /LM#>@'4?\ "5Z:/$PT']]]K(^]L^3.W=C.<YQ[
M8]ZW*X-]0N3\5EL5:)8C!@-Y$>\?N\_?V[NO;-6?".OZC+K6J:)K=P);NV;=
M&^Q4W*.#P /8CZT7 [.BN)\/>(M0UG7M6O7N=FA688(@C7#8[YQGH">O<5B_
M\)CKFOW4SZ=JNE:/:1MA!>2H'<>^X-^@ ^M%P/4**XGPMXONKS5Y-$U1[6:Y
M"EHKFT<,D@ R>G&<<]OH*R?#VM>+_$5W<6]O?P1PV\X,L\D2!MA.-JC:0> 3
MT_&BX'IE%%<_K.JZA_:D.C:,D1O)(_.EGFY2"/.,X[DGH*8'045RLL/BK1HF
MO6U2#5X8QNEMWMA"VT<G85ZGZU>U2]OI-*M=7T:3S8T F>VV _:(B,D ]0P'
M(Q^M%P-RBN9M]=D\1:K;Q:+<%+" "6[N-@.[(^6(;@>?7TJK+J/B&\\5ZII.
MG2P1P0B)OM$R!O(!3)"J/O,3SR<<&BX'845R5S/XB\-(+Z^OX]7T]2/M %N(
M98EZ;E"\$#OG_P"N%UK5-6/B73].TB>)8[RV9][H&5.<[_4\< 9QS1<#K**Y
MN_U#4](M+'3(IEU/6;MF"2R1B- !R78+T !'UJ,Z?XOMA]HCURUO7')M);01
MH?8.O/TS^-%P.HHKE]4\32_\(E#JEBJP23R)"S3C(MB6VL6_W3D5:L#KEA#<
MF^N8=4@6$RPW$:"-V;^X5'&/0BBX&]17(^'KOQ#?PV>J'4;.]M;D_OK58PGV
M<'^ZPR21W!_^O5J_U+5=1UF;2-$:*W%LH-U>RIO\LL,A57H3CGGBBX'245RL
MLWB'PZ!=ZAJ$.JZ<"//;[.(98@3C< O! ZG-:&N:S/9-:6>G0)<:C>DB!7.$
M4 9+M[#]:+@;54=-U6#5#>"!)%^R7#6S[P!EEQDC!/'-8XT_Q=;C[0NNVMU(
M!DVDEH$C/L'!W?0U%X%E>>#6I986AD?5)6:)CDH2%R/PHN!U=%07MY#I]C/>
M7!Q%"A=R/05S5M'XKUN!+\:G#I$4HW16JVRS-M/(WENA^GZ4 =917)Z3JNN'
MQ@VD:KY(6*R,FZ$?),=X <9&1P2",XR#3WO]:U_4+JWT:XBL+&UD,+WCQ"5Y
M)!U"J>,#IDT7 ZFBN9BNM;T*\MXM7NH=0L;B00K=)%Y4D;G[NY1QM)XS[U!K
M6JZXGBV+2=)\HB:S$A,H&V$[R"YXR>!C&<9(HN!UM%<KYNNZ!=V;ZEJL6I6E
MU.MNP^S+"\3-]TKMZC/7-6M9U74/[4AT;1DB-Y)'YTL\W*01YQG'<D]!1<#H
M**Y66'Q5HT37K:I!J\,8W2V[VPA;:.3L*]3]:?KVN3_9-)_LR[BM4U.0*+R5
M PB4KN'!XR>G-%P.GHK-T=-6A26#598;@QL/*N8UV&5?]I.BD>U:5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !3[/\ Y"#?]<OZTRGV?_(0;_KE_6A[ :5%%%9%!1110 4444 %%%%
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ME9170****Z#(**** "BBB@ HHHH **** "BBB@ HHHH TO#W_(S:5_U^0_\
MH8KVV7_6O_O&O$O#W_(S:5_U^0_^ABO;9?\ 6O\ [QKR,Q^./H=^$^%F?J>D
MV&LVOV;4+9)X@=P#$@@^H(Y'X4[3M,LM)M%M;"W2"%3G:O<^I)Y)]S5NBO/.
MHYKQM_R";/\ Z_X/_0JZ6BB@#"\36=Y+%97]A$)KBPN!/Y&<>:N"& ]\'BJG
M_"?:)MV'[8+SI]C^S/YN[^[C&,_C7444 8/AJSO$%_J-_%Y$^H3^:(,Y,:
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M7]:93[/_ )"#?]<OZT/8#2HHHK(H**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?BC_P BS;?]?B_^
M@/7;5Q/Q1_Y%FV_Z_%_] >NC"?QHF5?^&SR2BBBOI#R0HHHH **** "BBB@
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M*BBBLB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N)^*/_ "+-M_U^+_Z ]=M7$_%'_D6;;_K\7_T!
MZZ,)_&B95_X;/)****^D/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMZC*EC@'@=.>0>U:NL1Z;X#EN+VS@CEU"]D/V57'RVZ8&['XD_H.QKSW2O\
MD,67_7Q'_P"A"NL^*$A;Q';1_P *VJD?4LW_ -:B=&/MU%:)K5=[#C4?LVWN
MMC-A\>^(HKL3M?>:N<F)XUVD>G X_"M?Q];6U[IVF>(K:,1F\4+*!W)7(S[C
M!&?85P==_P"(?^26:'_UV3_T&2JJ0C3J0E!6UL3"3E&2D[G+^&]=?P]JZWRP
MB9=A1T)QD'T/8\4[Q/K[>(]6^V& 0*L8C1 V3@$GD^N2:QJ*Z?90Y_:6U,N>
M7+R] HHHK0@**** "BBB@ HHHH **** "BBB@ HHHH **** -+P]_P C-I7_
M %^0_P#H8KVV7_6O_O&O$O#W_(S:5_U^0_\ H8KVV7_6O_O&O(S'XX^AWX3X
M6<CXU\(R>)[>W:VG2*ZMR0OF9VL#C(..G2IO!GA=_#&G2QS3K+<3N&D*9VKC
MH!GD]^:Z6BO/L=1QWQ-_Y$]_^NZ?UI^@>#/#XT_3-0%A_I0BBF\SSI/OX!SC
M=CK6YKNB6WB#338W;RI$7#YB(#9'U!JY:6R65G!:QEBD,:QJ6ZD 8&:5M0.!
M#BV^,\AEP@FA 0L<9_=CI^((ILQ$_P :(#$0XBBP^TYV_NVZ_F*ZKQ!X3TOQ
M)Y;7J2)-&-JS0L%;'IR""/PI/#_A+2_#9D>R21YI!M::9@S8]!@  ?046 Y#
M0O\ D?O%/_7&;_T(4> O^1"USZR_^BA77VGA2QL]7O\ 4XY;@S7RLLBLR[0&
M.3CC/YDTND>%;'1=(N]-MI;AX;G=O:1E+#*[3C  Z>U%@/,%_P"24O\ ]A/_
M -EK6U+_ )&7P7_U[6_\ZZT> ]+'A\Z+Y]Y]F,_G[MZ[]V,8SMQC\*L3^$-/
MGOM+NVFN1)IJ(D(#+A@IR-WR\_ABE8#F?"O_ "4SQ!_NR?\ H:TWX56D175+
MID4R>8L88CD#DD?CQ^5==I_ABRT[7;S5X9;AKB[!$BNRE!D@\ #/;UIWA_PW
M9^&X9XK.6=UG?>WG,#@^V *:0'"^$(Y(]2\70V2['5)%A5> "&<+BM#X5_V?
M_95T$\O^T/-/F9^_LP,?AG-=-IGABVT6\U"]L9IC<7I+-YY#(K9)X  .,GUK
MS#4$TZ/5;D^*-'O+&X+Y#:;@1R^IPY(_%3^%+89L6_V#_A<<7]G>7Y66W^5]
MW?Y3;L8]_P!<UZG7EG@G1FN_%G]L6NGRV6EVZD0B4G+G;MZ]R<DGL.E>ITT(
M\^^*?_'KI/\ U\'^0J+XH1B:?08B,AY74_B4KKM?\-V?B..W2\DG00/O7R6
MR??(-)K?AJSUZ:RDNI9T:S<O'Y3 9)QUR#_=%#0'*?%.V@AT#3O*A1/*G\M-
MJXVKM/ ]N!^59GQ 2XEU?05:6**%K=0DD_,:OGDMP1C[N>#7H'B'PY9^);.*
MVO))XTCD\P&%@#G!'<'UJ;4=#T_5M.6QOH!-$@ 0DX92!C((Z&BP'!ZMH?BR
M[TU8-5U_1/L;D!/,VH,]MI\L8/TKM_#6GW6E^'K.QO)8Y9H5*EXV)4C)VX)
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M9:CK]GK$TMPMQ:!0BHRA#@D\@C/?UIEKX3TZVU;4-1W3R/?HR31R,"F&.2
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M:9I5G=P0><SW:%)KB5]TC Y[XQW]*ET?PU8:+I$NF1>9/;2LS.MP0V<@ C@
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M ]P>1ZY(K#U/P5KNFW#(+&6YCS\LENI<,/H.1^-<]6]9^,_$-C"(H=2D,8&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "GV?_(0;_KE_6F4^S_Y"#?]<OZT/8#2HHHK(H**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KB?BC_R+-M_U^+_ .@/7;5Q/Q0!/AFW]KQ<_P#?#UT83^-$RK_PV>24
M445](>2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!I>'O\ D9M*_P"OR'_T
M,5[;+_K7_P!XUXEX>_Y&72O^OR'_ -#%>VR_ZU_]XUY&8_''T._"?"QE%%%>
M>=1SGB!0_B+PV#VN9#^49-1>-K![JQLKD-=+#:7(EF:U;$J)@@LON,@_3-=)
M);PRR1R20QO)$28V902A(P2#VXJ2BP' "'P^;;[1_P )[JVS;NQ_:8W?]\XW
M9]L5;L=&M[_P?JJZ7<ZC,=0#%9+]OFD8# 8' ^5L#DUTQT72C<_:#IED9]V[
MS3;KNSZYQG-7J5@.<T?Q7I$FG1QW=W#8W4"B.:WN7$;(P&",'&1]*S],UFVU
MKXA&6S5FMX].=%G*D"7]XN<9Z@'CZYKI[K2M.O91+=Z?:W$@& \L*L1^)%3+
M:VZS+,L$0E5/+5P@W!?[H/I[4P.4T'5K7P_+=:+J\B6<RW$DL,LQVI/&S9#!
MCQGG!_\ UXUXO$UE>:O%IVG'[<Q!:::!@8X5QP2W0DGC K4NK.UO8O*N[:&X
MCSG9*@<?D:2UL[6QB\JTMH;>/.=D4809^@H Q-' _P"$Q\2''.;;G_MG3-?)
M'BKPSC_GM-_Z+KH4MX8YI)DAC667'F.J@,^.!D]\4DEO!++%+)#&\D1)C=E!
M*$\'![46 YW1_P#D=_$W^[;?^@&I? P \'6.!C[_ /Z&U;J6T$<\LZ01K-+C
MS)%0!GQTR>^*6"WAM85AMX8X8E^ZD:A5'T HL!S-I$9_&'B6 ,5\RV@7/IE6
M&:;X:U[3K#28=)U*XAT^^LE\J6*X81@XZ,I. 0>O%=.+:!9I)EAC6:4 22*H
M#,!TR>IQ7)7&GZS9C[-/HMIXCMD8FWEN9E$R*><.9 <XZ9%(!EUK5IJWCC04
ML3YT,#SAKE1\A8QGY5;O@#)QZBNUKF]*TW4;G4;?4=3M[>RCM8V2ULK=MVS=
MP2Q'&<<#%=)30'*7UTGA_P 8OJ5\&6POK=(1<8)6*12<!O0$'K3O$/BS1X]&
MNH;>ZAOKB:%TC@MV$I;(/7&< #DY["NGDCCFC:.5%>-AAE89!'N*JV^D:;:+
M(MMI]I"LB[7$<*J&'H<#D4 5_#7_ "*VD_\ 7I%_Z"*YOXJ?\BM!_P!?:_\
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MJ=Q8W _>0OMSZCL?Q&#52OITTU='CM6=F%%%%,04444 %%%% !1110 4444
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MK_R&*/[/E_Y^O_(8HN@(:*F_L^7_ )^O_(8H_L^7_GZ_\ABBZ AHJ;^SY?\
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MK_R&*/[/E_Y^O_(8HN@(:*F_L^7_ )^O_(8H_L^7_GZ_\ABBZ AHJ;^SY?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_HKP#_A(=;_Z#&H?^!3_ .-'_"0ZW_T&-0_\"G_QH_LR?\P?7(]CW^BO /\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH **** "BH+RZ2RL9[N4,8X(VD8*.2 ,G%5-#UNV\0::+ZT25(BQ3$H
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MK0]@-*BBBLB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAZA4S_2N>5:HJ4I+=2M^)K&G%S2\C&M?!-M:6D=SXCU2/3_,&4@&#(1[_P"
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M/$?BS2[W14DD6U#_ &F\\MD0H1@1\@;CDY]J (-?T[66\6:3LU[9YTLQMO\
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MJ]IJJ)$]H(5$<?W02&RRG&<-@$9SBNG/0UR7A>XN;OQ3K]S<VKVID6W*1/\
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MXOO/%YT6368I%MVS<RP0QE0HQN )0<]NG6M/6?$NN:CXE?0/#:QQO!_KKF0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "GV?_(0;_KE_6F4^S_Y"#?\ 7+^M#V TJ***R*"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M60*.?J/Y9]*74"7PI_R4[Q!])/\ T-:Z/7/&VC:!/]GN)9)K@?>B@4,R_7)
M'TSFN.^'M\VI^--4OF0(T\#.5!R 2RU9^'7D'7]9-_L_M;S>/,^_U;?C/OC-
M"8'7:%XLTGQ#E+.9EG49,$HVN!Z^A_ FJNI>.M'TG5Y]-O!<1R0J&,@C!0Y
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M/_A9\GV<IY_]FG[0%_O;UQGWQC\,4@+(\::7]N:#9=BW63R3?&$_9P_3;O\
MK[8KHJXV1+KPI:RSQ&WO_#S2&1XVQYD 9N2IZ.N3G'6NQ!#*"#D$9!IH#*UC
MQ%I^A3VL=^SQK<!RLF!M78,G/.>>@P#DU1MO&EA-<P13V6HV27#!89[NWV1R
M$] &R>M0^([>*Y\7^%XYD5T\R=MK#(R$!'Z@5/X[17\%ZB& .%4CV.X4@"Z\
M::?;RR".UU"YMXF*RW5O;%X8R.N6]O;-)XHDTG4/"+7EU+<2:?E)0]HP#MR
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MDMY(09&VQ1(NYY&]% ZUDCQOI\8)OK+4M.^4E/MMMY8D(&<*<XS]2*:OE_\
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MB3 @ Z<?KS1/$0A!3>S"-*4I<IP%%%%;F84444 %%%% !1110 4444 %%%%
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M6 *HZKI%CK5F;74+=9HLY&>"I]01R#5ZB@#C+?X8>'X+@2N;N=0?]5)*-O\
MXZ ?UKJ+K2[&\TTZ=/;1M:%0GE 8  Z8QTQVQ5NBBP'&0_##P_%,TC&[E!!P
MCRC:OTP >/<FK?\ PCUIX;\&ZQ:6<D\D;P32$S,"<F/'8#CBNHHHL!Y7X/\
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M/ >EW$,BWESJ%Y,Z[5N+FX\QXQG/RY&!T]*T[_23J&J:=-*ZFTLRTOE'JTO
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MMID-KJ5[?(TAEO-GF!B-HVC QQ27FE07NH6-[(\@DLF9HPI&"6&#GC_"KU%
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MI5](8#:RN6\E\$J4)YQP<C_(H:;X?MM<\0Z^=1,DUI%>?);B0JI<@98X(SP
M!^-.X'>44@    P!P!7F=Y'=>./&UYI4MY)!IECD-'&<%MI /L23W/04-@>F
MT5XYXX\+GPY:68MK^YFL7<@0SMGRWQU&,#D>W;O72^.=2OYM2TOPY87!MS>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;_6-&#@G_@(.?J1FO/Z*BI0C-\VS[H<:CBK;H]"AUGP7X=/GZ7:S7UV!\CR
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M(4:LE+FZA1116YF%%%% !1110 4444 %%%% !1110 4444 :7A[_ )&;2O\
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MKTIOB?3[K4;:P2UB\QHKZ&9QN PBGD\FMRBBP&+XCL+F_BTY;:/S##?PS/\
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M!]FA<-Y(*$98G[S$D#CCBM?3;&YM_$FMW<L>V"Y,/E-N!W;4P>.HY]:VJ*+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3[
M/_D(-_UR_K3*?9_\?[?]<OZT/8#2HHHK(H**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?BC_R+-M_
MU^+_ .@/7;5QWQ+B\SPH'_YY7"/^A']:Z,*_WT?4RK?PV>/T445](>2%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!I>'O\ D9M*_P"OR'_T,5[;+_K7_P!X
MUXKX:C,OBC2U'7[5&WY,#_2O:7.YV/J<UY&8_&O0[\)\+&T445YYU!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M /@*G^%'_"/:)_T!]/\ _ 5/\*/[3A_*'U.7<\ HKW__ (1[1/\ H#Z?_P"
MJ?X4?\(]HG_0'T__ ,!4_P */[3A_*'U.7<\ HKW_P#X1[1/^@/I_P#X"I_A
M1_PCVB?] ?3_ /P%3_"C^TX?RA]3EW/ **]__P"$>T3_ * ^G_\ @*G^%'_"
M/:)_T!]/_P# 5/\ "C^TX?RA]3EW/ **]_\ ^$>T3_H#Z?\ ^ J?X4?\(]HG
M_0'T_P#\!4_PH_M.'\H?4Y=SP"BO?_\ A'M$_P"@/I__ ("I_A1_PCVB?] ?
M3_\ P%3_  H_M.'\H?4Y=SP"BO?_ /A'M$_Z ^G_ /@*G^%'_"/:)_T!]/\
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M /@*G^%'_"/:)_T!]/\ _ 5/\*/[3A_*'U.7<\ HKW__ (1[1/\ H#Z?_P"
MJ?X4?\(]HG_0'T__ ,!4_P */[3A_*'U.7<\ HKW_P#X1[1/^@/I_P#X"I_A
M1_PCVB?] ?3_ /P%3_"C^TX?RA]3EW/ **]__P"$>T3_ * ^G_\ @*G^%'_"
M/:)_T!]/_P# 5/\ "C^TX?RA]3EW/ **]_\ ^$>T3_H#Z?\ ^ J?X4?\(]HG
M_0'T_P#\!4_PH_M.'\H?4Y=SP"BO?_\ A'M$_P"@/I__ ("I_A1_PCVB?] ?
M3_\ P%3_  H_M.'\H?4Y=SP"BO?_ /A'M$_Z ^G_ /@*G^%'_"/:)_T!]/\
M_ 5/\*/[3A_*'U.7<\ HKW__ (1W1/\ H#Z?_P" R?X5+!H^F6K!K?3K2)@<
M@I JD?D*3S./\H?4WW/&-'\(ZQK+KY-JT4)ZS3 JN/;U_"O5/#7A*R\.P[D_
M?7C##SLN#]%'85T%%<5?&5*RMLCHIT(PUW84445R&X4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gfmvgbft1fv3000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfmvgbft1fv3000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *P!AX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **1F"*68X &2:SEUVP:]^RF8++G W'@TG)+<3DEN:5%%%,844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !15*ZU2VM'V.69R#A4&2<=JJV6JR744UPQ@2
M-$+"!6W2#_>[?@,_6DFNY+G&]C.\4>(%L(S;1?/(_P A ZY]*\ZCTZ>\\2NT
M\DUMLA$J*",;@?F!/;MQ[UNZYJEKNDNKS$$LKY V99%'&>>GK6,NCW$;33I=
MW$S2@*@\L*3D]>>W3TKDG"=_:26CV/*KS<YW>J.J'C"?3(8WG<3Q[\.V1P/Y
MUJ_\)5<37<9M-/DDM73?YC?*,>N:X6WTVQ@*VE[<B[N)I-I0<*OL/Z_2KNN2
M2-:F&RFD!MX]L<<9R"!_#CWK2E65*5JBOW78/;5>6]SN]*UNZU"TGG^P2,8Y
M-JJI +#UY(%:EI=&Z1B;>>!E."LRX/X=B/I7!^$=>.E6,4.HLV^X(8)SF(>A
M%>@Q2I-$LD;!D89!'>NEU:<V^0[L-4<X*[UZBK(CYV.K8.#@YQ3JHRZ?8+<I
M<LBPS!L[T8H6/OCK^-/O;J>UV21VK7$/_+3RS\Z^X'<?CFG9-V1T7MN6Z*9#
M,D\*RQDE'&02"/T-/J1A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !45T[Q6DTD8S(D;,HQG) XJ6B@#YDOOCG\0]-91>Z796V
M_.SS[*1-V/3+<UZ+\*_'7C#Q7K-Y;^(M,2UM8[;S8G6T>+<VX#&6)!X)KDOV
MEO\ CX\/_P"Y+_-:]YTW_D%6?_7!/_010!\[?\+Q\?2ZO>6VGZ587HMY'!2.
MSE<A0V 3M?-=Y\-/C"WC#66T+6+".QU3:S1^62%D*\LNUN00,GJ>AKQ7PCX\
M;P!XSUC4%L1>&=I(=ADV8^?.>A]*['X9:?J_C?XN/XXEL/L5@CO,S*I",Q0Q
MA%/<\Y)]CZT =?'XE^(/_"[VTE[27^P?-*A/(_=>1CB3?CKWZ]>*U?C%\0M2
M\!6&E'2DMFN;R63=]H0L-B 9P 1W85RD6NZL?VF9M+.IW?\ 9XDP+7SF\O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ>*O V@>-$MEURT:?[,6,165D(SC/*D>@K9@TZUM]*CTR*(+9QPB!8^P0+M
M_*@#R3]G+4//\&:C8D_-:WFX#T5U!'ZAJ]DVJ6#;1N'0XYKG/"G@30/!9NSH
M=M)!]KV><&F9PVW./O$X^\:Z2@!"JD@E02.A(Z48&<X&?6EHH 0*JDD*!GK@
M=:Q?%?A73_&.B-I.IF46QD60^4VULKTYK;HH \H_X9\\&?WM1_[_ (_PK4\.
M_!KPOX8UVUUBP:]^U6Q)3S)LKR".1CT->AT4 %?/'Q^;^TO'?AO1QSN0 C_?
MDQ_2OH>N9U?P!X>USQ);:_J%I)+J-L$$3^<P5=I)'R@XZDT ,^(6E7.J_#G6
MM/LD9[A[4^6B]6*X.!]<8KR_X&^/?#ND>$IM%U6^AL+J*Y>4&<[5D5@.<^HQ
MC'TKWFO/]9^"_@K6]4?4)["6&:1MTBV\Q1')ZDCM^&* /(_C'XSTSQOXET;1
M]&E%S;6\FUYU'RN[D#"^H '7WK4_:#W7.M^%M$B^\L3!0.Q=E4?^@UZ@GPB\
M%17EC=1:1Y4MCM\DI,X&0Q8%AGYCD]36EK7@+P]X@U^SUO4K226^M"AA<3,H
M7:VX?*#@\T 5OB#H4^H_#'5M'TN,F46@6&->K!"#M'N0N*\M^"_Q*\.>'?"L
MNAZU<"PN(KAY%D="5D#8ZX'!!&/IBO<=<U*72-%NM0@L)[^2",N+:WQO?'I7
MS?/XX^&VNW,U[XC\%7%MJ/F,S"TE(63_ 'N5Y]>* &?%WQW8?$#7=)T?1=TE
MI;R[1.5QYDCD#@'G _6NN_:,T:<^'M O+:-OLE@\D,@4<)O";2?^^"/QKD?!
MVDO\0?B98ZAI.A)I?A_3'1MJ+\JJIR 6_B=C_GBOIN^L+34[*6SOK>.XMI5V
MR12+N5A]* /F[3/#'PAN]!AO[GQ+=V\QB#2V[2C>KXY 7;SS79?#'P7\/KO5
MX?$/AC4[^YN;!B3%.V"A92OS#'H36Y-\!_ DMUYPLKJ-<Y,27+!#_7\C7<:'
MX>TGPW8"QTBQBM+<')6,<L?4GJ3]: /"]$;^V_VI-0G^\EK+*/IY<?E_S%-^
M,N=:^,WAG1!\T86WC*^ADF.?TVU[%HW@#P[H/B.[U^PM)$U*[\SSI7F9L[V#
M-P3@9(I;SP#X>OO%T/BBXM)'U6$HR2^<VT%1@?+G% 'D7Q];^T/'7A;1QSN0
M,5]=\FW_ -E->C_%VX73/A-K"J< PI O_ F5:UM7\ ^'M<\2VGB#4+6274;0
M((7\Y@JA&++\H..I-:'B/PWIGBO2&TO5X7EM&=7*)(R9(Z<CF@#R#P=X>N]1
M_9LU&SL8R]W>B69$7J^UP<#W(3%4O@O\2O#GASPM-H>MW'V"XBN7E61T)60-
MCK@<$$8^F*]C-O;>!_!K1:/I=Q=6]A$3%9P-ND<9R0">2>3[U\_7'CGX;Z]=
M37OB/P5<6VH^8Q86DI"R?[W*\^O% #?B]X]L/'VM:5H^B[I+2WEQ]H*X\R1R
M!P#S@?K7T[;0K;VL,*#:D:!%'H ,5\P>$=)?XA_$NQOM(T*/2_#VF.C;57Y5
M13D;F_BD8_YXKZDH ^>_VAKAKWQ7X8T:/EPC2;?4R.%'_H!KN/C==+I7PCN[
M5#CSW@M4_!@W\D-=+K/@#P[K_B2TU_4;2274+3R_)?SF"KL8LOR@X/)-7/%'
MA/2/&.G1V&M0/-;1RB9525D^8 @'*D=B: .8^"E@-/\ A5I;,-K7!DG?\7(!
M_P"^0*\Y^!;'6OB;XFUP\ATDD!]Y9<C] :]ZL-(L],T2'2+2,QV<$(@C3<<A
M ,=>N?>LGPIX$\/^"C=G0[1X#=[/-+RL^=N<?>)Q]XT ?-1T308/BQK6E^-+
MBZLK=YY62=#C#,VY2W!^4J>OTKI+WPS\&;*[@MW\37TIE.-\+[T3W8A>*]P\
M4> ?#?C$H^LZ<LLR#:LZ,4D ]-PZCV-8FB_!CP3HEXMU'IKW,J'*F[E,@4_[
MO3\Q0!O>"O#&E^$_#L=AH\TLUG(QG221MQ;< <Y],8JG\4-(N]=^&VMZ?8@M
M<O"KH@ZML=7*CW(4C\:ZZLW7]4FT70[O48-/N-0DMTWBVM\;W^G\_7ZT >)?
M!GXE^&_#_A%M$UJY%A<0SO('="5D#<]0.HZ?@*YKXL^.++XB>)M'TC1=SV=O
M+Y:3E<&620J#@'G P/KS3IO&WPUUN>6^\0^"KBVU+>S.MG*0DASWY7GUXI_@
M;2)/'OQ/L]6TS0TTSP_I<B.JHORJ$.5!;^)R>30!U7[1VE3'1/#UY!&QL[.2
M6&0+T7<$VY_[X(KG;#PQ\'[C0H=0G\37<$AC#26[2_O%;'*[=O/-?1U_I]GJ
MMC+97]M%<VLHVO%*NY6%>>R_ ?P))=><+*Z1<Y,27+;#_7]: ,;X7^#/ %SJ
M<7B+PQJ5]<SV1(:.=L%"RD?,,>F:Y[PZHUG]I_5+@C<MI+-CV*+Y?\Z]ST30
M-*\.:>MCI%E%:6X.2L8^\?4GJ3]:R]&\ ^'M \0WFNZ?:R)J-X7,TKS,^[>V
MYN"<#)H \N_:2N2UOX>TY3\TLLLF/H%4?^A4?'70KE?AYX;FMXG:WTW$4VT<
M(&10"?;*X_&O4?$G@+P]XMO[2]UBUDGFM!B$K,R!><] <'FM^ZL[:^LY+2Z@
MCFMY5V/%(N58>A% 'S5HGAGX27_AVWO[WQ'=VESY2F>W>4!D?'S #;R,YQBN
MP^&?@[X=W^MPZWX:U2_N+O3WWF&=MI7(*@D8Z<UT5Q\"/ EQ=><+&YB!.3'%
M<L$/]1^!KL]#\-Z5X8TUK/0["&U0\D*.7;L6/4T 2V^OZ3=:S<Z/#?P/J-J
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MYY_2G>RYGLB9-)$ANULU%G),YECAW&:09SVR:Y#Q;<R7MLQ@*I)Y> [-]_W
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M8;E0,.I'3UHU/PE-=26\J7426LC;VC)Z9]<]O:MBRTW1]%:>QL1/?/-B1T)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!>"-4A=&PX9G5<CW&<UD_!74]1U+X>K?ZOJ4U[<37$KAYY2[*@PN.>V5/YT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"/[A'*GTSGZUJ^.=+M/"7QFN-1\2Z2U_H6H2-. "?F5QS@C'S*V>/3ZU?O\
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M%+^[:ZCMXC-:2,Q;:JL%903_  _,"/3!KWBO.OA?I_@^^L1XC\.^'9=+F=3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K$UWP?X=\2[3K.D6MVZ\"1TPX'IN&#C\:
MVZ* ,S1O#VC^'K8V^D:;;64;'+"% "Q]SU/XTL'A[1;759-4M])L8M0D)+W2
M6ZB5L]<L!DYK2HH S+;PYHEGJDFJ6VD6,.H2EC)=1VZK(Q8Y8E@,G)ZU9O\
M3K'5;5K74+."[MVZQ3QAU/X&K5% '.6'@#PEI=W]JLO#VGQ3YR'$()4^V>GX
M5N7=G:W]I):7EO%<6TJ[9(I4#(P]"#P:GHH J:=I6GZ/:_9=,L;:SM]Q;RK>
M(1KD]3@<5!;>'M%L]3DU.VTFQAOY<^9<QP*LC9ZY8#)S6E10!!>65IJ%L]M>
MVT-S XPT4R!U/U!K M?AWX.L[O[5;^&]-2;.0WD A3[ \#\*Z:B@!  JA5
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ME!R/]'7:#_N]/TKIZ* &QQI%&L<:*B*,*JC  ^E.HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** *UM:_9Y[J3?N\^0/C'W?E _I4TJ&2&1
M <%E(!]*I^=,FO>0Q)@EM]Z#'"LK8/YAA^57Z<D^HE;8\CU2TEL=3N'O;@M*
MBGRA$WRG/&2?Z5SVD6SO?7DEW;&?$(:,,,@DD_-CU]*]CN?"^GW>JK?2AV(.
M?*S\I/TKA?$1O-.^VK';@;F+84C[HZ5QU*:C3LHZWW/)K4'3?,]CE-=TZ>'3
MX[W3T8R%0;F(<Y],#U%<7K-G8VMF)6C<-,GF9=2"0>U>B7VK/I>C1I-"T9:(
M;Y A(!(YR17-SW>C:MX?A-P?MMSEE9P2#& 3@ ?ESWK.DI/7L8K1W6W4J6G@
MNPTG1+?4Y[V?^TI8A(OEL L>X9 ]^#S4MG)9-X7D@N ;C4&D<N1G"]A@#IQ5
M*TEN-0M?LAF*QVI2)7<Y !. *ORV<^AZU%I^F7:S"]_=,SC;@^OTHE?[6XYR
ME-NX?#2PB2YU#S+='NHQOCE; 9>OY"NDOX)M:E5[7:L=LVV5MP )],=S52ST
MYM'LO*?G4[Z3"NAS\GT_.K,&G:Y]G:WE6*&$2*F]1@\]23GDXI-RJ-VZ"G)S
MW1POB87-V@L[J15N;9C(WH3C@9],>GK7'S6=X9%6XRNY=RACV]J]?\<6MA!H
MTLUO;)));;0KH/FZ@<GJ0:\LE6]U-C*(9&6/.%4<*.N*Z:,H\MSJH-Q5KZ&A
MID]C\DDTS;@NW@DLOX5T4UHVNZ3#O+23>9LB)Z*N.3[=JR=.TZQDL/. 99E*
MA@.X)YR*O>(KB:#2+::PGDM(6<Q+"#CS!CEC^GYU-XN_?H82M.I:-[F9I^DS
M7L(LGF#JK,(S(WRX]JM6?AZ:"\FB6162-L-(3P@]ZK:5XAOM)B296C#Q,&1S
M&">/KUJ\OEW]F;^*Z:6^EF;S($0@LO4MV'4]!5*#:=W8)^T2=]F6Y([CSG:R
M42P@"-W\K@^I&?>O4?AQ)J[RO"\GEQ;,_,,C\JS_  5X%M]62SU.ZB=K7YB$
M>3H?I7JUCIEEIL92SMTA4]=M'L)1DK]#7"8>3:J;(B-C=&[6X^W?.$* >5Q@
MD'IGKQ4ODWO_ #^)_P!^?_KU;HKIYF>IRHJ>3>_\_B?]^?\ Z]'DWO\ S^)_
MWY_^O5NBES,+%3R;S_G\3_OS_P#7J.:VU%O+\O4$3#@O^X'S+W'6K]%/F8<J
M"N8\3Z;'Y+3QED=SDA.,GUXKIZBG@BN8_+F0,OI42NXM(F<>:-CRRVT^:+S&
MC$B*%.V-GX+=V'^>])!8K=Z)-9R1JUR)-DDDG0[B<?7C\L5Z9/I=I<6RV[1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5XW&593P:DI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;'&LC<<88D#_ -!--=1OH3T445(PHHHH **** "BBB@ HHHH **** "BBB@
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MU)Y8<>HH P_!4>H:II?BCXF:T\OF3V\XT^-F.V-0I7<H]L;0?8^M<HVG&?\
M9Q.I7=Y<B0:D944/Q(3B,!L]1C->Z^,-!N9/AK?Z!X?M5,IM!;6\(8(-O ZG
M Z9KS[7OA[XEE^".A^%K"Q6348K@2W<?G(H4?.3R3@\LO2@#!O?AT='^!_\
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M\)-XF:XN[6[E=K'3C,R0V\08A<JI&7..36MX.T+Q%8^,/$6L:^T#G4HK;RS
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MRNH03><" 8E5LEQDC..N*@77O'%O;_9)?""7-\J[1>17T:VSG^\03O4=\8-
M&;I"ZAXG\,^)O".J733:AI4YMHKX'#R<!X9#CHP.,_2K=KX\/_"KI==DC_XF
M=JAM)K<]?MBGR]N/=\$#T-;/@SPW/X>TZYDO[A;G5M0N&NKZ91A3(> %'90
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MAFR=P//(QGK63HOPY\0>'?%-AXBEM['4A)-(T^FVY\N.Q+D?/!N."1CG//\
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MD]3P/8<5U^GZ%J$'PCAT&2$#45TG[,8MXQYGEXQG..O>JNH>'-4G\,>"K*.
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M6\Z2@3N,B*'"<YXQ@=.O>E\7ZI;7?C-?"U\^IIX>TZRC>>#3X9)&N';[B.R
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MF7^J/\0XM*N9+?4HM1BGM7C;'[Q(D8*?8XQ^- 'JM%<3J'CF/_A6*>(K9?\
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M4(2=PC. QSW-=%7CO@'PO-XA?7GU+4+I='BUF[$5E;3-")9-_P S.RD,0.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)110 4444 %
M%%% !1110 4444 %%%% !1110 4E%% !1110 4444 %)110 5POQ(ECAM;,S
MD&)RT?E@?,Q.,5W5<IX^L8;KP\TTD'F-"P8,#@I[_GBML.[5$S.JO<9Y'IT>
M_5'M;> 7!X5%D..3Z+@].1Q7NEIIT+:?9K=VD'GQ0A2 H(4E<-BOGEM:2*Z\
MYKD03P<*(<@N?7(Z5Z?!\5;1M-B5+25[K[.#ND. 9 .?PS7=BH3G90U,:;4=
M9';OH.ER")6LXRD0 1,?+@9_AZ'K6+)\/M%:6X>-7B6>)D*J>A/?FN2O/BO?
MP:?%_P 2^);AL9E))4\9P%]?QJBWQ%\17<UP\9@B5T*B)4)V8[@^M84Z%9;.
MWS-'.'8ZS_A5FC?9IH_.G\UR"DO&4QVQW%0_\*ET?[2)!=7*H$ "@C.[N<^_
MI7%0?$?Q+%'-&9Q)Y>58L@SC'4>]+;^+O$FI2H8KVX(=,;4('7^OZUI[.O?6
M1/-#L=9'\-Y[#6I)K"Y M_L[+&SGD.5( (QZG.:Q9OAK=QQQI<ZC:6R.PQ(S
MDEG/:L[P_P"(M:TV\FMI+EQ WF%TE8Y)(/3N#G%7(? WB;5U2YN[@6\2Q[T$
MTNX\\].W4T[SC\4E85D]D5)O"DD-Y:Q#4+"9F#>85G "8]2?6L5[*:WG8R3J
MVPD M)P3W(]J]&\.^ ;.W#7.J)%<S2+^YB!.U1W)/0FJES:Z)87%QI]EIGF:
MJJF6* \[@<]#Z<'K35>G"5MQ.#M<Y;1[-[[4XHK2\"W/+-C*[0!Z?3^=/U#2
M?*D:.]U#;$3M63!)!]#Z50N-9OK0W1ATV.WOK0D$"(952/F)]3CTJ"REU":^
MBGOIG%HB&1%/648^8>YSQ71:\N9$6T.FTI-%T>621XXKJVR5D\UBY48[YXYK
MM](U>+4;.*YL7:*$?P #&/05YUI6G-;956=VE0RS1R#).3A5S]?TQ78^!?#>
MIV<\MS<N\=A*N4@8X(;N<=N<USXB"Y;ME0NWH=]:R-+:QNV=S+DY&*FIJ*$0
M*O0#BG5YAUH4BDI1Z4E "TM-I: %I:2B@!:*** "BBB@!:*2EH **** "BBB
M@ HHHH **** "BBB@ HHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *2EI* "H;F[@LX6EN)5C1>I-8NO>*+?2PL%OB>\D.(XUY&??TK
M@/$FK2ZEI]VD3?Z:P\UHF8HX48&,'L#_ #KIIX>4M9:(PJ5U%V6YU^H?$"PM
M+Y8;=/MD9'+0')![<5LPZPSVJW$D1BC<_*9."!]*\2T7Q!'/9PZ3% $U" &1
MFC("S'W/][/;\J]-LHGN+2.+4KP*CXVQ%>5?T!JJ]&,;<I-.HY;F^=2WLA27
M>-FY_+Q@4YKF=\ 12AB@*,>A^OO52/1K;27^TN\[*2%\M5,@_("MJUNH[J,M
M$LBA3C$D90_D17.UI<V6XVT27!EE9MS@?*3P*LU3_M:P%S]F:[B6;=MV,V"3
MZ#/6KE2TUN4FN@4444AA1110 4E%% !1110 444E !1110 444E !534K"+5
M-/FLYBPCE&"5."*MTE--IW0-7/"/$?A:WL]2:WG+PL,LK,G#(.,C'7-9NGRV
M5NUO'/#.+?+?,8QN ]?<5[]?:=!>KN>"%YD!\MI%R%/;/MFO"O$UI?Z1JDD#
MVT<KY822<GKSQZ#FO5H8A5%9[G).#B>I0^"?#U]IT9B/G*WS"92"3QQ5X>"M
M#$,,0M<+&?7EN",'\_T%>0:!XBU72KN&WM93 LSJ!&6^1L>N:]+O/&S/"!:V
M\D,C(&"R*"^.I;'0 #U]:PJTJRE92N7&4+:HO1>#/#6G6I$MJA4@AGF<Y-0C
M7O#ND,R10VD5M$P!DCV]?8#D]*Y/Q+J\SZ1+-#+)+*[%F*,6&WMQVXK!TF31
MVTQ!'&K:@,2W8D7>WU'^SVX]:%1<E[S$ZG\J/6VBTZZV:G;VEM-*P$HE*#..
MQK/\1VU]JZ0VVGW4<3DDM@G#?4CVS^=.T^^G:VMX1:+]FECW+(F %XS@CM[5
M(4FCO(9 T:QC[I!QDGC />N2TMF:7T(-4L)I=$BL[*YDBEA155@?3^'/]:=:
M6L=TD-VD#>;M"EBN&QZ'\:Z 6:-$ X(/L<5-%"D0PHQ4W+LSAM3\!'5-1>[2
M40^>"+A7YW>F/P[5#/\ #ZYDC^RQRQ)!&F$<,06]0?;_ .M7H=%;+$U$K)DN
ME%F'I7AFQL+6))(4DE0<L,X_^O\ C6Y116,IRD[LM)+8****D84M)2CKS0 E
M%%% #J*2EH 6BDI: "BBB@ HHHH 6BBB@ HHHH **** "BBB@ HHHH ****
M"EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!10 4ZFTM "T444 +1110 4444 %+24M !1110 4444 %%%% !1110 4444
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M[>;&5P%ZJ<8YJ>[UGQ#XG\07^D>&;JWTVRTU_)N]2EA\YVFQDQQH>.,\D]Z
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MPURSU'5]3TR#?]HTYHUGW+@9<$C![\"M*O*/!6G>(XOB/XG:Y\00RI!+;&]
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MBL;R'5I(?,(TN:2&XRN/F10QQZ\&I]%U:WUW1K35+0.+>ZC$D8<8;!]:\O\
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MZT[.UQ75[$]%,CECE!,<B. <':P.#3Z0PHHHH **** "BBB@!:*** "BBB@
MHHHH *I:KI%CK=BUEJ-NL\#$':21@CH01R#5VB@"EI>E6.BV"66GP+!;IR%!
M)Y/4DGDFKM%% !1110!#=22PV<TL$/G3)&S)%NQO8#A<]L]*\2\1?$^WUCPM
MJ.@Z_H%Q'J[[DB14&Q6S\IY.X$>P.?QKW.HV@A>02-$A<=&*C(_&@#P?Q%%?
MZ+^S_IUCJ*O'/<WBA8G^\J99P".WW<_C6I:_%Z/0_#-OH4N@Z@-?MH%MEMS&
M C,%VANN<<9P!_C76?$GP=J?C$Z-!9R6ZVMM<&6Y$SD$CY0-H .>-WI7=&-"
MX<HI8=#CF@#QK0OA[JZ?!W7K2=2FK:O_ *2(.A7:0RH?<X/_ 'T!7G6G7/P^
MT_1UL_$/A/5W\00Y21$F=%E;L?O@KVR /I7U93#%&SAS&A8="5&: /)M+\!Z
M9?\ POU@^'M"O-&OM7M-GD7D[,6*G<HY)P">,D#KR*YSP9\8+#P1X6@\-Z_H
MFIPZC8;HU2*)<2<DC.X@@\^_K7O],:*-F#-&A8="5YH \RU;QC=^(?@OKVKW
M&BW>F2-;O%''-SYF["AE[XY[@?C7F_B.*73_ -G/PS8)$YGO[WS60*<[?G/_
M ,1^=?2Y (P0"/2C8I !48'3B@#P[XF6#2^+/AMX8C0M'!)'YN!D!0T:_P D
M:D\;S7W@'XS1^-YM.GOM(NK80R-$,F([ A SP#\H/.,Y->Y%03D@9'0XH(##
M! (]#0!YAH?QGM?%'B:STS0_#VJ7-K(<3W+HJ^5Z' )&!WR1[9K(B1]3_:>E
ME*-Y5A98#8X!V8_FQKV5(TC&(T51Z*,4NT9S@9]<4 >,?"%'OOB/XXUAT;#W
M'EJQ'7+L?_9:Y[XVV-[:?$?3KC0IBNHZO9FTDBB/S.#\G/L0<9_V?:OH@*%S
MA0,^@KS?P_X"U:3XDZAXR\42VLLP&S3H('+K O(&<@<@?J2: .G\#^%+?P9X
M4L]'A*O)&NZ>4#_62'[Q^G8>P%=%110!QH5O^%S;L';_ &"1G''^O6LO2-6M
M/ &L:SI>O,UI97E_+?V5^Z'R7$IW,C-_"RGUZBO1<#.<<^M#*KKM=0P/8C-
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M_:&: . \&0^&[WQ%<WWASPU;V^GVT6R+51"8S-(3\RQ@C)4#JWKTSUKT&D
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MXCC*W5G&-(M0>Z1?ZR3_ ($W?VK5\-JP^)7C8D$ O9X..O[A:[2DP,YQR>M
M'GWA]6%A\0,J1G4KK''7]TM;/PV3R_AOX?7:5Q9IP:ZC YX'/6E  & ,4 <-
MX&5E\6^.25(!U-",CK^Z6NYI, =!UZTM !1110 4444 %%%% !1110 4444
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M.H^F* /1M%U)=9T'3M42,Q+>VL=P(R<E0ZAL9]LU>K \#?\ )/O#7_8*M?\
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M6+'3X-/M8K>!2(XE"KDY.*M5FY=BU'N(JA%"J, 4M%%26%%%% !12CK2=30
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MYY;F%DDD<QN ^PC*H!D9;&2W2O4:* .*T6RNHOBSXIO)+>5;::SLUCE*D*Y
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MMX3<RM9V]TV98;<L3&C>X':NOHH **** "BBB@ HHHH **** "BBB@ HHHH
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M )ZS_P#?TTS^SH?.\[S)_,V[=WFMTSGUJW12YF.R*_V1?^>L_P#W]-'V1?\
MGK/_ -_35BBCF8616-HO_/:?_OZ:/LB_\]I_^_IJS24<S"R*_P!D7_GK/_W]
M-'V1?^>L_P#W]-6**+L+(K?9%_YZS_\ ?TT?9%_YZS_]_35FDHYF%D5OLB_\
M]9_^_IH^R+_SUG_[^FK-)1S,+(I7.FK<QJOVJ[CPZOE)B"<'./I5PJ&&",BE
M'6@\<]J&VPLCDO%FCB/2[BZLK1Y9=N2D1PQQT]\>PKS+_A'?$WB6\DE:R$)
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M<$5PLFX2';Y>,E?7(]*\W7PIKK/^\TR=MSE?F0DD]>_;%,G\$>)%DEECTF5
M!O01L./PSU]JQ5&GI=_B6I2Z([Z?6O"&ME4F&R1Y/+!"X9>F#QV-9&JZ=H&F
MWDMN;L^;;KUZD9/3Z\URUUX6\0::%6>SE*R*%C:)=S;\9 &/\]:9%X=\1W^J
M2Q26MS),Q!F\U2,KP 3FMHPC'52T)=WNC?M8+6%'E^V0M$0#(6.",]*+^_\
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MI#"BBEH XGX@7,MO# ;6YDCN-C;%7.,_WC].:\_@\07$T"'5Y;2221'MS/<
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M)#J0WKG'I4C> - MR6DU%D=5VRDR*,CI^&35B^\*>'9[Z1Y]2,;#:73SE7'
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M[8>4O$N"ZJ[9!]R,#(]S5_SVO+2X"V\R#80ID7;N)'8=?SH:B@3;([?5!/'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@_7K*TMW%JL]M)"&!D.T,1RQ!QENG]TTDWQ!U'4/BHGA'P_:VMQ;6R[M1NI
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MSV6]0YP<JR,21CUSWK+MO',=G\,].\27EHOGW4:+#96JX\R5CA40<_\ Z@:
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M7IFK:5IES*XNM4+"V"QDAL#/)[=:V*X1==US3=8\*:9JUOI<LNI/.IDMT?\
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M\R33TMXDE,JK^\*!"V>2!G _4TG45K(%!WNS#ME%X;.UN&8P%99"FXCS&#X
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M7KM9K6WN)(I)H(I'A;?$SH"4;U4GH?I0MK;I<R7*P1+<2*%>4( S = 3U(%
M' ^ ->TW0/#T/A?6;N#3M4TO=#)'<.(Q*H8[9$+8#*PYS]:?!>6_BWXG:?J&
MD2"?3]%MIEGNT_U<DL@"B-3T; ^8XX'%=CJ6AZ3K*HNJ:797RH<H+F!9-OTW
M XJU;6UO9VZ6]K!%! @PD<2!54>P' H XWP"H&M>-& Y;6GS_P!\)27_ /R6
MC1_^P//_ .C%KLX;:"W:5H8(XVE??(40 NWJ<=3[T&UMVNENF@B-PBE%E*#>
M%/4 ]<>U $M>:>(IM-O/BS9V7B:ZCATNTL1=6,-PP6&><MAF8G@E0!@'UKTN
MJ&J:)I6N6ZP:KIUK?1*VY4N(5D"GU&1P: /']=\2-X8\0ZA<_#R3^U(YXVGU
M*RAB,MM;/_SV#+P&/=1UQ]*]:\-7ZZGX;L+Q=1BU'S806NHDV+(>YV]N>U6[
M#3;'2[86VGV5O:6X.1%;Q+&OY 8I]I96EA$T5G:PV\;,7*0QA 6/4X'>@#C/
MB;_J/"__ &,-M_Z#)5*TTQ]:U/XEZ7'((WNVCA5ST!:V !/MS7H4]K;W0C%Q
M!%-Y;B1/,0-M8=&&>AYZTQK*$"Y,*+;S7 _>31* Y.,!B<<D#IG- '#^$/&^
MB:?X;LM)UJ\ATK5-.@2VN;6Z;RV4H-NX9X8'&01531]>A\1?&4W%E#+]@CT.
M2.&Z9"HN/WR$LF>2H/ /<@XJ?'BNT06>M^%++Q,;=C]GU!98D9QV+(Z_*WJ0
M:U?#.C:S)KUUXD\0QV]M>2P+:VUE;OO6VA!W8+8&YB>N..!0!B^ -8L?"ME<
M>$=<N8;"_L+B5HVN'"+<Q.[.LBL>#][![BHM=\36&M?$GP;9Z8?M<-O>S&6\
MC&8E<P.!&&Z$XR3CI@5Z!J6C:7K,2Q:IIMI?1J<JMS"L@'TW XIT&DZ=:Q6\
M5OI]K#';$F!(X541$C!*@#Y>">E '(Z2H_X7/XC?'S#3;49_%J3QY_R-7@;_
M +"Q_P#1;5VRVMNER]RL$2W$BA7E" ,P'0$]2!1-:V]Q)%)-!%(\+;XF= 2C
M>JD]#]* ."LM5MO"/Q!UVUUEOLMOK4L=W9WLO$3$($:(L> 1MR >Q-9'Q>\6
M:3>>$7TO3[F*_N)+FW:0VS"18$$JG<S#@9. /K7J-Y8VFHVS6U]:P75N_P!Z
M*>,.I^H/%5+;PYH=G8M96NCZ?#:.P9H([9%1B.02H&"?>@#3KS[Q5+_PC?Q%
MTCQ7>(QTE[.33KB8#<+5F<.KL.RG&">U>@TV2-)8VCD171AAE89!'H10!R7B
M7QOH5MX?NOLE[;ZE=3P.MO:6L@E>9BIP,+T'J3T&:XK4-$EUCX%>%)8X);B/
M3Q:WD]O"Q5Y(E&'"XYR Q/'/'%>H6/AK0M+FEFT_1=.M)901(\%JB%P>Q('(
MK0@@AMH$@MXDBAC&U(XU"JH] !T% 'E0TGX6?V4-1.N2BWV[L'69]X]MF_=G
MVQ6KH\'A"R^'XCU+3I--T?5KACY.IS,[.S'Y69B24+!0>HP>]=>?#&@'4?[0
M.AZ:;T'=]H-HGF9]=V,Y]ZOW5I;7ML]M=V\5Q XP\4J!U8>X/!H \X\+W9L]
M:USP[INL/K&A6VGB>*9Y/--J[;AY/F?Q# !&>E9D.GW<_P (?!6JV<#W+Z-/
M!?R6R#+2QKN5@H[D!L_@:]5L-*T[2[3[)I]A:VEL228;>%43)Z\ 8JAK>EW[
MZ!]E\.746F74!5[<+&/*.#]QEQPIZ<<B@#/7XD^$'LQ<IKELV1Q$I)E)_N^7
MC=N[8QFO/+>YEO\ X0?$.ZGM7M7GU*Y<P2##)E8N#[^M=7]L\4B7ST^'FG+K
M1&W[;]KC\L'^]NV[\>WZUO\ ACPR-(\.R6.IM#?7-Y,]S?,8\QR2N<MA3_".
M ,]A0!K:,H70]/4# %M&!_WR*Y'X3_\ (KW_ /V%[S_T8:[I55%"JH55&  ,
M "HK>UM[2-H[:WB@1F+E8D"@L>IP.Y]: .6^(]A>7?AF*YL;8W4VG7L%^;9>
MLRQ.&90.YQVJW%X_\*RZ9_:']N64<6W++)*%D4^A3KGVQ725ER>&M!FU#^T)
M=$TU[W.?M#6J&3/KNQF@#D_!UO<RZ)XHUR>V>UBUBYFN;>&0881!-JL1V+8S
M^-,\ _\ )#++_L'3_P WKT)E5E*L 5(P01P144-G;6]H+2"VABM@I40H@5 #
MU&T<8H \NBT.Y\1?LYV>G68+7#6$4B1@X\PHX?;]3MP/<BH=,TGX97NCI>R:
MK<6K*G[Z"?6)XY(6'WE*E\Y!KUF"WAM8$@MX8X84&$CC4*JCT '2LZ[\,Z#J
M%Z+V\T33;FZ!R)IK5'?\R,T >2:W9Z)'\'O%E_H6GWMO:74B!9[N=Y#=*C "
M0!R2%Y('J *];UZZT>PT*;^W&A73' AE\]<H0QV@-[<U?N+2VN[9K:YMXIX&
M&&BE0,I'N#Q3YH8KB%X9XTEB=2KHZAE8'J"#U% 'G/A.6WTCQP- \/ZPVIZ%
M+9/<M"9_/%BP8!55^?E;)^4GMFO2:I:;H^EZ-$\>EZ=:6,<C;G6V@6,,?4[0
M,FKM '%^ % O?%Y Y;7I\_\ ?*57T9!_PNCQ-)CYAIUJ/YUV\-M!;F0P0QQ&
M5S)(40#>QZL<=3[T+:VZ74ERD$2W$BA7E" .P'0$]2!0!P^O_P#)8_"'_7K>
M?^@53^'VM:7X<TZ_\-ZM?6]C?V%]/F.YD$>^-G+*ZYZ@@UZ&]I;27,=R]O$U
MQ$"(Y60%D!ZX/49JGJ?A[1-:='U72+"^:/A&N;9)"OTW T <9X7GCUSQOXO\
M0V)\S3'@@LX+@#Y9G16WE?4 D#-8_P#S;.G_ %X+_P"C17K$%M!;6Z6\$,<4
M"+M6.- JJ/0 < 5'_9]E]A^P_8[?['C;]G\I?+QUQMQC% '#^)O^1]^'G^]=
M?^BEK.TCQ'8Z%\6/%T.I8M[:Z:U"WCC$:N$.$9NV021GT->F/:6TLT,TEO$\
ML&?*=D!://!VGMGVKE](\-RKXI\67&IV<,VGZFUOY22A760(A#94^Y'6@#'^
M(.OV&OZ/_P (IH<\.I:GJCQHJVSB18$#JS2.PX4 #\\59O8MGQ?T"$L?ET6X
M7=W^\@S77:9H>DZ*C)I>F6=BK_>%M L>[Z[0,U::UMVNDNF@B-PBE%E*#>JG
MJ >H'M0!XGX1\*^$;&WGT+Q-=3V.LV4SJX?4I;=)X]Q*R(-P4@CT_&NE\*:;
MX/;QOO\ #MO>WLEA V_46OI98(F;CRQN8AF(Y..F!7>ZEHFE:RBIJFF6=\J?
M=%S L@7Z;@<58M+.UL+9+:SMH;:!.%BA0(J_0#@4 3T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %4-5D=+:)%<QK+,D;R X*J3SS[]/QJ_3)8HYHFCE0.C#!5AD&G%V=
MQ-71E:E9066CW\MOOC<6LG21N?E//7K[TAN;E[K3%DMGA4R'+&0'=^[;TJVF
MD6*)(OE,PD0QMOD9OE/4#)X'TJTT$;&(L@)B.4]C@C^1-:<ZMW)Y68FC1!L3
MR6C[A)(?M!ER#\S#IFH-/O[BTT\([&2>[3S[7?SDN>5^@)!^A]JV$TBRBDWI
M&ZDDG F?;SUXSCO5E;:%$A18EVP@"/C.WC''X4W4BVQ*#,2T\V%+.W:>21H[
MR2-G8\M\K'G]*6VA6">W6Z63=,6C\^.;<DY()PP[<#(^G6M@6=N)-XC&[S#)
MG)^\1C/Y5%%I=G!.)HX<.,E<NQ"YZX!.!^ H]H@Y&98LX(1K#QJ5:$$1G>?E
M_=*>.?4FH=-(DDC%M;SVYB@S<&1_OY7Y<#)SSSGV-= ;:$B8%!B?_6<_>XQ_
M(4T6=N'1Q$ R1^6I!_A]/>CVFFH<FIS\2M<3V2O;270^P1L0)=N#GKR>:M7]
MN5FFF='EACC7;Y,V'@P.<#OZUH2:192F,M$P,:"-2DK+A1T'!%$VE64[*TD1
M)"A3^\8;@.@;GYOQS1[17_K_ #%R.Q;1@\:NIRK $'U%.H  &!P!16)J%%%%
M !1110 4444 %%%% !1110 4E+368#ZT +3'<(I8]A4;2F1#M]<53NI&%HT:
MLSR*.?4TTA-E/5=?CMK*?RQND4=%;H/6O.]1U#4;O7+;3K&Y-L9(LR"X;(YZ
M_B/05'XFNIM$TJ>,++.]PPD=MPW(3P!^9KB9+V[UK6[.1\PR1X<R!C@.!TXK
MTJ--1CYLY7)RW-3Q7J0-]:R2W<IBB:.*ZD7Y1(,_-C'MFMS4M/TN\,4QQY:[
M9+)MQ(VKT'H 3CKUJNEII/V\->QP22&WR'=NLIZY'TS3;B^D9H;-(!<GRA%'
M*HZ>P'MQ6]M;$WT':Q;_ -KP2&\>**0L"91_$.GR_F:K,T=M +>-K8VZ%<B4
M;LC'!.,$=ZLKX8\27VQY;&9HSD$&/;]/QK63X=ZX40LL._<%<EQR".3]!GI4
M^UA:UT'+(Y'4M0N78"2:5IHUS'AL1QK_ + ]*ZCPQ\0)-)TZWM+ADG0OU<G<
M,]A[57\0_#'5X+1I;>5+A(>/D)W,G7I7#>3<63[5/ER$X.Y>E5%0JQMNAZQ=
M^I])V6MZ=?WDEI;7*O/&,LF#T]O6M&OGSPWK\NCW8O!<?.C$;6_C']WZ5ZWX
M8\81ZY(+:=(X[K&0(VR#ZCV-<%?"N&L=4;0JIZ,ZFBBEKD-@HHHH *6BB@ H
MHHH JS_\?UI]7_E5JJL__']:?5_Y5:IO9"04444AA1110 4444 %%%% !12T
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !139"
M5B=AU"DBO-_ .H>+_%^G6VKWVLI:6<%U+&8HK6,M>*KL,L2/E'\/R\_*3WH
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M4WLA(****0PHHHH ***6@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** &3?ZB3_=/\JXOX30E?AIIZ.A4M-=;@1@_\
M?$O]*[>B@#S/PSKUE\.=-;PSXFD:RCM)I/L=Z\;>3<PLY8'< 0&&[!!_6KMI
M?'QOXWTK5-.MY1HFCI*ZWDJ%!<S2+LVH#R549)/<GVKOR >HHH \SMM:L_ '
MC7Q&FOLUII^K7*7EG>LA,3$H%="1T8$=^U6=&OHO&/Q*B\0:6LCZ/INGO;+=
MLA59Y7<'"9Z@ ')]:]"(!&",@]0:6@#A;%&_X7;JK[3M.BP@-CC/F&N4M-+\
M)>%-1U/3_&NAV:H]W)/9ZI<6N^.>)VW;2^#AE)(P>V*]EH(R,'I0!YKX9B\+
MZKXJ@G\+^%; :=:HSR:O]E\K$G\*PG'S'KD],5C^,];\/:I<-=:"MU;>.K:8
M16L20-'/(0V,2+T:,C)RW:O8J3 SG'/K0 B;_+7S  ^!NQTS7&>+$O-&\5:3
MXLM[26\M+>"6SOXX5W2)$Y5A(H[X91D#G%=K10!P&J_$C1]4TNXL/#,CZMJ]
MS$T4-M#$WR,1C,A(PH&<G/I63XWT*30/@A:Z,&\Z2T^S1LR G<P=<D>V<UZK
MC]:* "N+\=V%]%?:%XGTVT>\FT:=VEM8QEY89%VOL]6'! [\UVE% '%'XH^'
M+B+RM*FFU'4W'[K3H86$S-V# CY?<GI7.>'] O?$_P #KK2YE6#49KBYE"D?
M*)EN6<#Z%EQGT->KX ).!D]32T <)8_%+08;&.'79)=*U9%"36-Q"WF;QUV8
M'S ]B.N:K^!+^[U3Q_XROKK3YK*.6*Q^SQSKAS&!-@L.Q/7';(KT+ )!(&1T
M-+0!Q?PL1H_ \:LI4_:[DX(Q_P MFJ#P)$4\6^.G*$;]47!(Z@1BN[HH \SU
MZ-S\1/$3!&*GPI* <<$[^E4DA<_#OX:J8VRFH:>6&.F/6O6:* ,KQ."?">L
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M.1P*\ZT;2O!G@Y+G1?&NC6,<T,\C6VI7-IN2ZA9B5._!^89P0:]JI" 1@C-
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M^!M%N= \(65C>E?MGS33A.BN[%V ^A.*Z+ SG'6B@#D?B@AD^&VMHJEB85X
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M.F:=@9SCFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM0!=HHHH **** "BBB@ HJDVKV*:U'H[7 %_) ;A8<')C!P6].M7: "BBB@
MHHHH **** "BBB@ HHHH **J3ZG96VHVNGS7"I=W08P1'JX49;'T%6Z "BBB
M@ HHHH **** "BJ=GJEG?W-Y;VLXDELI?)N% /R/M#8_(BKE !1110 4444
M%%%% !1110 45!>7<&GV4]Y=2".W@0R2.1]U0,DT6=W!J%C;WMK()+>XC66)
MP/O*PR#^1H GHJMJ&H6NE6$U]?3+!;0KNDD;HHJ='61%=#E6&0?44 .HHHH
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MG*'=G=N]<?YZ5)#8K/;K&]VDTDH5CSG&>AQ]*]E\3^$+3Q%$&)\JXC5MK*
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M@/))('%9]Y_R6[2O^P)/_P"C4KJ?$&GRZMX;U33H9/+EN[26!'SC!9" ?UH
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M-8@A>QN8;Q[=&9%VM$S @;N 0#Z\5-K>B>#H+RPTE[_6-4O+V=%CLHM4DE(
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M<PW%S=6LD4-M"P=W)4\[1S@=2>@Q6SX(_P"1!\.?]@NV_P#12T <]\7VU@>
M]0&GQV;69A/VMIV8.HW+C8!P3]:G/BG5/#?A.UFUNRM9]5N9$M]/LM/D8_:"
M5&T98<=R3T JU\4/^2::[_U[_P#LPK)\7AM-OO!OB::-I--TMV6\VC/E++&$
M$F/13U^M $LVN?$/2;=M3U+0=(N;",;YK6PF<W,:#J1N^5B!V'6NRTC5;36]
M)M=3L9/,M;F,21M['U]ZS]3\8:!I6COJ<VJ6LEN%W1B&57:4]E0 _,3[53^'
M6G76E^!=.M[R$P3L'F,)ZQ!W+A?P! H ZFBBB@ HHHH **** "BBB@ HHHH
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH @-G:M>K>M;Q&Z1#&LQ0;PI.
M2H/7&1TJ>BB@#(U/PMH&M3K/J>BV%Y*O1Y[=7;\R*N0:986LD4EO96\3Q1&&
M-DC"E(R02HQT&0#CVJW10!2U+1],UF 0ZGI]K>1 Y"7$2N!^8J+2O#VC:$K+
MI6EV=D&&&^SPJA/U('-:5<W+XVTM/"=QXCBBO+FR@=D9(8=TA*OL.%SZ^] &
MR-+L!'=QBRMPEX2;E?+&)B1@EO[V1QS3ET^R2XAN%M(1-#'Y44@0;D3^Z#V'
M XJ6WF6YMHIU5U61 X5UPP!&<$=C4E $ LK5;UKU;>(73((VF"#>5!SMSUQG
MM5;5-"TG7(EBU73;2]1?NBXB5\?3/2M"B@#,MO#NBV<$$%MI-E##;RB:%(X%
M C<=& QP?>KDUG;7$T$T]O%)+ Q:%W0$QDC!(/8XJKK.MV6@VL-S?,ZQRSQV
MZ[%W'>YPOX9K1H K7VGV>IVS6U]:PW,#=8YHPZG\#532_#>AZ&S-I6D65DS<
M,UO J$_B!6I10!E:EX:T/6+B.XU/2+&\FC^Y)/ KL/Q(K41%C1410JJ,!0,
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MHHNPLB)+6WB??'!$C#NJ &I:**5QA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!SHT.Z_X6(VNDQ&S.E_8]N3OW^8&Z8QC ]:W8K:WA8M%!%&QZE$
M S4M% !40M;=9?-6"(2?WP@S^=2T4 (JJ@(50N3DX'>F^5'L*;%V'JN.*?10
M F!C&./2HX[6WB<O'!$C'JRH 34M% "%58@E02O0D=*&574JP!4]012T4 (4
M5@ R@@<@$4R6"&< 311R =-Z@XJ2B@!  !@# '04M%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #719%*NH93U!&137MX9-N^)&VG*Y4<&I** $P,YP,GO2T44 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU\]BL\9NDC$K0AOF"$X!QZ9!J>@ HHHH **** "BBB@ HHHH **** "BBB@
MHHJ!KRV2\2S:XB%S(A=(2PW,HZD#TH GHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG&1TK \<:;>6'PR^'GA:\W?:9[C?(AZKD\*?H)<?A73:DHU#]IG2;8#*Z?9
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M!,D;J\;PWS*RG((*18(-2WOC:YGUJ[T?PUHKZQ=61"W4K7 @@A8C(4N0<M[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI]LNFE/+-J(QL*^A%9VA>"/#OAN[>[TK3A#<.NSS'E>5E7^ZI<G:/88KH:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0[2W<;UT^Z:4W!7L&<':K?AQ5[XC6-W>>$7DLK<W,UE<0WHMQ_RV$3ARGOD
M\5;L?'/AJ^T==375[6* KN=9Y0CQGNK*3D$>E &1X1\::GXLE\20II\5E<:;
M(D,,4^<B0H=PDP>0&!&1CBL;X<GQ-_PD_B7[4-*^S?VH_P!L\KS-_F;%_P!7
MDXV].O/6K'PTU)-7\6>.+^*"2&.:]@*+(I5BHBP&P>FX -^-:?@/_D-^,_\
ML,M_Z M '3:YJJ:'H.H:K)&TB6=N\Y1>K;5)Q^E8'AC4?&5]):7>K6VC/IE[
M%YJM92.)+<$94'<2'SZC%=)JEY8V&E75UJ3HEC'&3.T@RH3OD=Q7G>E/9>'?
M'&CZ?X5U?[;I&K"5IM-683):*J%A)&>J+G P3CGZ4 ;FH^*-:U#7KS1/"=C9
MS2V.T7E]?.WD1.1D(%7EVQUP1BIM,U'QE9ZI;6>OZ98W=M<':+[2RRB(@9_>
M(Y)P<?>!Z]N:Q?"NH6OA'Q/XAT'6IDM);W4)-1L[B8[4N(Y,' 8\;E/!%=4W
MC#0O[9M-)@ODNKVY)VQVO[W8 ,[G*Y"KVR?6@#*U3Q5JUYXBN/#_ (5LK:XN
M[1%:\O+PL+>W+=$PO+,1S@$8K&UOQKXM\(06L>NZ;IMQ)>744%O>60<0Y9P&
M5U8Y5MN2#G!Q5C0]2MO"?CGQ#I.LNMJ-5N_[0LKN4X28,BJT>X\!E*]/<U1^
M*7BG3+G2K+2;"2.^G?4;5Y6@.];9!*I#,PX!)PH'?)H U;W_ )+GI/\ V I_
M_1JTB^)/%?B>XN7\)6NEP:7;S-"+[42[_:74X;RU0CY<\;B>>U&H+O\ CAI:
MY(SH,XR.H_>K7(^"O#/A6WTZ30]>OKNQUK3Y'CGB;4Y8%D7<=LB#< 58>E '
MH'AWQ+J<VLR^'_$=A#9ZLD/GQ/;N6ANHLX+)GD$' *GGH>]=77G'A73O"3^-
MWDT%;Z^FT^W8/J#7LDT,;/P8AN8AFQSQP,>M>CT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>arwr-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-11-22T20:54:41.6571718+00:00 -->
<!-- Version            : 5.0.1.702 -->
<!-- Package ID         : 591c69b5c8c44264a019b1bc2edccec6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:arwr="http://www.arrowheadresearch.com/20210930" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20210930" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.arrowheadresearch.com/20210930/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100040 - Statement - Consolidated Statements of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies" id="Role_DisclosureOrganizationAndSignificantAccountingPolicies">
        <link:definition>100060 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100070 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100080 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestments" id="Role_DisclosureInvestments">
        <link:definition>100090 - Disclosure - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssets" id="Role_DisclosureIntangibleAssets">
        <link:definition>100100 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100110 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100130 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100140 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100150 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlans" id="Role_DisclosureEmployeeBenefitPlans">
        <link:definition>100170 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100180 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" id="Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100200 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsTables" id="Role_DisclosureInvestmentsTables">
        <link:definition>100210 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsTables" id="Role_DisclosureIntangibleAssetsTables">
        <link:definition>100220 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100230 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100240 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100250 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100260 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100270 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail">
        <link:definition>100280 - Disclosure - Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail">
        <link:definition>100290 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail">
        <link:definition>100300 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail">
        <link:definition>100310 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" id="Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
        <link:definition>100320 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail">
        <link:definition>100330 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" id="Role_DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail">
        <link:definition>100340 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" id="Role_DisclosureIntangibleAssetsAdditionalInformationDetail">
        <link:definition>100350 - Disclosure - Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail" id="Role_DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail">
        <link:definition>100360 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - Stockholders&apos; Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail" id="Role_DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail">
        <link:definition>100400 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2" id="Role_DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2">
        <link:definition>100410 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100420 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail" id="Role_DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail">
        <link:definition>100430 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail" id="Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail">
        <link:definition>100440 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfRsusActivityDetail">
        <link:definition>100450 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100460 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100470 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail" id="Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail">
        <link:definition>100480 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100490 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail">
        <link:definition>100500 - Disclosure - Income Taxes - Provisions for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail" id="Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail">
        <link:definition>100510 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" id="Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail">
        <link:definition>100520 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100530 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="arwr_CollaborationAndLicenseAgreementsAbstract" name="CollaborationAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" name="BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_ContingentConsiderationPolicyTextBlock" name="ContingentConsiderationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" name="HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_CashReceivedAsDueUnderAgreement" name="CashReceivedAsDueUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_MilestonePaymentEarned" name="MilestonePaymentEarned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" name="DevelopmentRegulatoryAndSalesMilestonesPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" name="OrganizationAndSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_OrganizationAndSignificantAccountingPoliciesTable" name="OrganizationAndSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_JanssenPharmaceuticalsIncorporationMember" name="JanssenPharmaceuticalsIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CollaborationAgreementMember" name="CollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" name="TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_IncreaseDecreaseInCashAndInvestments" name="IncreaseDecreaseInCashAndInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_AgreementDate" name="AgreementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_NumberOfAgreements" name="NumberOfAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="arwr_AmgenIncorporatedMember" name="AmgenIncorporatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_OlpasiranAgreementMember" name="OlpasiranAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" name="LicenseCollaborationAndStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_OlpasiranAndAROAMG1AgreementMember" name="OlpasiranAndAROAMG1AgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CashReceivedAsDueUnderCollaborationAgreement" name="CashReceivedAsDueUnderCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_MilestonePaymentReceived" name="MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" name="AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" name="NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" name="JohnsonAndJohnsonInnovationJJDCIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" name="JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_ResearchCollaborationAndOptionAgreementMember" name="ResearchCollaborationAndOptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CommonStockPurchaseAgreementMember" name="CommonStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_JNJ3989AROHBVAgreementMember" name="JNJ3989AROHBVAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_JNJ75220795AROJNJ1Member" name="JNJ75220795AROJNJ1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_NumberOfDistinctPerformanceObligations" name="NumberOfDistinctPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_InitialTransactionPrice" name="InitialTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_RatioOfProfitSharingStructureForCommercialization" name="RatioOfProfitSharingStructureForCommercialization" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" name="PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" name="CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_LicenseAndCoFundingAgreementMember" name="LicenseAndCoFundingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_DeferredRevenueCurrentMember" name="DeferredRevenueCurrentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_NumberOfDistinctBundle" name="NumberOfDistinctBundle" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_HorizonTherapeuticsIrelandDACMember" name="HorizonTherapeuticsIrelandDACMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_AROXDHAgreementMember" name="AROXDHAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_ResearchEquipmentGross" name="ResearchEquipmentGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" name="EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" name="EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" name="EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CommercialNotesDueWithinOneYearMember" name="CommercialNotesDueWithinOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" name="CommercialNotesDueWithinOneThroughThreeYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CertificateOfDepositsDueWithinTwoYearsMember" name="CertificateOfDepositsDueWithinTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_NovartisMember" name="NovartisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" name="TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_AtTheMarketAgreementMember" name="AtTheMarketAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" name="CommonStockCapitalSharesValueReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" name="PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_TechnologyLicenseCommitmentsMember" name="TechnologyLicenseCommitmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_AROENacAndAROHIF2CandidatesMember" name="AROENacAndAROHIF2CandidatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_LeasePaymentsCommencementDate" name="LeasePaymentsCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" name="PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_NumberOfOptionsToRenew" name="NumberOfOptionsToRenew" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="arwr_LeaseExpansionCommencementMonthAndYear" name="LeaseExpansionCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_LeaseExpansionExpirationMonthAndYear" name="LeaseExpansionExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_CorporateHeadquartersInPasadenaMember" name="CorporateHeadquartersInPasadenaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_ColoradoOwnerLLCMember" name="ColoradoOwnerLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_ResearchFacilityInMadisonMember" name="ResearchFacilityInMadisonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_HalozymeIncMember" name="HalozymeIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_SubleaseAgreementMember" name="SubleaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_AdditionalLandSubjectToLease" name="AdditionalLandSubjectToLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" name="ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_SubleaseCommencementDate" name="SubleaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_TwoThousandsFourEquityIncentivePlanMember" name="TwoThousandsFourEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_TwoThousandsThirteenIncentivePlanMember" name="TwoThousandsThirteenIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_OutsideOfEquityCompensationPlansMember" name="OutsideOfEquityCompensationPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_TwoThousandTwentyOneIncentivePlanMember" name="TwoThousandTwentyOneIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" name="GrantDateFairValueOfOptionsGrantedDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" name="EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" name="HeldToMaturitySecuritiesFairValueNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" name="DeferredTaxAssetsInProcessResearchAndDevelopmentCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" name="DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_DeferredTaxLiabilitiesStateTaxes" name="DeferredTaxLiabilitiesStateTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_PercentageOfValuationAllowance" name="PercentageOfValuationAllowance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="arwr_FederalNetOperatingLossCarryForward" name="FederalNetOperatingLossCarryForward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_StateNetOperatingLossCarryForwards" name="StateNetOperatingLossCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" name="EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" name="EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" name="EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_EmployeeContributionsUpToThreePercentMember" name="EmployeeContributionsUpToThreePercentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_EmployeeContributionNextTwoPercentMember" name="EmployeeContributionNextTwoPercentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_ResearchFacilityInSanDiegoMember" name="ResearchFacilityInSanDiegoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" name="GlaxosmithklineIntellectualPropertyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_LeaseCommencementMonthAndYear" name="LeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_EstimatedPaymentsForOperatingExpensesYearOne" name="EstimatedPaymentsForOperatingExpensesYearOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription" name="TieredRoyaltiesOnNetProductSalesReceiveDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" name="MilestonePaymentReceivableAtStartOfPhaseTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" name="MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" name="CommercialMilestonePaymentsAtFirstCommercialSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_SalesRelatedMilestonePayments" name="SalesRelatedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>arwr-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-11-22T20:54:41.6571718+00:00 -->
<!-- Version            : 5.0.1.702 -->
<!-- Package ID         : 591c69b5c8c44264a019b1bc2edccec6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="arwr-20210930.xsd#TemplateLink" roleURI="http://www.arrowheadresearch.com/20210930/role/TemplateLink" />
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="arwr-20210930.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_HeldToMaturitySecuritiesNoncurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="arwr-20210930.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="arwr-20210930.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="10190.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:href="arwr-20210930.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchEquipmentGross" xlink:type="locator" xlink:label="arwr_ResearchEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_FurnitureAndFixturesGross" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="arwr_ResearchEquipmentGross" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNi" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2" xlink:href="arwr-20210930.xsd#Role_DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes" xlink:type="locator" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="arwr_DeferredTaxLiabilitiesStateTaxes" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="10150.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>arwr-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-11-22T20:54:41.6581715+00:00 -->
<!-- Version            : 5.0.1.702 -->
<!-- Package ID         : 591c69b5c8c44264a019b1bc2edccec6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="arwr-20210930.xsd#TemplateLink" roleURI="http://www.arrowheadresearch.com/20210930/role/TemplateLink" />
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="arwr-20210930.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="11480.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="locator" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivedAsDueUnderAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_OrganizationAndSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsIncorporationMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAgreementMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_CashReceivedAsDueUnderAgreement" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_MilestonePaymentEarned" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketableSecurities" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesNoncurrent" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_IncreaseDecreaseInCashAndInvestments" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11700.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentReceived" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfAgreements" xlink:type="locator" xlink:label="arwr_NumberOfAgreements" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OlpasiranAndAROAMG1AgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OlpasiranAgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AmgenIncorporatedMember" xlink:type="locator" xlink:label="arwr_AmgenIncorporatedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_AmgenIncorporatedMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_OlpasiranAgreementMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_OlpasiranAndAROAMG1AgreementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfAgreements" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_MilestonePaymentReceived" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentReceived" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" xlink:type="locator" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JNJ75220795AROJNJ1Member" xlink:type="locator" xlink:label="arwr_JNJ75220795AROJNJ1Member" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JNJ3989AROHBVAgreementMember" xlink:type="locator" xlink:label="arwr_JNJ3989AROHBVAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommonStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_CommonStockPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchCollaborationAndOptionAgreementMember" xlink:type="locator" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LicenseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsIncorporationMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAgreementMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_ResearchCollaborationAndOptionAgreementMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAgreementMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_CommonStockPurchaseAgreementMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_JNJ3989AROHBVAgreementMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_JNJ75220795AROJNJ1Member" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_MilestonePaymentEarned" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctPerformanceObligations" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_InitialTransactionPrice" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_MilestonePaymentReceived" order="12150.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctBundle" xlink:type="locator" xlink:label="arwr_NumberOfDistinctBundle" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="locator" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_RatioOfProfitSharingStructureForCommercialization" xlink:type="locator" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredRevenueCurrentMember" xlink:type="locator" xlink:label="arwr_DeferredRevenueCurrentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LicenseAndCoFundingAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAndCoFundingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAndCoFundingAgreementMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="arwr_DeferredRevenueCurrentMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_RatioOfProfitSharingStructureForCommercialization" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctBundle" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctPerformanceObligations" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_InitialTransactionPrice" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctBundle" xlink:type="locator" xlink:label="arwr_NumberOfDistinctBundle" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LicenseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AROXDHAgreementMember" xlink:type="locator" xlink:label="arwr_AROXDHAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_HorizonTherapeuticsIrelandDACMember" xlink:type="locator" xlink:label="arwr_HorizonTherapeuticsIrelandDACMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_HorizonTherapeuticsIrelandDACMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_AROXDHAgreementMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAgreementMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctBundle" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctPerformanceObligations" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_InitialTransactionPrice" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MarketableSecuritiesMember" xlink:type="locator" xlink:label="arwr_MarketableSecuritiesMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CertificateOfDepositsDueWithinTwoYearsMember" xlink:type="locator" xlink:label="arwr_CertificateOfDepositsDueWithinTwoYearsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommercialNotesDueWithinOneYearMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneYearMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" order="10080.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_CommercialNotesDueWithinOneYearMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="arwr_CertificateOfDepositsDueWithinTwoYearsMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_MarketableSecuritiesMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiCost" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="11300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NovartisMember" xlink:type="locator" xlink:label="arwr_NovartisMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="arwr_NovartisMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="locator" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="locator" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AtTheMarketAgreementMember" xlink:type="locator" xlink:label="arwr_AtTheMarketAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_AtTheMarketAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="10600.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePayments" xlink:type="locator" xlink:label="arwr_MilestonePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AROENacAndAROHIF2CandidatesMember" xlink:type="locator" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TechnologyLicenseCommitmentsMember" xlink:type="locator" xlink:label="arwr_TechnologyLicenseCommitmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="arwr_TechnologyLicenseCommitmentsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_AROENacAndAROHIF2CandidatesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="arwr_MilestonePayments" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_SubleaseCommencementDate" xlink:type="locator" xlink:label="arwr_SubleaseCommencementDate" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AdditionalLandSubjectToLease" xlink:type="locator" xlink:label="arwr_AdditionalLandSubjectToLease" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeaseExpansionExpirationMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseExpansionExpirationMonthAndYear" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeaseExpansionCommencementMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseExpansionCommencementMonthAndYear" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfOptionsToRenew" xlink:type="locator" xlink:label="arwr_NumberOfOptionsToRenew" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeasePaymentsCommencementDate" xlink:type="locator" xlink:label="arwr_LeasePaymentsCommencementDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_SubleaseAgreementMember" xlink:type="locator" xlink:label="arwr_SubleaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_HalozymeIncMember" xlink:type="locator" xlink:label="arwr_HalozymeIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_WI" xlink:type="locator" xlink:label="stpr_WI" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchFacilityInMadisonMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInMadisonMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ColoradoOwnerLLCMember" xlink:type="locator" xlink:label="arwr_ColoradoOwnerLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CorporateHeadquartersInPasadenaMember" xlink:type="locator" xlink:label="arwr_CorporateHeadquartersInPasadenaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_CorporateHeadquartersInPasadenaMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arwr_ColoradoOwnerLLCMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_ResearchFacilityInMadisonMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WI" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arwr_HalozymeIncMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_SubleaseAgreementMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_LeasePaymentsCommencementDate" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_NumberOfOptionsToRenew" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_LeaseExpansionCommencementMonthAndYear" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_LeaseExpansionExpirationMonthAndYear" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_AdditionalLandSubjectToLease" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_SubleaseCommencementDate" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="12220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:type="locator" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandTwentyOneIncentivePlanMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OutsideOfEquityCompensationPlansMember" xlink:type="locator" xlink:label="arwr_OutsideOfEquityCompensationPlansMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsFourEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsThirteenIncentivePlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_OutsideOfEquityCompensationPlansMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandTwentyOneIncentivePlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12310.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureStockBasedCompensationSummaryOfRsusActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="10820.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EmployeeContributionNextTwoPercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionNextTwoPercentMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EmployeeContributionsUpToThreePercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="arwr_EmployeeContributionsUpToThreePercentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="arwr_EmployeeContributionNextTwoPercentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription" xlink:type="locator" xlink:label="arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_SalesRelatedMilestonePayments" xlink:type="locator" xlink:label="arwr_SalesRelatedMilestonePayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:type="locator" xlink:label="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfOptionsToRenew" xlink:type="locator" xlink:label="arwr_NumberOfOptionsToRenew" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:type="locator" xlink:label="arwr_EstimatedPaymentsForOperatingExpensesYearOne" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseCommencementMonthAndYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:type="locator" xlink:label="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchFacilityInSanDiegoMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInSanDiegoMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_ResearchFacilityInSanDiegoMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_LeaseCommencementMonthAndYear" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_EstimatedPaymentsForOperatingExpensesYearOne" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_NumberOfOptionsToRenew" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_MilestonePaymentEarned" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_SalesRelatedMilestonePayments" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription" order="11840.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>arwr-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-11-22T20:54:41.6581715+00:00 -->
<!-- Version            : 5.0.1.702 -->
<!-- Package ID         : 591c69b5c8c44264a019b1bc2edccec6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security12b Title</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LONG-TERM LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LONG-TERM LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 145,000 shares authorized; 104,327 and 102,376 shares issued and outstanding as of September 30, 2021 and September 30, 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">REVENUE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Revenue [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Revenue Extensible List</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OPERATING EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Excluding Acquired In Process Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL OPERATING EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OPERATING INCOME (LOSS)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OTHER INCOME (EXPENSE)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL OTHER INCOME (EXPENSE)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">INCOME (LOSS) BEFORE INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET INCOME (LOSS)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NET INCOME (LOSS) PER SHARE - BASIC</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NET INCOME (LOSS) PER SHARE - DILUTED</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding - basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding - diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Diluted Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">COMPREHENSIVE INCOME (LOSS)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock - restricted stock units vesting, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock - restricted stock units vesting, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock - issued for cash, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock - issued for cash, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency translation adjustments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deconsolidation of Ablaris Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest Decrease From Deconsolidation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization/(accretion) of note premiums</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net Amortization Of Discount And Premium</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Maturity And Collections Of Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Notes Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercises of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET INCREASE (DECREASE) IN CASH</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplementary disclosures:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes (Paid)/Refunded</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="arwr_CollaborationAndLicenseAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreements [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Classified [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:type="locator" xlink:label="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and use of estimates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:to="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Use Of Estimates Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets subject to amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ContingentConsiderationPolicyTextBlock" xlink:type="locator" xlink:label="arwr_ContingentConsiderationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="arwr_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for contingent consideration obligations related to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ContingentConsiderationPolicyTextBlock" xlink:to="arwr_ContingentConsiderationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Accounting Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for Doubtful Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade And Other Accounts Receivable Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Held to maturity securities and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" xlink:to="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Short-term, Long-term Investments and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities And Marketable Securities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Intangible Assets And Goodwill Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summarized Information about Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions Used to Value Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share Activity Related to RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of the Net Deferred Tax (Liability)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions for Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Effective Income Tax Rate Reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivedAsDueUnderAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderAgreement" />
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash received as due under agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CashReceivedAsDueUnderAgreement" xlink:to="arwr_CashReceivedAsDueUnderAgreement_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment earned.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_MilestonePaymentEarned" xlink:to="arwr_MilestonePaymentEarned_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:label xml:lang="en-US" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development regulatory and sales milestones payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_OrganizationAndSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="arwr_OrganizationAndSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Janssen Pharmaceuticals, Incorporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_JanssenPharmaceuticalsIncorporationMember" xlink:to="arwr_JanssenPharmaceuticalsIncorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Janssen Pharmaceuticals Incorporation [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CollaborationAgreementMember" xlink:to="arwr_CollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda Pharmaceuticals United States of America Incorporated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Pharmaceuticals United States Of America Incorporated [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CollaborationAndLicenseAgreementMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Horizon License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2014-09</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201409 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2016-02</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2018-18</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201818Member" xlink:to="us-gaap_AccountingStandardsUpdate201818Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201818 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received as due under agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Received As Due Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Earned</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development regulatory and sales milestones payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory And Sales Milestones Payments</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="locator" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments" />
    <link:label xml:lang="en-US" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in cash and investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_IncreaseDecreaseInCashAndInvestments" xlink:to="arwr_IncreaseDecreaseInCashAndInvestments_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net increase (decrease) in cash and investments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Cash And Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount insured in FDIC per account</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash F D I C Insured Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of contingent consideration obligation due to discontinuation of clinical trials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Calculation of effect of dilutive stock options and restricted stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable To Share Based Payment Arrangements</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive excluded for calculation of effect of dilutive stock options and restricted stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:label xml:lang="en-US" xlink:label="arwr_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AgreementDate" xlink:to="arwr_AgreementDate_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfAgreements" xlink:type="locator" xlink:label="arwr_NumberOfAgreements" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfAgreements" xlink:to="arwr_NumberOfAgreements_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License agreements</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AmgenIncorporatedMember" xlink:type="locator" xlink:label="arwr_AmgenIncorporatedMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_AmgenIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen Incorporated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AmgenIncorporatedMember" xlink:to="arwr_AmgenIncorporatedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AmgenIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AmgenIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Incorporated [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OlpasiranAgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Olpasiran agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OlpasiranAgreementMember" xlink:to="arwr_OlpasiranAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Olpasiran Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Olpasiran Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License collaboration and stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:to="arwr_LicenseCollaborationAndStockPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Collaboration And Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Collaboration And Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OlpasiranAndAROAMG1AgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Olpasiran and ARO-AMG1 agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OlpasiranAndAROAMG1AgreementMember" xlink:to="arwr_OlpasiranAndAROAMG1AgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Olpasiran and ARO-AMG1 Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Olpasiran And A R O A M G1 Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement date</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Agreements</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash received as due under collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentReceived" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceived" />
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_MilestonePaymentReceived" xlink:to="arwr_MilestonePaymentReceived_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional remaining development regulatory and sales milestones payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received as due under collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Received As Due Under Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional remaining development regulatory and sales milestones payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Remaining Development Regulatory And Sales Milestones Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contract liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net Current</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" xlink:type="locator" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional targets for development, regulatory and sales milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" xlink:to="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Johnson and Johnson Innovation-JJDC, Incorporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:to="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">JJDC</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Johnson And Johnson Innovation J J D C Incorporation [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Janssen Pharmaceuticals and Johnson And Johnson Innovation JJDC Incorporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:to="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Janssen Pharmaceuticals And Johnson And Johnson Innovation J J D C Incorporation [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LicenseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LicenseAgreementMember" xlink:to="arwr_LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchCollaborationAndOptionAgreementMember" xlink:type="locator" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration and option agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ResearchCollaborationAndOptionAgreementMember" xlink:to="arwr_ResearchCollaborationAndOptionAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration and Option Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration And Option Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommonStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_CommonStockPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommonStockPurchaseAgreementMember" xlink:to="arwr_CommonStockPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JNJ3989AROHBVAgreementMember" xlink:type="locator" xlink:label="arwr_JNJ3989AROHBVAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_JNJ3989AROHBVAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">JNJ-3989 (ARO-HBV) Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_JNJ3989AROHBVAgreementMember" xlink:to="arwr_JNJ3989AROHBVAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_JNJ3989AROHBVAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">J N J3989 A R O H B V Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_JNJ3989AROHBVAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">J N J3989 A R O H B V Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JNJ75220795AROJNJ1Member" xlink:type="locator" xlink:label="arwr_JNJ75220795AROJNJ1Member" />
    <link:label xml:lang="en-US" xlink:label="arwr_JNJ75220795AROJNJ1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">JNJ 75220795 ARO JNJ1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_JNJ75220795AROJNJ1Member" xlink:to="arwr_JNJ75220795AROJNJ1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_JNJ75220795AROJNJ1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">JNJ-75220795 (ARO-JNJ1)</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_JNJ75220795AROJNJ1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">J N J75220795 A R O J N J1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Development, regulatory and sales milestones payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional targets for development, regulatory and sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Targets For Development Regulatory And Sales Milestone Payments</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctPerformanceObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of distinct performance obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfDistinctPerformanceObligations" xlink:to="arwr_NumberOfDistinctPerformanceObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctPerformanceObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of distinct performance obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctPerformanceObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Distinct Performance Obligations</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="arwr_InitialTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_InitialTransactionPrice" xlink:to="arwr_InitialTransactionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_InitialTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_InitialTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Transaction Price</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_RatioOfProfitSharingStructureForCommercialization" xlink:type="locator" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization" />
    <link:label xml:lang="en-US" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ratio of profit sharing structure for commercialization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_RatioOfProfitSharingStructureForCommercialization" xlink:to="arwr_RatioOfProfitSharingStructureForCommercialization_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="locator" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" />
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of eligible to receive tiered royalties on net sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:to="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash receivable as upfront payment due under collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:to="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LicenseAndCoFundingAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAndCoFundingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAndCoFundingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and co-funding agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LicenseAndCoFundingAgreementMember" xlink:to="arwr_LicenseAndCoFundingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAndCoFundingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Co-Funding Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAndCoFundingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Co Funding Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredRevenueCurrentMember" xlink:type="locator" xlink:label="arwr_DeferredRevenueCurrentMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredRevenueCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DeferredRevenueCurrentMember" xlink:to="arwr_DeferredRevenueCurrentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredRevenueCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredRevenueCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesMember" xlink:to="us-gaap_AccruedLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratio of Profit Sharing Structure for United States Commercialization</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ratio Of Profit Sharing Structure For Commercialization</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of eligible to receive tiered royalties on net sales</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Eligible To Receive Tiered Royalties On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received as due under collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Receivable As Upfront Payment Due Under Collaboration Agreement</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctBundle" xlink:type="locator" xlink:label="arwr_NumberOfDistinctBundle" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctBundle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of distinct bundle.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfDistinctBundle" xlink:to="arwr_NumberOfDistinctBundle_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctBundle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of distinct bundle</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctBundle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Distinct Bundle</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Contract liabilities, current</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_HorizonTherapeuticsIrelandDACMember" xlink:type="locator" xlink:label="arwr_HorizonTherapeuticsIrelandDACMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_HorizonTherapeuticsIrelandDACMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Horizon Therapeutics Ireland DAC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_HorizonTherapeuticsIrelandDACMember" xlink:to="arwr_HorizonTherapeuticsIrelandDACMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_HorizonTherapeuticsIrelandDACMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Horizon Therapeutics Ireland DAC</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_HorizonTherapeuticsIrelandDACMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Horizon Therapeutics Ireland D A C [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AROXDHAgreementMember" xlink:type="locator" xlink:label="arwr_AROXDHAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_AROXDHAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ARO-XDH Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AROXDHAgreementMember" xlink:to="arwr_AROXDHAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AROXDHAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ARO-XDH</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AROXDHAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A R O X D H Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchEquipmentGross" xlink:type="locator" xlink:label="arwr_ResearchEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research equipment gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ResearchEquipmentGross" xlink:to="arwr_ResearchEquipmentGross_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers, office equipment and furniture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Equipment Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Computer Software Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense for property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity securities FvNi accumulated gross realized gain loss before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" xlink:to="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity securities FV NI accumulated gross unrealized gain before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity securities FV NI accumulated gross unrealized loss before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommercialNotesDueWithinOneYearMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneYearMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial notes due within one year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommercialNotesDueWithinOneYearMember" xlink:to="arwr_CommercialNotesDueWithinOneYearMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Note Due Within One Year</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Notes Due Within One Year [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial notes due within one through three years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" xlink:to="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Note Due Within One Through Three Years</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Notes Due Within One Through Three Years [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CertificateOfDepositsDueWithinTwoYearsMember" xlink:type="locator" xlink:label="arwr_CertificateOfDepositsDueWithinTwoYearsMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CertificateOfDepositsDueWithinTwoYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Certificate of deposits due within two years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CertificateOfDepositsDueWithinTwoYearsMember" xlink:to="arwr_CertificateOfDepositsDueWithinTwoYearsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CertificateOfDepositsDueWithinTwoYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificate Of Deposit Due Within Two Years</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CertificateOfDepositsDueWithinTwoYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Certificate Of Deposits Due Within Two Years [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MarketableSecuritiesMember" xlink:type="locator" xlink:label="arwr_MarketableSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_MarketableSecuritiesMember" xlink:to="arwr_MarketableSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Held to Maturity, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Held to Maturity, Gross Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Accumulated Unrecognized Holding Gain</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Held to Maturity, Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Accumulated Unrecognized Holding Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Held to Maturity, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNiCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Fv Ni Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Realized Gains/(Losses)</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Fv Ni Accumulated Gross Realized Gains Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities F V N I Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable Securities, Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities F V N I Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Fv Ni</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NovartisMember" xlink:type="locator" xlink:label="arwr_NovartisMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_NovartisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NovartisMember" xlink:to="arwr_NovartisMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_NovartisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NovartisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Novartis [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PatentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PatentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization period of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Useful Life</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements in 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements in 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements in 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements in 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements in 2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements, thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense After Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Intangible assets subject to amortization, beginning balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets subject to amortization, Impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Finitelived</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets subject to amortization, Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Intangible assets subject to amortization, ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:to="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AtTheMarketAgreementMember" xlink:type="locator" xlink:label="arwr_AtTheMarketAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_AtTheMarketAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AtTheMarketAgreementMember" xlink:to="arwr_AtTheMarketAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AtTheMarketAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AtTheMarketAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital stock authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Share reserve for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="locator" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, capital shares value reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:to="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="locator" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of commission on aggregate gross proceeds from sale of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:to="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares value reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Value Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of commission to sales agent</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued to institutional investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Domain]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TechnologyLicenseCommitmentsMember" xlink:type="locator" xlink:label="arwr_TechnologyLicenseCommitmentsMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_TechnologyLicenseCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Technology license commitments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TechnologyLicenseCommitmentsMember" xlink:to="arwr_TechnologyLicenseCommitmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_TechnologyLicenseCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technology License Commitments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TechnologyLicenseCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Technology License Commitments [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AROENacAndAROHIF2CandidatesMember" xlink:type="locator" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ARO-ENac and ARO-HIF2 Candidates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AROENacAndAROHIF2CandidatesMember" xlink:to="arwr_AROENacAndAROHIF2CandidatesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ARO-ENaC and ARO-HIF2 Candidates</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A R O E Nac And A R O H I F2 Candidates [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual At Carrying Value</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePayments" xlink:type="locator" xlink:label="arwr_MilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_MilestonePayments" xlink:to="arwr_MilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeasePaymentsCommencementDate" xlink:type="locator" xlink:label="arwr_LeasePaymentsCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="arwr_LeasePaymentsCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease payments commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LeasePaymentsCommencementDate" xlink:to="arwr_LeasePaymentsCommencementDate_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:label xml:lang="en-US" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of leasehold improvements net of tenant improvement allowances.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:to="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfOptionsToRenew" xlink:type="locator" xlink:label="arwr_NumberOfOptionsToRenew" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfOptionsToRenew_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of options to renew.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfOptionsToRenew" xlink:to="arwr_NumberOfOptionsToRenew_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeaseExpansionCommencementMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseExpansionCommencementMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseExpansionCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expansion commencement month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LeaseExpansionCommencementMonthAndYear" xlink:to="arwr_LeaseExpansionCommencementMonthAndYear_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeaseExpansionExpirationMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseExpansionExpirationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseExpansionExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expansion expiration month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LeaseExpansionExpirationMonthAndYear" xlink:to="arwr_LeaseExpansionExpirationMonthAndYear_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CorporateHeadquartersInPasadenaMember" xlink:type="locator" xlink:label="arwr_CorporateHeadquartersInPasadenaMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CorporateHeadquartersInPasadenaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate Headquarters in Pasadena</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CorporateHeadquartersInPasadenaMember" xlink:to="arwr_CorporateHeadquartersInPasadenaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CorporateHeadquartersInPasadenaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Headquarters In Pasadena</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CorporateHeadquartersInPasadenaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Headquarters In Pasadena [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C A</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ColoradoOwnerLLCMember" xlink:type="locator" xlink:label="arwr_ColoradoOwnerLLCMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_ColoradoOwnerLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Colorado Owner, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ColoradoOwnerLLCMember" xlink:to="arwr_ColoradoOwnerLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_ColoradoOwnerLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Colorado Owner, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ColoradoOwnerLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Colorado Owner L L C [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchFacilityInMadisonMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInMadisonMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research facility in Madison.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ResearchFacilityInMadisonMember" xlink:to="arwr_ResearchFacilityInMadisonMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Facility in Madison</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Facility In Madison [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_WI" xlink:type="locator" xlink:label="stpr_WI" />
    <link:label xml:lang="en-US" xlink:label="stpr_WI_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wisconsin</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_WI" xlink:to="stpr_WI_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_WI_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">W I</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_HalozymeIncMember" xlink:type="locator" xlink:label="arwr_HalozymeIncMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_HalozymeIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Halozyme, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_HalozymeIncMember" xlink:to="arwr_HalozymeIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_HalozymeIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Halozyme, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_HalozymeIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Halozyme Inc [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_SubleaseAgreementMember" xlink:type="locator" xlink:label="arwr_SubleaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_SubleaseAgreementMember" xlink:to="arwr_SubleaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office space leases, in square feet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandSubjectToGroundLeases" xlink:to="us-gaap_LandSubjectToGroundLeases_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Land Subject To Ground Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeasePaymentsCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease payments, commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeasePaymentsCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Payments Commencement Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for leasehold improvements, net of tenant improvement allowances</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfOptionsToRenew_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options to renew</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfOptionsToRenew_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Options To Renew</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseExpansionCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expansion commencement period</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseExpansionCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expansion Commencement Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseExpansionExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expansion expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseExpansionExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expansion Expiration Month And Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AdditionalLandSubjectToLease" xlink:type="locator" xlink:label="arwr_AdditionalLandSubjectToLease" />
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalLandSubjectToLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional land subject to lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AdditionalLandSubjectToLease" xlink:to="arwr_AdditionalLandSubjectToLease_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:label xml:lang="en-US" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected payments of leasehold improvements, net of tenant improvement allowances.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:to="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalLandSubjectToLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional office space for lease</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalLandSubjectToLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Land Subject To Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected leasehold improvements, net of tenant improvement allowances</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expected Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_SubleaseCommencementDate" xlink:type="locator" xlink:label="arwr_SubleaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_SubleaseCommencementDate" xlink:to="arwr_SubleaseCommencementDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Commencement Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Lease Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 and thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Total operating lease liabilities (includes current portion)</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cash payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousands four equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:to="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2004 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousands Four Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousands thirteen incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandsThirteenIncentivePlanMember" xlink:to="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousands Thirteen Incentive Plan [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OutsideOfEquityCompensationPlansMember" xlink:type="locator" xlink:label="arwr_OutsideOfEquityCompensationPlansMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_OutsideOfEquityCompensationPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Outside of equity compensation plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OutsideOfEquityCompensationPlansMember" xlink:to="arwr_OutsideOfEquityCompensationPlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_OutsideOfEquityCompensationPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outside Of Equity Compensation Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OutsideOfEquityCompensationPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Outside Of Equity Compensation Plans [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandTwentyOneIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandTwentyOneIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:to="arwr_TwoThousandTwentyOneIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandTwentyOneIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandTwentyOneIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserve for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of restricted stock units outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options Outstanding, beginning balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Options Outstanding, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options Outstanding, Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options Outstanding, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options Outstanding, ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Outstanding, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price Per Share, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price Per Share, ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:type="locator" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant date fair value of the options granted during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:to="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value of the options granted</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant Date Fair Value Of Options Granted During Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized pre-tax compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period to recognize pre-tax compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSU awards vesting, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Description</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of RSUs, Unvested, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of RSUs, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of RSUs, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of RSUs, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of RSUs, Unvested, End of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value, ending balance</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee service share based compensation nonvested awards additional compensation cost not yet recognized share based awards other than options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized pre-tax compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional unrecognized pre-tax compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Additional Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" />
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Held to maturity securities fair value non current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:to="arwr_HeldToMaturitySecuritiesFairValueNonCurrent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term investments (held to maturity)</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments (held to maturity)</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Fair Value Non Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent consideration obligations</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" />
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:to="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets right of use assets/ lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:to="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes" xlink:type="locator" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes" />
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DeferredTaxLiabilitiesStateTaxes" xlink:to="arwr_DeferredTaxLiabilitiesStateTaxes_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Research &amp; Development</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Alternative Minimum Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of Use Assets/Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Right Of Use Assets Or Lease Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capital Loss Carryforwards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities State Taxes</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets (liabilities)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PercentageOfValuationAllowance" xlink:type="locator" xlink:label="arwr_PercentageOfValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of valuation allowance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PercentageOfValuationAllowance" xlink:to="arwr_PercentageOfValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance against deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Valuation Allowance</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_FederalNetOperatingLossCarryForward" xlink:type="locator" xlink:label="arwr_FederalNetOperatingLossCarryForward" />
    <link:label xml:lang="en-US" xlink:label="arwr_FederalNetOperatingLossCarryForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal net operating loss carry forward.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_FederalNetOperatingLossCarryForward" xlink:to="arwr_FederalNetOperatingLossCarryForward_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_StateNetOperatingLossCarryForwards" xlink:type="locator" xlink:label="arwr_StateNetOperatingLossCarryForwards" />
    <link:label xml:lang="en-US" xlink:label="arwr_StateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">State net operating loss carry forwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_StateNetOperatingLossCarryForwards" xlink:to="arwr_StateNetOperatingLossCarryForwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_FederalNetOperatingLossCarryForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross federal net operating loss carry forwards</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_FederalNetOperatingLossCarryForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Net Operating Loss Carry Forward</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_StateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross state net operating loss carry forwards</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_StateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State Net Operating Loss Carry Forwards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Income Tax Expense Benefit Continuing Operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Income Tax Expense Benefit Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision from income taxes</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" />
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" />
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to mark-to-market adjustments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" />
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation true-up on deferred tax rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At U.S. federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Deductions Stock Compensation Percent</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mark-to-market adjustments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Mark To Market Adjustments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">True-up on deferred taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation True Up On Deferred Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax rate change</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, penalties related to uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, interest related to uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Interest On Income Taxes Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EmployeeContributionsUpToThreePercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee contributions up to three percent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EmployeeContributionsUpToThreePercentMember" xlink:to="arwr_EmployeeContributionsUpToThreePercentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Contributions up to 3%</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Contributions Up To Three Percent [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EmployeeContributionNextTwoPercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionNextTwoPercentMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionNextTwoPercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee contribution next two percent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EmployeeContributionNextTwoPercentMember" xlink:to="arwr_EmployeeContributionNextTwoPercentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionNextTwoPercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Contributions Next 2%</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionNextTwoPercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Contribution Next Two Percent [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discretionary match percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee benefits costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchFacilityInSanDiegoMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInSanDiegoMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research Facility in San Diego.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ResearchFacilityInSanDiegoMember" xlink:to="arwr_ResearchFacilityInSanDiegoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Facility in San Diego</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Facility In San Diego [Member]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:type="locator" xlink:label="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_GlaxosmithklineIntellectualPropertyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxosmithkline Intellectual Property Limited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:to="arwr_GlaxosmithklineIntellectualPropertyLimitedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_GlaxosmithklineIntellectualPropertyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_GlaxosmithklineIntellectualPropertyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Glaxosmithkline Intellectual Property Limited [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseCommencementMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LeaseCommencementMonthAndYear" xlink:to="arwr_LeaseCommencementMonthAndYear_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:type="locator" xlink:label="arwr_EstimatedPaymentsForOperatingExpensesYearOne" />
    <link:label xml:lang="en-US" xlink:label="arwr_EstimatedPaymentsForOperatingExpensesYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated payments for operating expenses year one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:to="arwr_EstimatedPaymentsForOperatingExpensesYearOne_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EstimatedPaymentsForOperatingExpensesYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Estimated payments for operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EstimatedPaymentsForOperatingExpensesYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Payments For Operating Expenses Year One</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription" xlink:type="locator" xlink:label="arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription" />
    <link:label xml:lang="en-US" xlink:label="arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tiered royalties on net product sales receive description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription" xlink:to="arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" />
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment receivable at start of phase two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:to="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" />
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:to="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:type="locator" xlink:label="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialMilestonePaymentsAtFirstCommercialSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payments at first commercial sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:to="arwr_CommercialMilestonePaymentsAtFirstCommercialSale_lbl" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_SalesRelatedMilestonePayments" xlink:type="locator" xlink:label="arwr_SalesRelatedMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="arwr_SalesRelatedMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales-related milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_SalesRelatedMilestonePayments" xlink:to="arwr_SalesRelatedMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment receivable at start of phase two</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Receivable At Start Of Phase Two</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialMilestonePaymentsAtFirstCommercialSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payments at first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialMilestonePaymentsAtFirstCommercialSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payments At First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_SalesRelatedMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-related milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_SalesRelatedMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Related Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tiered royalties on net product sales receive description</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tiered Royalties On Net Product Sales Receive Description</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>arwr-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-11-22T20:54:41.6581715+00:00 -->
<!-- Version            : 5.0.1.702 -->
<!-- Package ID         : 591c69b5c8c44264a019b1bc2edccec6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/role/TemplateLink" xlink:href="arwr-20210930.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="arwr-20210930.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="arwr-20210930.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesNoncurrent" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="arwr-20210930.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="arwr-20210930.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="arwr-20210930.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="arwr-20210930.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies" xlink:href="arwr-20210930.xsd#Role_DisclosureOrganizationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:href="arwr-20210930.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="arwr-20210930.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestments" xlink:href="arwr-20210930.xsd#Role_DisclosureInvestments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestments">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssets" xlink:href="arwr-20210930.xsd#Role_DisclosureIntangibleAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquity" xlink:href="arwr-20210930.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="arwr-20210930.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeases" xlink:href="arwr-20210930.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="arwr-20210930.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="arwr-20210930.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxes" xlink:href="arwr-20210930.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlans" xlink:href="arwr-20210930.xsd#Role_DisclosureEmployeeBenefitPlans" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlans">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEvents" xlink:href="arwr-20210930.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" xlink:href="arwr-20210930.xsd#Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ContingentConsiderationPolicyTextBlock" xlink:type="locator" xlink:label="arwr_ContingentConsiderationPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:type="locator" xlink:label="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arwr_ContingentConsiderationPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="arwr-20210930.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsTables" xlink:href="arwr-20210930.xsd#Role_DisclosureInvestmentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsTables">
    <link:loc xlink:href="arwr-20210930.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:href="arwr-20210930.xsd#Role_DisclosureIntangibleAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesTables" xlink:href="arwr-20210930.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="arwr-20210930.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="arwr-20210930.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="arwr-20210930.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="locator" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivedAsDueUnderAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderAgreement" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arwr_OrganizationAndSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsIncorporationMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAgreementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember_li0l2" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_CashReceivedAsDueUnderAgreement" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_MilestonePaymentEarned" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketableSecurities" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesNoncurrent" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_IncreaseDecreaseInCashAndInvestments" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentReceived" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfAgreements" xlink:type="locator" xlink:label="arwr_NumberOfAgreements" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OlpasiranAndAROAMG1AgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OlpasiranAgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AmgenIncorporatedMember" xlink:type="locator" xlink:label="arwr_AmgenIncorporatedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_AmgenIncorporatedMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_OlpasiranAgreementMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_OlpasiranAndAROAMG1AgreementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfAgreements" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_MilestonePaymentReceived" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentReceived" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" xlink:type="locator" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JNJ75220795AROJNJ1Member" xlink:type="locator" xlink:label="arwr_JNJ75220795AROJNJ1Member" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JNJ3989AROHBVAgreementMember" xlink:type="locator" xlink:label="arwr_JNJ3989AROHBVAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommonStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_CommonStockPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchCollaborationAndOptionAgreementMember" xlink:type="locator" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LicenseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsIncorporationMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAgreementMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_ResearchCollaborationAndOptionAgreementMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAgreementMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_CommonStockPurchaseAgreementMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_JNJ3989AROHBVAgreementMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_JNJ75220795AROJNJ1Member" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_MilestonePaymentEarned" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctPerformanceObligations" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_InitialTransactionPrice" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_MilestonePaymentReceived" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctBundle" xlink:type="locator" xlink:label="arwr_NumberOfDistinctBundle" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="locator" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_RatioOfProfitSharingStructureForCommercialization" xlink:type="locator" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredRevenueCurrentMember" xlink:type="locator" xlink:label="arwr_DeferredRevenueCurrentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LicenseAndCoFundingAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAndCoFundingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAndCoFundingAgreementMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="arwr_DeferredRevenueCurrentMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_RatioOfProfitSharingStructureForCommercialization" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctBundle" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctPerformanceObligations" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_InitialTransactionPrice" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfDistinctBundle" xlink:type="locator" xlink:label="arwr_NumberOfDistinctBundle" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LicenseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAgreementMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AROXDHAgreementMember" xlink:type="locator" xlink:label="arwr_AROXDHAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_HorizonTherapeuticsIrelandDACMember" xlink:type="locator" xlink:label="arwr_HorizonTherapeuticsIrelandDACMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_HorizonTherapeuticsIrelandDACMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_AROXDHAgreementMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAgreementMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctBundle" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctPerformanceObligations" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_InitialTransactionPrice" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:href="arwr-20210930.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchEquipmentGross" xlink:type="locator" xlink:label="arwr_ResearchEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="arwr_ResearchEquipmentGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MarketableSecuritiesMember" xlink:type="locator" xlink:label="arwr_MarketableSecuritiesMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CertificateOfDepositsDueWithinTwoYearsMember" xlink:type="locator" xlink:label="arwr_CertificateOfDepositsDueWithinTwoYearsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommercialNotesDueWithinOneYearMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneYearMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_CommercialNotesDueWithinOneYearMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10100.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="arwr_CertificateOfDepositsDueWithinTwoYearsMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_MarketableSecuritiesMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiCost" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NovartisMember" xlink:type="locator" xlink:label="arwr_NovartisMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="arwr_NovartisMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="locator" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="locator" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AtTheMarketAgreementMember" xlink:type="locator" xlink:label="arwr_AtTheMarketAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_AtTheMarketAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePayments" xlink:type="locator" xlink:label="arwr_MilestonePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AROENacAndAROHIF2CandidatesMember" xlink:type="locator" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TechnologyLicenseCommitmentsMember" xlink:type="locator" xlink:label="arwr_TechnologyLicenseCommitmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="arwr_TechnologyLicenseCommitmentsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_AROENacAndAROHIF2CandidatesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="arwr_MilestonePayments" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_SubleaseCommencementDate" xlink:type="locator" xlink:label="arwr_SubleaseCommencementDate" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_AdditionalLandSubjectToLease" xlink:type="locator" xlink:label="arwr_AdditionalLandSubjectToLease" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeaseExpansionExpirationMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseExpansionExpirationMonthAndYear" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeaseExpansionCommencementMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseExpansionCommencementMonthAndYear" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfOptionsToRenew" xlink:type="locator" xlink:label="arwr_NumberOfOptionsToRenew" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeasePaymentsCommencementDate" xlink:type="locator" xlink:label="arwr_LeasePaymentsCommencementDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_SubleaseAgreementMember" xlink:type="locator" xlink:label="arwr_SubleaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_HalozymeIncMember" xlink:type="locator" xlink:label="arwr_HalozymeIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_WI" xlink:type="locator" xlink:label="stpr_WI" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchFacilityInMadisonMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInMadisonMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ColoradoOwnerLLCMember" xlink:type="locator" xlink:label="arwr_ColoradoOwnerLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CorporateHeadquartersInPasadenaMember" xlink:type="locator" xlink:label="arwr_CorporateHeadquartersInPasadenaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_CorporateHeadquartersInPasadenaMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arwr_ColoradoOwnerLLCMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_ResearchFacilityInMadisonMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WI" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arwr_HalozymeIncMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_SubleaseAgreementMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_LeasePaymentsCommencementDate" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_NumberOfOptionsToRenew" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_LeaseExpansionCommencementMonthAndYear" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_LeaseExpansionExpirationMonthAndYear" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_AdditionalLandSubjectToLease" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_SubleaseCommencementDate" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:type="locator" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandTwentyOneIncentivePlanMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_OutsideOfEquityCompensationPlansMember" xlink:type="locator" xlink:label="arwr_OutsideOfEquityCompensationPlansMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsFourEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsThirteenIncentivePlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_OutsideOfEquityCompensationPlansMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandTwentyOneIncentivePlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureStockBasedCompensationSummaryOfRsusActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes" xlink:type="locator" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="arwr_DeferredTaxLiabilitiesStateTaxes" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_StateNetOperatingLossCarryForwards" xlink:type="locator" xlink:label="arwr_StateNetOperatingLossCarryForwards" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_FederalNetOperatingLossCarryForward" xlink:type="locator" xlink:label="arwr_FederalNetOperatingLossCarryForward" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PercentageOfValuationAllowance" xlink:type="locator" xlink:label="arwr_PercentageOfValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_PercentageOfValuationAllowance" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_FederalNetOperatingLossCarryForward" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_StateNetOperatingLossCarryForwards" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EmployeeContributionNextTwoPercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionNextTwoPercentMember" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EmployeeContributionsUpToThreePercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="arwr_EmployeeContributionsUpToThreePercentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="arwr_EmployeeContributionNextTwoPercentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="arwr-20210930.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20210930.xsd#arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription" xlink:type="locator" xlink:label="arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_SalesRelatedMilestonePayments" xlink:type="locator" xlink:label="arwr_SalesRelatedMilestonePayments" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:type="locator" xlink:label="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_NumberOfOptionsToRenew" xlink:type="locator" xlink:label="arwr_NumberOfOptionsToRenew" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:type="locator" xlink:label="arwr_EstimatedPaymentsForOperatingExpensesYearOne" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseCommencementMonthAndYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:type="locator" xlink:label="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="arwr-20210930.xsd#arwr_ResearchFacilityInSanDiegoMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInSanDiegoMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_ResearchFacilityInSanDiegoMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_LeaseCommencementMonthAndYear" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_EstimatedPaymentsForOperatingExpensesYearOne" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_NumberOfOptionsToRenew" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_MilestonePaymentEarned" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_SalesRelatedMilestonePayments" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>arwr-10k_20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arwr="http://www.arrowheadresearch.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arwr-20210930.xsd" xlink:type="simple"/>
    <context id="C_0000879407_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="C_0000879407_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0000879407_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20210101_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMaximumMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMinimumMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMaximumMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-27</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseCollaborationAndStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-27</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapBalanceSheetLocationAxis_arwrDeferredRevenueCurrentMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">arwr:DeferredRevenueCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapBalanceSheetLocationAxis_us-gaapAccruedLiabilitiesMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618_20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20210618_20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapCashAndCashEquivalentsAxis_arwrCertificateOfDepositsDueWithinTwoYearsMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CertificateOfDepositsDueWithinTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_us-gaapTypeOfArrangementAxis_arwrAROENacAndAROHIF2CandidatesMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023_20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160101_20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HalozymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HalozymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionsUpToThreePercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20201001_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionNextTwoPercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119_20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122_20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_arwrAgreement">
        <measure>arwr:Agreement</measure>
    </unit>
    <unit id="U_arwrTarget">
        <measure>arwr:Target</measure>
    </unit>
    <unit id="U_arwrObligation">
        <measure>arwr:Obligation</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_arwrBundle">
        <measure>arwr:Bundle</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_arwrOption">
        <measure>arwr:Option</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0000879407_20201001_20210930" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0000879407_20201001_20210930" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0000879407_20201001_20210930" id="F_000007">0000879407</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0000879407_20201001_20210930" id="F_000008">--09-30</dei:CurrentFiscalYearEndDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20210930"
      id="F_000373">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20210930"
      id="F_000375">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210930"
      id="F_000378">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210930"
      id="F_000380">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20210930"
      id="F_000381">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20210930"
      id="F_000382">2020-10-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20210930"
      id="F_000383">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20201001_20210930"
      id="F_000394">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930"
      id="F_000395">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930"
      id="F_000396">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119"
      id="F_000765">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0000879407_20210930"
      id="F_000079"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0000879407_20200930"
      id="F_000080"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20201001_20210930" id="F_000104">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20191001_20200930" id="F_000105">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20181001_20190930" id="F_000106">http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0000879407_20201001_20210930" id="F_000620">P5Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0000879407_20201001_20210930" id="F_000621">P4Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000879407_20201001_20210930"
      decimals="INF"
      id="F_000635"
      unitRef="U_xbrlipure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000636"
      unitRef="U_xbrlipure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000879407_20181001_20190930"
      decimals="INF"
      id="F_000637"
      unitRef="U_xbrlipure">0.0150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0000879407_20201001_20210930" id="F_000646">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0000879407_20191001_20200930" id="F_000647">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0000879407_20181001_20190930" id="F_000648">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000879407_20201001_20210930"
      decimals="INF"
      id="F_000638"
      unitRef="U_xbrlipure">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000639"
      unitRef="U_xbrlipure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000879407_20181001_20190930"
      decimals="INF"
      id="F_000640"
      unitRef="U_xbrlipure">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0000879407_20201001_20210930"
      decimals="3"
      id="F_000642"
      unitRef="U_xbrlipure">0.862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000643"
      unitRef="U_xbrlipure">0.900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0000879407_20201001_20210930"
      decimals="3"
      id="F_000644"
      unitRef="U_xbrlipure">0.904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000645"
      unitRef="U_xbrlipure">0.920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <dei:DocumentType contextRef="C_0000879407_20201001_20210930" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0000879407_20201001_20210930" id="F_000032">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0000879407_20201001_20210930" id="F_000002">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0000879407_20201001_20210930" id="F_000003">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0000879407_20201001_20210930" id="F_000033">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0000879407_20201001_20210930" id="F_000022">001-38042</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0000879407_20201001_20210930" id="F_000006">ARROWHEAD PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000879407_20201001_20210930" id="F_000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000879407_20201001_20210930" id="F_000024">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000879407_20201001_20210930" id="F_000025">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0000879407_20201001_20210930" id="F_000026">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0000879407_20201001_20210930" id="F_000027">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000879407_20201001_20210930" id="F_000028">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000879407_20201001_20210930" id="F_000029">91105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000879407_20201001_20210930" id="F_000030">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000879407_20201001_20210930" id="F_000031">304-3400</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0000879407_20201001_20210930" id="F_000020">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000879407_20201001_20210930" id="F_000005">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000879407_20201001_20210930" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0000879407_20201001_20210930" id="F_000009">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0000879407_20201001_20210930" id="F_000011">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0000879407_20201001_20210930" id="F_000010">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0000879407_20201001_20210930" id="F_000019">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0000879407_20201001_20210930" id="F_000012">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0000879407_20201001_20210930" id="F_000013">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000879407_20201001_20210930" id="F_000014">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0000879407_20201001_20210930" id="F_000016">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0000879407_20201001_20210930" id="F_000015">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0000879407_20210331"
      decimals="-8"
      id="F_000018"
      unitRef="U_iso4217USD">5900000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0000879407_20211115"
      decimals="INF"
      id="F_000017"
      unitRef="U_xbrlishares">104525708</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000034">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#x2019;s 2022 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">184434000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">143583000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">10255000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">846000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">4362000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">4251000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">2191000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">1782000</us-gaap:OtherAssetsCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">126728000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">85020000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">56627000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">86890000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">384597000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">322372000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">48675000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">30881000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">13663000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">15363000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">245595000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">137487000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">17346000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">16137000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">272000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">264000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">710148000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">522504000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">9457000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">6829000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">14001000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">5389000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">9773000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">8061000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">2250000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">1095000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">111055000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">19291000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">17000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">146536000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">40682000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">23295000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">20043000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">131495000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">154790000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">20043000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000093"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000094"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000095"
      unitRef="U_xbrlishares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000096"
      unitRef="U_xbrlishares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000097"
      unitRef="U_xbrlishares">104327000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000099"
      unitRef="U_xbrlishares">104327000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000098"
      unitRef="U_xbrlishares">102376000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000100"
      unitRef="U_xbrlishares">102376000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">197000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">195000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">1053386000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">965410000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">-69000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">18000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">-644692000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">-503844000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">408822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">461779000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">710148000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">522504000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">138287000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">87992000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">168796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">206342000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">128875000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">81049000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">80981000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">52276000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">26556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">287323000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">181151000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">107605000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">-149036000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">-93159000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">61191000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">6120000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">9191000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">6958000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">2070000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">-583000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">8190000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">8608000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">6958000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-140846000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-84551000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">68149000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">174000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">-140848000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">-84553000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">67975000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20201001_20210930"
      decimals="2"
      id="F_000136"
      unitRef="U_iso4217USD_xbrlishares">-1.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20191001_20200930"
      decimals="2"
      id="F_000137"
      unitRef="U_iso4217USD_xbrlishares">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20181001_20190930"
      decimals="2"
      id="F_000138"
      unitRef="U_iso4217USD_xbrlishares">0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20201001_20210930"
      decimals="2"
      id="F_000139"
      unitRef="U_iso4217USD_xbrlishares">-1.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20191001_20200930"
      decimals="2"
      id="F_000140"
      unitRef="U_iso4217USD_xbrlishares">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20181001_20190930"
      decimals="2"
      id="F_000141"
      unitRef="U_iso4217USD_xbrlishares">0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000142"
      unitRef="U_xbrlishares">103745000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000143"
      unitRef="U_xbrlishares">100722000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000144"
      unitRef="U_xbrlishares">93859000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000145"
      unitRef="U_xbrlishares">103745000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000146"
      unitRef="U_xbrlishares">100722000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000147"
      unitRef="U_xbrlishares">98608000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-87000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">410000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">-370000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">-140935000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">-84143000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">67605000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930"
      decimals="-3"
      id="F_000154"
      unitRef="U_xbrlishares">88505000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">181000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180930"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">582903000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180930"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">-22000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180930"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">-487266000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180930"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">-555000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20180930"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">95241000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">12393000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">12393000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="-3"
      id="F_000163"
      unitRef="U_xbrlishares">1543000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">8274000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">8276000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="-3"
      id="F_000167"
      unitRef="U_xbrlishares">2197000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">-2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="-3"
      id="F_000170"
      unitRef="U_xbrlishares">3261000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">60518000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">60521000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181001_20190930"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">-370000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">-370000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181001_20190930"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">67975000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">67975000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930"
      decimals="-3"
      id="F_000178"
      unitRef="U_xbrlishares">95506000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">188000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">664086000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">-392000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">-419291000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">-555000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20190930"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">244036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930"
      decimals="-3"
      id="F_000185"
      unitRef="U_xbrlishares">95506000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">188000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">664086000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">-392000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">-419291000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">-555000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20190930"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">244036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">43383000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">43383000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="-3"
      id="F_000194"
      unitRef="U_xbrlishares">1111000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">7468000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">7469000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="-3"
      id="F_000198"
      unitRef="U_xbrlishares">1159000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="-3"
      id="F_000201"
      unitRef="U_xbrlishares">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">250474000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">250479000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191001_20200930"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">410000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">410000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191001_20200930"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">555000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">555000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191001_20200930"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">-84553000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">-84553000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930"
      decimals="-3"
      id="F_000211"
      unitRef="U_xbrlishares">102376000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">195000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">965410000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200930"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">-503844000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">461779000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930"
      decimals="-3"
      id="F_000217"
      unitRef="U_xbrlishares">102376000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">195000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">965410000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200930"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">-503844000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">461779000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201001_20210930"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">76673000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">76673000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20210930"
      decimals="-3"
      id="F_000225"
      unitRef="U_xbrlishares">1052000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20210930"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201001_20210930"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">11304000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">11305000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20210930"
      decimals="-3"
      id="F_000229"
      unitRef="U_xbrlishares">899000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201001_20210930"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201001_20210930"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201001_20210930"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">-87000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">-87000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201001_20210930"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">-140848000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">-140848000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930"
      decimals="-3"
      id="F_000236"
      unitRef="U_xbrlishares">104327000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210930"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">1053386000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210930"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">-69000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210930"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">-644692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">408822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">-140848000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">-84553000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">67975000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">76673000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">43383000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">12393000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">8267000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">5942000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">4439000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">-266000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">-525000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">-1069000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">9409000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">184000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">334000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">360000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">387000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">3711000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">2628000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">-821000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">4844000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">9522000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">1989000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">2450000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">223258000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">-63514000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">82804000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">1227000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">2229000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">1106000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">171224000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">-95391000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">173035000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">23567000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">11952000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">12001000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">240703000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">278964000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">90266000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">122592000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">50138000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">54521000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">-141678000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">-240778000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">-47746000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">2415000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">11305000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">7469000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">8275000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">250479000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">60522000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">11305000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">257948000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">66382000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">40851000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">-78221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">191671000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000299"
      unitRef="U_iso4217USD">143583000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20190930"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">221804000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20180930"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">30133000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">184434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">143583000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20190930"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">221804000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">27000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">-2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">103000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">-302000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000309">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 1. &lt;span style="font-style:italic;"&gt;ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Nature of Business and Recent Developments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them.&#160;Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#x201c;RNAi&#x201d;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#x2019;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company&#x2019;s pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-&lt;span style="color:#000000;"&gt;LUNG2 for chronic obstructive pulmonary disorder, ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens&lt;/span&gt; and ARO-C3 for complement mediated diseases&lt;span style="color:#000000;"&gt;. ARO-XDH is being developed for uncontrolled gout under a collaboration agreement with Horizon Therapeutics Ireland DAC (&#x201c;Horizon&#x201d;). ARO-JNJ2 and ARO-JNJ3 are being developed for undisclosed liver-expressed targets under a collaboration agreement with Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;).&#160;&#160;JNJ-75220795 (ARO-JNJ1) is being developed by Janssen as a potential treatment for patients with non-alcoholic steatohepatitis (NASH).&#160;&#160;&lt;/span&gt;ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#x201c;AATD&#x201d;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#x201c;Takeda&#x201d;) in October 2020. JNJ3989 (formerly referred to as ARO-HBV) &lt;span style="color:#000000;"&gt;for chronic hepatitis B virus was out-licensed to Janssen in October 2018.&#160;&#160;&lt;/span&gt;Olpasiran (formerly referred to as AMG 890 or ARO-LPA) &lt;span style="color:#000000;"&gt;for cardiovascular disease was out-licensed to Amgen Inc. (&#x201c;Amgen&#x201d;) in 2016.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.58%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During fiscal year 2021, the Company continued to develop its pipeline and partnered candidates.&#160;&#160;The Company announced positive interim clinical data on (i) AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the Company&#x2019;s second-generation investigational RNAi therapeutic being co-developed with Takeda as a treatment for the rare genetic liver disease associated with AATD, (ii) AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the Company&#x2019;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH), and (iii) AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the Company&#x2019;s investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma.&#160;&#160;The Company also presented preclinical data on the development of ARO-DUX4, the Company&#x2019;s investigational RNAi therapeutic being developed as a treatment for patients with facioscapulohumeral muscular dystrophy (FSHD), at the 28th&#160;Annual&#160;FSHD Society International Research Congress. The Company hosted a key opinion leader webinar on its cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, and presented positive clinical data from the Phase 1/2 clinical studies of ARO-APOC3 and ARO-ANG3 at the American Heart Association Scientific Sessions 2020.&#160;&#160;The Company filed two Investigational New Drug Applications with the United States Food and Drug Administration (the &#x201c;FDA&#x201d;) to begin a Phase 2b clinical study of ARO-APOC3 in patients with severe hypertriglyceridemia and a Phase 2b clinical study of ARO-ANG3 in patients with mixed dyslipidemia, and initiated these two Phase 2b clinical studies in the third quarter of fiscal year 2021. The Company also filed for regulatory clearance to begin a Phase 1/2a study of ARO-C3 for treatment of complement mediated diseases. In July 2021, the Company voluntarily paused AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the Company&#x2019;s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis, after receiving a preliminary update from an ongoing chronic toxicology study in rats that contained unexpected signals of local lung inflammation.&#160;&#160;New screening, enrollment and any further dosing of investigational ARO-ENaC have been paused pending additional data from ongoing nonclinical toxicology studies.&#160;&#160;The Company announced two collaborations during fiscal year 2021: a collaboration with Takeda to co-develop and co-commercialize ARO-AAT for alpha-1 antitrypsin-associated liver disease and a collaboration with Horizon to develop ARO-XDH, an investigational RNAi therapeutic for uncontrolled gout. In July 2021, the Company received Breakthrough Therapy designation from the FDA for ARO-AAT, which is a process designed to expedite the development and review of drugs that are intended to treat a serious life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s partnered candidates under its collaboration agreements also continued to progress.&#160;&#160;Janssen began dosing patients in a Phase 2b triple combination study called REEF-1,&#160;designed to enroll up to 450 patients with chronic hepatitis B infection.&#160;&#160;The Company is currently performing discovery, optimization and preclinical research and development for ARO-JNJ2 and ARO-JNJ3 for Janssen as part of the Company&#x2019;s Research Collaboration and Option Agreement with Janssen (&#x201c;Janssen Collaboration Agreement&#x201d;), and Janssen has began dosing patients in its Phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1).&#160;&#160;Amgen has initiated a Phase 2 clinical trial for Olpasiran (previously referred to as AMG 890 or ARO-LPA).&#160;&#160;The Company entered into two licensing deals during fiscal 2021: i) an Exclusive License and Co-Funding Agreement (the &#x201c;Takeda License Agreement&#x201d;) with Takeda for ARO-AAT, a&lt;span style="color:#000000;"&gt;nd ii) a Collaboration and License Agreement (the &#x201c;Horizon License Agreement&#x201d;) with Horizon Therapeutics Ireland DAC &lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;"&gt;(&#x201c;Horizon&#x201d;) for ARO-XDH.&#160;&#160;ARO-AAT is currently in phase 2 clinical trials and ARO-XDH is in discovery-stage.&#160;&#160;During fiscal year 2021, the Company earned&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;340.0&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;"&gt; in upfront payments from its collaboration agreements&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;20.0&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million &lt;/span&gt;&lt;span style="color:#000000;"&gt;in option and milestone payments. In total, the Company remains eligible fo&lt;/span&gt;&lt;span style="color:#000000;"&gt;r&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;5.3&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;billion in developmental, regulatory and sales milestones and various royalties on net sales.&#160;&#160;The revenue recognition for these collaboration agreements is discussed further in Note 2 below&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arrowhead operates lab facilities in Madison, Wisconsin and San Diego, California, where the Company&#x2019;s research and development activities, including the development of RNAi therapeutics, take place. The Company&#x2019;s principal executive offices are located in Pasadena, California.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is actively monitoring the ongoing COVID-19 pandemic. The financial results for the years ended September 30, 2021 and 2020 were not significantly impacted by COVID-19. Operationally, the Company experienced delays in its earlier stage programs due to a shortage in non-human primates, which are critical to the Company&#x2019;s preclinical programs.&#160;&#160;Additionally, the Company experienced delays in enrollment in its clinical trials.&#160;&#160;The Company&#x2019;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters in Pasadena, California have continued with limited impact, other than for enhanced safety measures, including work from home policies, and intermittent lab supply shortages. However, the Company cannot predict the impact the progression of COVID-19 will have on future financial and operational results due to a variety of factors, including the ability of the Company&#x2019;s clinical sites to continue to enroll subjects, the ability of the Company&#x2019;s suppliers to continue to operate, the continued good health and safety of the Company&#x2019;s employees and the length and severity of the COVID-19 pandemic.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Liquidity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Consolidated Financial Statements have been prepared in conformity with the accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;), which contemplate the continuation of the Company as a going concern.&#160; Historically, the Company&#x2019;s primary sources of financing have been through the sale of its securities and revenue from its licensing and collaboration agreements.&#160;&#160;Research and development activities have required significant capital investment since the Company&#x2019;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#x2019;s pipeline of drug candidates and its headcount have both expanded significantly.&#160;&#160;Additionally, significant capital investment will be required as the Company&#x2019;s pipeline matures into later stage clinical trials, as well as with the Company&#x2019;s plans to increase its internal manufacturing capabilities.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At September 30, 2021, the Company had $184.4 million in cash and cash equivalents (including $2.4 million in restricted cash), $56.6 million in short-term investments and $126.7 million in marketable securities, and $245.6 million in long-term investments to fund operations.&#160;&#160;During the year ended September 30, 2021, the Company&#x2019;s cash and investments balance increased by $160.4 million, was primarily the result of the $300.0 million upfront payment from the Takeda License Agreement and the $40 million upfront payment from the Horizon License Agreement, partially offset by cash used to fund the Company&#x2019;s research and development operations and general and administrative expenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&#x2014;The Consolidated Financial Statements include the accounts of Arrowhead and its Subsidiaries.&#160;&#160;Arrowhead&#x2019;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#x2019;s research and development facility is located.&#160;&#160;All significant intercompany accounts and transactions are eliminated in consolidation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation and Use of Estimates&#x2014;The &lt;span style="color:#000000;"&gt;preparation of financial statements in conformity GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation&lt;/span&gt;.&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&#x2014;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&#160;&#160;Included within Cash and cash equivalents on the Consolidated Balance Sheets is $2.4 million and $1.8 restricted cash at September 30, 2021 and September 30, 2020, respectively.&#160;&#160;Amounts included in restricted cash are primarily held as collateral associated with a letter of credit for the Company&#x2019;s &lt;span style="color:#000000;"&gt;lease for its corporate headquarters in Pasadena, California.&lt;/span&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&#x2014;The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments&#x2014;The Company may invest excess cash balances in short-term and long-term marketable debt and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investments in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 320, Investments &#x2013; Debt and Equity Securities and ASC 321, Investments in Equity Securities.&#160;ASC 320-Investments-Debt and Equity Securities requires debt securities to be classified into three categories: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-Maturity&#x2014;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trading Securities&#x2014;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-Sale&#x2014;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of stockholders&#x2019; equity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2021, 2020 and 2019, all of the Company&#x2019;s debt securities were classified as held-to-maturity.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-maturity investments are measured and recorded at amortized cost on the Company&#x2019;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests in shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#x2019;s Consolidated Balance Sheet as &#x201c;marketable securities&#x201d; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#x2019;s Consolidated Statement of Operations and Comprehensive Income (Loss). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment&#x2014;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets Subject to Amortization&#x2014;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&#x2014;The consideration for the Company&#x2019;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $0 at September 30, 2021 and September 30, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&#x2014; &lt;span style="color:#000000;"&gt;On October 1, 2018, the Company adopted FASB Topic 606 &#x2013; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and &lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;"&gt;across all industries. The Company&#x2019;s adoption of the revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#x2019;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen, Takeda and Horizon, and the analysis of the impact of this guidance on those agreements is discussed further in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 2 &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Typically, the Company&#x2019;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#x201c;CTA&#x201d;) or a New Drug Application (&#x201c;NDA&#x201d;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in our Consolidated Statements of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#x2019;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#x2019;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Whenever the Company determines that &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;goods or services promised in a contract&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; should be accounted for as a &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;combined performance obligation over time&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; either&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; the proportional performance method&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; or on a straight-line basis if efforts will be expended evenly over time&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance.&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; If the &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company determines that&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; the performance &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;obligation is satisfied over time, any upfront&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; payment &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;received is initially recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;as &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;deferred&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;on the Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Consolidated Balance Sheets&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#x2019;s current operating plan and, if the Company&#x2019;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaborative Arrangements&#x2014;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB Topic 808 - Collaborative Arrangements. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to Research and Development Expense or General and Administrative Expense, as appropriate.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allowance for Doubtful Accounts&#x2014;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development&#x2014;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#x2019;s research and development operations, and costs to acquire technology licenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per Share&#x2014;Basic net income (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees.&#160;&#160;During the years ended September 30, 2021, 2020 and 2019, the calculation of the effect of dilutive stock options and restricted stock units was 0 shares, 0 shares, and 4,748,958 shares, respectively.&#160;&#160;During the year ended September 30, 2021 and 2020,&lt;span style="color:#000000;"&gt; the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect. During the year ended September 30, 2019, the calculation of the effect of dilutive stock options and restricted stock units excluded 1,007,500 stock options and 11,500 restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&#x2014;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#x2019;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#x2019;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#x2019;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes&#x2014;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;span style="color:#000000;"&gt;&#x2014;&lt;/span&gt;The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its&#160;&#160;leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term.&#160;Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and became effective for the Company in the first quarter of fiscal 2019. In April 2016, the FASB issued an amendment to ASU No. 2014-09 with update ASU 2016-10 which provided more specific guidance around the identification of performance obligations and licensing arrangements.&#160;&#160;On October 1, 2018, the Company adopted this standard using the modified retrospective method. The Company&#x2019;s implementation approach included reviewing the status of each of its ongoing license agreements and collaboration agreements and designing appropriate internal controls to enable the preparation of financial information.&#160;&#160;The Company completed its assessment of the impact of the new revenue recognition guidance and determined that there will be no material impact.&#160;&#160;The Company&#x2019;s existing performance obligations under its ongoing license and collaboration agreements as of October 1, 2018 and prior were substantially completed prior to September 30, 2018.&#160;&#160;For these agreements that were ongoing as of October 1, 2018, any future option, milestone or royalty payments received will be accounted for under the sales-based royalty exception provided for under this new revenue recognition guidance.&#160;&#160;Additionally, there will be no impact to cash from or used in operating, financing or investing activities on the Company&#x2019;s Consolidated Statement of Cash Flows as a result of the adoption of the new standard.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842).&#160;&#160;Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases).&#160;&#160;The Company adopted this standard effective October 1, 2019 and &lt;span style="color:#000000;"&gt;elected the package of three practical expedients that permits an entity to i) not reassess whether expired or existing contracts contain leases, ii) not reassess lease classification for existing or expired leases, and iii) not consider whether previously capitalized initial direct costs would be appropriate under the new standard.&#160;&#160;At September 30, 2021, the Company has recorded right-of-use assets of $17.3 million and lease liabilities of $25.5 million on its Consolidated Balance Sheets for its research and development facility leases in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below.&#160;&#160;The adoption of this standard did not have a material impact on the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Income (Loss) and the Company&#x2019;s Consolidated Statements of Cash Flows.&#160;&#160; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808).&#160;&#160;This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 became effective for the Company in the first quarter of fiscal 2021 with early adoption permitted.&#160;&#160;The adoption of this update did not have a material effect on the Company&#x2019;s Consolidated Financial Statements. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <arwr:CashReceivedAsDueUnderAgreement
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20201001_20210930"
      decimals="-5"
      id="F_000350"
      unitRef="U_iso4217USD">340000000.0</arwr:CashReceivedAsDueUnderAgreement>
    <arwr:MilestonePaymentEarned
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_20210930"
      decimals="-5"
      id="F_000351"
      unitRef="U_iso4217USD">20000000.0</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_20210930"
      decimals="INF"
      id="F_000352"
      unitRef="U_iso4217USD">5300000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000353"
      unitRef="U_iso4217USD">184400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000354"
      unitRef="U_iso4217USD">2400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000355"
      unitRef="U_iso4217USD">56600000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:MarketableSecurities
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000356"
      unitRef="U_iso4217USD">126700000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000357"
      unitRef="U_iso4217USD">245600000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:IncreaseDecreaseInCashAndInvestments
      contextRef="C_0000879407_20201001_20210930"
      decimals="-5"
      id="F_000358"
      unitRef="U_iso4217USD">160400000</arwr:IncreaseDecreaseInCashAndInvestments>
    <arwr:CashReceivedAsDueUnderAgreement
      contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20210101_20210131"
      decimals="-5"
      id="F_000359"
      unitRef="U_iso4217USD">300000000.0</arwr:CashReceivedAsDueUnderAgreement>
    <arwr:CashReceivedAsDueUnderAgreement
      contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20201001_20210930"
      decimals="-6"
      id="F_000360"
      unitRef="U_iso4217USD">40000000</arwr:CashReceivedAsDueUnderAgreement>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000322">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&#x2014;The Consolidated Financial Statements include the accounts of Arrowhead and its Subsidiaries.&#160;&#160;Arrowhead&#x2019;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#x2019;s research and development facility is located.&#160;&#160;All significant intercompany accounts and transactions are eliminated in consolidation. &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <arwr:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000323">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation and Use of Estimates&#x2014;The &lt;span style="color:#000000;"&gt;preparation of financial statements in conformity GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation&lt;/span&gt;.&#160;&#160; &lt;/p&gt;</arwr:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_0000879407_20201001_20210930" id="F_000324">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&#x2014;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&#160;&#160;Included within Cash and cash equivalents on the Consolidated Balance Sheets is $2.4 million and $1.8 restricted cash at September 30, 2021 and September 30, 2020, respectively.&#160;&#160;Amounts included in restricted cash are primarily held as collateral associated with a letter of credit for the Company&#x2019;s &lt;span style="color:#000000;"&gt;lease for its corporate headquarters in Pasadena, California.&lt;/span&gt;&#160;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000361"
      unitRef="U_iso4217USD">2400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000362"
      unitRef="U_iso4217USD">1800000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0000879407_20201001_20210930" id="F_000325">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&#x2014;The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_20210930"
      decimals="INF"
      id="F_000363"
      unitRef="U_iso4217USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:InvestmentPolicyTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000326">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments&#x2014;The Company may invest excess cash balances in short-term and long-term marketable debt and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investments in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 320, Investments &#x2013; Debt and Equity Securities and ASC 321, Investments in Equity Securities.&#160;ASC 320-Investments-Debt and Equity Securities requires debt securities to be classified into three categories: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-Maturity&#x2014;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trading Securities&#x2014;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-Sale&#x2014;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of stockholders&#x2019; equity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2021, 2020 and 2019, all of the Company&#x2019;s debt securities were classified as held-to-maturity.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-maturity investments are measured and recorded at amortized cost on the Company&#x2019;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests in shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#x2019;s Consolidated Balance Sheet as &#x201c;marketable securities&#x201d; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#x2019;s Consolidated Statement of Operations and Comprehensive Income (Loss). &lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000327">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment&#x2014;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000879407_srtRangeAxis_srtMinimumMember_20201001_20210930"
      id="F_000364">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_20201001_20210930"
      id="F_000365">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000328">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets Subject to Amortization&#x2014;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. &lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <arwr:ContingentConsiderationPolicyTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000329">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&#x2014;The consideration for the Company&#x2019;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $0 at September 30, 2021 and September 30, 2020. &lt;/p&gt;</arwr:ContingentConsiderationPolicyTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="-6"
      id="F_000366"
      unitRef="U_iso4217USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0000879407_20210930"
      decimals="-6"
      id="F_000367"
      unitRef="U_iso4217USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000330">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&#x2014; &lt;span style="color:#000000;"&gt;On October 1, 2018, the Company adopted FASB Topic 606 &#x2013; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and &lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;"&gt;across all industries. The Company&#x2019;s adoption of the revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#x2019;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen, Takeda and Horizon, and the analysis of the impact of this guidance on those agreements is discussed further in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 2 &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Typically, the Company&#x2019;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#x201c;CTA&#x201d;) or a New Drug Application (&#x201c;NDA&#x201d;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in our Consolidated Statements of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#x2019;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#x2019;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Whenever the Company determines that &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;goods or services promised in a contract&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; should be accounted for as a &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;combined performance obligation over time&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; either&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; the proportional performance method&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; or on a straight-line basis if efforts will be expended evenly over time&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance.&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; If the &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company determines that&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; the performance &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;obligation is satisfied over time, any upfront&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; payment &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;received is initially recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;as &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;deferred&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;on the Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Consolidated Balance Sheets&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#x2019;s current operating plan and, if the Company&#x2019;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="C_0000879407_20201001_20210930" id="F_000331">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaborative Arrangements&#x2014;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB Topic 808 - Collaborative Arrangements. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to Research and Development Expense or General and Administrative Expense, as appropriate.&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="C_0000879407_20201001_20210930" id="F_000332">Allowance for Doubtful Accounts&#x2014;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0000879407_20201001_20210930" id="F_000333">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development&#x2014;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#x2019;s research and development operations, and costs to acquire technology licenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000334">Net Income (Loss) per Share&#x2014;Basic net income (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees.&#160;&#160;During the years ended September 30, 2021, 2020 and 2019, the calculation of the effect of dilutive stock options and restricted stock units was 0 shares, 0 shares, and 4,748,958 shares, respectively.&#160;&#160;During the year ended September 30, 2021 and 2020,&lt;span style="color:#000000;"&gt; the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect. During the year ended September 30, 2019, the calculation of the effect of dilutive stock options and restricted stock units excluded 1,007,500 stock options and 11,500 restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_0000879407_20201001_20210930"
      decimals="INF"
      id="F_000370"
      unitRef="U_xbrlishares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000368"
      unitRef="U_xbrlishares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_0000879407_20181001_20190930"
      decimals="INF"
      id="F_000369"
      unitRef="U_xbrlishares">4748958</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20181001_20190930"
      decimals="0"
      id="F_000371"
      unitRef="U_xbrlishares">1007500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930"
      decimals="0"
      id="F_000372"
      unitRef="U_xbrlishares">11500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0000879407_20201001_20210930" id="F_000335">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&#x2014;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#x2019;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#x2019;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#x2019;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000336">Income Taxes&#x2014;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000337">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;span style="color:#000000;"&gt;&#x2014;&lt;/span&gt;The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its&#160;&#160;leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term.&#160;Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000338">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and became effective for the Company in the first quarter of fiscal 2019. In April 2016, the FASB issued an amendment to ASU No. 2014-09 with update ASU 2016-10 which provided more specific guidance around the identification of performance obligations and licensing arrangements.&#160;&#160;On October 1, 2018, the Company adopted this standard using the modified retrospective method. The Company&#x2019;s implementation approach included reviewing the status of each of its ongoing license agreements and collaboration agreements and designing appropriate internal controls to enable the preparation of financial information.&#160;&#160;The Company completed its assessment of the impact of the new revenue recognition guidance and determined that there will be no material impact.&#160;&#160;The Company&#x2019;s existing performance obligations under its ongoing license and collaboration agreements as of October 1, 2018 and prior were substantially completed prior to September 30, 2018.&#160;&#160;For these agreements that were ongoing as of October 1, 2018, any future option, milestone or royalty payments received will be accounted for under the sales-based royalty exception provided for under this new revenue recognition guidance.&#160;&#160;Additionally, there will be no impact to cash from or used in operating, financing or investing activities on the Company&#x2019;s Consolidated Statement of Cash Flows as a result of the adoption of the new standard.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842).&#160;&#160;Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases).&#160;&#160;The Company adopted this standard effective October 1, 2019 and &lt;span style="color:#000000;"&gt;elected the package of three practical expedients that permits an entity to i) not reassess whether expired or existing contracts contain leases, ii) not reassess lease classification for existing or expired leases, and iii) not consider whether previously capitalized initial direct costs would be appropriate under the new standard.&#160;&#160;At September 30, 2021, the Company has recorded right-of-use assets of $17.3 million and lease liabilities of $25.5 million on its Consolidated Balance Sheets for its research and development facility leases in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below.&#160;&#160;The adoption of this standard did not have a material impact on the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Income (Loss) and the Company&#x2019;s Consolidated Statements of Cash Flows.&#160;&#160; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808).&#160;&#160;This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 became effective for the Company in the first quarter of fiscal 2021 with early adoption permitted.&#160;&#160;The adoption of this update did not have a material effect on the Company&#x2019;s Consolidated Financial Statements. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20210930"
      id="F_000374">2018-10-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210930"
      id="F_000379">2019-10-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000376"
      unitRef="U_iso4217USD">17300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000377"
      unitRef="U_iso4217USD">25500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000310">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 2. &lt;span style="font-style:italic;"&gt;COLLABORATION AND LICENSE AGREEMENTS&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Amgen Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September&#160;28, 2016, the Company entered into two collaboration and license agreements and a common stock purchase agreement with Amgen.&#160;&#160;Under the Second Collaboration and License Agreement or Olpasiran Agreement, Amgen has received a worldwide, exclusive license to Arrowhead&#x2019;s novel, RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the other collaboration and license agreement (the &#x201c;First Collaboration and License Agreement&#x201d; or the &#x201c;ARO-AMG1 Agreement&#x201d;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#x2019;s Common Stock, and $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement.&#160;&#160;&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated these agreements in accordance with FASB Topics 808 &#x2013; Collaboration Arrangements and 606 - Revenue for Contracts from Customers. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement.&#160;&#160;Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study for Olpasiran, which resulted in a $20 million milestone payment to the Company. During the years ended September 30, 2021, 2020 and 2019, the Company recognized $0, $20.1 million and $0.3 million of Revenue associated with its agreements with Amgen, respectively.  As of September 30, 2021, there were $0 in contract assets recorded as accounts receivable and $0 contract liabilities recorded as current deferred revenue on the Company&#x2019;s Consolidated Balance Sheets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Janssen Pharmaceuticals, Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 3, 2018, the Company entered into the Janssen License Agreement and the Janssen Collaboration Agreement with Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson.&#160;&#160;The Company also entered into a stock purchase agreement with JJDC (&#x201c;JJDC Stock Purchase Agreement&#x201d;).&#160;&#160;Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#x2019;s JNJ-3989 (ARO-HBV) program, the Company&#x2019;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#x2019;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company is responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989.&#160;&#160;Under the Janssen Collaboration Agreement, Janssen will be able to select three new targets against which Arrowhead will develop clinical candidates.&#160;&#160;These candidates are subject to certain restrictions and do not include candidates that already were in the Company&#x2019;s pipeline.&#160;&#160;The Company will perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, is sufficient to allow the filing of a U.S. Investigational New Drug Application or equivalent, at which time Janssen will have the option to take an exclusive license. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned candidate.&#160;&#160;Under the terms of the agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment &lt;span style="color:#000000;"&gt;by JJDC in Arrowhead Common Stock under the JJDC &lt;/span&gt;Stock Purchase Agreement, and milestone and option payments totaling $70.0 million, and may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $1.9 billion in development and sales milestone payments for the three additional targets covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement.&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated these agreements in accordance with FASB Topics 808 &#x2013; Collaboration Arrangements and 606 - Revenue for Contracts from Customers.&#160;&#160;At the inception of these agreements, the Company identified one distinct performance obligation.&#160;&#160;Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#x2019;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#x201c;Janssen R&amp;amp;D Services&#x201d;).&#160;&#160;Due to the specialized and unique nature of these Janssen R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation.&#160;&#160;The Company also determined that Janssen&#x2019;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for this option is accounted for separately. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined the transaction price totaled approximately $252.7 million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0 million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;amp;D Services to be performed.&#160;&#160;The Company has allocated the total $252.7 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;amp;D Services.&#160;&#160;The Company has recognized this transaction price in its entirety as of September 30, 2021 as efforts on its performance obligation have been substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. During the years ended September 30, 2021, 2020 and 2019, the Company recognized approximately $20.2 million, $65.0 million, and $167.5 million of revenue associated with this performance obligation, respectively. As of September 30, 2021, there were $0.1 million in contract assets recorded as accounts receivable, and $0 of contract liabilities recorded as current deferred revenue on the Company&#x2019;s Consolidated Balance Sheets.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has begun to conduct its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2 and ARO-JNJ3 under the Janssen Collaboration Agreement.&#160;&#160;All costs and labor hours spent by the Company will be entirely funded by Janssen.&#160; During the years ended September 30, 2021, 2020 and 2019, the Company recognized $0.5 million, $2.9 million and $1.0 million of revenue associated with these efforts, respectively.&#160;&#160;In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0 million milestone payment to the Company, and in September 2021, Janssen dosed its fifth patient in its phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1), which resulted in $10.0 million milestone payment to the Company. Each of these milestone payments was recognized entirely during the year ended September 30, 2021.&#160;&#160;As of September 30, 2021, there were $10.0 million of cont&lt;span style="color:#000000;"&gt;ract assets recorded as accounts &lt;/span&gt;receivable and $0 of contract liabilities recorded as curren&lt;span style="color:#000000;"&gt;t deferred revenue on the Company&#x2019;s Consolidated Balance&lt;/span&gt; Sheets.&#160;The $10.0 million milestone payment for the dosing of the fifth patient in its Phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1) was received in October 2021. &lt;span style="color:#000000;"&gt; &#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Takeda Pharmaceuticals U.S.A., Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 7, 2020, the Company entered into the Takeda License Agreement with Takeda.&#160;&#160;Under the Takeda License Agreement, &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Takeda and the Company will co-develop the Company&#x2019;s ARO-AAT program, the Company&#x2019;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales.&#160;&#160;In January 2021, the Company received $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.&#160;&#160;&#160;&#160;&lt;/span&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated the Takeda License Agreement in accordance with FASB Topics 808 &#x2013; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation.&#160;&#160;The Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#x201c;Takeda R&amp;amp;D Services&#x201d;).&#160;&#160;Due to the specialized and unique nature of these Takeda R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation.&#160;&#160;Beyond the Takeda R&amp;amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States.&#160;&#160;Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States.&#160;&#160;The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts will be recorded as Research and Development Expenses or General and Administrative Expenses, as appropriate. &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined the initial transaction price totaled $300.0 million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date.&#160;&#160;The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;amp;D Services.&#160;&#160;Revenue will be recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). Revenue for the years ended September 30, 2021, 2020 and 2019 was $90.8 million, $0 and $0, respectively. As of September 30, 2021, there were $0 in contract assets recorded as accounts receivable, $84.4 million in contract liabilities recorded as deferred revenue, $124.8 million in contract liabilities recorded as deferred revenue, net of the current portion, and $3.1 million in contract liabilities recorded as accrued expenses.&#160;&#160;The $3.1 million in accrued expenses was primarily driven by co-development and co-commercialization activities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Horizon Therapeutics Ireland DAC&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 18, 2021, the Company entered into the Horizon License Agreement with Horizon.&#160;&#160;Under the Horizon License Agreement, &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Horizon received a worldwide exclusive license for&#160;ARO-XDH,&#160;a previously undisclosed discovery-stage investigational &lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;RNAi therapeutic being developed by the Company as a potential treatment for people with uncontrolled gout. The Company will conduct all activities through the preclinical stages of development of&#160;ARO-XDH,&#160;and Horizon will be wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, the Company received $&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;40&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;&#160;million as an upfront payment and is eligible to receive up to $&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;660&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;&#160;million in potential development, regulatory and sales milestones.&#160;&#160;The Company is also eligible to receive royalties in the&#160;low-&#160;to&#160;mid-teens&#160;range on net product sales.&#160;&#160; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated the Horizon License Agreement in accordance with FASB Topics 808 &#x2013; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation.&#160;&#160;The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#x201c;Horizon R&amp;amp;D Services&#x201d;).&#160;&#160;Due to the specialized and unique nature of these Horizon R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation.&#160;&#160;Beyond the Horizon R&amp;amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined the initial transaction price totaled $40.0 million, including the upfront payment.&#160;&#160;The Company has excluded any future estimated milestones or royalties, from this transaction price to date.&#160;&#160;The Company will allocate the total $40.0 million initial transaction price to its one distinct performance obligation for the ARO-XDH license and the associated Horizon R&amp;amp;D Services.&#160;&#160;Revenue will be recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;amp;D Services.&#160;&#160;The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the years ended September 30, 2021, 2020 and 2019, was $6.7 million, $0 and $0, respectively. As of September 30, 2021, there were $0.1 million in contract assets recorded as accounts receivable, $26.7 million in contract liabilities recorded as deferred revenue and $6.7 million in contract liabilities recorded as deferred revenue, net of the current portion.&#160;&#160;&#160;&#160; &lt;span style="font-size:12pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928"
      id="F_000384">2016-09-28</arwr:AgreementDate>
    <arwr:NumberOfAgreements
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160928"
      decimals="INF"
      id="F_000385"
      unitRef="U_arwrAgreement">2</arwr:NumberOfAgreements>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928"
      decimals="-5"
      id="F_000386"
      unitRef="U_iso4217USD">35000000.0</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928"
      decimals="-5"
      id="F_000387"
      unitRef="U_iso4217USD">21500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentReceived
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20160928"
      decimals="INF"
      id="F_000388"
      unitRef="U_iso4217USD">30000000.0</arwr:MilestonePaymentReceived>
    <arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20210930"
      decimals="INF"
      id="F_000389"
      unitRef="U_iso4217USD">400000000.0</arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:MilestonePaymentReceived
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200731"
      decimals="-6"
      id="F_000390"
      unitRef="U_iso4217USD">20000000</arwr:MilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20201001_20210930"
      decimals="-6"
      id="F_000391"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930"
      decimals="-5"
      id="F_000392"
      unitRef="U_iso4217USD">20100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930"
      decimals="-5"
      id="F_000393"
      unitRef="U_iso4217USD">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20210930"
      decimals="-6"
      id="F_000398"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20210930"
      decimals="-6"
      id="F_000397"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003_20181003"
      id="F_000399">2018-10-03</arwr:AgreementDate>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003"
      id="F_000400">2018-10-03</arwr:AgreementDate>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003"
      id="F_000401">2018-10-03</arwr:AgreementDate>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003"
      decimals="-5"
      id="F_000403"
      unitRef="U_iso4217USD">175000000.0</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003"
      decimals="-5"
      id="F_000402"
      unitRef="U_iso4217USD">75000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentEarned
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_20181003"
      decimals="-5"
      id="F_000407"
      unitRef="U_iso4217USD">70000000.0</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003"
      decimals="INF"
      id="F_000404"
      unitRef="U_iso4217USD">1600000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003"
      decimals="INF"
      id="F_000405"
      unitRef="U_iso4217USD">1900000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003"
      decimals="INF"
      id="F_000406"
      unitRef="U_arwrTarget">3</arwr:NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003_20181003"
      decimals="INF"
      id="F_000408"
      unitRef="U_arwrObligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003"
      decimals="-5"
      id="F_000409"
      unitRef="U_iso4217USD">252700000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003"
      decimals="-5"
      id="F_000411"
      unitRef="U_iso4217USD">25000000.0</arwr:MilestonePaymentEarned>
    <arwr:InitialTransactionPrice
      contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003"
      decimals="-5"
      id="F_000410"
      unitRef="U_iso4217USD">252700000</arwr:InitialTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20201001_20210930"
      decimals="-5"
      id="F_000412"
      unitRef="U_iso4217USD">20200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20191001_20200930"
      decimals="-5"
      id="F_000413"
      unitRef="U_iso4217USD">65000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181001_20190930"
      decimals="-5"
      id="F_000414"
      unitRef="U_iso4217USD">167500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20210930"
      decimals="-5"
      id="F_000415"
      unitRef="U_iso4217USD">100000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20210930"
      decimals="-6"
      id="F_000416"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20201001_20210930"
      decimals="-5"
      id="F_000417"
      unitRef="U_iso4217USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20191001_20200930"
      decimals="-5"
      id="F_000418"
      unitRef="U_iso4217USD">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20181001_20190930"
      decimals="-5"
      id="F_000419"
      unitRef="U_iso4217USD">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <arwr:MilestonePaymentReceived
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20210930"
      decimals="-5"
      id="F_000420"
      unitRef="U_iso4217USD">10000000.0</arwr:MilestonePaymentReceived>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20210930"
      decimals="-5"
      id="F_000421"
      unitRef="U_iso4217USD">10000000.0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20210930"
      decimals="-6"
      id="F_000422"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:MilestonePaymentReceived
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrJNJ75220795AROJNJ1Member_20211031"
      decimals="-5"
      id="F_000423"
      unitRef="U_iso4217USD">10000000.0</arwr:MilestonePaymentReceived>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      id="F_000424">2020-10-07</arwr:AgreementDate>
    <arwr:RatioOfProfitSharingStructureForCommercialization
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      id="F_000425">50/50 profit sharing</arwr:RatioOfProfitSharingStructureForCommercialization>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="2"
      id="F_000426"
      unitRef="U_xbrlipure">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="2"
      id="F_000427"
      unitRef="U_xbrlipure">0.25</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210131"
      decimals="-5"
      id="F_000428"
      unitRef="U_iso4217USD">300000000.0</arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210131"
      decimals="-5"
      id="F_000429"
      unitRef="U_iso4217USD">740000000.0</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="INF"
      id="F_000431"
      unitRef="U_arwrObligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:NumberOfDistinctBundle
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="INF"
      id="F_000430"
      unitRef="U_arwrBundle">1</arwr:NumberOfDistinctBundle>
    <arwr:RatioOfProfitSharingStructureForCommercialization
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      id="F_000432">50/50 profit sharing</arwr:RatioOfProfitSharingStructureForCommercialization>
    <arwr:InitialTransactionPrice
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="-5"
      id="F_000433"
      unitRef="U_iso4217USD">300000000.0</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="-5"
      id="F_000434"
      unitRef="U_iso4217USD">300000000.0</arwr:InitialTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201001_20210930"
      decimals="-5"
      id="F_000435"
      unitRef="U_iso4217USD">90800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20191001_20200930"
      decimals="-6"
      id="F_000436"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20181001_20190930"
      decimals="-6"
      id="F_000437"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930"
      decimals="-6"
      id="F_000438"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapBalanceSheetLocationAxis_arwrDeferredRevenueCurrentMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930"
      decimals="-5"
      id="F_000439"
      unitRef="U_iso4217USD">84400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930"
      decimals="-5"
      id="F_000440"
      unitRef="U_iso4217USD">124800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapBalanceSheetLocationAxis_us-gaapAccruedLiabilitiesMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930"
      decimals="-5"
      id="F_000441"
      unitRef="U_iso4217USD">3100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapBalanceSheetLocationAxis_us-gaapAccruedLiabilitiesMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20210930"
      decimals="-5"
      id="F_000442"
      unitRef="U_iso4217USD">3100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618_20210618"
      id="F_000443">2021-06-18</arwr:AgreementDate>
    <arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210731"
      decimals="-6"
      id="F_000444"
      unitRef="U_iso4217USD">40000000</arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618"
      decimals="-6"
      id="F_000445"
      unitRef="U_iso4217USD">660000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctBundle
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20210618_20210618"
      decimals="INF"
      id="F_000446"
      unitRef="U_arwrBundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20210618_20210618"
      decimals="INF"
      id="F_000447"
      unitRef="U_arwrObligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618_20210618"
      decimals="-5"
      id="F_000448"
      unitRef="U_iso4217USD">40000000.0</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618_20210618"
      decimals="-5"
      id="F_000449"
      unitRef="U_iso4217USD">40000000.0</arwr:InitialTransactionPrice>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618_20210618"
      decimals="INF"
      id="F_000450"
      unitRef="U_arwrObligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20201001_20210930"
      decimals="-5"
      id="F_000451"
      unitRef="U_iso4217USD">6700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20191001_20200930"
      decimals="-6"
      id="F_000452"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20181001_20190930"
      decimals="-6"
      id="F_000453"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210930"
      decimals="-5"
      id="F_000454"
      unitRef="U_iso4217USD">100000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210930"
      decimals="-5"
      id="F_000455"
      unitRef="U_iso4217USD">26700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210930"
      decimals="-5"
      id="F_000456"
      unitRef="U_iso4217USD">6700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000311">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 3. &lt;span style="font-style:italic;"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment:&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers, office equipment and furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,661&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;662&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;631&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,869&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,539&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,864&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization expense for property and equipment for the years ended September 30, 2021, 2020, and 2019 was $6.6 million, $4.2 million and $2.7 million respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000339">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment:&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers, office equipment and furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,661&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;662&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;631&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,869&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,539&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,864&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">1661000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">662000</us-gaap:FurnitureAndFixturesGross>
    <arwr:ResearchEquipmentGross
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">27500000</arwr:ResearchEquipmentGross>
    <arwr:ResearchEquipmentGross
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000460"
      unitRef="U_iso4217USD">20654000</arwr:ResearchEquipmentGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">509000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">631000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">41869000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">25238000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">71539000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">47185000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000467"
      unitRef="U_iso4217USD">22864000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000468"
      unitRef="U_iso4217USD">16304000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000469"
      unitRef="U_iso4217USD">48675000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">30881000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0000879407_20201001_20210930"
      decimals="-5"
      id="F_000471"
      unitRef="U_iso4217USD">6600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000472"
      unitRef="U_iso4217USD">4200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0000879407_20181001_20190930"
      decimals="-5"
      id="F_000473"
      unitRef="U_iso4217USD">2700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000312">
&lt;p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 4. &lt;span style="font-style:italic;"&gt;INVESTMENTS&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments at September 30, 2021 primarily consisted of corporate bonds that have maturities of less than 36 months, a certificate of deposit and marketable equity securities. The Company&#x2019;s investments in corporate bonds consist of both short-term and long-term bonds and are classified as &#x201c;held-to-maturity&#x201d; on the Company&#x2019;s Consolidated Balance Sheets. The Company&#x2019;s certificate of deposit matures in less than 24 months and is classified as &#x201c;held-to-maturity&#x201d; on the Company&#x2019;s Consolidated Balance Sheet.&#160;&#160;The Company&#x2019;s marketable equity securities consist of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, corporate bonds and other asset-backed debt securities. Dividends from these funds are automatically reinvested.&#160;&#160;The Company may also invest excess cash balances in money market accounts, government-sponsored enterprise securities, and/or commercial paper.&#160;&#160;The Company accounts for its held to maturity investments in accordance with FASB ASC 320, Investments &#x2013; Debt and Equity Securities and its marketable equity securities in accordance with ASC 321, Investments &#x2013; Equity Securities.&#160;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the Company&#x2019;s short-term, long-term investments and marketable securities as of September 30, 2021 and September 30, 2020 by measurement category. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Held to Maturity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,430&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one through three years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;195,595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;196,643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificate of deposit (due within two years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,954&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;304,073&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,590&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one through three years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,574&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224,377&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,164&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,462&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized Gains/(Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,481&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,481&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized Gains/(Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000340">

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the Company&#x2019;s short-term, long-term investments and marketable securities as of September 30, 2021 and September 30, 2020 by measurement category. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Held to Maturity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,430&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one through three years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;195,595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;196,643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificate of deposit (due within two years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,954&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;304,073&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,590&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one through three years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,574&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224,377&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,164&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,462&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized Gains/(Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,481&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,481&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized Gains/(Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20210930"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">56627000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20210930"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">803000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20210930"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">57430000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20210930"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">195595000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20210930"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">1151000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20210930"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">103000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20210930"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">196643000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_us-gaapCashAndCashEquivalentsAxis_arwrCertificateOfDepositsDueWithinTwoYearsMember_20210930"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">50000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapCashAndCashEquivalentsAxis_arwrCertificateOfDepositsDueWithinTwoYearsMember_20210930"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">50000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">302222000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">1954000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">103000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">304073000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">86890000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">1590000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">88480000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">137487000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">4574000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">79000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">141982000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">224377000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">6164000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">79000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">230462000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">125000000</us-gaap:EquitySecuritiesFvNiCost>
    <arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">2481000</arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">135000</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">888000</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20210930"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">126728000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">125000000</us-gaap:EquitySecuritiesFvNiCost>
    <arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">2481000</arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000507"
      unitRef="U_iso4217USD">135000</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000509"
      unitRef="U_iso4217USD">888000</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000513"
      unitRef="U_iso4217USD">126728000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">85000000</us-gaap:EquitySecuritiesFvNiCost>
    <arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">95000</arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930"
      decimals="-3"
      id="F_000510"
      unitRef="U_iso4217USD">75000</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930"
      decimals="-3"
      id="F_000514"
      unitRef="U_iso4217USD">85020000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">85000000</us-gaap:EquitySecuritiesFvNiCost>
    <arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">95000</arwr:EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000511"
      unitRef="U_iso4217USD">75000</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000515"
      unitRef="U_iso4217USD">85020000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000313">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 5. &lt;span style="font-style:italic;"&gt;INTANGIBLE ASSETS&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The license agreement associated with the Novartis RNAi asset acquisition is being amortized over the estimated life remaining at the time of acquisition, which was 21 years, and the accumulated amortization of the asset is $1.0 million.&#160;&#160;The patents associated with the Novartis RNAi asset acquisition are being amortized over the estimated life remaining at the time of acquisition, which was 14 years, and the accumulated amortization of the assets is $10.2 million.&#160;&#160;Amortization expense for the years ended September 30, 2021, 2020, and 2019 was $1.7 million, $1.7 million and $1.7 million, respectively. Amortization expense is expected to be $1.7 million in 2022, $1.7 million in 2023, $1.7 million in 2024, $1.7 million in 2025, $1.7 million in 2026 and $5.2 million thereafter.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides details on the Company&#x2019;s intangible asset balances: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;subject to&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,663&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20201001_20210930"
      id="F_000516">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20210930"
      decimals="-5"
      id="F_000517"
      unitRef="U_iso4217USD">1000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201001_20210930"
      id="F_000518">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0000879407_us-gaapAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20210930"
      decimals="-5"
      id="F_000519"
      unitRef="U_iso4217USD">10200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0000879407_20201001_20210930"
      decimals="-5"
      id="F_000520"
      unitRef="U_iso4217USD">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000521"
      unitRef="U_iso4217USD">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0000879407_20181001_20190930"
      decimals="-5"
      id="F_000522"
      unitRef="U_iso4217USD">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000523"
      unitRef="U_iso4217USD">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000524"
      unitRef="U_iso4217USD">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000525"
      unitRef="U_iso4217USD">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000526"
      unitRef="U_iso4217USD">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000527"
      unitRef="U_iso4217USD">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000528"
      unitRef="U_iso4217USD">5200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000341">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides details on the Company&#x2019;s intangible asset balances: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;subject to&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,663&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000529"
      unitRef="U_iso4217USD">15363000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000530"
      unitRef="U_iso4217USD">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000531"
      unitRef="U_iso4217USD">13663000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000314">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 6. &lt;span style="font-style:italic;"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At September 30, 2021, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At September 30, 2021, &lt;span style="color:#000000;"&gt;104,326,672&lt;/span&gt; shares of Common Stock were outstanding.&#160;&#160;At September 30, 2021, 15,228,479 shares of Common Stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under Arrowhead&#x2019;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company entered into an Open Market Sale Agreement (the &#x201c;ATM Agreement&#x201d;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#x2019;s Common Stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#x201c;ATM Offering&#x201d;). The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At September 30, 2021, no shares have been issued under the ATM Agreement.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000532"
      unitRef="U_xbrlishares">150000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000533"
      unitRef="U_xbrlishares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000534"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000535"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000536"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000537"
      unitRef="U_xbrlishares">104326672</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_20210930"
      decimals="INF"
      id="F_000538"
      unitRef="U_xbrlishares">15228479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <arwr:CommonStockCapitalSharesValueReservedForFutureIssuance
      contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200831"
      decimals="INF"
      id="F_000539"
      unitRef="U_iso4217USD">250000000</arwr:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock
      contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200801_20200831"
      decimals="3"
      id="F_000540"
      unitRef="U_xbrlipure">0.030</arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20210930"
      decimals="INF"
      id="F_000541"
      unitRef="U_xbrlishares">0</us-gaap:SharesIssued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000315">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 7. &lt;span style="font-style:italic;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Litigation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business.&#160;&#160;If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss.&#160;&#160;There were no contingent liabilities recorded as of the year ended September 30, 2021. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Technology License Commitments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has licensed from third parties the rights to use certain technologies for its research and development&#160;activities,&#160;as well as in any products the Company may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. &#160;Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and upon certain sales level milestones. &#160;These milestone payments could amount to the mid to upper double-digit millions of dollars. During the year ended September 30, 2021, the Company did not incur any milestone payments. During the year ended September 30, 2020, the Company triggered $2.4 million of milestone payments related to the progression of the ARO-ENaC and ARO-HIF2 candidates. During the year ended September 30, 2019, the Company did not incur any milestone payments.&#160;&#160;In certain agreements, the Company may be required to make mid to high single-digit percentage royalty payments based on a percentage of the sales of the relevant products.&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000542"
      unitRef="U_iso4217USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <arwr:MilestonePayments
      contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20201001_20210930"
      decimals="INF"
      id="F_000543"
      unitRef="U_iso4217USD">0</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_us-gaapTypeOfArrangementAxis_arwrAROENacAndAROHIF2CandidatesMember_20191001_20200930"
      decimals="-5"
      id="F_000544"
      unitRef="U_iso4217USD">2400000</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20181001_20190930"
      decimals="INF"
      id="F_000545"
      unitRef="U_iso4217USD">0</arwr:MilestonePayments>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000316">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 8. &lt;span style="font-style:italic;"&gt;LEASES&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2019, the Company entered into a lease for its corporate headquarters in Pasadena, California.&#160;&#160;The 91 month office building lease between the Company and 177 Colorado Owner, LLC is for approximately 24,000 square feet of office space located at 177 E. Colorado Blvd, Pasadena, California. &#160;The increased capacity of this new office space compared to the Company&#x2019;s prior corporate headquarters will accommodate increased personnel as the Company&#x2019;s pipeline of drug candidates expands and moves &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;closer to market.&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease payments began on &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30, 2019&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and are estimated to total&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; approximately&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; $&lt;/span&gt;8.7&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million over the term&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="font-size:12pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The lease expires on &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;April 30&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, 2027&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;has paid&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; approximately $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million for leasehold improvements, net of tenant improvement allowances.&#160;&#160;The lease contains an option to renew for &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; term of &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;five years&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The exercise of this option was not determined to be reasonably certain and thus was not included in &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;l&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ease liabilities on the Company&#x2019;s Consolidated Balance Sheet at&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; September&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 30&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, 202&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 23, 2020, the Company entered into a lease expansion to add an additional approximately&#160;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,000&#160;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;square feet of office space at the same location for its corporate headquarters. Lease payments for the expansion began in&#160;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;July 2021&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;and the lease for the expansion expires in&#160;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;April 2027&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The lease payments for the expansion are expected to total $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.9&#160;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million.&#160;&#160;The Company has paid approximately $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.0&#160;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million of leasehold improvements, net of tenant improvement allowances, for the lease expansion.&#160;&#160;The increased capacity of this additional office space&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;compared to the Company&#x2019;s current corporate headquarters is intended to accommodate increased personnel as the Company&#x2019;s pipeline of drug candidates continues to expand and move closer to ma&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;rket.&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2016, the Company entered into a lease for its research facility in Madison, Wisconsin.&#160;&#160;The lease was for approximately 60,000 square feet of office and laboratory space and had an expiration date of September 30, 2026. The lease was amended in January 2019 and May 2020 to expand the rentable square feet by an additional 40,000 square feet and to extend the lease expiration date to September 30, 2031. Lease payments are estimated to total approximately $26.2 million for the term. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;The Company incurred approximately $11.0&#160;million of leasehold improvements for the additional 40,000 square feet, net of tenant improvement allowances.&lt;/span&gt;&#160;&lt;span style="color:#000000;"&gt;The lease contains two options to renew for two terms of five years. The exercise of these options were not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#x2019;s Consolidated Balance Sheet at September 30, 2021. In November 2020 and December 2020, the Company entered into amendments to expand the rentable square space by an additional&#160;10,743&#160;square feet and these amendments added a total of approximately $1.2&#160;million of lease payments for the remainder of the term.&#160;&lt;/span&gt; &#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the Company entered into a sublease agreement (the &#x201c;Sublease&#x201d;) with Halozyme, Inc. for additional research and development facility space in San Diego, California.&#160; The Sublease provides additional space needed to accommodate the recent growth of the Company&#x2019;s personnel and discovery efforts. The sublease is for approximately &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;21,000&lt;/span&gt; rentable square feet.&#160; The term of the Sublease commenced on April 1, 2020 and will end on January 14, 2023.&#160;&#160;Sublease payments are estimated to total approximately $2.0 million over the term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost during the years ended September 30, &lt;span style="color:#000000;"&gt;2021, 2020 and 2019 &lt;/span&gt;was $5.1 million, $2.4 million and $1.3 million respectively.&#160;&#160;Variable lease costs during the year ended September 30, 2021, 2020, and 2019 were $0.8 million, $0.8 million and $0.5 million respectively.&#160;&#160;There was no short-term lease cost during the years ended September 30, &lt;span style="color:#000000;"&gt;2021, 2020 and 2019&lt;/span&gt;. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of September 30, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,708&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,621&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2027 and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,569&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities (includes current portion)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for the amounts included in the measurement of the operating lease liabilities on the Company&#x2019;s Consolidated Balance Sheet and included in Other changes in operating assets and liabilities within cash flows from operating activities on the Company&#x2019;s Consolidated Statements of Cash Flow for the years ended September 30, 2021, 2020 and 2019 were $3.1 million, $1.8 million and $1.3 million, respectively.&#160;The weighted-average remaining lease term and weighted-average discount rate for all leases as of September 30, 2021 was &lt;span style="color:#000000;"&gt;8 years&lt;/span&gt; and 8.5%, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430"
      id="F_000546">P91M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430"
      decimals="0"
      id="F_000547"
      unitRef="U_utrsqft">24000</us-gaap:LandSubjectToGroundLeases>
    <arwr:LeasePaymentsCommencementDate
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430"
      id="F_000548">2019-09-30</arwr:LeasePaymentsCommencementDate>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430"
      decimals="-5"
      id="F_000549"
      unitRef="U_iso4217USD">8700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430"
      id="F_000550">2027-04-30</us-gaap:LeaseExpirationDate1>
    <arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430"
      decimals="-5"
      id="F_000551"
      unitRef="U_iso4217USD">3500000</arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <arwr:NumberOfOptionsToRenew
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430"
      decimals="INF"
      id="F_000553"
      unitRef="U_arwrOption">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430"
      id="F_000552">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023"
      decimals="0"
      id="F_000554"
      unitRef="U_utrsqft">24000</us-gaap:LandSubjectToGroundLeases>
    <arwr:LeaseExpansionCommencementMonthAndYear
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023_20201023"
      id="F_000555">2021-07</arwr:LeaseExpansionCommencementMonthAndYear>
    <arwr:LeaseExpansionExpirationMonthAndYear
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023_20201023"
      id="F_000556">2027-04</arwr:LeaseExpansionExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023"
      decimals="-5"
      id="F_000557"
      unitRef="U_iso4217USD">6900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20201023_20201023"
      decimals="-5"
      id="F_000558"
      unitRef="U_iso4217USD">4000000.0</arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160131"
      decimals="0"
      id="F_000559"
      unitRef="U_utrsqft">60000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160101_20160131"
      id="F_000560">2026-09-30</us-gaap:LeaseExpirationDate1>
    <arwr:AdditionalLandSubjectToLease
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20200531"
      decimals="INF"
      id="F_000561"
      unitRef="U_utrsqft">40000</arwr:AdditionalLandSubjectToLease>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20200531"
      id="F_000562">2031-09-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200531"
      decimals="-5"
      id="F_000563"
      unitRef="U_iso4217USD">26200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <arwr:ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20200531"
      decimals="-5"
      id="F_000564"
      unitRef="U_iso4217USD">11000000.0</arwr:ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <arwr:NumberOfOptionsToRenew
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201231"
      decimals="INF"
      id="F_000566"
      unitRef="U_arwrOption">2</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201231"
      id="F_000565">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <arwr:AdditionalLandSubjectToLease
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201101_20201231"
      decimals="INF"
      id="F_000567"
      unitRef="U_utrsqft">10743</arwr:AdditionalLandSubjectToLease>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20201231"
      decimals="-5"
      id="F_000568"
      unitRef="U_iso4217USD">1200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331"
      decimals="0"
      id="F_000569"
      unitRef="U_utrsqft">21000</us-gaap:LandSubjectToGroundLeases>
    <arwr:SubleaseCommencementDate
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331"
      id="F_000570">2020-04-01</arwr:SubleaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331"
      id="F_000571">2023-01-14</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331"
      decimals="-5"
      id="F_000572"
      unitRef="U_iso4217USD">2000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000879407_20201001_20210930"
      decimals="-5"
      id="F_000573"
      unitRef="U_iso4217USD">5100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000574"
      unitRef="U_iso4217USD">2400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000879407_20181001_20190930"
      decimals="-5"
      id="F_000575"
      unitRef="U_iso4217USD">1300000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0000879407_20201001_20210930"
      decimals="-5"
      id="F_000576"
      unitRef="U_iso4217USD">800000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000577"
      unitRef="U_iso4217USD">800000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0000879407_20181001_20190930"
      decimals="-5"
      id="F_000578"
      unitRef="U_iso4217USD">500000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000579"
      unitRef="U_iso4217USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000580"
      unitRef="U_iso4217USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0000879407_20181001_20190930"
      decimals="-3"
      id="F_000581"
      unitRef="U_iso4217USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000342">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of September 30, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,708&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,621&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2027 and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,569&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities (includes current portion)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000582"
      unitRef="U_iso4217USD">4708000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000583"
      unitRef="U_iso4217USD">4786000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000584"
      unitRef="U_iso4217USD">4621000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000585"
      unitRef="U_iso4217USD">4749000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000586"
      unitRef="U_iso4217USD">5050000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000587"
      unitRef="U_iso4217USD">13200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000588"
      unitRef="U_iso4217USD">37114000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000589"
      unitRef="U_iso4217USD">11569000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000590"
      unitRef="U_iso4217USD">25545000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0000879407_20201001_20210930"
      decimals="-5"
      id="F_000591"
      unitRef="U_iso4217USD">3100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000592"
      unitRef="U_iso4217USD">1800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0000879407_20181001_20190930"
      decimals="-5"
      id="F_000593"
      unitRef="U_iso4217USD">1300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0000879407_20210930" id="F_000594">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0000879407_20210930"
      decimals="3"
      id="F_000595"
      unitRef="U_xbrlipure">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000317">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 9. &lt;span style="font-style:italic;"&gt;STOCK-BASED COMPENSATION&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arrowhead has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan and 2013 Incentive Plan, as of September 30, 2021, 429,141 and 5,225,983 shares, respectively, of Arrowhead&#x2019;s Common Stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others. No further grants may be made under the 2004 Equity Incentive Plan.&#160;&#160;As of September 30, 2021, there were options granted and outstanding to purchase 429,141 and 2,066,533 shares of Common Stock under the 2004 Equity Incentive Plan &lt;/p&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and the 2013 Incentive Plan, respectively, and there were &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,159,450&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; restricted stock units granted and outstanding under the 2013 Incentive Plan. Also, as of &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 30, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;202&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, there were &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;957,565&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares reserved for options and &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;602,000 &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares reserved for restricted stock units issued as inducement grants to new employees &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;granted outside of the Company&#x2019;s equity-based compensation plans &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;under Rule 5635(c)(4) of the N&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;asdaq&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Listing Rules&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 18, 2021, the Company&#x2019;s stockholders approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (&#x201c;2021 Incentive Plan&#x201d;), which authorizes &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,000,000&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of Arrowhead&#x2019;s Common Stock. The maximum number of shares authorized under the 2021 Incentive Plan will be (&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;i&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;) reduced by any shares subject to awards made under the 2013 Incentive Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Incentive Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2021, there were options granted and outstanding to purchase &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of Common Stock and &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,400&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; restricted stock units granted and outstanding under the 2021 Incentive Plan.&#160;&#160;As of September 30, 2021, the total number of authorized shares under the 2021 Incentive Plan was &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,013,790&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares, which includes &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,190&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares that were forfeited under the 2013 Incentive Plan&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information about stock options:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September&#160;30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,539,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(217,820&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,051,344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,456,239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000620"&gt;5.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,501,055&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable At September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,510,091&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000621"&gt;4.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,302,948&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense related to stock options for the years ended September 30, 2021, 2020, and 2019 was $12.4 million, $9.7 million and $4.0 million, respectively.  For non-qualified stock options, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The grant date fair value of the options granted by the Company for the years ended September 30, 2021, 2020, and 2019 was $9.0 million, $34.6 million and $12.1 million, respectively.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The intrinsic value of the options exercised during the years ended September 30, 2021, 2020, and 2019 was $66.9 million, $44.1 million and $24.6 million, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2021, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $26.3 million will be recognized in the Company&#x2019;s results of operations over a weighted average period of &lt;span&gt;&lt;span style="color:#000000;"&gt;2.4 &lt;/span&gt;years&lt;/span&gt;. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#x2019;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to value stock options are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years&#160;ended&#160;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000635"&gt;0.4 &#x2013; 1.1%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000636"&gt;0.4 &#x2013; 1.8%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000637"&gt;1.50 &#x2013; 3.1%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86.2 &#x2013; 90.4%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90.0 &#x2013; 92.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000646"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000647"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000648"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average grant date fair value per share of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The dividend yield is zero as the Company currently does not pay a dividend. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The risk-free interest rate is based on that of the U.S. Treasury bond. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility is estimated based on volatility average of the Company&#x2019;s Common Stock price. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units (&#x201c;RSUs&#x201d;), including time-based and performance-based awards, have been granted under the Company&#x2019;s 2013 Incentive Plan, 2021 Incentive Plan, and as inducements grants granted outside of the Company&#x2019;s equity-based compensation plans.  At vesting, each outstanding RSU will be exchanged for one share of the Company&#x2019;s Common Stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at September&#160;30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,524,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,672,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(899,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30.65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(465,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,831,850&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61.24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended September 30, 2021, 2020 and 2019, the Company recorded $64.2 million, $33.7 million and $8.4 million of expense related to RSUs, respectively. Such expense is included in stock-based compensation expense in the Company&#x2019;s Consolidated Statement of Operations and Comprehensive Income (Loss). For RSUs, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For RSUs, the grant date fair value of the award is based on the Company&#x2019;s closing stock price at the grant date, with consideration given to the probability of achieving performance conditions for performance-based awards. The grant date fair value of the RSUs granted by the Company for the years ended September 30, 2021, 2020 and 2019 was $127.7 million, $149.4 million and $17.8 million, respectively. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2021, the pre-tax compensation expense for all unvested RSUs in the amount of $118.0 million will be recognized in the Company&#x2019;s results of operations over a weighted average period of 2.7 years.  Unvested RSUs that we have deemed not probable of vesting as of September 30, 2021, have the potential of generating an additional $35.7 million of pre-tax compensation expense if we deem them probable of vesting in a future reporting period.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20210930"
      decimals="INF"
      id="F_000596"
      unitRef="U_xbrlishares">429141</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930"
      decimals="INF"
      id="F_000597"
      unitRef="U_xbrlishares">5225983</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20210930"
      decimals="INF"
      id="F_000598"
      unitRef="U_xbrlishares">429141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930"
      decimals="INF"
      id="F_000599"
      unitRef="U_xbrlishares">2066533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20210930"
      decimals="INF"
      id="F_000601"
      unitRef="U_xbrlishares">3159450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000879407_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20210930"
      decimals="INF"
      id="F_000603"
      unitRef="U_xbrlishares">957565</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20210930"
      decimals="INF"
      id="F_000604"
      unitRef="U_xbrlishares">602000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210318"
      decimals="INF"
      id="F_000605"
      unitRef="U_xbrlishares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930"
      decimals="INF"
      id="F_000600"
      unitRef="U_xbrlishares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930"
      decimals="INF"
      id="F_000602"
      unitRef="U_xbrlishares">70400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandTwentyOneIncentivePlanMember_20210930"
      decimals="INF"
      id="F_000606"
      unitRef="U_xbrlishares">8013790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20201001_20210930"
      decimals="INF"
      id="F_000607"
      unitRef="U_xbrlishares">87190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000343">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information about stock options:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September&#160;30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,539,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(217,820&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,051,344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,456,239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000620"&gt;5.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,501,055&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable At September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,510,091&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000621"&gt;4.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,302,948&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000608"
      unitRef="U_xbrlishares">4539403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0000879407_20200930"
      decimals="2"
      id="F_000614"
      unitRef="U_iso4217USD_xbrlishares">16.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0000879407_20201001_20210930"
      decimals="INF"
      id="F_000609"
      unitRef="U_xbrlishares">186000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0000879407_20201001_20210930"
      decimals="2"
      id="F_000615"
      unitRef="U_iso4217USD_xbrlishares">65.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0000879407_20201001_20210930"
      decimals="INF"
      id="F_000610"
      unitRef="U_xbrlishares">217820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0000879407_20201001_20210930"
      decimals="2"
      id="F_000616"
      unitRef="U_iso4217USD_xbrlishares">40.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0000879407_20201001_20210930"
      decimals="INF"
      id="F_000611"
      unitRef="U_xbrlishares">1051344</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0000879407_20201001_20210930"
      decimals="2"
      id="F_000617"
      unitRef="U_iso4217USD_xbrlishares">10.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000612"
      unitRef="U_xbrlishares">3456239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0000879407_20210930"
      decimals="2"
      id="F_000618"
      unitRef="U_iso4217USD_xbrlishares">19.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0000879407_20210930"
      decimals="0"
      id="F_000622"
      unitRef="U_iso4217USD">149501055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000613"
      unitRef="U_xbrlishares">2510091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0000879407_20210930"
      decimals="2"
      id="F_000619"
      unitRef="U_iso4217USD_xbrlishares">12.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0000879407_20210930"
      decimals="0"
      id="F_000623"
      unitRef="U_iso4217USD">126302948</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930"
      decimals="-5"
      id="F_000624"
      unitRef="U_iso4217USD">12400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930"
      decimals="-5"
      id="F_000625"
      unitRef="U_iso4217USD">9700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930"
      decimals="-5"
      id="F_000626"
      unitRef="U_iso4217USD">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930"
      decimals="-5"
      id="F_000627"
      unitRef="U_iso4217USD">9000000.0</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930"
      decimals="-5"
      id="F_000628"
      unitRef="U_iso4217USD">34600000</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930"
      decimals="-5"
      id="F_000629"
      unitRef="U_iso4217USD">12100000</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930"
      decimals="-5"
      id="F_000630"
      unitRef="U_iso4217USD">66900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930"
      decimals="-5"
      id="F_000631"
      unitRef="U_iso4217USD">44100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930"
      decimals="-5"
      id="F_000632"
      unitRef="U_iso4217USD">24600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210930"
      decimals="-5"
      id="F_000633"
      unitRef="U_iso4217USD">26300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930"
      id="F_000634">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000344">

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to value stock options are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years&#160;ended&#160;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000635"&gt;0.4 &#x2013; 1.1%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000636"&gt;0.4 &#x2013; 1.8%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000637"&gt;1.50 &#x2013; 3.1%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86.2 &#x2013; 90.4%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90.0 &#x2013; 92.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000646"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000647"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000648"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average grant date fair value per share of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0000879407_20181001_20190930"
      decimals="2"
      id="F_000641"
      unitRef="U_xbrlipure">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_20201001_20210930"
      decimals="2"
      id="F_000649"
      unitRef="U_iso4217USD_xbrlishares">48.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_20191001_20200930"
      decimals="2"
      id="F_000650"
      unitRef="U_iso4217USD_xbrlishares">36.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_20181001_20190930"
      decimals="2"
      id="F_000651"
      unitRef="U_iso4217USD_xbrlishares">13.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201001_20210930"
      decimals="2"
      id="F_000652"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="C_0000879407_20201001_20210930" id="F_000653">At vesting, each outstanding RSU will be exchanged for one share of the Company&#x2019;s Common Stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000345">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at September&#160;30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,524,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,672,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(899,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30.65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(465,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at September 30, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,831,850&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61.24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930"
      decimals="INF"
      id="F_000654"
      unitRef="U_xbrlishares">3524025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930"
      decimals="2"
      id="F_000659"
      unitRef="U_iso4217USD_xbrlishares">44.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930"
      decimals="INF"
      id="F_000655"
      unitRef="U_xbrlishares">1672350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930"
      decimals="2"
      id="F_000660"
      unitRef="U_iso4217USD_xbrlishares">76.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930"
      decimals="INF"
      id="F_000656"
      unitRef="U_xbrlishares">899025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930"
      decimals="2"
      id="F_000661"
      unitRef="U_iso4217USD_xbrlishares">30.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930"
      decimals="INF"
      id="F_000657"
      unitRef="U_xbrlishares">465500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930"
      decimals="2"
      id="F_000662"
      unitRef="U_iso4217USD_xbrlishares">44.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210930"
      decimals="INF"
      id="F_000658"
      unitRef="U_xbrlishares">3831850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210930"
      decimals="2"
      id="F_000663"
      unitRef="U_iso4217USD_xbrlishares">61.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930"
      decimals="-5"
      id="F_000664"
      unitRef="U_iso4217USD">64200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930"
      decimals="-5"
      id="F_000665"
      unitRef="U_iso4217USD">33700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930"
      decimals="-5"
      id="F_000666"
      unitRef="U_iso4217USD">8400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930"
      decimals="-5"
      id="F_000667"
      unitRef="U_iso4217USD">127700000</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930"
      decimals="-5"
      id="F_000668"
      unitRef="U_iso4217USD">149400000</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930"
      decimals="-5"
      id="F_000669"
      unitRef="U_iso4217USD">17800000</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210930"
      decimals="-5"
      id="F_000670"
      unitRef="U_iso4217USD">118000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930"
      id="F_000671">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <arwr:EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201001_20210930"
      decimals="-5"
      id="F_000672"
      unitRef="U_iso4217USD">35700000</arwr:EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000318">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 10. &lt;span style="font-style:italic;"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level&#160;1 provides the most reliable measure of fair value while Level&#160;3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;1&#x2014;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;2&#x2014;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;3&#x2014;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&#x2019;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes fair value measurements at September 30, 2021 and September&#160;30, 2020 for assets and liabilities measured at fair value on a recurring basis.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30, 2021: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,434&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,434&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,430&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,430&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;246,643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;246,643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30, &lt;span style="color:#000000;"&gt;2020&lt;/span&gt;: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143,583&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143,583&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had a liability for contingent consideration related to its acquisition of the Roche RNAi business completed in 2011. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#x2019;s assumptions and experience. Estimating timing to complete the development and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining FDA and other regulatory approvals. In determining the probability of regulatory approval and commercial success, the Company utilizes data regarding similar milestone events from several sources, including industry studies and its own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. In November 2016, the Company announced the discontinuation of its clinical trial efforts for ARC-520, ARC-AAT and ARC-521.&#160;&#160;Given this development, the Company assessed the fair value of its contingent consideration obligation to be $0 at September 30, 2021 and September 30, 2020.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000346">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes fair value measurements at September 30, 2021 and September&#160;30, 2020 for assets and liabilities measured at fair value on a recurring basis.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30, 2021: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,434&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,434&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,430&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,430&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;246,643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;246,643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30, &lt;span style="color:#000000;"&gt;2020&lt;/span&gt;: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143,583&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143,583&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930"
      decimals="-3"
      id="F_000673"
      unitRef="U_iso4217USD">184434000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930"
      decimals="-3"
      id="F_000674"
      unitRef="U_iso4217USD">184434000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930"
      decimals="-3"
      id="F_000675"
      unitRef="U_iso4217USD">126728000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930"
      decimals="-3"
      id="F_000676"
      unitRef="U_iso4217USD">126728000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930"
      decimals="-3"
      id="F_000677"
      unitRef="U_iso4217USD">57430000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930"
      decimals="-3"
      id="F_000678"
      unitRef="U_iso4217USD">57430000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930"
      decimals="-3"
      id="F_000679"
      unitRef="U_iso4217USD">246643000</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930"
      decimals="-3"
      id="F_000680"
      unitRef="U_iso4217USD">246643000</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="-3"
      id="F_000681"
      unitRef="U_iso4217USD">143583000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="-3"
      id="F_000682"
      unitRef="U_iso4217USD">143583000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="-3"
      id="F_000683"
      unitRef="U_iso4217USD">85020000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="-3"
      id="F_000684"
      unitRef="U_iso4217USD">85020000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="-3"
      id="F_000685"
      unitRef="U_iso4217USD">88480000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="-3"
      id="F_000686"
      unitRef="U_iso4217USD">88480000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="-3"
      id="F_000687"
      unitRef="U_iso4217USD">141982000</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="-3"
      id="F_000688"
      unitRef="U_iso4217USD">141982000</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0000879407_20210930"
      decimals="0"
      id="F_000689"
      unitRef="U_iso4217USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000690"
      unitRef="U_iso4217USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000319">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 11. &lt;span style="font-style:italic;"&gt;INCOME TAXES&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes the guidance issued by the FASB for accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and &lt;/p&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Components of the net deferred tax asset (liability) at September 30, 2021 and 2020 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,371&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,937&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized Research &amp;amp; Development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;California Alternative Minimum Tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Operating Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;185,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,562&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,818&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,702&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of Use Assets/Lease Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,938&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capital Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;216,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171,080&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(194,255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(156,604&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,547&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,929&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company may not realize the benefit of all of its deferred tax assets. Accordingly, management has provided a 100% valuation allowance against its deferred tax assets until such time as management believes that its projections of future profits as well as expected future tax rates make the realization of these deferred tax assets more-likely-than-not. Significant judgment is required in the evaluation of deferred tax benefits and differences in future results from our estimates could result in material differences in the realization of these assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax asset in accordance with FASB ASC 740-10, &#x201c;Accounting for Income Taxes.&#x201d; This assessment included the evaluation of scheduled reversals of deferred tax liabilities, the availability of carry forwards and estimates of projected future taxable income.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&#160;30, 2021, the Company had available gross federal net operating loss (&#x201c;NOL&#x201d;) carry forwards of approximately $&lt;span style="color:#000000;"&gt;569.0&lt;/span&gt; million and gross state NOL carry forwards of $&lt;span style="color:#000000;"&gt;626.5&#160;&lt;/span&gt;million. The NOLs expire at various dates through 2041.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The provisions for income taxes for the years ended September 30, 2021 and 2020 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision from income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended September 30, 2021 and 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal effect&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-7.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-7.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-1.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-13.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mark-to-market adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-2.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;True-up on deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax rate change&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. The Company&#x2019;s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense.&#160;&#160;The Company has not recognized any unrecognized tax benefits and does not have any interest or penalties related to uncertain tax positions as of September 30, 2021 and 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns with the Internal Revenue Service (&#x201c;IRS&#x201d;), the state of California and certain other taxing jurisdictions. The Company is subject to income tax examinations by the IRS and by state tax authorities until the net operating losses are settled.&#160;&#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000347">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Components of the net deferred tax asset (liability) at September 30, 2021 and 2020 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,371&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,937&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized Research &amp;amp; Development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;California Alternative Minimum Tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Operating Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;185,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,562&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,818&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,702&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of Use Assets/Lease Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,938&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capital Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;216,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171,080&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(194,255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(156,604&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,547&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,929&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000691"
      unitRef="U_iso4217USD">2371000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000692"
      unitRef="U_iso4217USD">2086000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000693"
      unitRef="U_iso4217USD">22454000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000694"
      unitRef="U_iso4217USD">10937000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000695"
      unitRef="U_iso4217USD">324000</arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost>
    <arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000696"
      unitRef="U_iso4217USD">625000</arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000697"
      unitRef="U_iso4217USD">179000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000698"
      unitRef="U_iso4217USD">179000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000699"
      unitRef="U_iso4217USD">185431000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000700"
      unitRef="U_iso4217USD">151007000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000701"
      unitRef="U_iso4217USD">3562000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000702"
      unitRef="U_iso4217USD">2818000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000703"
      unitRef="U_iso4217USD">1702000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000704"
      unitRef="U_iso4217USD">1938000</arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities>
    <arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000705"
      unitRef="U_iso4217USD">1016000</arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000706"
      unitRef="U_iso4217USD">710000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000707"
      unitRef="U_iso4217USD">216259000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000708"
      unitRef="U_iso4217USD">171080000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000709"
      unitRef="U_iso4217USD">194255000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000710"
      unitRef="U_iso4217USD">156604000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000711"
      unitRef="U_iso4217USD">6360000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000712"
      unitRef="U_iso4217USD">2547000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <arwr:DeferredTaxLiabilitiesStateTaxes
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000713"
      unitRef="U_iso4217USD">15644000</arwr:DeferredTaxLiabilitiesStateTaxes>
    <arwr:DeferredTaxLiabilitiesStateTaxes
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000714"
      unitRef="U_iso4217USD">11929000</arwr:DeferredTaxLiabilitiesStateTaxes>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0000879407_20210930"
      decimals="-3"
      id="F_000715"
      unitRef="U_iso4217USD">22004000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0000879407_20200930"
      decimals="-3"
      id="F_000716"
      unitRef="U_iso4217USD">14476000</us-gaap:DeferredIncomeTaxLiabilities>
    <arwr:PercentageOfValuationAllowance
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000717"
      unitRef="U_xbrlipure">1</arwr:PercentageOfValuationAllowance>
    <arwr:FederalNetOperatingLossCarryForward
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000718"
      unitRef="U_iso4217USD">569000000.0</arwr:FederalNetOperatingLossCarryForward>
    <arwr:StateNetOperatingLossCarryForwards
      contextRef="C_0000879407_20210930"
      decimals="-5"
      id="F_000719"
      unitRef="U_iso4217USD">626500000</arwr:StateNetOperatingLossCarryForwards>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000348">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The provisions for income taxes for the years ended September 30, 2021 and 2020 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision from income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000720"
      unitRef="U_iso4217USD">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000721"
      unitRef="U_iso4217USD">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000722"
      unitRef="U_iso4217USD">2000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000723"
      unitRef="U_iso4217USD">2000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000879407_20201001_20210930"
      decimals="-3"
      id="F_000724"
      unitRef="U_iso4217USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000879407_20191001_20200930"
      decimals="-3"
      id="F_000725"
      unitRef="U_iso4217USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000349">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended September 30, 2021 and 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal effect&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-7.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-7.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-1.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-13.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mark-to-market adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-2.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;True-up on deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax rate change&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0000879407_20201001_20210930"
      decimals="INF"
      id="F_000726"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000727"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0000879407_20201001_20210930"
      decimals="3"
      id="F_000728"
      unitRef="U_xbrlipure">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000729"
      unitRef="U_xbrlipure">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent
      contextRef="C_0000879407_20201001_20210930"
      decimals="3"
      id="F_000730"
      unitRef="U_xbrlipure">-0.013</arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent>
    <arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000731"
      unitRef="U_xbrlipure">-0.133</arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent>
    <arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments
      contextRef="C_0000879407_20201001_20210930"
      decimals="3"
      id="F_000732"
      unitRef="U_xbrlipure">0.000</arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments>
    <arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000733"
      unitRef="U_xbrlipure">0.000</arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0000879407_20201001_20210930"
      decimals="3"
      id="F_000734"
      unitRef="U_xbrlipure">-0.293</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000735"
      unitRef="U_xbrlipure">-0.433</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0000879407_20201001_20210930"
      decimals="3"
      id="F_000736"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000737"
      unitRef="U_xbrlipure">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate
      contextRef="C_0000879407_20201001_20210930"
      decimals="3"
      id="F_000738"
      unitRef="U_xbrlipure">0.000</arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate>
    <arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000739"
      unitRef="U_xbrlipure">0.000</arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_0000879407_20201001_20210930"
      decimals="3"
      id="F_000740"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000741"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0000879407_20201001_20210930"
      decimals="3"
      id="F_000742"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000743"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0000879407_20210930"
      decimals="INF"
      id="F_000744"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000745"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="C_0000879407_20201001_20210930"
      decimals="INF"
      id="F_000746"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000747"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="C_0000879407_20201001_20210930"
      decimals="0"
      id="F_000748"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000749"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000320">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 12. &lt;span style="font-style:italic;"&gt;EMPLOYEE BENEFIT PLANS&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2005, the Company adopted a defined contribution 401(k) retirement savings plan covering substantially all of its employees. The Plan is administered under the &#x201c;safe harbor&#x201d; provision of ERISA. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to 100% of each participant&#x2019;s first 3% of compensation contributed plus 50% of each participant&#x2019;s next 2% of compensation contributed. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended September&#160;30, 2021, 2020, and 2019, the Company recorded expenses under this plan of $1.3 million, $0.9 million and $0.5 million, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to the employee benefit plans described above, the Company provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20201001_20210930"
      decimals="INF"
      id="F_000750"
      unitRef="U_xbrlipure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20201001_20210930"
      decimals="2"
      id="F_000751"
      unitRef="U_xbrlipure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20201001_20210930"
      decimals="INF"
      id="F_000752"
      unitRef="U_xbrlipure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20201001_20210930"
      decimals="2"
      id="F_000753"
      unitRef="U_xbrlipure">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0000879407_20201001_20210930"
      decimals="-5"
      id="F_000754"
      unitRef="U_iso4217USD">1300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000755"
      unitRef="U_iso4217USD">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0000879407_20181001_20190930"
      decimals="-5"
      id="F_000756"
      unitRef="U_iso4217USD">500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0000879407_20201001_20210930" id="F_000321">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 13. &lt;span style="font-style:italic;"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;San Diego Lease Agreement with ARE-SD Region No. 72 LLC&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 19, 2021, the Company entered into a new lease for a San Diego, California research facility.&#160;&#160;The 15-year lease is for approximately 144,000 square feet of office and research and development laboratory space to be constructed in San Diego, California.&#160; This lease will replace the Company&#x2019;s current research facility sublease for property located in San Diego, California.&#160;&#160;The increased capacity of this new facility compared to the Company&#x2019;s current research facility in San Diego will accommodate increased personnel for the Company&#x2019;s expanding pipeline of current and future drug candidates.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The estimated rent commencement date for the lease is in May 2023 after construction and leasehold improvements have been completed.&#160; The lease payments, which begin on the rent commencement date, will be approximately &lt;span style="color:#000000;"&gt;$119.0&lt;/span&gt; million over the initial 15-year term.&#160;&#160;The Company also estimates payments for operating expenses to be approximately $&lt;span style="color:#000000;"&gt;3.0&lt;/span&gt; million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $&lt;span style="color:#000000;"&gt;31.0&lt;/span&gt; million for leasehold improvements, net of tenant improvement allowances.&#160;&#160;Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional &lt;span style="-sec-ix-hidden:F_000765"&gt;ten-year&lt;/span&gt; term, with certain annual increases in base rent.&lt;/p&gt;
&lt;p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;F-25&lt;/p&gt;
&lt;hr style="page-break-after:always"/&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Exclusive License Agreement with Glaxosmithkline Intellectual Property (No. 3) Limited&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 22, 2021, the Company entered into an Exclusive License Agreement (the &#x201c;GSK License Agreement&#x201d;) with Glaxosmithkline Intellectual Property (No. 3) Limited (&#x201c;GSK&#x201d;).&#160; Under the GSK License Agreement, &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;GSK has received an exclusive license for&#160;ARO-HSD,&#160;the Company&#x2019;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).&#160; The exclusive license is worldwide with the exception of greater China, for which the Company will retain rights to develop and commercialize.&#160; &lt;/span&gt;Beyond the Company&#x2019;s Phase 1/2 study of (ARO-HSD), which the Company is responsible for completing, GSK is wholly responsible for clinical development and commercialization of ARO-HSD in its terr&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;itory.&#160;Under the terms of the agreement, Arrowhead will receive an upfront payment of $120 million and is eligible for additional payments of $30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to Arrowhead of up to $190 million at first commercial sale, and up to $590 million in sales-related milestone payments. Arrowhead is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent. The transactions contemplated under the GSK Agreement are subject to customary closing conditions, including clearance by the relevant competition authorities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119"
      id="F_000757">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119"
      decimals="0"
      id="F_000758"
      unitRef="U_utrsqft">144000</us-gaap:LandSubjectToGroundLeases>
    <arwr:LeaseCommencementMonthAndYear
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119_20211119"
      id="F_000759">2023-05</arwr:LeaseCommencementMonthAndYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119"
      decimals="-5"
      id="F_000760"
      unitRef="U_iso4217USD">119000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <arwr:EstimatedPaymentsForOperatingExpensesYearOne
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119"
      decimals="-5"
      id="F_000761"
      unitRef="U_iso4217USD">3000000.0</arwr:EstimatedPaymentsForOperatingExpensesYearOne>
    <arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119_20211119"
      decimals="-5"
      id="F_000762"
      unitRef="U_iso4217USD">31000000.0</arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119_20211119"
      id="F_000763">Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent</us-gaap:LesseeOperatingLeaseDescription>
    <arwr:NumberOfOptionsToRenew
      contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInSanDiegoMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211119"
      decimals="INF"
      id="F_000764"
      unitRef="U_arwrOption">1</arwr:NumberOfOptionsToRenew>
    <arwr:MilestonePaymentEarned
      contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122"
      decimals="-6"
      id="F_000766"
      unitRef="U_iso4217USD">120000000</arwr:MilestonePaymentEarned>
    <arwr:MilestonePaymentReceivableAtStartOfPhaseTwo
      contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122"
      decimals="-6"
      id="F_000767"
      unitRef="U_iso4217USD">30000000</arwr:MilestonePaymentReceivableAtStartOfPhaseTwo>
    <arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree
      contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122"
      decimals="-6"
      id="F_000768"
      unitRef="U_iso4217USD">100000000</arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree>
    <arwr:CommercialMilestonePaymentsAtFirstCommercialSale
      contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122"
      decimals="-6"
      id="F_000769"
      unitRef="U_iso4217USD">190000000</arwr:CommercialMilestonePaymentsAtFirstCommercialSale>
    <arwr:SalesRelatedMilestonePayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122"
      decimals="-6"
      id="F_000770"
      unitRef="U_iso4217USD">590000000</arwr:SalesRelatedMilestonePayments>
    <arwr:TieredRoyaltiesOnNetProductSalesReceiveDescription
      contextRef="C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122_20211122"
      id="F_000771">Arrowhead is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</arwr:TieredRoyaltiesOnNetProductSalesReceiveDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998770459576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 15, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARROWHEAD PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,525,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#8217;s 2022 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998770824904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 184,434<span></span>
</td>
<td class="nump">$ 143,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">10,255<span></span>
</td>
<td class="nump">846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">4,362<span></span>
</td>
<td class="nump">4,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,191<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">126,728<span></span>
</td>
<td class="nump">85,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments</a></td>
<td class="nump">56,627<span></span>
</td>
<td class="nump">86,890<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">384,597<span></span>
</td>
<td class="nump">322,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">48,675<span></span>
</td>
<td class="nump">30,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">13,663<span></span>
</td>
<td class="nump">15,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long term investments</a></td>
<td class="nump">245,595<span></span>
</td>
<td class="nump">137,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">17,346<span></span>
</td>
<td class="nump">16,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">710,148<span></span>
</td>
<td class="nump">522,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,457<span></span>
</td>
<td class="nump">6,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">14,001<span></span>
</td>
<td class="nump">5,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">9,773<span></span>
</td>
<td class="nump">8,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">111,055<span></span>
</td>
<td class="nump">19,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">146,536<span></span>
</td>
<td class="nump">40,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">23,295<span></span>
</td>
<td class="nump">20,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">131,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL LONG-TERM LIABILITIES</a></td>
<td class="nump">154,790<span></span>
</td>
<td class="nump">20,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 145,000 shares authorized; 104,327 and 102,376 shares issued and outstanding as of September 30, 2021 and September 30, 2020, respectively</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,053,386<span></span>
</td>
<td class="nump">965,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(69)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(644,692)<span></span>
</td>
<td class="num">(503,844)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">408,822<span></span>
</td>
<td class="nump">461,779<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 710,148<span></span>
</td>
<td class="nump">$ 522,504<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998766946264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">104,327,000<span></span>
</td>
<td class="nump">102,376,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">104,326,672<span></span>
</td>
<td class="nump">102,376,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998847824136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">REVENUE</a></td>
<td class="nump">$ 138,287<span></span>
</td>
<td class="nump">$ 87,992<span></span>
</td>
<td class="nump">$ 168,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 206,342<span></span>
</td>
<td class="nump">$ 128,875<span></span>
</td>
<td class="nump">$ 81,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">80,981<span></span>
</td>
<td class="nump">52,276<span></span>
</td>
<td class="nump">26,556<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">287,323<span></span>
</td>
<td class="nump">181,151<span></span>
</td>
<td class="nump">107,605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="num">(149,036)<span></span>
</td>
<td class="num">(93,159)<span></span>
</td>
<td class="nump">61,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">6,120<span></span>
</td>
<td class="nump">9,191<span></span>
</td>
<td class="nump">6,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">2,070<span></span>
</td>
<td class="num">(583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME (EXPENSE)</a></td>
<td class="nump">8,190<span></span>
</td>
<td class="nump">8,608<span></span>
</td>
<td class="nump">6,958<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="num">(140,846)<span></span>
</td>
<td class="num">(84,551)<span></span>
</td>
<td class="nump">68,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="num">$ (140,848)<span></span>
</td>
<td class="num">$ (84,553)<span></span>
</td>
<td class="nump">$ 67,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">NET INCOME (LOSS) PER SHARE - BASIC</a></td>
<td class="num">$ (1.36)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">NET INCOME (LOSS) PER SHARE - DILUTED</a></td>
<td class="num">$ (1.36)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic</a></td>
<td class="nump">103,745<span></span>
</td>
<td class="nump">100,722<span></span>
</td>
<td class="nump">93,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted</a></td>
<td class="nump">103,745<span></span>
</td>
<td class="nump">100,722<span></span>
</td>
<td class="nump">98,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (87)<span></span>
</td>
<td class="nump">$ 410<span></span>
</td>
<td class="num">$ (370)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE INCOME (LOSS)</a></td>
<td class="num">$ (140,935)<span></span>
</td>
<td class="num">$ (84,143)<span></span>
</td>
<td class="nump">$ 67,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998766740728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance, Amount at Sep. 30, 2018</a></td>
<td class="nump">$ 95,241<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 582,903<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">$ (487,266)<span></span>
</td>
<td class="num">$ (555)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, Amount</a></td>
<td class="nump">8,276<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">8,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock - issued for cash, Amount</a></td>
<td class="nump">60,521<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">60,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock - issued for cash, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">67,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance, Amount at Sep. 30, 2019</a></td>
<td class="nump">244,036<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">664,086<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="num">(419,291)<span></span>
</td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,506,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">43,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, Amount</a></td>
<td class="nump">7,469<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">7,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock - issued for cash, Amount</a></td>
<td class="nump">250,479<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">250,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock - issued for cash, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of Ablaris Therapeutics, Inc.</a></td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(84,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance, Amount at Sep. 30, 2020</a></td>
<td class="nump">461,779<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">965,410<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(503,844)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,376,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">76,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, Amount</a></td>
<td class="nump">$ 11,305<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">11,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="nump">1,051,344<span></span>
</td>
<td class="nump">1,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(140,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance, Amount at Sep. 30, 2021</a></td>
<td class="nump">$ 408,822<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 1,053,386<span></span>
</td>
<td class="num">$ (69)<span></span>
</td>
<td class="num">$ (644,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998855653304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (140,848)<span></span>
</td>
<td class="num">$ (84,553)<span></span>
</td>
<td class="nump">$ 67,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">76,673<span></span>
</td>
<td class="nump">43,383<span></span>
</td>
<td class="nump">12,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">8,267<span></span>
</td>
<td class="nump">5,942<span></span>
</td>
<td class="nump">4,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization/(accretion) of note premiums</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(9,409)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="num">(334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="num">(3,711)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,628<span></span>
</td>
<td class="num">(821)<span></span>
</td>
<td class="nump">4,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">9,522<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
<td class="nump">2,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">223,258<span></span>
</td>
<td class="num">(63,514)<span></span>
</td>
<td class="nump">82,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other</a></td>
<td class="nump">1,227<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</a></td>
<td class="nump">171,224<span></span>
</td>
<td class="num">(95,391)<span></span>
</td>
<td class="nump">173,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(23,567)<span></span>
</td>
<td class="num">(11,952)<span></span>
</td>
<td class="num">(12,001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(240,703)<span></span>
</td>
<td class="num">(278,964)<span></span>
</td>
<td class="num">(90,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sale of investments</a></td>
<td class="nump">122,592<span></span>
</td>
<td class="nump">50,138<span></span>
</td>
<td class="nump">54,521<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</a></td>
<td class="num">(141,678)<span></span>
</td>
<td class="num">(240,778)<span></span>
</td>
<td class="num">(47,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercises of stock options</a></td>
<td class="nump">11,305<span></span>
</td>
<td class="nump">7,469<span></span>
</td>
<td class="nump">8,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,479<span></span>
</td>
<td class="nump">60,522<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</a></td>
<td class="nump">11,305<span></span>
</td>
<td class="nump">257,948<span></span>
</td>
<td class="nump">66,382<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH</a></td>
<td class="nump">40,851<span></span>
</td>
<td class="num">(78,221)<span></span>
</td>
<td class="nump">191,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">143,583<span></span>
</td>
<td class="nump">221,804<span></span>
</td>
<td class="nump">30,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">184,434<span></span>
</td>
<td class="nump">143,583<span></span>
</td>
<td class="nump">221,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income Taxes (Paid)/Refunded</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="num">$ (302)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998763649944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1. <span style="font-style:italic;">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Nature of Business and Recent Developments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them.&#160;Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company&#8217;s pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-<span style="color:#000000;">LUNG2 for chronic obstructive pulmonary disorder, ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens</span> and ARO-C3 for complement mediated diseases<span style="color:#000000;">. ARO-XDH is being developed for uncontrolled gout under a collaboration agreement with Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;). ARO-JNJ2 and ARO-JNJ3 are being developed for undisclosed liver-expressed targets under a collaboration agreement with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;).&#160;&#160;JNJ-75220795 (ARO-JNJ1) is being developed by Janssen as a potential treatment for patients with non-alcoholic steatohepatitis (NASH).&#160;&#160;</span>ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) in October 2020. JNJ3989 (formerly referred to as ARO-HBV) <span style="color:#000000;">for chronic hepatitis B virus was out-licensed to Janssen in October 2018.&#160;&#160;</span>Olpasiran (formerly referred to as AMG 890 or ARO-LPA) <span style="color:#000000;">for cardiovascular disease was out-licensed to Amgen Inc. (&#8220;Amgen&#8221;) in 2016.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.58%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During fiscal year 2021, the Company continued to develop its pipeline and partnered candidates.&#160;&#160;The Company announced positive interim clinical data on (i) AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the Company&#8217;s second-generation investigational RNAi therapeutic being co-developed with Takeda as a treatment for the rare genetic liver disease associated with AATD, (ii) AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH), and (iii) AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma.&#160;&#160;The Company also presented preclinical data on the development of ARO-DUX4, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with facioscapulohumeral muscular dystrophy (FSHD), at the 28th&#160;Annual&#160;FSHD Society International Research Congress. The Company hosted a key opinion leader webinar on its cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, and presented positive clinical data from the Phase 1/2 clinical studies of ARO-APOC3 and ARO-ANG3 at the American Heart Association Scientific Sessions 2020.&#160;&#160;The Company filed two Investigational New Drug Applications with the United States Food and Drug Administration (the &#8220;FDA&#8221;) to begin a Phase 2b clinical study of ARO-APOC3 in patients with severe hypertriglyceridemia and a Phase 2b clinical study of ARO-ANG3 in patients with mixed dyslipidemia, and initiated these two Phase 2b clinical studies in the third quarter of fiscal year 2021. The Company also filed for regulatory clearance to begin a Phase 1/2a study of ARO-C3 for treatment of complement mediated diseases. In July 2021, the Company voluntarily paused AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis, after receiving a preliminary update from an ongoing chronic toxicology study in rats that contained unexpected signals of local lung inflammation.&#160;&#160;New screening, enrollment and any further dosing of investigational ARO-ENaC have been paused pending additional data from ongoing nonclinical toxicology studies.&#160;&#160;The Company announced two collaborations during fiscal year 2021: a collaboration with Takeda to co-develop and co-commercialize ARO-AAT for alpha-1 antitrypsin-associated liver disease and a collaboration with Horizon to develop ARO-XDH, an investigational RNAi therapeutic for uncontrolled gout. In July 2021, the Company received Breakthrough Therapy designation from the FDA for ARO-AAT, which is a process designed to expedite the development and review of drugs that are intended to treat a serious life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s partnered candidates under its collaboration agreements also continued to progress.&#160;&#160;Janssen began dosing patients in a Phase 2b triple combination study called REEF-1,&#160;designed to enroll up to 450 patients with chronic hepatitis B infection.&#160;&#160;The Company is currently performing discovery, optimization and preclinical research and development for ARO-JNJ2 and ARO-JNJ3 for Janssen as part of the Company&#8217;s Research Collaboration and Option Agreement with Janssen (&#8220;Janssen Collaboration Agreement&#8221;), and Janssen has began dosing patients in its Phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1).&#160;&#160;Amgen has initiated a Phase 2 clinical trial for Olpasiran (previously referred to as AMG 890 or ARO-LPA).&#160;&#160;The Company entered into two licensing deals during fiscal 2021: i) an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda for ARO-AAT, a<span style="color:#000000;">nd ii) a Collaboration and License Agreement (the &#8220;Horizon License Agreement&#8221;) with Horizon Therapeutics Ireland DAC </span></p>

<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">(&#8220;Horizon&#8221;) for ARO-XDH.&#160;&#160;ARO-AAT is currently in phase 2 clinical trials and ARO-XDH is in discovery-stage.&#160;&#160;During fiscal year 2021, the Company earned</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span>340.0<span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="color:#000000;"> in upfront payments from its collaboration agreements</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;">and </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span>20.0<span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million </span><span style="color:#000000;">in option and milestone payments. In total, the Company remains eligible fo</span><span style="color:#000000;">r</span><span style="color:#000000;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span>5.3<span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;">billion in developmental, regulatory and sales milestones and various royalties on net sales.&#160;&#160;The revenue recognition for these collaboration agreements is discussed further in Note 2 below</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead operates lab facilities in Madison, Wisconsin and San Diego, California, where the Company&#8217;s research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is actively monitoring the ongoing COVID-19 pandemic. The financial results for the years ended September 30, 2021 and 2020 were not significantly impacted by COVID-19. Operationally, the Company experienced delays in its earlier stage programs due to a shortage in non-human primates, which are critical to the Company&#8217;s preclinical programs.&#160;&#160;Additionally, the Company experienced delays in enrollment in its clinical trials.&#160;&#160;The Company&#8217;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters in Pasadena, California have continued with limited impact, other than for enhanced safety measures, including work from home policies, and intermittent lab supply shortages. However, the Company cannot predict the impact the progression of COVID-19 will have on future financial and operational results due to a variety of factors, including the ability of the Company&#8217;s clinical sites to continue to enroll subjects, the ability of the Company&#8217;s suppliers to continue to operate, the continued good health and safety of the Company&#8217;s employees and the length and severity of the COVID-19 pandemic.<span style="color:#000000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Consolidated Financial Statements have been prepared in conformity with the accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), which contemplate the continuation of the Company as a going concern.&#160; Historically, the Company&#8217;s primary sources of financing have been through the sale of its securities and revenue from its licensing and collaboration agreements.&#160;&#160;Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded significantly.&#160;&#160;Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials, as well as with the Company&#8217;s plans to increase its internal manufacturing capabilities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2021, the Company had $184.4 million in cash and cash equivalents (including $2.4 million in restricted cash), $56.6 million in short-term investments and $126.7 million in marketable securities, and $245.6 million in long-term investments to fund operations.&#160;&#160;During the year ended September 30, 2021, the Company&#8217;s cash and investments balance increased by $160.4 million, was primarily the result of the $300.0 million upfront payment from the Takeda License Agreement and the $40 million upfront payment from the Horizon License Agreement, partially offset by cash used to fund the Company&#8217;s research and development operations and general and administrative expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation&#8212;The Consolidated Financial Statements include the accounts of Arrowhead and its Subsidiaries.&#160;&#160;Arrowhead&#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#8217;s research and development facility is located.&#160;&#160;All significant intercompany accounts and transactions are eliminated in consolidation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation and Use of Estimates&#8212;The <span style="color:#000000;">preparation of financial statements in conformity GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation</span>.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents&#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&#160;&#160;Included within Cash and cash equivalents on the Consolidated Balance Sheets is $2.4 million and $1.8 restricted cash at September 30, 2021 and September 30, 2020, respectively.&#160;&#160;Amounts included in restricted cash are primarily held as collateral associated with a letter of credit for the Company&#8217;s <span style="color:#000000;">lease for its corporate headquarters in Pasadena, California.</span>&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk&#8212;The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments&#8212;The Company may invest excess cash balances in short-term and long-term marketable debt and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investments in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 320, Investments &#8211; Debt and Equity Securities and ASC 321, Investments in Equity Securities.&#160;ASC 320-Investments-Debt and Equity Securities requires debt securities to be classified into three categories: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-Maturity&#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Securities&#8212;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale&#8212;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of stockholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2021, 2020 and 2019, all of the Company&#8217;s debt securities were classified as held-to-maturity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity investments are measured and recorded at amortized cost on the Company&#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests in shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#8217;s Consolidated Balance Sheet as &#8220;marketable securities&#8221; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment&#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets Subject to Amortization&#8212;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration&#8212;The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $0 at September 30, 2021 and September 30, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212; <span style="color:#000000;">On October 1, 2018, the Company adopted FASB Topic 606 &#8211; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and </span></p>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">across all industries. The Company&#8217;s adoption of the revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#8217;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen, Takeda and Horizon, and the analysis of the impact of this guidance on those agreements is discussed further in </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note 2 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in our Consolidated Statements of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the Company determines that </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">goods or services promised in a contract</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> should be accounted for as a </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combined performance obligation over time</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> either</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the proportional performance method</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or on a straight-line basis if efforts will be expended evenly over time</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company determines that</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the performance </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligation is satisfied over time, any upfront</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> payment </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received is initially recorded </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deferred</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> revenue </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the Company&#8217;s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Consolidated Balance Sheets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#8217;s current operating plan and, if the Company&#8217;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborative Arrangements&#8212;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB Topic 808 - Collaborative Arrangements. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to Research and Development Expense or General and Administrative Expense, as appropriate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allowance for Doubtful Accounts&#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development&#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per Share&#8212;Basic net income (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees.&#160;&#160;During the years ended September 30, 2021, 2020 and 2019, the calculation of the effect of dilutive stock options and restricted stock units was 0 shares, 0 shares, and 4,748,958 shares, respectively.&#160;&#160;During the year ended September 30, 2021 and 2020,<span style="color:#000000;"> the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect. During the year ended September 30, 2019, the calculation of the effect of dilutive stock options and restricted stock units excluded 1,007,500 stock options and 11,500 restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;&#160;&#160;&#160;&#160; </span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation&#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes&#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.<span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases<span style="color:#000000;">&#8212;</span>The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its&#160;&#160;leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term.&#160;Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and became effective for the Company in the first quarter of fiscal 2019. In April 2016, the FASB issued an amendment to ASU No. 2014-09 with update ASU 2016-10 which provided more specific guidance around the identification of performance obligations and licensing arrangements.&#160;&#160;On October 1, 2018, the Company adopted this standard using the modified retrospective method. The Company&#8217;s implementation approach included reviewing the status of each of its ongoing license agreements and collaboration agreements and designing appropriate internal controls to enable the preparation of financial information.&#160;&#160;The Company completed its assessment of the impact of the new revenue recognition guidance and determined that there will be no material impact.&#160;&#160;The Company&#8217;s existing performance obligations under its ongoing license and collaboration agreements as of October 1, 2018 and prior were substantially completed prior to September 30, 2018.&#160;&#160;For these agreements that were ongoing as of October 1, 2018, any future option, milestone or royalty payments received will be accounted for under the sales-based royalty exception provided for under this new revenue recognition guidance.&#160;&#160;Additionally, there will be no impact to cash from or used in operating, financing or investing activities on the Company&#8217;s Consolidated Statement of Cash Flows as a result of the adoption of the new standard.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842).&#160;&#160;Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases).&#160;&#160;The Company adopted this standard effective October 1, 2019 and <span style="color:#000000;">elected the package of three practical expedients that permits an entity to i) not reassess whether expired or existing contracts contain leases, ii) not reassess lease classification for existing or expired leases, and iii) not consider whether previously capitalized initial direct costs would be appropriate under the new standard.&#160;&#160;At September 30, 2021, the Company has recorded right-of-use assets of $17.3 million and lease liabilities of $25.5 million on its Consolidated Balance Sheets for its research and development facility leases in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below.&#160;&#160;The adoption of this standard did not have a material impact on the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss) and the Company&#8217;s Consolidated Statements of Cash Flows.&#160;&#160; </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808).&#160;&#160;This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 became effective for the Company in the first quarter of fiscal 2021 with early adoption permitted.&#160;&#160;The adoption of this update did not have a material effect on the Company&#8217;s Consolidated Financial Statements. </p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998867584728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2. <span style="font-style:italic;">COLLABORATION AND LICENSE AGREEMENTS</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amgen Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;28, 2016, the Company entered into two collaboration and license agreements and a common stock purchase agreement with Amgen.&#160;&#160;Under the Second Collaboration and License Agreement or Olpasiran Agreement, Amgen has received a worldwide, exclusive license to Arrowhead&#8217;s novel, RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the other collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, and $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement.&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement.&#160;&#160;Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study for Olpasiran, which resulted in a $20 million milestone payment to the Company. During the years ended September 30, 2021, 2020 and 2019, the Company recognized $0, $20.1 million and $0.3 million of Revenue associated with its agreements with Amgen, respectively.  As of September 30, 2021, there were $0 in contract assets recorded as accounts receivable and $0 contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Janssen Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 3, 2018, the Company entered into the Janssen License Agreement and the Janssen Collaboration Agreement with Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson.&#160;&#160;The Company also entered into a stock purchase agreement with JJDC (&#8220;JJDC Stock Purchase Agreement&#8221;).&#160;&#160;Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company is responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989.&#160;&#160;Under the Janssen Collaboration Agreement, Janssen will be able to select three new targets against which Arrowhead will develop clinical candidates.&#160;&#160;These candidates are subject to certain restrictions and do not include candidates that already were in the Company&#8217;s pipeline.&#160;&#160;The Company will perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, is sufficient to allow the filing of a U.S. Investigational New Drug Application or equivalent, at which time Janssen will have the option to take an exclusive license. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned candidate.&#160;&#160;Under the terms of the agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment <span style="color:#000000;">by JJDC in Arrowhead Common Stock under the JJDC </span>Stock Purchase Agreement, and milestone and option payments totaling $70.0 million, and may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $1.9 billion in development and sales milestone payments for the three additional targets covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated these agreements in accordance with FASB Topics 808 &#8211; Collaboration Arrangements and 606 - Revenue for Contracts from Customers.&#160;&#160;At the inception of these agreements, the Company identified one distinct performance obligation.&#160;&#160;Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation.&#160;&#160;The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for this option is accounted for separately. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the transaction price totaled approximately $252.7 million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0 million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;D Services to be performed.&#160;&#160;The Company has allocated the total $252.7 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services.&#160;&#160;The Company has recognized this transaction price in its entirety as of September 30, 2021 as efforts on its performance obligation have been substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. During the years ended September 30, 2021, 2020 and 2019, the Company recognized approximately $20.2 million, $65.0 million, and $167.5 million of revenue associated with this performance obligation, respectively. As of September 30, 2021, there were $0.1 million in contract assets recorded as accounts receivable, and $0 of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has begun to conduct its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2 and ARO-JNJ3 under the Janssen Collaboration Agreement.&#160;&#160;All costs and labor hours spent by the Company will be entirely funded by Janssen.&#160; During the years ended September 30, 2021, 2020 and 2019, the Company recognized $0.5 million, $2.9 million and $1.0 million of revenue associated with these efforts, respectively.&#160;&#160;In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0 million milestone payment to the Company, and in September 2021, Janssen dosed its fifth patient in its phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1), which resulted in $10.0 million milestone payment to the Company. Each of these milestone payments was recognized entirely during the year ended September 30, 2021.&#160;&#160;As of September 30, 2021, there were $10.0 million of cont<span style="color:#000000;">ract assets recorded as accounts </span>receivable and $0 of contract liabilities recorded as curren<span style="color:#000000;">t deferred revenue on the Company&#8217;s Consolidated Balance</span> Sheets.&#160;The $10.0 million milestone payment for the dosing of the fifth patient in its Phase 1 clinical trial for JNJ-75220795 (ARO-JNJ1) was received in October 2021. <span style="color:#000000;"> &#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Takeda Pharmaceuticals U.S.A., Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 7, 2020, the Company entered into the Takeda License Agreement with Takeda.&#160;&#160;Under the Takeda License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales.&#160;&#160;In January 2021, the Company received $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.&#160;&#160;&#160;&#160;</span>&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the Takeda License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation.&#160;&#160;The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation.&#160;&#160;Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States.&#160;&#160;Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States.&#160;&#160;The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts will be recorded as Research and Development Expenses or General and Administrative Expenses, as appropriate. <span style="font-size:12pt;">&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the initial transaction price totaled $300.0 million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date.&#160;&#160;The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;D Services.&#160;&#160;Revenue will be recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). Revenue for the years ended September 30, 2021, 2020 and 2019 was $90.8 million, $0 and $0, respectively. As of September 30, 2021, there were $0 in contract assets recorded as accounts receivable, $84.4 million in contract liabilities recorded as deferred revenue, $124.8 million in contract liabilities recorded as deferred revenue, net of the current portion, and $3.1 million in contract liabilities recorded as accrued expenses.&#160;&#160;The $3.1 million in accrued expenses was primarily driven by co-development and co-commercialization activities. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Horizon Therapeutics Ireland DAC</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 18, 2021, the Company entered into the Horizon License Agreement with Horizon.&#160;&#160;Under the Horizon License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Horizon received a worldwide exclusive license for&#160;ARO-XDH,&#160;a previously undisclosed discovery-stage investigational </span></p>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;">RNAi therapeutic being developed by the Company as a potential treatment for people with uncontrolled gout. The Company will conduct all activities through the preclinical stages of development of&#160;ARO-XDH,&#160;and Horizon will be wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, the Company received $</span><span style="Background-color:#FFFFFF;color:#000000;">40</span><span style="Background-color:#FFFFFF;color:#000000;">&#160;million as an upfront payment and is eligible to receive up to $</span><span style="Background-color:#FFFFFF;color:#000000;">660</span><span style="Background-color:#FFFFFF;color:#000000;">&#160;million in potential development, regulatory and sales milestones.&#160;&#160;The Company is also eligible to receive royalties in the&#160;low-&#160;to&#160;mid-teens&#160;range on net product sales.&#160;&#160; </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the Horizon License Agreement in accordance with FASB Topics 808 &#8211; Collaborative Arrangements and 606 - Revenue for Contracts from Customers. At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation.&#160;&#160;The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#8220;Horizon R&amp;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation.&#160;&#160;Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the initial transaction price totaled $40.0 million, including the upfront payment.&#160;&#160;The Company has excluded any future estimated milestones or royalties, from this transaction price to date.&#160;&#160;The Company will allocate the total $40.0 million initial transaction price to its one distinct performance obligation for the ARO-XDH license and the associated Horizon R&amp;D Services.&#160;&#160;Revenue will be recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;D Services.&#160;&#160;The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the years ended September 30, 2021, 2020 and 2019, was $6.7 million, $0 and $0, respectively. As of September 30, 2021, there were $0.1 million in contract assets recorded as accounts receivable, $26.7 million in contract liabilities recorded as deferred revenue and $6.7 million in contract liabilities recorded as deferred revenue, net of the current portion.&#160;&#160;&#160;&#160; <span style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998764993864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 3. <span style="font-style:italic;">PROPERTY AND EQUIPMENT</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s major classes of property and equipment:<span style="font-size:11pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers, office equipment and furniture</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,661</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,654</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">509</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">631</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,869</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,238</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross fixed assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,539</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,185</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,864</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,675</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,881</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense for property and equipment for the years ended September 30, 2021, 2020, and 2019 was $6.6 million, $4.2 million and $2.7 million respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998860431560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Held To Maturity Securities Classified [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 4. <span style="font-style:italic;">INVESTMENTS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments at September 30, 2021 primarily consisted of corporate bonds that have maturities of less than 36 months, a certificate of deposit and marketable equity securities. The Company&#8217;s investments in corporate bonds consist of both short-term and long-term bonds and are classified as &#8220;held-to-maturity&#8221; on the Company&#8217;s Consolidated Balance Sheets. The Company&#8217;s certificate of deposit matures in less than 24 months and is classified as &#8220;held-to-maturity&#8221; on the Company&#8217;s Consolidated Balance Sheet.&#160;&#160;The Company&#8217;s marketable equity securities consist of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, corporate bonds and other asset-backed debt securities. Dividends from these funds are automatically reinvested.&#160;&#160;The Company may also invest excess cash balances in money market accounts, government-sponsored enterprise securities, and/or commercial paper.&#160;&#160;The Company accounts for its held to maturity investments in accordance with FASB ASC 320, Investments &#8211; Debt and Equity Securities and its marketable equity securities in accordance with ASC 321, Investments &#8211; Equity Securities.&#160;&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s short-term, long-term investments and marketable securities as of September 30, 2021 and September 30, 2020 by measurement category. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Held to Maturity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,430</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195,595</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196,643</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of deposit (due within two years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302,222</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,954</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304,073</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,890</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,590</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,487</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,574</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,982</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,377</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,164</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,462</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized Gains/(Losses)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,481</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(888</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,728</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,481</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(888</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized Gains/(Losses)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998763404056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5. <span style="font-style:italic;">INTANGIBLE ASSETS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The license agreement associated with the Novartis RNAi asset acquisition is being amortized over the estimated life remaining at the time of acquisition, which was 21 years, and the accumulated amortization of the asset is $1.0 million.&#160;&#160;The patents associated with the Novartis RNAi asset acquisition are being amortized over the estimated life remaining at the time of acquisition, which was 14 years, and the accumulated amortization of the assets is $10.2 million.&#160;&#160;Amortization expense for the years ended September 30, 2021, 2020, and 2019 was $1.7 million, $1.7 million and $1.7 million, respectively. Amortization expense is expected to be $1.7 million in 2022, $1.7 million in 2023, $1.7 million in 2024, $1.7 million in 2025, $1.7 million in 2026 and $5.2 million thereafter.</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides details on the Company&#8217;s intangible asset balances: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,363</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,663</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998765084040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6. <span style="font-style:italic;">STOCKHOLDERS&#8217; EQUITY</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2021, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2021, <span style="color:#000000;">104,326,672</span> shares of Common Stock were outstanding.&#160;&#160;At September 30, 2021, 15,228,479 shares of Common Stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under Arrowhead&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into an Open Market Sale Agreement (the &#8220;ATM Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s Common Stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At September 30, 2021, no shares have been issued under the ATM Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998763388168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7. <span style="font-style:italic;">COMMITMENTS AND CONTINGENCIES</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Litigation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business.&#160;&#160;If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss.&#160;&#160;There were no contingent liabilities recorded as of the year ended September 30, 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Technology License Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has licensed from third parties the rights to use certain technologies for its research and development&#160;activities,&#160;as well as in any products the Company may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. &#160;Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and upon certain sales level milestones. &#160;These milestone payments could amount to the mid to upper double-digit millions of dollars. During the year ended September 30, 2021, the Company did not incur any milestone payments. During the year ended September 30, 2020, the Company triggered $2.4 million of milestone payments related to the progression of the ARO-ENaC and ARO-HIF2 candidates. During the year ended September 30, 2019, the Company did not incur any milestone payments.&#160;&#160;In certain agreements, the Company may be required to make mid to high single-digit percentage royalty payments based on a percentage of the sales of the relevant products.<span style="font-size:12pt;">&#160;</span>&#160;&#160;&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998860434648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8. <span style="font-style:italic;">LEASES</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the Company entered into a lease for its corporate headquarters in Pasadena, California.&#160;&#160;The 91 month office building lease between the Company and 177 Colorado Owner, LLC is for approximately 24,000 square feet of office space located at 177 E. Colorado Blvd, Pasadena, California. &#160;The increased capacity of this new office space compared to the Company&#8217;s prior corporate headquarters will accommodate increased personnel as the Company&#8217;s pipeline of drug candidates expands and moves </p>

<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">closer to market.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease payments began on </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and are estimated to total</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> approximately</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span>8.7<span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million over the term</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:12pt;color:#000000;">&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease expires on </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 30</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2027</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has paid</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> approximately $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million for leasehold improvements, net of tenant improvement allowances.&#160;&#160;The lease contains an option to renew for </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> term of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">five years</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The exercise of this option was not determined to be reasonably certain and thus was not included in </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ease liabilities on the Company&#8217;s Consolidated Balance Sheet at</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> September</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 202</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 23, 2020, the Company entered into a lease expansion to add an additional approximately&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,000&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">square feet of office space at the same location for its corporate headquarters. Lease payments for the expansion began in&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 2021</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;and the lease for the expansion expires in&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 2027</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The lease payments for the expansion are expected to total $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.9&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million.&#160;&#160;The Company has paid approximately $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million of leasehold improvements, net of tenant improvement allowances, for the lease expansion.&#160;&#160;The increased capacity of this additional office space&#160;</span><span style="Background-color:#FFFFFF;">compared to the Company&#8217;s current corporate headquarters is intended to accommodate increased personnel as the Company&#8217;s pipeline of drug candidates continues to expand and move closer to ma</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rket.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the Company entered into a lease for its research facility in Madison, Wisconsin.&#160;&#160;The lease was for approximately 60,000 square feet of office and laboratory space and had an expiration date of September 30, 2026. The lease was amended in January 2019 and May 2020 to expand the rentable square feet by an additional 40,000 square feet and to extend the lease expiration date to September 30, 2031. Lease payments are estimated to total approximately $26.2 million for the term. <span style="Background-color:#FFFFFF;color:#000000;">The Company incurred approximately $11.0&#160;million of leasehold improvements for the additional 40,000 square feet, net of tenant improvement allowances.</span>&#160;<span style="color:#000000;">The lease contains two options to renew for two terms of five years. The exercise of these options were not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#8217;s Consolidated Balance Sheet at September 30, 2021. In November 2020 and December 2020, the Company entered into amendments to expand the rentable square space by an additional&#160;10,743&#160;square feet and these amendments added a total of approximately $1.2&#160;million of lease payments for the remainder of the term.&#160;</span> &#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with Halozyme, Inc. for additional research and development facility space in San Diego, California.&#160; The Sublease provides additional space needed to accommodate the recent growth of the Company&#8217;s personnel and discovery efforts. The sublease is for approximately <span style="Background-color:#FFFFFF;color:#000000;">21,000</span> rentable square feet.&#160; The term of the Sublease commenced on April 1, 2020 and will end on January 14, 2023.&#160;&#160;Sublease payments are estimated to total approximately $2.0 million over the term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost during the years ended September 30, <span style="color:#000000;">2021, 2020 and 2019 </span>was $5.1 million, $2.4 million and $1.3 million respectively.&#160;&#160;Variable lease costs during the year ended September 30, 2021, 2020, and 2019 were $0.8 million, $0.8 million and $0.5 million respectively.&#160;&#160;There was no short-term lease cost during the years ended September 30, <span style="color:#000000;">2021, 2020 and 2019</span>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September 30, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,708</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,786</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,621</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,749</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,050</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027 and thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,200</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,114</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,569</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities (includes current portion)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,545</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for the amounts included in the measurement of the operating lease liabilities on the Company&#8217;s Consolidated Balance Sheet and included in Other changes in operating assets and liabilities within cash flows from operating activities on the Company&#8217;s Consolidated Statements of Cash Flow for the years ended September 30, 2021, 2020 and 2019 were $3.1 million, $1.8 million and $1.3 million, respectively.&#160;The weighted-average remaining lease term and weighted-average discount rate for all leases as of September 30, 2021 was <span style="color:#000000;">8 years</span> and 8.5%, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998763659608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 9. <span style="font-style:italic;">STOCK-BASED COMPENSATION</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan and 2013 Incentive Plan, as of September 30, 2021, 429,141 and 5,225,983 shares, respectively, of Arrowhead&#8217;s Common Stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others. No further grants may be made under the 2004 Equity Incentive Plan.&#160;&#160;As of September 30, 2021, there were options granted and outstanding to purchase 429,141 and 2,066,533 shares of Common Stock under the 2004 Equity Incentive Plan </p>

<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the 2013 Incentive Plan, respectively, and there were </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,159,450</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> restricted stock units granted and outstanding under the 2013 Incentive Plan. Also, as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, there were </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">957,565</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares reserved for options and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602,000 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares reserved for restricted stock units issued as inducement grants to new employees </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">granted outside of the Company&#8217;s equity-based compensation plans </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under Rule 5635(c)(4) of the N</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">asdaq</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Listing Rules</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 18, 2021, the Company&#8217;s stockholders approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (&#8220;2021 Incentive Plan&#8221;), which authorizes </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,000,000</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of Arrowhead&#8217;s Common Stock. The maximum number of shares authorized under the 2021 Incentive Plan will be (</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) reduced by any shares subject to awards made under the 2013 Incentive Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Incentive Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021, there were options granted and outstanding to purchase </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of Common Stock and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,400</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> restricted stock units granted and outstanding under the 2021 Incentive Plan.&#160;&#160;As of September 30, 2021, the total number of authorized shares under the 2021 Incentive Plan was </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,013,790</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares, which includes </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,190</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares that were forfeited under the 2013 Incentive Plan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,539,403</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.67</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65.57</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(217,820</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,051,344</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September 30, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,456,239</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000620">5.56</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,501,055</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable At September 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,510,091</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.23</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000621">4.58</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,302,948</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense related to stock options for the years ended September 30, 2021, 2020, and 2019 was $12.4 million, $9.7 million and $4.0 million, respectively.  For non-qualified stock options, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant date fair value of the options granted by the Company for the years ended September 30, 2021, 2020, and 2019 was $9.0 million, $34.6 million and $12.1 million, respectively.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intrinsic value of the options exercised during the years ended September 30, 2021, 2020, and 2019 was $66.9 million, $44.1 million and $24.6 million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $26.3 million will be recognized in the Company&#8217;s results of operations over a weighted average period of <span><span style="color:#000000;">2.4 </span>years</span>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value stock options are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years&#160;ended&#160;September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000635">0.4 &#8211; 1.1%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000636">0.4 &#8211; 1.8%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000637">1.50 &#8211; 3.1%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.2 &#8211; 90.4%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90.0 &#8211; 92.0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000646">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000647">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000648">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant date fair value per share of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.64</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36.35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The dividend yield is zero as the Company currently does not pay a dividend. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk-free interest rate is based on that of the U.S. Treasury bond. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility is estimated based on volatility average of the Company&#8217;s Common Stock price. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units (&#8220;RSUs&#8221;), including time-based and performance-based awards, have been granted under the Company&#8217;s 2013 Incentive Plan, 2021 Incentive Plan, and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans.  At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s Common Stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity of the Company&#8217;s RSUs:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September&#160;30, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,524,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,672,350</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.34</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(899,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.65</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(465,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.91</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September 30, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,831,850</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61.24</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended September 30, 2021, 2020 and 2019, the Company recorded $64.2 million, $33.7 million and $8.4 million of expense related to RSUs, respectively. Such expense is included in stock-based compensation expense in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss). For RSUs, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For RSUs, the grant date fair value of the award is based on the Company&#8217;s closing stock price at the grant date, with consideration given to the probability of achieving performance conditions for performance-based awards. The grant date fair value of the RSUs granted by the Company for the years ended September 30, 2021, 2020 and 2019 was $127.7 million, $149.4 million and $17.8 million, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021, the pre-tax compensation expense for all unvested RSUs in the amount of $118.0 million will be recognized in the Company&#8217;s results of operations over a weighted average period of 2.7 years.  Unvested RSUs that we have deemed not probable of vesting as of September 30, 2021, have the potential of generating an additional $35.7 million of pre-tax compensation expense if we deem them probable of vesting in a future reporting period.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998765053128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 10. <span style="font-style:italic;">FAIR VALUE MEASUREMENTS</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level&#160;1 provides the most reliable measure of fair value while Level&#160;3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&#8217;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes fair value measurements at September 30, 2021 and September&#160;30, 2020 for assets and liabilities measured at fair value on a recurring basis.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,434</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,434</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (held to maturity)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,430</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,430</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (held to maturity)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,643</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,643</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, <span style="color:#000000;">2020</span>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,583</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,583</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (held to maturity)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (held to maturity)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,982</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,982</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a liability for contingent consideration related to its acquisition of the Roche RNAi business completed in 2011. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s assumptions and experience. Estimating timing to complete the development and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining FDA and other regulatory approvals. In determining the probability of regulatory approval and commercial success, the Company utilizes data regarding similar milestone events from several sources, including industry studies and its own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. In November 2016, the Company announced the discontinuation of its clinical trial efforts for ARC-520, ARC-AAT and ARC-521.&#160;&#160;Given this development, the Company assessed the fair value of its contingent consideration obligation to be $0 at September 30, 2021 and September 30, 2020.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998769691048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 11. <span style="font-style:italic;">INCOME TAXES</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes the guidance issued by the FASB for accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and </p>

<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of the net deferred tax asset (liability) at September 30, 2021 and 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued Compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,371</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,086</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,454</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,937</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized Research &amp; Development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">California Alternative Minimum Tax</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Operating Losses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,562</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,818</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,702</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of Use Assets/Lease Liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,938</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,016</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital Loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216,259</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,080</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(194,255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(156,604</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,547</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,929</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,004</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,476</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company may not realize the benefit of all of its deferred tax assets. Accordingly, management has provided a 100% valuation allowance against its deferred tax assets until such time as management believes that its projections of future profits as well as expected future tax rates make the realization of these deferred tax assets more-likely-than-not. Significant judgment is required in the evaluation of deferred tax benefits and differences in future results from our estimates could result in material differences in the realization of these assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax asset in accordance with FASB ASC 740-10, &#8220;Accounting for Income Taxes.&#8221; This assessment included the evaluation of scheduled reversals of deferred tax liabilities, the availability of carry forwards and estimates of projected future taxable income.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2021, the Company had available gross federal net operating loss (&#8220;NOL&#8221;) carry forwards of approximately $<span style="color:#000000;">569.0</span> million and gross state NOL carry forwards of $<span style="color:#000000;">626.5&#160;</span>million. The NOLs expire at various dates through 2041.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions for income taxes for the years ended September 30, 2021 and 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total State</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision from income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended September 30, 2021 and 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At U.S. federal statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal effect</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-7.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-7.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-1.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-13.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark-to-market adjustments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-2.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">True-up on deferred taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax rate change</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense.&#160;&#160;The Company has not recognized any unrecognized tax benefits and does not have any interest or penalties related to uncertain tax positions as of September 30, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns with the Internal Revenue Service (&#8220;IRS&#8221;), the state of California and certain other taxing jurisdictions. The Company is subject to income tax examinations by the IRS and by state tax authorities until the net operating losses are settled.&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998860431560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 12. <span style="font-style:italic;">EMPLOYEE BENEFIT PLANS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2005, the Company adopted a defined contribution 401(k) retirement savings plan covering substantially all of its employees. The Plan is administered under the &#8220;safe harbor&#8221; provision of ERISA. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to 100% of each participant&#8217;s first 3% of compensation contributed plus 50% of each participant&#8217;s next 2% of compensation contributed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended September&#160;30, 2021, 2020, and 2019, the Company recorded expenses under this plan of $1.3 million, $0.9 million and $0.5 million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the employee benefit plans described above, the Company provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998769691048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 13. <span style="font-style:italic;">SUBSEQUENT EVENTS</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">San Diego Lease Agreement with ARE-SD Region No. 72 LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 19, 2021, the Company entered into a new lease for a San Diego, California research facility.&#160;&#160;The 15-year lease is for approximately 144,000 square feet of office and research and development laboratory space to be constructed in San Diego, California.&#160; This lease will replace the Company&#8217;s current research facility sublease for property located in San Diego, California.&#160;&#160;The increased capacity of this new facility compared to the Company&#8217;s current research facility in San Diego will accommodate increased personnel for the Company&#8217;s expanding pipeline of current and future drug candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated rent commencement date for the lease is in May 2023 after construction and leasehold improvements have been completed.&#160; The lease payments, which begin on the rent commencement date, will be approximately <span style="color:#000000;">$119.0</span> million over the initial 15-year term.&#160;&#160;The Company also estimates payments for operating expenses to be approximately $<span style="color:#000000;">3.0</span> million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $<span style="color:#000000;">31.0</span> million for leasehold improvements, net of tenant improvement allowances.&#160;&#160;Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional <span style="-sec-ix-hidden:F_000765">ten-year</span> term, with certain annual increases in base rent.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<hr style="page-break-after:always"/>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive License Agreement with Glaxosmithkline Intellectual Property (No. 3) Limited</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 22, 2021, the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;) with Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;).&#160; Under the GSK License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">GSK has received an exclusive license for&#160;ARO-HSD,&#160;the Company&#8217;s investigational RNAi therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).&#160; The exclusive license is worldwide with the exception of greater China, for which the Company will retain rights to develop and commercialize.&#160; </span>Beyond the Company&#8217;s Phase 1/2 study of (ARO-HSD), which the Company is responsible for completing, GSK is wholly responsible for clinical development and commercialization of ARO-HSD in its terr<span style="Background-color:#FFFFFF;color:#000000;">itory.&#160;Under the terms of the agreement, Arrowhead will receive an upfront payment of $120 million and is eligible for additional payments of $30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to Arrowhead of up to $190 million at first commercial sale, and up to $590 million in sales-related milestone payments. Arrowhead is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent. The transactions contemplated under the GSK Agreement are subject to customary closing conditions, including clearance by the relevant competition authorities.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998766631192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation&#8212;The Consolidated Financial Statements include the accounts of Arrowhead and its Subsidiaries.&#160;&#160;Arrowhead&#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#8217;s research and development facility is located.&#160;&#160;All significant intercompany accounts and transactions are eliminated in consolidation. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation and Use of Estimates&#8212;The <span style="color:#000000;">preparation of financial statements in conformity GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation</span>.&#160;&#160; </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents&#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&#160;&#160;Included within Cash and cash equivalents on the Consolidated Balance Sheets is $2.4 million and $1.8 restricted cash at September 30, 2021 and September 30, 2020, respectively.&#160;&#160;Amounts included in restricted cash are primarily held as collateral associated with a letter of credit for the Company&#8217;s <span style="color:#000000;">lease for its corporate headquarters in Pasadena, California.</span>&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk&#8212;The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments&#8212;The Company may invest excess cash balances in short-term and long-term marketable debt and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investments in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 320, Investments &#8211; Debt and Equity Securities and ASC 321, Investments in Equity Securities.&#160;ASC 320-Investments-Debt and Equity Securities requires debt securities to be classified into three categories: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-Maturity&#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Securities&#8212;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale&#8212;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of stockholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2021, 2020 and 2019, all of the Company&#8217;s debt securities were classified as held-to-maturity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity investments are measured and recorded at amortized cost on the Company&#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests in shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#8217;s Consolidated Balance Sheet as &#8220;marketable securities&#8221; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss). </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment&#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets subject to amortization</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets Subject to Amortization&#8212;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration&#8212;The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $0 at September 30, 2021 and September 30, 2020. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212; <span style="color:#000000;">On October 1, 2018, the Company adopted FASB Topic 606 &#8211; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and </span></p>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">across all industries. The Company&#8217;s adoption of the revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#8217;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen, Takeda and Horizon, and the analysis of the impact of this guidance on those agreements is discussed further in </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note 2 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in our Consolidated Statements of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the Company determines that </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">goods or services promised in a contract</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> should be accounted for as a </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combined performance obligation over time</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> either</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the proportional performance method</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or on a straight-line basis if efforts will be expended evenly over time</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company determines that</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the performance </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligation is satisfied over time, any upfront</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> payment </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received is initially recorded </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deferred</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> revenue </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the Company&#8217;s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Consolidated Balance Sheets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#8217;s current operating plan and, if the Company&#8217;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangement</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborative Arrangements&#8212;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB Topic 808 - Collaborative Arrangements. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to Research and Development Expense or General and Administrative Expense, as appropriate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Allowance for Doubtful Accounts</a></td>
<td class="text">Allowance for Doubtful Accounts&#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development&#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Share</a></td>
<td class="text">Net Income (Loss) per Share&#8212;Basic net income (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees.&#160;&#160;During the years ended September 30, 2021, 2020 and 2019, the calculation of the effect of dilutive stock options and restricted stock units was 0 shares, 0 shares, and 4,748,958 shares, respectively.&#160;&#160;During the year ended September 30, 2021 and 2020,<span style="color:#000000;"> the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect. During the year ended September 30, 2019, the calculation of the effect of dilutive stock options and restricted stock units excluded 1,007,500 stock options and 11,500 restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;&#160;&#160;&#160;&#160; </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation&#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes&#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases<span style="color:#000000;">&#8212;</span>The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its&#160;&#160;leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term.&#160;Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and became effective for the Company in the first quarter of fiscal 2019. In April 2016, the FASB issued an amendment to ASU No. 2014-09 with update ASU 2016-10 which provided more specific guidance around the identification of performance obligations and licensing arrangements.&#160;&#160;On October 1, 2018, the Company adopted this standard using the modified retrospective method. The Company&#8217;s implementation approach included reviewing the status of each of its ongoing license agreements and collaboration agreements and designing appropriate internal controls to enable the preparation of financial information.&#160;&#160;The Company completed its assessment of the impact of the new revenue recognition guidance and determined that there will be no material impact.&#160;&#160;The Company&#8217;s existing performance obligations under its ongoing license and collaboration agreements as of October 1, 2018 and prior were substantially completed prior to September 30, 2018.&#160;&#160;For these agreements that were ongoing as of October 1, 2018, any future option, milestone or royalty payments received will be accounted for under the sales-based royalty exception provided for under this new revenue recognition guidance.&#160;&#160;Additionally, there will be no impact to cash from or used in operating, financing or investing activities on the Company&#8217;s Consolidated Statement of Cash Flows as a result of the adoption of the new standard.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842).&#160;&#160;Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases).&#160;&#160;The Company adopted this standard effective October 1, 2019 and <span style="color:#000000;">elected the package of three practical expedients that permits an entity to i) not reassess whether expired or existing contracts contain leases, ii) not reassess lease classification for existing or expired leases, and iii) not consider whether previously capitalized initial direct costs would be appropriate under the new standard.&#160;&#160;At September 30, 2021, the Company has recorded right-of-use assets of $17.3 million and lease liabilities of $25.5 million on its Consolidated Balance Sheets for its research and development facility leases in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below.&#160;&#160;The adoption of this standard did not have a material impact on the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss) and the Company&#8217;s Consolidated Statements of Cash Flows.&#160;&#160; </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808).&#160;&#160;This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 became effective for the Company in the first quarter of fiscal 2021 with early adoption permitted.&#160;&#160;The adoption of this update did not have a material effect on the Company&#8217;s Consolidated Financial Statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and use of estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contingent consideration obligations related to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998763691272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s major classes of property and equipment:<span style="font-size:11pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers, office equipment and furniture</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,661</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,654</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">509</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">631</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,869</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,238</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross fixed assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,539</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,185</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,864</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,675</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,881</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998765082376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Held To Maturity Securities Classified [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock', window );">Summary of Short-term, Long-term Investments and Marketable Securities</a></td>
<td class="text">

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s short-term, long-term investments and marketable securities as of September 30, 2021 and September 30, 2020 by measurement category. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Held to Maturity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,430</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195,595</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196,643</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of deposit (due within two years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302,222</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,954</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304,073</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,890</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,590</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,487</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,574</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,982</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,377</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,164</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,462</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized Gains/(Losses)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,481</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(888</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,728</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,481</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(888</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized Gains/(Losses)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998765153992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides details on the Company&#8217;s intangible asset balances: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,363</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,663</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998770342328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September 30, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,708</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,786</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,621</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,749</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,050</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027 and thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,200</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,114</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,569</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities (includes current portion)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,545</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998763398296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized Information about Stock Options</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,539,403</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.67</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65.57</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(217,820</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,051,344</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September 30, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,456,239</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000620">5.56</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,501,055</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable At September 30, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,510,091</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.23</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000621">4.58</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,302,948</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Stock Options</a></td>
<td class="text">

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value stock options are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years&#160;ended&#160;September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000635">0.4 &#8211; 1.1%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000636">0.4 &#8211; 1.8%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000637">1.50 &#8211; 3.1%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.2 &#8211; 90.4%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90.0 &#8211; 92.0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000646">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000647">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000648">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant date fair value per share of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.64</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36.35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Share Activity Related to RSUs</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity of the Company&#8217;s RSUs:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September&#160;30, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,524,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,672,350</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.34</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(899,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.65</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(465,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.91</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September 30, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,831,850</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61.24</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998855666728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes fair value measurements at September 30, 2021 and September&#160;30, 2020 for assets and liabilities measured at fair value on a recurring basis.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,434</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,434</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (held to maturity)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,430</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,430</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (held to maturity)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,643</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,643</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, <span style="color:#000000;">2020</span>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,583</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,583</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (held to maturity)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (held to maturity)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,982</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,982</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998763684248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Net Deferred Tax (Liability)</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of the net deferred tax asset (liability) at September 30, 2021 and 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued Compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,371</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,086</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,454</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,937</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized Research &amp; Development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">California Alternative Minimum Tax</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Operating Losses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,562</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,818</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,702</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of Use Assets/Lease Liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,938</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,016</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital Loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216,259</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,080</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(194,255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(156,604</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,547</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,929</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,004</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,476</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provisions for Income Taxes</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions for income taxes for the years ended September 30, 2021 and 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total State</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision from income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Effective Income Tax Rate Reconciliation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended September 30, 2021 and 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At U.S. federal statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal effect</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-7.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-7.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-1.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-13.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark-to-market adjustments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-2.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">True-up on deferred taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax rate change</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998767284440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Oct. 03, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,434,000<span></span>
</td>
<td class="nump">$ 143,583,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,627,000<span></span>
</td>
<td class="nump">86,890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,595,000<span></span>
</td>
<td class="nump">137,487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_IncreaseDecreaseInCashAndInvestments', window );">Net increase (decrease) in cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Fair value of contingent consideration obligation due to discontinuation of clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Calculation of effect of dilutive stock options and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,748,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,346,000<span></span>
</td>
<td class="nump">$ 16,137,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Right-of-use liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU No. 2014-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU No. 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member', window );">ASU No. 2018-18</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded for calculation of effect of dilutive stock options and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,007,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded for calculation of effect of dilutive stock options and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Amount insured in FDIC per account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderAgreement', window );">Cash received as due under agreement</a></td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Horizon License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderAgreement', window );">Cash received as due under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderAgreement', window );">Cash received as due under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IncreaseDecreaseInCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in cash and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_IncreaseDecreaseInCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998767243656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 28, 2016 </div>
<div>USD ($) </div>
<div>Agreement</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,479,000<span></span>
</td>
<td class="nump">$ 60,522,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,287,000<span></span>
</td>
<td class="nump">$ 87,992,000<span></span>
</td>
<td class="nump">$ 168,796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,055,000<span></span>
</td>
<td class="nump">$ 19,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements | Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">Sep. 28,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfAgreements', window );">Number of agreements | Agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember', window );">Olpasiran Agreement | Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember', window );">Olpasiran Agreement | Amgen | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments', window );">Additional remaining development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseCollaborationAndStockPurchaseAgreementMember', window );">License Collaboration And Stock Purchase Agreement | Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember', window );">Olpasiran and ARO-AMG1 Agreement | Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional remaining development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseCollaborationAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseCollaborationAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998768295464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 03, 2018 </div>
<div>USD ($) </div>
<div>Target </div>
<div>Obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,479,000<span></span>
</td>
<td class="nump">$ 60,522,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,287,000<span></span>
</td>
<td class="nump">87,992,000<span></span>
</td>
<td class="nump">168,796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,055,000<span></span>
</td>
<td class="nump">19,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 252,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">Oct.  03,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Research Collaboration and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">Oct.  03,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments', window );">Number of additional targets for development, regulatory and sales milestone payments | Target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | J N J3989 A R O H B V Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | Obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,200,000<span></span>
</td>
<td class="nump">65,000,000.0<span></span>
</td>
<td class="nump">167,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-75220795 (ARO-JNJ1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-75220795 (ARO-JNJ1) | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">JJDC | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">Oct.  03,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">Janssen | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional targets for development, regulatory and sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_ResearchCollaborationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_ResearchCollaborationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ75220795AROJNJ1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ75220795AROJNJ1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998860659864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 07, 2020 </div>
<div>USD ($) </div>
<div>Obligation </div>
<div>Bundle</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,287<span></span>
</td>
<td class="nump">$ 87,992<span></span>
</td>
<td class="nump">$ 168,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,055<span></span>
</td>
<td class="nump">19,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">Oct.  07,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_RatioOfProfitSharingStructureForCommercialization', window );">Ratio of Profit Sharing Structure for United States Commercialization</a></td>
<td class="text">50/50 profit sharing<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | Bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | Obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | Minimum [Member] | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | Maximum | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 740,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash receivable as upfront payment due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RatioOfProfitSharingStructureForCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of profit sharing structure for commercialization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RatioOfProfitSharingStructureForCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=arwr_DeferredRevenueCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=arwr_DeferredRevenueCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998925464936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 18, 2021 </div>
<div>USD ($) </div>
<div>Obligation </div>
<div>Bundle</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,287<span></span>
</td>
<td class="nump">$ 87,992<span></span>
</td>
<td class="nump">$ 168,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,055<span></span>
</td>
<td class="nump">19,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | ARO-XDH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">Jun. 18,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | Obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | Bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | Obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | Maximum | ARO-XDH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="nump">$ 660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash receivable as upfront payment due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROXDHAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROXDHAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998763479032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Computers, office equipment and furniture</a></td>
<td class="nump">$ 1,661<span></span>
</td>
<td class="nump">$ 662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ResearchEquipmentGross', window );">Research equipment</a></td>
<td class="nump">27,500<span></span>
</td>
<td class="nump">20,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Software</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">41,869<span></span>
</td>
<td class="nump">25,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total gross fixed assets</a></td>
<td class="nump">71,539<span></span>
</td>
<td class="nump">47,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(22,864)<span></span>
</td>
<td class="num">(16,304)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 48,675<span></span>
</td>
<td class="nump">$ 30,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research equipment gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998763692392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense for property and equipment</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998847882744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held to Maturity, Amortized Cost</a></td>
<td class="nump">$ 302,222<span></span>
</td>
<td class="nump">$ 224,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held to Maturity, Gross Unrealized Gains</a></td>
<td class="nump">1,954<span></span>
</td>
<td class="nump">6,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held to Maturity, Gross Unrealized Losses</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to Maturity, Fair Value</a></td>
<td class="nump">304,073<span></span>
</td>
<td class="nump">230,462<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Marketable Securities, Amortized Cost</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax', window );">Marketable Securities, Realized Gains/(Losses)</a></td>
<td class="nump">2,481<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable Securities, Gross Unrealized Gains</a></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Gross Unrealized Losses</a></td>
<td class="num">(888)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable Securities, Fair Value</a></td>
<td class="nump">126,728<span></span>
</td>
<td class="nump">85,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=arwr_CertificateOfDepositsDueWithinTwoYearsMember', window );">Certificate Of Deposit Due Within Two Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held to Maturity, Amortized Cost</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to Maturity, Fair Value</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneYearMember', window );">Commercial Note Due Within One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held to Maturity, Amortized Cost</a></td>
<td class="nump">56,627<span></span>
</td>
<td class="nump">86,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held to Maturity, Gross Unrealized Gains</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">1,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to Maturity, Fair Value</a></td>
<td class="nump">57,430<span></span>
</td>
<td class="nump">88,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneThroughThreeYearsMember', window );">Commercial Note Due Within One Through Three Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held to Maturity, Amortized Cost</a></td>
<td class="nump">195,595<span></span>
</td>
<td class="nump">137,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held to Maturity, Gross Unrealized Gains</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">4,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held to Maturity, Gross Unrealized Losses</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to Maturity, Fair Value</a></td>
<td class="nump">196,643<span></span>
</td>
<td class="nump">141,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=arwr_MarketableSecuritiesMember', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Marketable Securities, Amortized Cost</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax', window );">Marketable Securities, Realized Gains/(Losses)</a></td>
<td class="nump">2,481<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable Securities, Gross Unrealized Gains</a></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Gross Unrealized Losses</a></td>
<td class="num">(888)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable Securities, Fair Value</a></td>
<td class="nump">$ 126,728<span></span>
</td>
<td class="nump">$ 85,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities FV NI accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities FV NI accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities FvNi accumulated gross realized gain loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=arwr_CertificateOfDepositsDueWithinTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=arwr_CertificateOfDepositsDueWithinTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneThroughThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneThroughThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998765374312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization of license agreements in 2022</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization of license agreements in 2023</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization of license agreements in 2024</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization of license agreements in 2025</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Amortization of license agreements in 2026</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Amortization of license agreements, thereafter</a></td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible assets</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible assets</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=arwr_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998769930312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Net Excluding Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, beginning balance</a></td>
<td class="nump">$ 15,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets subject to amortization, Amortization</a></td>
<td class="num">(1,700)<span></span>
</td>
<td class="num">$ (1,700)<span></span>
</td>
<td class="num">$ (1,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, ending balance</a></td>
<td class="nump">$ 13,663<span></span>
</td>
<td class="nump">$ 15,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998847658344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Capital stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,326,672<span></span>
</td>
<td class="nump">102,376,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued to institutional investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">ATM Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock shares value reserved for future issuance</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock', window );">Percentage of commission to sales agent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember', window );">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common Stock, Share reserve for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,228,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on aggregate gross proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998859601768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember', window );">Technology License Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember', window );">Technology License Commitments | ARO-ENaC and ARO-HIF2 Candidates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROENacAndAROHIF2CandidatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROENacAndAROHIF2CandidatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998768196968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Option</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Option</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California | Halozyme, Inc. | Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases, in square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 14,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_SubleaseCommencementDate', window );">Sublease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases, in square feet | ft&#178;</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Payments for leasehold improvements, net of tenant improvement allowances</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_LeaseExpansionCommencementMonthAndYear', window );">Lease expansion commencement period</a></td>
<td class="text">2021-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_LeaseExpansionExpirationMonthAndYear', window );">Lease expansion expiration month and year</a></td>
<td class="text">2027-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California | Colorado Owner, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases, in square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_LeasePaymentsCommencementDate', window );">Lease payments, commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Payments for leasehold improvements, net of tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember', window );">Research Facility in Madison | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases, in square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AdditionalLandSubjectToLease', window );">Additional office space for lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Expected leasehold improvements, net of tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalLandSubjectToLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional land subject to lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalLandSubjectToLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected payments of leasehold improvements, net of tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LeaseExpansionCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expansion commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LeaseExpansionCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LeaseExpansionExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expansion expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LeaseExpansionExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LeasePaymentsCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease payments commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LeasePaymentsCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to renew.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of leasehold improvements net of tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SubleaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SubleaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_HalozymeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_HalozymeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998770523256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 4,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">4,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">4,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">5,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2027 and thereafter</a></td>
<td class="nump">13,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">37,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(11,569)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities (includes current portion)</a></td>
<td class="nump">$ 25,545<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998767457144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">3,456,239<span></span>
</td>
<td class="nump">4,539,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">RSU awards vesting, description</a></td>
<td class="text">At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s Common Stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod', window );">Grant date fair value of the options granted</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">34.6<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">66.9<span></span>
</td>
<td class="nump">44.1<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 26.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 64.2<span></span>
</td>
<td class="nump">33.7<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod', window );">Grant date fair value of the options granted</a></td>
<td class="nump">$ 127.7<span></span>
</td>
<td class="nump">$ 149.4<span></span>
</td>
<td class="nump">$ 17.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 118.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Additional unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 35.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
<td class="nump">429,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">429,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
<td class="nump">5,225,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited</a></td>
<td class="nump">87,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">2,066,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of restricted stock units outstanding</a></td>
<td class="nump">3,159,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember', window );">Outside Of Equity Compensation Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
<td class="nump">957,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember', window );">Outside Of Equity Compensation Plans | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
<td class="nump">602,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">8,013,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of restricted stock units outstanding</a></td>
<td class="nump">70,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards additional compensation cost not yet recognized share based awards other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant date fair value of the options granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998847797912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summarize Information about Stock Options (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, beginning balance | shares</a></td>
<td class="nump">4,539,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Outstanding, Granted | shares</a></td>
<td class="nump">186,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options Outstanding, Cancelled | shares</a></td>
<td class="num">(217,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Outstanding, Exercised | shares</a></td>
<td class="num">(1,051,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, ending balance | shares</a></td>
<td class="nump">3,456,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable | shares</a></td>
<td class="nump">2,510,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, beginning balance | $ / shares</a></td>
<td class="nump">$ 16.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Granted | $ / shares</a></td>
<td class="nump">65.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Cancelled | $ / shares</a></td>
<td class="nump">40.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercised | $ / shares</a></td>
<td class="nump">10.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, ending balance | $ / shares</a></td>
<td class="nump">19.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable | $ / shares</a></td>
<td class="nump">$ 12.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">5 years 6 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">4 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 149,501,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 126,302,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998770381048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">86.20%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">90.40%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of options granted</a></td>
<td class="nump">$ 48.64<span></span>
</td>
<td class="nump">$ 36.35<span></span>
</td>
<td class="nump">$ 13.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998770034152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSUs Activity (Detail) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Unvested, beginning of period | shares</a></td>
<td class="nump">3,524,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted | shares</a></td>
<td class="nump">1,672,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested | shares</a></td>
<td class="num">(899,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs, Forfeited | shares</a></td>
<td class="num">(465,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Unvested, End of period | shares</a></td>
<td class="nump">3,831,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, beginning balance | $ / shares</a></td>
<td class="nump">$ 44.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">76.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">30.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">44.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, ending balance | $ / shares</a></td>
<td class="nump">$ 61.24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998770844056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Short-term investments (held to maturity)</a></td>
<td class="nump">$ 304,073,000<span></span>
</td>
<td class="nump">$ 230,462,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent Consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">184,434,000<span></span>
</td>
<td class="nump">143,583,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">126,728,000<span></span>
</td>
<td class="nump">85,020,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Short-term investments (held to maturity)</a></td>
<td class="nump">57,430,000<span></span>
</td>
<td class="nump">88,480,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesFairValueNonCurrent', window );">Long-term investments (held to maturity)</a></td>
<td class="nump">246,643,000<span></span>
</td>
<td class="nump">141,982,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">184,434,000<span></span>
</td>
<td class="nump">143,583,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">126,728,000<span></span>
</td>
<td class="nump">85,020,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Short-term investments (held to maturity)</a></td>
<td class="nump">57,430,000<span></span>
</td>
<td class="nump">88,480,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesFairValueNonCurrent', window );">Long-term investments (held to maturity)</a></td>
<td class="nump">$ 246,643,000<span></span>
</td>
<td class="nump">$ 141,982,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesFairValueNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities fair value non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesFairValueNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998763686744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998855659704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued Compensation</a></td>
<td class="nump">$ 2,371<span></span>
</td>
<td class="nump">$ 2,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock Compensation</a></td>
<td class="nump">22,454<span></span>
</td>
<td class="nump">10,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost', window );">Capitalized Research &amp; Development</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax', window );">California Alternative Minimum Tax</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Losses</a></td>
<td class="nump">185,431<span></span>
</td>
<td class="nump">151,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible Assets</a></td>
<td class="nump">3,562<span></span>
</td>
<td class="nump">2,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities', window );">Right of Use Assets/Lease Liabilities</a></td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">216,259<span></span>
</td>
<td class="nump">171,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(194,255)<span></span>
</td>
<td class="num">(156,604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="num">(6,360)<span></span>
</td>
<td class="num">(2,547)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DeferredTaxLiabilitiesStateTaxes', window );">State taxes</a></td>
<td class="num">(15,644)<span></span>
</td>
<td class="num">(11,929)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">$ (22,004)<span></span>
</td>
<td class="num">$ (14,476)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use assets/ lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxLiabilitiesStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxLiabilitiesStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998770060888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_FederalNetOperatingLossCarryForward', window );">Gross federal net operating loss carry forwards</a></td>
<td class="nump">$ 569,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_StateNetOperatingLossCarryForwards', window );">Gross state net operating loss carry forwards</a></td>
<td class="nump">626,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Unrecognized tax benefits, penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FederalNetOperatingLossCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal net operating loss carry forward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FederalNetOperatingLossCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_StateNetOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State net operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_StateNetOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998770096728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provisions for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Total State</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision from income taxes</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998766709688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">At U.S. federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal effect</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent', window );">Stock compensation</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments', window );">Mark-to-market adjustments</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(29.30%)<span></span>
</td>
<td class="num">(43.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate', window );">True-up on deferred taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to mark-to-market adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation true-up on deferred tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998847590552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employee benefits costs</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember', window );">Employee Contributions up to 3%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Discretionary match percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of compensation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember', window );">Employee Contributions Next 2%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Discretionary match percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of compensation</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139998767348424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Nov. 22, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Option</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | GSK | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo', window );">Milestone payment receivable at start of phase two</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree', window );">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription', window );">Tiered royalties on net product sales receive description</a></td>
<td class="text">Arrowhead is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum | GSK | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale', window );">Commercial milestone payments at first commercial sale</a></td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="nump">$ 590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases, in square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_LeaseCommencementMonthAndYear', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EstimatedPaymentsForOperatingExpensesYearOne', window );">Estimated payments for operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Payments for leasehold improvements, net of tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Subsequent Event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments at first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommercialMilestonePaymentsAtFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EstimatedPaymentsForOperatingExpensesYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated payments for operating expenses year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EstimatedPaymentsForOperatingExpensesYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LeaseCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LeaseCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable at start of phase two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableAtStartOfPhaseTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to renew.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of leasehold improvements net of tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered royalties on net product sales receive description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M-6G1O,:9K-335(V3DRDO!,_2A$J6@ N:T6+!P*QQ)\ Q>)Q=@H\??@$?0%J
M^8K7@A:).!U+-7,S?KS8S'+1S8(ML\Q8>0((/ (88F08/CU\.-P?/E;KW2X:
M;Q>-6W_$MNC'AX>KVSDXG\VNYC.'0[)U2%J'GLTA%2N@0@,6S07[5J=KFK%"
M&D/5N0I;5TV6K2<H\CSBG8[7NR$QF'G$C\C6; ^IMT7J.9&>+Q:\5L!4"BZ8
M0OF4,1/&SHF_.SG$OC^ J%M%7F#&YV_Q^4Y\]Q4K:9H ]ET1E6#& /K:M!X)
M\ ";P0C[R PNV((+G.#NY(I5*BNK2KU;0(5@YC<<:'-C%*,!0-T(A1$V PRW
M $,GP*^T>F&R>:E ,(4SE:DYA*$^.0Y"' TPZF:1WZ:@"62T!1DY0<Y6O))
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M=PF;D[<[7 FR!=^*)+3X#]XJK-$#JQUE)*V">09IG)6?X7M5B(, $QT)0%4
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M7WCO/LV#.^YLT^]!NY?/@6COV:VPARO=F4"S!4#Z+< MR7EU,[#:Y3G.5A^
M;]<SFH3E"57T]XZRXG1$6593L8QU7X05( L:W8(JF,R#G45;7+-G0/H]@Z:2
M2CWRZ[A8OWU3ZA,%T+.@U5V_%3A'L7?O'YQEI3A?%V>"%*S(+F/E^4[]M#YW
M'!6G;9WG-_!J4IX>-C3E8>9#F*_CC(($OW)*OL[RWLW+\\'RAI%M<6+V0A@C
M:7&YP6&$<P'@W[\2PCYOQ _4I[3#?P%02P,$%     @ '81V4^.9RWAD!@
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M1AX.&L?M$.RD/ZS>+LTXED*63U"T13=X"-7]?("W8RC3UA',H4W#G\"@H,Y
M?Y7F#^W %1VQ*G<;-3V%!\&.-_L=T&0:89L>Z"')'YC;N201L!3?AR#?G;PX
MZ T=DQQF.GCP-3#LUQ9XJEMOQ","1T\3J]#ZO#$ _4CS>&AYNS%@QBA$  YZ
MCL$:?I$1,K(=G+(^L.A(A4;?8(P40R&@EH5I$2TB$L; '([ H1K0'Z Z:_ 5
M2K/24U@K?$KLZ>F*;@$@6N,C6K$<>5Z"*0L*=2!VRLDX<$0(UX?&8:MPZ^"-
MDGW0 -S #5;L!YDM[/&&=52-9ZJ_@1F1R(7$;3!N4=%JMG43C&JY)\ES$3;8
MW@[XO+4C,8<!_T'<1#+ZPXZB9?6<N"BP8 $8SJ$"W0S<)(+KE5-JYL!:@2Y&
ME8Q@@V9A_8([@8$_O7GS=GHZ28^:M 1H+/SCR=-Y7_$->'^@=3@2GLHS?)=W
M#0#)%E6Z;C#.+R>=UQPQJW<M'&T4OHQ19./0%87!(J9SG'OHON,WD?.+]*=P
MV<#91-@M.048[L.._KD8]MQ[/GKO??^2PQ]LU-W#<#+C)X<\(48N<#J<(?R7
M-C8< YB);XQ#!^R@#AW*,-*'<J>L 3.?/=JA]() EJA'5KIIF M@K,5OOV;/
M?YIG0NSW'Q<_I.>+N!,?!_ZO266SO\Z6%&U3JK-978,S!-.^^9:7G46T^IY]
M?"+2>3U]V[%1";2/89VH=??. :T3Y9_H-Y4ALL+)!\[[8+QD4J?/[YCU[XU$
M^76"@9AY<Y3(#D+'P<.TGOLEL@9/>NF:@KY;ZWO&0^!3E/^'@$K+DJ,(H +
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M #%\LE%_5'IO <,1OC=[Y/1](&F,L_^.(!,.T^_+]I<@&G<+6EGNCZ*>[R]
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M#\#WJ[INW1\X 7;MTO)>_0]02P,$%     @ '81V4Q3?PP,O$   JST  !@
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M. +P\8V")R?])<YR&>(B_/[$B G+\C):FA@"0MW!LK1OJBI3U%;#S5;9=67
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M*6&Q[C7)H/KJD3RUR\GO/[W?.WAY^I*]($#Y]>R?%>\<=*XOEE+'>\1OG >
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M)-3MTYI%HF8T+ML8;] [(H58V(>(YA[_,+#S\9KM,&N):P61[(GHAO:.)XW
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M"@1E63'+-5DW,[9+5 ,RK7.!^HL;\:A3H0HXV' 9XPV5880L$AI, :(Y=P-
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M$[,C\]ZCO:B*A?[! ;)F563Z*[UU$"4-P/-I ;,U%[1 ]PN4B_\ 4$L#!!0
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M8XNC [ZT(8=O;C%Q]#T0+?:& _O1J/D8!6,<H%FA%^D,_NUO'F4'88D_C3&
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MF0.7<O JH:7*G$3>Q/2R+PNII#,7B#@^I99X.C9>?2/V!\]K[A-HC@S.=[3
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M"<F]'DZW$W,* $(00'?21^;%&TU6=L-0L@EVAR#L;%VQ92C:%7DO&EH=VEI
M4;^CVK&N@[-MP3/ (PE+SP&$LVUL#\XZ+4QJ*LI*KW] UZ.@07IU&O0J3&]8
M%3?@5A3,* .XMLJT!2CN7B^8</JFU:"%$-)KDM3,6L[I7)'"C VL@"=YHTR-
MS+8$0)978 1,; 5E87)0@%D-*X)03=[9R3%%,Z5%]X5PE;PVO8V)7:!UPYL
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M+\#SK07>E ^X0/@]U1_^!U!+ P04    "  =A'93!&:Y<_@"   A!@  &0
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M0=%.KDW%D4Q3!+8VP+,VJ))!'(;CH.)"^;-)NW9E9A/=H!0*K@RS355Q\[@
MJ==3/_*W"]>B*-$M!+-)S0NX ?Q67QFR@IZ2B0J4%5HQ _G4GT=GBZ'S;QV^
M"UC;G3ESG:RTOG/&,IOZH2L()*3H")R&>S@'*1V(ROBS8?I]2A>X.]_2/[>]
M4R\K;N%<RQ\BPW+JG_HL@YPW$J_U^BML^ADY7JJE;;]LW?F.$I^EC45=;8*I
M@DJH;N0/F_^P$W :[@F(-P%Q6W>7J*WR@B.?38Q>,^.\B>8F;:MM-!4GE#N4
M&S2T*R@.9TN%7!5B)8'-K06T[/TM)\L>30(DOO,*T@UKT;'B/:PH9I=:86G9
M)Y5!]AP04&%]=?&VND5\D'@#]3%+P@&+PS@ZP$OZ;I.6E^SA?=$Z6PLIV5QE
M[&7K%\*F4MO& /LY7UDT=&=^'4@[[-,.V[3#?6V0E+*&\NC\9=;7_O-AW&T)
M+->2]"14P= =%ZN-OA<96+J1R(6TC&X\DM^YKFJN'M^].8VCDX^6B:?TW*6G
M*RVY2L&>><O_MBPI=?6;U,-0,UYI@^(O=U+RW@L'UXWE*K-'WJ)#,(Z,#@RA
M6H'9GEKHO?6BT2 9)]Z2*A&&!(W>!V_^C!<-3L+0.TR*'"D9C,?):R<2[$B@
M E.T0K<LU8W"3@W]:O^6S#L)/;EW#]$E-X50EDG(*30\/AGYS'3B[@S4=2NH
ME4:29SLMZ3T$XQQH/]<:MX9+T+^PLW]02P,$%     @ '81V4YI;A8RO @
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M72OFQ\Q$H]F=NZZPE,VS K)73XW- 4)K_0.UAPA7*VPQ?4"'!(0K$F"BR)(
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M*\[ 0-, WB^$T$\WYK-G_>5]^A]02P,$%     @ '81V4V9G"O,\!0  (18
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M&863O@F WY="Z(<;\TJN?"L\_@]02P,$%     @ '81V4\C2AR!5!   01$
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M*8M=LW]-\28$VFW ]8E2=C5P#HJ[U> ?4$L#!!0    ( !V$=E-<L[@TI (
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M=UBT/;TU%-_8+I=RI7NF'9;Z&01A'/3ZFG.U-4R"_F%-_@%02P,$%     @
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MPV$\&!W5D7_0FQ94KFV/KZ ^2JZK-K6YVWQ'S&SW[+?+JX^0.R+78",HIRN
M!E<#V%Y6?7TUT&)C.]U[H:%OMI<9? M1:1; _$H(O1^8#9JOJ^E/4$L#!!0
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MHF%1*YT&53H#,)UO^8C%@WWVJ/-ZX'HJ-'.GS<_<IZ:T8-@!>N8LDX!L#*L
MA[L%&(32%[-$(7T;>%-D,-[@H.?\ L2%'3M;."#2B$6A'B62D*$7=,$B\8\F
MP9Z>+W1/>T%WL_MB T\>,LX-.R"G2P,-?E6UQK8M8 (3?3()?8YDROQ2;.2>
MF9+D]QG+.)J8X\T+ H<<4BL^HJG?PEAL&PF&.TF1/']*PZP8XX)F)HPVX.1#
M#';W?GKS1K=6"NV:[3$8;C([=+D1;F@B[=MC&P2&.T3%/%_$VK>?DZ]]CV"P
M?'C$Y18YT!99^<>P_H]$E@I3O.A"'WD-F[3&2%TWZ)9)%O#$U),M+LBG%6WL
MO6[96#W%L/+]<-F<E@YZ:[-%&R^LD&)8^6Y+*B*]KT5D4Q$%*(S33#SF)-&1
M)CH\,=&JGS!-FJ7?$(LB,6>:3LW'HV&-R^TQ$ZNQ!-;8JM19\<QBA=*Z$X<B
M:(IF ZHY&>P['C0\6T$F>*<(EV0I%HF:(GV@S)MA8YPPMH[3VW=<*,ZE*1^6
M\QV$Z;2$6KZ9_6'KS;2Z36"]W;'PS86(M$$@T,T\X=D>NKX>09MA59JXKRH'
MQ(HQ@?7S&AJBQAN,A[C@$#1'$:N[!-;='U:F,:E/TX R$:O.!)ZIKU<8N;=5
MXQIOP%P<O?/.A8?0#EIM)["V[U!#XQ)JN88&7NM661$GL(AO._N,-^ L'@H5
MC1V20FK%FL*R^IH-9ESZ7CE'M1Y%J95O"DOL^G$NXPF?LZBU8C? ]3:>>ZA5
M; HK]N^S^)YG9K-$+DX2*5'$I\NT]>G8F-:G;MRR2TN/;F#E_LRE3LN?HG/F
MAU&HGHUN?&+Z**89^(*^F2.9;G\)E+<59_JZXDRM.%-87W]8$<]H_?E(WVE5
M1&JUFL):O6V9GVW 65%!TF]Z]K@+ L70OEN]I[L]0]E0=.<;X+8H.BOQ%);X
M_U9TY[1A9F_A@)5Z"DOT#MWFG-;';TS6'R!=-:PB?=+&5M<*OPL+_]+;%;%<
M4E4?@*OHO(1?D2S'<^E:^ W+W/9B<VT/<&'1/GM*N5_M\__7LZY*ORMWI>$!
M2'?I!9=Y;?N)90^A9E[$)]K..?!TQEGQ)K2X4"+-WWG="Z5$G'^<ZHF:9V:!
M_GTBA%I<F-=HU?OHXW\!4$L#!!0    ( !V$=E-_LE*XP0(  +<'   9
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MAF_)F;2_L&UB0P^6:ZEXT8!U!@4MZW_RV!BQ!X@NC@#B!A"?"D@:0'(JH-<
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M.DE+GY#PP!D^"V>S@QY!#8]13>X';;D__!I(]"RHR+.G5&IEM5FJ">F$?U>
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MOHR8[<>]=]"T86(V!FG^@EG3"P'6!]#YUA@\.'X(QS<G_P=02P,$%     @
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M)64Y",VD( J6PV#<O)CVK;TSN&.PT3OOQ"I92'EO!Y?I,(@L(>"0&(M \?$
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MC;R:GV"?]6WQ&<8WZ2NJ,BP>A,,2(:-&%Y.K?./S R/7KG<LI,%.Y%Y7^*T
MRAK@^E)*LQW8 -77Q^@_4$L#!!0    ( !V$=E-[YY<0; (  +T&   9
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M-^,S4YN;4OJ/IBGL#U1MF;GN)6P,97 [-EE53;%L.B@K5SZ>)9IBY)J%>5]
MV0 SOY$2#QV[0/=BI7\!4$L#!!0    ( !V$=E-K\G#;.@,  )0+   9
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M:"TX_?V !0AAG6@>_^Q,@RZF%1X_[]U_=_ $\\(-+)3XJ\JQG 6W <NAX(W
M9[7] W9 U]8O4\*X7[9MQTYN I8U!E6]$],,ZDJV__QUMQ!'@GA(D.P$R<^"
M\8 @W0E2!]K.S&$]<N3SJ59;INUH<K,/;FV<FF@J:;=QB9K>5J3#^4>9J1K8
M9_X*AEVQ9;N;3!7L0U& 6V-V&,.>.0)[ADS)K!(5=SOQYA&05^+M-$2:D+4-
MLUWPAS9X,A \3M@G);$T[(/,(3\U"(FDPTGV. ^)UW$)FQ%+HW<LB9*X9T*+
M7Y='GNFDW>JFSB\]N[KLL3*94*;1P/Z^?S&HZ0!_\X08=R'&+L1X(,0]LB^C
MY8@5D(/F@AGDV*"B/=2T5WU[XO=+XE$4_=:W=)?K3H"N.Z!KK]$2[1E#>R#?
M,4F)C,[B'@[<F>R#\GM.AI@NEIT@W71(-V>05+9F=!0H^1KWT?0A^#WB4=J/
M<$:6_E]WPC#I&"9>HT]<KZ]075%Z6-.F\/P[)2?*YVCZ6/Q>T=!V7"P[0;GM
M4&Z]/E^Y:-K4Q05=8UQFO=^)W^1-<F=7MB_K+<XHQVF/\H3DKB.Y\UK]B27H
MOKG[98/K[Y<E9]8_C@Z73N1U^JP;N&HVC+: KES0&O+VB^^]0_Q>@S"7ZTYI
MCJ[0V$]#Z=TF6Y:57*YZS](9AV&&BW6G#,F!(?$Z'6[[JKVS< ?52^/W&J:Y
M6-?2A$?U30UZY<H^0PFUD=C6!EUO5UK>NX+JI_X'6W*ZNNE@T]:KE-Y6E31,
M0$&6T6A"-X-N2\"V@6KCJJ@7A523N<>2RF;0=@"]+Y3"?<,&Z KQ^7]02P,$
M%     @ '81V4Z'=XMSP @  S D  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3(N>&ULO59M;]HP$/XK5K1)K;21-Z"E J32=%JE=4)%W3Y,^V"2@UAU[,QV
M2OOO9SO!A0X"FJI^(7ZYY[GG?,?9PQ47#S('4.BIH$R.O%RI\L+W99I#@66'
ME\#TSH*+ BL]%4M?E@)P9D$%]:,@Z/L%)LP;#^W:5(R'O%*4,)@*)*NBP.)Y
M I2O1E[HK1?NR#)79L$?#TN\A!FH^W(J],QW+!DI@$G"&1*P&'F7X4421@9@
M+7X06,F-,3*AS#E_,).;;.0%1A%02)6AP/KS"%= J6'2.OXTI)[S:8";XS7[
M%QN\#F:.)5QQ^I-D*A]YYQ[*8($KJN[XZBLT ?4,7\JIM+]HU=@&'DHKJ7C1
M@+6"@K#ZBY^:@]@ A/T]@*@!1*\!W3V N '$QP*Z#:!K3Z8.Q9Y#@A4>#P5?
M(6&L-9L9V,.T:!T^82;O,R7T+M$X-;XN2LJ? = $&"R(0E.*F42?T666$9,9
M3-$-J^O+Y.DD 84)/=46][,$G7PX11\08>B64*KWY=!76I7A]M-&P:16$.U1
M$$;HEC.52W3-,LBV"7P=CHLI6L<TB5H99U!V4!Q\0E$0A3L$71T/#W; DZ/A
MX: EFMAE*+9\\1Z^1*>%0;:5()00F5(N*P'HUS>]C6X4%/)WB[NN<]>U[KJ'
M"F)>^Y,HY5+MS&M-U+=$IK\\CL-.//0?-X_Z7YN@,]BV27;9])S-5A0]%T7O
MN"BN=&D),J],\4I4E4AQ%']L.:>^\]!_C[2<.7=GK0$99@'V#RF>=0-0:8Y*
M$"DPI=OSKNRT\X5!T F"MH,X=\K.6YFF3@7B"UTLA;Z2I&T6NU2U<\4'- V<
MIL'_I/\[/"D4M3D(@Y>^&;Q'_L.-1AV^<04<(.P=JH P>M$6O6$-'""+]LGR
M-ZZY L32/A=,?ZJ8JF\'M^J>))?V(GZU/C%/%7M]OM#4[YQ;+)9$5PJ%A:8,
M.F>ZS8CZZ5!/%"_M93KG2E_-=ICKYQ8(8Z#W%YRK]<0X< ^X\5]02P,$%
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MA;RV6Z[E4[>C>[O7<JME.)F'M_T,1O(M OF6.I)*\8VQORBOPHG:"7:VM4(
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M]8[_J7<NIUW*UY[O-3[_/ZDNYWO3]?&7Y??)T:MRP3G ;_O'+U!+ P04
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MR4\^ 5!+ 0(4 Q0    ( !V$=E,'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ '81V4TR /*[M
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ '81V4YE<G",0!@  G"<  !,              ( !RP$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  =A'934<(7_F<&   F&@  &
M            @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ '81V4RZ^_?1O!@  2!D  !@              ("!J0X  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !V$=E-Y)+;$:@(  )<&
M   8              " @4X5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  =A'93*I5 L*@%  "Q%0  &               @('N%P
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ '81V4^.9RWAD
M!@  ZAX  !@              ("!S!T  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( !V$=E/F@6GVL 8   \:   8              "
M@68D  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  =A'93
MRH2OG.\H  "_A@  &               @(%,*P  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ '81V4Q3?PP,O$   JST  !@
M     ("!<50  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M !V$=E/:F2=Q7P,  /@&   8              " @=9D  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  =A'93$B_<Y$0%  " #@  &0
M            @(%K:   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( !V$=E. M$FHJ0,  !\)   9              " @>9M  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ '81V4^&!/:KE P
ML @  !D              ("!QG$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  =A'933V'I.J\$   5"P  &0              @('B
M=0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !V$=E.T
M&V#T@0<  %$5   9              " @<AZ  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ '81V4SU)7JTL#   C2(  !D
M     ("!@((  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M"  =A'93&$7>UL8'   X%   &0              @('CC@  >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !V$=E-"'3J@80D  +L7   9
M              " @>"6  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!
M A0#%     @ '81V4Q_71'[8 P  *0@  !D              ("!>*   'AL
M+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  =A'9329%(8T8&
M  !2#@  &0              @(&'I   >&PO=V]R:W-H965T<R]S:&5E=#$Y
M+GAM;%!+ 0(4 Q0    ( !V$=E-Q IFF<2$  %MU   9              "
M@02K  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ '81V
M4P1FN7/X @  (08  !D              ("!K,P  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  =A'93T/<!K[L#  #Y"0  &0
M        @(';SP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( !V$=E.ID!M+AP(  &T%   9              " @<W3  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ '81V4YI;A8RO @  P 4
M !D              ("!B]8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  =A'937+"!%I($  !0"@  &0              @(%QV0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !V$=E/VGJS3
M%@,  /T'   9              " @3K>  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ '81V4[\,Z1'7!   ZPL  !D
M ("!A^$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  =
MA'93HBQB/ T'  #5)0  &0              @(&5Y@  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !V$=E/1ZNMNO00  &,5   9
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M970S,RYX;6Q02P$"% ,4    "  =A'93 4#HD&X"  #K!0  &0
M    @($Q!@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M !V$=E,)&8%<PP0  .T7   9              " @=8( 0!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ '81V4WT&@HIH P  9PT  !D
M             ("!T T! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    "  =A'937+.X-*0"  !D!P  &0              @(%O$0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( !V$=E.*E_9AV ,
M &D-   9              " @4H4 0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ '81V4Q]QUP[  @  * @  !D              ("!
M61@! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  =A'93
M*D1"IV4&  ";'@  &0              @(%0&P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( !V$=E-_LE*XP0(  +<'   9
M      " @>PA 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ '81V4^@Y'?O4!@  3B(  !D              ("!Y"0! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  =A'93]BL.,  $  #"#@
M&0              @('O*P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( !V$=E/$-@PQ90,  ) +   9              " @28P 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ '81V4S,)B\9(
M P  @ H  !D              ("!PC,! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    "  =A'93:-Z5]H<#  "@#@  &0
M@(%!-P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( !V$
M=E.KLO85"0(  '\$   9              " @?\Z 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ '81V4^3;OI_K P  &@T  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( !V$=E/,;J>D2P4  -X2   9
M  " @<A- 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M'81V4YDSZC8G P  #!,   T              ( !2E,! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  =A'93EXJ[',     3 @  "P              @ &<
M5@$ 7W)E;',O+G)E;'-02P$"% ,4    "  =A'93K'0&B6($  !@(P  #P
M            @ &%5P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ '81V
M4WQ^Z1O4 0  QA\  !H              ( !%%P! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ '81V4RIDTJ;* 0  FQ\  !,
M         ( !(%X! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #T /0"B
)$   &V !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>165</ContextCount>
  <ElementCount>396</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail</Role>
      <ShortName>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Summarize Information about Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of RSUs Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail</Role>
      <ShortName>Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Provisions for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Provisions for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail</Role>
      <ShortName>Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arwr-10k_20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="arwr-10k_20210930.htm">arwr-10k_20210930.htm</File>
    <File>arwr-20210930.xsd</File>
    <File>arwr-20210930_cal.xml</File>
    <File>arwr-20210930_def.xml</File>
    <File>arwr-20210930_lab.xml</File>
    <File>arwr-20210930_pre.xml</File>
    <File>arwr-ex311_6.htm</File>
    <File>arwr-ex312_15.htm</File>
    <File>arwr-ex321_10.htm</File>
    <File>arwr-ex322_14.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gfmvgbft1fv3000001.jpg</File>
    <File>gfmvgbft1fv3000002.jpg</File>
    <File>gfmvgbft1fv3000003.jpg</File>
    <File>gfmvgbft1fv3000004.jpg</File>
    <File>gfmvgbft1fv3000005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>78
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arwr-10k_20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 165,
   "dts": {
    "calculationLink": {
     "local": [
      "arwr-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arwr-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "arwr-10k_20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "arwr-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 511,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 31,
    "http://xbrl.sec.gov/dei/2021": 4,
    "total": 35
   },
   "keyCustom": 53,
   "keyStandard": 343,
   "memberCustom": 41,
   "memberStandard": 21,
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Investments",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Intangible Assets",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Stockholders' Equity",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Leases",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Stock-Based Compensation",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Fair Value Measurements",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Employee Benefit Plans",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Subsequent Events",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Investments (Tables)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Leases (Tables)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928",
      "decimals": null,
      "lang": "en-US",
      "name": "arwr:AgreementDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003",
      "decimals": "-5",
      "lang": null,
      "name": "arwr:InitialTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007",
      "decimals": null,
      "lang": "en-US",
      "name": "arwr:AgreementDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Horizon Therapeutics Ireland DAC - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_deiLegalEntityAxis_arwrHorizonTherapeuticsIrelandDACMember_us-gaapTypeOfArrangementAxis_arwrAROXDHAgreementMember_20210618_20210618",
      "decimals": null,
      "lang": "en-US",
      "name": "arwr:AgreementDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FurnitureAndFixturesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
     "shortName": "Property and Equipment - Summary of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FurnitureAndFixturesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Property and Equipment - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail",
     "shortName": "Property and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail",
     "shortName": "Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Intangible Assets - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
     "shortName": "Intangible Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail",
     "shortName": "Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail",
     "shortName": "Stock-Based Compensation - Summarize Information about Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20181001_20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail",
     "shortName": "Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20181001_20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail",
     "shortName": "Stock-Based Compensation - Summary of RSUs Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecuritiesFairValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail",
     "shortName": "Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "arwr:PercentageOfValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "arwr:PercentageOfValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20180930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Income Taxes - Provisions for Income Taxes (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail",
     "shortName": "Income Taxes - Provisions for Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail",
     "shortName": "Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Employee Benefit Plans - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail",
     "shortName": "Employee Benefit Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_deiLegalEntityAxis_arwrGlaxosmithklineIntellectualPropertyLimitedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20211122",
      "decimals": "-6",
      "lang": null,
      "name": "arwr:MilestonePaymentEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Organization and Significant Accounting Policies",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Property and Equipment",
     "role": "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20210930.htm",
      "contextRef": "C_0000879407_20201001_20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "arwr_AROENacAndAROHIF2CandidatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARO-ENac and ARO-HIF2 Candidates.",
        "label": "A R O E Nac And A R O H I F2 Candidates [Member]",
        "terseLabel": "ARO-ENaC and ARO-HIF2 Candidates"
       }
      }
     },
     "localname": "AROENacAndAROHIF2CandidatesMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AROXDHAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARO-XDH Agreement.",
        "label": "A R O X D H Agreement [Member]",
        "terseLabel": "ARO-XDH"
       }
      }
     },
     "localname": "AROXDHAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AdditionalLandSubjectToLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional land subject to lease.",
        "label": "Additional Land Subject To Lease",
        "terseLabel": "Additional office space for lease"
       }
      }
     },
     "localname": "AdditionalLandSubjectToLease",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional remaining development regulatory and sales milestones payments.",
        "label": "Additional Remaining Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Additional remaining development regulatory and sales milestones payments"
       }
      }
     },
     "localname": "AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_AgreementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement date.",
        "label": "Agreement Date",
        "terseLabel": "Agreement date"
       }
      }
     },
     "localname": "AgreementDate",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "arwr_AmgenIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen Incorporated.",
        "label": "Amgen Incorporated [Member]",
        "terseLabel": "Amgen"
       }
      }
     },
     "localname": "AmgenIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AtTheMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market agreement.",
        "label": "At The Market Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "AtTheMarketAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and use of estimates.",
        "label": "Basis Of Presentation And Use Of Estimates Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Use of Estimates"
       }
      }
     },
     "localname": "BasisOfPresentationAndUseOfEstimatesPolicyTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash receivable as upfront payment due under collaboration agreement.",
        "label": "Cash Receivable As Upfront Payment Due Under Collaboration Agreement",
        "terseLabel": "Cash received as due under collaboration agreement"
       }
      }
     },
     "localname": "CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashReceivedAsDueUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received as due under agreement.",
        "label": "Cash Received As Due Under Agreement",
        "terseLabel": "Cash received as due under agreement"
       }
      }
     },
     "localname": "CashReceivedAsDueUnderAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashReceivedAsDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received as due under collaboration agreement.",
        "label": "Cash Received As Due Under Collaboration Agreement",
        "terseLabel": "Cash received as due under collaboration agreement"
       }
      }
     },
     "localname": "CashReceivedAsDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CertificateOfDepositsDueWithinTwoYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of deposits due within two years.",
        "label": "Certificate Of Deposits Due Within Two Years [Member]",
        "terseLabel": "Certificate Of Deposit Due Within Two Years"
       }
      }
     },
     "localname": "CertificateOfDepositsDueWithinTwoYearsMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License agreements",
        "verboseLabel": "Horizon License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "xbrltype": "stringItemType"
    },
    "arwr_ColoradoOwnerLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Colorado Owner, LLC.",
        "label": "Colorado Owner L L C [Member]",
        "terseLabel": "Colorado Owner, LLC"
       }
      }
     },
     "localname": "ColoradoOwnerLLCMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommercialMilestonePaymentsAtFirstCommercialSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payments at first commercial sale.",
        "label": "Commercial Milestone Payments At First Commercial Sale",
        "terseLabel": "Commercial milestone payments at first commercial sale"
       }
      }
     },
     "localname": "CommercialMilestonePaymentsAtFirstCommercialSale",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommercialNotesDueWithinOneThroughThreeYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial notes due within one through three years.",
        "label": "Commercial Notes Due Within One Through Three Years [Member]",
        "terseLabel": "Commercial Note Due Within One Through Three Years"
       }
      }
     },
     "localname": "CommercialNotesDueWithinOneThroughThreeYearsMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommercialNotesDueWithinOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial notes due within one year.",
        "label": "Commercial Notes Due Within One Year [Member]",
        "terseLabel": "Commercial Note Due Within One Year"
       }
      }
     },
     "localname": "CommercialNotesDueWithinOneYearMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommonStockCapitalSharesValueReservedForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, capital shares value reserved for future issuance.",
        "label": "Common Stock Capital Shares Value Reserved For Future Issuance",
        "terseLabel": "Common stock shares value reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock purchase agreement.",
        "label": "Common Stock Purchase Agreement [Member]",
        "terseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contingent consideration obligations related to acquisitions.",
        "label": "Contingent Consideration Policy [Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_CorporateHeadquartersInPasadenaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Headquarters in Pasadena",
        "label": "Corporate Headquarters In Pasadena [Member]",
        "terseLabel": "Corporate Headquarters In Pasadena"
       }
      }
     },
     "localname": "CorporateHeadquartersInPasadenaMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_DeferredRevenueCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue current.",
        "label": "Deferred Revenue Current [Member]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrentMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.",
        "label": "Deferred Tax Assets In Process Research And Development Cost",
        "terseLabel": "Capitalized Research &amp; Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopmentCost",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10140.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets right of use assets/ lease liabilities.",
        "label": "Deferred Tax Assets Right Of Use Assets Or Lease Liabilities",
        "terseLabel": "Right of Use Assets/Lease Liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DeferredTaxLiabilitiesStateTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions.",
        "label": "Deferred Tax Liabilities State Taxes",
        "negatedLabel": "State taxes"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesStateTaxes",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development regulatory and sales milestones payments.",
        "label": "Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Development regulatory and sales milestones payments",
        "verboseLabel": "Development, regulatory and sales milestones payments"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock compensation.",
        "label": "Effective Income Tax Rate Reconciliation Deductions Stock Compensation Percent",
        "negatedLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to mark-to-market adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Mark To Market Adjustments",
        "terseLabel": "Mark-to-market adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation true-up on deferred tax rate.",
        "label": "Effective Income Tax Rate Reconciliation True Up On Deferred Tax Rate",
        "terseLabel": "True-up on deferred taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_EmployeeContributionNextTwoPercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee contribution next two percent.",
        "label": "Employee Contribution Next Two Percent [Member]",
        "terseLabel": "Employee Contributions Next 2%"
       }
      }
     },
     "localname": "EmployeeContributionNextTwoPercentMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_EmployeeContributionsUpToThreePercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee contributions up to three percent.",
        "label": "Employee Contributions Up To Three Percent [Member]",
        "terseLabel": "Employee Contributions up to 3%"
       }
      }
     },
     "localname": "EmployeeContributionsUpToThreePercentMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards additional compensation cost not yet recognized share based awards other than options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Additional Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Additional unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity securities FV NI accumulated gross unrealized gain before tax.",
        "label": "Equity Securities F V N I Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Marketable Securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity securities FV NI accumulated gross unrealized loss before tax.",
        "label": "Equity Securities F V N I Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Marketable Securities, Gross Unrealized Losses"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity securities FvNi accumulated gross realized gain loss before tax.",
        "label": "Equity Securities Fv Ni Accumulated Gross Realized Gains Loss Before Tax",
        "terseLabel": "Marketable Securities, Realized Gains/(Losses)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAccumulatedGrossRealizedGainsLossBeforeTax",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_EstimatedPaymentsForOperatingExpensesYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated payments for operating expenses year one.",
        "label": "Estimated Payments For Operating Expenses Year One",
        "positiveLabel": "Estimated payments for operating expenses"
       }
      }
     },
     "localname": "EstimatedPaymentsForOperatingExpensesYearOne",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected payments of leasehold improvements, net of tenant improvement allowances.",
        "label": "Expected Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances",
        "terseLabel": "Expected leasehold improvements, net of tenant improvement allowances"
       }
      }
     },
     "localname": "ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_FederalNetOperatingLossCarryForward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal net operating loss carry forward.",
        "label": "Federal Net Operating Loss Carry Forward",
        "terseLabel": "Gross federal net operating loss carry forwards"
       }
      }
     },
     "localname": "FederalNetOperatingLossCarryForward",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_GlaxosmithklineIntellectualPropertyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxosmithkline Intellectual Property Limited.",
        "label": "Glaxosmithkline Intellectual Property Limited [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxosmithklineIntellectualPropertyLimitedMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant date fair value of the options granted during the period.",
        "label": "Grant Date Fair Value Of Options Granted During Period",
        "terseLabel": "Grant date fair value of the options granted"
       }
      }
     },
     "localname": "GrantDateFairValueOfOptionsGrantedDuringPeriod",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_HalozymeIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Halozyme, Inc.",
        "label": "Halozyme Inc [Member]",
        "terseLabel": "Halozyme, Inc."
       }
      }
     },
     "localname": "HalozymeIncMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held to maturity securities and marketable securities.",
        "label": "Held To Maturity Securities And Marketable Securities Table [Text Block]",
        "terseLabel": "Summary of Short-term, Long-term Investments and Marketable Securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_HeldToMaturitySecuritiesFairValueNonCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held to maturity securities fair value non current.",
        "label": "Held To Maturity Securities Fair Value Non Current",
        "terseLabel": "Long-term investments (held to maturity)"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValueNonCurrent",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_HorizonTherapeuticsIrelandDACMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Horizon Therapeutics Ireland DAC.",
        "label": "Horizon Therapeutics Ireland D A C [Member]",
        "terseLabel": "Horizon Therapeutics Ireland DAC"
       }
      }
     },
     "localname": "HorizonTherapeuticsIrelandDACMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_IncreaseDecreaseInCashAndInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in cash and investments.",
        "label": "Increase Decrease In Cash And Investments",
        "terseLabel": "Net increase (decrease) in cash and investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndInvestments",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_InitialTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial transaction price.",
        "label": "Initial Transaction Price",
        "terseLabel": "Initial transaction price"
       }
      }
     },
     "localname": "InitialTransactionPrice",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_JNJ3989AROHBVAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JNJ-3989 (ARO-HBV) Agreement.",
        "label": "J N J3989 A R O H B V Agreement [Member]",
        "terseLabel": "J N J3989 A R O H B V Agreement"
       }
      }
     },
     "localname": "JNJ3989AROHBVAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JNJ75220795AROJNJ1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JNJ 75220795 ARO JNJ1.",
        "label": "J N J75220795 A R O J N J1 [Member]",
        "terseLabel": "JNJ-75220795 (ARO-JNJ1)"
       }
      }
     },
     "localname": "JNJ75220795AROJNJ1Member",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceuticals and Johnson And Johnson Innovation JJDC Incorporation.",
        "label": "Janssen Pharmaceuticals And Johnson And Johnson Innovation J J D C Incorporation [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JanssenPharmaceuticalsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceuticals, Incorporation.",
        "label": "Janssen Pharmaceuticals Incorporation [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Johnson and Johnson Innovation-JJDC, Incorporation.",
        "label": "Johnson And Johnson Innovation J J D C Incorporation [Member]",
        "terseLabel": "JJDC"
       }
      }
     },
     "localname": "JohnsonAndJohnsonInnovationJJDCIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LeaseCommencementMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement month and year.",
        "label": "Lease Commencement Month And Year",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementMonthAndYear",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "arwr_LeaseExpansionCommencementMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expansion commencement month and year.",
        "label": "Lease Expansion Commencement Month And Year",
        "terseLabel": "Lease expansion commencement period"
       }
      }
     },
     "localname": "LeaseExpansionCommencementMonthAndYear",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "arwr_LeaseExpansionExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expansion expiration month and year.",
        "label": "Lease Expansion Expiration Month And Year",
        "terseLabel": "Lease expansion expiration month and year"
       }
      }
     },
     "localname": "LeaseExpansionExpirationMonthAndYear",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "arwr_LeasePaymentsCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease payments commencement date.",
        "label": "Lease Payments Commencement Date",
        "terseLabel": "Lease payments, commencement date"
       }
      }
     },
     "localname": "LeasePaymentsCommencementDate",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "arwr_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LicenseAndCoFundingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and co-funding agreement.",
        "label": "License And Co Funding Agreement [Member]",
        "terseLabel": "License and Co-Funding Agreement"
       }
      }
     },
     "localname": "LicenseAndCoFundingAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LicenseCollaborationAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License collaboration and stock purchase agreement.",
        "label": "License Collaboration And Stock Purchase Agreement [Member]",
        "terseLabel": "License Collaboration And Stock Purchase Agreement"
       }
      }
     },
     "localname": "LicenseCollaborationAndStockPurchaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_MilestonePaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment earned.",
        "label": "Milestone Payment Earned",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentEarned",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableAtStartOfPhaseTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable at start of phase two.",
        "label": "Milestone Payment Receivable At Start Of Phase Two",
        "terseLabel": "Milestone payment receivable at start of phase two"
       }
      }
     },
     "localname": "MilestonePaymentReceivableAtStartOfPhaseTwo",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.",
        "label": "Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three",
        "terseLabel": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received.",
        "label": "Milestone Payment Received",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "verboseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis.",
        "label": "Novartis [Member]",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional targets for development, regulatory and sales milestone payments.",
        "label": "Number Of Additional Targets For Development Regulatory And Sales Milestone Payments",
        "terseLabel": "Number of additional targets for development, regulatory and sales milestone payments"
       }
      }
     },
     "localname": "NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of agreements.",
        "label": "Number Of Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfAgreements",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctBundle": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of distinct bundle.",
        "label": "Number Of Distinct Bundle",
        "terseLabel": "Number of distinct bundle"
       }
      }
     },
     "localname": "NumberOfDistinctBundle",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of distinct performance obligations.",
        "label": "Number Of Distinct Performance Obligations",
        "terseLabel": "Number of distinct performance obligations"
       }
      }
     },
     "localname": "NumberOfDistinctPerformanceObligations",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfOptionsToRenew": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options to renew.",
        "label": "Number Of Options To Renew",
        "terseLabel": "Number of options to renew"
       }
      }
     },
     "localname": "NumberOfOptionsToRenew",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_OlpasiranAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olpasiran agreement.",
        "label": "Olpasiran Agreement [Member]",
        "terseLabel": "Olpasiran Agreement"
       }
      }
     },
     "localname": "OlpasiranAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OlpasiranAndAROAMG1AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olpasiran and ARO-AMG1 agreement.",
        "label": "Olpasiran And A R O A M G1 Agreement [Member]",
        "terseLabel": "Olpasiran and ARO-AMG1 Agreement"
       }
      }
     },
     "localname": "OlpasiranAndAROAMG1AgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesTable",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_OutsideOfEquityCompensationPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside of equity compensation plans.",
        "label": "Outside Of Equity Compensation Plans [Member]",
        "terseLabel": "Outside Of Equity Compensation Plans"
       }
      }
     },
     "localname": "OutsideOfEquityCompensationPlansMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of leasehold improvements net of tenant improvement allowances.",
        "label": "Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances",
        "terseLabel": "Payments for leasehold improvements, net of tenant improvement allowances"
       }
      }
     },
     "localname": "PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on aggregate gross proceeds from sale of common stock.",
        "label": "Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock",
        "terseLabel": "Percentage of commission to sales agent"
       }
      }
     },
     "localname": "PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of eligible to receive tiered royalties on net sales.",
        "label": "Percentage Of Eligible To Receive Tiered Royalties On Net Sales",
        "terseLabel": "Percentage of eligible to receive tiered royalties on net sales"
       }
      }
     },
     "localname": "PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_PercentageOfValuationAllowance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of valuation allowance.",
        "label": "Percentage Of Valuation Allowance",
        "terseLabel": "Valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "PercentageOfValuationAllowance",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_RatioOfProfitSharingStructureForCommercialization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of profit sharing structure for commercialization.",
        "label": "Ratio Of Profit Sharing Structure For Commercialization",
        "terseLabel": "Ratio of Profit Sharing Structure for United States Commercialization"
       }
      }
     },
     "localname": "RatioOfProfitSharingStructureForCommercialization",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_ResearchCollaborationAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and option agreement.",
        "label": "Research Collaboration And Option Agreement [Member]",
        "terseLabel": "Research Collaboration and Option Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndOptionAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ResearchEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research equipment gross.",
        "label": "Research Equipment Gross",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentGross",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ResearchFacilityInMadisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research facility in Madison.",
        "label": "Research Facility In Madison [Member]",
        "terseLabel": "Research Facility in Madison"
       }
      }
     },
     "localname": "ResearchFacilityInMadisonMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ResearchFacilityInSanDiegoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Facility in San Diego.",
        "label": "Research Facility In San Diego [Member]",
        "terseLabel": "Research Facility in San Diego"
       }
      }
     },
     "localname": "ResearchFacilityInSanDiegoMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_SalesRelatedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-related milestone payments.",
        "label": "Sales Related Milestone Payments",
        "terseLabel": "Sales-related milestone payments"
       }
      }
     },
     "localname": "SalesRelatedMilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_StateNetOperatingLossCarryForwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State net operating loss carry forwards.",
        "label": "State Net Operating Loss Carry Forwards",
        "terseLabel": "Gross state net operating loss carry forwards"
       }
      }
     },
     "localname": "StateNetOperatingLossCarryForwards",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_SubleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Agreement.",
        "label": "Sublease Agreement [Member]",
        "terseLabel": "Sublease Agreement"
       }
      }
     },
     "localname": "SubleaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_SubleaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease commencement date.",
        "label": "Sublease Commencement Date",
        "terseLabel": "Sublease commencement date"
       }
      }
     },
     "localname": "SubleaseCommencementDate",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceuticals United States of America Incorporated.",
        "label": "Takeda Pharmaceuticals United States Of America Incorporated [Member]",
        "terseLabel": "Takeda License Agreement"
       }
      }
     },
     "localname": "TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TechnologyLicenseCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology license commitments.",
        "label": "Technology License Commitments [Member]",
        "terseLabel": "Technology License Commitments"
       }
      }
     },
     "localname": "TechnologyLicenseCommitmentsMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TieredRoyaltiesOnNetProductSalesReceiveDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered royalties on net product sales receive description.",
        "label": "Tiered Royalties On Net Product Sales Receive Description",
        "terseLabel": "Tiered royalties on net product sales receive description"
       }
      }
     },
     "localname": "TieredRoyaltiesOnNetProductSalesReceiveDescription",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.",
        "label": "Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]",
        "terseLabel": "2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants"
       }
      }
     },
     "localname": "TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandTwentyOneIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one incentive plan.",
        "label": "Two Thousand Twenty One Incentive Plan [Member]",
        "terseLabel": "2021 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsFourEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousands four equity incentive plan.",
        "label": "Two Thousands Four Equity Incentive Plan [Member]",
        "terseLabel": "2004 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandsFourEquityIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsThirteenIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousands thirteen incentive plan.",
        "label": "Two Thousands Thirteen Incentive Plan [Member]",
        "terseLabel": "2013 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandsThirteenIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20210930",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Security12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r51",
      "r99",
      "r100",
      "r245",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r244",
      "r255",
      "r370",
      "r375",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r588",
      "r626",
      "r628",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r244",
      "r255",
      "r370",
      "r375",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r588",
      "r626",
      "r628",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r244",
      "r255",
      "r322",
      "r370",
      "r375",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r588",
      "r626",
      "r628",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r244",
      "r255",
      "r322",
      "r370",
      "r375",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r588",
      "r626",
      "r628",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r99",
      "r100",
      "r245",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r154",
      "r155",
      "r291",
      "r293",
      "r627",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r291",
      "r293",
      "r627",
      "r643",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "C A",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "W I",
        "terseLabel": "Wisconsin"
       }
      }
     },
     "localname": "WI",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update201409 [Member]",
        "terseLabel": "ASU No. 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU No. 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201818Member": {
     "auth_ref": [
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.",
        "label": "Accounting Standards Update201818 [Member]",
        "terseLabel": "ASU No. 2018-18"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201818Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39",
      "r554"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r29",
      "r157",
      "r158"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37",
      "r224"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r54",
      "r55",
      "r56",
      "r615",
      "r636",
      "r640"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r53",
      "r56",
      "r63",
      "r64",
      "r65",
      "r102",
      "r103",
      "r104",
      "r482",
      "r631",
      "r632",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r415",
      "r416",
      "r417",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r106",
      "r107",
      "r108",
      "r109",
      "r119",
      "r166",
      "r167",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r232",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r447",
      "r448",
      "r449",
      "r450",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r551",
      "r592",
      "r593",
      "r594",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r377",
      "r379",
      "r421",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r379",
      "r407",
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r85",
      "r211",
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Of Intangible Assets",
        "negatedLabel": "Intangible assets subject to amortization, Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive excluded for calculation of effect of dilutive stock options and restricted stock units"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r143",
      "r146",
      "r151",
      "r186",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r476",
      "r483",
      "r513",
      "r552",
      "r554",
      "r599",
      "r614"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r11",
      "r13",
      "r48",
      "r95",
      "r186",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r476",
      "r483",
      "r513",
      "r552",
      "r554"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r169",
      "r171",
      "r203",
      "r602"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r380",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r463",
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination Contingent Consideration Liability Noncurrent",
        "positiveLabel": "Contingent Consideration",
        "terseLabel": "Fair value of contingent consideration obligation due to discontinuation of clinical trials",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.",
        "label": "Capital Units Authorized",
        "terseLabel": "Capital stock authorized for issuance"
       }
      }
     },
     "localname": "CapitalUnitsAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r659"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Capitalized Computer Software Gross",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r34",
      "r87"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r20",
      "r88",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r81",
      "r87",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r81",
      "r523"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash F D I C Insured Amount",
        "terseLabel": "Amount insured in FDIC per account"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r102",
      "r103",
      "r105",
      "r166",
      "r167",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r232",
      "r411",
      "r412",
      "r413",
      "r447",
      "r491",
      "r493",
      "r494",
      "r514",
      "r516",
      "r517",
      "r518",
      "r521",
      "r522",
      "r534",
      "r551",
      "r592",
      "r593",
      "r629",
      "r630",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r102",
      "r103",
      "r112",
      "r166",
      "r167",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r232",
      "r411",
      "r412",
      "r413",
      "r447",
      "r491",
      "r493",
      "r494",
      "r495",
      "r498",
      "r514",
      "r516",
      "r517",
      "r518",
      "r521",
      "r522",
      "r534",
      "r551",
      "r592",
      "r593",
      "r629",
      "r630",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r106",
      "r118",
      "r168",
      "r194",
      "r418",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement Accounting Policy",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r466",
      "r467",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r230",
      "r603",
      "r619"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r231",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Shares reserve for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r554"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value; 145,000 shares authorized; 104,327 and 102,376 shares issued and outstanding as of September 30, 2021 and September 30, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r296",
      "r299",
      "r376",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r68",
      "r607",
      "r621"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "COMPREHENSIVE INCOME (LOSS)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income Net Of Tax [Abstract]",
        "terseLabel": "OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r137",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r279",
      "r281",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract With Customer Asset Net Current",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r279",
      "r280",
      "r292"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "positiveVerboseLabel": "Contract liabilities, current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r279",
      "r280",
      "r292"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r444",
      "r454"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense Benefit",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r444",
      "r454"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State And Local Tax Expense Benefit",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r445",
      "r454"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense Benefit",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r25",
      "r26",
      "r435",
      "r600",
      "r613"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedTotalLabel": "Total deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r445",
      "r454"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State And Local Income Tax Expense Benefit",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10150.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets Capital Loss Carryforwards",
        "terseLabel": "Capital Loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10130.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10120.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets Goodwill And Intangible Assets",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net Operating Losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets Property Plant And Equipment",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax": {
     "auth_ref": [
      "r441",
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax",
        "terseLabel": "California Alternative Minimum Tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits",
        "terseLabel": "Accrued Compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock Compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities Property Plant And Equipment",
        "negatedLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan Cost Recognized",
        "terseLabel": "Employee benefits costs"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent",
        "terseLabel": "Percentage of compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match",
        "terseLabel": "Discretionary match percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r85",
      "r222"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r85",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization expense for property and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r69",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r120",
      "r122",
      "r127",
      "r128",
      "r129",
      "r132",
      "r133",
      "r502",
      "r503",
      "r608",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share Basic",
        "terseLabel": "NET INCOME (LOSS) PER SHARE - BASIC"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r69",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r122",
      "r127",
      "r128",
      "r129",
      "r132",
      "r133",
      "r502",
      "r503",
      "r608",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Diluted",
        "terseLabel": "NET INCOME (LOSS) PER SHARE - DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Income (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r97",
      "r429",
      "r455"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "At U.S. federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r429",
      "r455"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r429",
      "r455"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate",
        "terseLabel": "Tax rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r429",
      "r455"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r429",
      "r455"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State taxes, net of federal effect"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted average period to recognize pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r63",
      "r64",
      "r65",
      "r102",
      "r103",
      "r104",
      "r107",
      "r115",
      "r117",
      "r134",
      "r193",
      "r269",
      "r276",
      "r415",
      "r416",
      "r417",
      "r449",
      "r450",
      "r501",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r631",
      "r632",
      "r633",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r512"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities Fv Ni",
        "terseLabel": "Marketable Securities, Fair Value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities Fv Ni Cost",
        "totalLabel": "Marketable Securities, Amortized Cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r504",
      "r505",
      "r506",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r246",
      "r248",
      "r249",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r362",
      "r505",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r504",
      "r505",
      "r507",
      "r508",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r246",
      "r323",
      "r324",
      "r329",
      "r362",
      "r505",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r246",
      "r248",
      "r249",
      "r323",
      "r324",
      "r329",
      "r362",
      "r505",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r246",
      "r248",
      "r249",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r362",
      "r505",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r246",
      "r248",
      "r249",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r362",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r509",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r96",
      "r428"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Federal Income Tax Expense Benefit Continuing Operations",
        "totalLabel": "Total Federal"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense Benefit Continuing Operations [Abstract]",
        "terseLabel": "Federal:"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r176",
      "r180",
      "r182",
      "r183",
      "r184",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r247",
      "r267",
      "r492",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite Lived Intangible Asset Useful Life",
        "terseLabel": "Amortization period of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization",
        "terseLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Five",
        "terseLabel": "Amortization of license agreements, thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months",
        "terseLabel": "Amortization of license agreements in 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Five",
        "terseLabel": "Amortization of license agreements in 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Four",
        "terseLabel": "Amortization of license agreements in 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Three",
        "terseLabel": "Amortization of license agreements in 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Two",
        "terseLabel": "Amortization of license agreements in 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r216",
      "r219",
      "r591",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r212",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r216",
      "r591"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Net",
        "periodEndLabel": "Intangible assets subject to amortization, ending balance",
        "periodStartLabel": "Intangible assets subject to amortization, beginning balance",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures Gross",
        "terseLabel": "Computers, office equipment and furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill And Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r210",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets Policy [Text Block]",
        "terseLabel": "Intangible Assets subject to amortization"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r164",
      "r172",
      "r197",
      "r200"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities",
        "totalLabel": "Held to Maturity, Amortized Cost"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r174",
      "r178"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities Accumulated Unrecognized Holding Gain",
        "terseLabel": "Held to Maturity, Gross Unrealized Gains"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r175",
      "r179"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities Accumulated Unrecognized Holding Loss",
        "negatedLabel": "Held to Maturity, Gross Unrealized Losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesClassifiedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Held To Maturity Securities Classified [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesClassifiedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r170",
      "r172",
      "r197"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10280.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Held To Maturity Securities Current",
        "terseLabel": "Short term investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r173",
      "r177",
      "r602"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities Fair Value",
        "terseLabel": "Held to Maturity, Fair Value",
        "verboseLabel": "Short-term investments (held to maturity)"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r170",
      "r172",
      "r197"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Held To Maturity Securities Noncurrent",
        "terseLabel": "Long term investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r85",
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment Of Intangible Assets Finitelived",
        "terseLabel": "Intangible assets subject to amortization, Impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r143",
      "r145",
      "r147",
      "r150",
      "r152",
      "r596",
      "r605",
      "r609",
      "r624"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "INCOME (LOSS) BEFORE INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r430",
      "r433",
      "r440",
      "r452",
      "r456",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r116",
      "r117",
      "r142",
      "r428",
      "r453",
      "r457",
      "r625"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Provision from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r426",
      "r427",
      "r433",
      "r434",
      "r439",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Income Taxes (Paid)/Refunded"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r84",
      "r589"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase Decrease In Other Operating Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Share Based Payment Arrangements",
        "terseLabel": "Calculation of effect of dilutive stock options and restricted stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Net Excluding Goodwill [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10070.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income Expense Nonoperating Net",
        "terseLabel": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r79",
      "r82",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "negatedLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income Net Amortization Of Discount And Premium",
        "negatedLabel": "Amortization/(accretion) of note premiums"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r185",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment Policy [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r597",
      "r610",
      "r642",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject To Ground Leases",
        "terseLabel": "Office space leases, in square feet"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r14",
      "r223"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee Operating Lease Description",
        "terseLabel": "Operating lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "terseLabel": "Estimated lease payments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r95",
      "r186",
      "r513",
      "r554",
      "r601",
      "r617"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r95",
      "r186",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r477",
      "r483",
      "r484",
      "r513",
      "r552",
      "r553",
      "r554"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r23",
      "r24",
      "r95",
      "r186",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r477",
      "r483",
      "r484",
      "r513",
      "r552",
      "r553"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities Noncurrent",
        "totalLabel": "TOTAL LONG-TERM LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Noncurrent [Abstract]",
        "terseLabel": "LONG-TERM LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreement"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual At Carrying Value",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r9",
      "r40"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10270.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r57",
      "r59",
      "r65",
      "r67",
      "r86",
      "r95",
      "r106",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r126",
      "r143",
      "r145",
      "r147",
      "r150",
      "r152",
      "r186",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r503",
      "r513",
      "r606",
      "r620"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "totalLabel": "NET INCOME (LOSS)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r277",
      "r481"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest Decrease From Deconsolidation",
        "terseLabel": "Deconsolidation of Ablaris Therapeutics, Inc."
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r276",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "TOTAL OTHER INCOME (EXPENSE)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "OTHER INCOME (EXPENSE)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "TOTAL OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r143",
      "r145",
      "r147",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "OPERATING INCOME (LOSS)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r542",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "positiveLabel": "Total operating lease liabilities (includes current portion)",
        "terseLabel": "Right-of-use liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r537",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating lease cash payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r535"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r547",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r546",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r531",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases Future Minimum Payments Due",
        "terseLabel": "Estimated lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r6",
      "r101",
      "r138",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r47",
      "r554"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10260.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r41",
      "r554"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10080.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments To Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r380",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r208",
      "r209"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10250.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds From Sale Maturity And Collections Of Investments",
        "terseLabel": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r77",
      "r410"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from the exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r57",
      "r59",
      "r65",
      "r80",
      "r95",
      "r106",
      "r116",
      "r117",
      "r143",
      "r145",
      "r147",
      "r150",
      "r152",
      "r186",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r475",
      "r479",
      "r480",
      "r486",
      "r487",
      "r503",
      "r513",
      "r609"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r37",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r226",
      "r645",
      "r646",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r36",
      "r223"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "totalLabel": "Total gross fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r21",
      "r22",
      "r225",
      "r554",
      "r611",
      "r618"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r225",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r21",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r21",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments Of Notes Payable",
        "negatedLabel": "Principal payments on notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r20",
      "r87",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r276",
      "r418",
      "r554",
      "r616",
      "r635",
      "r640"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r102",
      "r103",
      "r104",
      "r107",
      "r115",
      "r117",
      "r193",
      "r415",
      "r416",
      "r417",
      "r449",
      "r450",
      "r501",
      "r631",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r139",
      "r140",
      "r144",
      "r148",
      "r149",
      "r153",
      "r154",
      "r156",
      "r290",
      "r291",
      "r590"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Provisions for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Components of the Net Deferred Tax (Liability)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule Of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Summary of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r212",
      "r215",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule Of Finite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule Of Intangible Assets And Goodwill Table [Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r380",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]",
        "terseLabel": "Summary of Share Activity Related to RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r385",
      "r397",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summarized Information about Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Assumptions Used to Value Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r44",
      "r93",
      "r135",
      "r136",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r262",
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r378",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Description",
        "terseLabel": "RSU awards vesting, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Number of RSUs, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "verboseLabel": "Number of RSUs, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of RSUs, Unvested, End of period",
        "periodStartLabel": "Number of RSUs, Unvested, beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, ending balance",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of RSUs, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number",
        "terseLabel": "Number of restricted stock units outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Common Stock, Share reserve for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Options Outstanding, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period",
        "negatedLabel": "Number of Options Outstanding, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "terseLabel": "Number of shares forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "verboseLabel": "Number of Options Outstanding, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r387",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Options Outstanding, ending balance",
        "periodStartLabel": "Number of Options Outstanding, beginning balance",
        "terseLabel": "Number of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, ending balance",
        "periodStartLabel": "Weighted-Average Exercise Price Per Share, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r378",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r380",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r403",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares Issued",
        "verboseLabel": "Shares issued to institutional investors"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r543",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short Term Lease Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r96",
      "r428",
      "r453"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.",
        "label": "State And Local Income Tax Expense Benefit Continuing Operations",
        "totalLabel": "Total State"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "State And Local Income Tax Expense Benefit Continuing Operations [Abstract]",
        "terseLabel": "State:"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r46",
      "r63",
      "r64",
      "r65",
      "r102",
      "r103",
      "r104",
      "r107",
      "r115",
      "r117",
      "r134",
      "r193",
      "r269",
      "r276",
      "r415",
      "r416",
      "r417",
      "r449",
      "r450",
      "r501",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r631",
      "r632",
      "r633",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r134",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r269",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Common stock - issued for cash, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r269",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Gross",
        "terseLabel": "Common stock - restricted stock units vesting, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r28",
      "r269",
      "r276",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Options Outstanding, Exercised",
        "terseLabel": "Exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r269",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Common stock - issued for cash, Amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r27",
      "r28",
      "r269",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Gross",
        "terseLabel": "Common stock - restricted stock units vesting, Amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r269",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options, Amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r64",
      "r95",
      "r102",
      "r103",
      "r104",
      "r107",
      "r115",
      "r186",
      "r193",
      "r276",
      "r415",
      "r416",
      "r417",
      "r449",
      "r450",
      "r473",
      "r474",
      "r485",
      "r501",
      "r513",
      "r524",
      "r525",
      "r529",
      "r632",
      "r633",
      "r681"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest",
        "periodEndLabel": "Ending Balance, Amount",
        "periodStartLabel": "Beginning Balance, Amount",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r276",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r530",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r530",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r530",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r530",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r555",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade And Other Accounts Receivable Policy",
        "terseLabel": "Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r176",
      "r180",
      "r182",
      "r183",
      "r184",
      "r247",
      "r267",
      "r492",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r106",
      "r107",
      "r108",
      "r109",
      "r119",
      "r166",
      "r167",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r232",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r447",
      "r448",
      "r449",
      "r450",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r551",
      "r592",
      "r593",
      "r594",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsHorizonTherapeuticsIrelandDACAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Type Of Revenue Extensible List",
        "terseLabel": "Type of Revenue [Extensible List]"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r425",
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties Expense",
        "terseLabel": "Unrecognized tax benefits, penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits Interest On Income Taxes Expense",
        "terseLabel": "Unrecognized tax benefits, interest related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r544",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r121",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number Of Diluted Shares Outstanding",
        "terseLabel": "Weighted average shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r120",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "terseLabel": "Weighted average shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20210930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r660": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r661": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r662": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r663": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r664": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r665": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r666": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r667": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r668": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r669": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r670": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r671": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r672": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r673": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r674": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r675": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r676": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001564590-21-057888-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-057888-xbrl.zip
M4$L#!!0    ( !V$=E//ZUAJP&(# "@X,@ 5    87)W<BTQ,&M?,C R,3 Y
M,S N:'1M[+UI=^)(MBCZ^;VUWG_0=5?W=;XV)(/GK,J[2(PSJ;*Q#^"J[OZ2
M*Y "4*60* VVZ5]_]]X1&@"!D<& 9/4ZI]* %,../<<>?OX_SR-#41ZY[>B6
M^<M!N5@Z4+BI6IIN#GXY\-Q^X?S@_WS^__[?G_]7H:!<73=;2DUU]4=^I3NJ
M83F>S0\[MQ^4IFGH)E?^]:5]HUQ9JC?BIJL4E*'KCB\_?GQZ>BIJ?=UT+,-S
M81ZGJ%JCCTJAX ]<MSG#'Y0KYG*%_G>I5$J5<J%<+E0JW4KI\N3X\KA</#TY
M+Y^53_Y9*EV62I$!?A<;4"+_NU1.BJ5BN7A6JD0>O&?J#S;@2O,J^N!%63V]
MZ)VHY^KQ<>7TF)7*%[UR3ZUP356Y>AI=J36>V/I@Z"J'Z@=:(NS7-+EA\(ER
MK9O,5'5F*!U_IT< &K6HU Q#:>-KCM+F#K<?N5:4HPY=. $X!=.Y?.[9AO[+
M001J^$W1L@<?*Z52]2- T(4)^$'D>2U\(?KPZ4?QH_\HLY_LJ9&9;5M/0\XT
M&];#;'5(9X(;*EU42_YKGE-P)V/N!*_VF=.C.?Q?Z)5"J5RHEB,O#1@;Q[Z#
M/\2\XKAC>WH?#E>+ ^OQ(_Y"+P2/VNZB-04_Q<U@N[$OQ#VJJPO6HJM32S&9
MKCKQC])/4P_S9W48_RS^,O6HYMHS6YS"!?CY(_Z,[Y1PZ9$WN1X_!_PP-87J
MV3;0^23^:?_7Z5<LSW3M16^('Z=W;'JC2AQV5DJP9Y>;CMXS> $?XS;1OU.H
M% /<>P:6\F,* D]5&J!\<7'QD7X-,,ZU%Y+-Q4?XU7]P;LAI L.?>\P)"$QW
MK.-*^6P928HG@C4[>MR*X='RQW_=WG34(1^QPBP=Z\^+9B@CT2-K1<X:H!TP
M'&_T F[ 0P4"K*X&[[W\TO0+^K,;_T*XIH^NS4RG;]DC.D!<\DFA5"E43B.#
M% !+I@;RL>:E<<Y#JER,",A #XB3 C?#?T?<921Z"OPO3W_\Y:!NF8!M;J$+
M>SQ05/'IEP,7D/ CO:U\Q/=<W34X_(&\LE N_?CN<\,B/ 2_?_0?^/FC/Q6*
MA-97D HFB%"7V\HC"IU*\?1,<O>>I4T^_ZSICXKC3@S^RX&F.V.#3? 0.:[Z
M__E9?[[$X;B-G\1'7=.X21_I,SS;$B>CZ-HO!]??2_@_@(S)1C@DUR]K('$U
ME+K7!AO(/3Z[;=Z'W=/CYV<7QZ4SW%*I#.\&>SOXW&>&PW_^.#7/2W,?1^?V
M!?XUZ 3,N(=G+>T:OG.2K>/ZWPD7<19=1,.$TYG481DV,YJFQI]_XY-D"PA_
M3;B0\^A"ZL0[)3#^#:*U86JHUB1;2Z%0NBA42XD64CVK^@N1DO:R/F3F@#?-
MFDH,&I2Z>UL'%65L\/"K#C CC=F:\S#68*$US1J[7%NR7CEZ3?O3<UP\>>?:
MLEO\*3J+9<*?*J=?:\^Z$[RT:%H P7'IXI:/>MR. ,*UO63(63T[V004FB/@
M1# R,QK]/E?=](+C/-U(<5JJ;  *YZ6,(,6&P%%.-U*<E\\W 87*QJ  .LL+
M3'Z;H"##H(RV04* ;$2 [ &5; 8_+HYGP8$:Y%V_S1_!:.&-P(:YT9UENP2U
MX(8/ !RDH] >4,>LC0;<;)JJ98\ML'^X)I<L)Q-SU6P;3P!W'[QX9XR9H\/W
M-5.KM>]JMU_+M8'-Z:%PV[,JQ<O6^-]N=!5VQ&'8#K<?X8,8+2'4YN1OBJ!6
MOO"A5MHRU$[3#+5S";7RQ5:A=G8ZAVLWW'$XOQN31\$<W' PY]O<Y$_,Z')[
MM 1RCNT"(W%I9U^Y-;#9>*B##D^@0#=4O>:#"Y@23.!.[@T&H#*U!MB98WSO
MRP0A&0"O+7UKUTS5#3B.IMEAYI7.!]8T^#M>SP%;%09HP&F[P1CQ/T<X&_SO
MXN#S?;FTU':ZMIE*[E7/U,7&'[Y+Q\5#Y^H@8LJ<7<P) &LTT@5KAHVB)0U0
MY2 !^ OFG>]'=/1+4S? V@;V>_#97Z:_I%>N,T:=>^TZ2\G7.8>'Y=*&),7N
MV':YM"&VO3L>6BYMB(?NCJ&=5N80NS-D-D>G)"#U: PSD(,LPJJ_3,)'[MF$
MN/<3:$-WI)4Z=YZ+WD:\T/F#XQ4$UVJ/P!T'P!9'3#?A>Z06Q'-/\,A*,@2]
M/_GWZ6VE?)5PHW,6R+H;;3QS6]4=!N>[XD;+"3=ZC!N]6+K1.!9&USICS^81
M#G9:G2,WVMR7E_?_97;_UTRW?V>&QVN.XXT$,-JZ\^,:Q'03MF=SQVV#8+L%
M&(R\92)P?M.*QE5]Q SGEX-FZ_K@<ZE8*ATG9N+Q$)BCUKV P"SW>DL(G.TG
M!&:87PP$RB>E9!+R]#C^M%]#[W%[;3R/P=+DVFO(^O3?U=MDS.LX_N"VOYDY
M4?N:S<PY"'>UF5FA^^)F5J>T^#V^*:6QYTUPVW)Y0[QF3K/?"PBLP&W+YYN!
MP'&\:K5S"+S,;:L;PH'C.7_G1B'@4_KOE@'#H+V[ :VCBA X/ZUL" )S#LX]
M@< 2.B (7)26"]S5(3!GJ6X# NOQ0@F!#6E=QV^K>;\> B_B0"4>!^C+2,P
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M-LL&HD>AZB=A[0E<,XK.*X6X8X%P7=.9/>DP@]_U.ZZE_@BC -SND MK/2[
ML72>KO2-[06;+P2K?^._$+"[\("<OWVJQC:0T8\]S+$RI5@YH^0"7B:-,XQB
M\MLJN>O@:FJ%^+XCT*Y4QCMWR.DR4'='4_$&7:X.3<NP!A.9HQ%Y*$N6>QP
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M>2F8ML 4X)N0':_B>UJ%$2%(]A#(.S*KIG1:*08GY4J/V$TR[1(OQ>'<J.G
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M0ED@(*&)Q3D3$R\.=;DJQ^&CG@'6&S>'>+$#,@V9E&]IX?Z$S.AQ%R]\0(:
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M.;S0< "G!/<7L =IW7ADAH>!!!1LPOK<!9G4!6/+9CTR%(_\>TF,7N#D6"*
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M"PIA5&Q$,DW/&(DZ5)&GQ0-%18H1)AK?RV@[+'45U&VC?\5;?F4W/XQD;.L
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MP805V_5]6?%#R*L[>?7^JS4T'> %__A;]?R3_^EH>5C-KZU?"]6+\POE$*'
MT?-N\SZW;>$?!T.9HN2__/Z!RETR32/W833<< 8FF S#;'48$T0D$E,BT)J"
M#GHT(EUQP]<Y6?OB8MH=PKO!,@ "LQ>23ECM"_!!A#LZ(L18AD$*[ZF<-:&1
M7MDWU%P0#36'F$=S,1@ AI_*9R=A/($3$W6 +90!#64&52R" 5J8UJ,X9+I"
M+L-/OU[5?>S&OS\H(TR&9,I/9R?%,(2!_^6A)!,IBS[YA.NL"Y=QQ[74'W/G
ME.Z J9.W*06S=^BY+P$U4\FR<2$S@KM,YQ[^5"Z>8M5"0X8H!U$R/G7XH7^Q
M%#>3H0O\WHJ=>6[.B^B</LM$]^/\]'XZ]PJLUK^RA9D7<%+)*XO*G@5#38&Q
M[]G([%<+1Q,;'>E:P>5P.,M.BX FGL=[WMGG5P"P9?H1(C+J[04P5DCIVS=@
M=W2,,"&WN0Q?62I*\+XN%"=[MI>S/5M/*2+Z*,@IB,V+AN!%J!LSKD,])7-!
M>*'N2<QQ1N_$7\^J9Z?T!,66O*"@IMO&"( 14[6#,IRB#&A*;UZY8I??SB"L
M#_DEK"V/@3@PF-\F :R$'I8."&:C5/6IR+^1I>%M&'9#4**K9U,!A$=1#9WJ
M 6C8+(Z' 7W14#L1.<<QVD:!,Q5Q<Y*M^A6#1#T/8N\R#TDJO4&P&@)<M77!
MH>%M3)_'[84I19CU;VK,U@I6OZ!B/*'IJ0:W7+^_G?CHB(_,L 88^\!45T0T
MJ#*A(9)IA=?UG*XIR7JA3AV836\&H7U1L#N>W6>X3S@SV*-R^.V+4QN S8=)
M5R+4B$HM6%H8E@DC>9A/IX]&GDFWQ,B7R;81%5SPC4?=]ISI8"Y,ZY>)62QZ
MFTQWE%,G%UYI"@P,:XD(I!CY%T2^PWDZ3=-'7-4R\;RF[2R"6Z02E4.N+CI1
MEP+15*Z)? EJL*$\T6E%1PJD3C&A+S6_6=WUS2J2\N+;O)A2;M\BM/([H?1A
M8A:_[\['N+JU;]L6885C".Z (XNXHL(K<@6TJI?FGRV,B]6,8>YWV^:N>GIR
M<7R6)=UMZOHV)/8II2U2P_I7!O*2 [+[%?ML0$\=OLL8,M3"AG8O]KX#S0AH
MQAIA<.<1W=? M\91E!6$]-\,17%,(4:?()$&IX@R/Y*5RIJ42I6SDX3A%:FD
MSRN_Y $Z5P,%O\T',+?IH,?6\$@-F[6^L,XG?G=R6JZ>5L\N M=3-UI)L"XM
MC'GQW?3M#.6PW6A<%\K9E.65GKS:%3[IHQDF0 $7? $/B"?V)5TP=W^8F3K#
ME2Z#P18[/WT'C +00_%1YI_XP<>5?[:$97SH?@#H*#4RCK'1Q <?\\2EI/3/
MM&I*S;!$\ANGR (T=UL<ZU,^<L0G/QH)K,Z.+-F"=2HBXDC6]7UGZ%B;4@\$
M'U&^O*:1KL\^%I1PCG"4XW/8 ?\AQVA&2Z?2&>18L6NL6*E(6^7B9+YW1C:9
M5*QJ6Q_J[T&SG>80&!Q:D,&A6S<FW@G$5Z&^D_/3X^I%UJDOIE&[C/#_)K-R
MFB-,C?6O1J.(DRF4"+QX/JT5KBBH,XX<"U]MRQN_$H+N<)Y89TDR4Y!=K4W4
M>?6]Z.,AX_VG$JMN44!O1$&J6P6A!('F-.=51^X>?K[RO>QDG&<LRC<PSF=L
M\WG]>M99%T9LRY,@,%[Y]\_"G(]8S4ML]VFY^A(AO]T19^ID5Y+'55"&,]9)
M[O1MP@?WFS/N1V^YSDMMY;:ZFHBPV*MU+99<4W['?^[7JB7+W:LU+?&H$,.W
M;/K7\L#LXH.)"/(DSPT(*5 ;15)/A2F'>[4M6&OSNK572RJ(-CT5]@'%;"#4
M"RV&0G[>]105M:$3:[_ _.T+KPWV:D4?E'O+T4EO6NR[HV"/R)T1:C)^U(+!
M3,R+JV%Q&#$EMT5VZ4WWPVNB)/==R8FHKW/^'B.2#"STF(3^WV7.'C]IL##P
M= VX2JCG^L[@)8P]5GU]'>>:HD934N-4M!!B^2IX%8]1-]G*%E]%*3ZN7IR\
M"R>5S(0'M+*97R^&##!NZ^,A]2?PL^0!XYL86BD3:/&IX")"N67V#YE+N](E
M=[/5:7[]ULVH(;V0$06>K@%ZNA8PIC<XDVA^<^QE.%KR3#?C;L/C6=4LBYIB
M;W,-@_)KJ#A'^,E90I=D"GE,S*7(_"6(0!+102KTZF8*(VKF%".0OG!9X&"*
M*[SH_YZ%TZK>[WC89PK*J]#=!;"HZOD[H[NC%W3(17S>F7.IKLK/E</[1NOK
M0[-5J&14RJ]@8TA1/N_DGBX*MLCEO<2B.(H_+CG62_9"+IU?; I>.CDIO;>0
M]*,I-6X]%-MLD%+ 3=X%+Y': 3"$'?"5K:! SGZ6*RFGIV?E4J9BU C)3BJ5
MTMG%R?)J.O!D^<.1_V=%()O\5$U_%G,(A&"SLM-CI#>]J#BQI(]()'4T6K^[
MZ2KP.)8N<L*$T"!%%NN VSIWL29RM]V\_=GQQE,>;X+*^<G?/V'W\\)0;+Q<
M ;QYY#:55)*7P@#=@\_=VY\_P@B?E3&P =R[WW0GICO(=&O)L.T(MBQ@6)K8
MA"]^<&4\M!SX?P/D S53'(G^E8%WH@J2H'5_4ZM^2-**%<X$%JY:.+ *.X8G
MK3#?^+!5ZWS[, 5''_FF<(^:+LXU=)'EE#Q3TQW5L!R_[T-!;AG!($J'X(K]
MHE7SA_/:PE!KUE'>:9NA$5X)9:  6K"/H%H9?16T[F/J7YZ.7(XI3Y9M:$^Z
M!G;_?+<Q'<O^CET^D@723I=7)[LS@$IT6*)RB/T%=-&0:):EWGY5SB]*Z*Q#
M1+ZYKWUXN4N@ SC[@XJ. >(.J7> '9G.IPH8NWP4;9(4J792/9FNYS%3.DOD
MT_Y4*1=/HD]1"UMD)=B%**X$%F:Z$[CEP[/=F:)5L8)"Z<'RGMBR^D8_G9;/
MIA<M*6]JS<N:AE%IFYAB)2*_/P02LK6EE9;,:.FAGXY+,\51Q @13I1H-9'*
M/1$4\K$C4J,IRA+G2]^$V+*XYDWU555=Z(3G&E/XX'NASE%8IDAT\RYH\(P;
MJ7N$N"Q (QKFB.H9\3 1Q'.DQ  G2]I99,N!:N8S#I_8<?OIYM/A+E=I8<;&
MJ(8$#6EJP$V4'WQ"U4U@$I$%&'GBD'V8:]<D^^F(*B.Z^</O#C'?M41EMJ9;
MC\QO!BZ*0F.7)@ >V(::G% %'89CMSG+H).YN;I1#"H(7Y2,T0%U@SJSS-<A
M$55%8#._>K @ZDO+P[H%5)0E,"F=R-6W.W/U'0&DB>5L_J0R!K0S#HL1S:]$
ME?H8&,GN+]1E&R1 R!_FV '9NF%=$[$_60T)&U<%B5WE<(]^YQO9V[L&R(P-
M+C 7 U0OO_HV3M?!RKTN]<WH"-V4&M)0TJC*12F(1U\65TH9J[%X]B9!DHM*
M[FZO7?@6HH8L6_\OX$\W6E:UB14$@52N:O64:[,O;B]0<N63H9H[U5(:^T9Y
M0$C(B8).O"\WSNY+1?5?5]\$IP)V .17+JY6*?#E_M=S3:^IB!+5U&*BXK].
M):MLRQL,J?12R#Z9O'6/J#'^#([>;M6B-CMV^A&0I'F"@I:A"1#?;YC6'C']
M$4Q^R^TGX/ZDXM-]/FD^"*]@A=%US=H+!/3Y9L-T/C^%_6SG.NN21N9O94E;
M75^'/IU2^-9HMGODS[9,VPO5.M^O8#T5INM:VA@LX;=<GBU"F1T=3A+-1BJD
M[Z[Q+I']"MK9,[R*697PY'"BV6"GFA3F".^_Y!KB%E9P(FT%^),5Y+ ,+,\M
M*E\QG$74Z0/-P?++Q8&YU?>,T#8%C+3)>^1W):06G.28 ZI&[[QG(_%B>SZ)
MF3W#LC2J$XZ?'DS=I<09;)MW)-MYH8=I9-G( (#7422G3TNXNM"M16WWIDKC
M,JRR9VN"'6$^:_@LCA?M369A#)&'9:L+0"U"$Q,<AZH5A@W*E!''<-(![ASU
M+;^YKQPLF$&SL&699$O8CK OVB)0^R\K O^@<5G?$O7KL/L?T3.V';5U4KQ\
M6 MCF[1.V2 20>!,1F/ 9%@GH@KH@>@XHVT&;!!F!:V6ZBCZSK?@F$3G0VP@
M.5$<R[-%PV"'FBV%)W;H/*";Y!N@=D21A2]!'P>%%H@?4,<' U9?1ZDC/Q]A
M%<?8^H(^0AF6.2B@> H:"</>@: 00J(SI"\'>H(/_FGI_J%;]@!(Z<V<?D2Y
M.O9Q4Y-P@@1$CE+2OS"BXQ;ETG&W7\!:ZNNB(!N5Q8RJ(.E6JF@[Q%5&7 7:
MUIV1(C%7(=_W(Y6&Y(;A<Q31BU0@;,1[CKPG[/>']J7D'<!X1-MNWY2;L6;#
ME_S&G\H5JD2:K/Z/9I??N!L[DH:M@5'4(F;JC@KVD"UEK:'W0>E1!<D&'1PC
M3-=2 M# IC5@"'*MP4BRP0W!A@I:LB>P@DDA:5D];BCW-KHY8;)*J73JE^'1
M;=2@?A3IO4*/K.BI#@=8)!2)UB9"PM:-?FU08%A#,&EP4BJ=&NE$;OF,@AQG
M0V TFO5DAD"3!GD!V3SQ(JRQFK34YMX5H.^,4.T=@7FO>K+-'=9<Q<*JBF9[
M T=TW@2,02X5-(!50@05:&N[=$\#Z.O7;D7'!:S!;\,J=#E86/A56%$]$#BB
MBBY.'-R91.?7=)0K&,$&QR7GEZAGL\!;BJ]+M, Y>WZWWRB.(.Z3-HK+#[<E
MMBSQ#+5QN8@GRS,TL90Y)&>:AK2I&/BL$ 0.UH71  _M'SQ2AMZ-EH\:H2?3
M]_(4E0<G\*I*-XL;MO4D(1+4_H7W!-G/]_9 S._A$$)']I<6N1R0EALL$[8Z
MP >E]>;O]0BV8%CJ#W\Y8A.1+:,<]-1AM![^V[A%ENK(T]2RR98,^FB@.+;Z
MR\&@/WH<]/INN?]8+>'_JL4_QX,#Q=5=W.8!6(PN_B.W#0:=.[P\*9V-GS_)
MF]-J]0(^H/]D 9M8$2(1-K$;H%#3YKX^\*C][EA7I5P*91E('^'ZG.&KEJIZ
M-I*;*-#DX'S(X07N^FV@44-%=H$"*VR50^R$6)*-9AW3_)]P:A@ P4//A].A
M;];@ST>!BZ+=[-1]_X2XA!%+D%HQUO1V9 L7C1I.DQS&ZQ?!$?#]C]'%^E/(
M3M;R$ZE\-!I&Y0J>)-37@8VM75Q9%=L@'P3JGB.\&C9Q0!C="=8[@D]3_A0P
MA<<QXCQ;OLCS-7V12S:Y2U8RY[#:S3I(]@CE1JI^CE">A$*J,E#W)ZY0#-%R
M/5*P%PL#8IY&?&8&^(QHJ@Q1BG!-^-AP2_[U1Z3Y/!.=5433>+1[%,VS@YKO
M0O*2@)P39J]OZ;!R,?.W-W9^XQ.EICW"E[[GD/9)_HF(<:/<BF8!$[E937_T
MMRMH&BU.& Y^<DFX]RS0D^U?#DH'PF88,V1_P><Q7A[+SW(<\4:!/+!CAU_Z
M?WQ2A. JEX %B!EL^J]&-O3 !-YBC6>DG( J'+;+"S@W8N43;.9@$4^B];]H
ML:V$^+!PR[[\&_-<:_63,+@+3*0@X92$,51FKBQ^_NAJ+\*G6JQ6]P$^2Y#Z
M?\_L^7^O!<PEY2>6<S"-J_(Z0$SXA:D_, W&U K1C>QJ4\DZY,Q-CX@#LOST
M4X27+4"@K%+.%.P6G&XL)L1#7[Y&^GAIM1.:?:4C#*DXSXJTQX _!SV:R<[_
MQ]].+CXILX<(_['Q/\B1X5]@VCGOWD,,S'EWSKMSWIT-WGT?YWE#CYBT;^1-
M6]CBRAJA9\&O]!YQA!U$7& 'OC.+^'S.YE.)K#F;S]E\SN:SP>;;;*QKXMI<
MEZEQ*LV;,^CTHEG.H',&G3/H;#!H"HSRKZ=U=Y+SY?1B5\Z7<[Z<\^5L\.6[
M,0;M>:8,(/(<'G:EQBM;A__E"><W)K>:(N(IB(FGQ,B)R0'\#MY*1L(X^N(>
M-TQF%RYQ9FHYUT\E[N9</^?Z.=?/!M>?#P3%X#:0 L#L,7+4HTP3D?MB.Q@D
M2PU5_:#L(-<M$@$M0GF#X&=.)4U$KA9%^/TP+?4'1D@75^/_*4Q4Z!(T_%C%
M6S]&^K#;UC=5.><#MM*ATCGISFZ8KV:S%> %=8>"FD?P%*!H 3&;E)4IQ)U)
M*^.FB)/6'<=#H29Q71 !*CT@[0R_X(_CVJ A81(!A6)C)&=1;A)_#A+^54K>
MLF+J^T13,\<PLN58X^$DJ%"R0<"$<.EYNH'Q>68DJ8S!2E2,X0.=#O,H\%<1
M[&KXUV@(.-0+ ^@]\J&N8KYD)'O4$=GSCA^C'R1U: I&:B(00*\<4'0%C2TC
M7'&C?LPYPV0,2@HP.29&]3DF:G"1Z:0.^0B&IWP3_&QS2C+ DBPCS.60A>UD
MZ6N1N3M)F!BU=PD9W;="!1FK;.N8%T'Y0$,8 HY%1/:3=>!'>OH^=WA2)+LL
M+R7FO^9P0U9KM#U#'AHS!I:MN\.1$^8(]4%1MY[\<&TJI>&(8Q45TX&63,XU
M_!-E%D6B$CZJ,")E]5W*Y6/&DRZ,G8 4!0L0Y@G"EQ+NL/2&/8M5XAF?LKE,
MO.(F4 EF(<X43@P,GGG 12+9:9.^E14*4,>EM Z1@QU=P\(,HO2D!D34CK L
M6G#8;X+,%G9V!S _4C5\%@387@K6+% 7-N_U&1ZM".G79"(Q9IL[O@$;6,>@
M ;DB0I=I(\ I3!,(;IQ$"G 0>X!8"?-@4I(FZZ0 ]Z<$X$@>KX&Q"2,@$=!:
M=!R;$ND=S+B"Q?LY5TZ8OD?+\_-N_+HP4UE4@J%[8^##;DB41\H3%U51>L"P
M.24IL6A4-:90(Q%1.J'M11*8CN [@('C^KJ?2"]5 !B.+O,62 9$.3^P$KR:
M$RO%8@#/H !2"-W4J7=O@P.+UL5QAIA7-Y=&)588'(>0RE3^Q@_>H'4<*89G
M#@!F'DBT(URZ*O/6*'=L/C%V86+$XN*A^Y,7L209Z7B%9*33\VHD&:E46IZ,
ME *5'(54/62>Z5::93*2$#YS&H],Q076,;!,*L+K(D$&;$.A:@.49"NDKTR*
MTB-)69BQT</<#] V;6D!^NI3H##%"/>>;3&-$OY!5.N63%L(Y7PH,6=6'257
M!T.OHFI"^-I1H'M'JKK!5GP=($[DDYHJN52A-RE(?M5CCBZ6(6T /]4JZ'&"
M^8KS4,9B*2-+"P(+I/"?Z-S0PASH&!&?L2I0%VMF7J5%KU[5X?7FEC)E7$4K
MR"&R)?3*O3EG0IUMOY:T(15RSW8549#B' ;HJXCZ"J1&MXB#Z61T4_D_F8$:
MY[:8R?;70',R\4=AO#WRJ4%E"NH"XT58:I@R2&:@!4)E*/5/3LNW_3J A.B"
M8P>>0Y$@.Y<-*+)T50OLI['KH;9MLQ$G3X6?2#^](-+4^6 B=N[X6R>/!\*-
M[K*8.Y-TK#BJS;GIFP:A[2J3(&45#M\2=GQ9$-Z@8;D<S:!RBH8U)46$*DK9
M^  JLO$VD,JX4\7++TY--> BGJQKIF*Y @10NK6Q)06Y9XK^@IK";7G<:.>)
M:D(ZY;<*/ .,N 7[R+',(^4/=(N!=62*"A@=X#M7.A]81TH=S@N69>JLJ'2\
MGH.U5D2](*S)(27#;'ECYCA<EG3R9^,Z5<T0H>]@@?;#(['H:\O#K'5[C)<1
M7,$]_N5AB5!;=O=Q&!P!FUY037&\$15)@H7@  NA 3]0&27B/V@34S-,L$2M
MI\L\G74_K[#RR]_\\C>__,W&Y6_EK*JTJ8;:E;S>-4'?8N1!")L)5$M'5$4U
M#]1,+^[E7#OGVCG7S@;7IK*O!:M? )V]@ :[K(MMD5U-%H/CRLC+<K5R!&^!
M@8T],YR_BDH?6W/DC#RMZ)@S\IR1YXP\&XR\3E7]7"XN]A5FTNU:Z(/)^71Z
ML2WGTSF?SOET-OCTO4V-$K %C65.E*%%\1.R253@I%=:?O-5__G@YJ-.E_M'
M5!NVWP?N3D$)?;^7PR.W'=D=*Q@MY_WIQ>"<]^>\/^?]V>#]3;- _%[!6  +
MFT!@UL!$4=E85-O7\Q*/J4:YG%GGS#IGUME@UC7A01E9&G;=HNZ&U!HW2*50
MCY1'W<;<!9$*0,'_II\(YK=4R77O]")ESLYS=IZS\TRQ<[^ON BV%2ES&,OH
M.!A$F#/K]*)<SJQS9ITSZVPPZ\!10KEWTPG446>)+.Y ;9F_WMXKZ"D'V!@Y
M'T\O-N9\/.?C.1_/!A^_MXS)""\KQWR,:>-'<WGDI(:/IIK_.A,3$XAD.C4S
M15- 9YKQ'WZ[OZD?*:W;]I%RVSE2N*L6/^1L/[W(F[/]G.WG;#^;;%^XQF<X
M__UO1]@37:,<[IZ'RSI2X%=F4]FK$7>'ED;.=)X7^4TYBN;,/6?N.7//!G.O
M6^8C%J.@Z$2J8V29?8NJ@.BJ;3FJ-9X<*7W#>E+4"?:]<VWX?..-=),_1PJ-
M_-7N%N[K;3&$H9M42,0OZC$)]?Y7%O8-2E>L5O5HA6(6J]4U3%#JH6FZ(&RX
M2M5%[FTLY^"*BPEJUSVP.<=+B47EQ7SDW?_"C$%M+4 5U[8,L.S&8]MZILA6
M8Z(<ETX5JK.G*6/F4AG.P[" 5^6TJFBZ#7 2A<:FJJ<$=<B$BE"]F'HTK,:)
M9#.F0A3A=U3^"(@I4E+SA"[ZAQ/-MK2)"?!219EIOP+MAVAEL8:'9P:$@XQ(
M$Y4X1!C ]/9.CTN*ZMDV; S+=7)3]("DG>*C1E YY\FR#>T)M2.JT7AR!KO!
M$I-4JU<\3X=(!3N[,64YX@:EJKA4%+BO&P@7467;\D3,,<T9V=:1W[SRP:1R
MW90AZ&!AH &2/1;HJ+6;]W?*8:UOPR1*FP\$,XC'YSNLY"AKY #X:A[6R3%T
M&.:+S?ZK&UCOPV0:UOW .L?T#TX"T&4.X))R+_84'>=(POY(^5JO*X=?/:,/
MH CJH<#?GJGJ!DSWS0)0_V;AMIJ.S3A,UP3X,_H'L-:A/VWVUY'R*ZAX#(;^
ME8WQGS8?>SV (D92_V;9')Z[X3UFXNRW_%E7K2,BHO]P9L"9'REWM?NF#Q1S
M-6#<<]N#_\*^]?$8^". N>TYM.MKKLG='"D=!B<#!\!ZN-H.'!(;PXJ.  68
M+B;O,OT)5_U@>P./ </]'=#VOQXWX(7?=>X"+LO"+W#N0T6L<E&1XA5Y9X2U
MS+'/!+SFM8R%^$!7%KS-#H^TGJB$UA0W1)[$'$F_<33^,G_T2Y\ZW'[$QN*R
M C*POZ#N54SU]#<HFBLY))8!]XM\4]E5NL29;H/NETTF%BS[O409\%01Y\MD
MA9\6*0+Q9LNVC4I%KA3G\,U%,HW.2\7CTU4L33F=&.&D> P;\K]JTXE-?]>5
M(/$_?PF!)B8^.2^>P\1REP1"!TQZ32F/7<77#OU?)<@7/T"K6ORS32N<__T@
MV?E&@8B?IPZ\ F#%[W;&OZ1<^XJ:R0JF\:8/]+A<+!]O[$#?Q8DU')=T.DWY
M-V?VH?,!F53C>:P+0?W_1T_QHZ1.GT:!MM&,^>6@<A![O+TYVZ[1:-0;Y4^;
M/G?R5.6$^EI%0_F*PDATW%AVWCO@R5.'62J>G:3@/'>C;WW[\KNR>Y:[RGF]
MDP.IE*H5+ Q6/:7_GN64E=*#K-6Z.6'MT7D ,9T029WG))72([RYK^4DM4?G
M@5(J)Z:4'MX__G9Q?/*IT&BQ>JX![M/!5$J5\UQ0I?H(:_=W]6I.5'MT(J'V
MA_\]+N6DE=*#K+6^WG=O<N+:IS/)956*#^];\[HB=,&<IO;H6("FCD,_X-X)
MK/"2;,$Q)23 %0Y[YI&,G?>WSE7Y[$MY#P1;?K2;)^6+G'RS?<;WK?N;6DZ\
MV3M8D+WEG'BS?<;73'4M6RE7<OK-W-D&-^G[9J'F)[WADVZW;W,"SMZQ NGF
M CCC9XS^IU-Q%YE3<.9.-Z?@[)^QI. Z1O+K9D[$F3M@(.+J+!$O3CV.Y)VK
MU*4ENEW**5HM&7DWG>?+)9GI-+1#=!WP0L_F[$>!]6$_E\QX8A/G0/F89T3E
M&5%Y1E2>$;5&1E2N *5?/LX7#MG-.NK/Q]67B\3D6E@ZL:Q2JN17B1D_XV_U
MWW/*S=RI N7.V4\YY6;KC+\UK\M[D*&4G^OF:7??\ISR,]XT[;:_E7/2S=RQ
M NGN6PI]?L8;#YV]SDDW>\=:*55+%+E3R0DXVR=]W;XOY!2<O7/-]>;LG_%O
M[5KG_[+WY<]M6UFZ_PHJTS-COX(42=[B]+RN4KS$3L>.RLOTFQ]!\E)"# (<
M+%+8?_T[Z[WG8J'DR&F+BJ:F'5LB@;N>]3O?N;NZMVY;Q]+]=U?W=NWQR?-V
MLW8/[V[OK=O9.\5[^_?XY/7#O^=EUKB[^WOK]A8I@.[N[^W>X_?_\_>[FWOK
M=O4NWGS[]_C#VY=[-X4QY6YS_X +C%'G405\6:NMZ6E/-%F9[+%Q[2=_G=7[
M/\=-@_W-3JEO"[6OK)8)-G/9TNR)^Z"XW[29"7V</]:Z>I5DBU^[IEUI_Q?[
M*QB9*[%)2K/;'7R>2U>MY(.;GY72ZW/W._EHLS#8+)G69J]V!<&DM:,/[OWH
MH> N/=SCQG&+LI*^T37P];S\EW7IZ;<-@Q%_"^=0.A/EI>_.\VM7Y\TBG_=;
MF,5]>K9T$]O:$>RJK<!LQSC3CPT'^I(ZRJ;)CW!WX):ER>LV*^ _[]=9CMVU
M+O+VGZ[F/EHR3/ Q3Q?5ZO[E#<9Z7<6D>=CV3F$C#;]2:<PEG<9LCZ]^9Z]!
M%R_;"2[)BJ8R??:2LEO-7(WR2(^>[145=;JCYKSPWVP.^DX/L3^1?M_'=E.W
MD :G&R+;(,<6/T)[[(K3O%OUUMWOS7-7PA7_Y'?G95[R)W07S>MEE]+D50?+
MA6-]C?<,/RU;_-;!Q^D5?.7>7SB0$_=YR4R7OF3C,EHDYVL7J!.@RV#J\&-L
M2.]"/RII)AC6%-M9-:[%[\"^S%Q177S/FNT+Z+>=;$VE#U+)<T@VSC?_0IOQ
M\<'^H^_NZK.^H+[^RO59#Y[N/SSZ%]=G399T_LX]W'NR?_15]_!W56QMO\QW
MK:UV]D9S'RNTF6#;O):L4&ER'TEORY+!*L9A,&S%7O_, _,5I/_.G8:OY+YD
MO8;)(YW!Z='2&/N;O]V3LKL?P;:=MU6#[D^=GX,P ?<!++X5+-[)WR]]S/VO
M5[W74RLWK[#WAO&7W-WMW=S0P=V^Q^'<<V8Q>0!>6NM.Z[R\?W<);\J>>3[L
MI_SGW86\19M[R85\?'<A;]Z>87/*+<2:=U=Q-[=U>!5'[5EQDN[NXXW9.'\?
MQ_$'=_=Q-[>58@\9IHC@^C6P2<F]1YCO>GCTU[WU6=6LSS!HO\I7^?SN,MZ8
M7;N[AK=L0T_.-DU.<;YY5A2;I,AF>8%JL/SDZN;NXMV4?9IL27MW\79S0W^P
MMVY>N.R<\KAW%^^&[=/=Q;ME&_H!?E!\VI1W=^W&;<U=_/.6;>@'^I2K:P25
M:0#F[K[=E.V9+,>ZNV^[N:$_/__YW=U%NWG[<G?1;MF&GKAUBPAX?]>2>\].
M3O:.Z]/[R=VUNRF[='?M;MF&CER[_WGS8._PX-5=CN#&;-(DL]WU,,9_*)3X
MEI4.7&WC;8W)K0"$W[)=_!IP\5>V7$RAX5](APX/Q4OZOR]^*.Z4Z^\K;,WK
M19*W4@%Y!87Z+]O0.TT[9=\^'+F;=]7\NUG-?WG[P*^^<EA4R\@=6(M%W9V&
M\B&9,%7BSK.UXY)9+&\OW&_T^3I;YXMBD[CSJCB')=Q/CINDZ>9G:7+ADE6V
M24K'1<O5K,WR,D%Q@&N?%?[I^1Q6$IZ]KG-8Y!8+H5<K5\]S$$]<+HY;675U
M,H=74G%RLY_\3]4ES5G5%3 (=Y[#:F&-\1+A?W63Y+BV^3+G,F8$(1T=_/5=
MWGQ*7O(GZ$>'?\7?GF1UF[S&ZF.W2@Z/N7(X;Y+CLNQ@F._<NH(/P"A>8A75
MX<'>WZ])X'"T__C)5R1P>%N5>R_PS#>PR[!W/_,&++10G\1YDRSK:@5OGY^Y
MSY(,CR^3.7[\_Z(.F;^4R2^PY5A/?W2(J,/#PS3P,239_'^[O,8SJO< Z^C@
ML'=M/F^2&:Q2Z1JJ&W]5+9<PPG+OYXP7!@D$YOMT$5[N#W^=_-PN]I-[6(7M
MYBTM=NK/(GY #N']?5MU3D7N.*B&+@I<B^H<CO,BZ9KD(F_/DO:BPKL":[Y)
M&K@6<T>C VW>N>^_1G&Y,=LO;^@IU$!<@GX&ILD>OALW]@)6?;*.E\9_Z<&[
MTMD1NR;KVNKJYZAP+<C]/5FG[Z]TB,=U["4&F%A'^P\>W(3UV7)O_[,WY_^\
MUF*.=26\DA!8N'G%UBV_\(>! 4L3^5J3D@+)827EU5Z/!P=DQ.._7EYI>5MO
M3K1V$[L[>A+&5U^^YKV'*^Q0_RL_U!4HCF4-E@VH2+1MB&+&L7BN7;,&<8\_
M_^0VHP0NJ&I4@J/*@77,3T]!0>%29FWS/5HZ58E(LC3Y^/8X3< >JA8=FEUL
MLRY 9X.[WLV0P@7>#/_IYFT'[_Z/?WOT]*_XF?Z)&6^#?:<H;MAQOU,4=XKB
M3E'<#D5Q#*YS?>J2UF4K--&;>8YN:0/JP/T&.@/^-6</U3O@%6Q%19Q>%:7%
MU!??3ZXFSR_GP+EB7.+@JSIMAX?BR)SYH/0Z.W5[L]IEG_:R)<SG^ZRXR#;-
M-\FW=WKL!M[&+Z;'MDBQ*UR#'0O&G70U1B];MA+SQD8"4HDJ9 W6UK$E&>(8
M.0H5$"ZU2VH.X(#L QL1[$0*O/DPFV=<_)[L4(G^D/!YAB=\)K(Q.3X%"Q>#
MG\G,M1?(*2GOAT\>%^6F *%V<I;!R.<4+,F*1@(B]R3((9_2,$?"O((_=<4F
M^0XC,0=/DGLXAOCC.B3]&ENT^+DH<J7A*IW MN&^>?X.K6@:' _BI9O5'=K?
MAT<TDJ=^T/39\3'@HX;CN,H GN7MAD-(:R<C>._6K2.:Q\.G'):*%N/9+Z_Z
M@XA#28GY,*D/^70S&E6Z+4'JG^-C[,*YAMN@OI;RML*/5M4B7VJ\'W=@474@
M*?;0;RHQJM93N'"$ R5I_&5QW&99XU)PO4ZS.L6L /(]U/R )E]P"0*HJC0Q
M6GP%JX7A1$DXP/^B1RM=YZ*"&;<)7,$B;\Y"1#+#+9<3A#^\; [1SA\CMZBL
MUH("^-$RX3S].L$'+E\?#.^#$#(^*:P^_&9>YS.V9C[NO]_7Z_FVVD^>I@=/
M'J9'!X\BV?4&=KG,DA_R"IG)DGO+;S]]F]FK>C_%UUR =L;_Q@]M]D&$/#B$
MIR('-KS@T6'ZZ,D!+_#3],'!@_3H\8$]"5U95/-/\'>S+UF9%=5IX^\^^-K^
M]A#;*/S +]>%JXWPG6WZ$R!QC$YXU^!W?0R9)Y,FLZZ%\:Q0&*\QY2";&<F;
M020X/O3+KB:6-SW\(P>^%QE@;KBNX1CQ50X/?"AKX4TE<0/#O\"*/N7#N()I
M9F7>D#&+HZ:SOX1U(9)7/1C16;"2SY,?C^SEP7</TT=/01)^ESY^!%O[Z#']
M]>EA^N0[^NN3IX_3AP\?XE^_.WB:/CI\I)O]Z/ [V.RC*\N[&Y^A 65PY-4*
M'BM6C+M-LOVZ1(9C%)&&JM=+;TX/N@6GG=02P&2@V"]T$?"\D0;$Q-P:"8OK
M=H,2._DI*TF=X])1[O$4!H570A^5&9)K&.:>4_V-YW;&XR!'H:XV6=%N]F8.
MK_>I#E',*4Q#SBC^1\8 @1;W,."'TCQY?O)L?(QJD\&$:M? DS%#NG"@QZLU
M/<GF//G6[Z&B6> 3%MT<V8I/81D:T Y) \,J:$!Y,R\J_!0/!!<"'C0#J40K
M3/%('%/@--]//M(\\#H7@Q.6^N7"U.W,P;8@>XJ(EC7\K&MTV&3IX-";K( -
MA"/EFA;V'S\F*?-ETJU5;1;5A8J>17Z:M_B%(BAE,#SK)K W%YJ3E.FS4()_
M@(W5D+87L30'=8NF)[(6D@%:N[F#76V0\?@3 TJ),AI\!QIMWM!P8,]_Q2@M
M@@2295[#PH8MH"G%2M2GK3&'=X5%PNGR/LETX1B@'PZ6@9RP'$]]*:N'P0&4
MGKK;NYUA/C;I2YC9,>R8)I3?PD;4;;[C#0-^*5'YPWX](,O]$1.<*YL[A5M(
M^\%YR$J>?P*N'6A/\;2V>0_W^H:]_Z;_C/<(Z(;KFB9KXSVR16F'Y3/=^GE1
MQV)C\B81J$-D%5@:CJ3>?A+[I6*6#,>5CK\0;O5%UGB1G%G)H_+]DAX+2751
M\I.$)K]@&\S/W9A @RQ^2J_WIEMO_DWL,(?11:IHQ%'=\R_O.VHX"3_[T>D:
M'(Q_BFR!?9/'9O@/\66:1 [X9=2W1[?.&XZK#@00F.ZZU'2-4"+-JW-':F_8
M#R,78S+*6 G13]T5\MO(L1D,;VH^?F!P78QF#BJ;MHA>((L):KLJT V6Y@:T
MZ>#!%(M48!)G^BU8=CIZ0=$;!>)7 @1RK6< #VPOEQ>?4STR.*!/)<CZ,_B?
M]:>^_/(%O>T/\M0YG+B&Q@1*^V9.&I;='U=:@B)?4=L&OW8XP6#-N-_RAI4L
M#'[980K27YEQ2\BT_!C_ *GZ>;92D\M$D>BVB@! Y0G[-',@K9V*8P;X/+Z?
M&E3?^%O@*;"EY?A1!QU_14OMP4%DAYVZ4DM9FOUDIY7XLZQ>Y'"PFGD'MEDO
M-H@+,=!<@D\Z7L$J[+Q^#^&YH^_X4&U1\@C)FEZ@+"P0*09\Q@H^\[ZMYI]&
MM*A91FNNOR0K]0K[D/)WU11&5R6IUNS-5[$4&%YZ= ;>_;)W_.;'P_^".S_,
M=&%[HJ37CHCW\9N_I=B0:/8W?*%1PANRZ^%G_9O2"E=.Z#DSCP\=WR2[".\=
M7-Q^I'IT%2(]^DNQSIJ\SLJA#35<K<L7:-#-J02U6:0\:5BZY+NG!\D]7,>?
M3X[OL]^"WE5)6@+9$]A2 :O$CXP#3F&@]*P5Z+@Y*X?:B;;@K\(3NKE+7.'.
M:>6*?%W!>UJ7E_>R^Z$!$$QG=*G1:UXX!$>S.FL^"7B6-PMWKH*]@C_AJ_U]
M@6UT<&3W$W#J8>_/S!'7Y80W7YQ5^$I4HNCXHW.-S_8N6]^1'.!^[<8CZMK'
ML,R-:K-/#L_U*34-BN\H7*NPK7]Y\$A]3K09NC581O!B[ZWB"/YR=+@??8HP
MQ0C[)3!YXD"3MFAR@(/9<JA_H_,M[:O]P;!7?6 -Z3C1.@4==$I+1'M+8Q;O
M^2^/#Y_L']A1R66.AFX6$YW@4]@GV,S-5@\]&M!K;/=TVH&( 6'W7;R0YF[\
MY?# #&;P3#&::4F6L/W512Z]Q++%"O:=HI+B%]+BDE!;(&4K_"2<?C21DS7)
MQ<.>D]\?->63C@Z.#J;'?/0[QPRO;7,_W@S373"@HS"@INT6FVCD<6,OCO=N
MV]TL\@7^\O#@(-YK?@*;*9^_PV)"M9%D\;=G\D#F(=0\/?)!1"?$-?":^\"&
MCV!M'TLR,)=V',)P])D0AEW-S0T1,5\MP!P)L) ;%P-?4N9TS[-03,(.Q\JU
MZ$Z OG=N(>4 /N_&5VSI,)#KR)OBVP6NS[HKM%L>?F42)?1UUD1-N9LVKGEL
MOP4A@%)(U9NK\VK!S?W<#1O_XH:-!YWA&S8DN8M$]'WXE%$C=/5NV#BSQ7F.
M#LD-&Y:77C=L7"PM;]B@\O:&#2BY:=N6W[0!$=(%0W/E@N.(Z/DU-TZ!(JSN
MA@V)U>.^P0/O;(S1@@_?2;1U"H4HT<6?X+D-:)%1Y&%_,88H<&$S^!WAR!C<
M_76#DUK0RNG'[[:E'\<"8Q(4TZ4<?"+.8TWM#/[REW4/*MI_]L1FQ@E,^7 ,
MX-F&Q1_TSN[->3*RZH?WT_-GDY_J#0X^.G79KG*^KNS"W9@#%H)NDR<D];_Z
MC+#I6'SLI[<_[3UX^MU3CI:^^N&_3;1T[/,M,IKL8413CE33S>9=FY6NZIIB
MXZ-,=!KZB6#C\\V<":G@Z#%0NJXPMX< $!NX7L.+@OR9G]58F9><.?PY)MU^
M2,YSQ/SEY=+-.6SY@]M4@A7N3X!#2(??'H78T7 -PO).AU$U0'/U<.KXN_:W
MWK084_>GO@03HBSLU45>%(@'RB1<UCC,.GH,%'P^*9&G@M.#'M U1&K0@S3G
MZ/?7LE]\H-;VX2?<RUXP329;#8>FK?,Y0R@H3%R)X<7I=O,$LNL9XUK4X'=L
MID+:ZWSM8$PNCG32F,%EIV@YIGD02+!)R9E?Z0$D< =(C+$CBW>9%LS#V4"I
M<T4#G/YE1V#5V4976S,<&"5M"1["8.PA $ZWQ[X,1-6G%"]7TRV7.95E43 6
M@[\2ERY00%#4E]"JKRGFCS@O06W 3CY'MA2#4J$ TO]V^7E6T,'(_.;"V8V/
MR5F&G79#L -/2/8IQC]<)CNW(@T]D(/3Z?!5O*$PCZ5];=YXRWLQ/,C73N#@
M^A&>CU_G%F$@?S8I<NW\U;W\?O*7PR>/3'H E=8@DY7")_&CT2>OF,JZI(12
M=N2;OZ%-)-I@2DK,.?'5H(U%0X(QA?P$E3KVLEAMA7VEX<3^Y8G)@>!WS^]K
M*NQP_W$R"W.Z!(K:A(?CN;W$HL$'W+.O>OH9KQJ^B06^R>VHW*>;B7PN5]4P
M^\F5C>%+$C>(<8(WAT0-SW65+_9:!^LQ,J8!B($+"GP&:.I[4[5DS&A#F%Y:
MPOTK6!B?Y],>[)9#^P$$P"+K^[.D=([W_WBW]F8XLA0E[F=P^SC:(6B6BQ;W
M7G9,\3:._9 %GO9RK[H-]J3>BQX^"L<,LG]J!.D5!>[@QO/SLMC%8+4]K_;4
M<AP3RY00.OZPW<EJ"&1S?2^+UV'4U6K!Q&2UPV4@Y\ZC2A#?6($1@88@;4U6
MK,^RO4.8+SA<]6;=D#AFLVV^V4_^ 1\2+?2Q)+#B^Q9-VE1G"Y;>4JH ',%#
MV;R!I8K ? N/ 'YT\.VC URC90YBZHP+03S'2K3+OW0ME?V-O%VVB5Y78!X2
M/W-:5#,TY@>F$M=KG7*R407VE#D8@Q!U4SWNU=^@J^@ L >.#OX=/W+TZ-]1
M/I=N3#8/C'U]X%\>1)B%4:-$2R_&!A2\[FT(!U.=8?2[+S'YRY.'9A"W2ZE,
M*9)1U!N=@5=5G?\3/F++$)/7B$^&[SP_?G:+-<I/'1ACAP391+J_+8'1S\40
MZJ)>HD@N6_LQ+2+?";6GR13R;7(0%N\0Q0]B+"9+: T]_ ;+!Z(3D85GR!(-
M$A\%\+W_]_P5%]]&,;%(9*]=A:AYFG)7FJ*,TZJ;!A:)BBK)_LNPL)<A%KE!
MY-L 08,%4UPB9F4#+J6N1"2+;)7?I!\]7 YXW)=P=_O8+T4>/KQ,.A( 32>T
M150J(/!QY-E=0X"F^K9M7D-0%:)EP>[?B_T&N)VG3G5';-]_%GLH2>(KR5T6
M$3FZC///@7E]AC3Y$1VUDC;H':]E3C"+769#-7/*NO8,CIS=V)X!D[4<-7!8
MLUND>!M;QT>FJ/!&%'C>]!"52<4!:5 C;:WE+K]V==XL) 1IR17PR2\ZC%K!
MA8 7HZLOK,I$;R''%]^WJC 41P]'<77:L%P?U&=("9JCBI34GT.M_TP36-$.
M4<Y@Q*7)_W9P=K@2!&67_2V.#TO=3W$5UJ ;LU-Z(ER:FK@=:J206GQR;DT_
M!SV"(5%^YZIBMI9L02CYAK^)=R%%$Q>69M;Q)WR)JJS@BIB&F9.:28>7Q,C,
M*SF3]K*A2#2F>2B4)AD+8AKG* RM:] +%2/]E+(1SIQ?:S+.Z8TLRN#;<ZZW
M14'(-=I4_V-$BQ;7CATA/1@X(JQSVGHTL@*WF9,L2#&=$XLW>P <8\4)X1GL
M]-&UOY;\;SXC=G3FC!-0'93+'H>AJZ;=&TCPE%8'2ZQ/2ZK#HMHX@L7+_&1!
MU60(5<:R^*%>&\<#/WCW'__VX+N_/K>:CH=..$)Z)NX&; \53U$E\ QF*4H7
M(\=46Y67L![X(]A<9OT=B-8=!\P^N"9@]HHJQ<C@H5:Y^LR_'%SV:XSB'7.F
M$RI/;S <O><D;<:N\B0()CX!W_PMV>YO[8B>?#VJ$*D,Z_FQD36G09^B#4;7
M6Z6IR.X0&WW)BC1Y656+E-8ZE1!60_Q R?$\=CE>/G]V'.J4\!<G5(:9O')@
MD9TE[UU]#K8M?B_UX2 K%%$==063$^@XL-9"I6C$L,,S$FW/0>Z6R67'1>Y^
M\C++"Q1:')%8%YN!N"[<J3S+2.4(0SVN-UIJQD#2;]'5:B^H-K.6N.BH-&@B
M_Q,L9$*Q$5D &Y\G[1JNA\/==\Q28XM4P/*%!_P*UHIP0I2JJ93H)D-D>4:)
M4GX#Z0%40,L.%#YF5/3$X(LX .4;4L2=*'#A%G5VP?=0!XPF [T""RJZ9LT]
M)_ 3 ^(+V_?B(N/*5B;QL[JQW:S9GS+;(9\*!A-8-^";F1\T+O\GD@NGG*3A
M9A@U*:AX5$8[5G7/VLG+7SN_A,N<O(\YJ$3P1^ BMLC> D]B3R/5-:2QXJ/<
M+*N#KV2N'9EOH%P;CSI!;AG\D+%=DS.Z,'.BO^+0)[T#+,56A@>#/:WJ4\E2
M+"7ZY\>(CF"=P^D@4\?D@ANSS2GGBI\[7!U]T$\=?!;YD>AL)\<@_^K2;9KD
M1XJO%G1SOT7[BG8(5![H>5R"ES!]<">++ ?_'T5#T^5L6(1/@P4KX_"/\<.$
M&31NWLE=_3P_[.BF">3C4B\,%O([]REB=D%GE"PQ8<>6<X>F'$(NJ*W)J*!9
M(48=+H641Y*,I$0\ITNE&.S[*=97YKK\72KOYBWQO</[[$MPAY?6WVFWYZ6-
M1,PJJI9O6O+]\I54PN4:4,!7J;\LOQ!H1F36RZWQ>8=3T(OV#6N\UZC?-$[V
MX\\G/MAF%!&S,^[ZZA_)ZH-Z6H$P5U2(*!#.VD^B4(X-"D57Z_7;YWZUT'\[
MZV#<1G&HG\P8%;H),_!K0>6ZY9)I)FF?JJ[E(9#:Q#<(Z4+_@:2)A!4)%OIV
M;,L#V18O:V883XNJIS&6*GJ$_#,RK6=55B_"7KS[(1ARM5NCAUZ2WTCXF!#P
MS F<2,L;_X965RFGI##5+6['&C^4-1;\F&_?M0!#$74FRA2T4O=,G'G\\*$I
M-L?8S+24F7=UC;M&TL9_?R!KYC\^&Q4V1 T"5P?,6R7IE-) "MSHS=&F06*V
MKHGT@/20&E6>[ RV0:\N_HRO8XBK--CE!Y;Z=FSU(]WJ&HVDD'N9EGK;A=S;
MY]Y#H@7:]?5YK%H IMEPZ&FC(D6.$TQ9A!#YHEB_AA_"8%8.ECSR)IT1CA./
MT+I&.4'8R*5QS&[%6CT96ZO8>$%H%LQ]A?(45PM$]=K-/1LP+F<<]H6_Y106
M1H@U_SUGAS3@=.TU#GYWQAIS'2%(X(6GM5L0P)2"B/HOX5>KEAQRY*<I*TB#
MPJ-O+45R*Q[TB/!Z,RJ\>+#T"O+;SS3$[V>*O69 Y2_$DA.!RU%C+X]1 I;R
M!.^5!UPJ-=]#8DXPPUUYVI[Y8#L_= VC;C>W0YY]I_),4GF(2&@HC"+1E7#G
M>/+HDM&FT>4UL3>YVJ:!SVZOS%/K3=A@/G;9Q.B[G[R-!YGH"GR.6C:^P-9V
M05.\\2XO.'&$F<$+JB?_W8LW[_W)QSA%]"9U1N2-"^.[?ZZ'O"6L_'MSDR-;
M\#F] TS>_+W,DPJXP&UX^WS$@[4;>UOBMB<1>( 784[F.A<\3"V#;-8W?P,#
M\CP'D:?+P2MH75PCHDGZ^>P[$2=ATJ\!V_U<F7F(GKA!KVJ>-:YO/F9)+;Z<
M4^2PAR5TC=18*&""G?'!_*B,P9=^:,2K+_7C2Q;RL.!3QT'=7RBP%-QVX=D/
M;KD+]U$-7!+HE"">L?8D,7^V:6B@"CN/M:W:PY+NFI.BOE2)JK;U#Y?"!U)=
M\?O1S4+-E,O/E')(@A/Z?HPN&H6^GQS3A4D(!8*V SK&9)ZVFG;NBM88]RYR
MJ6F'&<W/\BY6U7G)3=XD8I<5&Y[B(FNSE&1>=I[E!07/ _($?ID03I):>:/B
MI04NX$K$&)40AAE+F@?#.FL\"3W+A_WD/9[1_FPX>2T2&1.TKMZC!LAM]5L^
MQU7UGY);0FO $6:-!B,P9W OD%-LGI>(.:('<6P>[8V\[)P$[G&XN!=\Q,F\
M7?@-PH8VN)(<NN/016-B%P\.8.$VC3R*T"SK-HK6=F6!UUC\;;:&,.6@JU1G
M>4.DJ,0524V@_[?#^>*E,HRS67#Q>OZZ;-/<L;#@'U;&;SVKB@7QJ/$BDY!(
M_;SU#.JIQT'1><0D<$$ 43C778L7B&ZS'ZJ?D^L/"<4AQ6>H67,FYSFU'I@_
M%=S"N6KE0QI#I1.D1%E]%USAJ3"0H4[=\13UPS\F17WCC+>K]J'[H\?QTM.Q
MZ9%2(SOK'VO!;M.Q#9E:/+]T_^P7\,XEU-L"+SQQRB7'O5_G!-2C%F"46HML
M196D>CV9\!=>-28(HFQ1PI_FK!DS<Y:G%2L&\S$<CV;8AN.:R@E69;&)>HOX
MKV*](UD \(JH](@D_TLBOLK0;TX1_*+M#)!/LII7/M_'Z^Y_FC?<K@:W2,CO
M,?-*$/NS'/07:Q_]/$>&%S#Y:C]Y6[%/#EM0]@0UPJ ">?Q@V^KQA0E;SI6H
MW#4[VJ4LN:A1@R"F'E5G9,+,LB8/Q5LLE</IL\G5JX^([$Z[^;@ M$DH3E=6
MR>' L=P/%I3[\$3'2]WTX=-DQ=E.]+/'UA'\K85#;:WUL(07]?9':"TN)UO?
M-Z]J;%:K67=?:X'VX!IC45P%,J=$FJ8B+Y"]A2,Q&_TF797QP:,6TL'_KO39
MC?._7E% ^EG?!0.5^;Y;*YP//@$^_I_$&7LV",Z?D]'23M*!YKW\EF__44F\
M7QP=BZIINC7"8%0(4J2)KE!X6%6/9@8PQ-_SBX0VEYV>;=!3_R4^X!F!T*5.
MPP_22*&\EJM'1=!EPWDCDDAX6X*YEHLXF>=K7AH<.%AY/1+4I+^X&* 31]%+
M>)5W3#41!#%(A2QGP.K4#"79=QX:1]%#^)<8N5\Y@I8P@+1KF (1'I;#:E.Y
M5$B*$,8Q2HS,:_1D\DR^+AXEV?9!O_@$R8A-C2N"CB.J- 8!\7=@6.6"@462
MT R.PX3_X]7@ZT#%2K+[];L?1E)U)MEG-ZKT (-^QH[-=0^W4Q@0K2-H(2''
M[F^PGHB\]:9/PX#L+$HXAO@S#I=>IN$"\:48L.O?#Z:J&0&?#'ADX3)L+E26
M'7I3K$_\$X?#GSXX\5D3!/#@X <EQ"? JR(TCN@)>HG8W=.1:*OU$30!.6PV
MD/':O"6;819;:3$&*>O!4;G@FD)O"J%;N,1#[_L OGW]B@MA&)&W !/!18H6
MCJ#>T0_TFOW3ZCRY<#/,\>X\'N?5:/H5A5! TP1Q1%<#Z^'EPN(!)W9G+W+)
M-#IW=9&MN:V#$'FXQ?>[OE1"^?.]0NIC0'Y";5DPG5]0-Y-6,T%4IL:XM4U?
M^PUHB2BXP$W M(R6>^6P/&,AP<8_DS.C<$Z1>!L[4K55 =>*FOAE,[  UU*?
M &J">E&N^I4+[K=Y[?3!5%X+-CN53%&4Z91:W("=G=4T)Y_?!G%+C6JM,MCY
MJR"LX%OV-ZJ7IGB1ME61783E6RM@"G[/&;3EQJ]JB)_1RC41(W'>?.+@'JBJ
M@K!_-4S;*U55O[ '\XV!)'@00A!R=(#<0H^03Q>J%^$&!\8S>6#HCW]Y2_;S
MP>?L)[F4&5$4#7<T3;B2'N\W:-I3A_C3]9D(25CK-6[M('2(:H(B]0/HRTC$
M36KU8:-+*J*DB#'I4O3(-$8Z?B3,61HY'0$[/<"]H+PFPQ=.X-X,1H#E\H2;
M+5SO4:D>)36)?2[9V@+J?FL]5>\ANW^RI($AFI7@$!I#?"RS<+F5,K#;(A.7
MVDG5V,>,E2Z*XB5HX!K]]WY$OIK/.VSTQKHJU58'O&]R(T:A?A@"8FV-L OJ
M%#5'^/VR*Z0>0!P8$3-X18C9F_'YY#KM)R^Y_A3'&R(Y<AI\(H:P^QPXPU])
M8,,-8X&V? ".%6X$3IDKW*/L%S9_+!>>)\N6%09MBU8-LUA@75[C[WQ7@D?I
MUM1[7C0UW87]Y#V(X0*5GW<DYJ2^QP9O( !C$\FI1L+8^]Q+Q[HAV'M!_92&
MM/&('R+1.IY'9)F- >8$K\CM\6RY!@.)/ H&8U8S['7>)^WH2E]CJ"<.<WK2
MIILLEU[0*MB- M*)P#L10I*\><R^[%&!^)A %(3+ $2#+K]Z3$B@=EJ;U&"<
M<#,9IQT/3;WOIW;>AACVRS]-..H8CL2*0A->0O708AX6TL^!1M6E-EYT24*8
M\IR#W&R<'V8=X!:1)K2]!,<P5O,S<#;!(M_TBIH#7HNH%B47$>J3Q[QVX8[<
M&B21,R,IA(G:BSXVCJN&S24.GD"CO9T4KE!D%Q(_B,[JJ@+M!F]NV.P*77@M
MY"$K(Q9&Q5^E"IF#3__EP?[AX1//FD $JGF#N[(!88]D(:#JQ-P)34=YKZ,D
MI^;IXP@]KY!2#-%2X7B1FK@W3E+46H,T'.7CI^G#PP>CXU/63T26"1SOUXX\
M.A^UV7'SB$^$#]+D];Q;,32DZ:5W+K)<X\AFXV%EO G)C:78;5[T>3HY9)LT
M*[1>9UV#Q6A4:K>D'N14VC?WE"78!9/1/O"L1P<'B0.946V<BRP)_T,Z#$LD
M$.6B4;Y:G%OB0!J%M/Q'\*1$;]8!<46I-,0\RSA7+]&MLWPM:#IAZQI\*V?P
M:__'*B#(CL"',H;IPM6<N!<N!#+O24KT'L#V1\(\S"@=KOQ(JK_7(ME^$Z\H
M\!IM5:CL0LG:S.N<>2,C0>.7R).N5/4:MXM;YF5*=HH6D+V0(X]4Z:'@D/XA
MD]Q (T4@%KFO8C7C0'!-/?O&HC$!YN]%)O: T\&Z(3WJCN,F'MWA)OZEXU##
M6NS\AD^Z!(=L/8'H=7'3'DLB7L)T"ID*,?PFTGJ2-G[R$*T81#_8=+9Q'_@I
MFD:*"CU"9.GBS,GUZ=TW2])<>'P_@=#7^-TV$&8@69%(6%T!=!K%:K%DK)&M
ME85[RPZ=+@NK8;2<*#L$:]2POYP.AJG..1J#-HD@R<ZQ%_,@[1=Z\^[;#UI9
M%J!=9*71D!OT NUX?T&?I[?@^$SZM(2!EY($U$<1+$PDV]X"/G>V=6U))R$!
M&:=MK'_OR[A.*RG+8DN9)B %^G@BT+3;3]Y4!+&<G\7F%\K/E9.V\S/]>LC.
M8&H3[-GVK D%WQ2B@P?KU#@*TO2ZR>/D!3"^!N>4?$!^NF#'#8_+)8-H\M]T
M$/ZUNK/1;*5TCSB.#.CBI9RS 5^P/)15*'),UE3+;$\N(3_A\FO'\ &B(Y1,
MH[9;+"CXA* C QD,5)H:=\[[H[,],6&Q3JF\/)RK_5M2 /T#7ZS Y<!B(-R/
M$*(@*U3C%&VHH.G7#7$EEHVIYDV$@>X%00A0)?G9OEO#]D@>0#W*VM\.JI@"
M<1.58YLZIGHT=XKU0G&<AW*]IM['QU/@*#:MY-P]UT,<-I:;X;UI33"HYW=L
M_+A4Q=GTJG]^=&A[_&?GP\AZ8D@_J(++Z[[OG"58#,,@ V+K(RP,8X;-35<8
M812KHZ02G\WPD'G5(0)1*@)6SAN_IQT\#_E"")2?TT=7JZ[T8@F!ZJE433!K
MB_P$2V8+I<+WNX;9"#3$ _1<&UFX192)#,5JFG:I084UQ#&6>F@:M[?&E(WO
M1-%6X+#<FH.0FXHFLA.6#(6-G&/RVZA1.7L<VGRX7S[*;5!A@S#S=+;A+>"N
MY8@D99 B'+L%5J?HK4PGGD5P55 -CN+;MF@>P\-U7(K"MSC/(C:WA@P_RD_Z
MKY#48_6*M"^2U?)!+U2!["TS=&8A&! Z8E-V9G-&IWOF0AB'F.X92,5--,1_
M,Y%KC:IC8D%U9OS:1H-#(W6Z<(@9X,/ZO=&UCK^/K#6233E#BR?[Q&I[3IBW
M+WJ*OTIT^D//87@N,TL(7O GPDO^4AHHLNA4NS##PJNWDN?#% Z%JP8E1C'A
M9B]4':JAMQ9#YS;^AOJ& /$AXDE,H,@AQ;$A[Z$)DZZ3WW+8J_<-86C\IVLB
MAEI+J]@W+2Q G:(WL]ZL8U1#%'0^GAR=2=*#=5R(==5#/XL?8_0LDT!&*MB3
M-]KF'Q(UK^IHH+F6&&C84HH+4 2(S=^34]3!A_@P4!8PFULT1.HLQ"DYMO>C
MF'[@^->:>868JB/JS0<Y7ST[;&KK8Z]09=PBN*V2>#F+WL,K>E&1$1(<*=82
MM%Z\X$A;Q@K$KAW9(6!!OSAWTNNI/X,H:1!?#)T5W(<<?H:4LU2? *=F82KC
MK8I85$Y"B QSEROEB=0\JM7B)G;>R'CM!9%J1@XG":XC;VG="-"D*\;JTUP\
M6I&N">%Y__7 @YHIEYOY7JI4=@QY0V*Z3DC7G#\ /6I6D^V*'CY>"3ZSJ&DL
MGQ4B;%/AB]:2N3<,:^[Q"OHWF7PAF++G#NX,>1_*.D>6.*.DHT'S T<(:2NI
MB'&>7EFM$"O<(Z,XZOK6,X*S,A..NY5#BN.\644/0FM?,9F(6<"K43,V,2/L
MF43WM>C9T*XQ8UX65]N&JMK>BEE]@GQN F [%Z8,/D^Z&Y$^\(>/ZEP6*B.,
M;J.MEI'I1I.;,[(A4OCJB1&%]UEEIC_-_L1Z?H(%+1C'9,R)':61%G_:BR*/
M<)H3O5_:;^"G$]?S-/#-&>W<@V7? FEC,7=X-,C'G45K4U$T&!>1"E,1 >52
MBM%%.!X39:G['I(V*M1<HQ0MEPSQQ^?V[(Z QJ<GT3LYAFIOGF^O9X(]EPY\
M,%9;<-Y055[C&^G!-_OX@4P?%4#WX,M<,+JIZ58KC/C+=$ ADJ;"S'IXI?X6
MAQ589/UMRHIB:!ZZ.O1DI<63)0WW48:J%ST.R><AY3?8#)!PRQSUM&<9Q$?"
MXV@T#9>I2W16]H570*U<^NAP;U[F$G&*#!JMEC $!QX!9DJ\R>S;PO-ETY&[
M'U@(W4=^X3PJ\V_-VUAN@P E:<VI5OR(S;=2@E6H-R7FC0N);42(]V(B.^J+
ML!J+FQU/I'(B7S#12W>A:9RC@X/TX." !/-YONA,#J)'Z:P1Q$N_AL2NPFT9
M<K>UXP@ 5M4T(-@1",BX-P,T(&09IB!"&Q,U$<27#Y0/T=MX\=AD@M>H$3RZ
M$MK4"CT'[B](*1%N4VB?NM2"4GSXON[O8/,H45^X*/_-:02P%5S)E6&J"OD<
M+*4-6UN!T;9H8N#3AI8 _<CL-XR%P!>R4^4+)3A'3?>(3'(E4(H[;4V,-&3>
MM+Q9A(+DU6Q(F?HH5*W)NZN\&UU4>O3*.5,YI"9^R';)XO8NBBKIP(J%@GPE
ME601.4N;'!TFS_9?[K_;3TX0;_7@\/&@@PXML1I Y>2=\RY*5F@NEA(]R$4Y
MQ< MMALEJ>(^#\'L\O:%'=?[+?)0#J]NC@>.4VDS-_K92N\H9ENOD]>M D4\
MO@-%_&OQGU&U/5VH9NHBL9Y3)CLU?]JHAY;2$2%4(CA$\D!T=D7#S0L"87*A
M(#+5&,ZQU]:=\2BFJ=L=*EX+WU^J,7"WB%).76V5;$%QY?P6DMZ#.1O3570
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M]'UG>X+QU-Y5>M[4E.5=LO\NV7^7[+^!R7[68J(*193:SF1GTB.3?"CRD^X
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MYBR,OPCSM?"RAX_ 0MS8IFG4[W,M3?>VK"0*0TQ$,)!4&I$U/DG?ZV3I%]6
MMZ3?$[SHP8$T;TM[D*X 3DBQY*@56(4VDI>Y,+S>S7-&>96"%S:S%@"7E*UE
MYR"\J4M6-7(^=SYG_Z$2<)Q/OL/RO!?F^$<'C^[-[F-OKA[DHMC0N2D5T]6O
M7R@GA>D?A>#HOV<$P.&;32'^/)KP (E"S?CVDV,$>#&D->V)SK T^$UI3]:T
M+-V_F%1,#:(3=G%OB-X,4+0^^#*TS(Y'/@*_3'6,(XLV@,C8D39AH"#/4OT^
MW:!+90(6ZOGFP:/R!R]L>JD4^./N^I9[L/.8O1.W !6#8.SWVO<--N1%.$1_
M%G2>1UV'%7GG&CAJ<*VPC "NDV^F=O @->B](78O=*I %#YAHGW=G&\M'YCV
M61I--ZS7RI_ MBR7D61(KTH<R^9 XOC>JVL_';AEZVJMQ=Q29!1Z;2XJ7]8>
M0U;I=8S-&G]6#^9F2DAP5O&<]I-_*)#/E=G<-^OEIG1I #P::XTAT^;E<%(W
M6%Q/)>G8/$7!P+2>]$ANT_/A#&MU^9/1GF#)0-<66& 4F*RE$VOO/;C#<C5B
MG<6/I?JSLM]B0KY*E=C4"9T[:F(M12IM6+#HA%NB7F3Y.?5, !'8M+(SC*FV
MV VO(&<;4QO-)IP?E2\.B KQO.^"[=AJA)-+YR:L+,5>OHZ7A\Q.^94(2?]Z
MW_8WI<H,;%5! #XZ&31:J?D_1;PY=8?)L*@.L>NP4H&"8 #NYHI)FCS9#%KI
MH-N*7T](06^H8&SWK:U0OY%2BU'TVBZ\P8\U":BSVD3A/+@R5<\;3*5;LIXD
M;6-E6SXWV"X3'X5M^?RY)H$D%D742&S ZHZN:T,--[,%%O1P;Y.N*+C@IB8D
M/A_?)A2O]=X4]TXZEJHE.H.]QC'4:F71U2YNPN;OBMX0H0>0?Y!X^JU5:L"E
M61'M/\:]9V :+&:P$I"*/>C87N2-F[A<Z67ST;(^W!5I(6MKT:IZC441MGOF
MKI_=H!ZC2A+<$RD#V:R=5!FIH1IZ#43?84/L(QQZ6/?WK30:7E#O<%_?$]6U
MT 5H6Y XOLE[J(/#KM.AI3?\+KQ6ZCN,-X_EI=H2RS??-.UY(MLZR'5VKOW$
M2%#S'ILO2.$)#&:/!A/-NM?(/O=U  J;9SG;]$\=&1#++*^)!@ _S 6+R46-
M4KGT<L)?0W*IZ8$@H%4?.NEOS\<6>]:3#8!5J?;F<Z6TU]JZ5V%,1ONS=A14
M"Y@,I FDM"BF&^=6HF[%+QU.IJ^M9$KB+(9M-ML9&EE1Z,A4+\F7!QJ=;-S:
M!7U&RRA][->FEH$;FE+(H_4EPW@V4 <QHPA2K\.^8'6\^3WQW_F3Q(5&@]HK
M7SU@9Q/*-'RY5RU.ZH('%DZXG#*)[/G(#1UL+PXYV9>W82NQ@I>>IRP!O8$F
M"VX"$NRYE^S9TEMHB1+?TMWY6Q_57>VZ3S3!R<&>D:SLG\0O.M9SY>,56:CG
MU$,J,LT5^6FNE<H9WY"0MX@/IJ$#F2AS5>L]_$2I)/U9K\WF8-":6H&;DLY0
MHL-O+[!-ZL*W=:.QVP[$EKHB:M7&_8<_T'T)KY0+XT5Y@[I/@INPI'MG6<%2
MD 3&S+47&!DFU\<+5LJULQY[_?9Y('X(9IS_!'-\K$&"C#]TZCOT4-]$/909
MG9B5L=.2NPX;VC4L'5E@B+Q823C):U OQS*TW^'S+5N2AP]U&[QAV,ND>+L3
MQ[N?_%+RPND#3?$RB>CQ*DQ<]^CD^4 F"T!=TKC<MO<Q=G]F5BM$GN54B!D5
M(ZD9[XE]W'_OEQ9?_:$&CQ\MD>27Y1*#\GR:&@.PB#U+/\ 0YNS?G:J.-HR:
MH9-'-BR5V_]BLOCSH02W"+[Z]#/AJ_WE'L]L3TWR>DN]8]KV9^1]*]CK?1Z$
M<;/-BM@!Q8FRX.BPP0KHLNU BSPCOY8H]_!N"L6(_VF?>^\B:X@EAOQ6+/C-
ML%LWK-#<K6:@.8\.#A^K9^(:RZ>%LA+LM,+5G %V QVW 'FI+511F;=PC%M6
MNI9(YB4YUL1]QR9XF(+XP"%WAUI">SASUU4D%*$?,^\*CR2T^^PX-P!O+I*+
MJBX6\$%D6)J3L#]SQ=H&)T-NQ^8O0MS3YYLB#2$1SO[#T">";S7+3:\Y$D?M
MXLZL\#U0JAUX;%W.K)MH"2ZR=:O=Y\L*&0Y[G@Z[_$W$?Q%BKKVEHG[1^$GJ
M2;RDK!J3!IF-:ZNJ:+Q*UKE$;:.7U,K/]/6+B!K"HF?"A_0AVE.FD2 3*]I7
M)3/CP2$+!KF03;>"=^5,EC"]3U-]U2<SA#0T>PPU6H9Y)NW^O!C9EV4UI]5!
MC:@ML]5G'YQ</NU?3'2*X)A5Q>*SA<[OE3#O.$Z+1^K8+'E,B23.ZXL.>59A
MN3^6H[Y++/ANB_/R6DG@J+<W-:9$HVH[M7U$ 2K+$#@2NA8IGM0(C&)7J:&[
M#=D+V_[9$S#AGL%P-[V@4Q191 (6<JV)4;36U-ROX+XT"VWF>8H!@Y*YB0>=
MDE.T$CF#Q5+?"Y-4R0?3N/5GVN^*GDIB*D67!18$VUL'.N1>,[G4"!_EE)0P
MZCJ;?\I.Z4MDMYXZ'!P2&2>?G%O3+WSG^53; RC?:MU&U,O1>WRJQ),14X (
M.?BXD?1Y51"<Y/?O.NYLDURXHDA(!*U@%^<HY)NLP&VW%*]I?^9>&E* .U(W
ML&$Y+(9.P\^?MK[S'50;8LJ@.:(RJ2B>PVG]9BC_LVM,E+6\GF%"/_@0H5!R
M,H8.%18<W]!F1V-F]-U:Z<K@)I?V?,O2(+,X^%KX 9P*HB9H45&(]_N1QQJ-
M;]TU[B_- *,*X5+!&Z([Y1-JO*:JGM6!AKM\SFI/?>]M]Y,(/[-2CF$_B,FA
M5J$!Y<2K_[7-P9ZKUZC!1!XC10 L;*9/FXHDF)>*D!6*6R$A% @6? 9<X0+D
MB=(Z4?1YY%7V^.TG[\Q6VS&4NMZ;_FH'2*,0*-?CCY P(X<S,PP=%[[O2)%1
M+B$ 72:>L6T8Q![F3C.)D(+0R>::?@L!4CD*NJQ;[8<=4(_O<\4NBA[[.ZS>
M @X )7TQBH7@[!'[ 4VLGT!OH AX<)B"+W)TX.,L].[<!,C2.*3\XB,S$D:F
MG,^?#4>3*K@(W^K='WUMZI]75A=,HK_E68J5=(SD> OR%O:Q3%YCNA'O7P//
M0LANYY%C8$FU%0@9?+O_&/RO_UV^DKUUTC7IC8*P74J+BWC6%H-$+"RJP.1(
MF72R_96U]\.S 4<[^HGX^64>,A<?_XZ(JR+/.$MFE^V EXU'"X^C[Y-9SH@N
M=B)I\S.R072?>;T/&<V! 1QU3+EG +SD3>8_M>,70]=FS+O..'0K?@4X1"YI
MYCGJ+O#7X3<@6>Z%?"&&4\$4K%8L>5MXU7+9W!<Y!IX/^WW+C@X36A+P<8KQ
MV<CNR*F"+>90;(\*E!!(G-_"W'\C7$QV!@9)&2M+5BN4[Z=YT[M77=M1ZGU>
MG9:^9\B/5;6 #;==XT_$YO*']<<W)^&P@JVR=MJ%9-EK. ]_0[; 7+*\*P=B
MV9(>\N+!\T!=S#LVC\GY6X1SK(K$T%4KV.?BK ([#6RUB<G 6E)JYV.?_]_V
MOA!\ O<#T.8%.W[.60'(#6=G6RXP6X(J6EG2D-0B<#L]G=%2) )@ 3$\U9[5
M6"2(UZ#"]4'](;$]RFVRO \LW!K<SSS7<.T$JL%OEN-#"%P^V)3M9/Y8/!ZP
MT^3<$60(/](XNVFI2D-VDU9:#9DM*DKTXF_?\&$3TXC^!4]^#N;67"(&O!Z\
M!EA P1&VQ:)F[!Y!E[V-<)JM_3KDZ$+!@3$V"8QJ;Y5](B<&+!>T.%#NXCP,
MBUQ+H'Q7<-;XK,/$V$K'.7"[1C]SC@3:<(=@2*MHABN9X8)GR!>(V-0;[]9F
MG%6AMA:<?J$4R! EL:QAY2^JFM<$,T9K3.4L4M.:AN>F23).^Z$#4U(F&CVI
MAJMB2@'],$B#&%'7.;H:."QSDK[GK"'-..S>.W-7CPX.C]+>[J)@X>]\A(G>
M>Z9K^('6\'[O^P</^]^_YT,JT9/Z7SQ\3*L<<I^"1H@?AL?J\.GC[Y)[C2'+
M$]>$O\/G#<Z*Z>[#"\06DQ)/N^8^J #>+T3OJ2K!!!$V-1+[2ML_(*(+]XB5
M4WAG4 ]$&NTQX$3)SV-1K= [?CLN S^<<5'8U>1 W*66A4O_L[V3=.05(GS6
M_*YOR*'.GF5-Z!<%,K#_Z.=@!W/>&*78BE$A%*)=%DX<EH]_#\R>&&[XH8:;
MV\9AIE-"4;ZM, J]\5+2#EP 0KKG& ^04XR>J"0:T"D,6F&%-JQ8H"-C#T]/
M[KWX>!_ORI-OGSQ\E'KU E*"I3\A#&VL6$#-]%2R8P4MUI " \.3E=?18S$_
M#<HPS,\O2[S5KX@,?4[]NO2*&T?VF-J!^#U\\^I=Z!A29%TY/W/:YZIV9YB@
M9=L^I&/A_]\CL @'+DI6QBG-8@AYC(+<:K)1,1O,HR#!/8[N[RS+Y?X:['&$
M<,;WZ*Z"8Y5YU"1!".;5.@0WXQ-QS^V?[N/^TK<\&@[>?IZ#G@/;-3LMX<!A
M/Y1HA(C'S,7:PJB]&M5-M6PO"!)O8W@2< LF=(2H1,>,PBF"B-(WJ0)C:@-8
MU 8$,'(9+*7WG0^RY<TG?"21S-Z7H)SDI$@:LNJ61(G I?4DJ>&(ES1,*EJ:
MP:B%?I<MT?.<V0WRJJA.:>!$CY^1]\#M'O0!2["P[V-0=(4P*W809UE=YZ!-
M4R_E241'?-O+P?F0*"K!M<BRR,Y!MYHOR&9K?[H/9[T#+#B7>5$A,SO\X"T\
MBI.0C^Q!SA(&CE<D4*WQ#+<#YQ3[BS]UA1J=^) '\A",V*QKJGL,H02,EH*S
MA%F<@;[9;6C!T<$UH06[DN>? LS]J\?Q7#/#/\@MM*@##/=@C.]6I+_D(G/B
M:CEP&T93@U2<WM4U3 #D'?M-(; $"C@VG(U% J;.X;='!]^^>.:59<_(#A\.
MM@\([J;+N-9#[*"DV32@+7LUG9S<O-H<?!6VSP.3L\>B7<5YY)R*%.P;&+9E
MD*R*6$^I)C"R?N9?BD"U>'LQUJIL)%!/932]]TL7#._Z8M\@A/"U!IT[1%BS
M)Q;U5&@OL.@=,S.MXV)/\!N^YR)T70[N3(<S/)8T3;!ZWMJX(ZEKTQKB!?C
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M6?,I?!ZG!SO$L)F*MC=09X7,(.+)$'V&O-!:/X*=O0IM@]0#<\6,XJ7A-;4
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MBC_OSL,?=![VD__.*PT.:C\E0L $W+%(PMMT._M9FQLVOEZ0<*XDCY2-(Z
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M-?B#*72)EQDZ9D;^C^>)HP_[L1LI@WVTB(916CAPV*<<KP>'%7B)/4Y^R[#
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M#[&S[9LEF++F$MUDGKQ<^!8T3?L[>_)OAC!X^^D;KOW!QGDFOC4FW#0(.-P
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MZ .0LF/M?)FG]V0>ER8O\55TA-TQ (QOWA4 X]T/]"<\OL>"8# :Y#M0X)X
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MSQD_5TC A'[-DSB2_?8:!G*@=#2!+^1P\8VRA185Q>>/$U%L;0U&('9!0-L
M?F*^]RZYT&P!>,C"TIGVC@A(S"O5=#1;B=Y]W+=MDZ"!*4\RDW(EQJN-$@_C
MW[<P!S2'(UD0721ZV;;S(-7[B77VUQ35E2/O+'F'DHJ_[&-G,?%H'*/B-O!V
MUW;@6+1-VC>H GW;P'6YKMSE[.IN#29=%>^6EC>* 6&?1QQJ7@_^%N@#P$+
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M%EP=$;$(HEFL+\\S96?*A@]&LW4+(*&L;>ME$4!8R"%R%\#@'3R7_U&T;0_
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M/IF$Y1574AX0<I:1Z6-KID467%VB@XFYR>,=E R:I'(T]6P[I.]$30J94P%
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M%4EFBY+46)[QEC5NDS'^DC\O&8U6JAXOZ%JN.!T@<:6ER_O&19!<6@BDH"9
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MZ\G5"_W4<Q5JWS#<+U?X9><)E'G; Y6>H>8[L ,5FP6J7%"+PU59)=?^N,I
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M#)HQQJN1)9'96,.'?%_M(2R[-.@P\OZ -]1S@XN.58U&TAWB7!1K[J_((<:
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MP.^00+]QGXZ\X\ =5A9,]>Z761M!H P RS2>QX5'T>--6IO)+%$5>(NHC.<
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MZFJN6C[E4:HUX@D4ZHJYOY!J%LM<937%_HJ D'P4\>-T,P[Z0F0-;SPO,?[
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ML7?9,\-NZ>6&QT"O\OO@OZ_E5P!,I,:*)] '$!*G";D3U))(SSCZN4;[*&A
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M6(5":O3B4&%1#M;(2*32N/XUN:5W:ADP[L!U^C8CF!C*J_,MR^N:6Y*!!+A
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M[FZQW6%D6,)5@[/Q_,.XK>O<\#*/C9&!V-8<!^4S36'C$'@^ECW#;$CDC[U
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M;2Z@[4JKVUA+/DT8S)T'G(!Q.)$%5,!K# ?X'@!?8&:"8TLKJ0?IS%""OQK
M6L^ML+^0PVX 7^$-UR#H)S:\I\*.P?7 0UW;6$=!Q+"]$;S)Y.)U(&TXG" "
M(QEKS<*'XP\]>)PC:%(1#Q+2&]B>FSPE'FTRA\<IZ;5@SF/#]J5,CPS;#;EK
MP#A2SL&=_+^1+>CPE()EU1S',HC"R.?)-(5".3"XI;J(5X!@1C#44'+4-,9&
M/R&]X,JL4E59P;7F.-'_6!AG5$6K=+NUC*ZT:I56O;.YLG3U2DN?NV]&6Z1[
ME/]=3V['OG<':I,5N"5&$T3+$RP,AQ!]W0V9"1?9)BAAB$@NJ# (BT#WX&F1
M(^C AD!DCJH9!O!@$R8W?0](O/<3A!&$.@@CZS$6XBD!0IK.RRTH>B*XR\41
M/=+R^4 ,^2!E,J&!?!0:/KAIB$^8F6+A937QW1,M7"2S6JO2;.@9F84OM*Z^
MN<S6]4J[+BU\;%&>+:_(M7"8B.J<-:G$'B(9(P;[84:V4P^16M.L;7Y& /(2
MX<2<M&7PGPGW<7].VN;E<0I8Y"I\\G #F,_03R8T-N[X81\(]^/0&,!\WAO.
M@_$8'+"C(FO9/P$9NLG8\P0:H6?^P,@$!5CTRT^$N<(,N,P]-(U@./ENV@K\
M\PBGH<QDNA7%!B2.@5)J1&AH%1M2[$ 4&Y4\=ECX)<5&MHY[56S(Z.T5&Y((
M/A0;D]Y4S8"U<<^<4B-2T8"M![84&_5RSX^!=5_X^&CLR9C\WG B(PF2 W&G
M-\;/$AU!R SHQ\1LD/PQ<C&%=P<#P>\PX38:.]XCYQ!]6[;/S="+\Q$F]T,#
M FQ,L@ FA!L@J/V*&4$QY+Z#28'! .Z0P?I(Q,WQ2*W96#[.)O[V2T?7VA^"
M>#2 $DR1Y<!+! R'64BD .^KR/#<<008#!&-&D$0C>3\,+G#Y[(>DYS7 JXO
M!2:3X&F" ##DCP+\SNA#Z"]H8K"1_1/'&(-C,4PY\(%A^X(;0!:XP'@P?"M@
M\7E'2(6ELI@=R"HR&9+0(8C?%)DDPK[C+O<-!^:%) "FQ/F?8+DT+8#;D^DG
M<"F8NFP&%J40.X'I"_6JV+ [>WZ5%(+,&5:;Q.2BTU<&F(M6R-LD7NNMYM.)
M5\Y&QG\\'U$R"(NUSB283!P+CD_= /_G&/U)*E(\061'AYX#6C4:^Z A^$N
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M%+5J\7R&?C*AL7''#_L^-WX<&@.8SWO#>3 >@P-V]'P4.<%SRT*T##G_$X%
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MK+> 1AIW7);/RK [$?M52K14@1Z&6/LBZES&H)DH!)A2<!SO05#+>03-,.U
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M3K9+)B#D$W_TX@!^EN3?1+,;[4B'Z466B/_?QHQZ5UDPD 6))I&!YC)*1I'
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M-@."M'8;H1/<9GGL\L&%P.7+E^--=HKUQK[MP'.2:(<P3SDP#_4:5-G_OC8
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MX1C",<H8L_QPC*ZHY!&.40O'M ''Z,_",<W7Q3%?C<?X -*Y5KDE%G<","F
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MX)8Q>P'[7KVN]JKRNMES6=OSE7@$MM1320);M)Q5(K U6WBG9)Q20IQ H(M
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MH--0%>1L3I!=&?,=L-3T',]__XNNZ4V]NW#,KW70:39U_<DP?]SY7N1:A_$
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M$)+&2!#RE2#DRNV'_^*NR\,AZU79U\?@[Q_>0_##WJ)Q)<7VA#.?@S//;->
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MQM/AD?4@IQHT8 #[96&_RCS[29WK2E7;<6Q752N=_*@/^GWD^HW8#M)?7AC
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M0>;++O/@N2P\E]JFW9;GLN]N=)H-M5[!S AR4H4:$@HH= TC'(:V*)I0W&#
M/*Z&PY''!LSQK6>F6 [_-U/>V:[OHT/VT&A1S?&#)4\^O=N<)E.U/PEMO!'*
M>)[4Q9Y4Q2]<$:]9<//XH+]DV<23HG*:9,AFA\S(7"AZ+$P$32VB/XA[V6
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MCQW%XN_SY,D!3EX@YO & ^8SH272A,GZ[D?+T1V#DS1?$/Z!/ _W3!$KN)&
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MO$PJ0)3^-#X:,$0;'H"" !2 @00,8 @B0$ ?2, 091L !0$H  ,)&, 01("
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MU\<KO0J4$J!PT/.M@03T@1@*H <B0$ =**!PT*-+@03T@1@*H <B0$ =**
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MCB7;B8]#!PBZ1_KMPRP!A[5\F8.X*G2P.24'"]2#" Y@!XA_>7$ .X =*$!
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M.;<X=Z36TG#R"#FAQLDC,/'EE'RB.*!,'7$8 0B(:@?( >)?8AP0AX$=*$!
M5#W #A#_$N, =LB6I6L</$N'?-JQB-_[7,K7M^TI2-:J*WW7,YDW7E_?M2U3
MB;X7%7:/="[)P9'7M',E5"RIQ,H[FZOQ>SECG^NY$OQD]C-3AOQW U]A_.E-
MY9Z- IGI5FJ:J@BE/%1W2,*QR0;D<5M[H@UC;Z U7KERF4:B6$5>4RYP';>N
M':P]?"V=2EI Z!4("N" H(X#*Q 4"*K0N("@  X(ZGBQ D&!H J-"P@*X("@
MCA<K$!0(JM"X@*  #@CJ>+&21?_@IQW,H&S.U_;<>NZC%8A*GIRZYNY8H%L.
M,R]US^'@^OF> -92.ZT&F5F5H&G"U@4T31@<T/018(4X$G%DH7$!00$<$-3Q
M8@6"VED@V<H42"(*!,D>\!B#%7T@IAOV;:94SW+L UF,3')]^ZYM;@M55EP^
MZ[;N&$S1@QS[._)!:)%/5#Z B+95)J 1:[J03E=AMT\/"5!NX!_M%LU=.%!4
MX%WA/KWT/=OR!]Q4^3/^4SMU&)3\SDT8^('N"+ARRL?S3X>N(X^:FJ;BL_M>
MG8;:T)ID.FV7^5Y+V0)6!U1>-B1 Y3E"^0LY%,'B.V?Q)4F0SL(3'0?\'9CG
M1Z3<<PP[%+C=NIZ<@Q$$GM4/ YTO_H-[[3J"Y#W7MOE7>ISNN0\0[)WYI_1>
M:;?![4405G [D "W@]O![;OA]K9&FMN[7%[$+77[5K?,GG.NCZQ M_.(\)O-
MNJJU$>(70J[A!@ )N %P ^ &[&@:9KM"VP_8Y(R:M4=I=JI@_R*(\\%.JP'Q
M@_B/$$J*Q-\![Q^$]ZND>7]YE]UJDE\K U"O=-1JIP(?H BB#1^   CP 8X&
M2HH^ (+_ SD!-=).P.*+;Q[O-QKY-5. Z\'UX'IP?2&@!-<?*]=O3O6IL^EW
M3O5;[=)7ZW55JV&7OA#22*@%<JGEB;HBC_O4*ZK4G3ZG\[C;S:GB,,N\!W./
M -3&7A(=#PC@O:UE4"(*.(!U:.  UBD&4&"= H,'UB&" UB'!@Y@G6( !=8I
M,'A@'2(X@'5HX #6*0908)T"@P?6(8(#6(<&#F"=8@"5ZG8!Z10&.Y .$1Q
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M4V;<,,)A:.L!,TMEQV^" ?-*]<;B!&Z/#9CC6\^L5&_><PQWR)1W7US?/WQ
M!<8FS-C((163V3L@=A"[?.\+]F@95G!P,P_S#?--%AMJYAN!60JW:]?A"^\$
MGFO;?-5*9<-[XH68#R-^<$.!K!F,,XQS"K<'-]!M_^#F":F$G0YZ/;^ZTJ[.
M=Z!36P]ZI0W!9]W6'8,I>J#<LU' AGWF*35-5:I:I9-5:78&Q@+..2(LMF/U
MW2WZ[.3PA7Q2;JM% J;TC/=L2.VBX8$*=/^T7L3?KSS=$/402NA8P1U[_.WD
MV_>7OF=;_H"3L'^B6.9O)U??^:-5VHT3Q=&'?%U"__1)UT<?[N5W;L+ #W1'
M0'&BB-B//X2\TKGXF=9N=>I:ZWO\F_M YY:5K\;E7Z$5O(K='?Z03N!W7RQ_
M_*6H*%;6Q'Z59OB[,,%:IZ:=*"8S+/X&_F\GI[431;RF'OQV8KT$'YQP:+I!
M_'<N=H8N,*R=?.HTU(;6_.>OLV_\B9S8(G(C@0*(%<0*F$"L^1.KY;OU:J7U
M[?YBAE>;*5X5S#?@[\ \/^+)GF/8H<#DUO7$5;M!X%G],-#[-GMPKUTGD7,=
MIR'W3L93QJVTVZ!;8G))U*2 ;D&W@ ETNS^Z;9&FVVF#@JC9[SEQQ7X><7"S
M65>U-@)A:B),U/J F<',@ G,G!6Z=YM3<YLV-4]K4V4?QDQK0E2M_U:$+,7V
M-$G*M4X5A$Q,<C-W6X"+C\G(@XL+ 5,SV48!*LZ)BCNDJ?B.!;KE,/-2]QQ^
M=7]=WETK3JY7.FJU4P$M$Y-BT#+L/6BY*# A1-X%+W<TTKR\^.*;1\6-1@/T
M2TQ80;^PZZ#?%$R_D$,(S+N#;>-.9>_$N]5F;[5>5[4:-GNI"5Z.C5X[:Y[<
MNM&K>=9N+$2!SC![J;VG?=UGHG5U.&*.KPL%H7< Q$Z<'#I X-P-X/"F,U/R
MLVE.R<$"]2"" ]@!XE]>', .8 <*$!!5#[ #Q+_$.( =,F4ZJ_.9SJ[YG] /
MQ-Z?_^ N:5"1LR!D.N4\D4VY8W^%EL_7_YYYSY;!;IEGN>8=,]PG1U[E3]T.
MV=Y:9RK\]?A_5+7,:=5Z3:VU:[EE56&"CMP$@8$A_B7& 0R,^(P"!$35 ^P
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MYP=N"UJMRHL#W)9L#0WMC1H:[B8V47ZM^U/WS-\]U_?I-S4T\G-]8$R.W)B
M2R'^)<8!7)HI!;#X%/LE*0""3+J+Q@;8BB.W%:!*B'^)<0!5?LQPLCSG'TI<
MN65WPX(CY4&@]*0T\Y'RX,[CLMFEDWRB.( [,725 @1$U0/L /$O,0YH80 Y
M$(" J': '"#^)<8!H0/8@0($1-4#[ #Q+S$.8 >P P4(<"H!#1SF"OLMN<LH
M"D<50_<']!I@P-[H.RHO#F#O+)7\5:VR424_?W3Y)^J5^W6UJ6EH6B0GH$2-
M![@3XE]B',"=&2KW.3]M4HU(@#FG]-@ -9*3/Z*V =0(\2\Q#J#&3-28.L1W
MG]2X96'^6@%FM:&I]58=/$I.6(D:$O HQ+_$.(!',3V4 @1$U0/L /$O,0ZH
MV@<Y$(" J': '"#^)<8!H0/8@0($1-4#[ #Q+S$.8(=,&S3UO#=H\MQ6P7$#
M]$0,QPW0P.'*]?C%',4(/8\YQJLB?V;K4N]U\S^A'XC]49]>'P_\%+1/E1<'
M^"GH+J0  5'U #M _$N, ]@![$ ! J+J 7: ^)<8![ #V($"!$35 ^P \2\Q
M#F"'3#M@C?D=L)M@P#S14>2Q 7-\ZYGU',,=LB^N[\=9]_,XZ?X@GBFZ4]<Q
M'Z89^.XD 7_-@IO'!_TEKYXFPPB'(;\),Y<]Y^9MP/5*?C,R8&:.W,R 92'^
M)<8!)>H(P0A 0%0[0 X0_Q+C@! ,[$ ! J+J 7: ^)<8![!#I@1=\^ ).J32
M"BYT&*5/ X<+QG7,=VW+C.K4W4>EV[?YUWSE@>NT/F)A8!F^JG"%/J/7ZP'W
M!2TVY<4![@OZKRE 0%0]P X0_Q+C '8 .U" @*AZ@!T@_B7& >P =J   5'U
M #M _$N, ]@![$ ! J+J 7: ^)<8!U1<@QP(0$!4.T .$/\2XX#0(5--76N^
MIN[:=43YF^?:-E_GGA,PC_G!!3,\IOOLRG.'<[4[.?6S+KYOAI-L&SC+EIY@
M$C4:X$R(?XEQ &=FXLSV+CD35%=P>2(T%SU93Z[T7<]DWGB1I2PJT?>BB>$C
MW>.K>>1UY]<L4"S9(Z*\LUW??R].(5"" 5."G\Q^9LJ0_V[@*XP_O:G<LU$@
M'5"EIJF*4,A#=7 DW)5L0!ZW#2?:Y_4&6N.5*[M])(%5Y OE M=QZ]K!NKK7
MTJFD!81>@:  #@CJ.+ "08&@"HT+" K@@*".%RL0% BJT+B H  .".IXL0)!
M@: *C0L("N" H(X7*]G@ 'YZ$[YWF]?L=.9K=FX]]]$*Q*3(G I8[UB@6PXS
M+W7/X>CZ:Y>N2J$[/1&5"$,]^.W$>N&K% Y--XB_F*SY:=?51J-&9K(D"'NE
MH+X'5Y/$A:C]!U<7!RL$DP@F"XT+@DF  X(Z7JQ 4#N+)BM:IF@2H6")Z?9]
M+ATAV[;IK.@(,=VP;S.E>I9C1\AB4))+VW=M<UN4LD+R6;=UQV"*'N38Z9$/
M0HL<H_(!1+1M,@&-6-.%G+H*NWVZ28!R R=IMVCNPHNB N\*%^JE[]F6/^"F
MRI_QH2KS/M2]_,Y-&/B![@BX<DK,\T^'KG,?N,:/24Y^L?^UEMM5T:IJK=4D
MTWF[S.]:2A<P.^#RLB$!+L\1RE_(H0@:WSF-+\F$5%,L+GAVP-^!>7[$RCW'
ML$.!VZWKR1,7@\"S^F&@\\5_<!?/SM@[]2?XO4-GJ@:XG2RC@-NI( %N![>#
MVW? [372W-[E\B)NJ=NWNF7VG'-]9 6ZG4>(WVDVU#S/;X8;<+3D S> "A)P
M ^ &P W8@1M0I^T&&$8X#&W^3?,F&#!/?,MC ^;XUC/KR5%_ZX?^;5!^$608
ME \D0/DEH/P.&'][8#/4-S9(4_[23KL\JBH;6DUMU^MP!(H@VIG[Z^ #P >
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MM5[10,K$1)@J/X"40<J'A@FD7$34-B;EJD:;E*?5KK*S8Z;9(:K_7S\L;H.
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MP4)P +5Q)$XGR@9X;VL9E(@"#F =&CB =8H!%%BGP."!=8C@ -:A@0-8IQA
M@74*#!Y8AP@.8!T:.(!UB@$46*? X(%UB.  UJ&! UBG&$"ENBQ .H7!#J1#
M! >0#@T<0#K%  JA3H'! ^L0P0&L0P,'Z ,)'")2 6=0Q.; .E(Y. IQ\?FO
MLCF.?VI:SYN]_,R[_GWFB64#45+J1L',,RR1?H.)GKRWQ7_1G:.%$7/W+"-Q
MY];FZ[S!JCX,F*(;ACL<Z<XK%S/^EX!?7O?XQXYB\;=Y\G1;&>E>H+B/2C!@
M/A/MAK)E5$P)4AXM1W<,BW_)'T\:\,_FERC3@JQLSI(BJ*U I1RW7"I[XI:5
MZFB1*5XH?),[[5.GKTY;\0L-O/$;C?0G=MKWF/[C5'_D+_1!MW_JK_Z)\BO9
MM<YN839=^ZP+W?4\]^> Z:9R.]#Y9P8+ \O0;5]5>HZ14M?BOJELMYZ,//&_
MNX_?SW5_\/W*=G_Z)Y_.DY9K^C5AVL37%/DUY7B6X],[R^%&VPU]W3']][D8
MK.BIJP>C?_X",=-+XH\S'K^=:">*P6Q;>$.<R";_COTG^>^9U_Z@AX'[,<Z7
M<"_'UD<^^S#^CX]*[&5I6AP1IIK<]M2.V&B=:>VLYYSFU5>]GN4\+L][G!*H
M'W#QEWG?[8-[WQP)_G#\Q3D4%:Y;AV_]K&MGC?5.!U\:O:YKWG.<1K 6DEEA
M^U^F>[["^'.9L^<R+M&IG8.WU]"5!@;K=TV7A%!(V[3BL,M.S!9I;"9\4Z5
M-Y5*EF&:Y>:C%:<!@WJ.=!11TL)ETA*80)C HS*!&DP@3. A- "F#:9MIZ:M
MTCFX:5O7DRBS"<R<@-C94.(X)[&GN6V'R6:?=^__4*Z^W/S[7KFZN_FJW-Q>
MWG4?>M>_*]WSA]Z?O8?>Y?T'<N.B)7GM(P=4Q"V&@XY:/U#U#W!*XJ2MY28
M*@)0':Q>#C" 3PZ]ZC!2Q< )?%(8J, G)&  GX!/@!/XI/!0E9Y/#E87M<.T
M9%4[(YZ6O&:!8LF3O95WMNO[F4^ W&%7+BB^3/V%AX$A\TF-NT- DC>5[MO#
MH)+AJ.7J_#&+MY[[: 5?N&U;?52B5M&T2DZ''E?JFMJNMW,[/!%JGI- @=Y
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M_\N_0HN#*H:UW3$_\"PC8*;X0]<Q9S](?/.6>9;+G1G#8[K/+ECTO_S?=BA
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MBC!' H"#N(O_,V-<E1P1[6"AD[5DRC/[O);[-?5+H6\V_VO&G*])_=\QEV3
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M"^@^&T-]> /&I+;,6/W)2AS-N!8-&ZW&RS&QW;WSREH2<R\A'E2)EG2R6$B
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M"[@9YZ0DK60KKC+W^$1%J;C()1TJRX;&<'O<L!E&*)F3'DO4&!N1 2Y(,V[
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M\)A=")_EM0!8+B"F;$CM?'(V0L8FB#$YR3/%Y#PVZB\I[Q4-3Q+IQYH1P%=
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M#5)C78RD)5-JZ9%!: L;QRL P+&BDN==%06J<N-CXS\P6XI;);)7BB]*=T8
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MVU*)_BL5Z>.P$(HOVYYS,TCJ+_/2"U7Y7RKPDW;@=:F"^N/^<PH^F4L(Q\(
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M5I7M0/>*5^98E&1?%O:"0"%(Z67&G?!@'$*'H77#:PUCND_Q:"&L>"/Q1LM
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M)R9 :2_<G(>Y1[SE1CCV[N @./83H_)ZL-6RZ[0F;C5K^>\2N)JX &=:KG(
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MS G3#2HT+[1>/1M6:;VZ)[V::_V\J5[=(K_>J[4[^?'Q6J^J>,)TTOW(#'C
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M3D2TF%...4J(N?,(.9U!_O,T_-6S(;1.\Y^(V+G$ZZ#8 /%]H8B5:4YWE?1
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M2BMJ)=M,:1VM=?2%W#'U=+2.AA\-U=;=):IMR[!XM]8<:$5]&B=-"8]:2=3
M10-K%+T<%\230@R:9LNQV:*OBIH8M%*;]("S_AB56X+*18PXF]M0[LIM.[1/
MDWL+SUDEKUCS9X>3ZS6+SK"'I2:_5AA:86C^5(.5-(L48Y%6&%IA7!"YM312
MFC]Y8(QFD6(LT@I#*XP+(K>61DKS1X>DE&>15AC')K^FM3[JET#^HX[0TARX
MZ M0AA0X$)3CV UK9 )//,>2R6N'E!;34J8-,SS+@@9/YE;L%*X_I7\E_BZ
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M4J:= ?6C!SOSHR\%['V)NF&GK67.3Z9HQ7TRK%)/<:?13UIQ[PX M7+L^X@
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M7JJGI#?#-VHEO0-L0^<P^$:%$(I:BY^OHCBP<[TR+Q1H4G9\*:^5]5DHZ\V
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MBQHS1[A>PU.]7M\9J3>X4JWN3JY4L.&=&IW'G<K1?]D]:C;:JUTD>:<&^;E
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M6NPV@@43'5VF#7NY[AIX!:_A"6C-@AILG=7%6TL/JLEJ%CKJ-)4^CYB@&L3
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M_"1,]:1[A!'/,$M6F!6=S.]KI5*[ME2R!7 C@I1LR]7"P'A%S[T/Z2VY,A?
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MR59J\HFJ-)<9YVRR*,VD 7:&DG(=,!2+O\+KEN4QM\9?F<PG5K N(#+ B "
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MF&#@MOQ!=4*&>LF[Q^RM71&5$E"6':HG_RHI"<@-2S+.6-T5!P\]$3X)X3(
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M#>QC8[K:SC>FJVY^G'6C7FJVM[<S KFF$V<(FB&M!PX%,P=B:AU1H1G2AT9
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MAIP86N+//1$^">&F]V*@(R]:()8X1@6NFW0'XB@@6!F.RH @0#\J8P]\95G
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M;G[XE8,SB8:QU(X5Y;6F5T+\/CMX3I+H &W.I^+=9?NY/+ M&'!<Q" TSSX
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M3S;J>]D*^'RL)M/)%H%+3"<:>,MRL!K:[X:"P3MKVHNC$<);^P*^@Z89T\=
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MB0=:#-TI&-]!R/2:HV2,%EFNKQ2E*5UN63V@QCF:(X_$/E.BP\5K$IL?.F"
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MT9*S!1Q"AQBH$5&M7W]17Q=TJ>5!#;@X8LJU/][X.HD-RPS8[HP*(94M4<^
M6L AYBIF=@OPUX$,9K1O>_[89S?4#?0,EO3+78SI6V?.(QEDZAA-"RPW<4CL
MN# D7+YX 7M1MXA-Y77IA^>R_8#:#>L=C1JXS-27FBL5!]("!K%:R>X7+9]]
M:J0$+G46S^G;(/O?./9[WEA*?PJ1TZ,B03B]OWNX?0BH8>;*K_0< L7,[UN_
M])/5VB"S?G,DHD[8<$KP>0@6<.VH%>%-@I@6D+]#WQVA1Q!1/;CD^E!MO8A0
MTR+6(\ _(=-8G D90;*?-_I&;NM[';=:WP7W,JYG.?V'JI4%\%F:0G1+#FM+
MHE2ED\FE26M37+6*68MP.8KM#BZ@CYB&'\ )C:8CO*0G7S)(^.B1_T2(;('K
MS5Y<QTG35>(^(;2F0ZTU,0NY\'$E7NCK&4 '$KO2[89W,?P1$.N@.\$0S@07
MKA@=72G8V<>#J\O.Y\YGI?1K$8+&A?MX>56O<"F"QH5[?WE=KW I@EJ$&Q%^
M^^/-@5U>ENSG6\NZMG3M5#["/<)/\#7M44 !^=%9'0%ET[<E"6NV6%CL[$?@
M1>%@^$.EB*:0D)XZ@=G<1TN8SH"0%Z2 B$$OT1.80?FZAW):!R>2/C51S;EV
ML\PF(*U4FF1#!<@01RD0R6^[ )*/B#4:>+-X)KXZ,QYJCCGP2X&Y[8<:8VY
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M*W1J*R3"ZTT<N&*E(H6/'W6+'1H5ZH8_YL28"J(UU=I;[J@,HB07F6YDFXW
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M@^(!5).8O"<FW*IEU*4)7S0:JRG3S!!)=X7X^@$EBC=-Q]_34U^3CGVCI!P
M9>'-,6*GUE&?5GS2<*RN7#N%Z19)<@AB]O99UEC;OVM6!TVDY; 2'6/#WWI/
M;[B]** A#?FF\5A/V9;JA:=!DD7D+%W/F(^_;UCTND'/H5%7K+PS[$Y4FJ7&
M6[7E(P)-(U=0OAU#SZI[5;AY_WP#MS"%&(PU?,K?8QZ_JEJ^!$$S( 89N/.-
M#(B\P1VIUL:Y^^,D\H@B+<7. KVX%[CW G#@,V$-*.^>;AE]WM;?6H?\IME9
MA__Z[_1 APBXVI9MXO FEP8 E<8D:O34$52A;S>SKV (5ENADU[!TYM&)UJ
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MYP5D7,>0\ 8%<T"X@X*]#^[:U1BFT75-[=9%FJ;]AC9-'D[;$]5;VOCAHLJ
M2C0D:E?J7,"+!W [:LTW^KT'J;!-NAZN\@>8<FDR'/QA]$CJ<ZM[H"1!?02E
M&-CWO44<HR\!]@&Z2C]#A[M\>X@+ #TY E9#$VDI=1;(<<>C'.E&F/(LT0(5
MUXG\[@9F$ -+;F3/\'0=(WJ*=OY$,L\UO$Z*G,EB9I"\BZ4H8TK/B 6V?KB:
M"H!(0Y,S "MNX+2HXP0XRXD\[#Q($SRO9M<PI;4T#+9_@Z0,:G/WD[;O55<P
M!_S1Y#>7*,N^!7L<&"EO/QQ+%C>DJ$3/,>+.5/ "UP4J/FS5JNHXXN.HU9[G
M&BYI<@)>V]*'4>JSEQ9Y@\<,ZNR^MB)0)H C"YJ>(;C<@<6Z3;67A$P$?BO#
MA> O":>9(,LW^D9)/%TT+-0.&.'BT]L:#E(I/'UZ\E7_<5/U/LQOK*8I*V1J
MX V]9$R+N[:2_1JJ[/;#<E1BMT=/'D,0%]JGQ75Y25T//.,*?A&.1E.4X!]#
M5H&,26?@+NJT]0%4Y>7B."-LGOC6Q/##Y;3Q1J:ZGANV<;&?_M*-:>'!'CAR
M9\:@W>Q4MWFI3I__[W9!^LS>[,TP.54O+=5]0NH$J:@V<]NZ>FK7VNU6OUZ3
M?ZJGO!ERT4R(,N+J)$&.MFW/$=@5;=NSJB\P<<9=U3BX^HL/66]VS 39 V:^
M)M$1E&\?4)J?X#_N7H%+E-S3'X'883JH=Y:NI#1/M/- +3SP40]9(U#(TNR<
MW:H 0 6:]@0Y?(";0PQ7VV8N-):Z2%E6CYY&Y T.&=79.7 .+@3Q#D\;%)N@
MCBRH>X8(QPUP5RW@4D\O\_RG=^ZV[D.747 7Q3A"%9%*W[FUR-OMI33 SNG,
MQUE&K/)2H^\2*"2C?R8E1L#'9!-E=$,*-X 6Y_ C&)A8R4 C+2EX9F@1]5/!
M+NB?J]7 ]+&@"ISM-W'TWI/=A66+,(\>C4*##6XV)@E=[JX"1_1/2*X9MRC=
M\=)#=^B0 RH0OXGT)"I8M)?6%8,9,O.WC9;U1.<5=<T\0"&5IT&%-T5:? G2
MC:A,TI6#%<'*LL.._<YN@#'A;->@]"5QD"!=L2*%O^@Y#NN0,I.H8\&@!B*0
M*5PORW@&(A,7#U#Y&J&I%!&(5N=GG*IWG"L*8-'Q?$PBO)\DXW._$E)F[6[J
M4Q3%\;$BL;ARJKNI'E;?W'[T.%C9L"J%]9(69"_,@E164D*E.Q:YJ(@\EGFY
ML"I[IY6G7,+) F\\MUEAS8>'-,5[4'JP8"-<66%LP]0L"#):]S_Z"(T?!I)[
M#_$4J! 5!#D0ODZMDHONT[&0&Q-LC6W6$'Y1YM82UP2S$4Z<6XUL=6167H6U
M,[B%*99S'3RUZ=E& %-D8<-VE%BZ>(>^VZ.$QB&\A,H?(""OB@JA:%+O-^7A
MY+>^A1D]DV@-*!HXS!3^EB!1P[LC3/@4"BJK)9=Z/,>=OU'DG9ULA ,--C9L
M0IFMDZ*.CU%&M^)D>>+?ZPH;MM :!S25/V/<6^*!,"O02^OR@4?Q#KAHG^93
M4#C?;B'9CL%2=S=!#DGUHR3$08SNYFQ$!1T^-LQ#G:_3XY92'-$^B$2@+I)O
M\<+ 3%H#ABXL<S:)EI A:PXF(:.K:&60/; J('"SR,X.\&.R@>GB/H5TARV=
MNCM(1[=:83]=)^FWM!=#RIF"( ,;O $\$+X@*!C[D&TKBQU2T65_I\4.*_H0
MQ3#+\:S';RO(\WVXD3:>KJ]KVDP[.2>F4K(">WY/ RDS'\QC !0DH2TM8Q!J
MG]S ^T-,4'_&.Z+; #,JN66<729M)<IT-<U'D8^;$KE"_9BT%(*><69$#+ K
MY2@LSXL' +K8(Q/=:UGI*KT/$E[0FS"([I-H&X7!40T\O'^_C!*XS.%.WE8U
MJ6M:K!8W)W8K2L*LM9+EJ-*S)X]6S"P!F6/@W'[ILM&)[7+*(]@MY?0OF]7'
MR,!>!=W/"VEQ^UV#F1S0"D(<%2 EA[:?J2 #K=0]'GSL:MQ]AU$9#+^[1X^O
M-S!BYU#X!QJ]:.3"__C[);P/XG/,,W]>/$524VKKU]0ML86,B\(AF %@'*8-
M%'W*1CW:\$BQ\;%.P6="WIEU,B9G:!=$B:QIUK^CISZ1AGVC],4<6[6+NC3@
MBR9C48G@,R-M?/+VER#),IA</P3I+@CA(<<1.<[( 6"Z1ZR;Q >XNX.IC!FJ
M4M2<QJ4Y.%FH<>Z@P?X5J G@P_),'5NDI^%YX"B&(L[:?%4U\ACBFOA-&ZR;
M(/C,.(]^H;?&PUMMQ7K^DBNL 0(&Q<[;"([8$H)NZ,1_LPKH^4.0@-J7_+AJ
MZP<02>G52["X^Q .Y,9+1,1D0:?O*H($)&_H"B5!]9LU_BD+0OJ>0GX2UB:M
MCY@BJW\Y7I?CZ9H#,L1B9M!S-Q9YTS.%.G<@LE>?##O[*Y96@Y+RUE)QC=Q/
M1+NE7C=1-S?4(D//+J5E4$+2BO,6D8X@2,[8"G8V.ANZ'D;<.P)KOKL.?H6;
MH+%H)H^!R-.E((<97G;L8(I_72VDX4;1M\V8:%J:"5,GL8$)=+1!82(!)A/)
M0>-2 5$L'P*(%5-!UM"9K5F( 8K;Q&44T@Q4BQ%J^G'&M2'VF_VJW>P=+5'(
M:P2J<#N+E6YR5B;)+O)C+&#P"C+FMEDN9KRX9U4$M'U=TZ_9&8#W"-,[5 :3
MGU$:_1.CYB":C#FH]I4/?;C3&)>MX[PLS87S"?ROYMD$_M7?;\@F2O;8KO$%
M=5.J$7#1W0>K-:.A6'RW.ZUCMVL9M2K#"XUR2Z54[9R6R5NB_(QU]!4#W;E:
M!_EMC\>32:M"/-%KW2I'C) ?@J=H=]BI66;C2WHZK!&Q;YV<_/36V*YAU*D$
M;[09UQ0YKE5&B895UK^DJ4>1B .K9.0EE#F:>;:J&G5JPQNUQCH:G4;4^I*?
M,QC]CB[)HTT4'\@U457&_?PIC \;N+G !D$>VQ[8IG*U;38H??_<3D#U4MRI
M& 870.[$<E 64> EW9-@M,N_$>P,C0C<"[:IN-><0"$I(*("05;ZS/:XJ?#[
M9]!%:J*TA%;]704[*)^3*D_+MJ%4M$>+(*\ 8>IS'&D!;S 8-!7I.U #;DG8
MJ2?.6G*I\]T^1L\0"L5=U7-Z>H@8=%3O(NIB#>=A^>%A9)"TLKQ%@;M&P:56
MPG>R1-&VRJ$WMQ_5_6* D#XJO81=^$=[K5(_'$4.+J2D/:^AB?LP 3?@%GR<
MS'<6FW\<>+.U"Y3V=%U5WF>J$398$Z@P<K"2JQX=WN9!L@G2308^[C=![LLZ
M3@MA9*3@6:%9+/<JS@"S!OU-@*?94/&<]@W27/BU?]\XQ[Y&[RMTL5Y8CM\Y
MM*C+1PBX7Y2O'#B+Z::JT@Q**V!&\.[-VQ_>_*CQM$&.H$$PDV'@P%]N/X(K
M]!T@7$[>_.B'CZBAA[24. NDXL&@QGAZZ6=_>//.KI\)!-V@5S)PZF=_.'GS
MSG\_.T9/TL\:2IP%4E)^AGEZZ6=_>OLGNWXF$'2#7LG J9_]Z>3MG_SWLV/T
M)/VLH<19("7E9YBGG0R!J4O$F15A(L( *LV\M1![H8!1RNG6GL9)U-*=R;!B
M840%,[#( &8'*#^;F? N:]C6L[L:!6S]%CUN2EVT1V1,S(6?I/BK"(A.Y=>9
M#CL^'G'%G 5'.N**?P%WSXCE'FHMDS ES<//(/OO,B%NC5DNDT?(CS1EUI$*
MQ#3?^<@0=_)$JV ,-IPSB!(0DN!';#&JN/OP3DL)3Z2LVOX*K=;O9+D8Y#_G
MOQVB1^P%Y/@^/PW2]!FO#FA+,KU;6DG2-BX'I5C9#Z#"G2%A[<?61Q?;UBM=
M!<7.#,?C:U^ZVB)3 ?U!X \6.2@D8#WZQCZ,^!"DO\*<U$JM,IU4G++]^_J(
MM=%S\4BEX (RS])X>P%!,HKR4?GQD=YETZ?]6EZ(1D3Z)$;%^N*;8H'Q;=<*
M8T[#Y'"5JZ>"(U@F53!;RHS-3=0B,ER<+4^7"6U<NMB1$P>5L-5!0-]U6@DZ
M.!*E=+%9L8:MV-0(4[ G)Q'LW,6/*-8/$)+2FY=@B.<G%^ ,+,$IX&P XS.V
M+URG",.?/U_'Y 0PV9#E!=V'?LS@]A!?1ENE5;84.7UH),@[:69)F=*0# N.
MK\"!\@0Q9NJ'VZA@B324.@/<X@9DE"&=;TJ6@/$$E[VXN?&V]X<L2F"6G:+=
M79304X931$^[L6#XIRS:0%:&HVR:?(5Q/Z0I5)NA#!GI(VW$V+[OTO;ECZSK
M_1:$I23DQTH4@.[BZ)[]2 [G<P0V4<8^?>"?P-_&$M"R"7AC%L2>+/CM6!2R
M"N"LK8='D$(2((@"*EE 39BRT?4SJ,09.[;0Y38]O(RQS#N4T.=]V2+'YGIW
MH-NF-6)/%/%:?,./D<4RIBH!Q@8W?3LQY^[BFB\.R<$]CQ:0-C0E/Y6OP3*:
MO\_R(3.ZFDBK4Q[VQX,_#RXLVA.RC]S\;4?<)3-Q ).'O<LEIWN51&"-BN>Z
M1*CRSD\4RX]WNM(/I=6WW9883O8TW-FV'HMU4D896+S_WJ(4A"\L*-FU.7L%
M">R</'AD7W%E6C:*#$QSN''Z0(+C,A%? T5)&.UCV)GJ1A\LR#5NML+&X)Q*
MGZV#U0\5AAPIBNTB"WE>B;_-RD2_ Y4)_Y%)!3[G*=Y];?'F:JCGX&@GD18L
M"%F$;,;6$M<,99G4G\EQ44!/0BC@XLPFBN!P>(9_'B64E+PFL!#.V\>@0D]T
MO'GQ9\V2;(24&FISMQI+P868RUFON?@38I:['?Z_Y"CRG*[J78>98W[C&DV3
MOV?A)BK%*W99+V,UTVEFAC&H'<Z78%+FL:B2"S#!QHY'JST]V4[N+TG>1GFZ
MK1)B.DGH0]Q!TD'^9'3_D)^@[<DA@R#F?+S)\1H"!TEJS%,@N/N4/ !E4EVQ
MF.:]ER]49-?F;=_2S&2O47&2LEYU;""1Q(>\]'9]HVZ-]&>:=Z!Z=2"O!%?;
MDI[\VX6VKVKB>TS*"<B,#3G&]:M53 \(:$!#HSPON T?X.80P]6VUG[SN(UD
MV/%GL:GCFMS+J,R(+KCKQW#[TCCH5<%E)(?*G5U6R^Z;86<?UGHO3BJL)RMR
MAQ:)W&/]\JPOGMKP?&L1U=WC,Q#Z1%73D/'J;'</$X,&F)W?UUVQM=-SLW8C
MO+QK1CF$")+1E(_:KV?&8T;FGNE4WE@0U4WOQE6\#[((QRS=;HW=!#0-H(N@
M$_\KF?G53GH0%22E+"\1J!5&*=5OL8B$6_'C3LFM^22?8IMS/JT%?(WE?0CT
MFZMJT=:T(PU>3IR\6+*$1XL9ENRTY[+X%0-,K "9(C WQ,6@4L!]W..45=,N
M!+$9<R8;>*P[9@<KB&2SN%DM/OSTUGPMT4W*>$[K(NUZ?8&QP(Q/"&>_ HT"
M@,?+CGYM>@Y6^U*DAI23=8G;41VO4,B P U8X?_[ 8B#FJRDI84CH,NB4IU2
M%H15O@97UQ;E<'KJ8WC^=2E;QF^T? @7AH=< ON2C"R>S+XFNJJM'3C5[FF]
M%#=N2MJ?&3?U'6FMN$K+!:F_DL<UH4G3!&O'Z>U50>L[DX*9],I<C:CFLD^%
MB9/5>D_9UL;9@4_K=RW D;;.M7(UFM51"Y;2!MA-0-/8N@@Z,:RC>K.EE?E@
M0(/@("F=:1G&8K.)B(Z"^ :2/IE1<J]8E57^GM "*]U++6/6;FX?2[&P/7*Y
MP$:C%*\/5FS1DI!EV&8S'TK6,.^8#%U5-'<YXE@8;'MY\\:1JKMBYW9GH-YR
MYQ96QFZECYN"%]4/"C86MD^>Q.3:%M%60'XYZHF/-%/* ^S64%<X6;G!C),#
M9,_SDSP-POR7*'\X/6!F.YBRI_)8PD660?R_FW7PY*9Y+Q7#SIC:!E)FX)_:
MK+=4'T3!5^[5A:OCZ..Q$^SR*YB?JI=BDR)G<JXW2-[%F3"'*2"</'D7HX(;
MTE#@##"*&_ 0AJ#@""A+0 H/GRJ6*!MZ=%'&XW60WD/:A%=N?E#>M]ED:?K(
MPU@$UX]#JFDR9Q+2FD#"$N+5P!K"JSV= VL[>I5B"5*MTX^_H(<DHYDB_*=E
MDJ!'BNI?_G)V6F5\*C5QUB:MZ1WJK)QX 6=.C;KXN9+DA(CR"M2$\<'$#4P
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MS0UZ#F)2JV&57,&<KH&E[5:7O*;QZK%S8L&5*,2,(1<&Y*BHM 1R*@]("X$
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M U1WB!<1Z6I\2?J;+I,<*RBB34=)D63I>A$Z5/4QDN?B]BZ8<0>4/:CX R:
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MQ!3H(\]\56NJY%\[7P-KD)L]>W&8'_)R,ZN8':C5%=/6+;/ >[5M*DKIMGF
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M?,#D-Z]+]K(PX%,NB3Z%-#3KHD.GM<\5@Y/Z+(MH>(P=GUZTH66MI?8B7S]
M5E"\++"A."7WD=!TYVZ23J:M17Z2/\"3'6587;3Z,&U(X(,DE>8I%K6[[_4'
MV6([/HC.8\0BQ^X,>5/D2O[)"G[0,QE^&G2I4^&C@X#^GJB5H'WS88=1Y?&4
M?S4[^I%!4@KS$H78  !'3A#LHSR(/R91GBT.> .1DH8E2E[00<$ @%:*#OR
M\0$912$H.>$M60JB+#OTWW&,ZA'],"$YY?D)25Q'@_( %9/1SQXQ,9BF<$.=
M\_8AP&/2\XPA2@:'9[V4'9Q5%OR8K[P"&64I^(P?;B*)'5+3I-\XQ4V(V*3"
MF'GC1]=!NDIO<W++3GLO7<.42JCO3]T4;>'5Q6$$_]H'*7CTIT>5(I:=_M6O
MT7G@UN%OF"E8I8"Q9?W% &;,_'#T1 G"]'V0P<TIVI&L5[J#7Z0IUB3==+U_
MKCYR'3R37RV^!.GFZD"V8GCQRT+58Q#%Y,KZ J7T0$4IR\*9# 8Y (YD<K V
M1;L=2IAMO6)&!#!-F#Y"#Y>GSNT-C87A2[6M(CF%&A(5 8AB D%.DJ\B?H[+
M"JBP@$E+-Z]\A5$(#+#$[-S5]+25&3^U?;XK8+QH5+UA7K#!W"X.^2&%2^X*
MTB>QNN0U3P;UV#DYP>51A2\RPF+_RX"DZXTBR+!-\):*5 8;'TYZ#6T#60#E
MM8Y-X[4 N:\([N%J2YACG9*$UF1Q?Y_2[%/:-/8Z12&$F^P"#_@VB/EGN:#2
M!FZ%EZ:U6^#MQ/0KN<AKL;"4#.#_#0K9P#WMW+OGT@%B=R##\A7?*9S'!T^P
M:5'(-GHSC)4MRR]V,B@='\VO8J8<?WR\\@3%H1R?Z]FVII"#3OA,$K"TI@)O
M DAM@]X5/7)$XT.&8XB5NSAO1A\?#1PO^2J)P JO&<NPR1J>%U(!(A8@<A7?
M*>QIDGUP1FQ3[>2V_CW#/0&G8P>61YC>H>H5 '/+B#(@MA@E61[E!S+E8:^-
MDD>(0UCJ23GP5C2:.[N:MGS2?%Q3.:,\MCVOR(MVZH0Y?>*N_/2E@X"^GEL)
MVH^_E T0^/CURJ4?%R2E+B\QB+75/XX#J#YI:?^^/=6[>>)RI'X_K;[KR4NW
MDGQ4?+?)3_(4ICE0]2<Q713L*=_5$YF9V'WWDYD^1?FI_F[KM_64!H8/"8K1
M_3/K60<%)JJ/7"1(Z2;*#Y)V\S"D9%O6,PHKQCX<.BG AQ1UZ3E48F 2<.),
MY:.43V.*989C+XG^9G5^%82+9(-_^GEY\>XT2#;1)LBAJN=+4-)-XQZB[":S
M_F9U0MC2-R?D'X0SJ%C[X/GRZ"$U7?J-5"WOGL%TV@63A53\<0;%_7X!;L *
MG -B>>3]#/OWSV ):L.:+$._N="YU,G2[R%B;PEVZ2Y;OV4I=NE;POXP4#V+
MXDM;B?N.0>E>&DOAX:@%.<JR4Y3D47(/D_!Y$8;I(8@7^6F0IL_XE_3&1L5=
M) D:-,268>#B1H^SS/'2.KB+XBB/AB+V6.ZC!B+2TN4L .,N1C@"@27@/,$B
M!P57=A=INB3]$,7DAB2!/,E):F;I^J;F0N:(DI,E9LD%[#D;'Q:5W?I'_=KQ
M2]?U6[EC59LO#!T)'C<EOAZ46,ZQ+F&0E;*2R1+[,<TN/,,K2FDG&Z"B:02]
M5)TX'^586@,]TREX K+$]L$5Y1!#\CK42Y/C)%=;RN$!Q9OE;I^B1U;3^PKF
MJ^T:)D&2"[]>Q#'Z0K)/Y,.W,1_=]#@SOFY2XPJ[)&74"ZE )(@%$IB3O^94
M,O%/("AE\\&(;9D/L@F7EB,46>&K/0$I6Z,;F, OTO;=]75-LVTGY\0:>8(Y
MMC;$F)&\EI2P\\' !F!!$OK2,@=J?N=/^R AV5=BP*6=+1?)AA2T5YM8)<B9
MS+"#Y!U.M;#@79]K=X0[/;U[QOQ]L"=%7)&&@BW8&_XA2JF"+5A;%S$KMM9.
M?!1+@R5K[^UL ,]V*^M3;;^-V3KK@ED&(17J#&9A&M'@JIP#UTO&X)BDFZS]
MTRS&## 3%-CYE18G QA2T*#'X,2FN+AZA(_V,,V?28FT''LLJ9VV9X\1UWBL
MRA6A9<B9/.,>)._ E5!R?\(:"*UKK0S\\"$5!)&&*F> %O>M@A^M]Y?3"\N2
M)7FS2IA.5:^Z2Q5$)HTBUC+D' !7D?^7F_4@*.-F357. "T9-V,^9BD5\!2E
M>X17E/!G&&Q^.P0IL9=E<AUDP08F@6).D"0U[8>)$M0=O=GFG('(FO0Y+9A[
ML+U0@Q*I*]5_V.J7S:V8+64Q\VQHL>RH;&4*96DN3+[X7\V)%__J[[34#G&4
MGR"Z3X/]0Q0&L>R*=H" NKGU$K1O82*':?U?#@HDI2$OU<ZMO^0"1#9V%IQR
M]@[OFX.47UH.$-!4?!?!%V_O@U @*0UYJ?;"WAF7AK6K+OUJ]I[!\+M[]/@Z
MR_<ILW?R$[5U9N7X7W\_74C9<_%1#16RK[JH)QM'6Y0FT<0KLJ8:46/,$ZNL
M6$V Q1A1\Q0=$@S2'B]6GE6:H'5_5\]IVVBY6'A67#QH+C4( !I2CF_*CCOT
M/.(ZX ;NL=0/00;+&OK-\:JM"Q0(ZL$AS>"K< AU_)"6&F>!%?>GBJO0&*+%
MR:R=/,5X([M!JR\)3"\O3Y6/FMJ_KGU(T4;.T6$28P4HKU< <_/A=GH #R2A
M* ]U7X]#1XJW<03D3OBX36YPB?_GU-J#4%)(#)O(PT40DO<8S\OD0["),I0H
M^N,@'4WC&*#KQ$,+GF#+F9*37L[6!U>5Q0RIZ-!G?$0O+L&Y. ;'W)U'&4[<
M-9)E.1+#4URI7?XO2^E=/OFHYI;UEZ5]&_@ERK"/9-$ X*-L\@4MHL:0)]88
M-[-?P-)TDO@YB-$_GW=PF82*TT++-S4#S1$E)Z&_X/**]#;T(=9WJQ[U*\8O
M-8O>JZ+C"46.Z](28:VMNFX/=_25AVXCR\[O:Z+>0<^)BQ6\JEVF#WXVA B2
MT92/VA<][UCUYM[G5/BX2^[)ZF&T9[%>ZE3%&"1E.]?VTEV%C.ZDVTO?"F7(
M(CB8%7UIJVC&*&C%5H!RZ52K/21O&Y)[*MP:ICM24SO)TR!4ZGHD0\T4K#[J
M+KR+H(5_L_/)A:3P.O*B8<WYCTW=ETI^W*L(1U9UG?$<W9N"9(-GS'_ ,%^C
MGU)T2#94,+7)J9N( 3Y=1!V4;-INHQ"";!_@_TL7#]DK<E*4D9PY"+;0EZSG
M8;20M *]1:9P&/(<C[,!:P08(^8V%@ITC%!4XC@J%Q4E7AV7E)C%B&)Q,&49
M I$7..L=BZ.Z<[4@GK$6)Q^B)-H==H649VIEM:1)&I0_DV-AWQ;/LSS:T;:7
M<<TJ_8AQJF B38W.!#CN<HUU0U;T\>%L*V<\4RBR96U%SIX=\]?&) *\55N#
MMWW?9&5W3,]51!<>D0]'\?&6W#V (!E%^:C\VN13<: SSEL+G9Q\J/13ZV%5
MN#3I7-9>Y^>55*&?%Z*;N*$6O&LJI0&B. #+0_[*)!+_!!822AGOV((6F0EB
ML@<T/;.HD;*[*19(.]AZE?,:6XNDC)GGYQ=MP T<7AQIT7.0^H\M.#MZ?&$>
M7EQ6JQ*-K;M4E=]CB&OBX\C&F9!M\8T=\<>L -6ZBFHK_X2-+D(]3=M\'%QS
ME<+'5=LC4Z[TI3;A:WM\+DLJ]4'764]I3@/L@$]8;LJ"-]XRXI+7QW[6/.N0
MIVEWSFKC\;6==BCC.;#,Z-;I7+#K7WB4?/5./+HZW6PV$>O!6CO;IBRE\VSZ
MB>AV3>DAZJ:U3<D0Q"2 9_P$'J^4J/_XD'\C!1>2UJ!6P44\(V Z<#-6 61K
M_#0-T1)_)S9;R%95[.ZLC"QW8N*#D=LV,.0"2&^C6JT-5!72D'C36YZK6>@#
MY7Q \=%8FA>DEW:&XI6CUQ9RA9=/>Q;JE7[BAFK&/AP=2%G6;B313< P;7:4
M]A%E"JJ7C2,&P6FF+TNUB_ #B-8$9@>Y%FY'$3<&X%F"Q2G*E'(LV[YMZ_:=
M4'-_*Q%B+GZ<%_0@T9D(4>G(/ZVWIS> TUZ%NS'R3T$:D:+/6C;>\F5]91\1
MLV_A!0OO#+P;!32H(.\T'C>4/9UQWSZ@-">W=5K6W?9M?64?4W,P^1,>)^06
MV3L+[X$"#2O)/[7'@L99/OMT9BY[5'T%G_+U%Q@_0GJ=H_$42X>'^R/X)D_[
MCH45_\X//S+&6N,JI5V_<\55YZH%$%$ DX7=A7J12M6F-'(_N_Z"7/AV2=H]
M])R5$T_^?EZ>W 14PX%KVIP9>%KN2B3 [HJ\=E+,V4G&@D!\)*P),R>N^L,,
M7;4&JZZS5AJ='80&#DN$\-EE+[ R7'DLHST.VH27$W_]_?S\M8:IIKM6^IP;
M?OK.2F3PVE>C1V>S*Z,]$M:8EQ-?_<,,?57$5-=72WW.#3\#7\4R^.JKBRVV
M2Y<.VV#@'O4:0R>N^T>:99X_P!0&A-F\/+D=<0UW;E'T+-'5<FPJAXQ[.]"!
M):-&.<D<HV-?DY^]"E$?DPVIH4J*NV_.GT+\T<6._,M:B.IFX,B(NQ@:HODC
M0S.!]^2]P65ERR09[4#RLR)2(!_Z<A-EAKILF.I7]KP05@Q3HA2 B0&8'%:"
M5,?8[8QQC[(HQ^%4#$L -1)C8LXS@AGX)DK"^+#!/X6'-*7O]U!*$N*^G39=
MJ8C6^BE+%05;"30%Q1%2EX+LP;,W3P/P=.8QU97F)Q0=^4S7@P",X0F_P.C^
M 8>BQ2/^[3V\@:0YBUC[3JELBSIM6Y -\W)01I[S/ D84Y 67+FC^5.Q0!OT
M3L^35?C< .[PUH(]X/Q!*8!0M;&GY,P$OGS&UQDW>.5Y#;$:U);GZK0=0=W"
M:P1?+E9I(/6FAI,VVK).W*GIN2$KZ\2% (!( +@(H^=AA@]P<XCA:GO[$*3P
M/99T<XIV>YAD]/'((DVQFME3G??/U6?X F+Q)4@W:Y)+JI2^:8^I0?JA+2$<
M)(MRT<B[*,H84,Y % ^(\H'WS[4/<AD!%1)\IF)Z4L'<OL$A9YB^&..*I[$K
MN<=YZR]H_8 .69!L,G)U>?[;@3:O(N$0[_>OL;85.XPH4-1\-2;-P<E[/LP=
MY 5[L,7D *0"@*B0 .RQ"#Z\[E-'%^GI>!Y(UJ^+WOP &#]0,@2$H_F#P)&'
MQ0,,,<R2+<U#:!^?M5Y$XC#7#U&:0YC8BAR]]"Q86P_]$:)&SKE['C)D0&T+
M&(/*G0. ]6#Q]GNG4<+Y:%IC1,'558!8'?(LVN!U&(M#XDJ'\,D4XX,L.4WK
MDB/O)#IPUJ1@!5]+A.*JD,0&+\K0* **-#0[ _!J-RP<.;RHYY-M;3U/>9N'
MBC%'%\L/S,5*8OT%N\7S*H&65A+]],PGHC[ZSE<2(*?< 4J@WTL)*51;EA+#
MVIT#@HTTM;<NEQ+N1].RE ",*U@ET'@M8>ELE9WBX$$NGB*EV_[&%_6/H6J$
M'!0RH\= A+X?9XOM"D>]^O!*N7%3K^ S(3ZZY>H?6E9*23;$^:Z"'3Q#Y+92
MZ8+ "7^34@7VY7GY[NC4BM 8Z+Q$BRGN LS/_X4P1<J/T[F62 L^,WD';IPD
M-7F^V\?H&<+;'(6_LD8#KA9&!2M >?&N!E8&<0.S/(U(241*^F,2Y=G-[4=7
M ZG8\:%0AN ;S#(;/?MQT!6Z/.%2IS&U#6X.W7Z0NXO20\.>/G#1=^E;'VR+
M-J4RD4BB-W_[49@D;)B.F\!#RE2BA ; TV ?Y4%,Y<QP=(3I(]Q<H)1U+5QF
MV8'4F56),QK$]<U"F9FC*)*!E'&DM:HCSLR/D*"/-C)6].R0Y?[-N/,U N</
M.-*%! "+4'3W7 XB[MD2@C>F(B?)>9!LHN2>-:T:9471S7R"":)+F#&ZFJ&*
MJ1^QPIT]V5A-]$/UXFS'VEJCZ$(GR F8H+.)5U<H8:,H\G7P/H[>O$P4PI3D
MF< R%>1S&>C2:K^=T;GT0/?;+R?NZ=BEC5"HC._78(/6 B:6G ?-*DVO%'[6
M890W/V5+V<4A?T!I]$^X&2=F=C*?PC@[A'$9#3.V@0A*9G,/?D/69"72]0+U
MXBS'7@PKFQ#S?>M"PNP\"U=\X8HWVEL8D8UVMDRN::_A,?>IK>RGVVVTB#-"
MT-HRKK./61(F97&KVHG5"S0?Z]M505*\_@+7YDW&/=_PLS;JMWF0YD=NV+*'
M?P7NX'V4T.?N=T$\Q_/'G_ '\](.?TI1-LZ=9A_[Z5RS11P[AO4(TSO4$MM;
MC8I*\5+B?)^!68SSG<B]0&.R'N>9I%6(!U38N86R\Z=]E-+O3+)(;64_G?6U
MB..B9M] *#LE<V(<OY1@UF=B%H-9)W8OR9Q<!3-!4MN+5G* 3BZ:X>;LD&+[
M9K39[EY( L3*@FD89<8G$CH>5_)^^>OT\T12)Y =%<]TB<X1)14MQD\1:&$^
M91!J"./RV*7/NX@$+V5&ZS(NJ_-9*VXOSI <S&6EG'.[Z#J> !I5SHJ)ZCJ-
MU/(;1Q/)BWR6/A%='7J55?^*@G %5T#9DC45,UZE [ YA455LW637#6,_5=B
MHDX3L8[*']:MW;N(V_D^J_7<:;2H:U.L*5ZW*8OIL-KJ<-R=UQFQ Y.U\LI2
M$_.OR#P5(N_ F\S.P^:7%G];CLJ\"<+*LDUHZHJR3AJ.YW;.[<J&;49E+?R_
M-GNU'Y];S\]?8)!FXOL8HI4DF]3@%22=-#Q+7HK,*#SK6*_=X*R,_==EJ2X"
M,Q^$C;#\4D^*FC>#"D'BQ=P2^G+0+BV2%Q=!OD]>+_+.<>S#=26\OQ*S='IK
MZ>.^X6X8F#OEN:QL?':*DCP-POP0Q*3YV3OEB#NV>(9F/JZX(T3BJH6=P)PV
MLO,H_$YDP\U0/ 7X7Z&]BB'Z3BY"W^G>?G:;_[NY1>ON:;0++Z6VKI.(-YWU
M:X@[:;3V=>4\D4%;#-W:EO 5&J_ET-V[MN[VA=%;\%H\-%KBH41)%H6?@O@P
M5:9@4P@O$J_J0CDHVWU_G]*W!Z#D!"@KCZ*I4QMSD];7!MN+M2>GJ7O29NG]
M^K2N^JF6H4=2>#%A-Z0:,<Z]["5DE\VY62FVHOAR[<OANJ]AI*.O[18Q#4AP
MTS[UG#^1'Y46:K(4#5KB2'%P4)R:/ L]8<B&H@% QM&/H**(*-+3ZSS0XXY;
MLNSN1WX^!*%<?S^:$'N&65T$44H]>K45LWWKKXUEW$J+K&:O.#4V3IK^43Y@
M0^;O+18"/!(IR!/._ &6E9[OF3!@0Z6A?V*Y CXT ]0T 62 P8S@%N.I"M;F
MK0.G&&TL#I3P!H0YF^I),<%:'CTV:";!8)T#/X]YCA*SUB@/XNE.?.3DF3PQ
MH%<^^TY7+3A+=RM<#<XLL]*F/=K/2Y' ]6NP/5<9*;7422K]U"=(90LYF#Y&
M(6R'Z HECS C-Q9D4!D57/S[*<KR*Y3_#>8W,$3W":DP*Y:C40F@(PFD;\6C
M"&@_A'Y,TI(3V*?P) ^>/-X0CFN7:!)XOPH;Y*&TZA_)1.[>U)9BLQ":\3A9
M^PP1'7\P!UAX4$E?:TXY>OE 9Z"P^>("I?Q7Y'-*!_1C2^:A8;=*ZBX[! 3\
M1IQM\4&.0!E^O^;HVV_*8X3A'D/XNLQVU,#,E[RD7YXXDMF<%I3'+XLL.^S8
M_+)(-A]@_H V*$;WSXN[C":\C')8H"+.!/LU>?$\VZX)!UV"Z+2%MR \^%R(
M/_>6OQIF;>/,0=4^7L\N-I";&=+S["QZC#8PV=P$^3C'B/+">!(7VH2SORXK
MJ(/G",9S/RI4-CA7/MN-W8LW+M=33B$Y*"V7R#[K]=)-E/UZD4*2[0))5T@R
MH ]1$NT.N\E"8Z],GAAQCXSV R5A=K+%W$#$V8$4\WL%=HSC"PR=,G;I*H(.
M8ONUV*#K>$H& ,@(0#$$&E#!AR&SGFM@#9[\"ZR%3#X;-9-QS,#*.'XM@;5A
MEZ,&5A';K\4&)PNL0V8]@\!:+,(_H1B3B:/\V8M]?%,<3TRY73S[D;2B_P)C
MYH#)N=[)MV'W%9C7:+OY2OCY[^?; 9EZ1S\@E=?&[&Q77[%YR1MY.8,<-X3Z
MN)D?P?BF"J@O8C_?@<_$._H!J?RV;5>[^EI@?;$;>3F#'#FP>KB9'\'XI@NL
M$^[G[X;QN5/!9[Q"6Q)23/ "?5 J^X&RM*LXVD+P392 9QBDV;<>14NW5F:C
MIH$D;B_7HL3H=R<7_.XT8M\L"U;U-F8Z?D<ZYJ-&9=&F>V.F*.H(&>3WK0^.
M]S %&9W<A;>04L^.O5^!&MJSQ4>16L;PE=FN]:>2P^W96E^FSR9<G\$L3",Z
MV%%B<(W?!,8I\'=PJW[[$03L-0)YFT!;I&\JAC./A&VF8B.\'4'R$LS"6B Z
MD[$?SX+*^6\'O%-?)EF>TL(TV2I_@.GZ(4AX6"T?[[ N[J-$'G6A)K!#52%=
MM3QGU,EJ#L>T[!7XR+F*'<[Q'_<#559F$=>TK=5&\-,#_*NQ3&MAE(D/!/D!
M'0 @(RA7>]6C0C:(EQ-QZZMQ/P)N4R8?K;HNHQVCQAN'.U0N&INA=EZMS&T;
MY"@QM0W4K\7X1HZHS?WSRXFHG^A$X5=$;<KDHU'7930TZA^942>T7/6F(Z(R
MCB\]H';8XR@!M0W3%V][TP14-H27&% O4+J%D7<QM44L'TW[2,PQ(FO)]*4'
MUV[;'"6^=H#[-=CA-%&V'(5,H/5"[PX/!JOVX=W'@O@S,@>"<YN32JWZD<%@
M55X?HX>\_*Y.OH\Z*K;>[XKGX'<!UEA?[^:7,05JN,*X!^3^9D1X9_:3':N_
ML.P)Q1.\F4PB<TB0LSV($5KS=DPD7^5YOV=SR%Q2Z_RT^HFO%+ZZ2:5^BCF3
M2459:!_=2W$0TTTJ7^.5AV=SBI:M_,OH_;A5^>KF%'[@><!8S61"49/81\=2
M&<%T4\G7=L>CY@)C7O\H&,J_S'VZ2R,R0./YPPO$ICF-KZZ;9$,43#92!_%R
M#8AUVJ<L-AO:0T2BIU5)CGVSJ7.9R=4+,34[YDXKMI.&RV73FHPWK<EH(+FC
M@204 TY2'H3S9V)!.;+Z!T/2N29!.7B&.1!:Y8F4.0E$ U%. A%_>>M#"^>I
MK;.:GCT09\2^(>YZ\5F(6QX(Z6%7K7%BUK^Z;YJ%D<F%\;8KW#CVR]?R(W7N
M%(CR;Q^O]XT6[][,2C;C2B4;.-@),5^+%LVM6]#]&"8NMY7Z&<:;-?H0X#TQ
MWFG>PI#\-X)9N6_$PS@]I"E>2TOO>Y1H:FY2%'@XV5$0_J1+ZXY+@'<6A0AB
MV9V$[!28&#ZL^7701KH:'V4U+182@WFV2#:747!'ZA!BT3[ (#ND<+-*;HBX
M:93<XP]@.=/BG]B[HFP=W,5*1^86F>JO%JP)87^6J==+P\+1CIB">*"0#ZP2
M4$I(/R7*"*B0X#,5TY/>F?8-#CG#],485SR-73D.6>^?N;AD7KE(X6\'F(3/
MBZ=(::LN1<Z")723MQ] !$Z@9.69_TN@U^;90VJ< 5+'WOC^&;1"!CX3KM-Y
M6)L>SM NB)1*J4F1LX!;-_FOT\,DT&OSL"$US@"I8P_K<"_&U L'R\KY]@-4
M+1DF1\\N<$WZ+I?!KT3\LE?5TL1?C^N$<\#EVM4Z!^AZG2X3EI.?&=<I%X[E
MCS]',,5(/SQ?PD=L,/IKQUZ*5A8E/1R<;D%+=B @^X#%)\^<3@[-]K7DH$[G
M@5SKBK(50LK8HV5E=JP;.PO,'L*6@VD7HZ_:*94@'IH2^S4\*S@')LE6A"=?
MI2Z3_2'/:.AX:[ X;2-C ;QCLO8]CX7-GAX5DSA9#RYM+M6E*(\Q.'87QHG-
M8V^G7TH* W]GQS7>N7&-=VY=XYV_KM'$9< UWKES#:L8]+O&.Z]<XWL[KO&]
M&]?XWJUK?.^O:S1Q&7"-[]VYAE4,^EWC^^E=P^!6\#)*X#*'.[US"CN,I[T7
M+07Q_^*=B JHK"_H]OW8 BW?P#< ?E'6YN@F7LK0W 2UTR![P&*1_Y#G5H]!
M7-M%GT59&",R%)6 I4!4WSRDF=@/-(0G/;D)R0^PXNY'F%#'%&FK=3;XQ0)T
MQ _I#P)C\?"FXCVV.RX>@R@F>3D7*+W%@E6)AF?P+J_^I>*-\C3UP93EX> J
M/TA_A3EA+22A^N&'RF B787.!3CNA"53\B09$+:@X@0(8^'?5MX@#Z;ONNB<
M<ON TOP$&^L.1#0;GIT2?_/0R)X>:.OL94)X;:.,DOL7.DQNL#3??8U P5DT
M5V'>N"+O&1A[*U;[_I#AE6&6G:+=793P)R )Z=N(.>"?LF@#4_KK8NWYC$4(
M;2I@CS(\S,=RY5.R!S7^+V6X=0<61AN*[ &ZBZ/[P,H3E#.XA7@ FW7PQ/82
MR^0Z12%6PPW,(+E"PJN5,W+R@?8[JH=,_BV*'G'-1RDZS)R\3EGLT %#=@>W
M*(4@B*F"*&Q;^C"%_8/\_@NIQY"1WV^X\("\ PN(^"#(\S2Z.["U!8YC&[@Y
MA'E$_P5W>Y0&Z3/81%O\14C)D-D?A\"3/1LU2/FPZ59A4PV<OI[WXA6\D?$A
M8]S[W\C(.LP-*<*QVG[,^$'!*KW$NV\H;,?U_46&MBUW&>;EQ%O.CBP?6RX1
MA;C%(8/\=Z]!3*0!<26.EQ:L8 V=!BR+A*G]"@1O,1P0_TK/6#L(F5MF*V&7
M0;L9B@MS>SX*Q_BOP4 LSHC(E R/W9X4'Y$V@18+[4%DE">'1\YR!?/%79:G
M02BU+I&CH[^A[:-K?^M3!D_,CI\%^W'V( 434E&;SY#$G6@ S M\+KB-?KQ^
M-'3\0_&[<U9@H%84+=F\APG<1KG2"9\)%XNP2G-U4-DA#--#HP:!IXZH;@%]
M;JJH\_FBW>/BY,?R]UR61B%%O $KQ)E/"&BO%")[ ."6_Q2&U"V/_8!RFZ/P
MUQ<53B2LR4J@&4+I)5J.M>#475"'"&M^@#[=&5W]_GP?Y4%,Z_P4?,&_![O]
M?P"!]YQ'VV,0I(8[/R LQTY,0)!C .SQYJE3_.\H/PW2]'F+4E:9*L9(DL/Y
M1_@A2J+=88<_9SH?R?.Q&SUD^;IP@3C"+),H  )'P%D2>_%WOE&VBH%Y10V%
M.5O P#S!A $U:=3-8Z3P@(/8'J;Y\S56?(X#&,FEH='+*!CT4+4(?"<7!TFI
MT1.I8.?ST= PDGT./*#+^:#6XYP%9T!9T^FZ9#ZY(Z[V]%HZN;]$65:+'4:>
MV$?6(JC=;.S[(CD++/D!PM"75#$=4/N<<DBK,P*PQRWK6-;GS<G=\B>$-E^B
M.,;!8IGD6*\D<X#]R<@O>^E:Q+6'CWW/K#CX/57*@-KGEX-*G1. /9Y9\*93
MI0*X(_EF\8ME$J*=TM.&05(6 :R3=GAY>0,?83+4[6<RG^L J\_-VC3G.3 ]
MSE3^CO%S<"XV5NJ1:'TW18X1YLI'^IIR%1]2S7BL/8"RH:_$H8-5"A1&/U*<
MY >U=C<6W40MNF@7$V>'V70)ZFD$'82Q+Y;V:W(VD/6XHXB@;YN(%,MDMEU@
M%&RN*PE%2WY$6IYP/V+M3X[SL'UUJCHTO8O^2F%^PM"WD$][P]I(;O"IR-I?
M%$G[1C[11LXB,L?D#6'ZD<&4P/L@AT7SR4_'+QD\]90>]/K<IDN-/B,U[% 5
M;(MAV)R[E[#8-,_C[2)F!;!VX@XWQ6+V.6;Z9^^<:P"[=M?J4Z/W.+6YE5AU
MPYM<7T$HV]>D<J1M0^GJZJUU9O/ZRE0)VD$?'./R= 08)?U3[QI5XZ3'Q;.E
M5E.]+5X863ZJ<OCN:@@D-J1U_Y#<1E!VSEE7@TZX;*=C[E1M=*U:U[I_7UP^
MBO,K.O;"UA(*N]7H)40=_L,X-=UH\BUS?1UFM%UNDK*X :N3MG^H1%:$+4=*
MX!MA93]0EV2R;7,'@GU;YC9U>HY6SU:YL;0WK;1Q#;%H21[<P]56[T!)BHSF
MH^M^LDZ>7%<L.RIC^/!66A(UI*!&CQ$23R):#OA <!]$2=8:T\S7GV,,D+N[
M8'JKK=&96(>S7T!2K"?&8>,X/^V"W>Y(>[P4+4VCDJ#MQ/<Y7Y#@"1*5:70Q
MN0$+"6_ K\!\" $J6")5O6K5\*![I#[:\E4\9$AIVM8P:2>FQ3:00X;E12$.
M!1R1HE)]CP?B3$,O^<!6,B18F&E&&R6?;HIH=YP SN[[ 6=J/K*Q?.X8ODS.
M[>8SQ%@\8AM";O0--S>I\IR!/^WE#WE9Y< #EI4+C9),YW;-A(M!Y75MK@[>
M3S%9/+E^LX ZLJ?G^2+<B,O"&5KQ1)Z+ BI90"7,A+=\O+XKE_Q(=2K./4C*
MH+AZ/VD'69 R96]'*X OB1%25)CG>,0U*$#A7"U>-=7I='_8T3FD'J)H?OK9
MS\%= HH?KJ2(7,OAM(S^YH%2\ZAZ>/;R?U'J=C$Z[A+%54XRE\0/AS2 V&CE
M.?Z*TXN5YM@>3'>[I-45]D37FTMS7OKF8,K;1<4W+)$GVTQK5H!L:WSNB-<.
ME6C7-B+.##>@-77:V(8.$33>_/0S^#JVI)*H'6],990W"X0:F]2F(WJPB"[6
M]S(!2V?+*D?7?$LDP^=KV;XJ8=FRB977Y9QP:VYHY6?%N2R+QU@.3[$H<K75
MI?+XX;K&D%M8^TZUYO5JK6NEMYO;^4>PX^L4/489R27C[;CH8 =>:,AE_9QO
MMS D=3C+P=Q@S=Y 8LQ1'%%MG96-9F@%<;&$,\]YD\X,LL5.,Q/%#OL1$E?S
M!RBT_@%W,/\"80)2N$=ICF>UR@0 Y/;^S1TSOV]I:S;RVW#PD_A/^P/YU-TS
M"/;[^)EX">6-OY/E45@FT)!,C ,&]5DDB)T)9J1OT3Z%Y-_\3]^0%(UOF:V&
ME?>A:J?9['N4T<KTH:!J'S*I+/L&<F"$6IE^,@*0%L2D*REI1+S8_./ .Z!:
M=?1.'@Z]NX/GOUS:MDOOL(I/<G2RHZH&0:7KN;CVD NH^'.OV3ESXG5Z@!_W
MJT1X]$(^9-6).WDX=.(.GDZ<N)2GZ278<T690(Z%.CGL ?ZQ]I*!?'8N)C]D
M,"HFWPO2*&W]9*1<%/DKMT4TK'U89:]MA9W^OLP">P<]S'+P\;O;[UKFG-2;
M3;E-,T$.\'@!)L%W[54L%?;KA NHRP065:97*5;S.V,?U\DHL_UL1.VAOQD?
MM\;2Q=?1S34[XGC%'@!LRR "J:3S"1Z#5J$8-?I1F+,%J,:)[F- &[5+O#@M
MZBC1TCPO>2&CU;2#2BYPW.00<-'&49'3 P8Q0G[HW&"_@(&J&@ 1 ZP18.*
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MWW27$&B.:5+_M3LJSQR7$!#<]-X2MFV ?D.&]6<(2P=Y_HW[8/B&!><;;AW
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M<(,45WX=+"M686$]M!@NJ7=S&9I7KJJ780<'!80(T,5J*1AU7M'8"B8 !31
MA 3B@YW"E0J+0=T?#.LS@ \%<"T$A>".YR?E%/B5%))B! .SO!*KY  S0JI9
MSY#P*^8H"$$&YG-V_Z#RW&D4;Z31UL?U!INV/^A;DPJ(.!,,N4*M5A0C&K7
M,RP3D$#4L,J90"]!8R&%6V :V;0M4MO[W;LTL/**Z%J9X0/G96E07I@<*&5]
MVDL2;9A7P!<<$ZX@FTE@%HSP'"F+(E!,!?8 M44.L>OE\2<I^3.845GXLXK@
M\C2%0D#, !:[(:$O<]D6L2<T-^=X3Q>8"''#ADHBUH6[78-MHB-=2G,LD]*O
M5Y DK@HP?P)X0 +T.?2+OS2/LRIB!#!O.@6O$672]B,;/7^/.(')1"=)81#Z
MM<B]8=5,6P?]^!@#UK)PH2-?"NH?Y.W<,B4%#L$)OB9=*@Y5*?<W(+P<^?MD
MT.MUT&I*[3+-X=GWG./,!T6/1QFP%G#/N>"RO Y=DZ\_&J*'\>Q9L6K_$>6N
MO_RSBHWUU7'$Z+#.B-7)1)_>(\?=*%:6VE$H6)PV=IE6? <LF<$%V7%^1^R+
M-20N'&<"]/.+[ !O(-18#&7PC:A59.=?"@'J>V(7*O$7I]<OMZKMP;T2"P,!
MOL8Z'F\$B>#@F3(E+*O+.:<7&.-#8O91WI<4_BE%=<>\E[_+0C#<HC:<8,I@
MHN7+ WPK-\I"!*: @Z%>J(=$8R'+V"(#5P#&WI@R<&Z\C;_,)%*5G3W(%:F!
M0U,'U+D_ZN W_TRG=' ]A%JA9EK..,9;12?EHRE31@>>Y5(O.(S.ISK$ WJ%
M/N#N_TLR:M[+$;<]*0^8=[XSY@'PH#\3,_ATOI:.@9G<O*VU:A!EI;0Y3<#2
M93NGC%5M_Y+@;2V\):A5&(0%&HF6DN:6=ZL?AU ;,S<%=H'A-=S/X <CLW(=
MP*A&JE6"[$$INCW ZTS']E7$L>,)>7X,).Z24Z!3%@.C.ITZZ;0Z;73"4>38
M53B"C2M$2N17IE4=(Z_?>L^X!*-JOU_!%7#=^_:X L-4;//#->.BX'%3;3H-
MR!YXZ2NV9X(QR;\;&^Y\%^4M:F^VZ*LJ?S.@'ZQRY80[SMX#F+9R4!E *@O]
M0QO2:K[9SR$SXBG!)R?*/0'][CA;*V?=I?ZKEO^[JOH#7I<^ZQ@5V6CS*\9O
MSJ%;H]5WR */I0MN_)1<>8JW[9M?1/]-DZ^E@)?%@EO^[^!O&CP=#;8HPB)?
M[$-?*/T?=X%Y2"U2_N/<453^A]Y?4$L#!!0    ( !V$=E-%EK4JR@0  +(5
M   1    87)W<BUE>#,R,5\Q,"YH=&WM6%MOXC@4?A]I_\,9JAE1"7(!VID%
M6HE)TRG:+JUHNI>GE4F<QI*QL[:!,K]^CY/0VW:87M3+5MN'@D^.C[_OG&/'
M'_WW>T=!].=Q" ?1KX=P?/KE<!A K>FZO[<#U]V+]LH''<?S(5)$:&:8%(2[
M;CBJ02TS)N^Z[F*Q<!9M1ZHS-QJ[F9GRCLNEU-1)3%+;_>E=W]J*3TH2^VF8
MX12_$+5037K>;OE_^9Z#7OC,73WLNROW]\TFC+Y"(,6<*D,5S+<<SVDYVY^@
MV;0.$YDL\?-=/P=MEISNU P]-TW"V9GH*G:6F=Z4J#,FFA-IC)QVO?S"8F1>
M#(L93"14F*[WH9=*89H+:N=V)Y(GI4&S;[3K6_=BF)(IX\MNQ*94PX@N8"RG
M1%2N%DA72#4EO QN; 93-*!5T-)K3A0CN")4CK7=\#QC$V:@W7)\Z+OY[NVL
M8L1)U7I:?NL5\0K"<33<'P:#:'@T@J-]" Z&X3Z$?X3!:33\+403/@W'C^3\
MFDIY?#H^.1V,(HB.8'QZ&(+?)DV_4Y]LPM&XLFPEE>7MT,;:1@<AG&!AQ\-H
M&)Y@D8.#P>AK"(,@LJ7W?VYWWA#AP6@/_,]PZIPX@6-Y%RWNM[>\FR3OMUT[
MSE;GP[U95!FHT#V*V+ !0::81G09'KL#\8UP=+=61E,(SVD\,VQ.X2A-68P>
M,H6!4G)A3VXXS@C&B2FZQ(3K!@Q%[$#=9!0^;GQNM;Q>(*<Y$<MBY/<V&X Q
M#$N7#<AG2L\0#!@)XQFGF,TZV:RVBE25;:N>7-A2L(%/$)'"MQ2F)3R/,R+.
M* QB8Q\734=$<K54-+8OM(\;_K;7L_5J8!!BH,XV2YL-.1!B1CB,:2X5!A*P
MC^D!WVO^LEJTH@&8SV*\I$0!Q1HFN$)NZ'2"J6EC\);7\AN0SCA?0HR3N,6Y
M8"8KIBGZ]XPI.L72:QOZ!CKD;YD7I.](MU'PK;.K=)BP92<V,F(0AC"!.)D
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M&)OBIH?Q"I8$D1V68$Q*S"J0[L[^<!,K&G@NT@52D#CGSVD[Y$]SZ92JNM%
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MJ-GU'?'\%"ZL7'5#2*9G#XK G0:DW5#10DY!;# K7R) &UB#,L! LH^RYF&
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M9REF_.^9P?C))3)R3NO67P8-9(;_F85,M][T-"EU+I_RVAA=7!&A@MGG+="
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M_P(5<#'V&<7WYBX:$:0K@$FUQFGE_YN#,HS=%KII?@)0NR%-7,?F3QNZ*.T
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M;MW421RDUQ4U0+IH0.^:JJJAX?#\>M-,?+N;5O>K!C?1O\)X WLJ3-0YVUJ
M:6Y-P;+.J)D4EZ)\,@YK-75RCBBB.H.85\Z*O61/@,+"H#3&< 7U,"*P$4SV
MV\Y?>.PC>Y6=R&^QCEO$X22W:B$C42<?QOB8_C<0<;7(CT81ZP>3<0;"/4 D
M$6<8\+#_\C"EL=3S+H:[R7]P_+SW+S$\X+_&<*Z '98R+45$4);M7-Q,EP-]
M[/P'>QZ@S _C/JJN5.P_PRU>CA%-5CF(B(Y3O3G*[+K'#%[OF' PZ]H9+LIN
M.HU.V6TD+G;)49]8ZIY^TTKW57:+ONP\VF K&580"WX+-4'$KEY!R:IUN,AT
M:DH[Y4+[D:<2Q."V_8(RHFY6\R71T2%8TMBPXK^B@_3-0/W+E0W-/ZUKM\R=
M915+"@S#G?046JYFDQL!$H_!;4M9=;6(C)^<32Y%2R+<[6%F!OT7@V:G3%4H
M)OE"K]4KBB]2O-S,OP;>UM&&@5U>(N5/D'/A<QQ)N"7SFJO97>8H+U!H6</W
M!V0)Y?M_6JA_Z0WV;7G.25$\*F!F?+P0H]C^8PT2LA9+#%[(#'@>]^S+'R&&
M_)H[;YE&%O\BC&_C!)FR\):_.X5+(=1WT3F2VOAL=(J&H6?.L+X0;&9!,R$/
M]RKI!K1[LZDO=B<84KBP%, N*;5=G'@*C7::-D<6,M#NAGNDU^9?)3BF\Z+6
M# 2,:N(,Q#5CLRD]%0_=D$1GN^ V6%9%D\2:'8@XM[U:8<W''8_1M4"3<L>3
M>13U/C&=J;(%3C <X4A]+%;'I" =PV%&23GL&A^=9OV7IV4N\GT]6MTX#>44
MZ\R<VUK$T!!/9K0Z^:V<CSB6F^*/\'LUI*_ N)(0/XCQ$(.1^LX?*7(%[!;\
M^_/F&JACJ.Z3>/?IDHF%@1"[B(_W6<_[Z?QU<IWN[)A9!DZ;O$:AJX0SR..'
M6+#_>!VSQTZ_O<859N7A92>\R%A3IA;# >(.;,<+0L)55MRJ-4$A2)T\S_@A
M/::$YY$66<G2-6*>C,2(2>'MJ(_V]QRK%@89:S&/9>X%6UQO!(@G__[+ ]0?
MXO6D2(0RG7):Q+%'DCQ+<Z_ G+@?=#YL:^#3W: :HIA[4#;Q:^%75V-JC&';
M7RZ_'NSJS1S]T<!]0T^*\=>"P$*X&Z[>CA3#R>^/WX#_$"[JJ]2N'Y+KG6SE
M6A'-/4M;Z[(3QFC:<,)FON@FQQPK*&=S@SI^UO68.^(RB3DD&,*FCF]&L.FX
M2-#6E34C%?(\?:3&NTX7528D/V%W'*5(!?93]GC1[.H3IH3WC#;=:3QH6$_U
ME5"F1-,G\[G]B\/K:8=2.)[TN,/<5(I/LMJALT/ E[O9(1KD.\+2 IOO^#-,
MB,K@*9@(6:JV4D659:C?@M6FD6Y9.UJ6TQXI/E]NX/,%IAEOY4'!=_;(2=8O
M!:>2J6^LJ@DP4'@^46*,W78Z\Q7XD.$_6TK@V-W@$.)&DS/H[.Q&MT!7$^.S
M#BLXYS/ : 1;6C>@,LIU^*>^?<ZBEB][50GR;F]")*W>*&7C4OWX2HC_51;7
MWSP21?H7)!H9OVB6T*D02!3 8V3OW/X4,AHT_DNURQY;_T/W;"W1YFV)S$W)
MK6O&'7Z!J2O+Z1 ;8%N8?)5S5OF/+[QD6*&!9P_10)G1=/*_[3G+S!"PL615
MLORS5W/8__V^\KS68[@<"OS#\1II=(NQGXV#M$[60E&)QH6SE.>(?LT*9P'^
M09AC2'6(E\E*#"%_VL*?@U%9BLYGTG*)PFOU(JKD^W]<V/,*G9F(%I.1;9#C
M$IC!FL&KR[<GJB$D ]-ZP?(,' QO9VBURU3FVUOHZK_2[[KFJ0@HOL*X@F6$
M_#$<6:XYAKPK*I>0:/0/T2C/K8T0)6UY)J])M>^8J)9]#$@R[/8QG.;Y<KO2
ME#7L3[VEEV!E,_ Y0)&<L.U(6\1=[R??2T\6LKQVKO9&N>FMMO?\6".1V Z'
ML+(SESUU1SCFYX[9(<9:_L".1%'-F!WWYQ&87>0OX1+#C2%J]_#]=?BW+V (
M(MV:BJ:ZB1<#$2(7,]T-#S=<#Z083LN&WNOEYRN_8:G.+^Q3-V .%:4JW(&Y
M>&F>+LS&W]1G&RRX$T0'5YT?$^[-E79TVUEP]V\N*F;=Q-F!=0E%^W=D/L=#
MHZLZNQ9\N::S?GQ?\V!-[WKPP=\7Q;?\9>_!5B%/V6[< VPQ%P6&LWL9:UZ'
M3?RKVK[<=FS];ERTN[!:(:'S_AZQ+ZY+A# M*5B<5]@-7_&F<N H;<@)G3]E
MF;C"^VSUWD.1\OVAG2WU0M)K"A[Y,\73ONZTF2KN(U5=>W=_]A.WW\T+*=$)
MQ T3V^+6I_YFM%X[PN69-,7?H>-N5+-=3Z;?]3\3;)/IA4W RP;<,@7/F%P'
M2"*J1$#!+GV,4YGWKV2!+I_(0.1OUQ:B*$:X^_=*,^OO N(_2234V,>0S)F=
MJ[?">],VV7XJVDVS8X2^T T6E-M&HI:+]K*4!]%UG[D.N?C/K7H;?DTW+^_Y
MTU<I3I%<CHAK&PMXPEZ?"@-V*)'%'-$9(XI_");CF22K2J'=OD;PF.3W+\83
M<X=U-& )*N@10SR<*$]T?%YR=+^^I_.Q [)"SZ0(/*$^6TI)EC4Y?V2#$-:A
MA[NGF#(S&>3O2&&=%S:YH0&&O&S4*60'ST#@4]/+:_"!<%Y%S9*6N$$.T>4@
M\63T@E5,F;/^2'3KQL=)R)+J+8:=X/M(^(NDK%O%;_K6^PO;-F-HH%3U\LNK
M--#U)!KPU#()W&TEYF]64FRM5*+J-]8*B[@OIF(7FM2M>]X/O; K@50],]HT
MD.M6O<+910,7W:UI7K?.*[OM8Q$V5+#4!-DR=EZ1)^X<71MQ+LH>(#S(ADDC
M&BC_ZW94J=/4 I(3#<0&'Z.:B5#!T+P7"!*F$#AQ[*KJ%>V'UOW5UMA<^.3X
MX#K5*JO$L_=J/EQC,=L9/?$=&:>BLQ!8)X3!0"NJB<^M<19*0%<"4S-E;W23
M>"79Q[ ,&@P?<&/ EW8YO$[,VE28K]]R&_5DLC&!^Z>;C@QO4A#N28T@4&2Q
MMVE^VU<29G5GKE'I[QQ&)LB6$$;2M$]JDKITCX^>\M%CJR[U_T'!=[#J?]N%
M%I(IE\[/#'^CBO.+="36Z_!G$F4D8E,J\(BY_.2 LFQ8IC1 6+C)F\ XCQF3
MZ0E W^0-<C+^A-RE=5Y?4)G\J&+QG]L?Q@?,UQ%>ZR#%XPN?Y_#CD$,W9<',
MR<,D\Q.'=O'LLPV?Q_H7-J<-#@[][/IS)%MO-PTMC>;\09"1Z$PTX ="L97,
MV-$^G'#,:H)63Y)X1FM4J@CV7A9'Q"M-TF?TQ_5L6@R_HO@AD<A>>K(<=%^]
MO]@S3J)J%_[,D>VMQH^%P+YK-V8R-Q,5XJ:\Y1$7$];^7;)+"EK627M^R*,%
MHUDLXC>DJS"L9Y(2 PVJU)"^PM6,ZTO0]3TM8O?I0R]>78;G]:Z;Q:E?Z]>9
M&B'_3;N&"AMO3M)%)K='Y/)%G2<>"GQ,\H]]9\8B(P+(Q@?0Q1$:&"]#_*=-
ME850QZ0-?<CF\L5D.YSTMT08OQ!%_(]"8.2G*=:N#M1'YRX<;-TIP8@'LB-;
M /O(%RZTV2BR3.&[]/!D@E8^3 XE0^:Q>J.GBU#2;DS3+W _\VUM_D4GZF]9
MZ-F*>JU* ('=@9<QTT)//-W:RN8[MS>#=^?VE*B!A>@[?!LST(32XN!5:D0.
MEYD7L_^YQ6F9.+E!^;H1W>R@ ?A[O_S52R1B#W1YMT#6BE]TT1)-5NOUW],;
M=+;4_KX5I>2\,[-C&_UC=5%/,\T,6ODM:%KV;8%XB6?I-]:Z,[;HI3R'MZI)
M"7Z][PH1\9U1JWA1CY7#X62_QG#(GZFL+"J!(,-U;/M(O1SK.<(TB_S.FT5M
M@HF!$N>@/8DD7T*[[[\J,MZV! _/"BCSVJNIL+^1H _ZYFA5UIK,[Y5:<GG*
M/J;W% T$'R.%^+B7KMXPW<_NZBKL5>_#8F X*_%>XHF$\1D&*PLVOLP*9_O\
M/_5?NZI8>/EG<[A8<Z.>2JR!7ASYT/ T%B46C?#[)?R31H292J)0OHX#L],X
MZ?!4KR1O__'OC]5:&68%V[Y6-[]IET9=_Q3//&.8)+^/!MB4Y:.HNFI2\J3G
ME@)M7'= )1\@&DBPG9'-U[W'.H.\?00Y'1\U&!X$T%DQY/,=JBK73IW/'G!]
M^VYI4!J=/1KC9(V))Q=R\V$O92C[HT?X]/3//X$NO&C@WH>,@0J'+5Y?J@?!
ME/3R?6C 7:UUO''>SK.4T[0F\!Z8Y#Z8)H""+ Y%41DO63<660NR3)=Y]BS)
M)>[F1+"']U"Q369MNYJ6QMJ!."?=M-"&VHJ$LO5SX8'4MGAR40O^P^4;Z7$T
MX/%G;K %GE9I@77$DW&T'B#BJF>?H]=209O/WL\XVF/VA3HJUJI0/3J_7BAK
M7[ZV88J3GW,<[&:?0$2)Z4U;,(O%CFQ4>]!_>9MNQ&*I'.((H];$"FP9\N7\
M8-R;HN27D]&\M;VUN"QA.%,6_<L1^=S$R_ORJ_Y?63BD-*[']2X)/\KZ3N9V
MS(PB:26ZHKB!I-S4^!TSVRPVSHNW( KO($]<F#,:,.[ZZSYFV2XM[:^Q% 5C
MDD$WEJXD :(6K>OX6[:.W:]EU=<_;40O _02^N:K7QV<#[L>R^-!UT<<BQ:0
M"I.)PW_&86HDW&%ED]3E%'@)#N[K)[]]"$SV6TC&?:5?)WVM',Z^Y_G#;GUB
M%$4?'+#F]@+?,^/M%"<859\M=FXDRE['6(=5/DC!^'ZN=18-K'Z81P,?KB 6
MITG]9^+;BX(C2"+^">LES#$^)6A#&%/Z1R&Y.J=YH@( (Z.CFG^9T*:%OE:[
M?.UYO+A^@=-NALPM$:DVH=5:V 0:^&5*<@5Q.).+O;UM[4;X)W>;(.KOIY.>
MA--&D02A =_G'R-.6CO79K.6/0U"Q9V_.6".^M;=\NJFA 2=WRIV*E>EV.7&
MJ*I5D%H\^ 5<5;9TYK%483*LF=N0!V5'D;(][[(MR@8 @G=PE:^P5J+S9FG\
MB!]XGCGXS>[V5*U<1*L&_LV9NH@(E2=:+F]B0XB^AV(QB/^\GI)X9*B'L&L_
MC?2*(+VW1!:/Y<5@/5)>>/WT*69(^+5CJ#_]^*%Y5.+P^+/G?0>_>XZ'5HAZ
MFC72!6O8>?+6H5*"_>=D?4BAT>&D530 ':BK:Z:7B>U3707!X,6&3*,.33)%
M-NY'I#9JC4JN9\95A$&@[TAE/&-A[S,(N1[8"\XK\\F"@$KVQ[?(3Y@5O;N&
MT8 &[D_@(4!33'O9J>F!HJN>MDAT=K7-5-<([ORDRD!YY#-A[-Q*6FHBD,)^
M@)%C%15*\5Q*GV@2Y>:QYI?;1$M:I9WY^M$"FQQ4<JY1+_"P#5F< VOBMEAC
MKO:I=W@T5V%^JB/K&EV/-?J^ 15HMR;RH*HISCS*G 03#W#!H&F_R#46Y#2.
M7QO!(G%Y\P0-7),I9]_^0#VI*;PMWKS-=O5+&MI-C:J[G!]OF,_ GC&P?6JQ
M_]N%<2*6A*ZDSCB?P6,06:$"0S+D>D9F+\GN"A-D66NSKT]\E0*I@P/66]AI
M)/Q"55_<2#YN=5PZO7% >ELM-;,/R8^_/"INQ*W_2YV]M1VWP#RCU#%90J4%
M2=3O Y>ZWE'<QC6#>_M&D]7%5FWC)F:<O;^#+6D>2D@,C170B'G5QB!;$6_X
M7AQ20RR=&SU46\^LYJGLQ@'<S/< T(8)59^J]J%QZ9LSZF",$7J72B;^\P_?
M#(6AL+#VR8<.",,#K%GNF.:>5V;S$U!7.!KH)W'L10-RTUU&>$@):A=V_HW(
M==QCE@&?2!;*ZR#=]8Y$]E6SU57.D5DB^)$1[_'Q?J3;GUQ++#$S,T=0!TY(
MW.=^VS/N7LU^NEM9K$U]9/ ZBG3#4-,=KVH+#33>Q=*#>;OQ>&FH*B'$)(SI
MAO5S9U-LJ\UE#R_BK8TAJ'+\H]'!]\X16P^'QZL1#_<( 5)M7'%:8983B_J8
M@V634ZPY 3.' ]^;LV5QZ!"2X]1_ONPV0UP%@6RZ\W(O8L:AO9T@(K_RX>ZQ
M&*%3T>7XW0F/?=TET$EI2/!&@P\KLV-U D?EKV?.J6: ]YCE?4.A.U#WXNU=
M&F>&!J3)MKU[D]$ [EFG7M4?U5>J K2-T1+*4_O"93\(*_)439S&.=X!%#V2
M)L.>?>()FLN=*;ZT( .2UW81_&_KOG_J91:3I-ZX(.5[8""_(]->N7VP/ NQ
M$C?DKLVG@LR-K*=L^=.B@;ZP8@A, 7*N.YTJ@2\J0?J;@:I>"@O[-*KXO TK
MQL7.2O:D.S$D9\&F9GQ!5 !_Z#<[JTD"KG, EM2N[$^G%**,NP^,U[X1][@J
M385X;"Q>6V:=)&:LA7V48@HIL?FJ5P7B>07FRK]M78R_2O]>_GJT2<)J]9;_
MP-Y0Q\2#:\D+7T7ROA/02Q;F=3+2>>G!9$[^JCWZC9/\/=1K:G]2;7Q[3,G6
MB9\P?APWFE=[2VO#&LX63'+)D>>XI&89P]4M3SK"5L,L< 7Z7>9_4'\%VM"
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MGLGU#GM?Y SB6DK#WUR#?X)L#N#26W".K[X;]MV^A[MJ?IIPC'DVD1:.PWL
M?UH-1;5SS'*<(GQL_?/(Y>6=HYSEA//GXU+"TN\^G"8?$D;0\%1MT7&H!SI)
M+CT,J2;*-1>-^$D\S2PQJ#Q. (#SC:W4^*'E"&:1K!=CHP.$JA!C&8;U*QMX
M'7L;*;QN9;*^.GQMH(G7>,K]CN# 05R%VP;[<MZO(N2\#*XQ5LI;PO';"!IA
M2EDNP.(O01FY==A,>AVPM"*_=>2.(:;_.Z;E.\9%X4>*9O*)(T@+GL[LD@)E
MY=M\A>[.8C)A)UFJB@]^+LZKA<LM!]U>H<.#V_U+_&YE$?CT,:8Q;W,"B3X8
M X2?,,2\C,A))EIWTD@.DT2=Q%=$A]X +:(.H"(Q(0.GL!H'@6YAD[K%]P?9
M)[%>(7"\ ;C,L<@]@ GI8_K@98),)YI>G/ &IR@82&I45IL.537-:<>5HU&W
MZ"Y.G.\KL?2QLWW7-E:.!*:)CC0!M/YZK_\0[VE^(4?F+HT8/>QN7;/]ML5N
M2JV0#Z[PJ9BD@]8AS5SA(0JHJ<DYV\_TI$N%/_@ IS-Q;FE/UZ4?FA?9O]$=
M[>\<<JOQC;N]WB*NB/TP48XRF(# O,9Q )VM\U2/?N8D[S$'IFY[JM#%:+3W
MN(TKO9C@/&;KK8N-G';<Y^D5TZT)&N#5B6;SMP+) O^2/FN*0WX\)WBO@,4>
M.H:\]/AW>P=1[<8L'W'CIPDUUH+#G)E(GM:N$U#2MJV8!1""7&2:]_0_K+L!
MK@CL7D\:X3=WW0,P,Y=MYK8=C"JWCQU[AX'8V_.0"T=L;9L9!8\19UN?7*LZ
MR)>>EZ+<RZ<_GU\_E:^K27Y]Q'&T%?^8A)_@)I$6C9*9'K6P$$Q+HO-7L7#[
MLE[<'?&K,43VM5+5,F3]014;3CW=3_GB&@ZS:H\CY^K&C>LG(?!=:@GVV'O
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MA\<Y*?%?3ZK-YTZYS;K'</D^#4LP^0KHYD+%=>V6."\<Q7:D<+@'?-*H;#A
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M6K2)[;<G=%S46N^OOQ3ZO:\.ID)5/OWQ[K3P=,)FW>90!,\!8]/ L&ZU1#3
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MAD3/JM170A&:U8Q>#EZ*J&^2RO60QM"<+]I]"8W9XC^DT8^'ZP:B["W;G+'
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M:^SOE;*V?'T3S>M(DS=0!@)>_B[*@:C)+=)1.$H;3O#&2$IG#GUT.ZF M[J
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M8HCCB6$H&Z&GK.3L8YI,3^^^]!>ZI!C0FN-1JM,C^WFN"7Y9*G51!RZ[CGT
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M?KD\=FJ8V7B2QR^XC3'!VU+<P=B=Y(VF4"]'ZZ:6:99,JV8L"#TT1%Y)C+V
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MV@T?D[QPI$0 SP.$F[@'[/S02Q>?84BWC=&'2E(4X>M*G-E=61[Y.O<0O7U
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M+&ZNX,;&E'&&WVQ%'W)G",>=\SU@7AH"V4$X@TKU%O:4; MUWP9XT7=XY[8
MLGS-$F(G8W[8R*RY[#^"W@%D:H;.2,I38]-&C&P VWY4]P!:&E+0S,N''-2P
MQ$NOG;Y3C*2VMKZE3G;-D_@DUR^RU:P"8^&R1[FJ:;4%Q^:27":"MAYRNM$8
MD_+X[-DQH[Z'B#N5K65;NM)ETJJDN2]&LG.S9*5/C6%FL!1#X 9/D_0>?-6P
MDFH0S#&WP&"WS<#,XISNEWZQE7"R_:[ZERO1T+H0EHR&ZK; N4AL0)6C[$E9
ME>V*@:52^H#]XF"D2=R09*U?4UOKCD]ZTST 4Z,[?T4!AV^;N#ZY8#LZ!1N%
MS8O1M8UTP^WNU21FRZKV]RKXV[VK[/G9!:;%TV-$38!@"?+%)"_'4R^J=S7+
MUI-8S]B'!ZE=7(_$,;+N;(* ^.E0N !TKHC>$AI29.=S=WR7RMOBNPJ-,6U7
MR+=)#=8;^IZ1K A8_]$#DIP0F[P#;)V7AV?;3'R<W)[F>*_Q#:V$Q['].1<W
M0F8Y06<)0X[N%\S.E6]7DZK,7_:Y116;/9)V=OYU J&F-"&UON=O 4:2:L$1
MZCTEZN<GW97YL]?!K% _.7?B7KTAS3-<FE'8I/M%WN.6T)93EH$'L*+R %;
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MN:E5IW<E_2-]U!W2.^<NA74J$ME?)S%AV8RK$%N++L@(Q2^+GD'2(H$1HWN
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MX=W8CV=X8M[;XO.D?6)*^Q\AY3$VIU1)"M6I1G\+"/PSN6#S7R4%%C1GTT[
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MZFV?<.+F;I<I][3Z/BHR+A_^0>G7Q"";L,_NA7T=TB1TBA/?HWO^^UV03@9
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M6VHX_3?'H[ &'S2Z%<ZE/FZY]B5WB--"FC9J15YU0X6SCVM-X\RWV+W[3T^
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M;1GSEW.F)'H-/8$X.=_I56J-#O8IXDLR9Q1[^S^?0D8\ AA3YVX3_Z'P!M>
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M-8H;\Y(DV7^#BDOD8U-K.]';.8"WQV%&QC<4G4VLUO7'(I"_1&;UTW+.D_+
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MP, K5$58Q)']O:&T.;VP_#1EBZU]FK:3?I]N$5^%G4$9P-0ZM0$]&)^K0V#
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MN+K!,692;CP_)@#)/1'[H"O6/Y<'\8#:A%<@(,:W&B%ZBZ!9+H:!KA^#,'+
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M_G?5GC3=%,(J8;&GSS9P%L9!EJ1:!APN)D7'? \]+:ZHZP&?W$E.4M *]V<
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M1&=D)C410QN8VC<52D@3QX8,HV2-DI1@8"C/>)*&CA%T$#_,>E'9<=VM[?E
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MB2$6L80/IM;5-(OR-AZ<(RYZ<8I"TD/%<NV0"NBKB]\<R\M'TF2! Z.N*
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M@I9' !%HSH=ST4Y?'S)L-#3A;2/&2L>-[[5#(7FFS%T56+!;:W109G^-QZ9
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MM\!KQ]+@]8D+;X'A(3O5IB]Q5A@U:N+6-)ODK+0&M!EK,/+4QYQ ::<KL*_
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M+&U66D>%#UJE6_I<=<IT\5WESXP367*H/3V=YE?>%(A!C@WE!KI,8Z@M_3F
M'V;!#55?Y0R$K)OB/[KI#24PWV_L4.RCP0\R]X[K(>)7ZERK>2!G>G("3O:>
M ":M89!#'><PQMM/JER&],MDM]]O?#714\;=028$P^X%^^?,V</.3-7#?(O)
M?:,)O^(I=K!0ZBO6JTW%RKN\M]2V_VA$QK8D.#B.I!^CZ:TB_$D#=\61H_EY
MY5%^<[S8 CL676)10UU#3?10?6/XJN2.I?H7BIOG@)Z)KD? E_Z>".KMI;Q;
MFP]S@[3LIV/ G?JU&VXH<5.X6%'&JUBK=%J+GT&P.$Q5/PU%1XS:7LZ$OO/W
MBK$+,FRJ6%@-I.@YJ"7=]#P3N6U<NT$K\\,%G+K'84H_ A["9Z!IX_*2=44O
M*B;A(XEJF'YN@R=1NESK#6%F3>&BYO\'>V\=%N?W[ DV@8007(); @D$=X>&
M$#Q <*=)L$#C[HT$"2X!$MS=W5V#>W!HW&FDL:99OG-W9^?.W/N;?7Z[<V=W
M]OM'/6\_U:?/^[Y]ZE1]ZIPZ5:"FF (-&G'&"LJ1'&D(J5L"H-=KZ"N)V"]-
MLKQKL.%4"<]/IU1Y*)78[:!7X9>&SZ0"N[^54-#+7TZ%?26V>*MMK),+D'M=
M@-7A-+AOKQ_?EUXR'U6MG+7@%CE/FNQN8Z;"]6X'QP1=8"]&]ID!6#.I/I*'
MJ%+,B4-DO4S=*S#<?$OSQ)?+?I^YMLQ6?LJ9(E5Z567ZZ.@PNS8B=O;W<KW5
M<B>+#%D_ZLM)-7&'Q+F_EDI)VW*]R*S82R?Q[?TUWQ&E/+M HZXYP;NNEHF2
M;@I:V:<X^)[I%(GI0I P(&J? A 4/&3.CQ78CLB.?[GQ.4B3#,TSM-@VQZ(N
M[/6B!3RZ)*RVQZXHB#H8-4;\)8+W ?"Z+N[1WX^![+YN;/]709TN$U*4G/0J
MK_O) 44A'$0XOCA=64U5M6TA4N[6V#U&QQ@\GSO$&GCTQ 5Q23.BUF.S+K1+
M.Q"SC2?X%HDD$%P1H#N6+;U+I9FI4J8L#?]Z9-OE/J'.PM*B=Y+G5]/Z-7=5
M:3*WO4YH3A!IZ;KVYPBZ[\]>XHMK4/N^T$3M4TSOAIDP("=FL7*>6,]HN8G]
M>E=_6?Y^0D0P+^JYXN>O<V:3]SH/@$E?G&9?*@[.<?)Y Q)YA:@:ME\FU>9B
M1GZNYG,"(X:9M"+F74VBLZUE4KG[>DE#<@3H2AT)0';H:D;>[H+4UEB8=0N_
M2V^IT\&O-Z;,G888" K,!X"W5J64A35:U1!VB\H@YW!9"(KCONS!]7A"PL2R
MG%/":6F/+_-O/'0C8<+I"R)MC.*QMG>/X+'L\5\$H=^\N" O=_YL[H5GJ"MA
MA[?U82)XP5O:0\W(3HSMKZ".];&_LJG-T)!*K*>JJ4V;1-Z4\.J!VK=?80BC
M++9Y8"&#2SWT%[SC>X==N746AT1 ^UMN/ZI<UV)B%)LF+^[VB!6:,?6"04V3
M764R4"EFE"X+W10N!*^%R">&M)GMLRRCW-3$<,H[RC-OSC'Y[HEL<F#$(>TI
MO,BVE$V;[*4$J=)Z_T>_44B\QTTH7]COK]-]TLO?[*,^JA,G60?Z&9L;6UN!
M3DB_J(_-/0E#V;EMG71SA";M)][%_MZFQ'@2BSY8<W%!ZW29,\5F#*/IE2C<
M6UP976!/4LU!/7M)Y6&2A@QJ)=X?78"S,QTO4(2<I\9F?$[/_#>4  MZ]$&2
M5&!Z)+M,2-(9!46^Q>>& /3",4%T6@>!37NU/[L^&-.\;DYWF$=F[O2;LJ&9
MZG=;*#3ZQBNM9M#9E3-"[&%\9?S]V PC"*K*@@5<$R4P-;6UP2:+-)[[Y@7+
MTV@.P$6Y*"P*\0,7^Z^J'U0>+[62ND:A4.;O1[0)7]MG!F!!)K>$ WD=FTAZ
M"W;GK/["17^V$IIAK%875T0D[AJ8O2/A2HQVKJQ%I<!W.+TI.)+?&"TJ VG6
M!*18." /"H9COUX= 0?WC&PS'4F,"M(5]BO-EQK@RH=]F"@M>=V)SS"\NF(\
M"$QEMD1'W2A>ST.(3[)_E%;!8MPB*:18S&_5@8$B>2*4NR?W;L&#SLZNWS"V
M..8'1#8=/+',DR;F+JCDK_J;I/-MK=M&ES\IO+VDL#M41ML\E9$P^*"KE/QT
M;.'SU!%=@ZBIK#K_]K.OU:@C(G+KS7<@E*_-T)B%(4]]Z?P?.*X^J:+%//,(
M(/%[R!&5T6_QM\L:K@%[L<D077A25A/;CT2:KP9<@V:C7IU/CL?*[)-8GN)B
M6+@(&08%*'O6U3?8"F!FH(;["AD9YZI>!^;I[_L0.]=*Q\J:ZLBSO_$=$*"Z
MW3DM*PIU0>TI*17!?/LSSM!2*(?_,]#]B:^/S9W2L!%\\'8NXYI";M+::=#6
M*:^=P]"(:\47=RC-%R!\N5V?.U'3>(S=LV"=$D<81]>1VRYB5@X =) ^B15W
MRRO.LR3W:7=>U^-[/8O<%L2W1XALG%(] );*=OJ2L&+=J(6IA/CL3502>#>K
M"FCOE041S,6>PCILV4V>7W6AG-]^93^=]D"==N85)?Z'SR?.T\HTM3Y:[IW3
M>A-T1,CL!J #NW2@MAN"VQ.E)W<:^ DMZAP^*GV,>I* @"75\K:0</ 0=E-6
M5'3+O Y2%>V$AJ$$KAFA^U\L0<;X@->P,M3>[Y[KR@2K#P#S+=;+K[( W!.:
MG[AVCG\IEC()-+Z*$CZ8#)8L1R%YH,K%DX;%"%2UV19O*F2V]=:>IN0])1G1
MS3>G-<KP-'<J !%O!H48_GB?W_HNJXYX@_VV$F11M!T'?5VO1N4CKO!_D:W=
M"<FN,"A"YY,@W').\F%?B\Z.)@BL>:!<U3X/'U+PC A^M_.!Q@(^ "U1K:"6
MRK7TP0KK++7U_!JL<O:'S^BMM$\OB!(GM=?6C4YINEP$5;2P.6EH]$>R3J)P
MC!M]I Q:T,G2G/';[SE#@FF*7(/;#&^EZ]_/WT+_9;S"4$9VJ:FG>10*;6Q;
MI)P+/A@S;XTU,#G@'.O?:N$^0D/2O%:O)L7<M;K) "C8O\1KS M'_A;G\L J
M\T<Q0#T<3^99-62=<KQ]%S,?LL8$"<1&&;,@V)U+(V\:]V+UPAZHMUWA$B+H
M]]^,/[C8N]826B&$&?JM'[T7N*02M?JH=(6?,22P.# 8)2IZ,'G$4RK4.7]X
MR&J=&D26&?@I9J^CF*"7<D)$M:]*>JV8+CP(O9)(&X=BW<IUXT.2G%E$B<Z
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MG\?MN]UJM <NC%14I<N:1BOE'BM$\Z'=R.CO  ,EUMAOT*^S=R%QT[KHZ0^
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MD2MPZ/&[%51KM%>;UJW: )\3425A6*^B[0;V6[#P]RV+4L-E_R%;>WP=];0
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M>_\SG.^=;^9[Y[N9V60RV>N7O=9OK6<]S]I[8 XS\8#P63-+,X"-]5)E4P4
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M&\ZGH=?4-BR..J\2UYH>?4OK;<5N]KU)7)O[!U;[[;1-^;#:E#HI]^A)^8_
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M;X5@F1E L_IS^C#]US3ANW'WBP["\FZ2B:0F_F_F-]YHWX;^<=-A#L0>V/E
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M9Z.N.9#8^X(UQAEMZ%(L;9]!2[  F$H:%8 1!C^H'I\2^G7)+%X@?J.S^7Y
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M5*E:%-76)G=@"(>MZ(K/ 54H"6 - ;W[:C$Z^]?VP$1Q4D$KU[#.^/F2-R$
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M7\VI9;_@L'; J2(:<?*WGCGE[XO;?87]7%]_V/&%BZ?:#DV<XO"3N41'P0]
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M=VT9$,QNA5S&N\A 80\5-L-4VS_)=@Y][U_DZ[K0!M! S>$3Z-J!9@J0A/Z
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MOT"MO;I# >9N("F V.]M<&/CR;$= ^3C-A1@USP0A>7Z*$B.?DX55EF\RQ3
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M]Z:<!6HTO/^3OZ;O7NO4M9'M<Q+5C;'WPN_XSR:V=/F8'GHN@+MLIP;"/E.
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M+J<;OXJZ%21V3?3;,0.X*!MHDN(,[J?877#/Q(>(<K\V:&+#42JV-10CC H
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M;[$3B5+GL3\,-W@B=AIJ?+)E-CO61->@Z,B%$&D5N('0(N)#7Z,9)P!^['L
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M6\O&_LS(PG,I%SOV4ZQDQ\OW/LG+U5%ZGY-'\BRR7:_B+6U1DO]\\K7\DYD
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M6+XQB%(G??<(+#*E,FJUBI4,QIQ>]EI=R/QL>)I+(J\2/E.,*<%$H248Y]E
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M0S?%&B0Q!*-0-M IB&FI;-C/(?4;E>/W7N-IUD5<MIX\>H@-;$/OF;*=GQ9
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M_S]>R?]*IDI@#!]-!_\"-Z<()E:#HPUT;3$Y>4-I+ PS\]N<G@P5@@]18@0
MM&J2+"G8?G,XXX9UT20"U.2H!D)D$B=D^723""09+W0A4]O84P(,+ +!^[-B
M6 P4J=RQUK&$:@-307X[H-<(-)]@F$/07_X.FECK) **[XD +(8@Y8<B B,.
ML%T$).%?[<8]PSG#.<,YPSG#.<,YPSG#.<,YPSG#.<,YP_D_"*?];SC2UV]$
MWCO'&<X>AHD595*B)0*19!A34MBJF@1&!7D1@=X/?U]4L4.*3^$@S#-0!.Q
MRG>?"%#,6.+\D_Y:T+KS/D3IVAGD&>09Y!GD&>1_'20&%4 $W,PAZ UL<RR
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MR:<I'6F\7W3#)E*<M4ST"?E*/MW1-Y)(N3A5%-,V"[JJ@]4GM+:*/) *$X7
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M>X^%K#ZU[LN4]L6J-+"MS@6,OA&&I[0["+XM;Q445(&O_%474YPW^&KU9['
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MA3RY)WK9KX3%"A3\W8T&YP0?*,7:__UC19KWV?_H"2#Y[Y)_U+K Z3_ !LZ
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M9*Y<BT"Q)O-7_OQ_QRPX]\Y'&PF-:$6S\J2A: :FV4K8VLX2@=!-!+J-+LR
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M!&3W:Q)!M:I[EK3PB698)@)XMJVX4C/(,61#;!!E01K?Z*P.$DFKL"\%KXA
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M MD[9UE<T)N)G'MKBB\U$I._/"U%XJP;6O?6+F:S,V[?/2796%\=Z:EV83T
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M&*J:J[U&5U*AVY?W7,.RFJ-]JKY(J:3%C?0&3YW%"6HUY)M9&YBKG@L[ ^K
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M[-J$B8[!X/3.H$.U;=#+9)<'XO&)K,_)UO/._Y+D7P+TC671+KT%?6!I[&B
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MNG,;[W??'_C"_D7T;NR="I=Y9T(ZL%MYAP[XH]:2:-P>L%4,=1W:BA7#NBJ
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M%UN((73.6E-X/I#+29O4MBR1^BIB:))LG*<'(=8CJ<-@M#XIE#P0H6T@W.G
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ME8\#,VS/IVKA&:2 IU5HP4!?*V)9$_.87XA7OY'PE>_4T95\_N33=, Y\F
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M0&R:#I1N*Q$M.I602N (<;ISQ(DFL2/2Y#K2$W9)5YR8XS3P5.".[V(H>BB
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M!BI!1*(M:I]:97.GH'P;&AM3AT#"?4G.U5PW&"^_!/O] 7X!?MLBBI/K8ZB
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M$NNH@+]ZJ0!TD1,5T \<[X%'*]MNJ?V3+_](:8<L+OWH(HHDU1X&&]X"-_\
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M1_08K69$_*HPR\\+R#_8?$E.[0";4@'<$08_B*%LV*%O!!#]_>W'??$-B-C
M/-!OY08$74&[\N?&=ZKWP@R3L:R2L=)ZMBG!7]-X.&[+_=X>J8"!B#<(-($A
MW@UC7(&J$-UQ3AP=FMH5/F<Z;K.LA;0\Z^?O69BQJXV"E*4_Z6;-964\VX+>
M[R&:$T)QH6V509C!MBT^G7DG[P[_KX5S"7:?1525KJ2YQH[XZD,FGMWW#]H
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M1RY 86Z3M,C%/EI<B(+*SK%DSK$<V^*N"9&&(L;O89?LT$J"A?T%KN.3,/P
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MN:0?=Z"I[,>B-A#TLB#*=$B].SH7O\Q*.\LQ^6N');>YU!B#.2VZQKITUJ@
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M^YSSG/N=??:^ES\F#ZQGS=\<&8PQYAA9<\YE9D8__=3$Y*YR/#/[!@7@5.>
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M$S?(])L'=X@JU/_R0/8RY@344?KYE'2(\=#@=^R$*<'B8V.2KU^XI@MO/R#
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M83%GS-8UB<K2.&;2<9_I@UWDGG "Z -K@^S3+V-^KU& K3N(:>*-#'D*D!7
M20%"+C7"MBE _]8&0IIX%<-. 9;B.Y%8/1@%Z W$# T1;*))?Y;J:!"O48#W
MI>\H0& _!1 :H !,,7^"WC5K!3()1=;.)I_KYT4.J,500_P;F/0^<G'/CQE\
M'BA.+0WYJ5-92QJ& J22D/GYN ;V X._=^?G)-"2@VL]20=0XDO-?R@AA'"$
M:$:]JL)/3;^4D!1 ;I\"Z.NW/Q7?_5O_OV@@0M6= MS<E:8 )VP1F&4*@)K_
M"<4=!]'4JT]4* #]8PI =OMS4%KT]O]0@1 "$WR"'+4&(Y]JV4,.40!H3PVR
MC8$ (T>N^9'/S%, XN@J20W*OH0>_UM?_!(F$KK-/H3<'*, <ZE0'!^AFL3V
M T/D#OMSWCP9F?*( D1RXC DEA^;1-$>"K"''MU_&B@^ *O\6V?L /(T<DD\
MCP),EU. +EEDF]*LY[[()R0HPT 50Y](G>&HKG9:NAVY+_AI&C1*H0"_8.CM
M;:)9%L;U[]U;L\AGJ>6WV1T*@'&B $G.5%&\.Z:W]:E%.=Z1LX>,VB-;MY+/
MPJ(IP+:F'0:?3]7H @:VO RB-0*'_U'_?V YIQ?C,$L9U!QZYJMT"@GZBU@7
M<6AZ_S\R/70%TM9T@EI^-=U<A(S/^6S.?7FD!N?&-7Z'XK4PD>:S)D/>%.#>
M&PH@GDI5\ZX6-99ZYC?W\UK!?W74OC(;356$CO&XUQZKCG<2^5J#?-O3??4D
M_YO0V >7ZN9^J37RXE=C9E$.<EY*&O<$(,P)+3@WG/A(YAI6E]F4/3='K,_P
MU6=C.W9^*S,7:W31#.PH\79FAZI<3"=^_E[=T>=]EQ2)-C+L42W*QL[W5UM9
MC":S;4JT^UP%^M+L&)V$YF9Y*_?'J(6D !XYRH79/EY0  # "8 +>'+T?2YZ
M-2Q+]Q,YL835.OB?MNSN/W\[D3\)2?@EAX560)J8Z0('&AGT:<#ONLG?XG"3
M]S1=)^S?>7R[NW7BY+W' :F_[0^R"63'=#.]G&4].=&NED>(@5<^7FZ%OY0_
MFO\TM8[)C&\VR^#E#/M0B%T=1%2*&B>T*JHGF0ULJPIBIYLA-(CCH$4!",'V
MO:CU2'3+<A5+/'O"+2HL]$OQO.;7+7DU?S4W@N;N25"04,@\P="!897K/SF]
MU$@;831B%W.W/BZ;DW=C_G*]OXG0I;.Q3B'+L %!H*D(Z+Y%__&+X+>09HAE
M-$- @(.H^S'Y)?-/6N>U7GU::;<S.9[P^)9;'A?&F[5P*.YI3;S9>F'5/)V(
MWX72LF>3_95?$#=ZMU0Q,?C$6*\?\5>:.X^_F?5*%M.K</FL9^(JB?2WS%=[
ME3<>OVL_;*#AA?JW7PSZ[_Q !Y%RH$=4)F42_=TS19H2(I_"@C8D+SP9R1TN
MF<)ZS)Y=OWG3OIF6;_']>^:2B^@N:=#)$[R((?&9A4'Q5E * ,DF<T^0Z:GQ
M3Y,=JT_DH,;PSJ6C.U71Q"1J0?^$ZMO4P#W0#C>B5E#42$+8AV+3,3-9U G&
MR^8,-:0_I,:TP""HE?,A^Y!]R#YD'[(/V8?L0_8A^Y!]R#YD'[(/V8?L0_8A
M^Y_%1GMFVJZGRE. BFD4!;#$7/A'R(2_P=XS?V_ K"LL4H#OV9X'=_8HP$[1
MEM$_&.$?RPV0W";(0X%(DNO_,[((CI0.G7D_#QU$.D\SBN_2Y>G&>O_\B3QG
MB&Q5"IS^(Q&9GRJ1/8:8>!52] XY[DD=H>36].Z[7Q1@U6P>0I1)6:< U.$A
MV&DBARX%Z#KS[](513QSE-9SG1\[&(!L*[/YO'.@"4'G&R5J8)Q@X,4/0M+K
MG%C#SS/I\HC$"2AF]2JDQ.JOF+E\HDPU\0R,'"_>@@(EJ0I)&*  IZ@R'>>D
M -G1^'PR@Q,%F-VFV1^M)N41*<#^L#L%<,% R96!.LA6%62S!@58PM6+4I4]
M1@% $@3?-XTW0.XKHNF1,U5(,I0Z;, _8]CW=J,$=!?T/X#M_L=GYT'7EJG]
MN.WO8RI@8>R139YK8WU09O4@Z+V+: 82BBA"@#5/G:@:#+P$+^WO$!"/BZH9
M6;-S?O_JR02O#/N^/<GY/;///W%)Z1&ZTI*2,8Z R+,N3((6>?'R+S(N/1_3
MY2.$=17$B!4XWB\\H<MZY/F*]@QS8#*QAOKY# (O!(ZB>"F <X.T+BF^4=A%
M@!D_NI:/!JTZ4%SK:$M_WO:G)]^M*V/");]/X2Y4U]0,X5YKU"8Z;,UMI=B:
M.D*J YG "4A'PH^J51PZ;.?DW+ <)#PUMF5E_.X"OTV_GO/\_8&T(HDE\]-/
M0T*:WS-_LAWQJ8MJ[/<L,->'$O'A6U,65$'R7 2A9!4SFYM1/-K\=G$G+":#
MSR>8.IZ[^EN(GBP=R$*\^4X;W]FZ&0D[0O6+?EZB :FX$AG+LD26!JW4*]71
M^1HYD-.5C76V7EE13UQ,Q^]$H1R:6&I5Z1IR)6X$?@L<0G*JJQ#=01(^95<&
MA.$LU 60[G#YT784KZJM,_N.N\*=Q/.1R[66' (F\VN;%W]UUP1?S+D??LL0
M@#I*^O*K;Y>-P2PF7QW@OJ\P!+^976!125Z,]S(3Q]/.=JX1"$@RW1"V3GI<
M=P;3@>*!][<*\(QL8PFZ35-RPTXC][]7J/0\%\C\L/S+NE]P;.H:MW^BH!U#
MZ%:LCC5?X$^$'!B30[P&^LU,0S1E.4PS)+^M^0;XU*0JUM1&*FE,M0H)M(X.
M!JF=>4$C% 1TB00!*]IJ0"&+Z[CQKV<9C/KZJ8\>W8_>&M=^SJ_Y.HFSOVJ<
MF$,U[6CR )1K&\V-X"6]1CH%'#QCP$EW\C_\L6)S*9W#!]\9=BY*>$1.W-SO
M0TW=:85DUW=5S[*,7:Y$=OM/0$%AS@15#A]I;H0Z*9\L/$'4&]I\*+T3=\-\
M>&'8YYGO[^+4DHIQA[82EU,*$O<TYS3IHKSF9VFT:-?DVD<J<QS=ZB(EL_@=
M:EXKVD',$I,U%W6/]S8,/W"SP'Z.:ES[J//R5F "[Q54T^BBPGHFWJY3  K:
M9<+ !)Q?3+T"%G+,1<2(L)[P/,FN!)YGI47C$SJV0+A9=N[!ZVD5CI/,BM!S
MR&8>=7%X/^XN.%37:;E1AT=K$#PR<T#:U@R%\L8AA%>VE;F.Y +Y^Z>1FT]?
M:+Z]D#1N%2GH(CFN1&/OX B0?OX/_0G#C_3TG)AH0]*J:BBT)D2$JTC:3'6K
MO",]N&^O%;N@$<X>QZ52'W<JUTSLG=WCOF)C2(\^Z,^\+N]/ 4(7I*@_7SBA
M28UF"_[3T3]E$A?,8TN+O7X4WV(-[&>1D.3225:NNC.X6&"(DIWUR>].C:GU
M6$:%$)P&!8/@NJH=>+*HXP^BA[6!04>/5'-+J4"XX&M6'W[+R@\%PZ&.GTFI
MK^Z31B\(#9(KG=%S162!:P=W*,"W7YQD!NA!60+H3[NN0 %N?(6!$A1@HWL+
MB9-_A"'1+% GC_,1%$"6*IVI4R\%:/L.I_YZG7R! K2<4D@AW:+^93FQ/Y*%
M24+_%0+%SD$JIDG,EY$SU%A9=Y$"1(ZU4$,E[3L*,!,-(0XLDBPBB'><(E#;
MTC@8\6RK/W+8";53@BFQ%-\3HP 1+ZANN*W:3C7-?O):]M]DCDNCQNFK_ACR
MR4P*T"N ''F#/!3O4+Q#\?Z_+AZ)AA1)%21+78DP&K?M28U/;(XQ%M9/3*LK
M1C+C,N5_TW-%SD6][?:\]FI"*&C-?4*/9OLQB@.$R7^]-.9C]\;6%;?2$4?_
M)DW5A-OTPV"^GE&^8;[@.U?1+JNWN0'E/[&8G(2(G]II,X^5#?H>$_4<;#(X
MZ:PN-5_GLL"Y5O(8.YG&/>U[57CGPW4302ZE2@$/Q\2# @TY<^4BM%@W%\21
M&Y*9;[8BLOV_?<?E?\8V%)MTZQ&M9\DCU&EU83@;UB/$&Z<O (^YC5]X^3!.
ML!_I=49OY7W2N:BW]LDUJF?/"M"=^(R*G^9&7,8S8Y'19!&P"G?19YKI1T/;
MHR]8@=VU>??U\\>">R5"G3S/>7_Y@L;U[V:0B@/%R*,VBL,(7=RD]]TA(FNU
MH4@X4=S%6X*CZP'?'K.8QEDSB:!3E\C)^XMA4ZP+4X(/BAZH%?4H(H\:7NI<
M2,I;T3$1**(+SO4I>G#/7=3Z@V&,X;L1P5\)IU5O]=1 F'52RO;)7C'YHMA+
M+"D2QAS45#A+?VS0<.#"9F]>5BWJFU/;-"CIM/8+*ZFS>@<?GOP!_G5"B_"L
ME':K9,[^@O;=HO2<+?7 =)EX.#,3LME'_?34E)#Z.3Q328Z5"N!A:'H_6HO[
M7(C3T3VS7[)ZZ?G)P8HLN=#')[,LI,QGDVXIR/#1C&:(;O6?"M @O_6R+X,D
MHXN)KQYN7;+VHM8L]\QV B%+\]B<2XFMPRT+.P368'UV(QD?@I1.MXGHMU 3
M29M2L;2DI]8K2!430EV\ZX,+ENQ;^[)[GQN+^.B3+TI"A J[/E>\7N^2[=^0
MF>%<+S]0)P\D"MG0$%ZCA,OGWN9\VQ2.9ABAXT[<%2][*Q_D'4;[L0O-2^@D
MLK/M6H#/9B4]FS+.$82J]LG/'^WNA]5HM&C%WEU7T;N%_8YYC?Y1V+*#=$6'
MOX0';FWJ/ZFK"<@M__Q:/""R/N15DN*8P4L/Q?L:MH$C7N:NR(K-=MZ.ZJAY
MGI!V\5C^0:$Y):%325K](ACO+N)&Q,!TF%TGU\_@*J]WICV<S(-]CS;$F36Y
MPTJ,>"441CZQ>:6)7^N0NIMVCL[]:[7Z8'6<ZDW0C.'=8)/#JT_]BJ^M+/K'
M^\*>&K3>*B_1H=<QGO>WR!?5K%J&C(ZN'1S B32D7"+LSY*BC/K]\(;<Y=Z"
MGU:U@'I?4K%G\)G[L8M+C,\*8-U0XNG%&U74 C$!#"ML?2AX  V5RKQR?(:C
M!I9RECE?+0YIQ@Z*Q-P[E_Q(@0NGB!1!1[?97KS_T63R]KV"ONJJMNM&:9YZ
MEQ+$?ON;H"?+=R@ (YAR&=?'G9NVX/-Q^Q.[%[Q03-&Y6Y:4SGVQ?=SP95U=
M76-#</1%]-?^AG_W_?TSZJ)@B 6^NK6?TVU*8'#Q>^6DRLT&E/;@^JC/:#79
MP IN!YERNJ\YE"&.R?M\-:>KXBSW W <V-!]!.S(TA#G GN0>.U-+H3NMT I
MA >X2A#'Z0>IBY '>/HJ_7$8^B6>^=[&]/RELG/E Q6?/*R3(&7+9$M=R=J.
MP3['E*)33Q?71/#,L\BU_!GF<>]=Y1&?.+=[( SK#C6!'D$X%=K<6TG9[TC^
ML%SV<<B7H:?Z-2Z@QVK9(:8_U<4&)RVFS3\WI;\A$7CVFWT-1Z(;C]U/)^?G
MTNYOMZ"A8EU=_/+QSXJ,+G,">XZW[9E?-:I%3'4N7X7TP%KZ?]!VP,I^@+H'
M]D114-)!H:-+U=J=:A_X^B>K[!LEV!Z2R831R-TK%=XP2__-9VRU'LDF.*:Z
M9D@6M!+9Y!DO#^%LY"9/0LJ?O&/*G$UG;MW=A9PF<[N^&Z@WPG;APETDW".A
MGT<D[&,;BFI5'6^]%@4L;D8='!=L927O9,5QS?X.8]%6:WQ (S*8Z!CR*,HA
M(O#*>;,[$P&G@Q8%9AX$08\%"L.+=JGE<7"<R[A"4S/>"@8RX*NLW73KP0(<
M,W<[GW)XD4/>/3J/BF<G5/QS3:/Q!5&E<[X,1QO;G.Z;;8?@,&O^G@3.9B23
M*ELFXC8AI35.&CL9CW)P;61MD+^UKR+T_(DUR^_9%RTW1%>X8D?'%K0>W _#
MQ:4E?;!@2=L6DKIFMW)53A((- J<F/Y$ =J9.98Q)\A2Q*.C#][->JZ1/DRL
M/#5.W4O2JK?.NW'D6H'S>,A-OT6#*M;S.D>YG+8<?F#I%=XM0ZHAZ^C9 Q(M
M]G<8TKZ?!;3J</FPO)LA0="/Y1!'TEI9MDNX%%DOIUS2EAW5&/T:8+)U?C*Q
MYOT72(7L<V/6YJLB!<"1P/P"HO/1K='=3##JP![!2'!Z3KX RC05$=YA8\<E
MJF"LZGQ+GW)JUY33!D12 K):'_5X/GKQQ=[B_IOL*Z>_[%G'S4,^:C9+QSS=
M7+] @.W6$E)"/-09X58XX;C\I7W.ENJ;E75QQ3D9VG+ICN.3C=UR#!A%P<B0
MA^&*(^GO\M=DU<]_V\!4?!<_\$>6,3#>/G',DIWWS6UH:!!=\W:1LMZGW-4G
M,0$YULT!CMH:J9,AFLDS'P3CE;VN\OC\6PL _VM#BF+P1LE'=T-'&P)[\^Q_
M0^N'XP(?CBY#B6<6R7IL-A0 [2Y#39>&BWX]P(37M))U&@4IP*=&:LZEJ[EW
M 1=!3/.0IP!E$?S@UO$S!C!%Q-G_Y2,?QJ$?/S#^6=%[-7;63(3  I4C^#[+
M/:!'=C7!&<@MG11 0RU 584"7#BA20'L$'44P.@BRJP)M66%CR"]^BQ-SO\&
M_<B !'^'D&NH^>)[R3MW)RA 9SUDIT.:1./J2MZPDM;8@ZSBQIY*?[F8%6WW
M?_ILD_]H#9K>#TJBVQMT</VM&-IBC]R8.V\E*]UUN'X\5VGW/WVN)?'S5<7F
M?CWQO;6RH<U*79)X:RU[W3W7\<H_0=:J<$-8>\[\%KOF.87%Y6WT6 (H@7B<
MWQFG;$;;[<E8<R_A%:K::N;HD*K7='P&*A52?GPW(3]P$'/24XYP>G"T3;Y'
M_$[%S5+'R',/?AR5C&5].KI_ WLE-Q%4>6EWR?C,RE"WS.T5GV&S@UM79-J-
M?P_:$%%E^2<FI\\;?")JX!34'7".#N%M(TFYJCU2/<-IF(B(= D)6+G[07WC
M^&/3L@4SIXW-)L\?";L.I'CR:1<D%\95<ZARDV/ER257:=OBY"0N 7B2\[K$
MC!/31N;')G>&Q.$T9GU\9S1T)@U6Y=( PO) _6OX[PU^#*VY?>[G/V'\Y@7=
M%$ZQIZU_=?47@2AVH5&8F8I&?D)5OAT>W29O6AN>C5\8U8^<O!#=(Y=CJ&J5
M[1:)-3W%K9/\^.I9]%WQ+8;=)]\0FCC/!.@I=S*/R_CS47?BM;Q>M?:PRK;S
M4[U"1B+C%XS'SP!^)Q17062RJN?L8F1,FW]U7*>2A =_+I^>6)P+Z4&Q)?SD
M8&J^3MBQ/=&62UX(=,:NTX_%>C,!9EP]Y*A#FFBR:9=S_0G6$E4].K/.A4_M
M':E%T?FPQ"Z,_]C!:%**C.9D(!,IOO[:@2!YXG?5J+M4[@RC]'4,@>EYB59Q
M%V/];JEML(65&#\-$'SMF#<L&<*Z,PUJ!XHAM BG[<[;@._,S.?ZKFEMS$V$
M9+Q9'LI$KP20Z9$$W5;42:CC^GYF!?2,JE&.%3S@SEL+IO>ED@,>0C-[SQ7*
M+RJ>??%,? _R]85+DJZ,C/54N6KZE.Y$<[S*ZRL*PR0WTC6\IEP??/1XY*S$
M[JOLV((4AY]RM^J3#+\*ON[.?6@CMY:M9%+"9>R&*Z!3ZW]-T)7J4?1D"\<6
M%WK%T<:T.R5?=)T/\0]UN1Y/5S7U:I9.AZ[N0TT)&_0]%#P'"5E\:0!B9OT%
MS[.;;W]Q$&^5K;[XI( "^)K/\#W2<]O70;>@06&) 2(;/C^H4:"'OAU--/@V
M2U ;J0^B"W7Q9XWB9N(55N)-4F:5@=56$I-G3>7S7'!,?F^W<D/;S7P>[[5/
MFK3,0'\T%"/KE(==QW8F71PI0(ZJ>.L-FN;/CC0ND:VM*&Y>(2SLS&O!UZ;C
M-GTYO'J]UG_BZ"M(5MB_Q];)_[8]PK YI#)'D"53Z2RYLP<\QI7N)L._&/P2
M/7:ZR8E+J=?/I)VH\:ENF,B,"V X&3N:\M08/]%V0O?+Q*.:WPM!T(L(3B\\
MVA)T%<;[5L>7DB_Q/W9>EZ.#5MFP%93@-IZDH]86OMZ/JQ'DWR58)W1,LP8.
MDGG !+SRKZ:GP38KXS9Q:IMMGG1=]:75V>W +\92+IHGL317KS'^$IT+@3T)
M[)]B36E%,LD&2,(T*H=VX$ZU_J-K W3);YO-IHP>V;W\HO0;#25HAB+,O _T
M0.GV)ZD!/=@ZR2/[@V1\J<&%Y++$ZH<L&?6_.NVN\HVV0:-W(6R!'/" -@&V
M88=/P[:$"V%5=3DY)4S9>=8YD2E/_"X%"QFPA=/"N2'ICP+%P(8\HCPI%Z'$
M'+6YTSDDIW]\>6%\2*_J\_#Y RV#!5W92QOT6H(+]Z]HWG4F92$=D-Q3X&H+
M!6 AGUR%_' 7B2KQ;#P+6L0PBMM\G K&S9\S9>!?4'?PO9=49Q7,^#1-_<BH
M!]1Y7:6M>OR,$?@40KN\>VL+SG$S?%=.P-ZEP?R47154!YA1M2",MF:H@9/X
MUM9&UGK"\?H@Z]X _@647][XSUM\0;R]-$*":G30Y,#G3,&-,#!W)N!@,QK*
MZ%O">;/*BE%DW;-PNMDCL>+D5ZV? Q\4.^V60;-L.!LNKCJ>J(DKX=4;*LTJ
MQS<L[B)J8P?*6GT?<4K.76YRH#V;F(%4!G[U1\-XB-KY\$+F""A#O7*C*"&D
MI5KYN?^Q)Y8FY<]&,QZNG^H,RD]"&F&G.Y!L8+3G:3AG>R!$GQFA-^!N:>6N
ME,OH5#BO'>_FTL_T%ML]Z\'TS"V1:@U1C?2(.]_5A98%^.L)GA$("Q?&O"+W
M_)NC/+FA'R\]PN<+W=)JIK^Z^"VU#C^D19!NPT33SG+49?X$K72''MH/;?/+
M;TF7KYB)*A]/LOI1BZ?MYA5Z.O>-MI<"T/BBXW@B(J&N6NKGEN1K]:++5R12
M3'_GN; GC9O<C1I1N"X3)I)T!T+3>(6H/4AFO5,*AS8-N=JPX3L:_$^4>'_0
M&[#^.7[CT4"_]\,DVYR[ZK8A(1W*HP,9C'ADS'HITCD%,Y2C1;SC[2_\/%FQ
MWD)2*$Y^NTOB.EG5)"%TBHF@'G6@YJ;..RR;Z%+:<R+KDWED\%Z"4+21F#K!
MMDM$9/4J9[W7@=Y2K70H0O0#_"F#^XUV=86)$Q%9DS]S"V,:WN59Y'@WA<ZE
MQ?]?[+UG6!3=MBY:B(@$;0$)DAI%@B*@$B6UB2P@($%2JX D 1&!1D*K2 XM
M(*" M!)%A 8!R;30! 61#$JFD2"QFUC0Z;1[W_N<NY??6M^W[EEG[WWNY4<]
M#S5Y:LYWO..=8XY17;,J)+5@P@@UU,>/1^CCDW)CLQ920Y\-Q<4,^69QC_@9
M'UL^I-BSW^OC.2&W6?6 S:!^3""40&I5F8D,\,L'9:_69ZQ=*KU^8.[QU#W>
M\E!+QT;!1YUJ![UL(3ATV(Y3;.TMJF@9P0Z;^VW.RNR+8DJP>)BS;.S4'E_K
MX[&5+0(B]YGC&A^J(/=1!S(4B0J#S;!#<+)*=3<5&BA?5]OSM434,^UZ=1ES
MX";AL?7BMHBG\I'/C'P*R_ ]P1*(=KQM;$M%X=P 3RKWLLQ]_7:!IFJG\J?[
M(F7,-8X^DV5_DB 0]2.8UWEH*S28#[&A9C#I]5;@98!)E0K'H^OEZHJ7'F;8
MC>A\?<51*>R_T.&?MSC^"M$RCD=&E*,...^TAE Y;:US.UD7[BI@OV_8?L_0
MW_^]WI*/TL_*?/=,'^/ZOK^SH0@R+4MEO3N'=(8? G!2[CG)0A^=^C83%[\I
M[_"3AT;4M6?A?4I+%22&T<# 08M68>::TO=$P2Y-MS<-@3E+12(159?*5$['
MLR?(WQ/==['5=WJD<!L/FXBG 8)GON9,)FU*W6T*,LHXBV2E7L%3 7Q;K4'Z
MK;LO-$0%0EOL76_-W3K=F_FS[67P]7N?#;/%CC2L:>FV#(FGP;["N&J/$*%<
MK;4&J#;0B3?-\7N&D\7IAJF[9L7!7^][L:9=F^7_%B47ZNJNQQ4=;3'M:J 8
M?&E9.&LMZ^X&]&5P+0W 95&5D5VF.-A6,SUO/OYKPR(*G*0!%XS8:< X+Y0<
M#S]' PZ18F%SZ5]@A%-*O_90(GL&)V%X5D0A#;BLX4D#0MZ/R^[$KB$?P(Y6
M0(RWNRL?H+YB[9"3W70#87,G)M$D_!0-2)"D >':Y+OTA#LO#+D2C:+J9%&/
M;O$CN\\]1TY8>LKN(&=H0 Y]83UDVNRY<W0-219*WD;V>::1NK</_.HS%M<7
M[+.S]CM&;;(*;"J<PJ1&+T$";9"KFE BI+*7&OD%1P/VX/Q_[5U4HD@;@8\S
MI)#=D%\WE!<KVJE9@>-CJ$_N]$[O>] YP0RBP?O(5L@.*\*)"M(KVA]1L#\P
M(2*H!;UN>!L*\@C\VJ**_>F*;#I,M*9&!([3 &;'>OB&P QU/?B2QS]'LS;Y
MTK(\#<CT/DTO;(K'?FT%I<<D?5.J2%[4^/JE7S^*J4JOTH WXTI;6:L"OSH6
M"']#7MB8I0I!B3CJXXPC-*!>!K9]#/6;%7BH5QZ%ZT4XE2GLW_9>>NY8H8E,
M:N;TX:!*-*#ANV<*16L;6P=].DSO<N[?!(V!$>9H0!QT_3"ADT+T^O?G47ZS
MXC=A]-$).H&OH!S:QE(/M@=BYY4Z*'/DL%]=:DW.PU0H_G\@@M\,"!]QH4MK
MYB8->'2S]M<VUC1J<A[Y@A$W=BZ<S@K!UWJ:!AC7>ZYH_U#\U:L2776#"YV_
MJ>!W$YHTIHQV).0@9+8#_[9Q='R]?%?)NTK^YY0,=Z8V%F7167RHJ^YS+TLX
M]\A^Z%-84M#_) /&CG9/882AA@Y*+:*^D:@L585D,6)'>%SPL7D>KH[7.CT_
M%:V<;PKH+83Y;Y66H=J!IE S93-F+T^G<#48'IS]KJFW+2[!<C'LYI.FP:9;
M$A?E\WMP WE6[JMFZ>FIT3'V?!]^]/A:./43)!Y3Q4VF9(XT355:'$F>*+X^
MP"@4W3(E-9'$JAPH]  154@2-+!*2,]BYO>*@<KG")05=7Z7^G_>_- ! . T
M $#.*^])QF+,(V5:=RS+='W_JV\R_'<\8/NP$^70/0KJ]A]Y8/QE;.=DK''N
M+HZ%$8=JFAVV=.S\ 4$15J4SJM[+YZC.A3,!$8L^ZBK3A<L3"0+#;)7/P\(0
MZ3K/'<\=J.)]/;6!6><DCC]6@Q%%&S5$"-I1[V[UR4,Y?J[^' I]%U%4R/X=
M]W#BT7$/QJR[EQ@>2X%;E _8B0PL%];1D\]U:.M)F1L-X"&+]GO,U!97][Y.
MP ?QG+,I?GQ7R=^%]8<](Q]F"9[5&5GE>"4#O<?)\JVRFN_!'(OX@::VT[BI
MXN>1:_WMT^?*F>RXGHTJ=^28IZ>;5I>0RZ=@>^SS;YLI8Z7RK#E"F[6>>:M<
MNS5KRA*1P]>8(7,FZMZUG/TYXHD_TJ^]3-28I23#)O+1[.7T<&@.98*Y!1V4
MOL@F95GVJ;R]P*<N:K5'P3++Y?*3140?N\K[,].ZF$P/K <4E'!:[+5'XN$A
M]<*]&S!NV\8E3^Z,C&BY*]N.$88.\9/LK>SVDA;*S'5(V=LK5VJ$;7&G[IW
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MWNMLJKP<$35USMX+$5^>G[:7Y-FGJ>JVVJX#.M+32S8NDAVU6W%,@?):S8\
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MA)=N-:"A@>+=L(FLU,TLDMH<_\&<;(3HY>J!4S[H"-_-L"&=^_2:2.BVB].
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M:VQ1L##WE_:;340RS]#IZIYZ'H3Y9%:W_.QMTS=& A.V;>G[UNY:'S]T;Q^
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MXD(*]N!:F9RJB^'%NL',"[:/Z:"KB[9K@F]P(N2+0]^N1IDH!5/U&ZCHYI.
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MDV0B7_HH6?FX7)O6D]$%/@I7TFQ?-,*#S(-P!SB(CR\/ZJHCF#YJG\&A1(#
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MG>]0./AZ/Y3G/][2_E<)7**/L/DSSN2C83$V6_=(9;^1_D;ZCT6Z]V_WT.2
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M$DJHANO/.=$HW!/LCU?:KO_N.^X=D1C0]NQ?>:&;O?"<,^N7YW\+_"WPOY/
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M6#YT5\^X:)K[9<C*6__Z@&EUM9TR1G,PQS9/QA)CF:GY(9.M^T0RK%/!(D_
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M]#'_^E14_N),B(^%5_^Q#R=-E<4D-)>UBVXF5;GDCPS2S*8XTO=:-X_I)LU
MKF(M7]]T.1>86O$W&#;G70W1?WFLRLM>O&.XG^P_)ZO7:.RH:BXSG4WC1#>[
M;?*4H2@\5G]\F](8!T72@7/D?+B(G=\^F93I]F>)M"B*R 6S^2P0'V9 .X\1
MHQVYC/R6#@]_P@EN(%&SLRLHDOASMTTI=Q3DU.0+@D-+R\@D-&0,[L=^NS8
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MJ([4U1ATLZGMG^GW<G;1K]<"<RVL:Q1PPT7<GW-CQK^(@/Y86X[/=&!*IL%
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M&+NJIR:RW58111.-AHRPS."W)!]=V%+E6(J>7Q><AW#$],"],'"1(R;26%Q
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M:\4VHJ3U[0/%4WEYWUL]4'X^8F1V*IHF&-B#W8=UQ.WV,>X^#\63M,X5$^E
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M=W2,8@$>=MB4SBQTL!A/:A 8<2D8TG-V9VKI[PE-#S4OUZG8R6VZP9I%>).
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MF7+D"@<M3,">=L"&4D,%.4[0@5"-#^"WDBXL\3$3#374A>Z2H9Q:;T%N'J#
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MUD(X(50JNGHE]<2XEM$W#_V_,L$U_D<$_S\UTR0<T1#[Z+WL"!BN\N!D^KA
M[!WFS2C9^S!P9?OC$7Y66H_\O3-]IIK\O,/DWKM>?SMPX^!HF\<A[4;!0*\C
MURD3#TCO#W\ OO_8ZNX_<TD>O$(<"EF;.NALH9"2)Z>\'+F6H2BJMC8\G>_2
M[7^C_-NKO9(T+NP#Y#<]X@R-]38=@ 80Q$(*(QTXYQV"))K8;Y]*+$M[H(2!
MKM 8Z,!KU28T)%%"!Z8N@XT51 XJRX0 '.AZ:#K AWGA[[AU_=O$7FJ^&N.6
M=#=A/CG2MBU),+/(PMEI9F%P<//&Z*%>S?<,[5418LQ(Q4P?F28$="RZ048P
M<!Q[ +SN8II&Q+9T,SJ4!Q[M<RF3?,A 4@_WE;1D6Y2X=:?":'1\XUY%X(7I
MTH3)SU;';TR/?6#8E* #K+AZY*J8#^P2)@60XA3]HZ"F*X(I6S:./+BRC]E;
MX@CV<<W"V3K.\);(HE,GRF,_.">67QW0_;_:N_)P*/?V_Y281+20W50JV<LN
MR[0A9,TN)LDZ(92E\)1M[(I0Q!39$I*M(A-C.4AV0C$SRL[,9&F8[3<ZY[S7
M6=[K]Y[W_9WK^IWW??OCN>9Z[J_G>W_NY7L_]WT]W^_M0OWR >S5O11S="6X
M$))+[X+OI&\/UN@/UO0I_ACL2()2Q3(\/QB92GMIY#]H4WDK'Z;H]$834@*$
MR/T!!$34@B$E(# =ZQKGJ<%+W/C &Q,J,?ML!C9:OZ^N!C;\2C8A_X"A8NG(
MW2^Z6RH6S,1N"61U79#7K0]M@U49AS$ !!AU-%B;>*UD-?N9@V$>0M!S>9?V
M(=23$;T#*OZW'@-MGXQY[J2?+Y)*O;A5<=/B[VQ8R  BO;'0]=UU:@P@+!-&
M5[(OX=G4_#L;YFYX SAM]#=O\*\T@?#^ 1%'>HX+6U&E0( !=&?ANJ@\P\QX
M\@2&LR-#Z!$$+A";SWP7)%@AM $?^'\DN$*O4(%@]9?(MA=$XRB7:.'H3SWS
M]WV-S_,'P6P79THVVMM/LR"A7*$BHR<$P48H+GIOO"//C.71G/!W;!=9IM6O
M MN0]!U@%'Q9AJS+ (#*<?HA] X0FP-6)S5Q<P:?!*.RN?J]%#45SI93##\V
MY_*^?)7M7A"UM:=ADWD0YQ>UJ<\6'$AU4 [$/:7+@]TS>&,JEP<U29,$'FKS
M.VMIQ5DKDIC-Y9'JT>]\,@OFZ?;RY+:G_8\?O4U)3?94+ 55?,!>>&2@5;0?
M%S31,'-RX'E[.09?;FT5F8NT1FZ[)FZ$&I1L?$S+*,R5.'QXJ8#WA@*%J= (
M*"Z=QA&ZDP&\$5'Y=L3D%S)<W9 AB6DJA%P\:OE88 H#8,E(^M5='4A.#+*B
M;?6#444BOC" @FQP8(#N2C\T'H6>3NEZ!790T13T,@/HI(NLT-_ <!"R,],^
MXQ$@$6+XX]F2WT(HFV  =,&."7$:5_8!)G$R]S=W8MD6S"F$F4:'.&J@9Z90
M*]?\OC/\SO [P^\,OS/\3V;H$4@7I:K?\T(VAO+?Y<K7E&]NG2R_ V]MI2JA
M6DP9@$)!#(RH5DQ OS^UVD4N@#7;LS2,[1N475F -)W+E,#6@_(W@FX&69JG
MJ+K=YW/?PJ9KL?>9=WION\:EMHJS'9#T_O8E3N@0H@_35V9F+MF78/O<-/^)
MSMT/_<X2AY<.S(]X=9S[@"M[S$Q:2&PWTBZE^FI,2:<AXG+#,/BYNH,>.YKP
M!_E-$ZR[BR7OQ,_J'YDR33;2J]7Y N]&_N/\Q5DH9J?PU:M64!T@:<JX['W2
M3$7L[[(7W=_-L^#V4Q7PR]3J,-D/>U!-E(N(A:VR_YA$F1X7W@)RA IK7SOX
M-A1";#ROJCYI+_K#F>$&]<SVMG71!TX/BUUQK3?U#I#5,??%Q>D'E4,8P$*J
MO]BW+W[3+/\RF'^Y)"D=C 7PZ-_HR?1W&6.M[>'OX+Z#^_/ 84OK^8./U49K
M^V%1G%V"MT_JY0[+3XEEY>]B7_Y!M2@%5X8A3UCG$KV1>Q3Y3PL:9@^P/&1I
M7QCMK;6B%!#I%[/^RXNI[^#^>\#MT1(FLQOIAM>I<M/"OE'/59/MB6,"CU\@
MW]#Y8UU@&G&YP]X7,9,?QBSMU @.MTQU!^BY:R80*%.LB;^J6']IG7\']^\.
M[LD0R*DE8J]3?IXLCE'(2;8XT#-__X1J6T.<P->&Y=+U;_^LZC!+ CQJ##A]
MIJ^A7MC\1(3IXV&<[D/:$ ,HSI/[]WI'S]_\X=WD5'?O @-P1\/H58 /Z@^H
M+GM\-7.) <R9UM#RJ0Q@O7]3RQ\P\PUPQ)N)MD3GIZ=-( )_P.K#/T,3^NGQ
MX\*N_]@)7']&YOG/".8@1!J=X&XB1%@=F1WAPZAWB02>+5@/:4%=BQM5%DY+
M_+@I /#?.U42_ Z&?8("*OWWC!WK";Z!X^A7ES4CG,@^XWA;6'77T>@=!1I3
M6S@GZ_MDB90XOP>L&AT'VPL>X#RD.BCR]5"^Z(<$5TZ=7:E6,8_4EXOTX#JE
M]]?2G/ , /ATOS,X/-KO_I5)9YV*/".!10Z!=%QYS($).Y;$8MU9ZU<*<76N
M^K4(ZTX=6^BC/^#E\$V=3,TB:+$ECDN+U) 2NWSYX$ZVX[H"L"]+(_5/R"P4
MDV !6G[EC04_+ .(A39=#\V8$YFK>ED=*!*]K33RDZ2>)CM;W=N."#+JT"-I
M(\1MEV%_T=WFG^$"MYI,\@2JD^.?F(?%>E8F>UOE:*&E\-G"[SY8FF9]OI^2
M,1EQ);!=Z?-!+T1AHR$ZP+YZZ-+U]'_"=+)!A##M8!+AC]C[/S<B_5_ \4A?
MG=NNQ5I17E%3587\'#NV-5DU5S0V=G-B>(V')'[%NVQ%T81E^L\ZMYZ66_A^
M1ME*,#'OVO;4A*<N=IG%R)T83L3 )[_&PL4;%B--)''D\CBOVW44LBHZ?MVK
MQ%TFZ]/Q!3G.=HLW7JV0\./0F/'==?8XXSU,Z:VT@"Z<#*A/DF_ PG9SM/84
M&(S/+U483LZ>J9$^D7GXI?.'$RT(O!-E+]EI-8Y6B480$L:V[AFQ6I @\C5E
M2(]QD)1BUP0?#Q[S#/<H#_1:G)63123(TA$O(U9WG5F=[V6O#HI]"O.%N1+(
MXH1Y D4E<*D9NBL4.LU7@B?P=DH/O2JM"%$NT"R\QQIX]>O+(,'>[0\W<;+N
MATP.)R.&Z(+T3A1G* _U.#F2I-!X[%):M@0Y*T3T$7ZT)>4*^F74/DZCCMD[
MK"=0.)/#+&MOF49VI(]8P:NYJ3Q^^$^A,.)KPDTMQ>#-1.5TK'?L&-^ YXC
M_.+B8A5' LPT\4JVX1CJB8TUZ/;^O+;48E6V@CQ&PFUH$4H^'! 7+#8!'7%=
ME>^C2N!#A!P&YD,/V5>-9>:?;PVZ<;G:?S?M88>P7?Q)C=(OHU?."+1M1NO7
M*5&$@]F)R%9N?GIWJ! QM32%)-8Z8FX+BUVQ4YU 4AS>C7=1CGW<VF-K&;Z@
M$'2PX_(2O]R8TI06V[?^&YUCF\@S1?3N5\;(%0YTM&!"TY"!<E&A88ACP8?S
MEQ7:"FS.=FW//.MT2N*6F+RG4(<))"6TV^$(68ABX@;RPEQ"U"?,F9Y*EPQ$
M8*J3$1DE\=6" =$7*FLK?3@:#GZ!9;J+IT@*;'Z!:^DUG_@!C8VO5T^>PL&;
MQL/U"N(H<F'0'4IRFT>#3T=:E-#W;U?W(NRDY:A.) 8M.N@8M"9)K/:_X/AR
M"U6"=BLCB[O.CU(, G-:6\:4B2OT%/SH&6H,]11.\V0(Q*+_Z;L &P\5?SG.
M(<M$=NXMI3W9M7YP@V 1L@R1@-4-OZS!01S"#%YGB[P0FZ/N=L?YY6WN#/RL
M-M"ICKK_Z7+%46DC0^!Z%8_I<=9_=.V;#D6NF?6*(J?!5  \R "(9A<@"P*E
M6"<:&S-5,+AV%([B7=_)U,HA!I 2/P3.M6R0J_2I7\MPV;(,(#D7Q@#*4[W;
M(6MB^ #J ZTCS-L!;YK"<>9J6^O#G?Q7SU_6]](BV4)AY*T[[]">!HK!OK3-
MX4<H!JL\3!PWB7RTR"1Z[/75P "Z/F<2O64M@)YOJE5V"_:I!L=-D?"%TXP?
M@A>8*Y1$@-!\XAC <=N,1S4,("D0-A</7]_</T#[4.T0]P4VU/Q\&7[;5)NG
M9:-'T)&0I65FU KY^?=/:3ST\Z5$GZ'"[A6<@R^B,&NQU_[4N7EY0N"SL%2#
MG\JC+95_YMS"66CHC)FYKS\5S /T?M,E!@(A<>#AM^B[R0X3+= ==:<*R$X8
M_^36[2W%16>?V>E*-T><>=<$P-U;-8OOD>1:X<AL :)_^,1H@KVWAAS>;=?4
MZ?[YXQD<Y ,F;=(RMP4$K'?X)2*^U- YIHK=5L%GD-BK'32]><(*BM=MS[IA
M7H7*Z(I0Y(V$;MMF@:4'DZ>WEUMOGLM80[4Z[*<55<*&IU99B2HWZ4(,P(NZ
MO5]C.RZ5G%MF/ZRG7/'HT9GXT?,M?=I[8SY0WT]OFI5:/IL9-NUB<\@XTYB_
MR/RMWX.^36:)^TND95@C.Z[PD+SRMJW 8J*+)%Z9Y'F'^D? %;2<1+*M,$Y+
MPL*'_739;S;@W?OCQ2W-BF.;]%/B<7QYQWQB4ZXK9HTA%P,PT)$ ;$WS:P<&
M@,G>02I-O8;WE%50^HIT>9$H8\N_.4V!=J_<)<'<^=Y586S\G48$NH9O?BIG
M[CH!F4/Z&%5>1+;536KJGI&N@;_W%-A_(M2</N?"-7\K["@\@@%P,@!7;D%;
ML,'ZZL:NE"UU<O@%%>P;,EAH$UAF51>4VTNH$E#,3]C=[E/Y,G,Q^V7S=0)U
MM]2J,0D55<=\L[-"^NL5@H^XB&J0=%ZKA,MIG(",H"R>9<B8Z%3+'%87<PW<
M=O=3<-U07@)VD?]-=XM37N90B5&B<;*+XO.5<QS&_.5JV4=QY:K'2MI#Z5P/
M[/US14/UFCNUQ=*YLR;?EQ6;)>Y)E4SUL6[?W:3/ZWJB#V-FL<^2W;?6PO>3
M8:V]NOT( W@Q8KRPCWC*CNP70'(U)M_!W0_>5)!;G8N'+6R-3,PFT<BRX^)M
M6=:>7T:S/EC*8>1&XG!RS1V9+ZB[2[<;M0]^),"JNN56+P_Z%/F_BL492" O
MIH\9*8==9X%W(>=AE .!F;JT=+0GE*FN2@803O7,IRJ2TINS+LXUCBAG:I#&
M6W,,?-0;9-,KHV)':3;;D/QO1&FM\\;.%)U@*3)^?+,6/U4FQ8(6CR-&K/N7
M3&@Z=(XV^_O[#FOLLHF;<1KSXA75W@(;;^@ZJR,5YJMJAF<-Z\R++4FU7+WG
M4?4$=X4L269%8@:3"Z*GDLONZ5S+TW9TXI=,S+R2M9A6IM&J4VHO>"_PI.H]
M.4_^OA*SYX6?)JB*Z16YSJ#'AY?F53$4GX+081!880![]+ $CL!W'<VVJ:^)
M?=Z'NA\;C*H;$!3:$>Z3.FN7]+1T^7$5,_;C3>,C0CCC1INGTAJ.^$P.3>]S
MYBG&W6+W#PPLYMR^9""2'[!V84> L,\/_&63]^E\U!.TNUK*,T/H9]R-"P$M
MX\3,8,/8KWC1)-)F]A7QOJ?B ]2/9JO-G_5V'3@M3;H0[Y,X,,U4I?<;[A'X
M&RC1U)@[M%]4I5M)+AIDT[#"%EX=5G1K2K=TV#94ZFEBP%]M<AIT3?UH?O/(
M#JXWE@Q@]I"VAI?HD7<6TB+!N0*)C69-0QBSSJ/OWPJ[C;-HR'OQ2PREZKW:
M5:2F4RG1UN>Y\)8<)Y^XJ\0BS&*V5<" 6\TT4A>)Z2DZE+VO<\0BE[>CD[]%
M5H8R(H7JAF.\1TYAIYJM5ZX1DQ*NQKW6Q71W^I6Y$?P$/3(,*[=>2L9_Z<^:
MV:KM-'EUS<BG)3AM8G6==J]G1;><C"SP&/&/#%P]-E:>_^K#S"N+)N//;]/3
MMXTZ?;'>L383GD&=H64S !<0R5>O1,NA*P=K]%$]<X-U2"H8>[C.L4L5QA"D
MDH!SGU?:/H0+Y?C+ $D5UK8?YN#J8(,<S*E+B&R\RD4KKA,C9>+4DO#<L2M)
ML2H9PL<^OT29HU6(L^)Z-]SM V1= [,WUT690$2"G!OK9'327&.*[SOEK6A8
MGHB(8@,M,/B7%7#WE=F8]G,6A5@UL0XS"8FB@G.I&0S TZ4OD8N'V*\V9]9J
M462A4V)KV:B;\4!&U$$_=?5S2J^EJ2\L=WP+>:X!M5M#Q0F/WH)8A\?6*3W1
M.5#9O]PV45N1=>9S@*S.9S5+,]6]*W/GO\9IL5/%2>T_U$L1N:.JRA1W+%S+
MQ[R8*I+ACY\:+PFU8J:]V^MW4^%D)8K8![+"Q)Z4I],9 P7Q5?<5/ZK8WAE#
MA,@;S W>NK@$2/&E.8VH<W(-4$X:J6EL:A.O"DZ[ADS?[L/F?K-=P7:@Z,+1
M5#?')6&1(-/ 6!/WQB?9HOZUEFCI!T$IY7,]>9%=\F]ES@_)- Y:3+?DG955
MV6ZP<YMO\M?T@X%Z(3/JT"8X=8\& E8NU_+B'&9\6]V^HF!%4OQVGX=QMZWF
MY_G>INWB-5*6Q;*Q'87+@@V:=&6PP1ATLQOG/479&FC0X+"INW+T/9;D/'%>
M3Z368-]Y93UMR"0#6"$YD!@ 9&]H=P9?,SPQ= =9 1N3WG0=%7[1P,:Q%]UW
M,-VR?_<\OD<CZ4C%8T*%MVEB&!H!PXXGO2]K@3Y'S>?"8K3VV73FD3'XCQ_1
MT;)7@X8N#>[9%_"F0F+3P"?."#8 9Z2K3^_&"W]EQX0"Q)8;30):-G'X^3GN
M2 SNR,LF'_Z\Q)QBO5:1Z :+,O?^Q&U'2B238_6?/B0$B:TA;CYOCB/9Q5Q1
MV[,?G%VTR71RW?;":FO?(WY,6IZDDOL)[9/\-=)*4@98I.2DZ9T%U#-40QE9
M AVIX:MA2'&DGB>.1U/E9*+9<5E<Y/.5 0=$G4W%;L4G'HOW;X4]*Z;""8+7
ME, XV@2\2:W%V^Y8BX;G95D6=O&M#:8=5^X2 ]U:A&P3--5JVZK'+<'S)CF%
MI^X8/5ZI3;5YV59[L';8_?F9:SRF#J;/_K<.;LVSX_!9MT=_:H?',T;')F_N
MB74A$>B@H$H2N$3N9IG.]Q9E %.DW,"O# "6 &C]VPS/"#VBHK4D:EO1:U1W
M@5O\4RA;@&Z%QN9K04B:R-9. _-7?:Z&,),^/$*H0FA-A9MU@)K<+!0Y\JYH
M?UNEK[D:].K$$H*B3*&'N#  M/=&W]W5&9(X=@AC')=F,AS( !HS7*/WUZA%
MC-FUBNV;&X@Z [G-/94HU<0 <)&@,V']8#UT(E'ZP@(#V*1$I36%<KG8Y ?<
M<['F'&(UYDXL)6U+.Y3EC=#WBS?'?E3$'?ZHPNXV/]_G,45""=/X_>KWX^NF
M--L#4Z0QV*7+9BW26NK;8]/V1]KT%6RK_##=UGAU[>%G=AL]G?,E*D(=Y*_T
MSGH&@+)!$T:92;LBZ#(.=CT=_\ID3LZ@-\+^AH@!O#D,V^@^_!L""8:',/.:
M9=5V9@WC($5]#>:5M3&%?NSC3>.UX:;O<JJKHX&/RZ@WF,'\%W/#*KS14X/>
ME%4&0#4$':'$1O3SK[1=X]P, ,L#I1K^GD!BJ6  Z\+.(%F.E^Z [NUG #%G
M\./KDL^AU .M04'K#$ /_G^6Y_?B%#& 77>:T<L6EV!DO<0O2ROT9#2)0,L,
M80!:%>!XS<:6BE\Q5:)%@)AM]([Q98-@9I%VTP1DXO@=H8FKBP%,^Z0RQ:NS
M6KO.+.[.T0^*Q8'33WX B2DBGZ?F: ?!B?%?>5+/K[@B*%L90!0O,]>:3B.#
M# !X^./NCK]#BA9!,8#NB8WS 8%E7U;H:054?5UFE=9C<9OI=8?4.[J&UO49
M0"MZU?,K=;V3 82.;VPK_(T;,\M13BF*'-@C0V0 ]$TG-A#]7=(.=::8CUHV
MSC63X)_G:#+&Y+N),@P@IWC?QDG^@'14V3)3\"1P?I2PMI))IZ$9P&[=7_$N
MFQ>C\UNM,K/X'#L<TT<VAW_;Y_AW2'O]F8*>BM_8"XY'=PRMVZ)($L)V#$#;
M\M3&&7Z"' P^PQ2<N>B':\:7YE1H%)!^*.F7G.'O=:E'RN9?,X#3-1BFH[!"
M-N#\/=+Q>::42 $XG:,93"];KH+AS51KZ+%/D0R _>B80RBZUXJNR0!^Z=O0
M7W!%/TLB.\*';]!CO)E/$+=Q;[2!_AWAUC #H'')HZE\S I##C[C 7Y?3=]7
MTU]Y-=6/T\(U%,K@5)"H\O[J7&8X5\X0'^O^VR55KUJFG5]<R;S(^=E2LXE/
MO?J3%"\]5G=>AB+'!>(L_Z94Q&"H('4369N8K.=*A(8M)[#A39'9O8.'/RVK
MZR>RBZR3AE3+SAT@.BF]F5SS5Q?(Q#HC&_#3%Y^<XM:O+3DWNR)FJ3BQ(,._
MU"ZA;[2:V+Z..M$(:C]E (?PYY-4W[Y 21:'MU=(RSI9)G*SQUIG=$$L>8MZ
M(IYT##>8%VTI4//S;9G1KKX__ZSHS$6=V?(<U)-"R KO084?<P2AC60 L;[/
MO<")XNA>X+A\[ENRT%/'7(6HEIM0[;_]W6N Y=N^J]F]&!^MNANK5+6"'[.-
MAY">LV/,R- UH?,MVP!">#HGQJETQ>_#OQK^:2N.:478$4UT2WK@U[\4NK_R
ML#;4:CWIL]&/Q+,Z#9<3"S1"^0E]9:\!PPT'_0OFVG^IX6\?[R4"-D;[K,.3
M3&G:@,&_K#?(.Y00S#F)&5(KM<JPG7;X^G#QF(M$S>%^1<]#>&R"1-GI[,M6
M?/[.MNI1":^\'(ZSB/$2TM:54]SS[=P&USWC;0T?[[0==2_V9'\>-<;+SG-T
M].[1+=K X='U%"O?;"33#YPUN9E!*3]?@<\R$;K]W$[;P&!QV$!A^^,L2='>
M\RLBA^%I7+Z#9GIJBJ7+.J:/='@E!R(/Z^2Y9-D4EGH\*-+1Z JXE*PW;579
M5TD!+%L:V]OLHO:D/;-C6X]V.@X*/B\_G5FM+>A%&36U"J"\9X$E'#K7O1'N
MX@L>;0CL5_UQU+/F]6C BN)SNP/UIWV'A[MV-RCE57:W=6"D=^KM9K[GA![I
M4$_DV\R,A*)VGW)T='7B>%!GZ?_,[O34%N?<R)W6V#O)W%OZUXQ/,?4F_TTH
M/_W!VHH C\7.KS57GH^USVD_,AK5[;T\A2C6E#.J>AF,?%%=7AT6L/UKN"&/
M@9@7(4V-8.E5(N/]2/EK=?77*T=9'[X*4X^V3HQHE7RU2_Z*/LFX_3J4&:GO
M+L.F2 6=A_I\4SP& P(L1[HZ'MK8#EHN>&HMQ%9?MTPO6*2P93HZU3G26UV]
M/>NNJZ0(>HFV*GE>C-ED'JMX[L&3G$*UN=L 1'-)[]M<N1+38->$7KNQY:CW
MC6K"!3V99(=83++JA)!3@IC#"VT+:/)-J:7,U1<DP@("C[ _AW.=[\3J/:V2
M,5.3EM/:/\N*K>[=^^(<9\7Q2_:9J0+1SFH_S%ZWFD:W;<Q[UOP6NX1@D:9^
MH5GHXVM4Q ?</#Y*^U[?VV)G?L[)?-$^C&.%MF7^-O[H2IQMO>B#&9K+$8_9
M!+T;$K $?17CS^0:9/D'PW1=R482ES/FQ?4!P;<^ J?=3AUIPGX(<HW X.=.
MYKZA&%1):_,?:U<QN2LT"8/ G$#R?ET,.G+L&%2$ ;B+N%$OD3$WKH_TU1=J
M]13,C#SHE9YO.BOB\N6ST&W.R#<F5L*A7T9'&Q!;E >[6[V]O05/;=F1T\IC
MJO/(3'7B..].'N#)0X"-5?97;N/OXRI @@I-PD<>Z-ZW:,7O8]7E-NK)BVAP
MG" Z/K.V]5"\TK_WZ5V)!ON#;S^M0-F)WMQ$(QO.8B11BN.$K<63=[XE<<WF
M^N]*I7:;MI=X)(7 I;W6G'@,#.%X!A#8]Z,78=LW-H_ $H++5_X_8PSP<W=4
MK0(J""?E,!.%/]#\__OU7W=!&,/_ U!+ P04    "  =A'93(&0MXE!R  #2
M@   %@   &=F;79G8F9T,69V,S P,# P,RYJ<&?4NW587,&;+MBX0]#@D #!
M(;AK@@<(UCB!H TT[H00($AP)[@VWC@T'ER#6V@DN#<$:QPVO[FS<W=F[N[>
MF;VSSVZ=Y_WG5#UUZGWJJ_J^[ZTZ3[^>U@#/5!55% $H*"@ \[\/X&D)\ :
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M!L@ KF[9"K[@_O\=G+FGTM5E>TT;!_,T*HP U%=NE<926/N'AGB;Z1G/IM^
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M^IW"3SYSJQ,7C@9J9(([;QIF"8CI">!I3546(Z$&-]H253P^^7!H&6$3!$:
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M(X'ZS<G:WLK5WFM+[+U< FKHX-R5:'(J2M&3F=7Z\-X8:>.4U+.SC75= !.
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M'-?:%OQZ\S?,+^/Z[^(A@:U!1QPP7&5&O4%'J&UEPMT#CYF/':\G6(1$LQ2
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M>4PLD<QKBZ2')X#?12L;VL1)@\1A7-#I/FIW[GMU#F:*GX4NGGHC00_'V!5
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M@'A3G+[!DV4*?:-H]?I8S'IE%%QI?(*]7_]KJ9NEM"5R>EXAEE7"*O7-$,N
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MSGF3]J[)ZW19@4QU2OUUYJ@UC5887UP?FB$,EA>6L(36\2Z#IY%O<)&$ZPE
M5H]/-"I47^SSD=,P=0>IY2Y^%N)$3%1*-]%2T6I,]UPYJ5?\4ZJ1O[IX2LYV
M^X#.G.+KPK-'SP9=_OBN9WXA:@IRF;/C+0V)?#O&M91;I4+JGC3?QZF^(87:
M=)T=T;O:+0DE_.83$OV41UP<#%*> Y,]]61"31HZ_$L&N@ '#L3)%6 F=-V:
M">Z*;3>I#@<E##!^H59)V=24'G=U8?/:??7^(? 0,V-Y7UW(XQ\F%/J_Y(CY
M_QJ4.2RS^74S&2^/>%@86G4=:4-F[X#"*86KAYK"^:79WSS*:<T_K?L]$R>J
M-CHX]KB3&"!P=\#_B8GB@1X$E 68XZ,8J,9):=A<'*FI=W@IT53>B]?,+D*:
M9CUI:$)".MFCV)F*=?\$JFZ?>,11[_&ID>VU[N1R38U*IFY5'C\+1O,>',&B
MJC8J@$['J6-[)-J_]W*HW4DUXZ^9M6';6EI5]RJ?-*F:0O_0/T'[!- Q6A"?
MZXAF $G+=V7$-[I-9/5W\4B=*:V;4I3E[<-KQN8J>1GW$)2O6A;;V>;!G;]5
MZIKQKE2SB)\ *)9Q\Y !D*'A5W(%SI&Q@'Z)J!NA;_-XW&=X#H5<^LS$R9+D
M$Y0F)#(<<_J1<";J9EN;Y2-Q4L0>)\^&NH;@(DOH+)M,*"-SX&:[GHRTR>9(
MKG2.FNT-\/77PLI&"]N?6_/%T+E-?OY$*FS&LJUG?I$!L;4[=!/4..L?.+U6
MO3S1]F?B[,?#!K4[&-]8BF%=0SYP*VW,Y4FRELL6&QQS6R7\,27<1OM%[WZ#
MNP<9"_#BP3-5TRRCR]0-??^:7!%0>9A9VU O#-A*M+?^\]BTBRFAR[ J0'H?
M:F_@H\U69-B(TSE[X%8;ND0IH_$$B-LV/F>I_<'_]C-Y33R5IUAR6;J7?)$;
M:9G,MT?Y5GNV4@&G=05RLP,$=])<G)PZYY$:B+-VX3G?4K')^2\@\Y7VBK2$
M[1?VHE%O$:^/#F;3_8PHW]%8SZ".>8W+ V>E1TT<<%!Z[UC7(\*^G(-G#D!D
M;\0IIE)OT*]D7A#)H?HO-Z!DRPGE@ZZUI_Z=U9%#ZF,-4]^9ATQTB&],2P2=
MXXN4ENV5_!S>5I)Q=>"NV(5]Y%C)*9P6BZNQG_'0UZ[D)[ T,Q!D;O]4<@;5
M36ZPT> A/!7N1K?R**BM=/[Y5NG%2.YT$PH^"A;CA5!6P<:8I1 S-YF6]OO_
MD\/>_R4 :GZ[+%P_(?A@W[,\#BY<91I'V<)/^H6_E=-%/5_>&IW&!SJ7@F2L
MOL,:=9I&)_&+Z7LF.F$$V.']9.R[_IL@^X,1A?XWKBDE)X]\I@HL1A(5K&*5
MB4^695#G:S4/35BON3/NJCK)SQI!#08+]# F*C1<OTV&B"JQ]A<5PX6'"-MB
MX_T*;Z%*9*OJ,FK0ALOQ(@/'\RY*VD]Y.8W-<&G8J^JJ0XHR@NQM9!(^1;$B
MH47VIYXWEM&HHT-#@BC%.7R39M-G6[]]71<+1F6R20>&P@L1YC@Z!Y@<:KP4
M=D9?VH1OHWT:XL:RAO#]+7=W;[Z,_/EL,4C>-;96_<R>XK9^V/Y4S;L0&G]G
M4^!$MT/BQ)P3660+^"P/:]=;QWOP?M_AX!7&MCNEGBB1(SG%T8R/]2?+_$$=
M8#QS#W*N]!E?4)NQ47'<FMENB6_0B*441V=R86#'7][,\JQJ;48(#YIVGD*+
M6\I +J _<B5J=I;&09QIMHH3:#2?=6(?FZL&_LG .%96H\R$290WIW-!KLCO
MWE=8F'ES+W\[,="6E</?-2<42@W>/#:6<+BTI GHU OM%43^G/V;#7!%D5DO
MY>5A'U<!X9*Y[7ZXO0^(Y8=14C7!:F_I $W4)BXH1H.OS*=+)+0A^%SLLO0^
MW C.4N<Q2E]<J:5@M>2?6918]_?[\3V1_UXL^G>(_R*';D5?D!H)&/A1>S:<
MR)<BI03AR0W8SN5Y<Y83/MTXA%]$'.\7V=O9('SF9'+$&F*L:#+RLT?+]=.4
MB%TE0OC$[X;GL\65@V)=8GUMI55157 D6]%_E66CA!!]VVPYI=M)<K85@'S#
M\W8S)?_X,7-P1&/CM1*C)>NA8=,3X-G%73 4J3*-LY;JSZZ6?Z<Z ,G<QC?$
MT4IHQH_,> +T)!U\YFR:XV&IBZ6Q^0C%:#'^]CY?A[3SB&PKR[)FWQ"8@Y,K
M/\7+;1&NVA))@Y/?E,HMR;*YC?U^G!!G$#UH#.  ^BP2_KYUQC)-M;,^7#?J
M9TV.2YO-"^^4+N:RI4012T;JF'9?9^=7$(+C;%>PJZ4URU6R=<S/!-;5NVBO
MFLV00T,X[]?+* 2K'/5X,5.<9BWJ*AOXISLSE"BM5=X@9H@RZ(O8UJQP+H$3
M4V,B5?61Y7B"=#(!-'5LU>;W;S$N-9G1B?DOPE62MBR=X?0U</(#N'A#^%@J
MY2]%S#<666Z*RF;M7N4UUSVW5_W3!L8& B "B%( ';SU&.7JV36KZ!J^I1AZ
M#KOG#W03>V^O>@5?>Z"4Z"_^%?A-C^3?<-)@8 T-N2N)HKWH(WVH,<ME$_SX
M*E+JI13'MM778\]HNJJO](0&6[2GLL_V.P7Y04:.7E[BJ?6^KW+ICNZ S)XQ
MK11;/,CNGFH3ZNQV7["K4)&X1KI_V;"W!?+Z*XK^E7]3_%)$+]J E$_YO#3^
MG <;POCM'&(SVV//D4=]K-8SD(TND0W_=:_K6B(1?4K@FS^.XH2%UJ[.'B?D
M5>E(@JH? DFLWZU89[-.8R]0Z@L/YEMWXAS*#=.$K_B^D?JMA]?214@R0,PJ
M<PGL!GM7Z>JGHQ\#%V>KTV%.1[52,M3S>=B[FOQ8'[3Z+8Q^I/B4-!WL.62G
MO_-VQ&(0QCJ#@@X]+/45TZ>TU-^T"CF_)Q"O$\;MGW5J7Y1LE.%X;/S\N#GT
MY<MGFS6@:4I+<Y;M<:P*U!QZ(D"=V+:ML"(\8W\S+B;CU5 &   P ?MJAL,K
MR]-\V\!_W-3Z#Z6%[U)9,OAC)A^3;]G0LA+HYS=I@XDP86#;Y\_"Z?RH0[2:
MSBU6L7[^&*F_N M!OS.XAW9#<W_0?.=U ^XY32F0?VO^K_0L_Q:#*4P#2+R<
M]$J:06";C4Y"!KPM9 )F/?A3C'SBF6Z\/W!V>KFGPI_&*RWBD$R5L@D@);I1
M*=6G-5R[!!KP)<\N4CIOV\SKYZF2MILH?0+(C$/ZW0T@K_+=H$=_D\IF"0U=
M%TY@#]&K9:M/8\.5N,LSCY/[G4 )/X#]#I2$O6WDJ$V!#(@E^Z^&92(54[3*
M.^>Y>"(D)0]?';BL!)O7M=B]]2=7B4^Y^ZGFFO4%L%%FU_EZ@9I;0LG8P)-;
M5<49FG%@^*G(N5[YF82%YBJ^0-#\%RF*R VHI+-O>:^%0_$^FZ=_@DPV_A7-
MQZ9GP]LM/&2I&->4M)>;Y!],KB,]C!>/MF"U=^HQ[>YF U?6:A3H1U_!-^.8
MOEU;A/< [P:@<"WT(5P^3BOH:,KZEUYU\>L\?'Z!+RK2738M":=TNS."PVL-
M#9%J;>F(HHR#+4B#,_& Y%C+S1,@G-%[0A5PLE>ES?!<,H>C<QH2-KU*0[;"
MFRU&.M2&=I-0O"QHGMTR\=Z!>G CVCO2RMA!7Z6RI*U)V4EM*,?(>>GUTE<N
M*9QNRCRBMP7-QH%4/L''!^/C,D1PZ$"A)?)0_>HW1]Y2L[+\G]_\FU2TEQOU
M@]^$")S[.BEG&_RE)OR+5OB:FIO9:1WI&=7B"5WDT-!^V ,NRCG'E2+53R(\
M3.6/V;D>!PE+Z!YJDGR4PD=79L+HNB\$#V4B4\?(8,^]D#ND'Z]JN;,',U^&
M#AYOT<CJ2X2]5AY7]/FG\7"J(9P"OQF]]6O,\O)OJ$BG$.6)+OWLT^R$];.S
MF2F'P+OA7YF;)V759R2ILYOL_JR^G*ZGZ*<AD:"1N1DO&T\FG\1?8[O&[*PI
M:W,9_=,[B]*]4\U_#6JW ZR=44\G9O9"@4PWE4S+\+8)5KSGTB\,\:AAGO;5
MVE9[_HGT"X Y"S40%S!94%MX:A;"W9&U7V[\O=KV3JC-Z>[L_,Q?A(Z04\X3
M3VFV:";54R2AKU[2M(>/D2&?(Y #4*^@->,9(V%@G#I3M=%",=/8/B"0G<BK
M)[U1_5^K_1AD9-&;W'7=&&<LE;=^-0-7T!^.F="EDS/Y1$_/@*L"V^VY33Y%
M?/XQ#5TL-5;N.A;0\Y3],"(WNWNK\X&*_T,;NP$\\YO;Y[6MC!4 &P ?95(7
M.(GG(T_8<6"OD[+X/HX#ESWQ.;%8-.JZQJ0?*;Q]07Y6\-![\IB:LEKH<!%?
MI%[=36&LHUN1"]_V&@7=\@LFWWO#_8;0X'@<-%8T5JBOZ>\8'B%NW'D!3Y!D
M# 32OV4AMRC:'(IM3C2BN'-C;ZIDVM8^?[%OW1&F FW,_*K^@@GU+;'":WE-
MDQK +=TF&<H!F3[-6HRW_GSZ=H</2U,B7"S(\.4*64SV<"-E?/. B/D6[8+U
M/T7MM"N[7Q<;U=H>. W:IXLZ!Y=(5K12M3'1OAQX=0)HPDV(5%-[>ZB=TMV+
MQNQLY(KE!/E>@)?NIR&+PUNUG%FW2<87[[%8GP#87!2/;^%.9;[6 >@+)"PC
MZ&Y 7Y%VQ\K7HVWHWI2T<]\DN5U:@V:Y&D?;U(8+8CF'*=A^F1Q1 CE&0QU)
M^/D&G3B+JEFF/JD'>E88*CEOX%5 C< ??7@$%XG?R<^Q>-HPL,'U &+X;CXG
MLO0AU79XT"@JBC-CM3:<^SO?33TPM*%LI(9QB^\6J)N#B?6F>?KE?#7%_+'A
M5CN_$EF,3(;;(HN/E(O2NP?.;+"_8=+;^N:6SA]1[\2S+_2OFES",\A4##]2
MPEVRS&NT%;'*A&HR0E=A%8M[XL VUE\%,XG(39UH)G47NLB"LH&I*X-4M$G7
M,0 (%I*?J5/[MZ<<?W691REN*E+BQZ/!X.OE7I DZ>QY!CCMJU7]#.LT8:,O
M3R*RVH&\HLCW&Z4YX,Z;KC H=U"H.$R&T$YGHM1>__EKH\(QEO[QZ74L202:
M*/V<XE*?4<I FG3>(UTS+$*Q3K9^Y6W,R]P3]S-S-_?[ZSP\X56:QL99C]'9
M5,M7N1\="]"C^>FR<L3O0RXKO[>C820;?4!Z00- [L7=7!3G;(HC0^N9;BF]
M'J6;U^'.4J$-DZ#Z"7?A C@(%F;PV[$;+UI40C4AUGT@H,*Y]_;L,'XEO"%U
M_'A\;6EY::0[4A00_7HMF/*9$A3POO&/<+HS4OULV812>]N:O^;5=A7?3OWI
M[&83G\*/D-,B$SL8O'$%F<12VQ0+MY:=*I&[ZT?Y!G!1]_AK*"*0:_7*QLP
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M_]PD5@WI.FY:A-\9"4=UW/&#%:J2M]/I'1@*I7*D_.]QI?8\/@Z\;M?>]<C
M[_4>%;HG#B>3.]S56&9<E16DYNUDF"E2EOPQ8 O7K2M\*#3O@*C8NCT-:?E-
M/HK)[U!./9KD*Y#LW1= @:*PJBX+/Z[C'QE\JH245E!UC3\;S,*3N+I5Z:J9
MNI5I9?I\E*L75QMM[NJV/?*LWT#?&^\U.6,8Z0J0EC @8&52C]&6Q*P=4=7;
MB:N(L=O(9U]N52N2)EG#MN2#^R9?%5_?\B]TD&%NN>AC.60*$\5*[W4,OJYN
MSD&HCIU3M;0G(!!.\P*8U?7P(8AYNU?*\NY8*V[ISFZ0CM8)0!8L7FAM,W.M
MKU6?EZO=V.#I*/@>2:)[E<][%?M.>S:O -Z:LLA[%5FU)/.XLG3G>)-\9,GO
M7%1(FZJ:/DBTE9Y+ZX$8A[RCET)2W%$G_7#D2BZ.A'R'EKQ_SQ$3%"^7T(T0
MG#@@'F-]ZZB8#"R<9E/+8Z1>(G1QG1Y;Z[R'J2@?.ZJ0CQ+X9AKAJ>NA_&LR
MD3DQY(_!A)]6F>'\W,**KFVM''?_++EF\B&V>O ;E:W?(9S'H@?@O" 1N.IK
MVZH^"[<2* [<9&70?KW5UY56!\?AC;EQ-$<K.:;\".M.:/TW^S>0Y"R:J<+Z
M7PI?W17P9-QI$BSB.X=SODU5CY%NMU%' BY:8A'V<1>\/!!HWY)ZO+.Y'SP6
M;XODJGAU-C8,;KUV56X_A48X/GXDO6%*+" >UHE;;#L(4[(PE0:BD'Q$@&6U
MN8Z1Q^C!&UH*=YW[Z N]R1J3(GM)Z#) *GCF&9Y_5=@%V<<C/H+Q6PWXCE*K
M>J4<BR5SS"PM239OTCKB%O.H88:IS\QQZNI"%)G90.M4VO6(^_OV\),'%1E-
MNN'(3V3\'P0VOLU ]I_9:J.ZB>F2H^]]5<NI4HXJ<>6+*"4 >/NZ&2Y.'*[Z
M-UGL4^!6(^#: #2J/ )]\$%!S9,I;-5=D$$423 '>='F/=?M=I^N"?MAE:ZR
MP[PXWXW;E^"],-[A.2\#X_$IB9:&AOJ6QBGXO2!D^%GW@TC+=%)#EBR2K'#:
MTK=>N#2Q3.8RI%2WBW68E2O"*)/LH^E/@3=!&R):#^QXN_K).0T$^I#ZGB&Y
M;2;9N\5&9,I+@?Y1(35DWK4Q5%NX0V[NXG*ZAMT+H.[3\^<$;I&R/2A-$<*(
MI-6:OZ=T<Q7LR![BR,9:X8YQ7>0?G->8/JRM31GTQW;3+)=WQL"K6*JUJ1'Z
M3;/!FW4B2S4=P'0ZC+H:O!B]T:8[60\1-H "8_BV'*BUX;H?2#=$.P^M$6,G
M16C !OOZ1EN[M1A($%]_KN[-H%J:-V_C!]Z4";,C&<*!+CV>Q;Q7T6F))G(N
MO(+89HO/IDM84H-+G%T;A3YD> @[!.WOSTCU Z)R>>MCY^HR-81S?7<RI[IK
M" B5.YC7F@:ZNOKT9T^/H\ILGNE;&I74B_9P:%)JWP>X*'"+^74;8K&8>4CL
M&Q035?S^&];(/3[)E45[OG7VO"=L)C24YM*B\OO^88[JBHK[/9-IH;"TMF;N
MX=:_+$GU\X>2VY!]>26 QE+ >6Q?V%@.19*;$/3/$LWG:EV:Y/-1<^2AQA"/
M1:Q&AM>^.GHR5FCO0FKD9 S=;1.WVUJ3(\X&4GI6L+;TV+'=_<66WX>/'F*R
MWI@EJT_E7/<1583T:4SQ"J.R3>X5*7EA'[/1&M4H4*T^?KOW66]#_<F59(H6
M'X)R8!A>O?J ,@8_A Q3&?C2,M_("R[FN.U4/9:Z"+0?G#&Y6\\4P3:&Q ZL
M]CN&CNG.\^MQ?EC%O#;P&QF)26\_]N?6@\\LZ+*96VL'UB9=:,V5J/EN:EOF
M8C9Y6_AB9%ZG"+1Y+2OL+)+:+=29.C^*EX(/5K .FF';1KXF4.P$HKQ:*42S
M8E),T0-!A:>?%JH8BFJM^XPG.WNY+BN:+;,XRKBJ2[RU#5M,?4$H7>AW3$$7
M8V)923,'7**5W]?J$JQI&]7*CJCB9%4$T#4W$>>R,%P:"*[OA0JT)4IL-FP,
ML_34-E_YCXF'R=?T>W"Z&/'WNO9[#3F@^3LI%&)Y"+4I=,\4?M"/MDOQ7RFQ
MAH,];K23=68"+4-0B?7\:BQES6Y47:,3;&':/BHE<-'NY+C6E)OS$Q0DJ3<N
M>!NOT0'.:OZE7\Z'XVE+P$B$K@-]R!"CK%FY%JJB!J>-_((P78]]0<B>X'Q]
M9=:PH-/5UY^)"FY+WMX_[2K=,O&IDM(0W1W]7='C$OB;'4P+[A'.SX'&1K+
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M2$S43R6<?<9I:(,QP'#.MY?/-L-U"V,=C[-XW5^_0J$LKZ+<@9A,\%A?*BE
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M/%>+RKC$E_@1:UMX4<VIU[Y9(,5<70D1ZQ'Q/)$2;XV8">7F*R_R'<'UYH-
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M#K=8;7G7.N\D\>#R,5'!(KTV<PW-M*[K!99QJ%ENKKAEW7C)U/6DO\^^:MY
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M;"QL,AP<,AXZ*CJ>_^GQ_!- @/'B!QH-,A(]X 4!$C(!TG,_  @ (*$B_=L
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MM[WOCGWB!,4Q_7@@"18='R^7YB7F_J*U>IGH'U\%<(?!4[?Q$)PWL\:S)B=
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M]P?["%GW;)3S$/D'T+'+&"DGOQY3"R#.@_8.=$4((3 NVZY!MJ'A4[9:XJ"
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M#'9#>&O=1%,8F?.35I\!['C@*SO W<IV_C/ T<_G?/^;=ZS$&%%-+D^*Q3/
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M[])<7EI2_8/[SQT@F(%_YG@WLG/'X_J59$NP:$0C_?1X3,P$1;6'@-=4S3/
MN!'4!+[9.\562B*E)!A:!X9:'3TQI%.S,A .X'N_K96A6;W/O ]!E&63&1CX
M_CJ[?MFG' K-W7&4@TAL9-E'%6! _1_<"-MFQ+',&HY][Q)/(U,$V?!QY5-*
MDG)\KB&8:^"IPM+F+S^1J1B :=W0&LX'N:RR#5*!8;WNE#AZE*2<I6,#%7<A
M+D'R'>PON$#JXRRU7Z.'%%L')[M[K4>OT,R<Z)JU;8,3HX8 .4IQ@S"N*L(M
M9,X_Y)3E;X]*5BG\V],X\CUHZVD9XXL$%+>:O!+"YGA/-=%1:[,AK%>DI3=B
M([_SHV3^N]:[92*C E@.LZ"U\M%56T0[-;.\<O><HI6A'"LZ.K*14"-(8R]G
M$UVXLD1;=J4L5FDF9._(8)Y?D5]<=2O,\D$,E>P-V:2_?\6W>8>M]@=]PK9
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M .LS;E"J;R,>@-7Y8HA:Y\;/1>FVV.;9<,\6VQK]53]?GN^<YJ7V'S?4?94
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M)UG3LK+L@@E9A;=;J3X)0T--R$=_R9U_,#_BBG?.7<A_:E.$]2)1YOJ?+:+
MZ52#!L']O/WP+ZS"F5*.KK\*.G9*L3>+,*X&"NW^[^['\J1CAOL+4>1O:O(,
ML.1ZPL&)UJ3:.K&&P:,9?-O$Y>4_P"?IMADU.0,7/U)[5^*\.3"59PT16HZ\
M&X9BO\:Q/@6==5-CH*QZ_-VUY#MO%.;?ZY$EKR2U;!D+CC:)G_',_6"_2]%C
M7&0L+_@)!\&>[^OIZ645]\ !OY_3>AP!3N.+HBW37[N6"^+?=$_*3V;Y=<D?
MGCFCW8L/Y_^,7G-0;L_G>"PRN+K5C!#7\E;^?BSSP6+ZA#)\VV<. U3"P=9A
M]7&%G#VE_H;Z<Q@NBL"':D87+[.HEL*RT:5 <?W]RA2+M=5GOX&+"NFN$I/>
M9./5.J6P/SVB/*R8K.0XI\3M63)C<<IL!?G_S>J7HG_@$=D\@VRFW)2K*GU(
M+(V*.<NG_LOBG;R7?8^6A\IP#]O.FLZ<!'.=7%%]G\<W9I,O%[@WTE:[9V6:
MW!*P<HL(94T&HOCOWFCE,#>:)RTU.Q$?/2'IV'T V-6Z2Q$YMK ,36U9NKP*
MESVW"E=R0/_ K+<I4/1?*>);&F"L=^9W23P$[RO8W[OOWQ.>ZI^2U,E?3LF*
MLV.2F7LB@L%7U7A3(($8*LW+PRG%V*3R,"9N\!W':AOK!MI-E9NO_NZ'W._0
MRZ$QMJG%R-5D_8VXHC2Y>(&MC#' K>U2$ 66OSM)7[V0QPEVKPJGVMO!'OII
MN=1\<M*?ZP'3//)I^$IG$G+<"J6EDGVV#P#)B0? 6HW"/$1J9Y'N9ETCWTX]
M:9]M$$6",P\)^.?6Y6O_?W]./JA,4*&TD'%&6^IS_0,@SR;@9+[P4#?O_(CP
M#LDV(< RB")VH"WX?D-2<GLC^P#P[Z/[]^>D9[(89S22]MGI:@P? ./U4E>'
M&I<<ZG\N(^[OHOGQ%>M;TUNF$;FZ)F._Y26$J/V_561%_)UECXVH8<__;Z@@
MU876X/:HD5*L-'):U-8J^^EAFF?MPC@UT&&-G6=0*L][]33\AYO/%\$TV,9/
M[]ZGU0RPX@= Z*I0YMA[I2-+6C=.GL:JMWY(6YO'NE6O8&F?J&]* !W.@?EX
MB.4IL)[.C.^("9<#<_)K]71R\52:P=MK78&X\4NR*.R.0M*;+ZF4[RUF72=\
M] ("),++2F7NLIX-N%.=$$0#M#&_\[\RI&]$<LW=,F4=D0]WF,=RQ#Z7<![U
MN<^RL>=?\M&\^:U(W%A6]7(#K:J&.$*N-"L^AL6E8$?A9%^1[-;S]')(4EA3
MHI8)C'^91RN>">-PDOL'PL*D&YT%;M,L).V=*^,&R#]+/P F5 5F'+]+$&MH
MOOWO%794D<$'(@4Z\<%"1XN4< NG,LXE(2^>1'][OW>Q-W/NBM+TP1@XI?P8
M?;[L<]"\%V@6CCOG@"F\L:21.L?,$')[/Q>I9T=E ( Y'L:$YK_F!IF2G?;T
MO3#;OW8,*IAAA 8;:*HJ?_'EM%/3%IKPG7\ >+2WG"D5U.:JV/C^F1*T@2\_
MOL0,2ODU5$V#C.@Z.3* FEC \1.S--N;N)-P@SW>5'U$9"-H_@)/AV.\*TF'
MODSKH&D-!K'<]QI]#[IB,X]V1JW0!JS+MTA%48ZUP]_0Z?M*3+S)4E?Z_-)T
M1;Y7<#I9@7J=;4PLK4\6GA"J(#_7)E&)?JG\2$6LFO>8T35N^%FBC,<%GC *
M(A5)^_B4$3P\WM^!G\PRRQ K)U#?BT%/;6D-V*1^KKC+(TT,D7RL_GV_P3 ^
M"'[T#K;%]'A;B5CH6SOR,5^>_.!V\P,@UI0F1@==L='*Z.5B.9/*^/4Q>9RL
M!1M/EQ3/CL"<S944N7O"<P/5L@5;0^XL7/][GBCQK9-?'B(76P&4>4;(\,9R
M7X?)OW:DMFRRTASPV\HXHH>N-1O%" 6X+(9GW>6<%G9)DM6W-J=-?X 2C#)N
M91][CEB$3-JI,IK$;)STK9$MVJ7C9;I='OD17 E+]3^ZR?DM6= "#'@"U+SU
M:#J5FRVO^IK6H4WTIUQ)#'#3/'BR6.:KB_[DA0AXN2O4H!Q#%()]41SX^CGH
M5]!,KK[S/ALF89?&/N6/='A"5.;TR+:ZH_ TXHN8Q<=B3[;+_@F_!(A+7 G%
M \#Z99G)JG'4XR(K.<+>4/A;*@EY/M,#!/[C;?7PQFN<B"/M81 VM(TA&+^-
MH 3S!W <>A+1P9R^'A^Q <0E2=&(7E?QI,N.)O;=/%,CY&QGPWQ\M3$Y>8_S
M  #IFZQ*W#!W?']5=TH9Z$*,9_[IS'7/B)87'>$.)\0$N\I.6')5@J.9#)3I
M,@7&YF@7W#_E2<_NM^1=>H2MJT1"!>6F(6[G> N['UF6"36],=8$-@/J'@#!
M.N_ON5O#&FILW#;H-[F=QJ1TQF]F, Y-22<8D /AAQ??3#;/7EXE-X\H[J19
MH 12$>TJ&L'X' I3#OXC?I6FN#K-N"G/L#F/<4IUA*L:FL<IP!X[O916K;9S
M*L#R^66NV:^'O!6O3L-INK!"4/EX0<B4[BS?_O!3*.8YC?2JTF7<VNI*;F>8
MU:U\S<S% R!B435Q9O5<0U5SEK$M\^U3T(ZMN2@BH8K#!IS0_QD#$\RP>.6
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MP<'PZQKW!Q](TT[_ET&,5T,0)GR]DJ]@%T;R#P#%J>(7G:-Y;]V8?!X/Y_7
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M3PE;>B]9\T;$W0J[1<_!>=TPPYZE&(]F@@\RC=B+A^U.$ARIR/;\4[I E+
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MA-E:"'-*1';=VF 6%S331:7S+8)IMX&V1>$:$DV$5,^E>?/%$^P.U&6E<>7
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M#IUD@;@3^XUF2ZW$X@D>S+W,J6HJ&--,0I DV:)M9BB,S^0NF32-<5#+@6]
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MV$M>YMO37HC'J4CSG9#2-<5[T;$YB\->$$I]@<F=O!'* &8]-C[80R\=F#W
MS\.E#KHO\:&5<^(6H:?&-I<ID\O-8RB9/FIN/TD[,,M8<VY#JG+M]^/R+??(
M7N]^]>RYH4EU"<]8(?K(_&\G9A+^]TCV[SS1KU;510!JMDQX6&,F[$,<-R:/
MWS =[1OJXUQ/K*)OVRL+C*"UND&:7=.D8(M^DX<.[QZ0]8/-]SF/J/XU.R%[
MBG*(G=4^>=XR\%6>E8K?_4\^:T*F,,;M8S(L!_-O7&EC^*FT9CFNF5"'%&=B
MH8&3"I]F;*<PCX$A+0;WZVW^YD($CZ$+6W63WH?8:!)2U?ZK"9[ (I]/N]$_
MLR.$UB!LC+\!2^VZ(DK<V=A#N@8R2X!]MLS ;-OSB':^,M"OD*N3"GI[K:36
M'JKJ_0G6IZ+-GLT8Z7C%M\,'(R@.Y#<'XA1EGLSAGX7D]^F+R48$53$,?'\#
MPJPKH;%*2XL'_'&VGJ$GW.R2IDXBN_=U9B))2W9Y%\H9LVRV]:5]<(()&=_F
MZVJ!Z(?'%DR)>YXP$ZK8;!^*ZRQAB(^(<Q^0P=A<O:M-XU=$EW+JI!&/ZFX(
M)^E>>_S(5Q9^]3[UNKF'R=J5PD[=/N"I]O&X38FE^VOG-M'#5 Y^"'DARK]J
M@-&Z@@(:,>!364,#H.&/I?F/V6(<_T7 P_$_./U:^#%^2OAA;F&=:>A9V6J$
M,B7D#$3#)V]P 8YJ.@'$< 8CENFNAE?!>:^D* <A I]#>\Y[2%K_^; +#2,B
M=7,=VY;6I"-#ES,(;3OX'3%&4HZRX(#[S>8:79P(+EQF7POJACB_-C1SXI%_
M$<CE@3GH&^MV5APDZBL)1_^^9<CO>-V6Q(=Z*F)2=DU?"Q+:Y"]K.$=YX.^8
M$^&@(I 9J>MYA7LT,-3GNA ZX))&43+0$=B7:/>6<%&_EYZSML%NSR XVTD2
M110<J >XM64+N?#LC^2O1EZS Q>:PH"\+FOYH;'!B1J^=SYP ]'FV !&KQGR
M&R#ROL+,];5+C20OTR_GLXW]X\O8*0SPM)'C!G[T<T1H'T7C7BN%GM%!N1Z"
MCHX$D-7M\U#)?21ZG%H/-QY0B10+*-B4LV\ 43.PH$Q4@ U\:^QS<E&:00#?
M5.=L6D36YOES/3M/K7,1TCOQ=UPBOC+K/W#$SU,@QK85F_Z>@]P(62TP//P[
M2='J%Y<7Q>^[NF#XC)(".^X;-+WM.6IPC$AWE6#MC*X[5#;O4CYM$ GXPXQL
M-P"-*FM510]PK1\8_T36.G.#?=,P]T7+ @F=9.Q'/+J8O8>HLU%$H6W:'33!
MJ@SF<"^ZHLCG.X@WP\/#MI\^+Z*VL?X%QM&Q<&N?=/3N69-3(U@Q$BM-.)2+
MH1:CPX<LOCVP_( B/'V3%GM1RGT+N^7K1O7PLQY:-Q.K$.\-I S #<5NN\7V
M*7WW:0FNI@/^<B$+>;CHLG-LRJ1DB^\"4?&*G_6,>QO3/,<)OR_E][?C5#)\
ME[*N+6CT":6G<_.3Y%[Q-YUO$,:]%](V')7EG*^)] N_N/P&N"6E"G\JO<G%
M&]P>!"LUQP%%F 8MY\[RKA+9O25:S(9/>VEGP*R_*I0B!L%=D+CW=KX5S\L7
M+2Q2@[@+J3CG?P7<0B'*K=6*%[2QC;Z3%%X_^FCHLYE:9S.'';;X$]SHMD5\
MB<7C #Z:)+M/N/#BUNV$2(K"#+>A;*+9R3303NS$(_J+JPEL7QR?A5)5=,_;
M^9('!N/%0/%EL=';KK;+DQ6RZBHEZX6OG>E;H?"P5!%YK"&W>KK &I9^&J]'
M*._"8_E2RWR[TA;(4W6V_9TOL.@0;-]EU3+'&#J1K!NQIC,'#SN0/Y\)$H:Q
MA=7./\AO=A$L6C\QM3;-5=Z\YH;9JO;MU(V@^[42. ]AH/HNN$N@D>Q[9NQ'
MWW!%4BR$\]F<GIHTAV!V+K._?)H@]T8*C/IV/0E@*3>^2/2:E8(+(<1\8Y3T
M;I_PA?H^)>,S?\A-?+)EV7\Q!#&X]-Y F;.N%@N_'Z AAHNEV%7;J1X+!52S
M-,GJ:P:?[@UJ(_F4#0J6G=WD$"!R^LGN9,,=0-?+'/P//SH4=/SV;6I3J*R]
MMD52UH*$R]G&^..,!Y\(6J=/SJN!-_J*C^JP15LVAUJ1SX5(25/.(_LX0L_/
MV *-X&A_@-)/R<Z]3#EN\\>*Q PQ8$GE@?&;N\QARM2]*H:FIQ/[R7ZK]4[2
MY[C,0KO6'R@"**WE&7BU-%UYL*,D?8-E69<?:6S?;N4*&%S$\4=:L\CZ?3J[
M:.JKI2+Y7N0E\<U9#QZ'2[@*OLXJC$4ZX-452HAKK. *RZ:"XT@Z\%,N@=*L
MYP%7GBFIU.%>Y*<2-#^DO;.[W+?7L6W4$<57NK7MS<VO%$&OA"5*:Y.1,+G6
M&*S*KA]8O542W+.XG@@YQ'4;9C];=TX#BQIS4_R\A@CEO'%D?WJ1Y^(U:\!Q
MA+1JBVSJ=-<^WL7&42CBZ"?SH+OLUX"BKZ[A'6L%[AOR)[=]P"KRSGDB9@;B
M!&')T_!)?MI8!KAV1,.IHI[C"TG<K_;C:#4ST^LIES)X 69#Y _6*-/,U6+I
M_6MT%PO!U\U05.TUIGDFG<]!I=%\27?H$&FU87&]<,5 FL5^]V</9D6VO+EK
M,#L8@[/X/>O&&4W_$Q_2P;66;+B()' K 6_IF+1\*!W[2F95K:>/Y8Y FG?
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M Q1ZNL_$F%<*"!&W#=\,B[2R\J, 9KA#$C7L/7L8>&G(%'>7[ LW0R#9ZPZ
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M2WHGX9H6*E^L9MRA4%5]S/>_0GC@B2[*^,=:18U=+5IOCQT)V+YX#M/=;7B
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MTR[D^2(P*=+-3M"5G,RZLQGLG#U?)[@'5VQ[?#)IQ#W<!=YWQ7%T%@5NK4?
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MW74<DP7^WP"\PP#&!3_Y4H&$P'0@5;!IDM2;52YR,T1\2/$,>^-Z9-KZ\D+
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MX4^U18O2ING!^RV_&"RHD'V1??#FYZE$DO<L,YOF9N'5D?PQAY]G+!HO=YN
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MTO#0_:=<;7U8]A^>S[AA^!PHV=@P0P\T>/RDV417*BUJ*B 84ZI7M"/%QPQ
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MH%2\L6*3YD.PX$3$6BQVT373_OV*CY+X(IMP]!7 ]F-:NI-87FZ(9HQJ'L!
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MLQ8M*2>%)SM,%JO*V,OTV>MNMW__8/JV82CE>8$?K??BRWBR?_W@RQ<[RX.
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MGNB<O=6G-40 PVMN2DBJHCJ"[GSRVV;]HT,C@=NMAG@RX\Y:0W2%G ;">H#
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MMRF8JT*?++YBD=PJ>\W-9Q2DJBC X:JH_I\Q&_^.VY@60U(PTR0T1Q4>$(@
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MC<SR%=]LU9JFCF#^/Z=4V@0B+53YP1]GP.#<IN:9D]SF('$6=AF[LMJ6WZ/
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M_526T 53[K1\HGQ?7>OE-@N/DWE 1_*U$[?KN- EWP2%M?QW0M+L>RL)GY@
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MA%2,:+G=U'F>=*=  Q'@6JJ/> 1 S'3KHS 19E510,8DRN\$)O.BL# <7$7
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MDH?(L\HMS]%1*F@;EOME/L (Q?$^/Y*DTB3:+NH5[H]V-Y 5X^SESZ*9^N1
M/FOUFC)IJ?E^'>6T%)>*VW8E\C^DP''WE NVQ/O%MQ,6>0DD0?VT\04 SW/M
M#!N!A]=PIJI2_06O..A@.>=F_4-_RJ3^L\FJIL63K7#:D#B[R=W_1_KG_Z/R
M'PZ:_N?"^OJ8OCY^)+F[4BIK9ZJ@@JT7FM1>2)<@5=5@P>TQ3- Y?KT'4@\7
M+7^_-51A5)O =P#IB-I>%S2V+RU5/!9[!+Q83%0N.4BJU<:UJ%2R0,_#JNJO
M)^.'%'LM!OIXEO%3<]0"16YE=>G"WA8*,:D+5&$PXK1_1Z\O4?2<M'YO15WT
MCFA&ZQ12(;?JR!O23=WZ"& -$^E-%'K3"_>+G:8W6,(_R%9<NP@@%RF/S&<Z
MX?6[C3CEC_DSSYBUS*5O?A-6YE4%C=SV,79*&:09SMI!SG@[>L!L["[,,/WI
MO$5,5?XF]JBV>J7F,VOYBYQ=_I ELS^EU5Y6/?SX^L/BOSSHH$.A:M_C.J_N
MV(8+]6[M0J,$?FQJ4VC;7,L5&(7W&#+-= ^D^?5&'&KP3[V5J_!VKR@ )OMZ
MDYU,G%.P.:+8)BZ^IT\CRWQO8A"QO)?TX#W_KF09X=@UE-3VS8:ID_!]8#T&
M"O@SVGAX*W"'+E6E37>R4YW!;+Q"KA'L=<>\?J\.:U]PY'^EXKL1 _-)6BWX
M4-)W\'IOGQ>Z5[+X#JZDP%^CP*L>J9I9G!%&U70$3%WWCZ-5, GSU+I6^,2"
M_=O?[R F'O:FOB)WJ\%KZ>7:@%/1]$KA(R!4LRR"SN"4:#4)+Z#93^&<>A8G
MB_H1<*JX76R;'34EY^8[3'I7T&FAQ1CO.R]2@1BCLL5'>TC%2S"_MHI]V_5Y
M0_QB,CZ4F]V9MEV2<MNU]B&K(U:AV)?EY5B'>4<OTN>7(1D/E!]C=F45^B]>
M0>QM/RLCEK#4NH>FL.BH2&AZ7]_P-T-E[EP7A^E^J)@-0O1N[MGF-Q$?"Q5,
MJ_P*9=*ML9FXQ1!7?%UVS1S]86_,Z[!JKFD_6UER ^':,L*3Q=!H)C5G4%;!
MVBJ!@=VD?,.O?)>?Z!1>-YO:VH9H^4:V<R^@T?KR45_P]L6->8+?^F@W[-[$
M>-<G.?J0H<JWKH6,>\/ZU%13>3WX"D1VAV=JU?3#NOY-$4'W7[A^'@%#8,W_
MKO[1AX[V9]1KK']QBY3 ERG_<TZ&E!10G'0_?5<6C5!^;A26YBU,Q,$WMR:+
M>^>K=,_6\#-0=+Q'^"*U)Y.OE6?=AGQ(1"'_ENH LJ(\PKX5M(2$%':(%P!J
ML?'U==SP8].8!F^1,\4E-J\HAJ*-3+T9+<9]I6&>M)1M>S* 4?S4UM@BJ.84
M(]97-NV6KS"[3+]@*_. CHN+A6@B83*(ZE8SD_R&D_1.,;J7'#1P(YY>U%:]
M7$VDN^6)\3PK!^#B9S<1@6H<$S)##@+ /JEUP#SV*VN/A-EI^07'O]M]JYVZ
M>P53EOLX?6>7NU JMI2TL)]*W+*1Q6R_J+0&^Y;XUL>T+268^ZVW*D8:PI(3
M<[^=-3@ $Z'5:3-7/,Y4>6G$]C+@1;?S'^HF,2Z=!YZY.[%2?;ZYX :M%>'Z
M[S)V+R4GQ^FP8^3;R+FY79;+?I?\%?0]D'R6?E?W!X ;U$+%HV\5_?*/+%PK
M:7W81\&1@V,M9>Q!4-LMDB#9A#X.84&&DJ%M)P-P(J_LC:71F#IF%^5AV(>V
MC2@3\D_TKC+@QPS(=P=E9-QH 6//7_/B!A,WOW445@+6R(X$9HY0N<C5NQJ6
MQ<]% =BBX<NAY]I0DLCS1;G6=-E,J)X.Q%#'W*"R9C8<%>=NWD8&X"RW'A_^
MAOZLMJ1PQEV IGDZ-_3+R'((LKB1B[>V$.P>^:KW$8!24=N4;#QCV=CT[34-
MRP\'W<X;8GVKB?FR-605=.!')4G*5_%]'.@4I+!Y\U3%V01I93-GS,_I_0;?
M:=Z*11RD5:XIW;9]['_@;F^>WJZ.TRGW'Z<\".<*XL?$Z;WH_Q1USHXL16ON
MQEN+U'?'+AO?"2][_?&R)2F8ZQ' D99SRB@CJK=1Q")[K^8DOX]JVM+,@C)R
ML;MT]QY.@&I:U)T8Z-PE<J/)&#K>TQ%6:O:I,+<HA70O'G21QH+"UKN6_?P
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M$ BT5PDU[H 5IR4)63^[Y2!AJAD5OJ3$QC=:E.P KOLNKDCS[D2CCB;<\<W
MD<.5=/7G[TDG. C2JV++4XL_99'&<O$G$7/ UJV@@\4"U^'],[:K!&%,(Q+H
MT)=Q1UZ.#MMBBC@Q8($M4UV1/&'!%+_KU><]P\]4W_:*)7XXBBSK5Y%BA ).
MN18/%(H@4':PC2NOI>YR:P[AF@-$2KRI)(4:UZ1T2B^SHJ3"Y@@K)<NL1C[<
MCGZ38,]0N?P $[V(X8>AT"DJZY<U+D;*^ )[VTJJT-;)NJ4HE&VKQ42DC:!=
M;-?Z>,?/UE/ 5D-HF(G7</ S"98KC*!X[Y58/M3K#SO,S"6N/0&?VMOCA.X:
MOBL2:0@,7 L)79%6NE&AN8ACG6YZ$)<4CU-:;KMAX:RV9#T"/AJXNYB6OAX:
MSIU4Y&!KS_V'T51-AN,?G]',?I  _R/P\.\U@>J73Z[WOZ0)\,SQS=JOZJRS
M;2FJ5OS::J'=TCS&!^G&1P#&W<?3D]@ZI5B1#P*OG5^F(GM=7D?A/#<$'AB$
M;N637'Y<6)9E;,CBCWHO1J9C'#_4.([NRWIZ%72AERFG[-/DP*0>Y<"(12_M
M(KV&.[)3 /#D_5?G_^P9PW=$T=-!?)Z^[&$>-K%'($NV\4: C(02X(?M]D )
M[_CB*^7L2AWIAS*(*JL;U6L&#3Q3H'76O<H^TZNMO$5^FI-YZLW9>#9G^RL4
ML[R[YF=;+;4IJ+X;:%\# T" 36.X1(RH:KP?S(#G0X@"UGL2X;(!\EW<=1E@
M<U&5F*T]"@2:E;<1@)#E4Z;5,>@I:AOM']'5#?E9$MO,C==?+T5ZI.XK#J=.
M%PCEX-TKC!I7G5K74VI1^,[0NPM@QB@6'& (T?7VZ#"KN'.@6>@?"YY_G\;@
MEG?ETI")3T>1AW9!-9B#;0_L RT?-[G_1"@IUS5G#82VMK5]!;>^D94&M-:8
M50AK0%7*-C#M09BX^-9S+CWBTD9[#J.4YECK,OX:-(8_UJONJ +L8)4O$>$]
M:;6#]I]=BT>+H8-<T 8N11?^JK7J<P:P>Y)7I4PTJ'9R[H*IHYG9G/\1T,H*
M&-M9S"P[=I:DC,L%4^EU!^"O\7M</@*,;Y7;$:GHG]YECNXO;9R"L1ETWQZL
MD$ZV]SMT^Q&,WRH8K3!-A%B+AXO>LZ6'/,BL1AM=7+@_ GZB6=NLGJG>43T"
M3!<? 8*[*,(0(Y*G8+;;RF&?][E?)>(#:J(]\8.CYL;)K5M%RI\^[^/*\A4;
M?]QI,!,QYY:!K7!(=6>U&1,?YO#;<?%DJNR[5&S@0Z=SP"XTO/,&7!@94(;0
M^YA@[TY:6=0<,^(1_;W !3:3W2KK)/=)%96$6AC^)A*\ZTW=DK=0L)+G^Q4S
MW<HR6#Y^A2U+LVNQ:QQ4 D<'$L13>>GK2A74TL,?>BT3>GBNY3Q_!'4>Q*@C
M;GN%W:]B?,D*=(=2>=Z!9=BG>CW91=\^TW$BW<QP[YZ;CPW8=#F5N/_RZA$P
M*1O(.-NJ7=[C8P,[8@;6ML(94X;%)FQ(]4"5RB/^<-0=%+ 6D!"1UY-:/[A!
M):'R,-Z4;&+P[H/G:\RJ[DBB:T"6 *YMSQROO3AN=.K4P7QJBE9S6[F$27/8
M4<X[1N.R]R/YKA.! 2^2#"=%J1SY4I)?/525+J^J1%+%@/(3D_Z@M(4=HNE;
M,4\%"E-9]8J_:H0K0\)AT<I<*T,K(M$E?,\I'5949B4[CK. 1#-[2<M+>RE_
MC*"82@V2%H'RE R>%.&@3=^/15X^:FUIUNZ;4Z)2A9(24^L9;) O#L@RHL+4
MC7R5:\JV5[V&SZ?J#*3IJ&9[1?*AC5A2#$Y409  <D#5^I&M$0Y"26..-O)5
MRAAZLMJ?NHA#9UUAC CW@UO9^3H?/6R!GB.;'4CYX3QIIT@V0@,_*0XH!41D
M/P(8^WN-+C;/[QT5LG401JX%"TD[XX7/UG?(1- Q-J8"N>U]93:R7^I5%,'N
M&11KIS:OP8^ .D,IOFX/XY+ND!FK.IW3_CC.BW&R52__6T5B IT%]IH\_NV7
M*5V <W/:8!R1N? O=T9Y!^)4P6Z-86/R#/A+T)%N@09W4E:I771!\>01A)U>
M[7P[OYVV%J"NVAK>FQ1T-AZI8@!T'V1@"*D/9)SV=5^/?SE>8G.#'F]V64:Q
M0)NR?[1L_/YCZ)KOR$Y2/W)=[2K1 3'Y17WX^I$X%+K^AW[L<G !O&W,_7%[
M2Z\1 VSLRPDGSK3S7.>@WW]?UV1ONFV=]K'*"C70(ZF+@3)HD2AO?5E]L5><
MY6^"REM$HITR#]\G4>_UY*A5"[L=$<1:Z*1^!"@"%J?K\ESAF/I3V)G-F")Z
MG\6GRFX'!8YA\3G]-* A:E:X0*2#@P0,9[H67K0X,$GU3L/SN=.^TXIZT2LI
MTN6#;$5E.JQL4E']P*]Z*C5D5(W>CCT&EI#AGA)8](+ZM-;D'T=GU%ZZ3UR]
MT=FMY4(#)Y*DP'+;A@Z2.RJ3BKU(BV)HP0:/Y"WL!SE!F/3G0RF,!,,F0X-2
MNQO_2GA#MU:S;[03Q\M3)6>24>J-Y]<H.,])-W%^5*J:-,D/DI$.[+.@A(JS
MPCDCWQQ_[(+Z9U]BVI 3S[@+.%,>%V$Q:&P&>BU/2RCN%,ZYVXU'^[^8OCCB
M8J^C,//J6_,[50E;/AT ,GQ]^DO$W&J/,FA8>0(CM+(P;EYKBBPWBRSB'>V2
M?(+KU;<X%S8)'3AZ=IFO[:E]5C;]TOW7Y>L&?-_),/Z3,P?*EUR)&!\FT';O
M3-8SK7K3MB-S;4!>]F]V9:]2X]9I0Z50,(>%1)J- 1A@-T,:.!H$#$:$ --8
M$MQ:OH52\:2BH;QT/;:CZ;25@+V"]W@*0R3.7@;$:D_P42@3K!M%U8[*FM>E
MW<-::WG>:O[PL#?.OZ"-^X8T:73P!^0U+3<Q1PJE0# G;PHM%;[EBJ^P8U"'
M&S:5V#5X<W[AO56*9(_0&[[=L6B('+^K0?IL>=&O&*RW:."X?IS2[+;GTJSY
MY<B34<X%,D6D*2U'T<A,'5SJI:1>?1K6L8Z-HM\4->8#EK67GO,)^YW*I>C:
M0XW)*<V3!G!?C;T#YMAZBR=5[LYE6\\XPNKC+D>7P<NZOWJR?^CC2 IA9"N>
MVYZ=4'F5*<U<C&/:@,S+ NCM4A+'^3K&*5$" (T;SN=C3MC>L0 7T",@JG)]
M;KYGA6(ZKV/V+I=W7#24MN[=Q( <8]:0D)A=""*SW*NZOY.\(#[R?!@C;$^3
MKGUJ>8CA&)6M[(PG)&PO2V1>S3[ 'A8?Y3T#J@U^=C$;K,?V0P4_3;";5Z89
M!2(IYGJ@NTK>JE30OX9Y_T9HH[FM67,1B_ES[#MD@ZHK#>^L[4 13B*O'ZT2
MV/G\*<" 4J,!D^I:V<7MMV2OXBW4!OG&@96^DA.FPBEU>7LD:;;85_A[B8,[
MG9F+N#T;%6C:B&0SVW;ZT[FJTE%/G"2D+.BZCTT:#XH\B5F*H?26//.2!N@X
M::V-03;Q[*"7O!S>O"Y(/\>8</Q\MSBWW=0:I6!&%#3GG1UN$4N7+CTGX=%@
MJZ*N93#I8V^2<%%RI[>.F?F22GQ5)9@M%JC6HF1G7<#L*-J2X1JJJE":ZH]?
MWX%PR**IB=-[6S]D_WZ\Z6B3AMNB3;-*_R20:5;48IT8SM_P::Y?,>26_QFE
MVU,ZE1K)M?@58P\:*!Q @,@Z^=!6,UEKAS;#-]QKPQ"Y:NXLVTK&*":]$RB2
MQ48-)/#J[\%*-62?=FNJ#3.N,=AS$;=W<2*;O2EF1HW+M!.!"%MFD_3>4LGI
MM[363CO6PJV(9D@XD/NY!T;K%N0[C9>L8J*L(GF!Z+]U7X''2LKV>0RK>W"R
M<<",\4XZ&\?'MVV#HJKH?8,8&UE94@/"J-\E+J%?O2K[J!E;FAX!7R0^3'?4
MV!=8=]3RO38R_\>I=P#P%C[,Q5<=$/LW4_3["0CG#745'206E&Q0*JR^S*+(
MRY83VPB(70C.3PE>7]%^,1K\UXV3PX4(D8I@'41&AK9_=JEIIY. <[G1XVJ$
MZ;#&:,%5,M%3+]HS-C)1UW4./<.Y6@X,V;J4/\ 6+K[1X>K%/FKT*<36]XQ3
M$:R9G\>KO:M$M;>QK)I9\^_KOALL];J2)4HB]U+D,IQ0NO6IGAI%U![@4GKU
M*+8EV%MF:]K0IA@E,UUK$&%Y+0EN5& #[!8094:3==%B/!!^8K57?R+ [E1B
MOSLMQ!B<EDK$XM^IP)EC+CB8(<3^5--N!>U-;=4V.6A#@;"J5(<@Y& @V:[(
M7$ OMO1\[Q- ()S:5LI4\?GMH-_=U3Y,^(DLWU1\;R,>-)%)>&=38XID,6'>
M=7Y_,X%N_B ,9PZM$_'!);;A=ZW/*6=GG-(=^"PKX=9U0Y#PQZUD&RX7PXNY
M*-)!L-?\P9MO9@^%[UO%%+0FX[7+TMLQ)%J-+)%8<WAV$ I64(G\ZK?/!8A.
M>82?$"6^^]\3^6@ (SANE#MI7>WI55@Y7?L<EO3GM'7I7R"("I*+$..EVJAJ
M=)\X\^G]?;DXUW3M(^#7LN*O_N*]N&W!? ="^<H!5'C+/'5=2,ENLWM''UCY
MXO9@F(4O@LZ'XKLC]3)9@D?MA\Z@ED!)\58-Z$KDVBXG.V]JQQR?TO#"I%EU
MM$:B.H"NM9_B%Y%S1K8B8&'NSK%4![&),%*>RFMM2AL .N@. ?I^*368 ZR"
M$IU8E23PO?+DY\_O1?I2TM0:9C+Z[-T+6]/559\_@UUOH@2+S/!/<MYQ*O7W
MCZ2]*);0#4=H=. ] C:NNFDNJ1L>:I&"U@=%0>*L")]#CYMW1'J5OZZKY04X
M4_]\_D[Y- 6\\PVM$K.LU9@F6SD_7/77.1O2/0(2*]=6;[8^/R6R98TY6+B$
MB!^^0C8.]#4ICP"UUM3!FNH(6*&O5:4%2J+/B^XD741(/@0:5Y9G?07R?OT9
M?'Z=?_M>:2EVE6UCPOU(!3[;O>O/>#H?>3R[^*'*YNCXAT9#XJL7Q-(8@FA.
MP#:'_0>V2=YE8J4]/DR;/'-Q=1E:CXR$[AS**O$9I-$N.,Z^XQ<,2(=YH'*X
M">YH#:90C,\YV<U,N '\N,B6SX]$=BI)V>(/75U[BDQS)M=7KVO5A GJS(/X
MVM[5&I1CZ:"1A7>+ O%]/B  OB0IP/@%8#NI'Z1ZRNC/WKB*G==+,23:?G=T
MUGF\V%B>/^O/J-_;'"-,'$V4A[T!S%H'UA$=!'=^PCZ"-@F6.U2T8^W->_SB
M&YSF,PMXU7QF$<<6S@XX@:B(E4V#??5R#*T'R^3*0)A,RMMRR=J.-<@NS_;B
M:I&&?=_.3.O.B!KY?U7"2"^-G1AI]/HM'374,X,G!S.0B[Z3;B<Z;3O^9?P'
MBH9$OUS+PX.F"C1)Y/9C2T68E,B4VXJ_G:$+EJ?+UEHE'PC5J?SVW127P>FZ
M@_S@[MV;6.IH8;LSO<)T<;K4(XQGGI0 X'R'0RU2)FRQDI1O469=A(I=>O(Z
M8<GFK.K%PFT,>%!\(XXM=4K4<[V2"//  $7NEUZTR*!QVO&9G X>&UX.TA\>
M_,%^9+"7@]R$KUL[Q?1%^"RO33EHCSY%BNUWLC'RR;YFM1.NJ);C$TRR^24#
MMB'A+@!/S%84Q(^)H.[K;Y:(<I%VH101(DWN&;+-'O$A>&F(;>8N&SR-TT6&
M!2SK&VG-BT:'ZH6Z]EF-\!!%:M%Z0!R$;3?%D7$O\X\*1C:T<O,U$H9$H 7E
MG%$DG]+3=Z9[H#C?UK>WNR_<,0=-11)7>%&-?VVX$L1X:_$7_=R;>P00UPG,
MGU2RY\S1AAXZF+3:N5G*0"=YD-&/D0 W<$F*2:^BW@>:CKIPB+!']B5%B1;I
M!1774C]A[+_B#^^-N5I1A?6613%37%PO_VZ1>P>OF,T/MR8-$92.7^.\,P#"
M\YS@W2R<X+-^!9][,XW6MDQB$98ZA5>"J +?-SR0*WB2]C[ T9.+].ZT$^T]
M]B_'QC6JXT1$&AU64%_*RELO?(N3IXVY444?A .C6GF<41#]P&F<5-%H_(YI
MJLO%&DK.[Y5C4RK<PEH=D:V:_,D^-GE[_!AJ<R<:K6\=H0DY:X,, 2_B9^#Z
M\1'GG!AZ'!7I?)=59?JK(PDR13VE@VSB.KY]GL:L%XSP/MO]5(\5 L0/JQ);
M]DF;YK"T-#=MX- [5GD=-AH8%D7),0L*9Q]T/-:M\MG^(^ T8<_; )(MEI]
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MJOVTN 3N9D:>'&=IFC W">I'0'('7/)F_4G7R=_/."$>./["GV72IV_H:CZ
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MXR3?U"IS\$#8#"QVDJJ$+R1*EF;JYF$3/DY>[ 0= TW'3/)40\VFM1?$9M&
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M*_S@.3BZNRJEU,80ZZ:C.+JOHC_]6$LW4Z:)MRG&4SQ*[I!/^='%HJH<D[W
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M\\CD:#^@J41(& U-=HUM B>4J?_,[>##2EDE7EY5E+MS,ZQ>;J.MLRAQ#'.
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M^U*_KK+1G L7N$B.G3837:M7'L:=13EEF+OK98B;/]K>37YCN!B3TMZ>W!1
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M^-:\3DD(U&\\WK4X"!;B+E&T64G!VS[#-/<HUNXE*TX6,<>&?:K7XH-](24
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M!FI"&8U)[WJ#%.6Q_=**K5C/BK\97$9Z><;4B;FU]5[&1"'Y\H!6L9'.)Q:
M3"Y\3>P@,=PU18P%)\+A)9TYO+*?"VAP-0Z5?W5-ICOW7ND"25,0KAG<R\=?
MIKA&<LHOC#;GNM<(;O>O5T2F\]Y..7JHE^M$J'<1-'9/PR<@9Z_P=?U(23K
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MX7\5_"_W)A8CZB;O)NDFR^IL[M8@=AU]O\OY#FB,M)NLV*S194BO[;=YO)5
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M'":NF8;VX$*Y+.IRW_["^?NH1%74'%_7GHW+*8G[CS0UC]L0S=;4-6G>M*"
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MG;H\;EM252]GU+PNQLI-2>J%M+WEZ#7WDCQUF[9M^:C5>\-CFJ(?,2GJUG>
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M:X127D4BO&&HJ-3QH!'P&O#G EDT5(4PQL%'E'V4X:=4I-]F@*O_M1BH=BV
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M+:?-3K'3X]EIJ'N/\ PZX* 'B6PYP).S,:FIKJG]D#*]4NPLK7WC2]PK7"R
M.4Q<-/SQ+I+_/K@&ZV&%W<>04AZ_AR2?5*5)_G=BH'\671WO+'UX1E2LJ@1;
MGQV IA\@E%+?4#%2P%#;4!TR-\<9'Z=]-U<LJ_[0"%UC3K-VHN+/MCSA+".L
MW7VK#3%!'P=4%MWTA[<:>+9/J&Y"[_/JTDC,TB:\0\M=!E,3H@GD,<<>Y0>#
MYB3:%!SFM/.69[+'+C(VKL-"T9M0$@[GNHEA$:Q,^1P#)\C4JZ!T&F[?"-')
M#]N69Z 62XX];6W4 .)9B8\[Z4*7OVB=J2<^H8EA:):ED$^H:9R']5>^RHUA
M@7BL36^5FKS/:PFYG$[[JLL&/V-.CXZT"!2VV.4*=GZ45REX6I@$D'<0"XRR
M9!\![%CTGA8Q5\Y.I5Q__OO_\@1%^>>SKO(C.@6["$N;I5QYKCP?W7[3+8^O
M\2,;>CX)WLOM/M'ZHJ,,I,^SODG2OB^)<M\$"*Q%/;-_(12E/;J174BE%OVS
M)4HV>U+?R*C-5">SN+K:/:Q]8.QI?YP6OBS61^Y.+&(+&#W*)2?W6Y48.:F>
MYX/5;NY/FYP=-YHO02S]6N';;TN(K-EMUUW*M>_EK&-$1WG!<'K#LM*1B];E
M?/E#_QUXO.#Q:>W8I6NS29O+.)'1YL^4Z?92==R[9978.D7B#LSG\L+(1SMO
M]WIQ$-[/G%S)*BLK2_5G]*4?$GF?TGS3/$OL+D'! RM$E46%>M4C(#DWGH84
M^'Z(.32AN;&G:FF(.^140+PF+V=:75[S>H2]=7=.AG,$8(*5):2YP]^:R!=%
M%Z,RPEZPC$7[1H;?Y'*WW =54;HK/&[]+MX0P>&.$IL3E82PWGN@UI!(0<F/
M3)*1:.[@@CYG56C3@X>^B1L3 :5+B#BTU\H_H\:B@CJ%MZ:<86+'5&49D):]
MNV1EV2-J\%G$Z==R/MBS41%V$?ZJREJ?_(.W@M83=AI+OGL343NJ:,<6C\*8
MG,LF513O:MJ<K@KCP0/81<G&$<GXD,J4S$:#]2K(F"IK%WDHT(4A<S.P,72W
M1GPM(YUFVPF+@4TRH0H3E^1&;':)%]>4RQ.=#/(8/N5Q18K+;6A;("CM(KJR
MAQ T] ]YB>C%@W)SL6]F?WNX^32/YS\-O;12I=NZ*(ZJJ)AMJ])A[9GYYO+C
M<"P=0/L<F]!CT_(C^;CK5XX]&DV*LM&;<E> [Y%KXM2YW29\F=Y/8MB8>5P.
M96XY$/(MJG<+#.@P4P/5.V^6&6T#+4?Z$;&7L#=^5E2@L3576MMW:X*SZ FH
M-,#D'[^;UVK_4[ZQ2%G=@5B";GJ\P]?DW2"W\[&=/Y;3/T=4_BN1_%=@T[^Q
M?UZLIHCDXL6US.*G&GVR-=#0V6N.32FU >L1:RJP-S)'70':6I,"Q"CWSX_"
MS =BO<\>=!:.G?"N+QP@8Q_MY%;<]9XWDJX[_64#/Y:$84$CLMQ\U$W,6*R0
M.<)JX\-<W_C3GS,=4(B-O6\D0C6U\8$C23=QY(:#9Q*MJT^_0,NY.\>"Q5KJ
MFNZB"<7W_>@L*]_/1 76):W&-M&V3K[65@!?>@20S3;+SF'<;0_ LJ@W*P[H
M,':L%B0T@ W3GP'6F\[!<@P*=OWYECU&[_PWS2HOR8I&CE"T8U*=MVZ:UF3@
M'U\<_@>+)X;\SQF(O['_6BQW4V@W)N-^;4"Z];LV4[9H0)LG007<=4F)>$)<
M"#F3%,K!W7/O9K2"Q^LE8+C"5ZWM0#6BAKF.\3]4TE2_L5,_VK:3%,-4GX@G
MRG4FL!365:;XGMXQS/3!1\<SRMY0?;2_MR=Y8&M<7-S<:P(;AFX\&#0(V*7A
M:3'%6W!.#\J7[.[8O8R:L?[M5/)*:PT^]V\BL7Y3D!,'B55BCK5P&[,QXC-
M)LC5=SYJXI"$O?/CA,9^>V5XOM7$A#4^S$0_[[:KR+YC'3WL=$-6I' XZ#)C
M=SAB/KB20[5^I]8_X2#>Z0O%I'#,H1TK#'C_")<CM2Q0.T37[)-,';LI"ZX
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M12L0Q/V5,"'(>! GXNL0 @TQJ/B^EV^.>G$XHP_-J[$(MO!)>'>H.<@Z'7_
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M?;<UU\-",<(//H2A>]/=_)=.<2J7L?Y* D-6QU1-UVOZ1X)+@C1HD ]!Y15
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M9(B0AG<:.OK8A<I%U.I7KPIB'-/78O'@1S:&3J,G*ONQ>47[6DV+H@ZLS8M
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M,S N:'1M4$L! A0#%     @ '81V4]*6Q.?K%   %>8  !$
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M &%R=W(M,C R,3 Y,S!?<')E+GAM;%!+ 0(4 Q0    ( !V$=E.Y 6^*ZP<
M  PH   0              "  8A[! !A<G=R+65X,S$Q7S8N:'1M4$L! A0#
M%     @ '81V4P_/.W7Q!P  $B@  !$              ( !H8,$ &%R=W(M
M97@S,3)?,34N:'1M4$L! A0#%     @ '81V4T66M2K*!   LA4  !$
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M+FIP9U!+ 0(4 Q0    ( !V$=E,@9"WB4'(  -*    6              "
M 2L/"0!G9FUV9V)F=#%F=C,P,# P,#,N:G!G4$L! A0#%     @ '81V4UH&
M4//3= $ 7IX! !8              ( !KX$) &=F;79G8F9T,69V,S P,# P
M-"YJ<&=02P$"% ,4    "  =A'93=)^2C3-V  !NYP  %@
M@ &V]@H 9V9M=F=B9G0Q9G8S,# P,# U+FIP9U!+!08     #P / -T#   =
%;0L    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
